doi	section	n_itc	study_number	questions	answer
10.1001/jamaophthalmol.2021.6284	general_information	NA	NA	condition_name	thyroid eye disease
10.1001/jamaophthalmol.2021.6284	general_information	NA	NA	country_first_author	usa
10.1001/jamaophthalmol.2021.6284	general_information	NA	NA	country_last_author	canada
10.1001/jamaophthalmol.2021.6284	general_information	NA	NA	positions	Academic, Private Data Analysis Company
10.1001/jamaophthalmol.2021.6284	general_information	NA	NA	methodologist_yn	Yes
10.1001/jamaophthalmol.2021.6284	general_information	NA	NA	funding_source	Pharmaceutical Industry
10.1001/jamaophthalmol.2021.6284	general_information	NA	NA	pharmaceutical_ties_yn	Yes
10.1001/jamaophthalmol.2021.6284	general_information	NA	NA	systematic_review_yn	Yes
10.1001/jamaophthalmol.2021.6284	methodology	1	NA	outcome_name	change from baseline in proptosis in mm
10.1001/jamaophthalmol.2021.6284	methodology	1	NA	outcome_short_name	proptosis change
10.1001/jamaophthalmol.2021.6284	methodology	1	NA	outcome_variable_type	Continuous (count, mean, ...)
10.1001/jamaophthalmol.2021.6284	methodology	1	NA	treatment_name_ipd	teprotumumab
10.1001/jamaophthalmol.2021.6284	methodology	1	NA	studies_number_ipd	1;2
10.1001/jamaophthalmol.2021.6284	methodology	1	NA	treatment_name_nonipd	intravenous methylprednisolone
10.1001/jamaophthalmol.2021.6284	methodology	1	NA	studies_number_nonipd	3
10.1001/jamaophthalmol.2021.6284	methodology	1	NA	paic_type	MAIC
10.1001/jamaophthalmol.2021.6284	methodology	1	NA	anchored_yn	No
10.1001/jamaophthalmol.2021.6284	methodology	1	NA	paic_form	Aggregation of multiple studies to estimate individual treatment effects (e.g. meta-analysis in a first step to estimate treatment A effect, then population adjusted indirect comparison using treatment A effect estimate)
10.1001/jamaophthalmol.2021.6284	methodology	1	NA	primary_outcome_yn	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.1001/jamaophthalmol.2021.6284	methodology	1	NA	variables_selection_justification	A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion), Literature based (clinically or methodologically relevant to adjust on these variables based on the literature search conducted for this specific purpose)
10.1001/jamaophthalmol.2021.6284	methodology	1	NA	pf_yn	Yes
10.1001/jamaophthalmol.2021.6284	methodology	1	NA	tem_yn	Yes
10.1001/jamaophthalmol.2021.6284	methodology	1	NA	adjustment_model_details_yn	No
10.1001/jamaophthalmol.2021.6284	methodology	1	NA	scale_choice_yn	No
10.1001/jamaophthalmol.2021.6284	results	1	NA	contrast_effect_type	Means difference
10.1001/jamaophthalmol.2021.6284	results	1	NA	direction_benefit	inferior
10.1001/jamaophthalmol.2021.6284	results	1	NA	ss_ttt_nonipd	419
10.1001/jamaophthalmol.2021.6284	results	1	NA	ss_ttt_ipd	79
10.1001/jamaophthalmol.2021.6284	results	1	NA	ss_adjusted_ttt_ipd	56
10.1001/jamaophthalmol.2021.6284	results	1	NA	weights_yn	Not mentioned
10.1001/jamaophthalmol.2021.6284	results	1	NA	covariates_yn	Yes
10.1001/jamaophthalmol.2021.6284	results	1	NA	covariates_n	3
10.1001/jamaophthalmol.2021.6284	results	1	NA	covariates_names	Age, Sex, Other(s)
10.1001/jamaophthalmol.2021.6284	results	1	NA	contrast_effect_direction	Numerator if ratio, or left side if difference
10.1001/jamaophthalmol.2021.6284	results	1	NA	contrast_effect_unadjusted_value	-2.38
10.1001/jamaophthalmol.2021.6284	results	1	NA	contrast_effect_unadjusted_pvalci	[-3.49;-1.27]
10.1001/jamaophthalmol.2021.6284	results	1	NA	contrast_effect_adjusted_value	-2.31
10.1001/jamaophthalmol.2021.6284	results	1	NA	contrast_effect_adjusted_pvalci	[-3.45;-1.17]
10.1001/jamaophthalmol.2021.6284	results	1	NA	adjustment_geographical	No
10.1001/jamaophthalmol.2021.6284	results	1	NA	ss_total_ipd	NA
10.1001/jamaophthalmol.2021.6284	results	1	NA	ss_adjusted_total_ipd	NA
10.1001/jamaophthalmol.2021.6284	results	1	NA	ss_total_nonipd	NA
10.1001/jamaophthalmol.2021.6284	results	1	NA	ss_anchor_nonipd	NA
10.1001/jamaophthalmol.2021.6284	results	1	NA	ss_anchor_ipd	NA
10.1001/jamaophthalmol.2021.6284	results	1	NA	ss_adjusted_anchor_ipd	NA
10.1001/jamaophthalmol.2021.6284	results	1	NA	effect_cutoff	0
10.1001/jamaophthalmol.2021.6284	results	1	NA	unadjusted_lb_ci	-3.49
10.1001/jamaophthalmol.2021.6284	results	1	NA	unadjusted_ub_ci	-1.27
10.1001/jamaophthalmol.2021.6284	results	1	NA	unadjusted_significant	TRUE
10.1001/jamaophthalmol.2021.6284	results	1	NA	adjusted_lb_ci	-3.45
10.1001/jamaophthalmol.2021.6284	results	1	NA	adjusted_ub_ci	-1.17
10.1001/jamaophthalmol.2021.6284	results	1	NA	adjusted_significant	TRUE
10.1001/jamaophthalmol.2021.6284	study_information	NA	1	ipd_yn	Yes
10.1001/jamaophthalmol.2021.6284	study_information	NA	1	ct_yn	Yes
10.1001/jamaophthalmol.2021.6284	study_information	NA	1	nct	NCT01868997
10.1001/jamaophthalmol.2021.6284	study_information	NA	1	country_study	international
10.1001/jamaophthalmol.2021.6284	study_information	NA	1	ct_phase	2
10.1001/jamaophthalmol.2021.6284	study_information	NA	1	ct_arms	2 or more
10.1001/jamaophthalmol.2021.6284	study_information	NA	2	ipd_yn	Yes
10.1001/jamaophthalmol.2021.6284	study_information	NA	2	ct_yn	Yes
10.1001/jamaophthalmol.2021.6284	study_information	NA	2	nct	NCT03298867
10.1001/jamaophthalmol.2021.6284	study_information	NA	2	country_study	international
10.1001/jamaophthalmol.2021.6284	study_information	NA	2	ct_phase	3
10.1001/jamaophthalmol.2021.6284	study_information	NA	2	ct_arms	2 or more
10.1001/jamaophthalmol.2021.6284	study_information	NA	3	ipd_yn	No
10.1001/jamaophthalmol.2021.6284	study_information	NA	3	ct_yn	No
10.1001/jamaophthalmol.2021.6284	study_information	NA	3	data_source_name	meta-analysis of clinical trials from 12 articles
10.1001/jamaophthalmol.2021.6284	study_information	NA	3	country_study	international
10.1002/edm2.259	general_information	NA	NA	condition_name	type 2 diabetes
10.1002/edm2.259	general_information	NA	NA	country_first_author	uk
10.1002/edm2.259	general_information	NA	NA	country_last_author	denmark
10.1002/edm2.259	general_information	NA	NA	positions	Academic, Pharmaceutical Industry, Private Data Analysis Company
10.1002/edm2.259	general_information	NA	NA	methodologist_yn	Yes
10.1002/edm2.259	general_information	NA	NA	funding_source	Pharmaceutical Industry
10.1002/edm2.259	general_information	NA	NA	pharmaceutical_ties_yn	Yes
10.1002/edm2.259	general_information	NA	NA	systematic_review_yn	Yes
10.1002/edm2.259	methodology	1	NA	outcome_name	3 point mace (cardiovascular death, non-fatal myocardial infraction, non-fatal stroke)
10.1002/edm2.259	methodology	1	NA	outcome_short_name	3-point MACE
10.1002/edm2.259	methodology	1	NA	outcome_variable_type	Time-to-event
10.1002/edm2.259	methodology	1	NA	treatment_name_ipd	semaglutide 0.5  +  1 mg
10.1002/edm2.259	methodology	1	NA	studies_number_ipd	1
10.1002/edm2.259	methodology	1	NA	treatment_name_nonipd	dulaglutide 1.5 mg
10.1002/edm2.259	methodology	1	NA	studies_number_nonipd	2
10.1002/edm2.259	methodology	1	NA	paic_type	MAIC
10.1002/edm2.259	methodology	1	NA	anchored_yn	Yes
10.1002/edm2.259	methodology	1	NA	paic_form	Simple (ie treatments effects extracted from two studies)
10.1002/edm2.259	methodology	1	NA	primary_outcome_yn	Yes
10.1002/edm2.259	methodology	1	NA	variables_selection_justification	A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion)
10.1002/edm2.259	methodology	1	NA	pf_yn	No
10.1002/edm2.259	methodology	1	NA	tem_yn	Yes
10.1002/edm2.259	methodology	1	NA	adjustment_model_details_yn	No
10.1002/edm2.259	methodology	1	NA	scale_choice_yn	No
10.1002/edm2.259	results	1	NA	contrast_effect_type	HR
10.1002/edm2.259	results	1	NA	direction_benefit	inferior
10.1002/edm2.259	results	1	NA	ss_ttt_nonipd	NA
10.1002/edm2.259	results	1	NA	ss_ttt_ipd	NA
10.1002/edm2.259	results	1	NA	ss_adjusted_ttt_ipd	NA
10.1002/edm2.259	results	1	NA	weights_yn	Yes, mentions that the weights distribution has been studied, and weights distribution reported in main article or supplemental materials
10.1002/edm2.259	results	1	NA	covariates_yn	Yes
10.1002/edm2.259	results	1	NA	covariates_n	6
10.1002/edm2.259	results	1	NA	covariates_names	Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Comorbidities and medical history (beside pathology/disease of interest in the comparison)
10.1002/edm2.259	results	1	NA	contrast_effect_direction	Numerator if ratio, or left side if difference
10.1002/edm2.259	results	1	NA	contrast_effect_unadjusted_value	NA
10.1002/edm2.259	results	1	NA	contrast_effect_unadjusted_pvalci	NA
10.1002/edm2.259	results	1	NA	contrast_effect_adjusted_value	0.74
10.1002/edm2.259	results	1	NA	contrast_effect_adjusted_pvalci	0.06
10.1002/edm2.259	results	1	NA	adjustment_geographical	NA
10.1002/edm2.259	results	1	NA	ss_total_ipd	3297
10.1002/edm2.259	results	1	NA	ss_adjusted_total_ipd	2633
10.1002/edm2.259	results	1	NA	ss_total_nonipd	9901
10.1002/edm2.259	results	1	NA	ss_anchor_nonipd	NA
10.1002/edm2.259	results	1	NA	ss_anchor_ipd	NA
10.1002/edm2.259	results	1	NA	ss_adjusted_anchor_ipd	NA
10.1002/edm2.259	results	1	NA	effect_cutoff	1
10.1002/edm2.259	results	1	NA	adjusted_pval	0.06
10.1002/edm2.259	results	1	NA	adjusted_num_pval	0.06
10.1002/edm2.259	results	1	NA	adjusted_significant	FALSE
10.1002/edm2.259	study_information	NA	1	ipd_yn	Yes
10.1002/edm2.259	study_information	NA	1	ct_yn	Yes
10.1002/edm2.259	study_information	NA	1	nct	NCT01720446
10.1002/edm2.259	study_information	NA	1	country_study	international
10.1002/edm2.259	study_information	NA	1	ct_phase	3
10.1002/edm2.259	study_information	NA	1	ct_arms	2 or more
10.1002/edm2.259	study_information	NA	2	ipd_yn	No
10.1002/edm2.259	study_information	NA	2	ct_yn	Yes
10.1002/edm2.259	study_information	NA	2	nct	NCT01394952
10.1002/edm2.259	study_information	NA	2	country_study	international
10.1002/edm2.259	study_information	NA	2	ct_phase	3
10.1002/edm2.259	study_information	NA	2	ct_arms	2 or more
10.1007/bf03261873	general_information	NA	NA	condition_name	attention-deficit/hyperactivity disorder
10.1007/bf03261873	general_information	NA	NA	country_first_author	usa
10.1007/bf03261873	general_information	NA	NA	country_last_author	usa
10.1007/bf03261873	general_information	NA	NA	positions	Pharmaceutical Industry, Private Data Analysis Company
10.1007/bf03261873	general_information	NA	NA	methodologist_yn	Yes
10.1007/bf03261873	general_information	NA	NA	funding_source	Pharmaceutical Industry
10.1007/bf03261873	general_information	NA	NA	pharmaceutical_ties_yn	Yes
10.1007/bf03261873	general_information	NA	NA	systematic_review_yn	Yes
10.1007/bf03261873	methodology	1	NA	outcome_name	change in the adhd-rs-iv total score from baseline to end-point
10.1007/bf03261873	methodology	1	NA	outcome_short_name	ADHD-RS-IV score
10.1007/bf03261873	methodology	1	NA	outcome_variable_type	Continuous (count, mean, ...)
10.1007/bf03261873	methodology	1	NA	treatment_name_ipd	guanfacine extended-release low dose
10.1007/bf03261873	methodology	1	NA	studies_number_ipd	1;2
10.1007/bf03261873	methodology	1	NA	treatment_name_nonipd	atomoxetine
10.1007/bf03261873	methodology	1	NA	studies_number_nonipd	3
10.1007/bf03261873	methodology	1	NA	paic_type	MAIC
10.1007/bf03261873	methodology	1	NA	anchored_yn	No
10.1007/bf03261873	methodology	1	NA	paic_form	Aggregation of multiple studies to estimate individual treatment effects (e.g. meta-analysis in a first step to estimate treatment A effect, then population adjusted indirect comparison using treatment A effect estimate)
10.1007/bf03261873	methodology	1	NA	primary_outcome_yn	Yes
10.1007/bf03261873	methodology	1	NA	variables_selection_justification	Nothing mentioned, not reported
10.1007/bf03261873	methodology	1	NA	pf_yn	No discussion (in the main text) of the status of prognostic factors of the variables
10.1007/bf03261873	methodology	1	NA	tem_yn	No discussion (in the main text) of the status of treatment-effect modifiers of the variables
10.1007/bf03261873	methodology	1	NA	adjustment_model_details_yn	Yes
10.1007/bf03261873	methodology	1	NA	scale_choice_yn	No
10.1007/bf03261873	methodology	2	NA	outcome_name	change in the adhd-rs-iv total score from baseline to end-point
10.1007/bf03261873	methodology	2	NA	outcome_short_name	ADHD-RS-IV score
10.1007/bf03261873	methodology	2	NA	outcome_variable_type	Continuous (count, mean, ...)
10.1007/bf03261873	methodology	2	NA	treatment_name_ipd	guanfacine extended-release mid dose
10.1007/bf03261873	methodology	2	NA	studies_number_ipd	1;2
10.1007/bf03261873	methodology	2	NA	treatment_name_nonipd	atomoxetine
10.1007/bf03261873	methodology	2	NA	studies_number_nonipd	3
10.1007/bf03261873	methodology	2	NA	paic_type	MAIC
10.1007/bf03261873	methodology	2	NA	anchored_yn	No
10.1007/bf03261873	methodology	2	NA	paic_form	Aggregation of multiple studies to estimate individual treatment effects (e.g. meta-analysis in a first step to estimate treatment A effect, then population adjusted indirect comparison using treatment A effect estimate)
10.1007/bf03261873	methodology	2	NA	primary_outcome_yn	Yes
10.1007/bf03261873	methodology	2	NA	variables_selection_justification	Nothing mentioned, not reported
10.1007/bf03261873	methodology	2	NA	pf_yn	No discussion (in the main text) of the status of prognostic factors of the variables
10.1007/bf03261873	methodology	2	NA	tem_yn	No discussion (in the main text) of the status of treatment-effect modifiers of the variables
10.1007/bf03261873	methodology	2	NA	adjustment_model_details_yn	Yes
10.1007/bf03261873	methodology	2	NA	scale_choice_yn	No
10.1007/bf03261873	methodology	3	NA	outcome_name	change in the adhd-rs-iv total score from baseline to end-point
10.1007/bf03261873	methodology	3	NA	outcome_short_name	ADHD-RS-IV score
10.1007/bf03261873	methodology	3	NA	outcome_variable_type	Continuous (count, mean, ...)
10.1007/bf03261873	methodology	3	NA	treatment_name_ipd	guanfacine extended-release high dose
10.1007/bf03261873	methodology	3	NA	studies_number_ipd	1;2
10.1007/bf03261873	methodology	3	NA	treatment_name_nonipd	atomoxetine
10.1007/bf03261873	methodology	3	NA	studies_number_nonipd	3
10.1007/bf03261873	methodology	3	NA	paic_type	MAIC
10.1007/bf03261873	methodology	3	NA	anchored_yn	No
10.1007/bf03261873	methodology	3	NA	paic_form	Aggregation of multiple studies to estimate individual treatment effects (e.g. meta-analysis in a first step to estimate treatment A effect, then population adjusted indirect comparison using treatment A effect estimate)
10.1007/bf03261873	methodology	3	NA	primary_outcome_yn	Yes
10.1007/bf03261873	methodology	3	NA	variables_selection_justification	Nothing mentioned, not reported
10.1007/bf03261873	methodology	3	NA	pf_yn	No discussion (in the main text) of the status of prognostic factors of the variables
10.1007/bf03261873	methodology	3	NA	tem_yn	No discussion (in the main text) of the status of treatment-effect modifiers of the variables
10.1007/bf03261873	methodology	3	NA	adjustment_model_details_yn	Yes
10.1007/bf03261873	methodology	3	NA	scale_choice_yn	No
10.1007/bf03261873	results	1	NA	contrast_effect_type	Means difference
10.1007/bf03261873	results	1	NA	direction_benefit	inferior
10.1007/bf03261873	results	1	NA	ss_ttt_nonipd	84
10.1007/bf03261873	results	1	NA	ss_ttt_ipd	147
10.1007/bf03261873	results	1	NA	ss_adjusted_ttt_ipd	49
10.1007/bf03261873	results	1	NA	weights_yn	Not mentioned
10.1007/bf03261873	results	1	NA	covariates_yn	Yes
10.1007/bf03261873	results	1	NA	covariates_n	6
10.1007/bf03261873	results	1	NA	covariates_names	Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Other(s)
10.1007/bf03261873	results	1	NA	contrast_effect_direction	Numerator if ratio, or left side if difference
10.1007/bf03261873	results	1	NA	contrast_effect_unadjusted_value	NA
10.1007/bf03261873	results	1	NA	contrast_effect_unadjusted_pvalci	NA
10.1007/bf03261873	results	1	NA	contrast_effect_adjusted_value	-3.7
10.1007/bf03261873	results	1	NA	contrast_effect_adjusted_pvalci	0.07
10.1007/bf03261873	results	1	NA	adjustment_geographical	No
10.1007/bf03261873	results	1	NA	ss_total_ipd	NA
10.1007/bf03261873	results	1	NA	ss_adjusted_total_ipd	NA
10.1007/bf03261873	results	1	NA	ss_total_nonipd	NA
10.1007/bf03261873	results	1	NA	ss_anchor_nonipd	NA
10.1007/bf03261873	results	1	NA	ss_anchor_ipd	NA
10.1007/bf03261873	results	1	NA	ss_adjusted_anchor_ipd	NA
10.1007/bf03261873	results	1	NA	effect_cutoff	0
10.1007/bf03261873	results	1	NA	adjusted_pval	0.07
10.1007/bf03261873	results	1	NA	adjusted_num_pval	0.07
10.1007/bf03261873	results	1	NA	adjusted_significant	FALSE
10.1007/bf03261873	results	2	NA	contrast_effect_type	Means difference
10.1007/bf03261873	results	2	NA	direction_benefit	inferior
10.1007/bf03261873	results	2	NA	ss_ttt_nonipd	84
10.1007/bf03261873	results	2	NA	ss_ttt_ipd	46
10.1007/bf03261873	results	2	NA	ss_adjusted_ttt_ipd	16
10.1007/bf03261873	results	2	NA	weights_yn	Not mentioned
10.1007/bf03261873	results	2	NA	covariates_yn	Yes
10.1007/bf03261873	results	2	NA	covariates_n	6
10.1007/bf03261873	results	2	NA	covariates_names	Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Other(s)
10.1007/bf03261873	results	2	NA	contrast_effect_direction	Numerator if ratio, or left side if difference
10.1007/bf03261873	results	2	NA	contrast_effect_unadjusted_value	NA
10.1007/bf03261873	results	2	NA	contrast_effect_unadjusted_pvalci	NA
10.1007/bf03261873	results	2	NA	contrast_effect_adjusted_value	-6
10.1007/bf03261873	results	2	NA	contrast_effect_adjusted_pvalci	0.02
10.1007/bf03261873	results	2	NA	adjustment_geographical	No
10.1007/bf03261873	results	2	NA	ss_total_ipd	NA
10.1007/bf03261873	results	2	NA	ss_adjusted_total_ipd	NA
10.1007/bf03261873	results	2	NA	ss_total_nonipd	NA
10.1007/bf03261873	results	2	NA	ss_anchor_nonipd	NA
10.1007/bf03261873	results	2	NA	ss_anchor_ipd	NA
10.1007/bf03261873	results	2	NA	ss_adjusted_anchor_ipd	NA
10.1007/bf03261873	results	2	NA	effect_cutoff	0
10.1007/bf03261873	results	2	NA	adjusted_pval	0.02
10.1007/bf03261873	results	2	NA	adjusted_num_pval	0.02
10.1007/bf03261873	results	2	NA	adjusted_significant	TRUE
10.1007/bf03261873	results	3	NA	contrast_effect_type	Means difference
10.1007/bf03261873	results	3	NA	direction_benefit	inferior
10.1007/bf03261873	results	3	NA	ss_ttt_nonipd	84
10.1007/bf03261873	results	3	NA	ss_ttt_ipd	82
10.1007/bf03261873	results	3	NA	ss_adjusted_ttt_ipd	38
10.1007/bf03261873	results	3	NA	weights_yn	Not mentioned
10.1007/bf03261873	results	3	NA	covariates_yn	Yes
10.1007/bf03261873	results	3	NA	covariates_n	6
10.1007/bf03261873	results	3	NA	covariates_names	Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Other(s)
10.1007/bf03261873	results	3	NA	contrast_effect_direction	Numerator if ratio, or left side if difference
10.1007/bf03261873	results	3	NA	contrast_effect_unadjusted_value	NA
10.1007/bf03261873	results	3	NA	contrast_effect_unadjusted_pvalci	NA
10.1007/bf03261873	results	3	NA	contrast_effect_adjusted_value	-7
10.1007/bf03261873	results	3	NA	contrast_effect_adjusted_pvalci	<0.01
10.1007/bf03261873	results	3	NA	adjustment_geographical	No
10.1007/bf03261873	results	3	NA	ss_total_ipd	NA
10.1007/bf03261873	results	3	NA	ss_adjusted_total_ipd	NA
10.1007/bf03261873	results	3	NA	ss_total_nonipd	NA
10.1007/bf03261873	results	3	NA	ss_anchor_nonipd	NA
10.1007/bf03261873	results	3	NA	ss_anchor_ipd	NA
10.1007/bf03261873	results	3	NA	ss_adjusted_anchor_ipd	NA
10.1007/bf03261873	results	3	NA	effect_cutoff	0
10.1007/bf03261873	results	3	NA	adjusted_pval	<0.01
10.1007/bf03261873	results	3	NA	adjusted_significant	TRUE
10.1007/bf03261873	study_information	NA	1	ipd_yn	Yes
10.1007/bf03261873	study_information	NA	1	ct_yn	Yes
10.1007/bf03261873	study_information	NA	1	nct	NCT00152009
10.1007/bf03261873	study_information	NA	1	ct_phase	3
10.1007/bf03261873	study_information	NA	1	ct_arms	2 or more
10.1007/bf03261873	study_information	NA	1	country_study	unknown
10.1007/bf03261873	study_information	NA	2	ipd_yn	Yes
10.1007/bf03261873	study_information	NA	2	ct_yn	Yes
10.1007/bf03261873	study_information	NA	2	nct	NCT00150618
10.1007/bf03261873	study_information	NA	2	ct_phase	3
10.1007/bf03261873	study_information	NA	2	ct_arms	2 or more
10.1007/bf03261873	study_information	NA	2	data_source_name	sallee et al. (2009)
10.1007/bf03261873	study_information	NA	2	country_study	usa
10.1007/bf03261873	study_information	NA	3	ipd_yn	No
10.1007/bf03261873	study_information	NA	3	ct_yn	Yes
10.1007/bf03261873	study_information	NA	3	data_source_name	michelson et al. (2001)
10.1007/bf03261873	study_information	NA	3	country_study	usa
10.1007/bf03261873	study_information	NA	3	ct_arms	2 or more
10.1007/s00432-021-03602-w	general_information	NA	NA	condition_name	unresectable hepatocellular carcinoma
10.1007/s00432-021-03602-w	general_information	NA	NA	country_first_author	italy
10.1007/s00432-021-03602-w	general_information	NA	NA	country_last_author	italy
10.1007/s00432-021-03602-w	general_information	NA	NA	positions	Academic
10.1007/s00432-021-03602-w	general_information	NA	NA	methodologist_yn	Yes
10.1007/s00432-021-03602-w	general_information	NA	NA	funding_source	No fundings
10.1007/s00432-021-03602-w	general_information	NA	NA	pharmaceutical_ties_yn	Yes
10.1007/s00432-021-03602-w	general_information	NA	NA	systematic_review_yn	No
10.1007/s00432-021-03602-w	methodology	1	NA	outcome_name	overall survival
10.1007/s00432-021-03602-w	methodology	1	NA	outcome_short_name	Overall Survival
10.1007/s00432-021-03602-w	methodology	1	NA	outcome_variable_type	Time-to-event
10.1007/s00432-021-03602-w	methodology	1	NA	treatment_name_ipd	regorafenib
10.1007/s00432-021-03602-w	methodology	1	NA	studies_number_ipd	1
10.1007/s00432-021-03602-w	methodology	1	NA	treatment_name_nonipd	cabozantinib
10.1007/s00432-021-03602-w	methodology	1	NA	studies_number_nonipd	2
10.1007/s00432-021-03602-w	methodology	1	NA	paic_type	MAIC
10.1007/s00432-021-03602-w	methodology	1	NA	anchored_yn	No
10.1007/s00432-021-03602-w	methodology	1	NA	paic_form	Simple (ie treatments effects extracted from two studies)
10.1007/s00432-021-03602-w	methodology	1	NA	primary_outcome_yn	Yes
10.1007/s00432-021-03602-w	methodology	1	NA	variables_selection_justification	Nothing mentioned, not reported
10.1007/s00432-021-03602-w	methodology	1	NA	pf_yn	No discussion (in the main text) of the status of prognostic factors of the variables
10.1007/s00432-021-03602-w	methodology	1	NA	tem_yn	No discussion (in the main text) of the status of treatment-effect modifiers of the variables
10.1007/s00432-021-03602-w	methodology	1	NA	adjustment_model_details_yn	No
10.1007/s00432-021-03602-w	methodology	1	NA	scale_choice_yn	No
10.1007/s00432-021-03602-w	results	1	NA	contrast_effect_type	HR
10.1007/s00432-021-03602-w	results	1	NA	direction_benefit	inferior
10.1007/s00432-021-03602-w	results	1	NA	ss_ttt_nonipd	331
10.1007/s00432-021-03602-w	results	1	NA	ss_ttt_ipd	278
10.1007/s00432-021-03602-w	results	1	NA	ss_adjusted_ttt_ipd	NA
10.1007/s00432-021-03602-w	results	1	NA	weights_yn	Not mentioned
10.1007/s00432-021-03602-w	results	1	NA	covariates_yn	No
10.1007/s00432-021-03602-w	results	1	NA	covariates_n	NA
10.1007/s00432-021-03602-w	results	1	NA	covariates_names	NA
10.1007/s00432-021-03602-w	results	1	NA	contrast_effect_direction	Denominator if ratio, or rightside if difference
10.1007/s00432-021-03602-w	results	1	NA	contrast_effect_unadjusted_value	0.8
10.1007/s00432-021-03602-w	results	1	NA	contrast_effect_unadjusted_pvalci	[0.66;0.97]
10.1007/s00432-021-03602-w	results	1	NA	contrast_effect_adjusted_value	0.83
10.1007/s00432-021-03602-w	results	1	NA	contrast_effect_adjusted_pvalci	[0.62;1.09]
10.1007/s00432-021-03602-w	results	1	NA	adjustment_geographical	NA
10.1007/s00432-021-03602-w	results	1	NA	ss_total_ipd	NA
10.1007/s00432-021-03602-w	results	1	NA	ss_adjusted_total_ipd	NA
10.1007/s00432-021-03602-w	results	1	NA	ss_total_nonipd	NA
10.1007/s00432-021-03602-w	results	1	NA	ss_anchor_nonipd	NA
10.1007/s00432-021-03602-w	results	1	NA	ss_anchor_ipd	NA
10.1007/s00432-021-03602-w	results	1	NA	ss_adjusted_anchor_ipd	NA
10.1007/s00432-021-03602-w	results	1	NA	effect_cutoff	1
10.1007/s00432-021-03602-w	results	1	NA	unadjusted_lb_ci	0.66
10.1007/s00432-021-03602-w	results	1	NA	unadjusted_ub_ci	0.97
10.1007/s00432-021-03602-w	results	1	NA	unadjusted_significant	TRUE
10.1007/s00432-021-03602-w	results	1	NA	adjusted_lb_ci	0.62
10.1007/s00432-021-03602-w	results	1	NA	adjusted_ub_ci	1.09
10.1007/s00432-021-03602-w	results	1	NA	adjusted_significant	FALSE
10.1007/s00432-021-03602-w	study_information	NA	1	ipd_yn	Yes
10.1007/s00432-021-03602-w	study_information	NA	1	ct_yn	No
10.1007/s00432-021-03602-w	study_information	NA	1	data_source_name	real-world data from unknown origin
10.1007/s00432-021-03602-w	study_information	NA	2	ipd_yn	No
10.1007/s00432-021-03602-w	study_information	NA	2	ct_yn	Yes
10.1007/s00432-021-03602-w	study_information	NA	2	nct	NCT01908426
10.1007/s00432-021-03602-w	study_information	NA	2	country_study	international
10.1007/s00432-021-03602-w	study_information	NA	2	ct_phase	3
10.1007/s00432-021-03602-w	study_information	NA	2	ct_arms	2 or more
10.1007/s11523-021-00803-8	general_information	NA	NA	condition_name	hepatocellular carcinoma
10.1007/s11523-021-00803-8	general_information	NA	NA	country_first_author	italy
10.1007/s11523-021-00803-8	general_information	NA	NA	country_last_author	italy
10.1007/s11523-021-00803-8	general_information	NA	NA	positions	Academic
10.1007/s11523-021-00803-8	general_information	NA	NA	methodologist_yn	Not mentioned
10.1007/s11523-021-00803-8	general_information	NA	NA	funding_source	No fundings
10.1007/s11523-021-00803-8	general_information	NA	NA	pharmaceutical_ties_yn	Yes
10.1007/s11523-021-00803-8	general_information	NA	NA	systematic_review_yn	No
10.1007/s11523-021-00803-8	methodology	1	NA	outcome_name	overall survival
10.1007/s11523-021-00803-8	methodology	1	NA	outcome_short_name	Overall Survival
10.1007/s11523-021-00803-8	methodology	1	NA	outcome_variable_type	Time-to-event
10.1007/s11523-021-00803-8	methodology	1	NA	treatment_name_ipd	lenvatinib
10.1007/s11523-021-00803-8	methodology	1	NA	studies_number_ipd	1
10.1007/s11523-021-00803-8	methodology	1	NA	treatment_name_nonipd	atezolizumab + bevacizumab
10.1007/s11523-021-00803-8	methodology	1	NA	studies_number_nonipd	2
10.1007/s11523-021-00803-8	methodology	1	NA	paic_type	MAIC
10.1007/s11523-021-00803-8	methodology	1	NA	anchored_yn	No
10.1007/s11523-021-00803-8	methodology	1	NA	paic_form	Simple (ie treatments effects extracted from two studies)
10.1007/s11523-021-00803-8	methodology	1	NA	primary_outcome_yn	Yes
10.1007/s11523-021-00803-8	methodology	1	NA	variables_selection_justification	Nothing mentioned, not reported
10.1007/s11523-021-00803-8	methodology	1	NA	pf_yn	No
10.1007/s11523-021-00803-8	methodology	1	NA	tem_yn	Yes
10.1007/s11523-021-00803-8	methodology	1	NA	adjustment_model_details_yn	No
10.1007/s11523-021-00803-8	methodology	1	NA	scale_choice_yn	No
10.1007/s11523-021-00803-8	results	1	NA	contrast_effect_type	HR
10.1007/s11523-021-00803-8	results	1	NA	direction_benefit	inferior
10.1007/s11523-021-00803-8	results	1	NA	ss_ttt_nonipd	336
10.1007/s11523-021-00803-8	results	1	NA	ss_ttt_ipd	455
10.1007/s11523-021-00803-8	results	1	NA	ss_adjusted_ttt_ipd	NA
10.1007/s11523-021-00803-8	results	1	NA	weights_yn	Not mentioned
10.1007/s11523-021-00803-8	results	1	NA	covariates_yn	Yes
10.1007/s11523-021-00803-8	results	1	NA	covariates_n	12
10.1007/s11523-021-00803-8	results	1	NA	covariates_names	Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Past treatments for the disease of interest, Comorbidities and medical history (beside pathology/disease of interest in the comparison)
10.1007/s11523-021-00803-8	results	1	NA	contrast_effect_direction	Denominator if ratio, or rightside if difference
10.1007/s11523-021-00803-8	results	1	NA	contrast_effect_unadjusted_value	NA
10.1007/s11523-021-00803-8	results	1	NA	contrast_effect_unadjusted_pvalci	NA
10.1007/s11523-021-00803-8	results	1	NA	contrast_effect_adjusted_value	0.59
10.1007/s11523-021-00803-8	results	1	NA	contrast_effect_adjusted_pvalci	[0.46;0.75]
10.1007/s11523-021-00803-8	results	1	NA	adjustment_geographical	NA
10.1007/s11523-021-00803-8	results	1	NA	ss_total_ipd	NA
10.1007/s11523-021-00803-8	results	1	NA	ss_adjusted_total_ipd	NA
10.1007/s11523-021-00803-8	results	1	NA	ss_total_nonipd	NA
10.1007/s11523-021-00803-8	results	1	NA	ss_anchor_nonipd	NA
10.1007/s11523-021-00803-8	results	1	NA	ss_anchor_ipd	NA
10.1007/s11523-021-00803-8	results	1	NA	ss_adjusted_anchor_ipd	NA
10.1007/s11523-021-00803-8	results	1	NA	effect_cutoff	1
10.1007/s11523-021-00803-8	results	1	NA	adjusted_lb_ci	0.46
10.1007/s11523-021-00803-8	results	1	NA	adjusted_ub_ci	0.75
10.1007/s11523-021-00803-8	results	1	NA	adjusted_significant	TRUE
10.1007/s11523-021-00803-8	study_information	NA	1	ipd_yn	Yes
10.1007/s11523-021-00803-8	study_information	NA	1	ct_yn	No
10.1007/s11523-021-00803-8	study_information	NA	1	data_source_name	real-world data from 12 japanese centers from march 2018 to may 2020
10.1007/s11523-021-00803-8	study_information	NA	1	country_study	japan
10.1007/s11523-021-00803-8	study_information	NA	2	ipd_yn	No
10.1007/s11523-021-00803-8	study_information	NA	2	ct_yn	Yes
10.1007/s11523-021-00803-8	study_information	NA	2	nct	NCT03434379
10.1007/s11523-021-00803-8	study_information	NA	2	country_study	international
10.1007/s11523-021-00803-8	study_information	NA	2	ct_phase	3
10.1007/s11523-021-00803-8	study_information	NA	2	ct_arms	2 or more
10.1007/s12325-014-0167-z	general_information	NA	NA	condition_name	relapsing-remitting multiple sclerosis
10.1007/s12325-014-0167-z	general_information	NA	NA	country_first_author	switzerland
10.1007/s12325-014-0167-z	general_information	NA	NA	country_last_author	uk
10.1007/s12325-014-0167-z	general_information	NA	NA	positions	Academic, Pharmaceutical Industry
10.1007/s12325-014-0167-z	general_information	NA	NA	methodologist_yn	Yes
10.1007/s12325-014-0167-z	general_information	NA	NA	funding_source	Pharmaceutical Industry
10.1007/s12325-014-0167-z	general_information	NA	NA	pharmaceutical_ties_yn	Yes
10.1007/s12325-014-0167-z	general_information	NA	NA	systematic_review_yn	No
10.1007/s12325-014-0167-z	methodology	1	NA	outcome_name	no evidence of disease activity (neda)
10.1007/s12325-014-0167-z	methodology	1	NA	outcome_short_name	No evidence of disease activity
10.1007/s12325-014-0167-z	methodology	1	NA	outcome_variable_type	Binary (eg rates)
10.1007/s12325-014-0167-z	methodology	1	NA	treatment_name_ipd	fingolimod
10.1007/s12325-014-0167-z	methodology	1	NA	studies_number_ipd	1;2
10.1007/s12325-014-0167-z	methodology	1	NA	treatment_name_nonipd	dimethyl fumarate
10.1007/s12325-014-0167-z	methodology	1	NA	studies_number_nonipd	3;4
10.1007/s12325-014-0167-z	methodology	1	NA	paic_type	STC
10.1007/s12325-014-0167-z	methodology	1	NA	anchored_yn	Yes
10.1007/s12325-014-0167-z	methodology	1	NA	paic_form	Aggregation of multiple studies to estimate individual treatment effects (e.g. meta-analysis in a first step to estimate treatment A effect, then population adjusted indirect comparison using treatment A effect estimate)
10.1007/s12325-014-0167-z	methodology	1	NA	primary_outcome_yn	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.1007/s12325-014-0167-z	methodology	1	NA	variables_selection_justification	Status of prognostic factor/treatment effect modified assessed in the IPD dataset, A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion), Literature based (clinically or methodologically relevant to adjust on these variables based on the literature search conducted for this specific purpose)
10.1007/s12325-014-0167-z	methodology	1	NA	pf_yn	No
10.1007/s12325-014-0167-z	methodology	1	NA	tem_yn	Yes
10.1007/s12325-014-0167-z	methodology	1	NA	adjustment_model_details_yn	Yes
10.1007/s12325-014-0167-z	methodology	1	NA	scale_choice_yn	No
10.1007/s12325-014-0167-z	methodology	2	NA	outcome_name	no evidence of disease activity (neda)
10.1007/s12325-014-0167-z	methodology	2	NA	outcome_short_name	No evidence of disease activity
10.1007/s12325-014-0167-z	methodology	2	NA	outcome_variable_type	Binary (eg rates)
10.1007/s12325-014-0167-z	methodology	2	NA	treatment_name_ipd	fingolimod
10.1007/s12325-014-0167-z	methodology	2	NA	studies_number_ipd	1;2
10.1007/s12325-014-0167-z	methodology	2	NA	treatment_name_nonipd	teriflunomide 7 mg
10.1007/s12325-014-0167-z	methodology	2	NA	studies_number_nonipd	5
10.1007/s12325-014-0167-z	methodology	2	NA	paic_type	STC
10.1007/s12325-014-0167-z	methodology	2	NA	anchored_yn	Yes
10.1007/s12325-014-0167-z	methodology	2	NA	paic_form	Aggregation of multiple studies to estimate individual treatment effects (e.g. meta-analysis in a first step to estimate treatment A effect, then population adjusted indirect comparison using treatment A effect estimate)
10.1007/s12325-014-0167-z	methodology	2	NA	primary_outcome_yn	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.1007/s12325-014-0167-z	methodology	2	NA	variables_selection_justification	Status of prognostic factor/treatment effect modified assessed in the IPD dataset, A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion), Literature based (clinically or methodologically relevant to adjust on these variables based on the literature search conducted for this specific purpose)
10.1007/s12325-014-0167-z	methodology	2	NA	pf_yn	No
10.1007/s12325-014-0167-z	methodology	2	NA	tem_yn	Yes
10.1007/s12325-014-0167-z	methodology	2	NA	adjustment_model_details_yn	Yes
10.1007/s12325-014-0167-z	methodology	2	NA	scale_choice_yn	No
10.1007/s12325-014-0167-z	methodology	3	NA	outcome_name	no evidence of disease activity (neda)
10.1007/s12325-014-0167-z	methodology	3	NA	outcome_short_name	No evidence of disease activity
10.1007/s12325-014-0167-z	methodology	3	NA	outcome_variable_type	Binary (eg rates)
10.1007/s12325-014-0167-z	methodology	3	NA	treatment_name_ipd	fingolimod
10.1007/s12325-014-0167-z	methodology	3	NA	studies_number_ipd	1;2
10.1007/s12325-014-0167-z	methodology	3	NA	treatment_name_nonipd	teriflunomide 14 mg
10.1007/s12325-014-0167-z	methodology	3	NA	studies_number_nonipd	5
10.1007/s12325-014-0167-z	methodology	3	NA	paic_type	STC
10.1007/s12325-014-0167-z	methodology	3	NA	anchored_yn	Yes
10.1007/s12325-014-0167-z	methodology	3	NA	paic_form	Aggregation of multiple studies to estimate individual treatment effects (e.g. meta-analysis in a first step to estimate treatment A effect, then population adjusted indirect comparison using treatment A effect estimate)
10.1007/s12325-014-0167-z	methodology	3	NA	primary_outcome_yn	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.1007/s12325-014-0167-z	methodology	3	NA	variables_selection_justification	Status of prognostic factor/treatment effect modified assessed in the IPD dataset, A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion), Literature based (clinically or methodologically relevant to adjust on these variables based on the literature search conducted for this specific purpose)
10.1007/s12325-014-0167-z	methodology	3	NA	pf_yn	No
10.1007/s12325-014-0167-z	methodology	3	NA	tem_yn	Yes
10.1007/s12325-014-0167-z	methodology	3	NA	adjustment_model_details_yn	Yes
10.1007/s12325-014-0167-z	methodology	3	NA	scale_choice_yn	No
10.1007/s12325-014-0167-z	results	1	NA	contrast_effect_type	RR
10.1007/s12325-014-0167-z	results	1	NA	direction_benefit	superior
10.1007/s12325-014-0167-z	results	1	NA	ss_ttt_nonipd	769
10.1007/s12325-014-0167-z	results	1	NA	ss_ttt_ipd	783
10.1007/s12325-014-0167-z	results	1	NA	ss_adjusted_ttt_ipd	783
10.1007/s12325-014-0167-z	results	1	NA	weights_yn	NA
10.1007/s12325-014-0167-z	results	1	NA	covariates_yn	Yes
10.1007/s12325-014-0167-z	results	1	NA	covariates_n	2
10.1007/s12325-014-0167-z	results	1	NA	covariates_names	Age, Past treatments for the disease of interest
10.1007/s12325-014-0167-z	results	1	NA	contrast_effect_direction	Numerator if ratio, or left side if difference
10.1007/s12325-014-0167-z	results	1	NA	contrast_effect_unadjusted_value	1.58
10.1007/s12325-014-0167-z	results	1	NA	contrast_effect_unadjusted_pvalci	[1.00;2.50]
10.1007/s12325-014-0167-z	results	1	NA	contrast_effect_adjusted_value	1.67
10.1007/s12325-014-0167-z	results	1	NA	contrast_effect_adjusted_pvalci	[1.08;2.57]
10.1007/s12325-014-0167-z	results	1	NA	adjustment_geographical	NA
10.1007/s12325-014-0167-z	results	1	NA	ss_total_ipd	NA
10.1007/s12325-014-0167-z	results	1	NA	ss_adjusted_total_ipd	NA
10.1007/s12325-014-0167-z	results	1	NA	ss_total_nonipd	NA
10.1007/s12325-014-0167-z	results	1	NA	ss_anchor_nonipd	771
10.1007/s12325-014-0167-z	results	1	NA	ss_anchor_ipd	773
10.1007/s12325-014-0167-z	results	1	NA	ss_adjusted_anchor_ipd	773
10.1007/s12325-014-0167-z	results	1	NA	effect_cutoff	1
10.1007/s12325-014-0167-z	results	1	NA	unadjusted_lb_ci	1
10.1007/s12325-014-0167-z	results	1	NA	unadjusted_ub_ci	2.5
10.1007/s12325-014-0167-z	results	1	NA	unadjusted_significant	FALSE
10.1007/s12325-014-0167-z	results	1	NA	adjusted_lb_ci	1.08
10.1007/s12325-014-0167-z	results	1	NA	adjusted_ub_ci	2.57
10.1007/s12325-014-0167-z	results	1	NA	adjusted_significant	TRUE
10.1007/s12325-014-0167-z	results	2	NA	contrast_effect_type	RR
10.1007/s12325-014-0167-z	results	2	NA	direction_benefit	superior
10.1007/s12325-014-0167-z	results	2	NA	ss_ttt_nonipd	365
10.1007/s12325-014-0167-z	results	2	NA	ss_ttt_ipd	783
10.1007/s12325-014-0167-z	results	2	NA	ss_adjusted_ttt_ipd	783
10.1007/s12325-014-0167-z	results	2	NA	weights_yn	NA
10.1007/s12325-014-0167-z	results	2	NA	covariates_yn	Yes
10.1007/s12325-014-0167-z	results	2	NA	covariates_n	1
10.1007/s12325-014-0167-z	results	2	NA	covariates_names	Age
10.1007/s12325-014-0167-z	results	2	NA	contrast_effect_direction	Numerator if ratio, or left side if difference
10.1007/s12325-014-0167-z	results	2	NA	contrast_effect_unadjusted_value	2.18
10.1007/s12325-014-0167-z	results	2	NA	contrast_effect_unadjusted_pvalci	[1.46;3.25]
10.1007/s12325-014-0167-z	results	2	NA	contrast_effect_adjusted_value	2.01
10.1007/s12325-014-0167-z	results	2	NA	contrast_effect_adjusted_pvalci	[1.38;2.93]
10.1007/s12325-014-0167-z	results	2	NA	adjustment_geographical	NA
10.1007/s12325-014-0167-z	results	2	NA	ss_total_ipd	NA
10.1007/s12325-014-0167-z	results	2	NA	ss_adjusted_total_ipd	NA
10.1007/s12325-014-0167-z	results	2	NA	ss_total_nonipd	NA
10.1007/s12325-014-0167-z	results	2	NA	ss_anchor_nonipd	363
10.1007/s12325-014-0167-z	results	2	NA	ss_anchor_ipd	773
10.1007/s12325-014-0167-z	results	2	NA	ss_adjusted_anchor_ipd	773
10.1007/s12325-014-0167-z	results	2	NA	effect_cutoff	1
10.1007/s12325-014-0167-z	results	2	NA	unadjusted_lb_ci	1.46
10.1007/s12325-014-0167-z	results	2	NA	unadjusted_ub_ci	3.25
10.1007/s12325-014-0167-z	results	2	NA	unadjusted_significant	TRUE
10.1007/s12325-014-0167-z	results	2	NA	adjusted_lb_ci	1.38
10.1007/s12325-014-0167-z	results	2	NA	adjusted_ub_ci	2.93
10.1007/s12325-014-0167-z	results	2	NA	adjusted_significant	TRUE
10.1007/s12325-014-0167-z	results	3	NA	contrast_effect_type	RR
10.1007/s12325-014-0167-z	results	3	NA	direction_benefit	superior
10.1007/s12325-014-0167-z	results	3	NA	ss_ttt_nonipd	358
10.1007/s12325-014-0167-z	results	3	NA	ss_ttt_ipd	783
10.1007/s12325-014-0167-z	results	3	NA	ss_adjusted_ttt_ipd	783
10.1007/s12325-014-0167-z	results	3	NA	weights_yn	NA
10.1007/s12325-014-0167-z	results	3	NA	covariates_yn	Yes
10.1007/s12325-014-0167-z	results	3	NA	covariates_n	1
10.1007/s12325-014-0167-z	results	3	NA	covariates_names	Age
10.1007/s12325-014-0167-z	results	3	NA	contrast_effect_direction	Numerator if ratio, or left side if difference
10.1007/s12325-014-0167-z	results	3	NA	contrast_effect_unadjusted_value	1.75
10.1007/s12325-014-0167-z	results	3	NA	contrast_effect_unadjusted_pvalci	[1.18;2.57]
10.1007/s12325-014-0167-z	results	3	NA	contrast_effect_adjusted_value	1.61
10.1007/s12325-014-0167-z	results	3	NA	contrast_effect_adjusted_pvalci	[1.12;2.31]
10.1007/s12325-014-0167-z	results	3	NA	adjustment_geographical	NA
10.1007/s12325-014-0167-z	results	3	NA	ss_total_ipd	NA
10.1007/s12325-014-0167-z	results	3	NA	ss_adjusted_total_ipd	NA
10.1007/s12325-014-0167-z	results	3	NA	ss_total_nonipd	NA
10.1007/s12325-014-0167-z	results	3	NA	ss_anchor_nonipd	363
10.1007/s12325-014-0167-z	results	3	NA	ss_anchor_ipd	773
10.1007/s12325-014-0167-z	results	3	NA	ss_adjusted_anchor_ipd	773
10.1007/s12325-014-0167-z	results	3	NA	effect_cutoff	1
10.1007/s12325-014-0167-z	results	3	NA	unadjusted_lb_ci	1.18
10.1007/s12325-014-0167-z	results	3	NA	unadjusted_ub_ci	2.57
10.1007/s12325-014-0167-z	results	3	NA	unadjusted_significant	TRUE
10.1007/s12325-014-0167-z	results	3	NA	adjusted_lb_ci	1.12
10.1007/s12325-014-0167-z	results	3	NA	adjusted_ub_ci	2.31
10.1007/s12325-014-0167-z	results	3	NA	adjusted_significant	TRUE
10.1007/s12325-014-0167-z	study_information	NA	1	ipd_yn	Yes
10.1007/s12325-014-0167-z	study_information	NA	1	ct_yn	Yes
10.1007/s12325-014-0167-z	study_information	NA	1	nct	NCT00289978
10.1007/s12325-014-0167-z	study_information	NA	1	country_study	international
10.1007/s12325-014-0167-z	study_information	NA	1	ct_phase	3
10.1007/s12325-014-0167-z	study_information	NA	1	ct_arms	2 or more
10.1007/s12325-014-0167-z	study_information	NA	2	ipd_yn	Yes
10.1007/s12325-014-0167-z	study_information	NA	2	ct_yn	Yes
10.1007/s12325-014-0167-z	study_information	NA	2	nct	NCT00355134
10.1007/s12325-014-0167-z	study_information	NA	2	country_study	international
10.1007/s12325-014-0167-z	study_information	NA	2	ct_phase	3
10.1007/s12325-014-0167-z	study_information	NA	2	ct_arms	2 or more
10.1007/s12325-014-0167-z	study_information	NA	3	ipd_yn	No
10.1007/s12325-014-0167-z	study_information	NA	3	ct_yn	Yes
10.1007/s12325-014-0167-z	study_information	NA	3	nct	NCT00420212
10.1007/s12325-014-0167-z	study_information	NA	3	country_study	international
10.1007/s12325-014-0167-z	study_information	NA	3	ct_phase	3
10.1007/s12325-014-0167-z	study_information	NA	3	ct_arms	2 or more
10.1007/s12325-014-0167-z	study_information	NA	4	ipd_yn	No
10.1007/s12325-014-0167-z	study_information	NA	4	ct_yn	Yes
10.1007/s12325-014-0167-z	study_information	NA	4	nct	NCT00451451
10.1007/s12325-014-0167-z	study_information	NA	4	country_study	international
10.1007/s12325-014-0167-z	study_information	NA	4	ct_phase	3
10.1007/s12325-014-0167-z	study_information	NA	4	ct_arms	2 or more
10.1007/s12325-014-0167-z	study_information	NA	5	ipd_yn	No
10.1007/s12325-014-0167-z	study_information	NA	5	ct_yn	Yes
10.1007/s12325-014-0167-z	study_information	NA	5	nct	NCT00134563
10.1007/s12325-014-0167-z	study_information	NA	5	country_study	international
10.1007/s12325-014-0167-z	study_information	NA	5	ct_phase	3
10.1007/s12325-014-0167-z	study_information	NA	5	ct_arms	2 or more
10.1007/s12325-017-0564-1	general_information	NA	NA	condition_name	chronic lymphocytic leukemia
10.1007/s12325-017-0564-1	general_information	NA	NA	country_first_author	belgium
10.1007/s12325-017-0564-1	general_information	NA	NA	country_last_author	uk
10.1007/s12325-017-0564-1	general_information	NA	NA	positions	Pharmaceutical Industry
10.1007/s12325-017-0564-1	general_information	NA	NA	methodologist_yn	Not mentioned
10.1007/s12325-017-0564-1	general_information	NA	NA	funding_source	Pharmaceutical Industry
10.1007/s12325-017-0564-1	general_information	NA	NA	pharmaceutical_ties_yn	Yes
10.1007/s12325-017-0564-1	general_information	NA	NA	systematic_review_yn	No
10.1007/s12325-017-0564-1	methodology	1	NA	outcome_name	progression-free survival
10.1007/s12325-017-0564-1	methodology	1	NA	outcome_short_name	Progression-free Survival
10.1007/s12325-017-0564-1	methodology	1	NA	outcome_variable_type	Time-to-event
10.1007/s12325-017-0564-1	methodology	1	NA	treatment_name_ipd	ibrutinib
10.1007/s12325-017-0564-1	methodology	1	NA	studies_number_ipd	1
10.1007/s12325-017-0564-1	methodology	1	NA	treatment_name_nonipd	obinutuzumab + chlorambucil
10.1007/s12325-017-0564-1	methodology	1	NA	studies_number_nonipd	2
10.1007/s12325-017-0564-1	methodology	1	NA	paic_type	MAIC
10.1007/s12325-017-0564-1	methodology	1	NA	anchored_yn	Yes
10.1007/s12325-017-0564-1	methodology	1	NA	paic_form	Simple (ie treatments effects extracted from two studies)
10.1007/s12325-017-0564-1	methodology	1	NA	primary_outcome_yn	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.1007/s12325-017-0564-1	methodology	1	NA	variables_selection_justification	Literature based (clinically or methodologically relevant to adjust on these variables based on the literature search conducted for this specific purpose)
10.1007/s12325-017-0564-1	methodology	1	NA	pf_yn	Yes
10.1007/s12325-017-0564-1	methodology	1	NA	tem_yn	Yes
10.1007/s12325-017-0564-1	methodology	1	NA	adjustment_model_details_yn	No
10.1007/s12325-017-0564-1	methodology	1	NA	scale_choice_yn	No
10.1007/s12325-017-0564-1	results	1	NA	contrast_effect_type	HR
10.1007/s12325-017-0564-1	results	1	NA	direction_benefit	inferior
10.1007/s12325-017-0564-1	results	1	NA	ss_ttt_nonipd	589
10.1007/s12325-017-0564-1	results	1	NA	ss_ttt_ipd	115
10.1007/s12325-017-0564-1	results	1	NA	ss_adjusted_ttt_ipd	35
10.1007/s12325-017-0564-1	results	1	NA	weights_yn	Not mentioned
10.1007/s12325-017-0564-1	results	1	NA	covariates_yn	Yes
10.1007/s12325-017-0564-1	results	1	NA	covariates_n	9
10.1007/s12325-017-0564-1	results	1	NA	covariates_names	Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Comorbidities and medical history (beside pathology/disease of interest in the comparison)
10.1007/s12325-017-0564-1	results	1	NA	contrast_effect_direction	Numerator if ratio, or left side if difference
10.1007/s12325-017-0564-1	results	1	NA	contrast_effect_unadjusted_value	0.5
10.1007/s12325-017-0564-1	results	1	NA	contrast_effect_unadjusted_pvalci	[0.22;1.15]
10.1007/s12325-017-0564-1	results	1	NA	contrast_effect_adjusted_value	0.24
10.1007/s12325-017-0564-1	results	1	NA	contrast_effect_adjusted_pvalci	[0.04;1.35]
10.1007/s12325-017-0564-1	results	1	NA	adjustment_geographical	NA
10.1007/s12325-017-0564-1	results	1	NA	ss_total_ipd	115
10.1007/s12325-017-0564-1	results	1	NA	ss_adjusted_total_ipd	35
10.1007/s12325-017-0564-1	results	1	NA	ss_total_nonipd	589
10.1007/s12325-017-0564-1	results	1	NA	ss_anchor_nonipd	NA
10.1007/s12325-017-0564-1	results	1	NA	ss_anchor_ipd	NA
10.1007/s12325-017-0564-1	results	1	NA	ss_adjusted_anchor_ipd	NA
10.1007/s12325-017-0564-1	results	1	NA	effect_cutoff	1
10.1007/s12325-017-0564-1	results	1	NA	unadjusted_lb_ci	0.22
10.1007/s12325-017-0564-1	results	1	NA	unadjusted_ub_ci	1.15
10.1007/s12325-017-0564-1	results	1	NA	unadjusted_significant	FALSE
10.1007/s12325-017-0564-1	results	1	NA	adjusted_lb_ci	0.04
10.1007/s12325-017-0564-1	results	1	NA	adjusted_ub_ci	1.35
10.1007/s12325-017-0564-1	results	1	NA	adjusted_significant	FALSE
10.1007/s12325-017-0564-1	study_information	NA	1	ipd_yn	Yes
10.1007/s12325-017-0564-1	study_information	NA	1	ct_yn	Yes
10.1007/s12325-017-0564-1	study_information	NA	1	nct	NCT01722487
10.1007/s12325-017-0564-1	study_information	NA	1	country_study	international
10.1007/s12325-017-0564-1	study_information	NA	1	ct_phase	3
10.1007/s12325-017-0564-1	study_information	NA	1	ct_arms	2 or more
10.1007/s12325-017-0564-1	study_information	NA	2	ipd_yn	No
10.1007/s12325-017-0564-1	study_information	NA	2	ct_yn	Yes
10.1007/s12325-017-0564-1	study_information	NA	2	nct	NCT01010061
10.1007/s12325-017-0564-1	study_information	NA	2	country_study	international
10.1007/s12325-017-0564-1	study_information	NA	2	ct_phase	3
10.1007/s12325-017-0564-1	study_information	NA	2	ct_arms	2 or more
10.1007/s12325-018-0734-9	general_information	NA	NA	condition_name	advanced or metastatic non-small-cell lung cancer
10.1007/s12325-018-0734-9	general_information	NA	NA	country_first_author	usa
10.1007/s12325-018-0734-9	general_information	NA	NA	country_last_author	usa
10.1007/s12325-018-0734-9	general_information	NA	NA	positions	Pharmaceutical Industry, Private Data Analysis Company
10.1007/s12325-018-0734-9	general_information	NA	NA	methodologist_yn	Yes
10.1007/s12325-018-0734-9	general_information	NA	NA	funding_source	Pharmaceutical Industry
10.1007/s12325-018-0734-9	general_information	NA	NA	pharmaceutical_ties_yn	Yes
10.1007/s12325-018-0734-9	general_information	NA	NA	systematic_review_yn	Yes
10.1007/s12325-018-0734-9	methodology	1	NA	outcome_name	overall response rate
10.1007/s12325-018-0734-9	methodology	1	NA	outcome_short_name	Overall Response Rate
10.1007/s12325-018-0734-9	methodology	1	NA	outcome_variable_type	Binary (eg rates)
10.1007/s12325-018-0734-9	methodology	1	NA	treatment_name_ipd	dabrafenib + trametinib
10.1007/s12325-018-0734-9	methodology	1	NA	studies_number_ipd	1
10.1007/s12325-018-0734-9	methodology	1	NA	treatment_name_nonipd	nivolumab
10.1007/s12325-018-0734-9	methodology	1	NA	studies_number_nonipd	2
10.1007/s12325-018-0734-9	methodology	1	NA	paic_type	MAIC
10.1007/s12325-018-0734-9	methodology	1	NA	anchored_yn	No
10.1007/s12325-018-0734-9	methodology	1	NA	paic_form	Simple (ie treatments effects extracted from two studies)
10.1007/s12325-018-0734-9	methodology	1	NA	primary_outcome_yn	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.1007/s12325-018-0734-9	methodology	1	NA	variables_selection_justification	A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion), Literature based (clinically or methodologically relevant to adjust on these variables based on the literature search conducted for this specific purpose)
10.1007/s12325-018-0734-9	methodology	1	NA	pf_yn	Yes
10.1007/s12325-018-0734-9	methodology	1	NA	tem_yn	No discussion (in the main text) of the status of treatment-effect modifiers of the variables
10.1007/s12325-018-0734-9	methodology	1	NA	adjustment_model_details_yn	No
10.1007/s12325-018-0734-9	methodology	1	NA	scale_choice_yn	No
10.1007/s12325-018-0734-9	results	1	NA	contrast_effect_type	NA
10.1007/s12325-018-0734-9	results	1	NA	direction_benefit	superior
10.1007/s12325-018-0734-9	results	1	NA	ss_ttt_nonipd	290
10.1007/s12325-018-0734-9	results	1	NA	ss_ttt_ipd	57
10.1007/s12325-018-0734-9	results	1	NA	ss_adjusted_ttt_ipd	34
10.1007/s12325-018-0734-9	results	1	NA	weights_yn	Not mentioned
10.1007/s12325-018-0734-9	results	1	NA	covariates_yn	Yes
10.1007/s12325-018-0734-9	results	1	NA	covariates_n	10
10.1007/s12325-018-0734-9	results	1	NA	covariates_names	Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Race/ethnicity, Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Past treatments for the disease of interest, Other(s)
10.1007/s12325-018-0734-9	results	1	NA	contrast_effect_direction	NA
10.1007/s12325-018-0734-9	results	1	NA	contrast_effect_unadjusted_value	NA
10.1007/s12325-018-0734-9	results	1	NA	contrast_effect_unadjusted_pvalci	NA
10.1007/s12325-018-0734-9	results	1	NA	contrast_effect_adjusted_value	NA
10.1007/s12325-018-0734-9	results	1	NA	contrast_effect_adjusted_pvalci	NA
10.1007/s12325-018-0734-9	results	1	NA	adjustment_geographical	No
10.1007/s12325-018-0734-9	results	1	NA	ss_total_ipd	57
10.1007/s12325-018-0734-9	results	1	NA	ss_adjusted_total_ipd	34
10.1007/s12325-018-0734-9	results	1	NA	ss_total_nonipd	290
10.1007/s12325-018-0734-9	results	1	NA	ss_anchor_nonipd	NA
10.1007/s12325-018-0734-9	results	1	NA	ss_anchor_ipd	NA
10.1007/s12325-018-0734-9	results	1	NA	ss_adjusted_anchor_ipd	NA
10.1007/s12325-018-0734-9	results	1	NA	effect_cutoff	NA
10.1007/s12325-018-0734-9	study_information	NA	1	ipd_yn	Yes
10.1007/s12325-018-0734-9	study_information	NA	1	ct_yn	Yes
10.1007/s12325-018-0734-9	study_information	NA	1	nct	NCT01336634
10.1007/s12325-018-0734-9	study_information	NA	1	country_study	international
10.1007/s12325-018-0734-9	study_information	NA	1	ct_phase	2
10.1007/s12325-018-0734-9	study_information	NA	1	ct_arms	2 or more
10.1007/s12325-018-0734-9	study_information	NA	2	ipd_yn	No
10.1007/s12325-018-0734-9	study_information	NA	2	ct_yn	Yes
10.1007/s12325-018-0734-9	study_information	NA	2	nct	NCT01673867
10.1007/s12325-018-0734-9	study_information	NA	2	country_study	international
10.1007/s12325-018-0734-9	study_information	NA	2	ct_phase	3
10.1007/s12325-018-0734-9	study_information	NA	2	ct_arms	2 or more
10.1007/s12325-019-00991-w	general_information	NA	NA	condition_name	relapsed or refractory acute lymphoblastic leukemia
10.1007/s12325-019-00991-w	general_information	NA	NA	country_first_author	canada
10.1007/s12325-019-00991-w	general_information	NA	NA	country_last_author	germany
10.1007/s12325-019-00991-w	general_information	NA	NA	positions	Academic, Pharmaceutical Industry, Private Data Analysis Company
10.1007/s12325-019-00991-w	general_information	NA	NA	methodologist_yn	Yes
10.1007/s12325-019-00991-w	general_information	NA	NA	funding_source	Pharmaceutical Industry
10.1007/s12325-019-00991-w	general_information	NA	NA	pharmaceutical_ties_yn	Yes
10.1007/s12325-019-00991-w	general_information	NA	NA	systematic_review_yn	No
10.1007/s12325-019-00991-w	methodology	1	NA	outcome_name	complete response rate
10.1007/s12325-019-00991-w	methodology	1	NA	outcome_short_name	Complete Response Rate
10.1007/s12325-019-00991-w	methodology	1	NA	outcome_variable_type	Binary (eg rates)
10.1007/s12325-019-00991-w	methodology	1	NA	treatment_name_ipd	inotuzumab ozogamicin
10.1007/s12325-019-00991-w	methodology	1	NA	studies_number_ipd	1
10.1007/s12325-019-00991-w	methodology	1	NA	treatment_name_nonipd	blinatumomab
10.1007/s12325-019-00991-w	methodology	1	NA	studies_number_nonipd	2
10.1007/s12325-019-00991-w	methodology	1	NA	paic_type	MAIC
10.1007/s12325-019-00991-w	methodology	1	NA	anchored_yn	Yes
10.1007/s12325-019-00991-w	methodology	1	NA	paic_form	Simple (ie treatments effects extracted from two studies)
10.1007/s12325-019-00991-w	methodology	1	NA	primary_outcome_yn	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.1007/s12325-019-00991-w	methodology	1	NA	variables_selection_justification	Status of prognostic factor/treatment effect modified assessed in the IPD dataset, A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion), Literature based (clinically or methodologically relevant to adjust on these variables based on the literature search conducted for this specific purpose)
10.1007/s12325-019-00991-w	methodology	1	NA	pf_yn	No
10.1007/s12325-019-00991-w	methodology	1	NA	tem_yn	Yes
10.1007/s12325-019-00991-w	methodology	1	NA	adjustment_model_details_yn	No
10.1007/s12325-019-00991-w	methodology	1	NA	scale_choice_yn	No
10.1007/s12325-019-00991-w	methodology	2	NA	outcome_name	complete remission rate
10.1007/s12325-019-00991-w	methodology	2	NA	outcome_short_name	Complete Remission Rate
10.1007/s12325-019-00991-w	methodology	2	NA	outcome_variable_type	Binary (eg rates)
10.1007/s12325-019-00991-w	methodology	2	NA	treatment_name_ipd	inotuzumab ozogamicin
10.1007/s12325-019-00991-w	methodology	2	NA	studies_number_ipd	1
10.1007/s12325-019-00991-w	methodology	2	NA	treatment_name_nonipd	blinatumomab
10.1007/s12325-019-00991-w	methodology	2	NA	studies_number_nonipd	2
10.1007/s12325-019-00991-w	methodology	2	NA	paic_type	STC
10.1007/s12325-019-00991-w	methodology	2	NA	anchored_yn	Yes
10.1007/s12325-019-00991-w	methodology	2	NA	paic_form	Simple (ie treatments effects extracted from two studies)
10.1007/s12325-019-00991-w	methodology	2	NA	primary_outcome_yn	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.1007/s12325-019-00991-w	methodology	2	NA	variables_selection_justification	Status of prognostic factor/treatment effect modified assessed in the IPD dataset, A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion), Literature based (clinically or methodologically relevant to adjust on these variables based on the literature search conducted for this specific purpose)
10.1007/s12325-019-00991-w	methodology	2	NA	pf_yn	No
10.1007/s12325-019-00991-w	methodology	2	NA	tem_yn	Yes
10.1007/s12325-019-00991-w	methodology	2	NA	adjustment_model_details_yn	No
10.1007/s12325-019-00991-w	methodology	2	NA	scale_choice_yn	No
10.1007/s12325-019-00991-w	results	1	NA	contrast_effect_type	OR
10.1007/s12325-019-00991-w	results	1	NA	direction_benefit	superior
10.1007/s12325-019-00991-w	results	1	NA	ss_ttt_nonipd	271
10.1007/s12325-019-00991-w	results	1	NA	ss_ttt_ipd	164
10.1007/s12325-019-00991-w	results	1	NA	ss_adjusted_ttt_ipd	70
10.1007/s12325-019-00991-w	results	1	NA	weights_yn	Not mentioned
10.1007/s12325-019-00991-w	results	1	NA	covariates_yn	Yes
10.1007/s12325-019-00991-w	results	1	NA	covariates_n	6
10.1007/s12325-019-00991-w	results	1	NA	covariates_names	Age, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Past treatments for the disease of interest, Other(s)
10.1007/s12325-019-00991-w	results	1	NA	contrast_effect_direction	Numerator if ratio, or left side if difference
10.1007/s12325-019-00991-w	results	1	NA	contrast_effect_unadjusted_value	2.63
10.1007/s12325-019-00991-w	results	1	NA	contrast_effect_unadjusted_pvalci	[1.35;5.12]
10.1007/s12325-019-00991-w	results	1	NA	contrast_effect_adjusted_value	2.81
10.1007/s12325-019-00991-w	results	1	NA	contrast_effect_adjusted_pvalci	[1.12;7.05]
10.1007/s12325-019-00991-w	results	1	NA	adjustment_geographical	No
10.1007/s12325-019-00991-w	results	1	NA	ss_total_ipd	NA
10.1007/s12325-019-00991-w	results	1	NA	ss_adjusted_total_ipd	NA
10.1007/s12325-019-00991-w	results	1	NA	ss_total_nonipd	NA
10.1007/s12325-019-00991-w	results	1	NA	ss_anchor_nonipd	134
10.1007/s12325-019-00991-w	results	1	NA	ss_anchor_ipd	162
10.1007/s12325-019-00991-w	results	1	NA	ss_adjusted_anchor_ipd	53
10.1007/s12325-019-00991-w	results	1	NA	effect_cutoff	1
10.1007/s12325-019-00991-w	results	1	NA	unadjusted_lb_ci	1.35
10.1007/s12325-019-00991-w	results	1	NA	unadjusted_ub_ci	5.12
10.1007/s12325-019-00991-w	results	1	NA	unadjusted_significant	TRUE
10.1007/s12325-019-00991-w	results	1	NA	adjusted_lb_ci	1.12
10.1007/s12325-019-00991-w	results	1	NA	adjusted_ub_ci	7.05
10.1007/s12325-019-00991-w	results	1	NA	adjusted_significant	TRUE
10.1007/s12325-019-00991-w	results	2	NA	contrast_effect_type	OR
10.1007/s12325-019-00991-w	results	2	NA	direction_benefit	superior
10.1007/s12325-019-00991-w	results	2	NA	ss_ttt_nonipd	271
10.1007/s12325-019-00991-w	results	2	NA	ss_ttt_ipd	164
10.1007/s12325-019-00991-w	results	2	NA	ss_adjusted_ttt_ipd	138
10.1007/s12325-019-00991-w	results	2	NA	weights_yn	NA
10.1007/s12325-019-00991-w	results	2	NA	covariates_yn	Yes
10.1007/s12325-019-00991-w	results	2	NA	covariates_n	6
10.1007/s12325-019-00991-w	results	2	NA	covariates_names	Age, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Past treatments for the disease of interest, Other(s)
10.1007/s12325-019-00991-w	results	2	NA	contrast_effect_direction	Numerator if ratio, or left side if difference
10.1007/s12325-019-00991-w	results	2	NA	contrast_effect_unadjusted_value	2.63
10.1007/s12325-019-00991-w	results	2	NA	contrast_effect_unadjusted_pvalci	[1.35;5.12]
10.1007/s12325-019-00991-w	results	2	NA	contrast_effect_adjusted_value	3.91
10.1007/s12325-019-00991-w	results	2	NA	contrast_effect_adjusted_pvalci	[1.53;9.99]
10.1007/s12325-019-00991-w	results	2	NA	adjustment_geographical	No
10.1007/s12325-019-00991-w	results	2	NA	ss_total_ipd	NA
10.1007/s12325-019-00991-w	results	2	NA	ss_adjusted_total_ipd	NA
10.1007/s12325-019-00991-w	results	2	NA	ss_total_nonipd	NA
10.1007/s12325-019-00991-w	results	2	NA	ss_anchor_nonipd	134
10.1007/s12325-019-00991-w	results	2	NA	ss_anchor_ipd	162
10.1007/s12325-019-00991-w	results	2	NA	ss_adjusted_anchor_ipd	133
10.1007/s12325-019-00991-w	results	2	NA	effect_cutoff	1
10.1007/s12325-019-00991-w	results	2	NA	unadjusted_lb_ci	1.35
10.1007/s12325-019-00991-w	results	2	NA	unadjusted_ub_ci	5.12
10.1007/s12325-019-00991-w	results	2	NA	unadjusted_significant	TRUE
10.1007/s12325-019-00991-w	results	2	NA	adjusted_lb_ci	1.53
10.1007/s12325-019-00991-w	results	2	NA	adjusted_ub_ci	9.99
10.1007/s12325-019-00991-w	results	2	NA	adjusted_significant	TRUE
10.1007/s12325-019-00991-w	study_information	NA	1	ipd_yn	Yes
10.1007/s12325-019-00991-w	study_information	NA	1	ct_yn	Yes
10.1007/s12325-019-00991-w	study_information	NA	1	nct	NCT01564784
10.1007/s12325-019-00991-w	study_information	NA	1	country_study	international
10.1007/s12325-019-00991-w	study_information	NA	1	ct_phase	3
10.1007/s12325-019-00991-w	study_information	NA	1	ct_arms	2 or more
10.1007/s12325-019-00991-w	study_information	NA	2	ipd_yn	No
10.1007/s12325-019-00991-w	study_information	NA	2	ct_yn	Yes
10.1007/s12325-019-00991-w	study_information	NA	2	nct	NCT02013167
10.1007/s12325-019-00991-w	study_information	NA	2	country_study	international
10.1007/s12325-019-00991-w	study_information	NA	2	ct_phase	3
10.1007/s12325-019-00991-w	study_information	NA	2	ct_arms	2 or more
10.1007/s12325-019-01156-5	general_information	NA	NA	condition_name	non-metastatic castration-resistant prostate cancer
10.1007/s12325-019-01156-5	general_information	NA	NA	country_first_author	uk
10.1007/s12325-019-01156-5	general_information	NA	NA	country_last_author	germany
10.1007/s12325-019-01156-5	general_information	NA	NA	positions	Academic, Pharmaceutical Industry, Private Data Analysis Company
10.1007/s12325-019-01156-5	general_information	NA	NA	methodologist_yn	Yes
10.1007/s12325-019-01156-5	general_information	NA	NA	funding_source	Pharmaceutical Industry
10.1007/s12325-019-01156-5	general_information	NA	NA	pharmaceutical_ties_yn	Yes
10.1007/s12325-019-01156-5	general_information	NA	NA	systematic_review_yn	No
10.1007/s12325-019-01156-5	methodology	1	NA	outcome_name	metastasis-free survival
10.1007/s12325-019-01156-5	methodology	1	NA	outcome_short_name	Metastasis-free Survival
10.1007/s12325-019-01156-5	methodology	1	NA	outcome_variable_type	Time-to-event
10.1007/s12325-019-01156-5	methodology	1	NA	treatment_name_ipd	apalutamide
10.1007/s12325-019-01156-5	methodology	1	NA	studies_number_ipd	1
10.1007/s12325-019-01156-5	methodology	1	NA	treatment_name_nonipd	enzalutamide
10.1007/s12325-019-01156-5	methodology	1	NA	studies_number_nonipd	2
10.1007/s12325-019-01156-5	methodology	1	NA	paic_type	MAIC
10.1007/s12325-019-01156-5	methodology	1	NA	anchored_yn	Yes
10.1007/s12325-019-01156-5	methodology	1	NA	paic_form	Simple (ie treatments effects extracted from two studies)
10.1007/s12325-019-01156-5	methodology	1	NA	primary_outcome_yn	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.1007/s12325-019-01156-5	methodology	1	NA	variables_selection_justification	A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion)
10.1007/s12325-019-01156-5	methodology	1	NA	pf_yn	No
10.1007/s12325-019-01156-5	methodology	1	NA	tem_yn	Yes
10.1007/s12325-019-01156-5	methodology	1	NA	adjustment_model_details_yn	No
10.1007/s12325-019-01156-5	methodology	1	NA	scale_choice_yn	No
10.1007/s12325-019-01156-5	results	1	NA	contrast_effect_type	HR
10.1007/s12325-019-01156-5	results	1	NA	direction_benefit	inferior
10.1007/s12325-019-01156-5	results	1	NA	ss_ttt_nonipd	933
10.1007/s12325-019-01156-5	results	1	NA	ss_ttt_ipd	806
10.1007/s12325-019-01156-5	results	1	NA	ss_adjusted_ttt_ipd	NA
10.1007/s12325-019-01156-5	results	1	NA	weights_yn	Not mentioned
10.1007/s12325-019-01156-5	results	1	NA	covariates_yn	Yes
10.1007/s12325-019-01156-5	results	1	NA	covariates_n	7
10.1007/s12325-019-01156-5	results	1	NA	covariates_names	Age, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Past treatments for the disease of interest
10.1007/s12325-019-01156-5	results	1	NA	contrast_effect_direction	Numerator if ratio, or left side if difference
10.1007/s12325-019-01156-5	results	1	NA	contrast_effect_unadjusted_value	NA
10.1007/s12325-019-01156-5	results	1	NA	contrast_effect_unadjusted_pvalci	NA
10.1007/s12325-019-01156-5	results	1	NA	contrast_effect_adjusted_value	0.91
10.1007/s12325-019-01156-5	results	1	NA	contrast_effect_adjusted_pvalci	0.736
10.1007/s12325-019-01156-5	results	1	NA	adjustment_geographical	NA
10.1007/s12325-019-01156-5	results	1	NA	ss_total_ipd	1207
10.1007/s12325-019-01156-5	results	1	NA	ss_adjusted_total_ipd	1171
10.1007/s12325-019-01156-5	results	1	NA	ss_total_nonipd	1401
10.1007/s12325-019-01156-5	results	1	NA	ss_anchor_nonipd	468
10.1007/s12325-019-01156-5	results	1	NA	ss_anchor_ipd	401
10.1007/s12325-019-01156-5	results	1	NA	ss_adjusted_anchor_ipd	NA
10.1007/s12325-019-01156-5	results	1	NA	effect_cutoff	1
10.1007/s12325-019-01156-5	results	1	NA	adjusted_pval	0.736
10.1007/s12325-019-01156-5	results	1	NA	adjusted_num_pval	0.736
10.1007/s12325-019-01156-5	results	1	NA	adjusted_significant	FALSE
10.1007/s12325-019-01156-5	study_information	NA	1	ipd_yn	Yes
10.1007/s12325-019-01156-5	study_information	NA	1	ct_yn	Yes
10.1007/s12325-019-01156-5	study_information	NA	1	nct	NCT01946204
10.1007/s12325-019-01156-5	study_information	NA	1	country_study	international
10.1007/s12325-019-01156-5	study_information	NA	1	ct_phase	3
10.1007/s12325-019-01156-5	study_information	NA	1	ct_arms	2 or more
10.1007/s12325-019-01156-5	study_information	NA	2	ipd_yn	No
10.1007/s12325-019-01156-5	study_information	NA	2	ct_yn	Yes
10.1007/s12325-019-01156-5	study_information	NA	2	nct	NCT02003924
10.1007/s12325-019-01156-5	study_information	NA	2	country_study	international
10.1007/s12325-019-01156-5	study_information	NA	2	ct_phase	3
10.1007/s12325-019-01156-5	study_information	NA	2	ct_arms	2 or more
10.1007/s12325-019-01157-4	general_information	NA	NA	condition_name	non-metastatic castration-resistant prostate cancer
10.1007/s12325-019-01157-4	general_information	NA	NA	country_first_author	uk
10.1007/s12325-019-01157-4	general_information	NA	NA	country_last_author	germany
10.1007/s12325-019-01157-4	general_information	NA	NA	positions	Academic, Pharmaceutical Industry, Private Data Analysis Company
10.1007/s12325-019-01157-4	general_information	NA	NA	methodologist_yn	Yes
10.1007/s12325-019-01157-4	general_information	NA	NA	funding_source	Pharmaceutical Industry
10.1007/s12325-019-01157-4	general_information	NA	NA	pharmaceutical_ties_yn	Yes
10.1007/s12325-019-01157-4	general_information	NA	NA	systematic_review_yn	No
10.1007/s12325-019-01157-4	methodology	1	NA	outcome_name	fatigue occurrence
10.1007/s12325-019-01157-4	methodology	1	NA	outcome_short_name	Fatigue occurence
10.1007/s12325-019-01157-4	methodology	1	NA	outcome_variable_type	Binary (eg rates)
10.1007/s12325-019-01157-4	methodology	1	NA	treatment_name_ipd	apalutamide
10.1007/s12325-019-01157-4	methodology	1	NA	studies_number_ipd	1
10.1007/s12325-019-01157-4	methodology	1	NA	treatment_name_nonipd	enzalutamide
10.1007/s12325-019-01157-4	methodology	1	NA	studies_number_nonipd	2
10.1007/s12325-019-01157-4	methodology	1	NA	paic_type	MAIC
10.1007/s12325-019-01157-4	methodology	1	NA	anchored_yn	Yes
10.1007/s12325-019-01157-4	methodology	1	NA	paic_form	Simple (ie treatments effects extracted from two studies)
10.1007/s12325-019-01157-4	methodology	1	NA	primary_outcome_yn	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.1007/s12325-019-01157-4	methodology	1	NA	variables_selection_justification	A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion)
10.1007/s12325-019-01157-4	methodology	1	NA	pf_yn	No
10.1007/s12325-019-01157-4	methodology	1	NA	tem_yn	Yes
10.1007/s12325-019-01157-4	methodology	1	NA	adjustment_model_details_yn	No
10.1007/s12325-019-01157-4	methodology	1	NA	scale_choice_yn	No
10.1007/s12325-019-01157-4	results	1	NA	contrast_effect_type	OR
10.1007/s12325-019-01157-4	results	1	NA	direction_benefit	inferior
10.1007/s12325-019-01157-4	results	1	NA	ss_ttt_nonipd	933
10.1007/s12325-019-01157-4	results	1	NA	ss_ttt_ipd	806
10.1007/s12325-019-01157-4	results	1	NA	ss_adjusted_ttt_ipd	NA
10.1007/s12325-019-01157-4	results	1	NA	weights_yn	Not mentioned
10.1007/s12325-019-01157-4	results	1	NA	covariates_yn	Yes
10.1007/s12325-019-01157-4	results	1	NA	covariates_n	7
10.1007/s12325-019-01157-4	results	1	NA	covariates_names	Age, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Past treatments for the disease of interest
10.1007/s12325-019-01157-4	results	1	NA	contrast_effect_direction	Numerator if ratio, or left side if difference
10.1007/s12325-019-01157-4	results	1	NA	contrast_effect_unadjusted_value	NA
10.1007/s12325-019-01157-4	results	1	NA	contrast_effect_unadjusted_pvalci	NA
10.1007/s12325-019-01157-4	results	1	NA	contrast_effect_adjusted_value	0.57
10.1007/s12325-019-01157-4	results	1	NA	contrast_effect_adjusted_pvalci	[0.37;0.88]
10.1007/s12325-019-01157-4	results	1	NA	adjustment_geographical	NA
10.1007/s12325-019-01157-4	results	1	NA	ss_total_ipd	1207
10.1007/s12325-019-01157-4	results	1	NA	ss_adjusted_total_ipd	1171
10.1007/s12325-019-01157-4	results	1	NA	ss_total_nonipd	1401
10.1007/s12325-019-01157-4	results	1	NA	ss_anchor_nonipd	468
10.1007/s12325-019-01157-4	results	1	NA	ss_anchor_ipd	401
10.1007/s12325-019-01157-4	results	1	NA	ss_adjusted_anchor_ipd	NA
10.1007/s12325-019-01157-4	results	1	NA	effect_cutoff	1
10.1007/s12325-019-01157-4	results	1	NA	adjusted_lb_ci	0.37
10.1007/s12325-019-01157-4	results	1	NA	adjusted_ub_ci	0.88
10.1007/s12325-019-01157-4	results	1	NA	adjusted_significant	TRUE
10.1007/s12325-019-01157-4	study_information	NA	1	ipd_yn	Yes
10.1007/s12325-019-01157-4	study_information	NA	1	ct_yn	Yes
10.1007/s12325-019-01157-4	study_information	NA	1	nct	NCT01946204
10.1007/s12325-019-01157-4	study_information	NA	1	country_study	international
10.1007/s12325-019-01157-4	study_information	NA	1	ct_phase	3
10.1007/s12325-019-01157-4	study_information	NA	1	ct_arms	2 or more
10.1007/s12325-019-01157-4	study_information	NA	2	ipd_yn	No
10.1007/s12325-019-01157-4	study_information	NA	2	ct_yn	Yes
10.1007/s12325-019-01157-4	study_information	NA	2	nct	NCT02003924
10.1007/s12325-019-01157-4	study_information	NA	2	country_study	international
10.1007/s12325-019-01157-4	study_information	NA	2	ct_phase	3
10.1007/s12325-019-01157-4	study_information	NA	2	ct_arms	2 or more
10.1007/s12325-019-01173-4	general_information	NA	NA	condition_name	atrial fibrillation
10.1007/s12325-019-01173-4	general_information	NA	NA	country_first_author	usa
10.1007/s12325-019-01173-4	general_information	NA	NA	country_last_author	italy
10.1007/s12325-019-01173-4	general_information	NA	NA	positions	Academic, Pharmaceutical Industry, Private Data Analysis Company
10.1007/s12325-019-01173-4	general_information	NA	NA	methodologist_yn	Yes
10.1007/s12325-019-01173-4	general_information	NA	NA	funding_source	Pharmaceutical Industry
10.1007/s12325-019-01173-4	general_information	NA	NA	pharmaceutical_ties_yn	Yes
10.1007/s12325-019-01173-4	general_information	NA	NA	systematic_review_yn	Yes
10.1007/s12325-019-01173-4	methodology	1	NA	outcome_name	arrhythmia recurrence
10.1007/s12325-019-01173-4	methodology	1	NA	outcome_short_name	Arrhythmia recurrence
10.1007/s12325-019-01173-4	methodology	1	NA	outcome_variable_type	Time-to-event
10.1007/s12325-019-01173-4	methodology	1	NA	treatment_name_ipd	ratiofrequency catheter ablation with ablation index
10.1007/s12325-019-01173-4	methodology	1	NA	studies_number_ipd	1
10.1007/s12325-019-01173-4	methodology	1	NA	treatment_name_nonipd	ratiofrequency catheter ablation with cryoballoon
10.1007/s12325-019-01173-4	methodology	1	NA	studies_number_nonipd	2;3;4
10.1007/s12325-019-01173-4	methodology	1	NA	paic_type	MAIC
10.1007/s12325-019-01173-4	methodology	1	NA	anchored_yn	No
10.1007/s12325-019-01173-4	methodology	1	NA	paic_form	Aggregation of multiple studies to estimate individual treatment effects (e.g. meta-analysis in a first step to estimate treatment A effect, then population adjusted indirect comparison using treatment A effect estimate)
10.1007/s12325-019-01173-4	methodology	1	NA	primary_outcome_yn	Yes
10.1007/s12325-019-01173-4	methodology	1	NA	variables_selection_justification	A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion)
10.1007/s12325-019-01173-4	methodology	1	NA	pf_yn	Yes
10.1007/s12325-019-01173-4	methodology	1	NA	tem_yn	Yes
10.1007/s12325-019-01173-4	methodology	1	NA	adjustment_model_details_yn	No
10.1007/s12325-019-01173-4	methodology	1	NA	scale_choice_yn	No
10.1007/s12325-019-01173-4	results	1	NA	contrast_effect_type	HR
10.1007/s12325-019-01173-4	results	1	NA	direction_benefit	inferior
10.1007/s12325-019-01173-4	results	1	NA	ss_ttt_nonipd	155
10.1007/s12325-019-01173-4	results	1	NA	ss_ttt_ipd	132
10.1007/s12325-019-01173-4	results	1	NA	ss_adjusted_ttt_ipd	125
10.1007/s12325-019-01173-4	results	1	NA	weights_yn	Yes, mentions that the weights distribution has been studied, and weights distribution reported in main article or supplemental materials
10.1007/s12325-019-01173-4	results	1	NA	covariates_yn	Yes
10.1007/s12325-019-01173-4	results	1	NA	covariates_n	1
10.1007/s12325-019-01173-4	results	1	NA	covariates_names	Age
10.1007/s12325-019-01173-4	results	1	NA	contrast_effect_direction	Numerator if ratio, or left side if difference
10.1007/s12325-019-01173-4	results	1	NA	contrast_effect_unadjusted_value	0.42
10.1007/s12325-019-01173-4	results	1	NA	contrast_effect_unadjusted_pvalci	[0.21;0.86]
10.1007/s12325-019-01173-4	results	1	NA	contrast_effect_adjusted_value	0.41
10.1007/s12325-019-01173-4	results	1	NA	contrast_effect_adjusted_pvalci	[0.20;0.85]
10.1007/s12325-019-01173-4	results	1	NA	adjustment_geographical	NA
10.1007/s12325-019-01173-4	results	1	NA	ss_total_ipd	NA
10.1007/s12325-019-01173-4	results	1	NA	ss_adjusted_total_ipd	NA
10.1007/s12325-019-01173-4	results	1	NA	ss_total_nonipd	NA
10.1007/s12325-019-01173-4	results	1	NA	ss_anchor_nonipd	NA
10.1007/s12325-019-01173-4	results	1	NA	ss_anchor_ipd	NA
10.1007/s12325-019-01173-4	results	1	NA	ss_adjusted_anchor_ipd	NA
10.1007/s12325-019-01173-4	results	1	NA	effect_cutoff	1
10.1007/s12325-019-01173-4	results	1	NA	unadjusted_lb_ci	0.21
10.1007/s12325-019-01173-4	results	1	NA	unadjusted_ub_ci	0.86
10.1007/s12325-019-01173-4	results	1	NA	unadjusted_significant	TRUE
10.1007/s12325-019-01173-4	results	1	NA	adjusted_lb_ci	0.2
10.1007/s12325-019-01173-4	results	1	NA	adjusted_ub_ci	0.85
10.1007/s12325-019-01173-4	results	1	NA	adjusted_significant	TRUE
10.1007/s12325-019-01173-4	study_information	NA	1	ipd_yn	Yes
10.1007/s12325-019-01173-4	study_information	NA	1	ct_yn	No
10.1007/s12325-019-01173-4	study_information	NA	1	data_source_name	solimene et al. doi: 10.1007/s10840-018-0420-5
10.1007/s12325-019-01173-4	study_information	NA	1	country_study	unknown
10.1007/s12325-019-01173-4	study_information	NA	2	ipd_yn	No
10.1007/s12325-019-01173-4	study_information	NA	2	ct_yn	No
10.1007/s12325-019-01173-4	study_information	NA	2	data_source_name	jourda et al.
10.1007/s12325-019-01173-4	study_information	NA	2	country_study	france
10.1007/s12325-019-01173-4	study_information	NA	3	ipd_yn	No
10.1007/s12325-019-01173-4	study_information	NA	3	ct_yn	No
10.1007/s12325-019-01173-4	study_information	NA	3	data_source_name	giovanni et al. 10.1111/jce.12409
10.1007/s12325-019-01173-4	study_information	NA	3	country_study	belgium
10.1007/s12325-019-01173-4	study_information	NA	4	ipd_yn	No
10.1007/s12325-019-01173-4	study_information	NA	4	ct_yn	No
10.1007/s12325-019-01173-4	study_information	NA	4	data_source_name	zhao et al. doi: 10.1016/j.acvd.2017.01.015
10.1007/s12325-019-01173-4	study_information	NA	4	country_study	france
10.1007/s12325-019-0873-7	general_information	NA	NA	condition_name	relapsed or refractory acute lymphoblastic leukemia
10.1007/s12325-019-0873-7	general_information	NA	NA	country_first_author	usa
10.1007/s12325-019-0873-7	general_information	NA	NA	country_last_author	uk
10.1007/s12325-019-0873-7	general_information	NA	NA	positions	Academic, Pharmaceutical Industry, Private Data Analysis Company
10.1007/s12325-019-0873-7	general_information	NA	NA	methodologist_yn	Yes
10.1007/s12325-019-0873-7	general_information	NA	NA	funding_source	Pharmaceutical Industry
10.1007/s12325-019-0873-7	general_information	NA	NA	pharmaceutical_ties_yn	Yes
10.1007/s12325-019-0873-7	general_information	NA	NA	systematic_review_yn	No
10.1007/s12325-019-0873-7	methodology	1	NA	outcome_name	restricted mean survival time
10.1007/s12325-019-0873-7	methodology	1	NA	outcome_short_name	Restricted Mean Survival Time
10.1007/s12325-019-0873-7	methodology	1	NA	outcome_variable_type	Time-to-event
10.1007/s12325-019-0873-7	methodology	1	NA	treatment_name_ipd	blinatumomab
10.1007/s12325-019-0873-7	methodology	1	NA	studies_number_ipd	1
10.1007/s12325-019-0873-7	methodology	1	NA	treatment_name_nonipd	inotuzumab ozogamicin
10.1007/s12325-019-0873-7	methodology	1	NA	studies_number_nonipd	2
10.1007/s12325-019-0873-7	methodology	1	NA	paic_type	MAIC
10.1007/s12325-019-0873-7	methodology	1	NA	anchored_yn	Yes
10.1007/s12325-019-0873-7	methodology	1	NA	paic_form	Simple (ie treatments effects extracted from two studies)
10.1007/s12325-019-0873-7	methodology	1	NA	primary_outcome_yn	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.1007/s12325-019-0873-7	methodology	1	NA	variables_selection_justification	Status of prognostic factor/treatment effect modified assessed in the IPD dataset
10.1007/s12325-019-0873-7	methodology	1	NA	pf_yn	No
10.1007/s12325-019-0873-7	methodology	1	NA	tem_yn	Yes
10.1007/s12325-019-0873-7	methodology	1	NA	adjustment_model_details_yn	No
10.1007/s12325-019-0873-7	methodology	1	NA	scale_choice_yn	No
10.1007/s12325-019-0873-7	methodology	2	NA	outcome_name	restricted mean survival time
10.1007/s12325-019-0873-7	methodology	2	NA	outcome_short_name	Restricted Mean Survival Time
10.1007/s12325-019-0873-7	methodology	2	NA	outcome_variable_type	Time-to-event
10.1007/s12325-019-0873-7	methodology	2	NA	treatment_name_ipd	blinatumomab
10.1007/s12325-019-0873-7	methodology	2	NA	studies_number_ipd	1
10.1007/s12325-019-0873-7	methodology	2	NA	treatment_name_nonipd	inotuzumab ozogamicin
10.1007/s12325-019-0873-7	methodology	2	NA	studies_number_nonipd	2
10.1007/s12325-019-0873-7	methodology	2	NA	paic_type	MAIC
10.1007/s12325-019-0873-7	methodology	2	NA	anchored_yn	No
10.1007/s12325-019-0873-7	methodology	2	NA	paic_form	Simple (ie treatments effects extracted from two studies)
10.1007/s12325-019-0873-7	methodology	2	NA	primary_outcome_yn	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.1007/s12325-019-0873-7	methodology	2	NA	variables_selection_justification	Status of prognostic factor/treatment effect modified assessed in the IPD dataset
10.1007/s12325-019-0873-7	methodology	2	NA	pf_yn	No
10.1007/s12325-019-0873-7	methodology	2	NA	tem_yn	Yes
10.1007/s12325-019-0873-7	methodology	2	NA	adjustment_model_details_yn	No
10.1007/s12325-019-0873-7	methodology	2	NA	scale_choice_yn	No
10.1007/s12325-019-0873-7	results	1	NA	contrast_effect_type	Means difference
10.1007/s12325-019-0873-7	results	1	NA	direction_benefit	superior
10.1007/s12325-019-0873-7	results	1	NA	ss_ttt_nonipd	164
10.1007/s12325-019-0873-7	results	1	NA	ss_ttt_ipd	203
10.1007/s12325-019-0873-7	results	1	NA	ss_adjusted_ttt_ipd	107
10.1007/s12325-019-0873-7	results	1	NA	weights_yn	Not mentioned
10.1007/s12325-019-0873-7	results	1	NA	covariates_yn	Yes
10.1007/s12325-019-0873-7	results	1	NA	covariates_n	9
10.1007/s12325-019-0873-7	results	1	NA	covariates_names	Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Race/ethnicity, Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Past treatments for the disease of interest
10.1007/s12325-019-0873-7	results	1	NA	contrast_effect_direction	Numerator if ratio, or left side if difference
10.1007/s12325-019-0873-7	results	1	NA	contrast_effect_unadjusted_value	1.02
10.1007/s12325-019-0873-7	results	1	NA	contrast_effect_unadjusted_pvalci	0.16
10.1007/s12325-019-0873-7	results	1	NA	contrast_effect_adjusted_value	1.62
10.1007/s12325-019-0873-7	results	1	NA	contrast_effect_adjusted_pvalci	0.04
10.1007/s12325-019-0873-7	results	1	NA	adjustment_geographical	NA
10.1007/s12325-019-0873-7	results	1	NA	ss_total_ipd	NA
10.1007/s12325-019-0873-7	results	1	NA	ss_adjusted_total_ipd	NA
10.1007/s12325-019-0873-7	results	1	NA	ss_total_nonipd	NA
10.1007/s12325-019-0873-7	results	1	NA	ss_anchor_nonipd	162
10.1007/s12325-019-0873-7	results	1	NA	ss_anchor_ipd	107
10.1007/s12325-019-0873-7	results	1	NA	ss_adjusted_anchor_ipd	NA
10.1007/s12325-019-0873-7	results	1	NA	effect_cutoff	0
10.1007/s12325-019-0873-7	results	1	NA	unadjusted_pval	0.16
10.1007/s12325-019-0873-7	results	1	NA	unadjusted_num_pval	0.16
10.1007/s12325-019-0873-7	results	1	NA	unadjusted_significant	FALSE
10.1007/s12325-019-0873-7	results	1	NA	adjusted_pval	0.04
10.1007/s12325-019-0873-7	results	1	NA	adjusted_num_pval	0.04
10.1007/s12325-019-0873-7	results	1	NA	adjusted_significant	TRUE
10.1007/s12325-019-0873-7	results	2	NA	contrast_effect_type	Means difference
10.1007/s12325-019-0873-7	results	2	NA	direction_benefit	superior
10.1007/s12325-019-0873-7	results	2	NA	ss_ttt_nonipd	164
10.1007/s12325-019-0873-7	results	2	NA	ss_ttt_ipd	203
10.1007/s12325-019-0873-7	results	2	NA	ss_adjusted_ttt_ipd	NA
10.1007/s12325-019-0873-7	results	2	NA	weights_yn	Not mentioned
10.1007/s12325-019-0873-7	results	2	NA	covariates_yn	Yes
10.1007/s12325-019-0873-7	results	2	NA	covariates_n	9
10.1007/s12325-019-0873-7	results	2	NA	covariates_names	Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Race/ethnicity, Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Past treatments for the disease of interest
10.1007/s12325-019-0873-7	results	2	NA	contrast_effect_direction	Numerator if ratio, or left side if difference
10.1007/s12325-019-0873-7	results	2	NA	contrast_effect_unadjusted_value	-0.18
10.1007/s12325-019-0873-7	results	2	NA	contrast_effect_unadjusted_pvalci	0.69
10.1007/s12325-019-0873-7	results	2	NA	contrast_effect_adjusted_value	0.15
10.1007/s12325-019-0873-7	results	2	NA	contrast_effect_adjusted_pvalci	0.76
10.1007/s12325-019-0873-7	results	2	NA	adjustment_geographical	NA
10.1007/s12325-019-0873-7	results	2	NA	ss_total_ipd	NA
10.1007/s12325-019-0873-7	results	2	NA	ss_adjusted_total_ipd	NA
10.1007/s12325-019-0873-7	results	2	NA	ss_total_nonipd	NA
10.1007/s12325-019-0873-7	results	2	NA	ss_anchor_nonipd	NA
10.1007/s12325-019-0873-7	results	2	NA	ss_anchor_ipd	NA
10.1007/s12325-019-0873-7	results	2	NA	ss_adjusted_anchor_ipd	NA
10.1007/s12325-019-0873-7	results	2	NA	effect_cutoff	0
10.1007/s12325-019-0873-7	results	2	NA	unadjusted_pval	0.69
10.1007/s12325-019-0873-7	results	2	NA	unadjusted_num_pval	0.69
10.1007/s12325-019-0873-7	results	2	NA	unadjusted_significant	FALSE
10.1007/s12325-019-0873-7	results	2	NA	adjusted_pval	0.76
10.1007/s12325-019-0873-7	results	2	NA	adjusted_num_pval	0.76
10.1007/s12325-019-0873-7	results	2	NA	adjusted_significant	FALSE
10.1007/s12325-019-0873-7	study_information	NA	1	ipd_yn	Yes
10.1007/s12325-019-0873-7	study_information	NA	1	ct_yn	Yes
10.1007/s12325-019-0873-7	study_information	NA	1	nct	NCT02013167
10.1007/s12325-019-0873-7	study_information	NA	1	country_study	international
10.1007/s12325-019-0873-7	study_information	NA	1	ct_phase	3
10.1007/s12325-019-0873-7	study_information	NA	1	ct_arms	2 or more
10.1007/s12325-019-0873-7	study_information	NA	2	ipd_yn	No
10.1007/s12325-019-0873-7	study_information	NA	2	ct_yn	Yes
10.1007/s12325-019-0873-7	study_information	NA	2	nct	NCT01564784
10.1007/s12325-019-0873-7	study_information	NA	2	country_study	international
10.1007/s12325-019-0873-7	study_information	NA	2	ct_phase	3
10.1007/s12325-019-0873-7	study_information	NA	2	ct_arms	2 or more
10.1007/s12325-020-01298-x	general_information	NA	NA	condition_name	age-related macular degeneration
10.1007/s12325-020-01298-x	general_information	NA	NA	country_first_author	japan
10.1007/s12325-020-01298-x	general_information	NA	NA	country_last_author	germany
10.1007/s12325-020-01298-x	general_information	NA	NA	positions	Academic, Pharmaceutical Industry, Private Data Analysis Company
10.1007/s12325-020-01298-x	general_information	NA	NA	methodologist_yn	Yes
10.1007/s12325-020-01298-x	general_information	NA	NA	funding_source	Pharmaceutical Industry
10.1007/s12325-020-01298-x	general_information	NA	NA	pharmaceutical_ties_yn	Yes
10.1007/s12325-020-01298-x	general_information	NA	NA	systematic_review_yn	Yes
10.1007/s12325-020-01298-x	methodology	1	NA	outcome_name	number of etdrs (early treatment diabetic retinopathy study) letters gained vs baseline after 2 years
10.1007/s12325-020-01298-x	methodology	1	NA	outcome_short_name	ETDRS letters gained
10.1007/s12325-020-01298-x	methodology	1	NA	outcome_variable_type	Continuous (count, mean, ...)
10.1007/s12325-020-01298-x	methodology	1	NA	treatment_name_ipd	intravitreally administered aflibercept (ivt-afl) with 2 weeks adjustment
10.1007/s12325-020-01298-x	methodology	1	NA	studies_number_ipd	1
10.1007/s12325-020-01298-x	methodology	1	NA	treatment_name_nonipd	intravitreally administered aflibercept (ivt-afl) : one injection every 8 weeks in the first year followed by prorenata regimen in the second year
10.1007/s12325-020-01298-x	methodology	1	NA	studies_number_nonipd	2;3
10.1007/s12325-020-01298-x	methodology	1	NA	paic_type	MAIC
10.1007/s12325-020-01298-x	methodology	1	NA	anchored_yn	No
10.1007/s12325-020-01298-x	methodology	1	NA	paic_form	Aggregation of multiple studies to estimate individual treatment effects (e.g. meta-analysis in a first step to estimate treatment A effect, then population adjusted indirect comparison using treatment A effect estimate)
10.1007/s12325-020-01298-x	methodology	1	NA	primary_outcome_yn	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.1007/s12325-020-01298-x	methodology	1	NA	variables_selection_justification	Nothing mentioned, not reported
10.1007/s12325-020-01298-x	methodology	1	NA	pf_yn	No discussion (in the main text) of the status of prognostic factors of the variables
10.1007/s12325-020-01298-x	methodology	1	NA	tem_yn	No discussion (in the main text) of the status of treatment-effect modifiers of the variables
10.1007/s12325-020-01298-x	methodology	1	NA	adjustment_model_details_yn	No
10.1007/s12325-020-01298-x	methodology	1	NA	scale_choice_yn	No
10.1007/s12325-020-01298-x	results	1	NA	contrast_effect_type	Median difference
10.1007/s12325-020-01298-x	results	1	NA	direction_benefit	superior
10.1007/s12325-020-01298-x	results	1	NA	ss_ttt_nonipd	607
10.1007/s12325-020-01298-x	results	1	NA	ss_ttt_ipd	124
10.1007/s12325-020-01298-x	results	1	NA	ss_adjusted_ttt_ipd	NA
10.1007/s12325-020-01298-x	results	1	NA	weights_yn	Not mentioned
10.1007/s12325-020-01298-x	results	1	NA	covariates_yn	Yes
10.1007/s12325-020-01298-x	results	1	NA	covariates_n	3
10.1007/s12325-020-01298-x	results	1	NA	covariates_names	Age, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease)
10.1007/s12325-020-01298-x	results	1	NA	contrast_effect_direction	Denominator if ratio, or rightside if difference
10.1007/s12325-020-01298-x	results	1	NA	contrast_effect_unadjusted_value	NA
10.1007/s12325-020-01298-x	results	1	NA	contrast_effect_unadjusted_pvalci	NA
10.1007/s12325-020-01298-x	results	1	NA	contrast_effect_adjusted_value	-0.99
10.1007/s12325-020-01298-x	results	1	NA	contrast_effect_adjusted_pvalci	[-3.90;1.93]
10.1007/s12325-020-01298-x	results	1	NA	adjustment_geographical	NA
10.1007/s12325-020-01298-x	results	1	NA	ss_total_ipd	NA
10.1007/s12325-020-01298-x	results	1	NA	ss_adjusted_total_ipd	NA
10.1007/s12325-020-01298-x	results	1	NA	ss_total_nonipd	NA
10.1007/s12325-020-01298-x	results	1	NA	ss_anchor_nonipd	NA
10.1007/s12325-020-01298-x	results	1	NA	ss_anchor_ipd	NA
10.1007/s12325-020-01298-x	results	1	NA	ss_adjusted_anchor_ipd	NA
10.1007/s12325-020-01298-x	results	1	NA	effect_cutoff	0
10.1007/s12325-020-01298-x	results	1	NA	adjusted_lb_ci	-3.9
10.1007/s12325-020-01298-x	results	1	NA	adjusted_ub_ci	1.93
10.1007/s12325-020-01298-x	results	1	NA	adjusted_significant	FALSE
10.1007/s12325-020-01298-x	study_information	NA	1	ipd_yn	Yes
10.1007/s12325-020-01298-x	study_information	NA	1	ct_yn	Yes
10.1007/s12325-020-01298-x	study_information	NA	1	nct	NCT02305238
10.1007/s12325-020-01298-x	study_information	NA	1	country_study	japan
10.1007/s12325-020-01298-x	study_information	NA	1	ct_phase	4
10.1007/s12325-020-01298-x	study_information	NA	1	ct_arms	1
10.1007/s12325-020-01298-x	study_information	NA	2	ipd_yn	No
10.1007/s12325-020-01298-x	study_information	NA	2	ct_yn	Yes
10.1007/s12325-020-01298-x	study_information	NA	2	nct	NCT00509795
10.1007/s12325-020-01298-x	study_information	NA	2	country_study	international
10.1007/s12325-020-01298-x	study_information	NA	2	ct_phase	3
10.1007/s12325-020-01298-x	study_information	NA	2	ct_arms	2 or more
10.1007/s12325-020-01298-x	study_information	NA	3	ipd_yn	No
10.1007/s12325-020-01298-x	study_information	NA	3	ct_yn	Yes
10.1007/s12325-020-01298-x	study_information	NA	3	nct	NCT00637377
10.1007/s12325-020-01298-x	study_information	NA	3	country_study	international
10.1007/s12325-020-01298-x	study_information	NA	3	ct_phase	3
10.1007/s12325-020-01298-x	study_information	NA	3	ct_arms	2 or more
10.1007/s12325-020-01378-y	general_information	NA	NA	condition_name	advanced hepatocellular carcinoma
10.1007/s12325-020-01378-y	general_information	NA	NA	country_first_author	usa
10.1007/s12325-020-01378-y	general_information	NA	NA	country_last_author	usa
10.1007/s12325-020-01378-y	general_information	NA	NA	positions	Academic, Pharmaceutical Industry, Private Data Analysis Company
10.1007/s12325-020-01378-y	general_information	NA	NA	methodologist_yn	Yes
10.1007/s12325-020-01378-y	general_information	NA	NA	funding_source	Pharmaceutical Industry
10.1007/s12325-020-01378-y	general_information	NA	NA	pharmaceutical_ties_yn	Yes
10.1007/s12325-020-01378-y	general_information	NA	NA	systematic_review_yn	Yes
10.1007/s12325-020-01378-y	methodology	1	NA	outcome_name	overall survival
10.1007/s12325-020-01378-y	methodology	1	NA	outcome_short_name	Overall Survival
10.1007/s12325-020-01378-y	methodology	1	NA	outcome_variable_type	Time-to-event
10.1007/s12325-020-01378-y	methodology	1	NA	treatment_name_ipd	cabozantinib
10.1007/s12325-020-01378-y	methodology	1	NA	studies_number_ipd	1
10.1007/s12325-020-01378-y	methodology	1	NA	treatment_name_nonipd	regorafenib
10.1007/s12325-020-01378-y	methodology	1	NA	studies_number_nonipd	2
10.1007/s12325-020-01378-y	methodology	1	NA	paic_type	MAIC
10.1007/s12325-020-01378-y	methodology	1	NA	anchored_yn	No
10.1007/s12325-020-01378-y	methodology	1	NA	paic_form	Simple (ie treatments effects extracted from two studies)
10.1007/s12325-020-01378-y	methodology	1	NA	primary_outcome_yn	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.1007/s12325-020-01378-y	methodology	1	NA	variables_selection_justification	Statistical imbalanced between treatment groups (independently of the status of prognostic/effect modifier), A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion)
10.1007/s12325-020-01378-y	methodology	1	NA	pf_yn	No
10.1007/s12325-020-01378-y	methodology	1	NA	tem_yn	Yes
10.1007/s12325-020-01378-y	methodology	1	NA	adjustment_model_details_yn	No
10.1007/s12325-020-01378-y	methodology	1	NA	scale_choice_yn	No
10.1007/s12325-020-01378-y	results	1	NA	contrast_effect_type	Median difference
10.1007/s12325-020-01378-y	results	1	NA	direction_benefit	superior
10.1007/s12325-020-01378-y	results	1	NA	ss_ttt_nonipd	379
10.1007/s12325-020-01378-y	results	1	NA	ss_ttt_ipd	326
10.1007/s12325-020-01378-y	results	1	NA	ss_adjusted_ttt_ipd	187
10.1007/s12325-020-01378-y	results	1	NA	weights_yn	Not mentioned
10.1007/s12325-020-01378-y	results	1	NA	covariates_yn	Yes
10.1007/s12325-020-01378-y	results	1	NA	covariates_n	11
10.1007/s12325-020-01378-y	results	1	NA	covariates_names	Age, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Race/ethnicity, Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Past treatments for the disease of interest, Other(s)
10.1007/s12325-020-01378-y	results	1	NA	contrast_effect_direction	Numerator if ratio, or left side if difference
10.1007/s12325-020-01378-y	results	1	NA	contrast_effect_unadjusted_value	NA
10.1007/s12325-020-01378-y	results	1	NA	contrast_effect_unadjusted_pvalci	NA
10.1007/s12325-020-01378-y	results	1	NA	contrast_effect_adjusted_value	0.8
10.1007/s12325-020-01378-y	results	1	NA	contrast_effect_adjusted_pvalci	0.3474
10.1007/s12325-020-01378-y	results	1	NA	adjustment_geographical	Yes
10.1007/s12325-020-01378-y	results	1	NA	ss_total_ipd	NA
10.1007/s12325-020-01378-y	results	1	NA	ss_adjusted_total_ipd	NA
10.1007/s12325-020-01378-y	results	1	NA	ss_total_nonipd	NA
10.1007/s12325-020-01378-y	results	1	NA	ss_anchor_nonipd	NA
10.1007/s12325-020-01378-y	results	1	NA	ss_anchor_ipd	NA
10.1007/s12325-020-01378-y	results	1	NA	ss_adjusted_anchor_ipd	NA
10.1007/s12325-020-01378-y	results	1	NA	effect_cutoff	0
10.1007/s12325-020-01378-y	results	1	NA	adjusted_pval	0.3474
10.1007/s12325-020-01378-y	results	1	NA	adjusted_num_pval	0.3474
10.1007/s12325-020-01378-y	results	1	NA	adjusted_significant	FALSE
10.1007/s12325-020-01378-y	study_information	NA	1	ipd_yn	Yes
10.1007/s12325-020-01378-y	study_information	NA	1	ct_yn	Yes
10.1007/s12325-020-01378-y	study_information	NA	1	nct	NCT01908426
10.1007/s12325-020-01378-y	study_information	NA	1	country_study	international
10.1007/s12325-020-01378-y	study_information	NA	1	ct_phase	3
10.1007/s12325-020-01378-y	study_information	NA	1	ct_arms	2 or more
10.1007/s12325-020-01378-y	study_information	NA	2	ipd_yn	No
10.1007/s12325-020-01378-y	study_information	NA	2	ct_yn	Yes
10.1007/s12325-020-01378-y	study_information	NA	2	nct	NCT01774344
10.1007/s12325-020-01378-y	study_information	NA	2	country_study	international
10.1007/s12325-020-01378-y	study_information	NA	2	ct_phase	3
10.1007/s12325-020-01378-y	study_information	NA	2	ct_arms	2 or more
10.1007/s12325-020-01599-1	general_information	NA	NA	condition_name	haemophilia a
10.1007/s12325-020-01599-1	general_information	NA	NA	country_first_author	sweden
10.1007/s12325-020-01599-1	general_information	NA	NA	country_last_author	sweden
10.1007/s12325-020-01599-1	general_information	NA	NA	positions	Academic, Pharmaceutical Industry
10.1007/s12325-020-01599-1	general_information	NA	NA	methodologist_yn	Not mentioned
10.1007/s12325-020-01599-1	general_information	NA	NA	funding_source	Pharmaceutical Industry
10.1007/s12325-020-01599-1	general_information	NA	NA	pharmaceutical_ties_yn	Yes
10.1007/s12325-020-01599-1	general_information	NA	NA	systematic_review_yn	No
10.1007/s12325-020-01599-1	methodology	1	NA	outcome_name	mean annualized bleeding rates
10.1007/s12325-020-01599-1	methodology	1	NA	outcome_short_name	Mean Annualized Bleeding Rate
10.1007/s12325-020-01599-1	methodology	1	NA	outcome_variable_type	Continuous (count, mean, ...)
10.1007/s12325-020-01599-1	methodology	1	NA	treatment_name_ipd	recombinant fviiifc
10.1007/s12325-020-01599-1	methodology	1	NA	studies_number_ipd	1
10.1007/s12325-020-01599-1	methodology	1	NA	treatment_name_nonipd	damoctocog alfa pegol (pooled prophylaxis)
10.1007/s12325-020-01599-1	methodology	1	NA	studies_number_nonipd	2
10.1007/s12325-020-01599-1	methodology	1	NA	paic_type	MAIC
10.1007/s12325-020-01599-1	methodology	1	NA	anchored_yn	No
10.1007/s12325-020-01599-1	methodology	1	NA	paic_form	Simple (ie treatments effects extracted from two studies)
10.1007/s12325-020-01599-1	methodology	1	NA	primary_outcome_yn	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.1007/s12325-020-01599-1	methodology	1	NA	variables_selection_justification	Literature based (clinically or methodologically relevant to adjust on these variables based on the literature search conducted for this specific purpose)
10.1007/s12325-020-01599-1	methodology	1	NA	pf_yn	No discussion (in the main text) of the status of prognostic factors of the variables
10.1007/s12325-020-01599-1	methodology	1	NA	tem_yn	No discussion (in the main text) of the status of treatment-effect modifiers of the variables
10.1007/s12325-020-01599-1	methodology	1	NA	adjustment_model_details_yn	Yes
10.1007/s12325-020-01599-1	methodology	1	NA	scale_choice_yn	No
10.1007/s12325-020-01599-1	methodology	2	NA	outcome_name	mean annualised bleeding rate
10.1007/s12325-020-01599-1	methodology	2	NA	outcome_short_name	Mean Annualized Bleeding Rate
10.1007/s12325-020-01599-1	methodology	2	NA	outcome_variable_type	Continuous (count, mean, ...)
10.1007/s12325-020-01599-1	methodology	2	NA	treatment_name_ipd	recombinant fviiifc
10.1007/s12325-020-01599-1	methodology	2	NA	studies_number_ipd	1
10.1007/s12325-020-01599-1	methodology	2	NA	treatment_name_nonipd	damoctocog alfa pegol twice weekly
10.1007/s12325-020-01599-1	methodology	2	NA	studies_number_nonipd	2
10.1007/s12325-020-01599-1	methodology	2	NA	paic_type	MAIC
10.1007/s12325-020-01599-1	methodology	2	NA	anchored_yn	No
10.1007/s12325-020-01599-1	methodology	2	NA	paic_form	Simple (ie treatments effects extracted from two studies)
10.1007/s12325-020-01599-1	methodology	2	NA	primary_outcome_yn	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.1007/s12325-020-01599-1	methodology	2	NA	variables_selection_justification	Literature based (clinically or methodologically relevant to adjust on these variables based on the literature search conducted for this specific purpose)
10.1007/s12325-020-01599-1	methodology	2	NA	pf_yn	No discussion (in the main text) of the status of prognostic factors of the variables
10.1007/s12325-020-01599-1	methodology	2	NA	tem_yn	No discussion (in the main text) of the status of treatment-effect modifiers of the variables
10.1007/s12325-020-01599-1	methodology	2	NA	adjustment_model_details_yn	Yes
10.1007/s12325-020-01599-1	methodology	2	NA	scale_choice_yn	No
10.1007/s12325-020-01599-1	methodology	3	NA	outcome_name	mean annualised bleeding rate
10.1007/s12325-020-01599-1	methodology	3	NA	outcome_short_name	Mean Annualized Bleeding Rate
10.1007/s12325-020-01599-1	methodology	3	NA	outcome_variable_type	Continuous (count, mean, ...)
10.1007/s12325-020-01599-1	methodology	3	NA	treatment_name_ipd	recombinant fviiifc
10.1007/s12325-020-01599-1	methodology	3	NA	studies_number_ipd	1
10.1007/s12325-020-01599-1	methodology	3	NA	treatment_name_nonipd	damoctocog alfa pegol q5d
10.1007/s12325-020-01599-1	methodology	3	NA	studies_number_nonipd	2
10.1007/s12325-020-01599-1	methodology	3	NA	paic_type	MAIC
10.1007/s12325-020-01599-1	methodology	3	NA	anchored_yn	No
10.1007/s12325-020-01599-1	methodology	3	NA	paic_form	Simple (ie treatments effects extracted from two studies)
10.1007/s12325-020-01599-1	methodology	3	NA	primary_outcome_yn	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.1007/s12325-020-01599-1	methodology	3	NA	variables_selection_justification	Literature based (clinically or methodologically relevant to adjust on these variables based on the literature search conducted for this specific purpose)
10.1007/s12325-020-01599-1	methodology	3	NA	pf_yn	No discussion (in the main text) of the status of prognostic factors of the variables
10.1007/s12325-020-01599-1	methodology	3	NA	tem_yn	No discussion (in the main text) of the status of treatment-effect modifiers of the variables
10.1007/s12325-020-01599-1	methodology	3	NA	adjustment_model_details_yn	Yes
10.1007/s12325-020-01599-1	methodology	3	NA	scale_choice_yn	No
10.1007/s12325-020-01599-1	methodology	4	NA	outcome_name	mean annualised bleeding rate
10.1007/s12325-020-01599-1	methodology	4	NA	outcome_short_name	Mean Annualized Bleeding Rate
10.1007/s12325-020-01599-1	methodology	4	NA	outcome_variable_type	Continuous (count, mean, ...)
10.1007/s12325-020-01599-1	methodology	4	NA	treatment_name_ipd	recombinant fviiifc
10.1007/s12325-020-01599-1	methodology	4	NA	studies_number_ipd	1
10.1007/s12325-020-01599-1	methodology	4	NA	treatment_name_nonipd	damoctocog alfa pegol q7d
10.1007/s12325-020-01599-1	methodology	4	NA	studies_number_nonipd	2
10.1007/s12325-020-01599-1	methodology	4	NA	paic_type	MAIC
10.1007/s12325-020-01599-1	methodology	4	NA	anchored_yn	No
10.1007/s12325-020-01599-1	methodology	4	NA	paic_form	Simple (ie treatments effects extracted from two studies)
10.1007/s12325-020-01599-1	methodology	4	NA	primary_outcome_yn	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.1007/s12325-020-01599-1	methodology	4	NA	variables_selection_justification	Literature based (clinically or methodologically relevant to adjust on these variables based on the literature search conducted for this specific purpose)
10.1007/s12325-020-01599-1	methodology	4	NA	pf_yn	No discussion (in the main text) of the status of prognostic factors of the variables
10.1007/s12325-020-01599-1	methodology	4	NA	tem_yn	No discussion (in the main text) of the status of treatment-effect modifiers of the variables
10.1007/s12325-020-01599-1	methodology	4	NA	adjustment_model_details_yn	Yes
10.1007/s12325-020-01599-1	methodology	4	NA	scale_choice_yn	No
10.1007/s12325-020-01599-1	results	1	NA	contrast_effect_type	Means difference
10.1007/s12325-020-01599-1	results	1	NA	direction_benefit	inferior
10.1007/s12325-020-01599-1	results	1	NA	ss_ttt_nonipd	110
10.1007/s12325-020-01599-1	results	1	NA	ss_ttt_ipd	117
10.1007/s12325-020-01599-1	results	1	NA	ss_adjusted_ttt_ipd	81
10.1007/s12325-020-01599-1	results	1	NA	weights_yn	Not mentioned
10.1007/s12325-020-01599-1	results	1	NA	covariates_yn	Yes
10.1007/s12325-020-01599-1	results	1	NA	covariates_n	6
10.1007/s12325-020-01599-1	results	1	NA	covariates_names	Age, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Race/ethnicity, Other(s)
10.1007/s12325-020-01599-1	results	1	NA	contrast_effect_direction	Numerator if ratio, or left side if difference
10.1007/s12325-020-01599-1	results	1	NA	contrast_effect_unadjusted_value	-2
10.1007/s12325-020-01599-1	results	1	NA	contrast_effect_unadjusted_pvalci	[-3.5;-0.4]
10.1007/s12325-020-01599-1	results	1	NA	contrast_effect_adjusted_value	-1.9
10.1007/s12325-020-01599-1	results	1	NA	contrast_effect_adjusted_pvalci	[-3.5;-0.4]
10.1007/s12325-020-01599-1	results	1	NA	adjustment_geographical	No
10.1007/s12325-020-01599-1	results	1	NA	ss_total_ipd	NA
10.1007/s12325-020-01599-1	results	1	NA	ss_adjusted_total_ipd	NA
10.1007/s12325-020-01599-1	results	1	NA	ss_total_nonipd	NA
10.1007/s12325-020-01599-1	results	1	NA	ss_anchor_nonipd	NA
10.1007/s12325-020-01599-1	results	1	NA	ss_anchor_ipd	NA
10.1007/s12325-020-01599-1	results	1	NA	ss_adjusted_anchor_ipd	NA
10.1007/s12325-020-01599-1	results	1	NA	effect_cutoff	0
10.1007/s12325-020-01599-1	results	1	NA	unadjusted_lb_ci	-3.5
10.1007/s12325-020-01599-1	results	1	NA	unadjusted_ub_ci	-0.4
10.1007/s12325-020-01599-1	results	1	NA	unadjusted_significant	TRUE
10.1007/s12325-020-01599-1	results	1	NA	adjusted_lb_ci	-3.5
10.1007/s12325-020-01599-1	results	1	NA	adjusted_ub_ci	-0.4
10.1007/s12325-020-01599-1	results	1	NA	adjusted_significant	TRUE
10.1007/s12325-020-01599-1	results	2	NA	contrast_effect_type	Means difference
10.1007/s12325-020-01599-1	results	2	NA	direction_benefit	inferior
10.1007/s12325-020-01599-1	results	2	NA	ss_ttt_nonipd	24
10.1007/s12325-020-01599-1	results	2	NA	ss_ttt_ipd	117
10.1007/s12325-020-01599-1	results	2	NA	ss_adjusted_ttt_ipd	62
10.1007/s12325-020-01599-1	results	2	NA	weights_yn	Not mentioned
10.1007/s12325-020-01599-1	results	2	NA	covariates_yn	Yes
10.1007/s12325-020-01599-1	results	2	NA	covariates_n	6
10.1007/s12325-020-01599-1	results	2	NA	covariates_names	Age, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Race/ethnicity, Other(s)
10.1007/s12325-020-01599-1	results	2	NA	contrast_effect_direction	Numerator if ratio, or left side if difference
10.1007/s12325-020-01599-1	results	2	NA	contrast_effect_unadjusted_value	-2
10.1007/s12325-020-01599-1	results	2	NA	contrast_effect_unadjusted_pvalci	[-4.6;0.6]
10.1007/s12325-020-01599-1	results	2	NA	contrast_effect_adjusted_value	-1.6
10.1007/s12325-020-01599-1	results	2	NA	contrast_effect_adjusted_pvalci	[-4.2;1.1]
10.1007/s12325-020-01599-1	results	2	NA	adjustment_geographical	No
10.1007/s12325-020-01599-1	results	2	NA	ss_total_ipd	NA
10.1007/s12325-020-01599-1	results	2	NA	ss_adjusted_total_ipd	NA
10.1007/s12325-020-01599-1	results	2	NA	ss_total_nonipd	NA
10.1007/s12325-020-01599-1	results	2	NA	ss_anchor_nonipd	NA
10.1007/s12325-020-01599-1	results	2	NA	ss_anchor_ipd	NA
10.1007/s12325-020-01599-1	results	2	NA	ss_adjusted_anchor_ipd	NA
10.1007/s12325-020-01599-1	results	2	NA	effect_cutoff	0
10.1007/s12325-020-01599-1	results	2	NA	unadjusted_lb_ci	-4.6
10.1007/s12325-020-01599-1	results	2	NA	unadjusted_ub_ci	0.6
10.1007/s12325-020-01599-1	results	2	NA	unadjusted_significant	FALSE
10.1007/s12325-020-01599-1	results	2	NA	adjusted_lb_ci	-4.2
10.1007/s12325-020-01599-1	results	2	NA	adjusted_ub_ci	1.1
10.1007/s12325-020-01599-1	results	2	NA	adjusted_significant	FALSE
10.1007/s12325-020-01599-1	results	3	NA	contrast_effect_type	Means difference
10.1007/s12325-020-01599-1	results	3	NA	direction_benefit	inferior
10.1007/s12325-020-01599-1	results	3	NA	ss_ttt_nonipd	43
10.1007/s12325-020-01599-1	results	3	NA	ss_ttt_ipd	117
10.1007/s12325-020-01599-1	results	3	NA	ss_adjusted_ttt_ipd	79
10.1007/s12325-020-01599-1	results	3	NA	weights_yn	Not mentioned
10.1007/s12325-020-01599-1	results	3	NA	covariates_yn	Yes
10.1007/s12325-020-01599-1	results	3	NA	covariates_n	6
10.1007/s12325-020-01599-1	results	3	NA	covariates_names	Age, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Race/ethnicity, Other(s)
10.1007/s12325-020-01599-1	results	3	NA	contrast_effect_direction	Numerator if ratio, or left side if difference
10.1007/s12325-020-01599-1	results	3	NA	contrast_effect_unadjusted_value	-0.4
10.1007/s12325-020-01599-1	results	3	NA	contrast_effect_unadjusted_pvalci	[-1.9;1.1]
10.1007/s12325-020-01599-1	results	3	NA	contrast_effect_adjusted_value	-0.6
10.1007/s12325-020-01599-1	results	3	NA	contrast_effect_adjusted_pvalci	[-2.0;0.8]
10.1007/s12325-020-01599-1	results	3	NA	adjustment_geographical	No
10.1007/s12325-020-01599-1	results	3	NA	ss_total_ipd	NA
10.1007/s12325-020-01599-1	results	3	NA	ss_adjusted_total_ipd	NA
10.1007/s12325-020-01599-1	results	3	NA	ss_total_nonipd	NA
10.1007/s12325-020-01599-1	results	3	NA	ss_anchor_nonipd	NA
10.1007/s12325-020-01599-1	results	3	NA	ss_anchor_ipd	NA
10.1007/s12325-020-01599-1	results	3	NA	ss_adjusted_anchor_ipd	NA
10.1007/s12325-020-01599-1	results	3	NA	effect_cutoff	0
10.1007/s12325-020-01599-1	results	3	NA	unadjusted_lb_ci	-1.9
10.1007/s12325-020-01599-1	results	3	NA	unadjusted_ub_ci	1.1
10.1007/s12325-020-01599-1	results	3	NA	unadjusted_significant	FALSE
10.1007/s12325-020-01599-1	results	3	NA	adjusted_lb_ci	-2
10.1007/s12325-020-01599-1	results	3	NA	adjusted_ub_ci	0.8
10.1007/s12325-020-01599-1	results	3	NA	adjusted_significant	FALSE
10.1007/s12325-020-01599-1	results	4	NA	contrast_effect_type	Means difference
10.1007/s12325-020-01599-1	results	4	NA	direction_benefit	inferior
10.1007/s12325-020-01599-1	results	4	NA	ss_ttt_nonipd	43
10.1007/s12325-020-01599-1	results	4	NA	ss_ttt_ipd	117
10.1007/s12325-020-01599-1	results	4	NA	ss_adjusted_ttt_ipd	45
10.1007/s12325-020-01599-1	results	4	NA	weights_yn	Not mentioned
10.1007/s12325-020-01599-1	results	4	NA	covariates_yn	Yes
10.1007/s12325-020-01599-1	results	4	NA	covariates_n	6
10.1007/s12325-020-01599-1	results	4	NA	covariates_names	Age, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Race/ethnicity, Other(s)
10.1007/s12325-020-01599-1	results	4	NA	contrast_effect_direction	Numerator if ratio, or left side if difference
10.1007/s12325-020-01599-1	results	4	NA	contrast_effect_unadjusted_value	-3.5
10.1007/s12325-020-01599-1	results	4	NA	contrast_effect_unadjusted_pvalci	[-6.6;-0.4]
10.1007/s12325-020-01599-1	results	4	NA	contrast_effect_adjusted_value	-3.3
10.1007/s12325-020-01599-1	results	4	NA	contrast_effect_adjusted_pvalci	[-6.4;-0.2]
10.1007/s12325-020-01599-1	results	4	NA	adjustment_geographical	No
10.1007/s12325-020-01599-1	results	4	NA	ss_total_ipd	NA
10.1007/s12325-020-01599-1	results	4	NA	ss_adjusted_total_ipd	NA
10.1007/s12325-020-01599-1	results	4	NA	ss_total_nonipd	NA
10.1007/s12325-020-01599-1	results	4	NA	ss_anchor_nonipd	NA
10.1007/s12325-020-01599-1	results	4	NA	ss_anchor_ipd	NA
10.1007/s12325-020-01599-1	results	4	NA	ss_adjusted_anchor_ipd	NA
10.1007/s12325-020-01599-1	results	4	NA	effect_cutoff	0
10.1007/s12325-020-01599-1	results	4	NA	unadjusted_lb_ci	-6.6
10.1007/s12325-020-01599-1	results	4	NA	unadjusted_ub_ci	-0.4
10.1007/s12325-020-01599-1	results	4	NA	unadjusted_significant	TRUE
10.1007/s12325-020-01599-1	results	4	NA	adjusted_lb_ci	-6.4
10.1007/s12325-020-01599-1	results	4	NA	adjusted_ub_ci	-0.2
10.1007/s12325-020-01599-1	results	4	NA	adjusted_significant	TRUE
10.1007/s12325-020-01599-1	study_information	NA	1	ipd_yn	Yes
10.1007/s12325-020-01599-1	study_information	NA	1	ct_yn	Yes
10.1007/s12325-020-01599-1	study_information	NA	1	nct	NCT01181128
10.1007/s12325-020-01599-1	study_information	NA	1	country_study	international
10.1007/s12325-020-01599-1	study_information	NA	1	ct_phase	3
10.1007/s12325-020-01599-1	study_information	NA	1	ct_arms	1
10.1007/s12325-020-01599-1	study_information	NA	2	ipd_yn	No
10.1007/s12325-020-01599-1	study_information	NA	2	ct_yn	Yes
10.1007/s12325-020-01599-1	study_information	NA	2	nct	NCT01580293
10.1007/s12325-020-01599-1	study_information	NA	2	country_study	international
10.1007/s12325-020-01599-1	study_information	NA	2	ct_phase	2, 3
10.1007/s12325-020-01599-1	study_information	NA	2	ct_arms	2 or more
10.1007/s12325-021-01700-2	general_information	NA	NA	condition_name	hepatocellular carcinoma
10.1007/s12325-021-01700-2	general_information	NA	NA	country_first_author	germany
10.1007/s12325-021-01700-2	general_information	NA	NA	country_last_author	germany
10.1007/s12325-021-01700-2	general_information	NA	NA	positions	Academic, Pharmaceutical Industry, Private Data Analysis Company
10.1007/s12325-021-01700-2	general_information	NA	NA	methodologist_yn	Yes
10.1007/s12325-021-01700-2	general_information	NA	NA	funding_source	Pharmaceutical Industry
10.1007/s12325-021-01700-2	general_information	NA	NA	pharmaceutical_ties_yn	Yes
10.1007/s12325-021-01700-2	general_information	NA	NA	systematic_review_yn	No
10.1007/s12325-021-01700-2	methodology	1	NA	outcome_name	overall survival
10.1007/s12325-021-01700-2	methodology	1	NA	outcome_short_name	Overall Survival
10.1007/s12325-021-01700-2	methodology	1	NA	outcome_variable_type	Time-to-event
10.1007/s12325-021-01700-2	methodology	1	NA	treatment_name_ipd	cabozantinib
10.1007/s12325-021-01700-2	methodology	1	NA	studies_number_ipd	1
10.1007/s12325-021-01700-2	methodology	1	NA	treatment_name_nonipd	ramucirumab
10.1007/s12325-021-01700-2	methodology	1	NA	studies_number_nonipd	2
10.1007/s12325-021-01700-2	methodology	1	NA	paic_type	MAIC
10.1007/s12325-021-01700-2	methodology	1	NA	anchored_yn	No
10.1007/s12325-021-01700-2	methodology	1	NA	paic_form	Simple (ie treatments effects extracted from two studies)
10.1007/s12325-021-01700-2	methodology	1	NA	primary_outcome_yn	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.1007/s12325-021-01700-2	methodology	1	NA	variables_selection_justification	A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion)
10.1007/s12325-021-01700-2	methodology	1	NA	pf_yn	No
10.1007/s12325-021-01700-2	methodology	1	NA	tem_yn	Yes
10.1007/s12325-021-01700-2	methodology	1	NA	adjustment_model_details_yn	No
10.1007/s12325-021-01700-2	methodology	1	NA	scale_choice_yn	Yes
10.1007/s12325-021-01700-2	results	1	NA	contrast_effect_type	Median difference
10.1007/s12325-021-01700-2	results	1	NA	direction_benefit	superior
10.1007/s12325-021-01700-2	results	1	NA	ss_ttt_nonipd	197
10.1007/s12325-021-01700-2	results	1	NA	ss_ttt_ipd	114
10.1007/s12325-021-01700-2	results	1	NA	ss_adjusted_ttt_ipd	63
10.1007/s12325-021-01700-2	results	1	NA	weights_yn	Yes, mentions that the weights distribution has been studied, and weights distribution reported in main article or supplemental materials
10.1007/s12325-021-01700-2	results	1	NA	covariates_yn	Yes
10.1007/s12325-021-01700-2	results	1	NA	covariates_n	9
10.1007/s12325-021-01700-2	results	1	NA	covariates_names	Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Past treatments for the disease of interest
10.1007/s12325-021-01700-2	results	1	NA	contrast_effect_direction	Numerator if ratio, or left side if difference
10.1007/s12325-021-01700-2	results	1	NA	contrast_effect_unadjusted_value	NA
10.1007/s12325-021-01700-2	results	1	NA	contrast_effect_unadjusted_pvalci	NA
10.1007/s12325-021-01700-2	results	1	NA	contrast_effect_adjusted_value	1.9
10.1007/s12325-021-01700-2	results	1	NA	contrast_effect_adjusted_pvalci	0.104
10.1007/s12325-021-01700-2	results	1	NA	adjustment_geographical	NA
10.1007/s12325-021-01700-2	results	1	NA	ss_total_ipd	NA
10.1007/s12325-021-01700-2	results	1	NA	ss_adjusted_total_ipd	NA
10.1007/s12325-021-01700-2	results	1	NA	ss_total_nonipd	NA
10.1007/s12325-021-01700-2	results	1	NA	ss_anchor_nonipd	NA
10.1007/s12325-021-01700-2	results	1	NA	ss_anchor_ipd	NA
10.1007/s12325-021-01700-2	results	1	NA	ss_adjusted_anchor_ipd	NA
10.1007/s12325-021-01700-2	results	1	NA	effect_cutoff	0
10.1007/s12325-021-01700-2	results	1	NA	adjusted_pval	0.104
10.1007/s12325-021-01700-2	results	1	NA	adjusted_num_pval	0.104
10.1007/s12325-021-01700-2	results	1	NA	adjusted_significant	FALSE
10.1007/s12325-021-01700-2	study_information	NA	1	ipd_yn	Yes
10.1007/s12325-021-01700-2	study_information	NA	1	ct_yn	Yes
10.1007/s12325-021-01700-2	study_information	NA	1	nct	NCT01908426
10.1007/s12325-021-01700-2	study_information	NA	1	country_study	international
10.1007/s12325-021-01700-2	study_information	NA	1	ct_phase	3
10.1007/s12325-021-01700-2	study_information	NA	1	ct_arms	2 or more
10.1007/s12325-021-01700-2	study_information	NA	2	ipd_yn	No
10.1007/s12325-021-01700-2	study_information	NA	2	ct_yn	Yes
10.1007/s12325-021-01700-2	study_information	NA	2	nct	NCT02435433
10.1007/s12325-021-01700-2	study_information	NA	2	country_study	international
10.1007/s12325-021-01700-2	study_information	NA	2	ct_phase	3
10.1007/s12325-021-01700-2	study_information	NA	2	ct_arms	2 or more
10.1007/s12325-021-01756-0	general_information	NA	NA	condition_name	relapsed/refractory diffuse large b-cell lymphoma
10.1007/s12325-021-01756-0	general_information	NA	NA	country_first_author	usa
10.1007/s12325-021-01756-0	general_information	NA	NA	country_last_author	switzerland
10.1007/s12325-021-01756-0	general_information	NA	NA	positions	Academic, Pharmaceutical Industry, Private Data Analysis Company
10.1007/s12325-021-01756-0	general_information	NA	NA	methodologist_yn	Yes
10.1007/s12325-021-01756-0	general_information	NA	NA	funding_source	Pharmaceutical Industry
10.1007/s12325-021-01756-0	general_information	NA	NA	pharmaceutical_ties_yn	Yes
10.1007/s12325-021-01756-0	general_information	NA	NA	systematic_review_yn	Yes
10.1007/s12325-021-01756-0	methodology	1	NA	outcome_name	objective response rate (orr)
10.1007/s12325-021-01756-0	methodology	1	NA	outcome_short_name	Objective Response Rate
10.1007/s12325-021-01756-0	methodology	1	NA	outcome_variable_type	Binary (eg rates)
10.1007/s12325-021-01756-0	methodology	1	NA	treatment_name_ipd	lisocabtagene maraleucel
10.1007/s12325-021-01756-0	methodology	1	NA	studies_number_ipd	1
10.1007/s12325-021-01756-0	methodology	1	NA	treatment_name_nonipd	salvage chemotherapy
10.1007/s12325-021-01756-0	methodology	1	NA	studies_number_nonipd	2
10.1007/s12325-021-01756-0	methodology	1	NA	paic_type	MAIC
10.1007/s12325-021-01756-0	methodology	1	NA	anchored_yn	No
10.1007/s12325-021-01756-0	methodology	1	NA	paic_form	Simple (ie treatments effects extracted from two studies)
10.1007/s12325-021-01756-0	methodology	1	NA	primary_outcome_yn	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.1007/s12325-021-01756-0	methodology	1	NA	variables_selection_justification	Nothing mentioned, not reported
10.1007/s12325-021-01756-0	methodology	1	NA	pf_yn	No discussion (in the main text) of the status of prognostic factors of the variables
10.1007/s12325-021-01756-0	methodology	1	NA	tem_yn	No discussion (in the main text) of the status of treatment-effect modifiers of the variables
10.1007/s12325-021-01756-0	methodology	1	NA	adjustment_model_details_yn	No
10.1007/s12325-021-01756-0	methodology	1	NA	scale_choice_yn	No
10.1007/s12325-021-01756-0	results	1	NA	contrast_effect_type	OR
10.1007/s12325-021-01756-0	results	1	NA	direction_benefit	superior
10.1007/s12325-021-01756-0	results	1	NA	ss_ttt_nonipd	523
10.1007/s12325-021-01756-0	results	1	NA	ss_ttt_ipd	248
10.1007/s12325-021-01756-0	results	1	NA	ss_adjusted_ttt_ipd	142
10.1007/s12325-021-01756-0	results	1	NA	weights_yn	Not mentioned
10.1007/s12325-021-01756-0	results	1	NA	covariates_yn	Yes
10.1007/s12325-021-01756-0	results	1	NA	covariates_n	7
10.1007/s12325-021-01756-0	results	1	NA	covariates_names	Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Past treatments for the disease of interest
10.1007/s12325-021-01756-0	results	1	NA	contrast_effect_direction	Numerator if ratio, or left side if difference
10.1007/s12325-021-01756-0	results	1	NA	contrast_effect_unadjusted_value	7.7
10.1007/s12325-021-01756-0	results	1	NA	contrast_effect_unadjusted_pvalci	<0.001
10.1007/s12325-021-01756-0	results	1	NA	contrast_effect_adjusted_value	7
10.1007/s12325-021-01756-0	results	1	NA	contrast_effect_adjusted_pvalci	<0.001
10.1007/s12325-021-01756-0	results	1	NA	adjustment_geographical	NA
10.1007/s12325-021-01756-0	results	1	NA	ss_total_ipd	NA
10.1007/s12325-021-01756-0	results	1	NA	ss_adjusted_total_ipd	NA
10.1007/s12325-021-01756-0	results	1	NA	ss_total_nonipd	NA
10.1007/s12325-021-01756-0	results	1	NA	ss_anchor_nonipd	NA
10.1007/s12325-021-01756-0	results	1	NA	ss_anchor_ipd	NA
10.1007/s12325-021-01756-0	results	1	NA	ss_adjusted_anchor_ipd	NA
10.1007/s12325-021-01756-0	results	1	NA	effect_cutoff	1
10.1007/s12325-021-01756-0	results	1	NA	unadjusted_pval	<0.001
10.1007/s12325-021-01756-0	results	1	NA	unadjusted_significant	TRUE
10.1007/s12325-021-01756-0	results	1	NA	adjusted_pval	<0.001
10.1007/s12325-021-01756-0	results	1	NA	adjusted_significant	TRUE
10.1007/s12325-021-01756-0	study_information	NA	1	ipd_yn	Yes
10.1007/s12325-021-01756-0	study_information	NA	1	ct_yn	Yes
10.1007/s12325-021-01756-0	study_information	NA	1	nct	NCT02631044
10.1007/s12325-021-01756-0	study_information	NA	1	country_study	usa
10.1007/s12325-021-01756-0	study_information	NA	1	ct_phase	1
10.1007/s12325-021-01756-0	study_information	NA	1	ct_arms	1
10.1007/s12325-021-01756-0	study_information	NA	2	ipd_yn	No
10.1007/s12325-021-01756-0	study_information	NA	2	ct_yn	No
10.1007/s12325-021-01756-0	study_information	NA	2	data_source_name	scholar-1
10.1007/s12325-021-01756-0	study_information	NA	2	country_study	international
10.1007/s12325-021-01846-z	general_information	NA	NA	condition_name	persistent atrial fibrillation
10.1007/s12325-021-01846-z	general_information	NA	NA	country_first_author	usa
10.1007/s12325-021-01846-z	general_information	NA	NA	country_last_author	uk
10.1007/s12325-021-01846-z	general_information	NA	NA	positions	Academic, Pharmaceutical Industry, Private Data Analysis Company
10.1007/s12325-021-01846-z	general_information	NA	NA	methodologist_yn	Yes
10.1007/s12325-021-01846-z	general_information	NA	NA	funding_source	Pharmaceutical Industry
10.1007/s12325-021-01846-z	general_information	NA	NA	pharmaceutical_ties_yn	Yes
10.1007/s12325-021-01846-z	general_information	NA	NA	systematic_review_yn	Yes
10.1007/s12325-021-01846-z	methodology	1	NA	outcome_name	arrhythmia recurrence
10.1007/s12325-021-01846-z	methodology	1	NA	outcome_short_name	Arrhythmia recurrence
10.1007/s12325-021-01846-z	methodology	1	NA	outcome_variable_type	Time-to-event
10.1007/s12325-021-01846-z	methodology	1	NA	treatment_name_ipd	thermocool smarttouch /thermocool smarttouch sf catheter with ai (stai)
10.1007/s12325-021-01846-z	methodology	1	NA	studies_number_ipd	1;2;3;4
10.1007/s12325-021-01846-z	methodology	1	NA	treatment_name_nonipd	second-generation cryoballoon (cb)
10.1007/s12325-021-01846-z	methodology	1	NA	studies_number_nonipd	5;6;7;8
10.1007/s12325-021-01846-z	methodology	1	NA	paic_type	MAIC
10.1007/s12325-021-01846-z	methodology	1	NA	anchored_yn	No
10.1007/s12325-021-01846-z	methodology	1	NA	paic_form	Aggregation of multiple studies to estimate individual treatment effects (e.g. meta-analysis in a first step to estimate treatment A effect, then population adjusted indirect comparison using treatment A effect estimate)
10.1007/s12325-021-01846-z	methodology	1	NA	primary_outcome_yn	Yes
10.1007/s12325-021-01846-z	methodology	1	NA	variables_selection_justification	A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion)
10.1007/s12325-021-01846-z	methodology	1	NA	pf_yn	Yes
10.1007/s12325-021-01846-z	methodology	1	NA	tem_yn	Yes
10.1007/s12325-021-01846-z	methodology	1	NA	adjustment_model_details_yn	No
10.1007/s12325-021-01846-z	methodology	1	NA	scale_choice_yn	No
10.1007/s12325-021-01846-z	results	1	NA	contrast_effect_type	HR
10.1007/s12325-021-01846-z	results	1	NA	direction_benefit	inferior
10.1007/s12325-021-01846-z	results	1	NA	ss_ttt_nonipd	389
10.1007/s12325-021-01846-z	results	1	NA	ss_ttt_ipd	191
10.1007/s12325-021-01846-z	results	1	NA	ss_adjusted_ttt_ipd	156
10.1007/s12325-021-01846-z	results	1	NA	weights_yn	Yes, mentions that the weights distribution has been studied, and weights distribution reported in main article or supplemental materials
10.1007/s12325-021-01846-z	results	1	NA	covariates_yn	Yes
10.1007/s12325-021-01846-z	results	1	NA	covariates_n	4
10.1007/s12325-021-01846-z	results	1	NA	covariates_names	Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Comorbidities and medical history (beside pathology/disease of interest in the comparison)
10.1007/s12325-021-01846-z	results	1	NA	contrast_effect_direction	Numerator if ratio, or left side if difference
10.1007/s12325-021-01846-z	results	1	NA	contrast_effect_unadjusted_value	0.39
10.1007/s12325-021-01846-z	results	1	NA	contrast_effect_unadjusted_pvalci	[0.27;0.56]
10.1007/s12325-021-01846-z	results	1	NA	contrast_effect_adjusted_value	0.35
10.1007/s12325-021-01846-z	results	1	NA	contrast_effect_adjusted_pvalci	[0.23;0.52]
10.1007/s12325-021-01846-z	results	1	NA	adjustment_geographical	NA
10.1007/s12325-021-01846-z	results	1	NA	ss_total_ipd	NA
10.1007/s12325-021-01846-z	results	1	NA	ss_adjusted_total_ipd	NA
10.1007/s12325-021-01846-z	results	1	NA	ss_total_nonipd	NA
10.1007/s12325-021-01846-z	results	1	NA	ss_anchor_nonipd	NA
10.1007/s12325-021-01846-z	results	1	NA	ss_anchor_ipd	NA
10.1007/s12325-021-01846-z	results	1	NA	ss_adjusted_anchor_ipd	NA
10.1007/s12325-021-01846-z	results	1	NA	effect_cutoff	1
10.1007/s12325-021-01846-z	results	1	NA	unadjusted_lb_ci	0.27
10.1007/s12325-021-01846-z	results	1	NA	unadjusted_ub_ci	0.56
10.1007/s12325-021-01846-z	results	1	NA	unadjusted_significant	TRUE
10.1007/s12325-021-01846-z	results	1	NA	adjusted_lb_ci	0.23
10.1007/s12325-021-01846-z	results	1	NA	adjusted_ub_ci	0.52
10.1007/s12325-021-01846-z	results	1	NA	adjusted_significant	TRUE
10.1007/s12325-021-01846-z	study_information	NA	1	ipd_yn	Yes
10.1007/s12325-021-01846-z	study_information	NA	1	ct_yn	No
10.1007/s12325-021-01846-z	study_information	NA	1	data_source_name	hussein et al. (2017)
10.1007/s12325-021-01846-z	study_information	NA	2	ipd_yn	Yes
10.1007/s12325-021-01846-z	study_information	NA	2	ct_yn	Yes
10.1007/s12325-021-01846-z	study_information	NA	2	nct	NCT02628730
10.1007/s12325-021-01846-z	study_information	NA	2	country_study	international
10.1007/s12325-021-01846-z	study_information	NA	2	ct_arms	2 or more
10.1007/s12325-021-01846-z	study_information	NA	3	ipd_yn	Yes
10.1007/s12325-021-01846-z	study_information	NA	3	ct_yn	No
10.1007/s12325-021-01846-z	study_information	NA	3	data_source_name	solimene et al. (2019)
10.1007/s12325-021-01846-z	study_information	NA	4	ipd_yn	Yes
10.1007/s12325-021-01846-z	study_information	NA	4	ct_yn	No
10.1007/s12325-021-01846-z	study_information	NA	4	nct	NCT03277976
10.1007/s12325-021-01846-z	study_information	NA	4	country_study	italy
10.1007/s12325-021-01846-z	study_information	NA	4	data_source_name	stabile et al. (2020)
10.1007/s12325-021-01846-z	study_information	NA	5	ipd_yn	No
10.1007/s12325-021-01846-z	study_information	NA	5	ct_yn	No
10.1007/s12325-021-01846-z	study_information	NA	5	data_source_name	gramlich et al. (2019)
10.1007/s12325-021-01846-z	study_information	NA	6	ipd_yn	No
10.1007/s12325-021-01846-z	study_information	NA	6	ct_yn	Yes
10.1007/s12325-021-01846-z	study_information	NA	6	nct	NCT02213731
10.1007/s12325-021-01846-z	study_information	NA	6	country_study	international
10.1007/s12325-021-01846-z	study_information	NA	6	ct_arms	1
10.1007/s12325-021-01846-z	study_information	NA	7	ipd_yn	No
10.1007/s12325-021-01846-z	study_information	NA	7	ct_yn	No
10.1007/s12325-021-01846-z	study_information	NA	7	data_source_name	circonte et al. (2015)
10.1007/s12325-021-01846-z	study_information	NA	8	ipd_yn	No
10.1007/s12325-021-01846-z	study_information	NA	8	ct_yn	Yes
10.1007/s12325-021-01846-z	study_information	NA	8	nct	NCT03012841
10.1007/s12325-021-01846-z	study_information	NA	8	country_study	international
10.1007/s12325-021-01846-z	study_information	NA	8	ct_arms	1
10.1007/s12325-021-01853-0	general_information	NA	NA	condition_name	severe haemophilia a
10.1007/s12325-021-01853-0	general_information	NA	NA	country_first_author	spain
10.1007/s12325-021-01853-0	general_information	NA	NA	country_last_author	portugal
10.1007/s12325-021-01853-0	general_information	NA	NA	positions	Academic, Pharmaceutical Industry, Private Data Analysis Company
10.1007/s12325-021-01853-0	general_information	NA	NA	methodologist_yn	Yes
10.1007/s12325-021-01853-0	general_information	NA	NA	funding_source	Pharmaceutical Industry
10.1007/s12325-021-01853-0	general_information	NA	NA	pharmaceutical_ties_yn	Yes
10.1007/s12325-021-01853-0	general_information	NA	NA	systematic_review_yn	Yes
10.1007/s12325-021-01853-0	methodology	1	NA	outcome_name	annualized bleeding rate (abr),
10.1007/s12325-021-01853-0	methodology	1	NA	outcome_short_name	Mean Annualized Bleeding Rate
10.1007/s12325-021-01853-0	methodology	1	NA	outcome_variable_type	Continuous (count, mean, ...)
10.1007/s12325-021-01853-0	methodology	1	NA	treatment_name_ipd	rviii-singlechain
10.1007/s12325-021-01853-0	methodology	1	NA	studies_number_ipd	1
10.1007/s12325-021-01853-0	methodology	1	NA	treatment_name_nonipd	rahf-pfm
10.1007/s12325-021-01853-0	methodology	1	NA	studies_number_nonipd	2
10.1007/s12325-021-01853-0	methodology	1	NA	paic_type	MAIC
10.1007/s12325-021-01853-0	methodology	1	NA	anchored_yn	No
10.1007/s12325-021-01853-0	methodology	1	NA	paic_form	Simple (ie treatments effects extracted from two studies)
10.1007/s12325-021-01853-0	methodology	1	NA	primary_outcome_yn	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.1007/s12325-021-01853-0	methodology	1	NA	variables_selection_justification	Nothing mentioned, not reported
10.1007/s12325-021-01853-0	methodology	1	NA	pf_yn	No discussion (in the main text) of the status of prognostic factors of the variables
10.1007/s12325-021-01853-0	methodology	1	NA	tem_yn	No discussion (in the main text) of the status of treatment-effect modifiers of the variables
10.1007/s12325-021-01853-0	methodology	1	NA	adjustment_model_details_yn	No
10.1007/s12325-021-01853-0	methodology	1	NA	scale_choice_yn	No
10.1007/s12325-021-01853-0	methodology	2	NA	outcome_name	annualized bleeding rate (abr)
10.1007/s12325-021-01853-0	methodology	2	NA	outcome_short_name	Mean Annualized Bleeding Rate
10.1007/s12325-021-01853-0	methodology	2	NA	outcome_variable_type	Continuous (count, mean, ...)
10.1007/s12325-021-01853-0	methodology	2	NA	treatment_name_ipd	rviii-singlechain
10.1007/s12325-021-01853-0	methodology	2	NA	studies_number_ipd	1
10.1007/s12325-021-01853-0	methodology	2	NA	treatment_name_nonipd	rahf-pfm
10.1007/s12325-021-01853-0	methodology	2	NA	studies_number_nonipd	3
10.1007/s12325-021-01853-0	methodology	2	NA	paic_type	MAIC
10.1007/s12325-021-01853-0	methodology	2	NA	anchored_yn	No
10.1007/s12325-021-01853-0	methodology	2	NA	paic_form	Simple (ie treatments effects extracted from two studies)
10.1007/s12325-021-01853-0	methodology	2	NA	primary_outcome_yn	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.1007/s12325-021-01853-0	methodology	2	NA	variables_selection_justification	Nothing mentioned, not reported
10.1007/s12325-021-01853-0	methodology	2	NA	pf_yn	No discussion (in the main text) of the status of prognostic factors of the variables
10.1007/s12325-021-01853-0	methodology	2	NA	tem_yn	No discussion (in the main text) of the status of treatment-effect modifiers of the variables
10.1007/s12325-021-01853-0	methodology	2	NA	adjustment_model_details_yn	No
10.1007/s12325-021-01853-0	methodology	2	NA	scale_choice_yn	No
10.1007/s12325-021-01853-0	methodology	3	NA	outcome_name	annualized bleeding rate (abr)
10.1007/s12325-021-01853-0	methodology	3	NA	outcome_short_name	Mean Annualized Bleeding Rate
10.1007/s12325-021-01853-0	methodology	3	NA	outcome_variable_type	Continuous (count, mean, ...)
10.1007/s12325-021-01853-0	methodology	3	NA	treatment_name_ipd	rviii-singlechain
10.1007/s12325-021-01853-0	methodology	3	NA	studies_number_ipd	1
10.1007/s12325-021-01853-0	methodology	3	NA	treatment_name_nonipd	rfviiifc
10.1007/s12325-021-01853-0	methodology	3	NA	studies_number_nonipd	4
10.1007/s12325-021-01853-0	methodology	3	NA	paic_type	MAIC
10.1007/s12325-021-01853-0	methodology	3	NA	anchored_yn	No
10.1007/s12325-021-01853-0	methodology	3	NA	paic_form	Simple (ie treatments effects extracted from two studies)
10.1007/s12325-021-01853-0	methodology	3	NA	primary_outcome_yn	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.1007/s12325-021-01853-0	methodology	3	NA	variables_selection_justification	Nothing mentioned, not reported
10.1007/s12325-021-01853-0	methodology	3	NA	pf_yn	No discussion (in the main text) of the status of prognostic factors of the variables
10.1007/s12325-021-01853-0	methodology	3	NA	tem_yn	No discussion (in the main text) of the status of treatment-effect modifiers of the variables
10.1007/s12325-021-01853-0	methodology	3	NA	adjustment_model_details_yn	No
10.1007/s12325-021-01853-0	methodology	3	NA	scale_choice_yn	No
10.1007/s12325-021-01853-0	results	1	NA	contrast_effect_type	RR
10.1007/s12325-021-01853-0	results	1	NA	direction_benefit	inferior
10.1007/s12325-021-01853-0	results	1	NA	ss_ttt_nonipd	111
10.1007/s12325-021-01853-0	results	1	NA	ss_ttt_ipd	146
10.1007/s12325-021-01853-0	results	1	NA	ss_adjusted_ttt_ipd	25.1
10.1007/s12325-021-01853-0	results	1	NA	weights_yn	Not mentioned
10.1007/s12325-021-01853-0	results	1	NA	covariates_yn	Yes
10.1007/s12325-021-01853-0	results	1	NA	covariates_n	4
10.1007/s12325-021-01853-0	results	1	NA	covariates_names	Age, Race/ethnicity, Other(s)
10.1007/s12325-021-01853-0	results	1	NA	contrast_effect_direction	Numerator if ratio, or left side if difference
10.1007/s12325-021-01853-0	results	1	NA	contrast_effect_unadjusted_value	0.55
10.1007/s12325-021-01853-0	results	1	NA	contrast_effect_unadjusted_pvalci	[0.17;3.12]
10.1007/s12325-021-01853-0	results	1	NA	contrast_effect_adjusted_value	0.74
10.1007/s12325-021-01853-0	results	1	NA	contrast_effect_adjusted_pvalci	[0.16;3.48]
10.1007/s12325-021-01853-0	results	1	NA	adjustment_geographical	No
10.1007/s12325-021-01853-0	results	1	NA	ss_total_ipd	NA
10.1007/s12325-021-01853-0	results	1	NA	ss_adjusted_total_ipd	NA
10.1007/s12325-021-01853-0	results	1	NA	ss_total_nonipd	NA
10.1007/s12325-021-01853-0	results	1	NA	ss_anchor_nonipd	NA
10.1007/s12325-021-01853-0	results	1	NA	ss_anchor_ipd	NA
10.1007/s12325-021-01853-0	results	1	NA	ss_adjusted_anchor_ipd	NA
10.1007/s12325-021-01853-0	results	1	NA	effect_cutoff	1
10.1007/s12325-021-01853-0	results	1	NA	unadjusted_lb_ci	0.17
10.1007/s12325-021-01853-0	results	1	NA	unadjusted_ub_ci	3.12
10.1007/s12325-021-01853-0	results	1	NA	unadjusted_significant	FALSE
10.1007/s12325-021-01853-0	results	1	NA	adjusted_lb_ci	0.16
10.1007/s12325-021-01853-0	results	1	NA	adjusted_ub_ci	3.48
10.1007/s12325-021-01853-0	results	1	NA	adjusted_significant	FALSE
10.1007/s12325-021-01853-0	results	2	NA	contrast_effect_type	RR
10.1007/s12325-021-01853-0	results	2	NA	direction_benefit	inferior
10.1007/s12325-021-01853-0	results	2	NA	ss_ttt_nonipd	32
10.1007/s12325-021-01853-0	results	2	NA	ss_ttt_ipd	146
10.1007/s12325-021-01853-0	results	2	NA	ss_adjusted_ttt_ipd	79
10.1007/s12325-021-01853-0	results	2	NA	weights_yn	Not mentioned
10.1007/s12325-021-01853-0	results	2	NA	covariates_yn	Yes
10.1007/s12325-021-01853-0	results	2	NA	covariates_n	2
10.1007/s12325-021-01853-0	results	2	NA	covariates_names	Age, Race/ethnicity
10.1007/s12325-021-01853-0	results	2	NA	contrast_effect_direction	Numerator if ratio, or left side if difference
10.1007/s12325-021-01853-0	results	2	NA	contrast_effect_unadjusted_value	0.07
10.1007/s12325-021-01853-0	results	2	NA	contrast_effect_unadjusted_pvalci	[-3.09;3.23]
10.1007/s12325-021-01853-0	results	2	NA	contrast_effect_adjusted_value	0.01
10.1007/s12325-021-01853-0	results	2	NA	contrast_effect_adjusted_pvalci	[-2.36;2.37]
10.1007/s12325-021-01853-0	results	2	NA	adjustment_geographical	NA
10.1007/s12325-021-01853-0	results	2	NA	ss_total_ipd	NA
10.1007/s12325-021-01853-0	results	2	NA	ss_adjusted_total_ipd	NA
10.1007/s12325-021-01853-0	results	2	NA	ss_total_nonipd	NA
10.1007/s12325-021-01853-0	results	2	NA	ss_anchor_nonipd	NA
10.1007/s12325-021-01853-0	results	2	NA	ss_anchor_ipd	NA
10.1007/s12325-021-01853-0	results	2	NA	ss_adjusted_anchor_ipd	NA
10.1007/s12325-021-01853-0	results	2	NA	effect_cutoff	1
10.1007/s12325-021-01853-0	results	2	NA	unadjusted_lb_ci	-3.09
10.1007/s12325-021-01853-0	results	2	NA	unadjusted_ub_ci	3.23
10.1007/s12325-021-01853-0	results	2	NA	unadjusted_significant	FALSE
10.1007/s12325-021-01853-0	results	2	NA	adjusted_lb_ci	-2.36
10.1007/s12325-021-01853-0	results	2	NA	adjusted_ub_ci	2.37
10.1007/s12325-021-01853-0	results	2	NA	adjusted_significant	FALSE
10.1007/s12325-021-01853-0	results	3	NA	contrast_effect_type	RR
10.1007/s12325-021-01853-0	results	3	NA	direction_benefit	inferior
10.1007/s12325-021-01853-0	results	3	NA	ss_ttt_nonipd	118
10.1007/s12325-021-01853-0	results	3	NA	ss_ttt_ipd	146
10.1007/s12325-021-01853-0	results	3	NA	ss_adjusted_ttt_ipd	123.6
10.1007/s12325-021-01853-0	results	3	NA	weights_yn	Not mentioned
10.1007/s12325-021-01853-0	results	3	NA	covariates_yn	Yes
10.1007/s12325-021-01853-0	results	3	NA	covariates_n	4
10.1007/s12325-021-01853-0	results	3	NA	covariates_names	Age, Race/ethnicity, Other(s)
10.1007/s12325-021-01853-0	results	3	NA	contrast_effect_direction	Numerator if ratio, or left side if difference
10.1007/s12325-021-01853-0	results	3	NA	contrast_effect_unadjusted_value	1.14
10.1007/s12325-021-01853-0	results	3	NA	contrast_effect_unadjusted_pvalci	[0.82;1.57]
10.1007/s12325-021-01853-0	results	3	NA	contrast_effect_adjusted_value	1.18
10.1007/s12325-021-01853-0	results	3	NA	contrast_effect_adjusted_pvalci	[0.85;1.65]
10.1007/s12325-021-01853-0	results	3	NA	adjustment_geographical	Yes
10.1007/s12325-021-01853-0	results	3	NA	ss_total_ipd	NA
10.1007/s12325-021-01853-0	results	3	NA	ss_adjusted_total_ipd	NA
10.1007/s12325-021-01853-0	results	3	NA	ss_total_nonipd	NA
10.1007/s12325-021-01853-0	results	3	NA	ss_anchor_nonipd	NA
10.1007/s12325-021-01853-0	results	3	NA	ss_anchor_ipd	NA
10.1007/s12325-021-01853-0	results	3	NA	ss_adjusted_anchor_ipd	NA
10.1007/s12325-021-01853-0	results	3	NA	effect_cutoff	1
10.1007/s12325-021-01853-0	results	3	NA	unadjusted_lb_ci	0.82
10.1007/s12325-021-01853-0	results	3	NA	unadjusted_ub_ci	1.57
10.1007/s12325-021-01853-0	results	3	NA	unadjusted_significant	FALSE
10.1007/s12325-021-01853-0	results	3	NA	adjusted_lb_ci	0.85
10.1007/s12325-021-01853-0	results	3	NA	adjusted_ub_ci	1.65
10.1007/s12325-021-01853-0	results	3	NA	adjusted_significant	FALSE
10.1007/s12325-021-01853-0	study_information	NA	1	ipd_yn	Yes
10.1007/s12325-021-01853-0	study_information	NA	1	ct_yn	Yes
10.1007/s12325-021-01853-0	study_information	NA	1	nct	NCT01486927
10.1007/s12325-021-01853-0	study_information	NA	1	country_study	international
10.1007/s12325-021-01853-0	study_information	NA	1	ct_phase	1, 3
10.1007/s12325-021-01853-0	study_information	NA	1	ct_arms	1
10.1007/s12325-021-01853-0	study_information	NA	2	ipd_yn	No
10.1007/s12325-021-01853-0	study_information	NA	2	ct_yn	Yes
10.1007/s12325-021-01853-0	study_information	NA	2	data_source_name	rahf-pfm-2004 - part 2 10.1111/j.1365-2516.2004.00932.x
10.1007/s12325-021-01853-0	study_information	NA	2	country_study	international
10.1007/s12325-021-01853-0	study_information	NA	2	ct_arms	??
10.1007/s12325-021-01853-0	study_information	NA	3	ipd_yn	No
10.1007/s12325-021-01853-0	study_information	NA	3	ct_yn	Yes
10.1007/s12325-021-01853-0	study_information	NA	3	nct	NCT00243386
10.1007/s12325-021-01853-0	study_information	NA	3	country_study	international
10.1007/s12325-021-01853-0	study_information	NA	3	ct_phase	4
10.1007/s12325-021-01853-0	study_information	NA	3	ct_arms	2 or more
10.1007/s12325-021-01853-0	study_information	NA	4	ipd_yn	No
10.1007/s12325-021-01853-0	study_information	NA	4	ct_yn	Yes
10.1007/s12325-021-01853-0	study_information	NA	4	nct	NCT01181128
10.1007/s12325-021-01853-0	study_information	NA	4	country_study	international
10.1007/s12325-021-01853-0	study_information	NA	4	ct_phase	3
10.1007/s12325-021-01853-0	study_information	NA	4	ct_arms	2 or more
10.1007/s12325-021-01884-7	general_information	NA	NA	condition_name	relapsed/refractory multiple myeloma
10.1007/s12325-021-01884-7	general_information	NA	NA	country_first_author	france
10.1007/s12325-021-01884-7	general_information	NA	NA	country_last_author	uk
10.1007/s12325-021-01884-7	general_information	NA	NA	positions	Academic, Pharmaceutical Industry, Private Data Analysis Company
10.1007/s12325-021-01884-7	general_information	NA	NA	methodologist_yn	Yes
10.1007/s12325-021-01884-7	general_information	NA	NA	funding_source	Pharmaceutical Industry
10.1007/s12325-021-01884-7	general_information	NA	NA	pharmaceutical_ties_yn	Yes
10.1007/s12325-021-01884-7	general_information	NA	NA	systematic_review_yn	Yes
10.1007/s12325-021-01884-7	methodology	1	NA	outcome_name	overall survival
10.1007/s12325-021-01884-7	methodology	1	NA	outcome_short_name	Overall Survival
10.1007/s12325-021-01884-7	methodology	1	NA	outcome_variable_type	Time-to-event
10.1007/s12325-021-01884-7	methodology	1	NA	treatment_name_ipd	belantamab mafodotin
10.1007/s12325-021-01884-7	methodology	1	NA	studies_number_ipd	1
10.1007/s12325-021-01884-7	methodology	1	NA	treatment_name_nonipd	selinexor + dexamethasone
10.1007/s12325-021-01884-7	methodology	1	NA	studies_number_nonipd	2
10.1007/s12325-021-01884-7	methodology	1	NA	paic_type	MAIC
10.1007/s12325-021-01884-7	methodology	1	NA	anchored_yn	No
10.1007/s12325-021-01884-7	methodology	1	NA	paic_form	Simple (ie treatments effects extracted from two studies)
10.1007/s12325-021-01884-7	methodology	1	NA	primary_outcome_yn	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.1007/s12325-021-01884-7	methodology	1	NA	variables_selection_justification	Status of prognostic factor/treatment effect modified assessed in the IPD dataset, A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion)
10.1007/s12325-021-01884-7	methodology	1	NA	pf_yn	Yes
10.1007/s12325-021-01884-7	methodology	1	NA	tem_yn	Yes
10.1007/s12325-021-01884-7	methodology	1	NA	adjustment_model_details_yn	No
10.1007/s12325-021-01884-7	methodology	1	NA	scale_choice_yn	No
10.1007/s12325-021-01884-7	results	1	NA	contrast_effect_type	HR
10.1007/s12325-021-01884-7	results	1	NA	direction_benefit	inferior
10.1007/s12325-021-01884-7	results	1	NA	ss_ttt_nonipd	122
10.1007/s12325-021-01884-7	results	1	NA	ss_ttt_ipd	95
10.1007/s12325-021-01884-7	results	1	NA	ss_adjusted_ttt_ipd	63.46
10.1007/s12325-021-01884-7	results	1	NA	weights_yn	Yes, mentions that the weights distribution has been studied, but weights distribution not reported
10.1007/s12325-021-01884-7	results	1	NA	covariates_yn	Yes
10.1007/s12325-021-01884-7	results	1	NA	covariates_n	8
10.1007/s12325-021-01884-7	results	1	NA	covariates_names	Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Past treatments for the disease of interest, Comorbidities and medical history (beside pathology/disease of interest in the comparison)
10.1007/s12325-021-01884-7	results	1	NA	contrast_effect_direction	Numerator if ratio, or left side if difference
10.1007/s12325-021-01884-7	results	1	NA	contrast_effect_unadjusted_value	0.6
10.1007/s12325-021-01884-7	results	1	NA	contrast_effect_unadjusted_pvalci	0.01
10.1007/s12325-021-01884-7	results	1	NA	contrast_effect_adjusted_value	0.53
10.1007/s12325-021-01884-7	results	1	NA	contrast_effect_adjusted_pvalci	0.005
10.1007/s12325-021-01884-7	results	1	NA	adjustment_geographical	NA
10.1007/s12325-021-01884-7	results	1	NA	ss_total_ipd	NA
10.1007/s12325-021-01884-7	results	1	NA	ss_adjusted_total_ipd	NA
10.1007/s12325-021-01884-7	results	1	NA	ss_total_nonipd	NA
10.1007/s12325-021-01884-7	results	1	NA	ss_anchor_nonipd	NA
10.1007/s12325-021-01884-7	results	1	NA	ss_anchor_ipd	NA
10.1007/s12325-021-01884-7	results	1	NA	ss_adjusted_anchor_ipd	NA
10.1007/s12325-021-01884-7	results	1	NA	effect_cutoff	1
10.1007/s12325-021-01884-7	results	1	NA	unadjusted_pval	0.01
10.1007/s12325-021-01884-7	results	1	NA	unadjusted_num_pval	0.01
10.1007/s12325-021-01884-7	results	1	NA	unadjusted_significant	TRUE
10.1007/s12325-021-01884-7	results	1	NA	adjusted_pval	0.005
10.1007/s12325-021-01884-7	results	1	NA	adjusted_num_pval	0.005
10.1007/s12325-021-01884-7	results	1	NA	adjusted_significant	TRUE
10.1007/s12325-021-01884-7	study_information	NA	1	ipd_yn	Yes
10.1007/s12325-021-01884-7	study_information	NA	1	ct_yn	Yes
10.1007/s12325-021-01884-7	study_information	NA	1	nct	NCT03525678
10.1007/s12325-021-01884-7	study_information	NA	1	country_study	international
10.1007/s12325-021-01884-7	study_information	NA	1	ct_phase	2
10.1007/s12325-021-01884-7	study_information	NA	1	ct_arms	1
10.1007/s12325-021-01884-7	study_information	NA	2	ipd_yn	No
10.1007/s12325-021-01884-7	study_information	NA	2	ct_yn	Yes
10.1007/s12325-021-01884-7	study_information	NA	2	nct	NCT02336815
10.1007/s12325-021-01884-7	study_information	NA	2	country_study	international
10.1007/s12325-021-01884-7	study_information	NA	2	ct_phase	2
10.1007/s12325-021-01884-7	study_information	NA	2	ct_arms	1
10.1007/s12325-021-01885-6	general_information	NA	NA	condition_name	non-metastatic castration-resistant prostate cancer
10.1007/s12325-021-01885-6	general_information	NA	NA	country_first_author	uk
10.1007/s12325-021-01885-6	general_information	NA	NA	country_last_author	germany
10.1007/s12325-021-01885-6	general_information	NA	NA	positions	Academic, Pharmaceutical Industry
10.1007/s12325-021-01885-6	general_information	NA	NA	methodologist_yn	Not mentioned
10.1007/s12325-021-01885-6	general_information	NA	NA	funding_source	Pharmaceutical Industry
10.1007/s12325-021-01885-6	general_information	NA	NA	pharmaceutical_ties_yn	Yes
10.1007/s12325-021-01885-6	general_information	NA	NA	systematic_review_yn	No
10.1007/s12325-021-01885-6	methodology	1	NA	outcome_name	metastasis-free survival
10.1007/s12325-021-01885-6	methodology	1	NA	outcome_short_name	Metastasis-free Survival
10.1007/s12325-021-01885-6	methodology	1	NA	outcome_variable_type	Time-to-event
10.1007/s12325-021-01885-6	methodology	1	NA	treatment_name_ipd	apalutamide + adt
10.1007/s12325-021-01885-6	methodology	1	NA	studies_number_ipd	1
10.1007/s12325-021-01885-6	methodology	1	NA	treatment_name_nonipd	darolutamide + adt
10.1007/s12325-021-01885-6	methodology	1	NA	studies_number_nonipd	2
10.1007/s12325-021-01885-6	methodology	1	NA	paic_type	MAIC
10.1007/s12325-021-01885-6	methodology	1	NA	anchored_yn	Yes
10.1007/s12325-021-01885-6	methodology	1	NA	paic_form	Simple (ie treatments effects extracted from two studies)
10.1007/s12325-021-01885-6	methodology	1	NA	primary_outcome_yn	Yes
10.1007/s12325-021-01885-6	methodology	1	NA	variables_selection_justification	Nothing mentioned, not reported
10.1007/s12325-021-01885-6	methodology	1	NA	pf_yn	No
10.1007/s12325-021-01885-6	methodology	1	NA	tem_yn	Yes
10.1007/s12325-021-01885-6	methodology	1	NA	adjustment_model_details_yn	No
10.1007/s12325-021-01885-6	methodology	1	NA	scale_choice_yn	No
10.1007/s12325-021-01885-6	results	1	NA	contrast_effect_type	HR
10.1007/s12325-021-01885-6	results	1	NA	direction_benefit	inferior
10.1007/s12325-021-01885-6	results	1	NA	ss_ttt_nonipd	955
10.1007/s12325-021-01885-6	results	1	NA	ss_ttt_ipd	NA
10.1007/s12325-021-01885-6	results	1	NA	ss_adjusted_ttt_ipd	NA
10.1007/s12325-021-01885-6	results	1	NA	weights_yn	Not mentioned
10.1007/s12325-021-01885-6	results	1	NA	covariates_yn	Yes
10.1007/s12325-021-01885-6	results	1	NA	covariates_n	9
10.1007/s12325-021-01885-6	results	1	NA	covariates_names	Age, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Past treatments for the disease of interest, Other(s)
10.1007/s12325-021-01885-6	results	1	NA	contrast_effect_direction	Numerator if ratio, or left side if difference
10.1007/s12325-021-01885-6	results	1	NA	contrast_effect_unadjusted_value	NA
10.1007/s12325-021-01885-6	results	1	NA	contrast_effect_unadjusted_pvalci	NA
10.1007/s12325-021-01885-6	results	1	NA	contrast_effect_adjusted_value	0.7
10.1007/s12325-021-01885-6	results	1	NA	contrast_effect_adjusted_pvalci	[0.51;0.98]
10.1007/s12325-021-01885-6	results	1	NA	adjustment_geographical	Yes
10.1007/s12325-021-01885-6	results	1	NA	ss_total_ipd	1150
10.1007/s12325-021-01885-6	results	1	NA	ss_adjusted_total_ipd	455
10.1007/s12325-021-01885-6	results	1	NA	ss_total_nonipd	1509
10.1007/s12325-021-01885-6	results	1	NA	ss_anchor_nonipd	554
10.1007/s12325-021-01885-6	results	1	NA	ss_anchor_ipd	NA
10.1007/s12325-021-01885-6	results	1	NA	ss_adjusted_anchor_ipd	NA
10.1007/s12325-021-01885-6	results	1	NA	effect_cutoff	1
10.1007/s12325-021-01885-6	results	1	NA	adjusted_lb_ci	0.51
10.1007/s12325-021-01885-6	results	1	NA	adjusted_ub_ci	0.98
10.1007/s12325-021-01885-6	results	1	NA	adjusted_significant	TRUE
10.1007/s12325-021-01885-6	study_information	NA	1	ipd_yn	Yes
10.1007/s12325-021-01885-6	study_information	NA	1	ct_yn	Yes
10.1007/s12325-021-01885-6	study_information	NA	1	nct	NCT01946204
10.1007/s12325-021-01885-6	study_information	NA	1	country_study	international
10.1007/s12325-021-01885-6	study_information	NA	1	ct_phase	3
10.1007/s12325-021-01885-6	study_information	NA	1	ct_arms	2 or more
10.1007/s12325-021-01885-6	study_information	NA	2	ipd_yn	No
10.1007/s12325-021-01885-6	study_information	NA	2	ct_yn	Yes
10.1007/s12325-021-01885-6	study_information	NA	2	nct	NCT02200614
10.1007/s12325-021-01885-6	study_information	NA	2	country_study	international
10.1007/s12325-021-01885-6	study_information	NA	2	ct_phase	3
10.1007/s12325-021-01885-6	study_information	NA	2	ct_arms	2 or more
10.1007/s12325-022-02054-z	general_information	NA	NA	condition_name	relapsed or refractory follicular lymphoma
10.1007/s12325-022-02054-z	general_information	NA	NA	country_first_author	usa
10.1007/s12325-022-02054-z	general_information	NA	NA	country_last_author	usa
10.1007/s12325-022-02054-z	general_information	NA	NA	positions	Pharmaceutical Industry, Private Data Analysis Company
10.1007/s12325-022-02054-z	general_information	NA	NA	methodologist_yn	Yes
10.1007/s12325-022-02054-z	general_information	NA	NA	funding_source	Pharmaceutical Industry
10.1007/s12325-022-02054-z	general_information	NA	NA	pharmaceutical_ties_yn	Yes
10.1007/s12325-022-02054-z	general_information	NA	NA	systematic_review_yn	Yes
10.1007/s12325-022-02054-z	methodology	1	NA	outcome_name	grade >= 3 treatment emergent adverse event
10.1007/s12325-022-02054-z	methodology	1	NA	outcome_short_name	Adverse Event
10.1007/s12325-022-02054-z	methodology	1	NA	outcome_variable_type	Binary (eg rates)
10.1007/s12325-022-02054-z	methodology	1	NA	treatment_name_ipd	tazemetostat
10.1007/s12325-022-02054-z	methodology	1	NA	studies_number_ipd	1
10.1007/s12325-022-02054-z	methodology	1	NA	treatment_name_nonipd	idelalisib
10.1007/s12325-022-02054-z	methodology	1	NA	studies_number_nonipd	2
10.1007/s12325-022-02054-z	methodology	1	NA	paic_type	MAIC
10.1007/s12325-022-02054-z	methodology	1	NA	anchored_yn	No
10.1007/s12325-022-02054-z	methodology	1	NA	paic_form	Simple (ie treatments effects extracted from two studies)
10.1007/s12325-022-02054-z	methodology	1	NA	primary_outcome_yn	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.1007/s12325-022-02054-z	methodology	1	NA	variables_selection_justification	A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion)
10.1007/s12325-022-02054-z	methodology	1	NA	pf_yn	Yes
10.1007/s12325-022-02054-z	methodology	1	NA	tem_yn	Yes
10.1007/s12325-022-02054-z	methodology	1	NA	adjustment_model_details_yn	No
10.1007/s12325-022-02054-z	methodology	1	NA	scale_choice_yn	No
10.1007/s12325-022-02054-z	methodology	2	NA	outcome_name	grade >= 3 treatment emergent adverse event
10.1007/s12325-022-02054-z	methodology	2	NA	outcome_short_name	Adverse Event
10.1007/s12325-022-02054-z	methodology	2	NA	outcome_variable_type	Binary (eg rates)
10.1007/s12325-022-02054-z	methodology	2	NA	treatment_name_ipd	tazemetostat
10.1007/s12325-022-02054-z	methodology	2	NA	studies_number_ipd	1
10.1007/s12325-022-02054-z	methodology	2	NA	treatment_name_nonipd	duvelisib
10.1007/s12325-022-02054-z	methodology	2	NA	studies_number_nonipd	3
10.1007/s12325-022-02054-z	methodology	2	NA	paic_type	MAIC
10.1007/s12325-022-02054-z	methodology	2	NA	anchored_yn	No
10.1007/s12325-022-02054-z	methodology	2	NA	paic_form	Simple (ie treatments effects extracted from two studies)
10.1007/s12325-022-02054-z	methodology	2	NA	primary_outcome_yn	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.1007/s12325-022-02054-z	methodology	2	NA	variables_selection_justification	A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion)
10.1007/s12325-022-02054-z	methodology	2	NA	pf_yn	Yes
10.1007/s12325-022-02054-z	methodology	2	NA	tem_yn	Yes
10.1007/s12325-022-02054-z	methodology	2	NA	adjustment_model_details_yn	No
10.1007/s12325-022-02054-z	methodology	2	NA	scale_choice_yn	No
10.1007/s12325-022-02054-z	methodology	3	NA	outcome_name	grade >= 3 treatment emergent adverse event
10.1007/s12325-022-02054-z	methodology	3	NA	outcome_short_name	Adverse Event
10.1007/s12325-022-02054-z	methodology	3	NA	outcome_variable_type	Binary (eg rates)
10.1007/s12325-022-02054-z	methodology	3	NA	treatment_name_ipd	tazemetostat
10.1007/s12325-022-02054-z	methodology	3	NA	studies_number_ipd	1
10.1007/s12325-022-02054-z	methodology	3	NA	treatment_name_nonipd	copanlisib
10.1007/s12325-022-02054-z	methodology	3	NA	studies_number_nonipd	4
10.1007/s12325-022-02054-z	methodology	3	NA	paic_type	MAIC
10.1007/s12325-022-02054-z	methodology	3	NA	anchored_yn	No
10.1007/s12325-022-02054-z	methodology	3	NA	paic_form	Simple (ie treatments effects extracted from two studies)
10.1007/s12325-022-02054-z	methodology	3	NA	primary_outcome_yn	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.1007/s12325-022-02054-z	methodology	3	NA	variables_selection_justification	A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion)
10.1007/s12325-022-02054-z	methodology	3	NA	pf_yn	Yes
10.1007/s12325-022-02054-z	methodology	3	NA	tem_yn	Yes
10.1007/s12325-022-02054-z	methodology	3	NA	adjustment_model_details_yn	No
10.1007/s12325-022-02054-z	methodology	3	NA	scale_choice_yn	No
10.1007/s12325-022-02054-z	methodology	4	NA	outcome_name	grade >= 3 treatment emergent adverse event
10.1007/s12325-022-02054-z	methodology	4	NA	outcome_short_name	Adverse Event
10.1007/s12325-022-02054-z	methodology	4	NA	outcome_variable_type	Binary (eg rates)
10.1007/s12325-022-02054-z	methodology	4	NA	treatment_name_ipd	tazemetostat
10.1007/s12325-022-02054-z	methodology	4	NA	studies_number_ipd	1
10.1007/s12325-022-02054-z	methodology	4	NA	treatment_name_nonipd	umbralisib
10.1007/s12325-022-02054-z	methodology	4	NA	studies_number_nonipd	5
10.1007/s12325-022-02054-z	methodology	4	NA	paic_type	MAIC
10.1007/s12325-022-02054-z	methodology	4	NA	anchored_yn	No
10.1007/s12325-022-02054-z	methodology	4	NA	paic_form	Simple (ie treatments effects extracted from two studies)
10.1007/s12325-022-02054-z	methodology	4	NA	primary_outcome_yn	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.1007/s12325-022-02054-z	methodology	4	NA	variables_selection_justification	A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion)
10.1007/s12325-022-02054-z	methodology	4	NA	pf_yn	Yes
10.1007/s12325-022-02054-z	methodology	4	NA	tem_yn	Yes
10.1007/s12325-022-02054-z	methodology	4	NA	adjustment_model_details_yn	No
10.1007/s12325-022-02054-z	methodology	4	NA	scale_choice_yn	No
10.1007/s12325-022-02054-z	results	1	NA	contrast_effect_type	RR
10.1007/s12325-022-02054-z	results	1	NA	direction_benefit	inferior
10.1007/s12325-022-02054-z	results	1	NA	ss_ttt_nonipd	72
10.1007/s12325-022-02054-z	results	1	NA	ss_ttt_ipd	99
10.1007/s12325-022-02054-z	results	1	NA	ss_adjusted_ttt_ipd	36
10.1007/s12325-022-02054-z	results	1	NA	weights_yn	Not mentioned
10.1007/s12325-022-02054-z	results	1	NA	covariates_yn	Yes
10.1007/s12325-022-02054-z	results	1	NA	covariates_n	8
10.1007/s12325-022-02054-z	results	1	NA	covariates_names	Age, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Past treatments for the disease of interest
10.1007/s12325-022-02054-z	results	1	NA	contrast_effect_direction	Numerator if ratio, or left side if difference
10.1007/s12325-022-02054-z	results	1	NA	contrast_effect_unadjusted_value	0.59
10.1007/s12325-022-02054-z	results	1	NA	contrast_effect_unadjusted_pvalci	<0.001
10.1007/s12325-022-02054-z	results	1	NA	contrast_effect_adjusted_value	0.45
10.1007/s12325-022-02054-z	results	1	NA	contrast_effect_adjusted_pvalci	<0.001
10.1007/s12325-022-02054-z	results	1	NA	adjustment_geographical	No
10.1007/s12325-022-02054-z	results	1	NA	ss_total_ipd	NA
10.1007/s12325-022-02054-z	results	1	NA	ss_adjusted_total_ipd	NA
10.1007/s12325-022-02054-z	results	1	NA	ss_total_nonipd	NA
10.1007/s12325-022-02054-z	results	1	NA	ss_anchor_nonipd	NA
10.1007/s12325-022-02054-z	results	1	NA	ss_anchor_ipd	NA
10.1007/s12325-022-02054-z	results	1	NA	ss_adjusted_anchor_ipd	NA
10.1007/s12325-022-02054-z	results	1	NA	effect_cutoff	1
10.1007/s12325-022-02054-z	results	1	NA	unadjusted_pval	<0.001
10.1007/s12325-022-02054-z	results	1	NA	unadjusted_significant	TRUE
10.1007/s12325-022-02054-z	results	1	NA	adjusted_pval	<0.001
10.1007/s12325-022-02054-z	results	1	NA	adjusted_significant	TRUE
10.1007/s12325-022-02054-z	results	2	NA	contrast_effect_type	RR
10.1007/s12325-022-02054-z	results	2	NA	direction_benefit	inferior
10.1007/s12325-022-02054-z	results	2	NA	ss_ttt_nonipd	129
10.1007/s12325-022-02054-z	results	2	NA	ss_ttt_ipd	99
10.1007/s12325-022-02054-z	results	2	NA	ss_adjusted_ttt_ipd	24
10.1007/s12325-022-02054-z	results	2	NA	weights_yn	Not mentioned
10.1007/s12325-022-02054-z	results	2	NA	covariates_yn	Yes
10.1007/s12325-022-02054-z	results	2	NA	covariates_n	8
10.1007/s12325-022-02054-z	results	2	NA	covariates_names	Age, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Past treatments for the disease of interest
10.1007/s12325-022-02054-z	results	2	NA	contrast_effect_direction	Numerator if ratio, or left side if difference
10.1007/s12325-022-02054-z	results	2	NA	contrast_effect_unadjusted_value	0.45
10.1007/s12325-022-02054-z	results	2	NA	contrast_effect_unadjusted_pvalci	<0.001
10.1007/s12325-022-02054-z	results	2	NA	contrast_effect_adjusted_value	0.35
10.1007/s12325-022-02054-z	results	2	NA	contrast_effect_adjusted_pvalci	<0.001
10.1007/s12325-022-02054-z	results	2	NA	adjustment_geographical	No
10.1007/s12325-022-02054-z	results	2	NA	ss_total_ipd	NA
10.1007/s12325-022-02054-z	results	2	NA	ss_adjusted_total_ipd	NA
10.1007/s12325-022-02054-z	results	2	NA	ss_total_nonipd	NA
10.1007/s12325-022-02054-z	results	2	NA	ss_anchor_nonipd	NA
10.1007/s12325-022-02054-z	results	2	NA	ss_anchor_ipd	NA
10.1007/s12325-022-02054-z	results	2	NA	ss_adjusted_anchor_ipd	NA
10.1007/s12325-022-02054-z	results	2	NA	effect_cutoff	1
10.1007/s12325-022-02054-z	results	2	NA	unadjusted_pval	<0.001
10.1007/s12325-022-02054-z	results	2	NA	unadjusted_significant	TRUE
10.1007/s12325-022-02054-z	results	2	NA	adjusted_pval	<0.001
10.1007/s12325-022-02054-z	results	2	NA	adjusted_significant	TRUE
10.1007/s12325-022-02054-z	results	3	NA	contrast_effect_type	RR
10.1007/s12325-022-02054-z	results	3	NA	direction_benefit	inferior
10.1007/s12325-022-02054-z	results	3	NA	ss_ttt_nonipd	142
10.1007/s12325-022-02054-z	results	3	NA	ss_ttt_ipd	99
10.1007/s12325-022-02054-z	results	3	NA	ss_adjusted_ttt_ipd	66
10.1007/s12325-022-02054-z	results	3	NA	weights_yn	Not mentioned
10.1007/s12325-022-02054-z	results	3	NA	covariates_yn	Yes
10.1007/s12325-022-02054-z	results	3	NA	covariates_n	7
10.1007/s12325-022-02054-z	results	3	NA	covariates_names	Age, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Past treatments for the disease of interest
10.1007/s12325-022-02054-z	results	3	NA	contrast_effect_direction	Numerator if ratio, or left side if difference
10.1007/s12325-022-02054-z	results	3	NA	contrast_effect_unadjusted_value	0.47
10.1007/s12325-022-02054-z	results	3	NA	contrast_effect_unadjusted_pvalci	<0.001
10.1007/s12325-022-02054-z	results	3	NA	contrast_effect_adjusted_value	0.37
10.1007/s12325-022-02054-z	results	3	NA	contrast_effect_adjusted_pvalci	<0.001
10.1007/s12325-022-02054-z	results	3	NA	adjustment_geographical	No
10.1007/s12325-022-02054-z	results	3	NA	ss_total_ipd	NA
10.1007/s12325-022-02054-z	results	3	NA	ss_adjusted_total_ipd	NA
10.1007/s12325-022-02054-z	results	3	NA	ss_total_nonipd	NA
10.1007/s12325-022-02054-z	results	3	NA	ss_anchor_nonipd	NA
10.1007/s12325-022-02054-z	results	3	NA	ss_anchor_ipd	NA
10.1007/s12325-022-02054-z	results	3	NA	ss_adjusted_anchor_ipd	NA
10.1007/s12325-022-02054-z	results	3	NA	effect_cutoff	1
10.1007/s12325-022-02054-z	results	3	NA	unadjusted_pval	<0.001
10.1007/s12325-022-02054-z	results	3	NA	unadjusted_significant	TRUE
10.1007/s12325-022-02054-z	results	3	NA	adjusted_pval	<0.001
10.1007/s12325-022-02054-z	results	3	NA	adjusted_significant	TRUE
10.1007/s12325-022-02054-z	results	4	NA	contrast_effect_type	RR
10.1007/s12325-022-02054-z	results	4	NA	direction_benefit	inferior
10.1007/s12325-022-02054-z	results	4	NA	ss_ttt_nonipd	208
10.1007/s12325-022-02054-z	results	4	NA	ss_ttt_ipd	99
10.1007/s12325-022-02054-z	results	4	NA	ss_adjusted_ttt_ipd	60
10.1007/s12325-022-02054-z	results	4	NA	weights_yn	Not mentioned
10.1007/s12325-022-02054-z	results	4	NA	covariates_yn	Yes
10.1007/s12325-022-02054-z	results	4	NA	covariates_n	6
10.1007/s12325-022-02054-z	results	4	NA	covariates_names	Age, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Past treatments for the disease of interest
10.1007/s12325-022-02054-z	results	4	NA	contrast_effect_direction	Numerator if ratio, or left side if difference
10.1007/s12325-022-02054-z	results	4	NA	contrast_effect_unadjusted_value	0.74
10.1007/s12325-022-02054-z	results	4	NA	contrast_effect_unadjusted_pvalci	<0.05
10.1007/s12325-022-02054-z	results	4	NA	contrast_effect_adjusted_value	0.65
10.1007/s12325-022-02054-z	results	4	NA	contrast_effect_adjusted_pvalci	<0.01
10.1007/s12325-022-02054-z	results	4	NA	adjustment_geographical	No
10.1007/s12325-022-02054-z	results	4	NA	ss_total_ipd	NA
10.1007/s12325-022-02054-z	results	4	NA	ss_adjusted_total_ipd	NA
10.1007/s12325-022-02054-z	results	4	NA	ss_total_nonipd	NA
10.1007/s12325-022-02054-z	results	4	NA	ss_anchor_nonipd	NA
10.1007/s12325-022-02054-z	results	4	NA	ss_anchor_ipd	NA
10.1007/s12325-022-02054-z	results	4	NA	ss_adjusted_anchor_ipd	NA
10.1007/s12325-022-02054-z	results	4	NA	effect_cutoff	1
10.1007/s12325-022-02054-z	results	4	NA	unadjusted_pval	<0.05
10.1007/s12325-022-02054-z	results	4	NA	unadjusted_significant	TRUE
10.1007/s12325-022-02054-z	results	4	NA	adjusted_pval	<0.01
10.1007/s12325-022-02054-z	results	4	NA	adjusted_significant	TRUE
10.1007/s12325-022-02054-z	study_information	NA	1	ipd_yn	Yes
10.1007/s12325-022-02054-z	study_information	NA	1	ct_yn	Yes
10.1007/s12325-022-02054-z	study_information	NA	1	nct	NCT01897571
10.1007/s12325-022-02054-z	study_information	NA	1	country_study	international
10.1007/s12325-022-02054-z	study_information	NA	1	ct_phase	1, 2
10.1007/s12325-022-02054-z	study_information	NA	1	ct_arms	1
10.1007/s12325-022-02054-z	study_information	NA	2	ipd_yn	No
10.1007/s12325-022-02054-z	study_information	NA	2	ct_yn	Yes
10.1007/s12325-022-02054-z	study_information	NA	2	nct	NCT01282424
10.1007/s12325-022-02054-z	study_information	NA	2	country_study	international
10.1007/s12325-022-02054-z	study_information	NA	2	ct_phase	2
10.1007/s12325-022-02054-z	study_information	NA	2	ct_arms	1
10.1007/s12325-022-02054-z	study_information	NA	3	ipd_yn	No
10.1007/s12325-022-02054-z	study_information	NA	3	ct_yn	Yes
10.1007/s12325-022-02054-z	study_information	NA	3	country_study	international
10.1007/s12325-022-02054-z	study_information	NA	3	ct_phase	2
10.1007/s12325-022-02054-z	study_information	NA	3	ct_arms	1
10.1007/s12325-022-02054-z	study_information	NA	3	nct	NCT01882803
10.1007/s12325-022-02054-z	study_information	NA	4	ipd_yn	No
10.1007/s12325-022-02054-z	study_information	NA	4	ct_yn	Yes
10.1007/s12325-022-02054-z	study_information	NA	4	nct	NCT01660451
10.1007/s12325-022-02054-z	study_information	NA	4	country_study	international
10.1007/s12325-022-02054-z	study_information	NA	4	ct_phase	2
10.1007/s12325-022-02054-z	study_information	NA	4	ct_arms	1
10.1007/s12325-022-02054-z	study_information	NA	5	ipd_yn	No
10.1007/s12325-022-02054-z	study_information	NA	5	ct_yn	Yes
10.1007/s12325-022-02054-z	study_information	NA	5	nct	NCT02793583
10.1007/s12325-022-02054-z	study_information	NA	5	country_study	international
10.1007/s12325-022-02054-z	study_information	NA	5	ct_phase	2
10.1007/s12325-022-02054-z	study_information	NA	5	ct_arms	2 or more
10.1007/s12325-022-02099-0	general_information	NA	NA	condition_name	unresectable hepatocellular carcinoma
10.1007/s12325-022-02099-0	general_information	NA	NA	country_first_author	germany
10.1007/s12325-022-02099-0	general_information	NA	NA	country_last_author	france
10.1007/s12325-022-02099-0	general_information	NA	NA	positions	Academic, Pharmaceutical Industry
10.1007/s12325-022-02099-0	general_information	NA	NA	methodologist_yn	Yes
10.1007/s12325-022-02099-0	general_information	NA	NA	funding_source	Pharmaceutical Industry
10.1007/s12325-022-02099-0	general_information	NA	NA	pharmaceutical_ties_yn	Yes
10.1007/s12325-022-02099-0	general_information	NA	NA	systematic_review_yn	No
10.1007/s12325-022-02099-0	methodology	1	NA	outcome_name	time to deterioration in quality of life
10.1007/s12325-022-02099-0	methodology	1	NA	outcome_short_name	Time-to-deterioration in quality of life
10.1007/s12325-022-02099-0	methodology	1	NA	outcome_variable_type	Time-to-event
10.1007/s12325-022-02099-0	methodology	1	NA	treatment_name_ipd	transarterial radioembolization
10.1007/s12325-022-02099-0	methodology	1	NA	studies_number_ipd	1
10.1007/s12325-022-02099-0	methodology	1	NA	treatment_name_nonipd	atezolizumab + bevacizumab
10.1007/s12325-022-02099-0	methodology	1	NA	studies_number_nonipd	2
10.1007/s12325-022-02099-0	methodology	1	NA	paic_type	MAIC
10.1007/s12325-022-02099-0	methodology	1	NA	anchored_yn	Yes
10.1007/s12325-022-02099-0	methodology	1	NA	paic_form	Simple (ie treatments effects extracted from two studies)
10.1007/s12325-022-02099-0	methodology	1	NA	primary_outcome_yn	Yes
10.1007/s12325-022-02099-0	methodology	1	NA	variables_selection_justification	Statistical imbalanced between treatment groups (independently of the status of prognostic/effect modifier), Status of prognostic factor/treatment effect modified assessed in the IPD dataset, Literature based (clinically or methodologically relevant to adjust on these variables based on the literature search conducted for this specific purpose)
10.1007/s12325-022-02099-0	methodology	1	NA	pf_yn	No
10.1007/s12325-022-02099-0	methodology	1	NA	tem_yn	Yes
10.1007/s12325-022-02099-0	methodology	1	NA	adjustment_model_details_yn	No
10.1007/s12325-022-02099-0	methodology	1	NA	scale_choice_yn	Yes
10.1007/s12325-022-02099-0	results	1	NA	contrast_effect_type	HR
10.1007/s12325-022-02099-0	results	1	NA	direction_benefit	inferior
10.1007/s12325-022-02099-0	results	1	NA	ss_ttt_nonipd	336
10.1007/s12325-022-02099-0	results	1	NA	ss_ttt_ipd	94
10.1007/s12325-022-02099-0	results	1	NA	ss_adjusted_ttt_ipd	53
10.1007/s12325-022-02099-0	results	1	NA	weights_yn	Not mentioned
10.1007/s12325-022-02099-0	results	1	NA	covariates_yn	Yes
10.1007/s12325-022-02099-0	results	1	NA	covariates_n	4
10.1007/s12325-022-02099-0	results	1	NA	covariates_names	Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Performance score
10.1007/s12325-022-02099-0	results	1	NA	contrast_effect_direction	Numerator if ratio, or left side if difference
10.1007/s12325-022-02099-0	results	1	NA	contrast_effect_unadjusted_value	NA
10.1007/s12325-022-02099-0	results	1	NA	contrast_effect_unadjusted_pvalci	NA
10.1007/s12325-022-02099-0	results	1	NA	contrast_effect_adjusted_value	1.06
10.1007/s12325-022-02099-0	results	1	NA	contrast_effect_adjusted_pvalci	0.725
10.1007/s12325-022-02099-0	results	1	NA	adjustment_geographical	NA
10.1007/s12325-022-02099-0	results	1	NA	ss_total_ipd	NA
10.1007/s12325-022-02099-0	results	1	NA	ss_adjusted_total_ipd	NA
10.1007/s12325-022-02099-0	results	1	NA	ss_total_nonipd	NA
10.1007/s12325-022-02099-0	results	1	NA	ss_anchor_nonipd	165
10.1007/s12325-022-02099-0	results	1	NA	ss_anchor_ipd	123
10.1007/s12325-022-02099-0	results	1	NA	ss_adjusted_anchor_ipd	78
10.1007/s12325-022-02099-0	results	1	NA	effect_cutoff	1
10.1007/s12325-022-02099-0	results	1	NA	adjusted_pval	0.725
10.1007/s12325-022-02099-0	results	1	NA	adjusted_num_pval	0.725
10.1007/s12325-022-02099-0	results	1	NA	adjusted_significant	FALSE
10.1007/s12325-022-02099-0	study_information	NA	1	ipd_yn	Yes
10.1007/s12325-022-02099-0	study_information	NA	1	ct_yn	Yes
10.1007/s12325-022-02099-0	study_information	NA	1	nct	NCT01482442
10.1007/s12325-022-02099-0	study_information	NA	1	country_study	france
10.1007/s12325-022-02099-0	study_information	NA	1	ct_phase	3
10.1007/s12325-022-02099-0	study_information	NA	1	ct_arms	2 or more
10.1007/s12325-022-02099-0	study_information	NA	2	ipd_yn	No
10.1007/s12325-022-02099-0	study_information	NA	2	ct_yn	Yes
10.1007/s12325-022-02099-0	study_information	NA	2	nct	NCT03434379
10.1007/s12325-022-02099-0	study_information	NA	2	country_study	international
10.1007/s12325-022-02099-0	study_information	NA	2	ct_phase	3
10.1007/s12325-022-02099-0	study_information	NA	2	ct_arms	2 or more
10.1007/s13555-021-00646-1	general_information	NA	NA	condition_name	mild-to-moderate atopic dermatitis
10.1007/s13555-021-00646-1	general_information	NA	NA	country_first_author	uk
10.1007/s13555-021-00646-1	general_information	NA	NA	country_last_author	denmark
10.1007/s13555-021-00646-1	general_information	NA	NA	positions	Academic, Pharmaceutical Industry, Private Data Analysis Company
10.1007/s13555-021-00646-1	general_information	NA	NA	methodologist_yn	Yes
10.1007/s13555-021-00646-1	general_information	NA	NA	funding_source	Pharmaceutical Industry
10.1007/s13555-021-00646-1	general_information	NA	NA	pharmaceutical_ties_yn	Yes
10.1007/s13555-021-00646-1	general_information	NA	NA	systematic_review_yn	Yes
10.1007/s13555-021-00646-1	methodology	1	NA	outcome_name	investigators static global assessment improvement score of 01
10.1007/s13555-021-00646-1	methodology	1	NA	outcome_short_name	ISGA improvement
10.1007/s13555-021-00646-1	methodology	1	NA	outcome_variable_type	Binary (eg rates)
10.1007/s13555-021-00646-1	methodology	1	NA	treatment_name_ipd	crisaborole ointment 2
10.1007/s13555-021-00646-1	methodology	1	NA	studies_number_ipd	1;2
10.1007/s13555-021-00646-1	methodology	1	NA	treatment_name_nonipd	pimecrolimus 1
10.1007/s13555-021-00646-1	methodology	1	NA	studies_number_nonipd	4;5;6;7
10.1007/s13555-021-00646-1	methodology	1	NA	paic_type	MAIC
10.1007/s13555-021-00646-1	methodology	1	NA	anchored_yn	No
10.1007/s13555-021-00646-1	methodology	1	NA	paic_form	Aggregation of multiple studies to estimate individual treatment effects (e.g. meta-analysis in a first step to estimate treatment A effect, then population adjusted indirect comparison using treatment A effect estimate)
10.1007/s13555-021-00646-1	methodology	1	NA	primary_outcome_yn	Yes
10.1007/s13555-021-00646-1	methodology	1	NA	variables_selection_justification	Status of prognostic factor/treatment effect modified assessed in the IPD dataset, A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion), Literature based (clinically or methodologically relevant to adjust on these variables based on the literature search conducted for this specific purpose)
10.1007/s13555-021-00646-1	methodology	1	NA	pf_yn	Yes
10.1007/s13555-021-00646-1	methodology	1	NA	tem_yn	Yes
10.1007/s13555-021-00646-1	methodology	1	NA	adjustment_model_details_yn	Yes
10.1007/s13555-021-00646-1	methodology	1	NA	scale_choice_yn	Yes
10.1007/s13555-021-00646-1	methodology	2	NA	outcome_name	investigators static global assessment improvement score of 01
10.1007/s13555-021-00646-1	methodology	2	NA	outcome_short_name	ISGA improvement
10.1007/s13555-021-00646-1	methodology	2	NA	outcome_variable_type	Binary (eg rates)
10.1007/s13555-021-00646-1	methodology	2	NA	treatment_name_ipd	crisaborole
10.1007/s13555-021-00646-1	methodology	2	NA	studies_number_ipd	1;2
10.1007/s13555-021-00646-1	methodology	2	NA	treatment_name_nonipd	tacrolimus 0.03
10.1007/s13555-021-00646-1	methodology	2	NA	studies_number_nonipd	3;4;5;8;9
10.1007/s13555-021-00646-1	methodology	2	NA	paic_type	MAIC
10.1007/s13555-021-00646-1	methodology	2	NA	anchored_yn	No
10.1007/s13555-021-00646-1	methodology	2	NA	paic_form	Aggregation of multiple studies to estimate individual treatment effects (e.g. meta-analysis in a first step to estimate treatment A effect, then population adjusted indirect comparison using treatment A effect estimate)
10.1007/s13555-021-00646-1	methodology	2	NA	primary_outcome_yn	Yes
10.1007/s13555-021-00646-1	methodology	2	NA	variables_selection_justification	Status of prognostic factor/treatment effect modified assessed in the IPD dataset, A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion), Literature based (clinically or methodologically relevant to adjust on these variables based on the literature search conducted for this specific purpose)
10.1007/s13555-021-00646-1	methodology	2	NA	pf_yn	Yes
10.1007/s13555-021-00646-1	methodology	2	NA	tem_yn	Yes
10.1007/s13555-021-00646-1	methodology	2	NA	adjustment_model_details_yn	Yes
10.1007/s13555-021-00646-1	methodology	2	NA	scale_choice_yn	No
10.1007/s13555-021-00646-1	results	1	NA	contrast_effect_type	OR
10.1007/s13555-021-00646-1	results	1	NA	direction_benefit	superior
10.1007/s13555-021-00646-1	results	1	NA	ss_ttt_nonipd	NA
10.1007/s13555-021-00646-1	results	1	NA	ss_ttt_ipd	1021
10.1007/s13555-021-00646-1	results	1	NA	ss_adjusted_ttt_ipd	627
10.1007/s13555-021-00646-1	results	1	NA	weights_yn	Yes, mentions that the weights distribution has been studied, and weights distribution reported in main article or supplemental materials
10.1007/s13555-021-00646-1	results	1	NA	covariates_yn	Yes
10.1007/s13555-021-00646-1	results	1	NA	covariates_n	7
10.1007/s13555-021-00646-1	results	1	NA	covariates_names	Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Race/ethnicity, Past treatments for the disease of interest
10.1007/s13555-021-00646-1	results	1	NA	contrast_effect_direction	Numerator if ratio, or left side if difference
10.1007/s13555-021-00646-1	results	1	NA	contrast_effect_unadjusted_value	2.04
10.1007/s13555-021-00646-1	results	1	NA	contrast_effect_unadjusted_pvalci	[1.47;2.82]
10.1007/s13555-021-00646-1	results	1	NA	contrast_effect_adjusted_value	2.03
10.1007/s13555-021-00646-1	results	1	NA	contrast_effect_adjusted_pvalci	[1.45;2.85]
10.1007/s13555-021-00646-1	results	1	NA	adjustment_geographical	NA
10.1007/s13555-021-00646-1	results	1	NA	ss_total_ipd	NA
10.1007/s13555-021-00646-1	results	1	NA	ss_adjusted_total_ipd	NA
10.1007/s13555-021-00646-1	results	1	NA	ss_total_nonipd	NA
10.1007/s13555-021-00646-1	results	1	NA	ss_anchor_nonipd	NA
10.1007/s13555-021-00646-1	results	1	NA	ss_anchor_ipd	NA
10.1007/s13555-021-00646-1	results	1	NA	ss_adjusted_anchor_ipd	NA
10.1007/s13555-021-00646-1	results	1	NA	effect_cutoff	1
10.1007/s13555-021-00646-1	results	1	NA	unadjusted_lb_ci	1.47
10.1007/s13555-021-00646-1	results	1	NA	unadjusted_ub_ci	2.82
10.1007/s13555-021-00646-1	results	1	NA	unadjusted_significant	TRUE
10.1007/s13555-021-00646-1	results	1	NA	adjusted_lb_ci	1.45
10.1007/s13555-021-00646-1	results	1	NA	adjusted_ub_ci	2.85
10.1007/s13555-021-00646-1	results	1	NA	adjusted_significant	TRUE
10.1007/s13555-021-00646-1	results	2	NA	contrast_effect_type	OR
10.1007/s13555-021-00646-1	results	2	NA	direction_benefit	superior
10.1007/s13555-021-00646-1	results	2	NA	ss_ttt_nonipd	NA
10.1007/s13555-021-00646-1	results	2	NA	ss_ttt_ipd	1021
10.1007/s13555-021-00646-1	results	2	NA	ss_adjusted_ttt_ipd	311
10.1007/s13555-021-00646-1	results	2	NA	weights_yn	Yes, mentions that the weights distribution has been studied, and weights distribution reported in main article or supplemental materials
10.1007/s13555-021-00646-1	results	2	NA	covariates_yn	Yes
10.1007/s13555-021-00646-1	results	2	NA	covariates_n	7
10.1007/s13555-021-00646-1	results	2	NA	covariates_names	Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Race/ethnicity, Past treatments for the disease of interest
10.1007/s13555-021-00646-1	results	2	NA	contrast_effect_direction	Numerator if ratio, or left side if difference
10.1007/s13555-021-00646-1	results	2	NA	contrast_effect_unadjusted_value	1.31
10.1007/s13555-021-00646-1	results	2	NA	contrast_effect_unadjusted_pvalci	[1.02;1.69]
10.1007/s13555-021-00646-1	results	2	NA	contrast_effect_adjusted_value	1.5
10.1007/s13555-021-00646-1	results	2	NA	contrast_effect_adjusted_pvalci	[1.09;2.05]
10.1007/s13555-021-00646-1	results	2	NA	adjustment_geographical	NA
10.1007/s13555-021-00646-1	results	2	NA	ss_total_ipd	NA
10.1007/s13555-021-00646-1	results	2	NA	ss_adjusted_total_ipd	NA
10.1007/s13555-021-00646-1	results	2	NA	ss_total_nonipd	NA
10.1007/s13555-021-00646-1	results	2	NA	ss_anchor_nonipd	NA
10.1007/s13555-021-00646-1	results	2	NA	ss_anchor_ipd	NA
10.1007/s13555-021-00646-1	results	2	NA	ss_adjusted_anchor_ipd	NA
10.1007/s13555-021-00646-1	results	2	NA	effect_cutoff	1
10.1007/s13555-021-00646-1	results	2	NA	unadjusted_lb_ci	1.02
10.1007/s13555-021-00646-1	results	2	NA	unadjusted_ub_ci	1.69
10.1007/s13555-021-00646-1	results	2	NA	unadjusted_significant	TRUE
10.1007/s13555-021-00646-1	results	2	NA	adjusted_lb_ci	1.09
10.1007/s13555-021-00646-1	results	2	NA	adjusted_ub_ci	2.05
10.1007/s13555-021-00646-1	results	2	NA	adjusted_significant	TRUE
10.1007/s13555-021-00646-1	study_information	NA	1	ipd_yn	Yes
10.1007/s13555-021-00646-1	study_information	NA	1	ct_yn	Yes
10.1007/s13555-021-00646-1	study_information	NA	1	nct	NCT02118766
10.1007/s13555-021-00646-1	study_information	NA	1	country_study	usa
10.1007/s13555-021-00646-1	study_information	NA	1	ct_phase	3
10.1007/s13555-021-00646-1	study_information	NA	1	ct_arms	2 or more
10.1007/s13555-021-00646-1	study_information	NA	2	ipd_yn	Yes
10.1007/s13555-021-00646-1	study_information	NA	2	ct_yn	Yes
10.1007/s13555-021-00646-1	study_information	NA	2	nct	NCT02118792
10.1007/s13555-021-00646-1	study_information	NA	2	country_study	usa
10.1007/s13555-021-00646-1	study_information	NA	2	ct_phase	3
10.1007/s13555-021-00646-1	study_information	NA	2	ct_arms	2 or more
10.1007/s13555-021-00646-1	study_information	NA	3	ipd_yn	No
10.1007/s13555-021-00646-1	study_information	NA	3	ct_yn	Yes
10.1007/s13555-021-00646-1	study_information	NA	3	data_source_name	schachner et al. (2005)
10.1007/s13555-021-00646-1	study_information	NA	3	country_study	usa
10.1007/s13555-021-00646-1	study_information	NA	3	ct_arms	2 or more
10.1007/s13555-021-00646-1	study_information	NA	4	ipd_yn	No
10.1007/s13555-021-00646-1	study_information	NA	4	ct_yn	Yes
10.1007/s13555-021-00646-1	study_information	NA	4	data_source_name	kempers et al. (2004)
10.1007/s13555-021-00646-1	study_information	NA	4	country_study	usa
10.1007/s13555-021-00646-1	study_information	NA	4	ct_arms	2 or more
10.1007/s13555-021-00646-1	study_information	NA	5	ipd_yn	No
10.1007/s13555-021-00646-1	study_information	NA	5	ct_yn	Yes
10.1007/s13555-021-00646-1	study_information	NA	5	nct	NCT00667160
10.1007/s13555-021-00646-1	study_information	NA	5	country_study	usa
10.1007/s13555-021-00646-1	study_information	NA	5	ct_phase	4
10.1007/s13555-021-00646-1	study_information	NA	5	ct_arms	2 or more
10.1007/s13555-021-00646-1	study_information	NA	6	ipd_yn	No
10.1007/s13555-021-00646-1	study_information	NA	6	ct_yn	Yes
10.1007/s13555-021-00646-1	study_information	NA	6	country_study	unknown
10.1007/s13555-021-00646-1	study_information	NA	6	ct_arms	2 or more
10.1007/s13555-021-00646-1	study_information	NA	6	data_source_name	abramovits et al. (2008)
10.1007/s13555-021-00646-1	study_information	NA	7	ipd_yn	No
10.1007/s13555-021-00646-1	study_information	NA	7	ct_yn	Yes
10.1007/s13555-021-00646-1	study_information	NA	7	data_source_name	eichenfield et al. (2002)
10.1007/s13555-021-00646-1	study_information	NA	7	ct_arms	2 or more
10.1007/s13555-021-00646-1	study_information	NA	7	country_study	unknown
10.1007/s13555-021-00646-1	study_information	NA	8	ipd_yn	No
10.1007/s13555-021-00646-1	study_information	NA	8	ct_yn	Yes
10.1007/s13555-021-00646-1	study_information	NA	8	data_source_name	chapman et al. (2005)
10.1007/s13555-021-00646-1	study_information	NA	8	country_study	usa
10.1007/s13555-021-00646-1	study_information	NA	8	ct_arms	2 or more
10.1007/s13555-021-00646-1	study_information	NA	9	ipd_yn	No
10.1007/s13555-021-00646-1	study_information	NA	9	ct_yn	Yes
10.1007/s13555-021-00646-1	study_information	NA	9	ct_arms	2 or more
10.1007/s13555-021-00646-1	study_information	NA	9	data_source_name	levy et al. (2005)
10.1007/s40258-016-0271-0	general_information	NA	NA	condition_name	relapsed and/or refractory multiple myeloma
10.1007/s40258-016-0271-0	general_information	NA	NA	country_first_author	the netherlands
10.1007/s40258-016-0271-0	general_information	NA	NA	country_last_author	usa
10.1007/s40258-016-0271-0	general_information	NA	NA	positions	Pharmaceutical Industry, Private Data Analysis Company
10.1007/s40258-016-0271-0	general_information	NA	NA	methodologist_yn	Yes
10.1007/s40258-016-0271-0	general_information	NA	NA	funding_source	Pharmaceutical Industry
10.1007/s40258-016-0271-0	general_information	NA	NA	pharmaceutical_ties_yn	Yes
10.1007/s40258-016-0271-0	general_information	NA	NA	systematic_review_yn	Yes
10.1007/s40258-016-0271-0	methodology	1	NA	outcome_name	progression-free survival
10.1007/s40258-016-0271-0	methodology	1	NA	outcome_short_name	Progression-free Survival
10.1007/s40258-016-0271-0	methodology	1	NA	outcome_variable_type	Time-to-event
10.1007/s40258-016-0271-0	methodology	1	NA	treatment_name_ipd	panobinostat + bortezomib + dexamethasone
10.1007/s40258-016-0271-0	methodology	1	NA	studies_number_ipd	1
10.1007/s40258-016-0271-0	methodology	1	NA	treatment_name_nonipd	lenalidomide + dexamethasone
10.1007/s40258-016-0271-0	methodology	1	NA	studies_number_nonipd	2;3
10.1007/s40258-016-0271-0	methodology	1	NA	paic_type	MAIC
10.1007/s40258-016-0271-0	methodology	1	NA	anchored_yn	No
10.1007/s40258-016-0271-0	methodology	1	NA	paic_form	Aggregation of multiple studies to estimate individual treatment effects (e.g. meta-analysis in a first step to estimate treatment A effect, then population adjusted indirect comparison using treatment A effect estimate)
10.1007/s40258-016-0271-0	methodology	1	NA	primary_outcome_yn	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.1007/s40258-016-0271-0	methodology	1	NA	variables_selection_justification	A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion), Literature based (clinically or methodologically relevant to adjust on these variables based on the literature search conducted for this specific purpose)
10.1007/s40258-016-0271-0	methodology	1	NA	pf_yn	Yes
10.1007/s40258-016-0271-0	methodology	1	NA	tem_yn	No discussion (in the main text) of the status of treatment-effect modifiers of the variables
10.1007/s40258-016-0271-0	methodology	1	NA	adjustment_model_details_yn	No
10.1007/s40258-016-0271-0	methodology	1	NA	scale_choice_yn	No
10.1007/s40258-016-0271-0	results	1	NA	contrast_effect_type	HR
10.1007/s40258-016-0271-0	results	1	NA	direction_benefit	inferior
10.1007/s40258-016-0271-0	results	1	NA	ss_ttt_nonipd	220
10.1007/s40258-016-0271-0	results	1	NA	ss_ttt_ipd	142
10.1007/s40258-016-0271-0	results	1	NA	ss_adjusted_ttt_ipd	138
10.1007/s40258-016-0271-0	results	1	NA	weights_yn	Not mentioned
10.1007/s40258-016-0271-0	results	1	NA	covariates_yn	Yes
10.1007/s40258-016-0271-0	results	1	NA	covariates_n	4
10.1007/s40258-016-0271-0	results	1	NA	covariates_names	Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Past treatments for the disease of interest
10.1007/s40258-016-0271-0	results	1	NA	contrast_effect_direction	Numerator if ratio, or left side if difference
10.1007/s40258-016-0271-0	results	1	NA	contrast_effect_unadjusted_value	NA
10.1007/s40258-016-0271-0	results	1	NA	contrast_effect_unadjusted_pvalci	NA
10.1007/s40258-016-0271-0	results	1	NA	contrast_effect_adjusted_value	0.96
10.1007/s40258-016-0271-0	results	1	NA	contrast_effect_adjusted_pvalci	[0.72;1.28]
10.1007/s40258-016-0271-0	results	1	NA	adjustment_geographical	NA
10.1007/s40258-016-0271-0	results	1	NA	ss_total_ipd	NA
10.1007/s40258-016-0271-0	results	1	NA	ss_adjusted_total_ipd	NA
10.1007/s40258-016-0271-0	results	1	NA	ss_total_nonipd	NA
10.1007/s40258-016-0271-0	results	1	NA	ss_anchor_nonipd	NA
10.1007/s40258-016-0271-0	results	1	NA	ss_anchor_ipd	NA
10.1007/s40258-016-0271-0	results	1	NA	ss_adjusted_anchor_ipd	NA
10.1007/s40258-016-0271-0	results	1	NA	effect_cutoff	1
10.1007/s40258-016-0271-0	results	1	NA	adjusted_lb_ci	0.72
10.1007/s40258-016-0271-0	results	1	NA	adjusted_ub_ci	1.28
10.1007/s40258-016-0271-0	results	1	NA	adjusted_significant	FALSE
10.1007/s40258-016-0271-0	study_information	NA	1	ipd_yn	Yes
10.1007/s40258-016-0271-0	study_information	NA	1	ct_yn	Yes
10.1007/s40258-016-0271-0	study_information	NA	1	nct	NCT01023308
10.1007/s40258-016-0271-0	study_information	NA	1	country_study	international
10.1007/s40258-016-0271-0	study_information	NA	1	ct_phase	3
10.1007/s40258-016-0271-0	study_information	NA	1	ct_arms	2 or more
10.1007/s40258-016-0271-0	study_information	NA	2	ipd_yn	No
10.1007/s40258-016-0271-0	study_information	NA	2	ct_yn	Yes
10.1007/s40258-016-0271-0	study_information	NA	2	nct	NCT00056160
10.1007/s40258-016-0271-0	study_information	NA	2	country_study	international
10.1007/s40258-016-0271-0	study_information	NA	2	ct_phase	3
10.1007/s40258-016-0271-0	study_information	NA	2	ct_arms	2 or more
10.1007/s40258-016-0271-0	study_information	NA	3	ipd_yn	No
10.1007/s40258-016-0271-0	study_information	NA	3	ct_yn	Yes
10.1007/s40258-016-0271-0	study_information	NA	3	nct	NCT00424047
10.1007/s40258-016-0271-0	study_information	NA	3	country_study	international
10.1007/s40258-016-0271-0	study_information	NA	3	ct_phase	3
10.1007/s40258-016-0271-0	study_information	NA	3	ct_arms	2 or more
10.1007/s40263-013-0102-x	general_information	NA	NA	condition_name	attention-deficit/hyperactivity disorder in children and adolescents
10.1007/s40263-013-0102-x	general_information	NA	NA	country_first_author	usa
10.1007/s40263-013-0102-x	general_information	NA	NA	country_last_author	usa
10.1007/s40263-013-0102-x	general_information	NA	NA	positions	Academic, Pharmaceutical Industry, Private Data Analysis Company
10.1007/s40263-013-0102-x	general_information	NA	NA	methodologist_yn	Yes
10.1007/s40263-013-0102-x	general_information	NA	NA	funding_source	Pharmaceutical Industry
10.1007/s40263-013-0102-x	general_information	NA	NA	pharmaceutical_ties_yn	Yes
10.1007/s40263-013-0102-x	general_information	NA	NA	systematic_review_yn	Yes
10.1007/s40263-013-0102-x	methodology	1	NA	outcome_name	the mean change from baseline in the adhd-rs-iv total score at the final on-treatment assessment prior to down-titration
10.1007/s40263-013-0102-x	methodology	1	NA	outcome_short_name	ADHD-RS-IV score
10.1007/s40263-013-0102-x	methodology	1	NA	outcome_variable_type	Continuous (count, mean, ...)
10.1007/s40263-013-0102-x	methodology	1	NA	treatment_name_ipd	guanfacine extended release
10.1007/s40263-013-0102-x	methodology	1	NA	studies_number_ipd	1;2
10.1007/s40263-013-0102-x	methodology	1	NA	treatment_name_nonipd	atomoxetine
10.1007/s40263-013-0102-x	methodology	1	NA	studies_number_nonipd	3
10.1007/s40263-013-0102-x	methodology	1	NA	paic_type	MAIC
10.1007/s40263-013-0102-x	methodology	1	NA	anchored_yn	Yes
10.1007/s40263-013-0102-x	methodology	1	NA	paic_form	Simple (ie treatments effects extracted from two studies)
10.1007/s40263-013-0102-x	methodology	1	NA	primary_outcome_yn	Yes
10.1007/s40263-013-0102-x	methodology	1	NA	variables_selection_justification	Nothing mentioned, not reported
10.1007/s40263-013-0102-x	methodology	1	NA	pf_yn	No discussion (in the main text) of the status of prognostic factors of the variables
10.1007/s40263-013-0102-x	methodology	1	NA	tem_yn	No discussion (in the main text) of the status of treatment-effect modifiers of the variables
10.1007/s40263-013-0102-x	methodology	1	NA	adjustment_model_details_yn	Yes
10.1007/s40263-013-0102-x	methodology	1	NA	scale_choice_yn	No
10.1007/s40263-013-0102-x	results	1	NA	contrast_effect_type	Means difference
10.1007/s40263-013-0102-x	results	1	NA	direction_benefit	inferior
10.1007/s40263-013-0102-x	results	1	NA	ss_ttt_nonipd	84
10.1007/s40263-013-0102-x	results	1	NA	ss_ttt_ipd	82
10.1007/s40263-013-0102-x	results	1	NA	ss_adjusted_ttt_ipd	NA
10.1007/s40263-013-0102-x	results	1	NA	weights_yn	Not mentioned
10.1007/s40263-013-0102-x	results	1	NA	covariates_yn	Yes
10.1007/s40263-013-0102-x	results	1	NA	covariates_n	8
10.1007/s40263-013-0102-x	results	1	NA	covariates_names	Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Race/ethnicity, Other(s)
10.1007/s40263-013-0102-x	results	1	NA	contrast_effect_direction	Numerator if ratio, or left side if difference
10.1007/s40263-013-0102-x	results	1	NA	contrast_effect_unadjusted_value	-9.2
10.1007/s40263-013-0102-x	results	1	NA	contrast_effect_unadjusted_pvalci	<0.01
10.1007/s40263-013-0102-x	results	1	NA	contrast_effect_adjusted_value	-7
10.1007/s40263-013-0102-x	results	1	NA	contrast_effect_adjusted_pvalci	<0.01
10.1007/s40263-013-0102-x	results	1	NA	adjustment_geographical	No
10.1007/s40263-013-0102-x	results	1	NA	ss_total_ipd	NA
10.1007/s40263-013-0102-x	results	1	NA	ss_adjusted_total_ipd	NA
10.1007/s40263-013-0102-x	results	1	NA	ss_total_nonipd	NA
10.1007/s40263-013-0102-x	results	1	NA	ss_anchor_nonipd	83
10.1007/s40263-013-0102-x	results	1	NA	ss_anchor_ipd	136
10.1007/s40263-013-0102-x	results	1	NA	ss_adjusted_anchor_ipd	NA
10.1007/s40263-013-0102-x	results	1	NA	effect_cutoff	0
10.1007/s40263-013-0102-x	results	1	NA	unadjusted_pval	<0.01
10.1007/s40263-013-0102-x	results	1	NA	unadjusted_significant	TRUE
10.1007/s40263-013-0102-x	results	1	NA	adjusted_pval	<0.01
10.1007/s40263-013-0102-x	results	1	NA	adjusted_significant	TRUE
10.1007/s40263-013-0102-x	study_information	NA	1	ipd_yn	Yes
10.1007/s40263-013-0102-x	study_information	NA	1	ct_yn	Yes
10.1007/s40263-013-0102-x	study_information	NA	1	nct	NCT00152009
10.1007/s40263-013-0102-x	study_information	NA	1	ct_phase	3
10.1007/s40263-013-0102-x	study_information	NA	1	ct_arms	2 or more
10.1007/s40263-013-0102-x	study_information	NA	1	country_study	unknown
10.1007/s40263-013-0102-x	study_information	NA	2	ipd_yn	Yes
10.1007/s40263-013-0102-x	study_information	NA	2	ct_yn	Yes
10.1007/s40263-013-0102-x	study_information	NA	2	nct	NCT00150618
10.1007/s40263-013-0102-x	study_information	NA	2	ct_phase	3
10.1007/s40263-013-0102-x	study_information	NA	2	ct_arms	2 or more
10.1007/s40263-013-0102-x	study_information	NA	2	data_source_name	sallee et al. (2009)
10.1007/s40263-013-0102-x	study_information	NA	2	country_study	usa
10.1007/s40263-013-0102-x	study_information	NA	3	ipd_yn	No
10.1007/s40263-013-0102-x	study_information	NA	3	ct_yn	Yes
10.1007/s40263-013-0102-x	study_information	NA	3	data_source_name	spencer et al. (2002)
10.1007/s40263-013-0102-x	study_information	NA	3	ct_arms	2 or more
10.1007/s40263-019-00672-w	general_information	NA	NA	condition_name	postpartum depression
10.1007/s40263-019-00672-w	general_information	NA	NA	country_first_author	uk
10.1007/s40263-019-00672-w	general_information	NA	NA	country_last_author	usa
10.1007/s40263-019-00672-w	general_information	NA	NA	positions	Pharmaceutical Industry, Private Data Analysis Company
10.1007/s40263-019-00672-w	general_information	NA	NA	methodologist_yn	Yes
10.1007/s40263-019-00672-w	general_information	NA	NA	funding_source	Pharmaceutical Industry
10.1007/s40263-019-00672-w	general_information	NA	NA	pharmaceutical_ties_yn	Yes
10.1007/s40263-019-00672-w	general_information	NA	NA	systematic_review_yn	Yes
10.1007/s40263-019-00672-w	methodology	1	NA	outcome_name	change from baseline for the hamilton rating scale for depression
10.1007/s40263-019-00672-w	methodology	1	NA	outcome_short_name	Hamilton rating scale change
10.1007/s40263-019-00672-w	methodology	1	NA	outcome_variable_type	Continuous (count, mean, ...)
10.1007/s40263-019-00672-w	methodology	1	NA	treatment_name_ipd	brexanolone
10.1007/s40263-019-00672-w	methodology	1	NA	studies_number_ipd	1;2;3
10.1007/s40263-019-00672-w	methodology	1	NA	treatment_name_nonipd	placebo
10.1007/s40263-019-00672-w	methodology	1	NA	studies_number_nonipd	4
10.1007/s40263-019-00672-w	methodology	1	NA	paic_type	MAIC
10.1007/s40263-019-00672-w	methodology	1	NA	anchored_yn	No
10.1007/s40263-019-00672-w	methodology	1	NA	paic_form	Aggregation of multiple studies to estimate individual treatment effects (e.g. meta-analysis in a first step to estimate treatment A effect, then population adjusted indirect comparison using treatment A effect estimate)
10.1007/s40263-019-00672-w	methodology	1	NA	primary_outcome_yn	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.1007/s40263-019-00672-w	methodology	1	NA	variables_selection_justification	Nothing mentioned, not reported
10.1007/s40263-019-00672-w	methodology	1	NA	pf_yn	No discussion (in the main text) of the status of prognostic factors of the variables
10.1007/s40263-019-00672-w	methodology	1	NA	tem_yn	No discussion (in the main text) of the status of treatment-effect modifiers of the variables
10.1007/s40263-019-00672-w	methodology	1	NA	adjustment_model_details_yn	Yes
10.1007/s40263-019-00672-w	methodology	1	NA	scale_choice_yn	No
10.1007/s40263-019-00672-w	results	1	NA	contrast_effect_type	Means difference
10.1007/s40263-019-00672-w	results	1	NA	direction_benefit	superior
10.1007/s40263-019-00672-w	results	1	NA	ss_ttt_nonipd	30
10.1007/s40263-019-00672-w	results	1	NA	ss_ttt_ipd	NA
10.1007/s40263-019-00672-w	results	1	NA	ss_adjusted_ttt_ipd	63.2
10.1007/s40263-019-00672-w	results	1	NA	weights_yn	Not mentioned
10.1007/s40263-019-00672-w	results	1	NA	covariates_yn	Yes
10.1007/s40263-019-00672-w	results	1	NA	covariates_n	3
10.1007/s40263-019-00672-w	results	1	NA	covariates_names	Age, Race/ethnicity, Past treatments for the disease of interest
10.1007/s40263-019-00672-w	results	1	NA	contrast_effect_direction	Numerator if ratio, or left side if difference
10.1007/s40263-019-00672-w	results	1	NA	contrast_effect_unadjusted_value	3.8
10.1007/s40263-019-00672-w	results	1	NA	contrast_effect_unadjusted_pvalci	[1.86;5.74]
10.1007/s40263-019-00672-w	results	1	NA	contrast_effect_adjusted_value	13.9
10.1007/s40263-019-00672-w	results	1	NA	contrast_effect_adjusted_pvalci	[9.84;17.10]
10.1007/s40263-019-00672-w	results	1	NA	adjustment_geographical	NA
10.1007/s40263-019-00672-w	results	1	NA	ss_total_ipd	NA
10.1007/s40263-019-00672-w	results	1	NA	ss_adjusted_total_ipd	NA
10.1007/s40263-019-00672-w	results	1	NA	ss_total_nonipd	NA
10.1007/s40263-019-00672-w	results	1	NA	ss_anchor_nonipd	NA
10.1007/s40263-019-00672-w	results	1	NA	ss_anchor_ipd	NA
10.1007/s40263-019-00672-w	results	1	NA	ss_adjusted_anchor_ipd	NA
10.1007/s40263-019-00672-w	results	1	NA	effect_cutoff	0
10.1007/s40263-019-00672-w	results	1	NA	unadjusted_lb_ci	1.86
10.1007/s40263-019-00672-w	results	1	NA	unadjusted_ub_ci	5.74
10.1007/s40263-019-00672-w	results	1	NA	unadjusted_significant	TRUE
10.1007/s40263-019-00672-w	results	1	NA	adjusted_lb_ci	9.84
10.1007/s40263-019-00672-w	results	1	NA	adjusted_ub_ci	17.1
10.1007/s40263-019-00672-w	results	1	NA	adjusted_significant	TRUE
10.1007/s40263-019-00672-w	study_information	NA	1	ipd_yn	Yes
10.1007/s40263-019-00672-w	study_information	NA	1	ct_yn	Yes
10.1007/s40263-019-00672-w	study_information	NA	1	nct	NCT02614547
10.1007/s40263-019-00672-w	study_information	NA	1	country_study	usa
10.1007/s40263-019-00672-w	study_information	NA	1	ct_phase	2
10.1007/s40263-019-00672-w	study_information	NA	1	ct_arms	2 or more
10.1007/s40263-019-00672-w	study_information	NA	2	ipd_yn	Yes
10.1007/s40263-019-00672-w	study_information	NA	2	ct_yn	Yes
10.1007/s40263-019-00672-w	study_information	NA	2	nct	NCT02942004
10.1007/s40263-019-00672-w	study_information	NA	2	country_study	usa
10.1007/s40263-019-00672-w	study_information	NA	2	ct_phase	3
10.1007/s40263-019-00672-w	study_information	NA	2	ct_arms	2 or more
10.1007/s40263-019-00672-w	study_information	NA	3	ipd_yn	Yes
10.1007/s40263-019-00672-w	study_information	NA	3	ct_yn	Yes
10.1007/s40263-019-00672-w	study_information	NA	3	nct	NCT02942017
10.1007/s40263-019-00672-w	study_information	NA	3	country_study	usa
10.1007/s40263-019-00672-w	study_information	NA	3	ct_phase	3
10.1007/s40263-019-00672-w	study_information	NA	3	ct_arms	2 or more
10.1007/s40263-019-00672-w	study_information	NA	4	ipd_yn	No
10.1007/s40263-019-00672-w	study_information	NA	4	ct_yn	Yes
10.1007/s40263-019-00672-w	study_information	NA	4	data_source_name	yonkers et al. (2008)
10.1007/s40263-019-00672-w	study_information	NA	4	country_study	usa
10.1007/s40263-019-00672-w	study_information	NA	4	ct_arms	2 or more
10.1007/s40263-021-00805-0	general_information	NA	NA	condition_name	relapsing-remitting multiple sclerosis
10.1007/s40263-021-00805-0	general_information	NA	NA	country_first_author	usa
10.1007/s40263-021-00805-0	general_information	NA	NA	country_last_author	usa
10.1007/s40263-021-00805-0	general_information	NA	NA	positions	Academic, Pharmaceutical Industry, Private Data Analysis Company
10.1007/s40263-021-00805-0	general_information	NA	NA	methodologist_yn	Yes
10.1007/s40263-021-00805-0	general_information	NA	NA	funding_source	Pharmaceutical Industry
10.1007/s40263-021-00805-0	general_information	NA	NA	pharmaceutical_ties_yn	Yes
10.1007/s40263-021-00805-0	general_information	NA	NA	systematic_review_yn	Yes
10.1007/s40263-021-00805-0	methodology	1	NA	outcome_name	annualized relapse rate
10.1007/s40263-021-00805-0	methodology	1	NA	outcome_short_name	Annualized Relapse Rate
10.1007/s40263-021-00805-0	methodology	1	NA	outcome_variable_type	Continuous (count, mean, ...)
10.1007/s40263-021-00805-0	methodology	1	NA	treatment_name_ipd	ozanimod
10.1007/s40263-021-00805-0	methodology	1	NA	studies_number_ipd	1;2
10.1007/s40263-021-00805-0	methodology	1	NA	treatment_name_nonipd	dimethyl fumarate
10.1007/s40263-021-00805-0	methodology	1	NA	studies_number_nonipd	3;4
10.1007/s40263-021-00805-0	methodology	1	NA	paic_type	MAIC
10.1007/s40263-021-00805-0	methodology	1	NA	anchored_yn	No
10.1007/s40263-021-00805-0	methodology	1	NA	paic_form	Aggregation of multiple studies to estimate individual treatment effects (e.g. meta-analysis in a first step to estimate treatment A effect, then population adjusted indirect comparison using treatment A effect estimate)
10.1007/s40263-021-00805-0	methodology	1	NA	primary_outcome_yn	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.1007/s40263-021-00805-0	methodology	1	NA	variables_selection_justification	A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion), Literature based (clinically or methodologically relevant to adjust on these variables based on the literature search conducted for this specific purpose)
10.1007/s40263-021-00805-0	methodology	1	NA	pf_yn	Yes
10.1007/s40263-021-00805-0	methodology	1	NA	tem_yn	Yes
10.1007/s40263-021-00805-0	methodology	1	NA	adjustment_model_details_yn	Yes
10.1007/s40263-021-00805-0	methodology	1	NA	scale_choice_yn	No
10.1007/s40263-021-00805-0	results	1	NA	contrast_effect_type	RR
10.1007/s40263-021-00805-0	results	1	NA	direction_benefit	inferior
10.1007/s40263-021-00805-0	results	1	NA	ss_ttt_nonipd	769
10.1007/s40263-021-00805-0	results	1	NA	ss_ttt_ipd	880
10.1007/s40263-021-00805-0	results	1	NA	ss_adjusted_ttt_ipd	744
10.1007/s40263-021-00805-0	results	1	NA	weights_yn	Yes, mentions that the weights distribution has been studied, but weights distribution not reported
10.1007/s40263-021-00805-0	results	1	NA	covariates_yn	Yes
10.1007/s40263-021-00805-0	results	1	NA	covariates_n	7
10.1007/s40263-021-00805-0	results	1	NA	covariates_names	Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Past treatments for the disease of interest, Other(s)
10.1007/s40263-021-00805-0	results	1	NA	contrast_effect_direction	Numerator if ratio, or left side if difference
10.1007/s40263-021-00805-0	results	1	NA	contrast_effect_unadjusted_value	NA
10.1007/s40263-021-00805-0	results	1	NA	contrast_effect_unadjusted_pvalci	NA
10.1007/s40263-021-00805-0	results	1	NA	contrast_effect_adjusted_value	0.8
10.1007/s40263-021-00805-0	results	1	NA	contrast_effect_adjusted_pvalci	[0.67;0.97]
10.1007/s40263-021-00805-0	results	1	NA	adjustment_geographical	NA
10.1007/s40263-021-00805-0	results	1	NA	ss_total_ipd	NA
10.1007/s40263-021-00805-0	results	1	NA	ss_adjusted_total_ipd	NA
10.1007/s40263-021-00805-0	results	1	NA	ss_total_nonipd	NA
10.1007/s40263-021-00805-0	results	1	NA	ss_anchor_nonipd	NA
10.1007/s40263-021-00805-0	results	1	NA	ss_anchor_ipd	NA
10.1007/s40263-021-00805-0	results	1	NA	ss_adjusted_anchor_ipd	NA
10.1007/s40263-021-00805-0	results	1	NA	effect_cutoff	1
10.1007/s40263-021-00805-0	results	1	NA	adjusted_lb_ci	0.67
10.1007/s40263-021-00805-0	results	1	NA	adjusted_ub_ci	0.97
10.1007/s40263-021-00805-0	results	1	NA	adjusted_significant	TRUE
10.1007/s40263-021-00805-0	study_information	NA	1	ipd_yn	Yes
10.1007/s40263-021-00805-0	study_information	NA	1	ct_yn	Yes
10.1007/s40263-021-00805-0	study_information	NA	1	nct	NCT02294058
10.1007/s40263-021-00805-0	study_information	NA	1	country_study	international
10.1007/s40263-021-00805-0	study_information	NA	1	ct_phase	3
10.1007/s40263-021-00805-0	study_information	NA	1	ct_arms	2 or more
10.1007/s40263-021-00805-0	study_information	NA	2	ipd_yn	Yes
10.1007/s40263-021-00805-0	study_information	NA	2	ct_yn	Yes
10.1007/s40263-021-00805-0	study_information	NA	2	nct	NCT02047734
10.1007/s40263-021-00805-0	study_information	NA	2	country_study	international
10.1007/s40263-021-00805-0	study_information	NA	2	ct_phase	3
10.1007/s40263-021-00805-0	study_information	NA	2	ct_arms	2 or more
10.1007/s40263-021-00805-0	study_information	NA	3	ipd_yn	No
10.1007/s40263-021-00805-0	study_information	NA	3	ct_yn	Yes
10.1007/s40263-021-00805-0	study_information	NA	3	nct	NCT00451451
10.1007/s40263-021-00805-0	study_information	NA	3	country_study	international
10.1007/s40263-021-00805-0	study_information	NA	3	ct_phase	3
10.1007/s40263-021-00805-0	study_information	NA	3	ct_arms	2 or more
10.1007/s40263-021-00805-0	study_information	NA	4	ipd_yn	No
10.1007/s40263-021-00805-0	study_information	NA	4	ct_yn	Yes
10.1007/s40263-021-00805-0	study_information	NA	4	nct	NCT00420212
10.1007/s40263-021-00805-0	study_information	NA	4	country_study	international
10.1007/s40263-021-00805-0	study_information	NA	4	ct_phase	3
10.1007/s40263-021-00805-0	study_information	NA	4	ct_arms	2 or more
10.1007/s40273-021-01015-8	general_information	NA	NA	condition_name	anaplastic lymphoma kinase (alk)-positive non-small-cell lung cancer
10.1007/s40273-021-01015-8	general_information	NA	NA	country_first_author	sweden
10.1007/s40273-021-01015-8	general_information	NA	NA	country_last_author	uk
10.1007/s40273-021-01015-8	general_information	NA	NA	positions	Pharmaceutical Industry, Private Data Analysis Company
10.1007/s40273-021-01015-8	general_information	NA	NA	methodologist_yn	Yes
10.1007/s40273-021-01015-8	general_information	NA	NA	funding_source	Pharmaceutical Industry
10.1007/s40273-021-01015-8	general_information	NA	NA	pharmaceutical_ties_yn	Yes
10.1007/s40273-021-01015-8	general_information	NA	NA	systematic_review_yn	Yes
10.1007/s40273-021-01015-8	methodology	1	NA	outcome_name	progression-free survival
10.1007/s40273-021-01015-8	methodology	1	NA	outcome_short_name	Progression-free Survival
10.1007/s40273-021-01015-8	methodology	1	NA	outcome_variable_type	Time-to-event
10.1007/s40273-021-01015-8	methodology	1	NA	treatment_name_ipd	lorlatinib
10.1007/s40273-021-01015-8	methodology	1	NA	studies_number_ipd	1
10.1007/s40273-021-01015-8	methodology	1	NA	treatment_name_nonipd	pemetrexed or docetaxel
10.1007/s40273-021-01015-8	methodology	1	NA	studies_number_nonipd	2;3
10.1007/s40273-021-01015-8	methodology	1	NA	paic_type	MAIC
10.1007/s40273-021-01015-8	methodology	1	NA	anchored_yn	No
10.1007/s40273-021-01015-8	methodology	1	NA	paic_form	Aggregation of multiple studies to estimate individual treatment effects (e.g. meta-analysis in a first step to estimate treatment A effect, then population adjusted indirect comparison using treatment A effect estimate)
10.1007/s40273-021-01015-8	methodology	1	NA	primary_outcome_yn	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.1007/s40273-021-01015-8	methodology	1	NA	variables_selection_justification	Statistical imbalanced between treatment groups (independently of the status of prognostic/effect modifier), Status of prognostic factor/treatment effect modified assessed in the IPD dataset, Literature based (clinically or methodologically relevant to adjust on these variables based on the literature search conducted for this specific purpose)
10.1007/s40273-021-01015-8	methodology	1	NA	pf_yn	Yes
10.1007/s40273-021-01015-8	methodology	1	NA	tem_yn	Yes
10.1007/s40273-021-01015-8	methodology	1	NA	adjustment_model_details_yn	No
10.1007/s40273-021-01015-8	methodology	1	NA	scale_choice_yn	No
10.1007/s40273-021-01015-8	methodology	2	NA	outcome_name	overall survival
10.1007/s40273-021-01015-8	methodology	2	NA	outcome_short_name	Overall Survival
10.1007/s40273-021-01015-8	methodology	2	NA	outcome_variable_type	Time-to-event
10.1007/s40273-021-01015-8	methodology	2	NA	treatment_name_ipd	lorlatinib
10.1007/s40273-021-01015-8	methodology	2	NA	studies_number_ipd	1
10.1007/s40273-021-01015-8	methodology	2	NA	treatment_name_nonipd	systemic therapy
10.1007/s40273-021-01015-8	methodology	2	NA	studies_number_nonipd	4;5
10.1007/s40273-021-01015-8	methodology	2	NA	paic_type	MAIC
10.1007/s40273-021-01015-8	methodology	2	NA	anchored_yn	No
10.1007/s40273-021-01015-8	methodology	2	NA	paic_form	Aggregation of multiple studies to estimate individual treatment effects (e.g. meta-analysis in a first step to estimate treatment A effect, then population adjusted indirect comparison using treatment A effect estimate)
10.1007/s40273-021-01015-8	methodology	2	NA	primary_outcome_yn	Yes
10.1007/s40273-021-01015-8	methodology	2	NA	variables_selection_justification	Nothing mentioned, not reported
10.1007/s40273-021-01015-8	methodology	2	NA	pf_yn	No discussion (in the main text) of the status of prognostic factors of the variables
10.1007/s40273-021-01015-8	methodology	2	NA	tem_yn	No discussion (in the main text) of the status of treatment-effect modifiers of the variables
10.1007/s40273-021-01015-8	methodology	2	NA	adjustment_model_details_yn	No
10.1007/s40273-021-01015-8	methodology	2	NA	scale_choice_yn	No
10.1007/s40273-021-01015-8	results	1	NA	contrast_effect_type	HR
10.1007/s40273-021-01015-8	results	1	NA	direction_benefit	inferior
10.1007/s40273-021-01015-8	results	1	NA	ss_ttt_nonipd	151
10.1007/s40273-021-01015-8	results	1	NA	ss_ttt_ipd	59
10.1007/s40273-021-01015-8	results	1	NA	ss_adjusted_ttt_ipd	53.4
10.1007/s40273-021-01015-8	results	1	NA	weights_yn	Not mentioned
10.1007/s40273-021-01015-8	results	1	NA	covariates_yn	Yes
10.1007/s40273-021-01015-8	results	1	NA	covariates_n	4
10.1007/s40273-021-01015-8	results	1	NA	covariates_names	Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Race/ethnicity, Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...)
10.1007/s40273-021-01015-8	results	1	NA	contrast_effect_direction	Numerator if ratio, or left side if difference
10.1007/s40273-021-01015-8	results	1	NA	contrast_effect_unadjusted_value	NA
10.1007/s40273-021-01015-8	results	1	NA	contrast_effect_unadjusted_pvalci	NA
10.1007/s40273-021-01015-8	results	1	NA	contrast_effect_adjusted_value	0.224
10.1007/s40273-021-01015-8	results	1	NA	contrast_effect_adjusted_pvalci	[0.154;0.312]
10.1007/s40273-021-01015-8	results	1	NA	adjustment_geographical	NA
10.1007/s40273-021-01015-8	results	1	NA	ss_total_ipd	NA
10.1007/s40273-021-01015-8	results	1	NA	ss_adjusted_total_ipd	NA
10.1007/s40273-021-01015-8	results	1	NA	ss_total_nonipd	NA
10.1007/s40273-021-01015-8	results	1	NA	ss_anchor_nonipd	NA
10.1007/s40273-021-01015-8	results	1	NA	ss_anchor_ipd	NA
10.1007/s40273-021-01015-8	results	1	NA	ss_adjusted_anchor_ipd	NA
10.1007/s40273-021-01015-8	results	1	NA	effect_cutoff	1
10.1007/s40273-021-01015-8	results	1	NA	adjusted_lb_ci	0.154
10.1007/s40273-021-01015-8	results	1	NA	adjusted_ub_ci	0.312
10.1007/s40273-021-01015-8	results	1	NA	adjusted_significant	TRUE
10.1007/s40273-021-01015-8	results	2	NA	contrast_effect_type	HR
10.1007/s40273-021-01015-8	results	2	NA	direction_benefit	inferior
10.1007/s40273-021-01015-8	results	2	NA	ss_ttt_nonipd	37
10.1007/s40273-021-01015-8	results	2	NA	ss_ttt_ipd	59
10.1007/s40273-021-01015-8	results	2	NA	ss_adjusted_ttt_ipd	24.5
10.1007/s40273-021-01015-8	results	2	NA	weights_yn	Not mentioned
10.1007/s40273-021-01015-8	results	2	NA	covariates_yn	Yes
10.1007/s40273-021-01015-8	results	2	NA	covariates_n	4
10.1007/s40273-021-01015-8	results	2	NA	covariates_names	Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Race/ethnicity, Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...)
10.1007/s40273-021-01015-8	results	2	NA	contrast_effect_direction	Numerator if ratio, or left side if difference
10.1007/s40273-021-01015-8	results	2	NA	contrast_effect_unadjusted_value	NA
10.1007/s40273-021-01015-8	results	2	NA	contrast_effect_unadjusted_pvalci	NA
10.1007/s40273-021-01015-8	results	2	NA	contrast_effect_adjusted_value	0.159
10.1007/s40273-021-01015-8	results	2	NA	contrast_effect_adjusted_pvalci	[0.052;0.356]
10.1007/s40273-021-01015-8	results	2	NA	adjustment_geographical	NA
10.1007/s40273-021-01015-8	results	2	NA	ss_total_ipd	NA
10.1007/s40273-021-01015-8	results	2	NA	ss_adjusted_total_ipd	NA
10.1007/s40273-021-01015-8	results	2	NA	ss_total_nonipd	NA
10.1007/s40273-021-01015-8	results	2	NA	ss_anchor_nonipd	NA
10.1007/s40273-021-01015-8	results	2	NA	ss_anchor_ipd	NA
10.1007/s40273-021-01015-8	results	2	NA	ss_adjusted_anchor_ipd	NA
10.1007/s40273-021-01015-8	results	2	NA	effect_cutoff	1
10.1007/s40273-021-01015-8	results	2	NA	adjusted_lb_ci	0.052
10.1007/s40273-021-01015-8	results	2	NA	adjusted_ub_ci	0.356
10.1007/s40273-021-01015-8	results	2	NA	adjusted_significant	TRUE
10.1007/s40273-021-01015-8	study_information	NA	1	ipd_yn	Yes
10.1007/s40273-021-01015-8	study_information	NA	1	ct_yn	Yes
10.1007/s40273-021-01015-8	study_information	NA	1	nct	NCT01970865
10.1007/s40273-021-01015-8	study_information	NA	1	country_study	international
10.1007/s40273-021-01015-8	study_information	NA	1	ct_phase	1, 2
10.1007/s40273-021-01015-8	study_information	NA	1	ct_arms	1
10.1007/s40273-021-01015-8	study_information	NA	2	ipd_yn	No
10.1007/s40273-021-01015-8	study_information	NA	2	ct_yn	Yes
10.1007/s40273-021-01015-8	study_information	NA	2	nct	NCT02604342
10.1007/s40273-021-01015-8	study_information	NA	2	country_study	international
10.1007/s40273-021-01015-8	study_information	NA	2	ct_phase	3
10.1007/s40273-021-01015-8	study_information	NA	2	ct_arms	2 or more
10.1007/s40273-021-01015-8	study_information	NA	3	ipd_yn	No
10.1007/s40273-021-01015-8	study_information	NA	3	ct_yn	Yes
10.1007/s40273-021-01015-8	study_information	NA	3	nct	NCT01828112
10.1007/s40273-021-01015-8	study_information	NA	3	country_study	international
10.1007/s40273-021-01015-8	study_information	NA	3	ct_phase	3
10.1007/s40273-021-01015-8	study_information	NA	3	ct_arms	2 or more
10.1007/s40273-021-01015-8	study_information	NA	4	ipd_yn	No
10.1007/s40273-021-01015-8	study_information	NA	4	ct_yn	Yes
10.1007/s40273-021-01015-8	study_information	NA	4	nct	NCT00585195
10.1007/s40273-021-01015-8	study_information	NA	4	country_study	international
10.1007/s40273-021-01015-8	study_information	NA	4	ct_phase	1
10.1007/s40273-021-01015-8	study_information	NA	4	ct_arms	1
10.1007/s40273-021-01015-8	study_information	NA	5	ipd_yn	No
10.1007/s40273-021-01015-8	study_information	NA	5	ct_yn	Yes
10.1007/s40273-021-01015-8	study_information	NA	5	nct	NCT00932451
10.1007/s40273-021-01015-8	study_information	NA	5	country_study	international
10.1007/s40273-021-01015-8	study_information	NA	5	ct_phase	2
10.1007/s40273-021-01015-8	study_information	NA	5	ct_arms	1
10.1007/s40744-017-0070-6	general_information	NA	NA	condition_name	active psoriatic arthritis
10.1007/s40744-017-0070-6	general_information	NA	NA	country_first_author	usa
10.1007/s40744-017-0070-6	general_information	NA	NA	country_last_author	usa
10.1007/s40744-017-0070-6	general_information	NA	NA	positions	Academic, Pharmaceutical Industry, Private Data Analysis Company
10.1007/s40744-017-0070-6	general_information	NA	NA	methodologist_yn	Yes
10.1007/s40744-017-0070-6	general_information	NA	NA	funding_source	Pharmaceutical Industry
10.1007/s40744-017-0070-6	general_information	NA	NA	pharmaceutical_ties_yn	Yes
10.1007/s40744-017-0070-6	general_information	NA	NA	systematic_review_yn	Yes
10.1007/s40744-017-0070-6	methodology	1	NA	outcome_name	response rates for acr 20 (american college of rheumatology) at week 24
10.1007/s40744-017-0070-6	methodology	1	NA	outcome_short_name	ACR Response Rate
10.1007/s40744-017-0070-6	methodology	1	NA	outcome_variable_type	Binary (eg rates)
10.1007/s40744-017-0070-6	methodology	1	NA	treatment_name_ipd	adalimumab
10.1007/s40744-017-0070-6	methodology	1	NA	studies_number_ipd	1
10.1007/s40744-017-0070-6	methodology	1	NA	treatment_name_nonipd	secukinumab 150 mg
10.1007/s40744-017-0070-6	methodology	1	NA	studies_number_nonipd	2;3
10.1007/s40744-017-0070-6	methodology	1	NA	paic_type	MAIC
10.1007/s40744-017-0070-6	methodology	1	NA	anchored_yn	Yes
10.1007/s40744-017-0070-6	methodology	1	NA	paic_form	Aggregation of multiple studies to estimate individual treatment effects (e.g. meta-analysis in a first step to estimate treatment A effect, then population adjusted indirect comparison using treatment A effect estimate)
10.1007/s40744-017-0070-6	methodology	1	NA	primary_outcome_yn	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.1007/s40744-017-0070-6	methodology	1	NA	variables_selection_justification	A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion)
10.1007/s40744-017-0070-6	methodology	1	NA	pf_yn	Yes
10.1007/s40744-017-0070-6	methodology	1	NA	tem_yn	Yes
10.1007/s40744-017-0070-6	methodology	1	NA	adjustment_model_details_yn	No
10.1007/s40744-017-0070-6	methodology	1	NA	scale_choice_yn	No
10.1007/s40744-017-0070-6	methodology	2	NA	outcome_name	response rates for acr 20 (american college of rheumatology) at week 24
10.1007/s40744-017-0070-6	methodology	2	NA	outcome_short_name	ACR Response Rate
10.1007/s40744-017-0070-6	methodology	2	NA	outcome_variable_type	Binary (eg rates)
10.1007/s40744-017-0070-6	methodology	2	NA	treatment_name_ipd	adalimumab
10.1007/s40744-017-0070-6	methodology	2	NA	studies_number_ipd	1
10.1007/s40744-017-0070-6	methodology	2	NA	treatment_name_nonipd	secukinumab 300 mg
10.1007/s40744-017-0070-6	methodology	2	NA	studies_number_nonipd	2;3
10.1007/s40744-017-0070-6	methodology	2	NA	paic_type	MAIC
10.1007/s40744-017-0070-6	methodology	2	NA	anchored_yn	Yes
10.1007/s40744-017-0070-6	methodology	2	NA	paic_form	Aggregation of multiple studies to estimate individual treatment effects (e.g. meta-analysis in a first step to estimate treatment A effect, then population adjusted indirect comparison using treatment A effect estimate)
10.1007/s40744-017-0070-6	methodology	2	NA	primary_outcome_yn	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.1007/s40744-017-0070-6	methodology	2	NA	variables_selection_justification	A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion)
10.1007/s40744-017-0070-6	methodology	2	NA	pf_yn	Yes
10.1007/s40744-017-0070-6	methodology	2	NA	tem_yn	Yes
10.1007/s40744-017-0070-6	methodology	2	NA	adjustment_model_details_yn	No
10.1007/s40744-017-0070-6	methodology	2	NA	scale_choice_yn	No
10.1007/s40744-017-0070-6	results	1	NA	contrast_effect_type	Rate difference
10.1007/s40744-017-0070-6	results	1	NA	direction_benefit	superior
10.1007/s40744-017-0070-6	results	1	NA	ss_ttt_nonipd	302
10.1007/s40744-017-0070-6	results	1	NA	ss_ttt_ipd	134
10.1007/s40744-017-0070-6	results	1	NA	ss_adjusted_ttt_ipd	49
10.1007/s40744-017-0070-6	results	1	NA	weights_yn	Not mentioned
10.1007/s40744-017-0070-6	results	1	NA	covariates_yn	Yes
10.1007/s40744-017-0070-6	results	1	NA	covariates_n	10
10.1007/s40744-017-0070-6	results	1	NA	covariates_names	Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Race/ethnicity, Past treatments for the disease of interest, Other(s)
10.1007/s40744-017-0070-6	results	1	NA	contrast_effect_direction	Numerator if ratio, or left side if difference
10.1007/s40744-017-0070-6	results	1	NA	contrast_effect_unadjusted_value	NA
10.1007/s40744-017-0070-6	results	1	NA	contrast_effect_unadjusted_pvalci	NA
10.1007/s40744-017-0070-6	results	1	NA	contrast_effect_adjusted_value	9.50
10.1007/s40744-017-0070-6	results	1	NA	contrast_effect_adjusted_pvalci	0.176
10.1007/s40744-017-0070-6	results	1	NA	adjustment_geographical	No
10.1007/s40744-017-0070-6	results	1	NA	ss_total_ipd	NA
10.1007/s40744-017-0070-6	results	1	NA	ss_adjusted_total_ipd	NA
10.1007/s40744-017-0070-6	results	1	NA	ss_total_nonipd	NA
10.1007/s40744-017-0070-6	results	1	NA	ss_anchor_nonipd	300
10.1007/s40744-017-0070-6	results	1	NA	ss_anchor_ipd	147
10.1007/s40744-017-0070-6	results	1	NA	ss_adjusted_anchor_ipd	79
10.1007/s40744-017-0070-6	results	1	NA	effect_cutoff	0
10.1007/s40744-017-0070-6	results	1	NA	adjusted_pval	0.176
10.1007/s40744-017-0070-6	results	1	NA	adjusted_num_pval	0.176
10.1007/s40744-017-0070-6	results	1	NA	adjusted_significant	FALSE
10.1007/s40744-017-0070-6	results	2	NA	contrast_effect_type	Rate difference
10.1007/s40744-017-0070-6	results	2	NA	direction_benefit	superior
10.1007/s40744-017-0070-6	results	2	NA	ss_ttt_nonipd	100
10.1007/s40744-017-0070-6	results	2	NA	ss_ttt_ipd	134
10.1007/s40744-017-0070-6	results	2	NA	ss_adjusted_ttt_ipd	76
10.1007/s40744-017-0070-6	results	2	NA	weights_yn	Not mentioned
10.1007/s40744-017-0070-6	results	2	NA	covariates_yn	Yes
10.1007/s40744-017-0070-6	results	2	NA	covariates_n	10
10.1007/s40744-017-0070-6	results	2	NA	covariates_names	Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Race/ethnicity, Past treatments for the disease of interest, Other(s)
10.1007/s40744-017-0070-6	results	2	NA	contrast_effect_direction	Numerator if ratio, or left side if difference
10.1007/s40744-017-0070-6	results	2	NA	contrast_effect_unadjusted_value	NA
10.1007/s40744-017-0070-6	results	2	NA	contrast_effect_unadjusted_pvalci	NA
10.1007/s40744-017-0070-6	results	2	NA	contrast_effect_adjusted_value	5.30
10.1007/s40744-017-0070-6	results	2	NA	contrast_effect_adjusted_pvalci	0.507
10.1007/s40744-017-0070-6	results	2	NA	adjustment_geographical	No
10.1007/s40744-017-0070-6	results	2	NA	ss_total_ipd	NA
10.1007/s40744-017-0070-6	results	2	NA	ss_adjusted_total_ipd	NA
10.1007/s40744-017-0070-6	results	2	NA	ss_total_nonipd	NA
10.1007/s40744-017-0070-6	results	2	NA	ss_anchor_nonipd	300
10.1007/s40744-017-0070-6	results	2	NA	ss_anchor_ipd	147
10.1007/s40744-017-0070-6	results	2	NA	ss_adjusted_anchor_ipd	79
10.1007/s40744-017-0070-6	results	2	NA	effect_cutoff	0
10.1007/s40744-017-0070-6	results	2	NA	adjusted_pval	0.507
10.1007/s40744-017-0070-6	results	2	NA	adjusted_num_pval	0.507
10.1007/s40744-017-0070-6	results	2	NA	adjusted_significant	FALSE
10.1007/s40744-017-0070-6	study_information	NA	1	ipd_yn	Yes
10.1007/s40744-017-0070-6	study_information	NA	1	ct_yn	Yes
10.1007/s40744-017-0070-6	study_information	NA	1	nct	NCT00195689
10.1007/s40744-017-0070-6	study_information	NA	1	country_study	usa
10.1007/s40744-017-0070-6	study_information	NA	1	ct_phase	3
10.1007/s40744-017-0070-6	study_information	NA	1	ct_arms	2 or more
10.1007/s40744-017-0070-6	study_information	NA	2	ipd_yn	No
10.1007/s40744-017-0070-6	study_information	NA	2	ct_yn	Yes
10.1007/s40744-017-0070-6	study_information	NA	2	nct	NCT01392326
10.1007/s40744-017-0070-6	study_information	NA	2	country_study	international
10.1007/s40744-017-0070-6	study_information	NA	2	ct_phase	3
10.1007/s40744-017-0070-6	study_information	NA	2	ct_arms	2 or more
10.1007/s40744-017-0070-6	study_information	NA	3	ipd_yn	No
10.1007/s40744-017-0070-6	study_information	NA	3	ct_yn	Yes
10.1007/s40744-017-0070-6	study_information	NA	3	nct	NCT01752634
10.1007/s40744-017-0070-6	study_information	NA	3	country_study	international
10.1007/s40744-017-0070-6	study_information	NA	3	ct_phase	3
10.1007/s40744-017-0070-6	study_information	NA	3	ct_arms	2 or more
10.1007/s40744-018-0106-6	general_information	NA	NA	condition_name	active psoriatic arthritis
10.1007/s40744-018-0106-6	general_information	NA	NA	country_first_author	australia
10.1007/s40744-018-0106-6	general_information	NA	NA	country_last_author	switzerland
10.1007/s40744-018-0106-6	general_information	NA	NA	positions	Academic, Pharmaceutical Industry, Private Data Analysis Company
10.1007/s40744-018-0106-6	general_information	NA	NA	methodologist_yn	Yes
10.1007/s40744-018-0106-6	general_information	NA	NA	funding_source	Pharmaceutical Industry
10.1007/s40744-018-0106-6	general_information	NA	NA	pharmaceutical_ties_yn	Yes
10.1007/s40744-018-0106-6	general_information	NA	NA	systematic_review_yn	Yes
10.1007/s40744-018-0106-6	methodology	1	NA	outcome_name	acr 20 response rate at week 12
10.1007/s40744-018-0106-6	methodology	1	NA	outcome_short_name	ACR Response Rate
10.1007/s40744-018-0106-6	methodology	1	NA	outcome_variable_type	Binary (eg rates)
10.1007/s40744-018-0106-6	methodology	1	NA	treatment_name_ipd	secukinumab 150 mg
10.1007/s40744-018-0106-6	methodology	1	NA	studies_number_ipd	1
10.1007/s40744-018-0106-6	methodology	1	NA	treatment_name_nonipd	adalimumab
10.1007/s40744-018-0106-6	methodology	1	NA	studies_number_nonipd	2
10.1007/s40744-018-0106-6	methodology	1	NA	paic_type	MAIC
10.1007/s40744-018-0106-6	methodology	1	NA	anchored_yn	Yes
10.1007/s40744-018-0106-6	methodology	1	NA	paic_form	Simple (ie treatments effects extracted from two studies)
10.1007/s40744-018-0106-6	methodology	1	NA	primary_outcome_yn	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.1007/s40744-018-0106-6	methodology	1	NA	variables_selection_justification	Status of prognostic factor/treatment effect modified assessed in the IPD dataset, A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion)
10.1007/s40744-018-0106-6	methodology	1	NA	pf_yn	Yes
10.1007/s40744-018-0106-6	methodology	1	NA	tem_yn	Yes
10.1007/s40744-018-0106-6	methodology	1	NA	adjustment_model_details_yn	Yes
10.1007/s40744-018-0106-6	methodology	1	NA	scale_choice_yn	No
10.1007/s40744-018-0106-6	methodology	2	NA	outcome_name	acr 20 response rate at week 12
10.1007/s40744-018-0106-6	methodology	2	NA	outcome_short_name	ACR Response Rate
10.1007/s40744-018-0106-6	methodology	2	NA	outcome_variable_type	Binary (eg rates)
10.1007/s40744-018-0106-6	methodology	2	NA	treatment_name_ipd	secukinumab 300 mg
10.1007/s40744-018-0106-6	methodology	2	NA	studies_number_ipd	1
10.1007/s40744-018-0106-6	methodology	2	NA	treatment_name_nonipd	adalimumab
10.1007/s40744-018-0106-6	methodology	2	NA	studies_number_nonipd	2
10.1007/s40744-018-0106-6	methodology	2	NA	paic_type	MAIC
10.1007/s40744-018-0106-6	methodology	2	NA	anchored_yn	Yes
10.1007/s40744-018-0106-6	methodology	2	NA	paic_form	Simple (ie treatments effects extracted from two studies)
10.1007/s40744-018-0106-6	methodology	2	NA	primary_outcome_yn	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.1007/s40744-018-0106-6	methodology	2	NA	variables_selection_justification	Status of prognostic factor/treatment effect modified assessed in the IPD dataset, A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion)
10.1007/s40744-018-0106-6	methodology	2	NA	pf_yn	Yes
10.1007/s40744-018-0106-6	methodology	2	NA	tem_yn	Yes
10.1007/s40744-018-0106-6	methodology	2	NA	adjustment_model_details_yn	Yes
10.1007/s40744-018-0106-6	methodology	2	NA	scale_choice_yn	No
10.1007/s40744-018-0106-6	methodology	3	NA	outcome_name	acr 20 response rate at week 16
10.1007/s40744-018-0106-6	methodology	3	NA	outcome_short_name	ACR Response Rate
10.1007/s40744-018-0106-6	methodology	3	NA	outcome_variable_type	Binary (eg rates)
10.1007/s40744-018-0106-6	methodology	3	NA	treatment_name_ipd	secukinumab 150 mg
10.1007/s40744-018-0106-6	methodology	3	NA	studies_number_ipd	1
10.1007/s40744-018-0106-6	methodology	3	NA	treatment_name_nonipd	adalimumab
10.1007/s40744-018-0106-6	methodology	3	NA	studies_number_nonipd	2
10.1007/s40744-018-0106-6	methodology	3	NA	paic_type	MAIC
10.1007/s40744-018-0106-6	methodology	3	NA	anchored_yn	No
10.1007/s40744-018-0106-6	methodology	3	NA	paic_form	Simple (ie treatments effects extracted from two studies)
10.1007/s40744-018-0106-6	methodology	3	NA	primary_outcome_yn	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.1007/s40744-018-0106-6	methodology	3	NA	variables_selection_justification	Status of prognostic factor/treatment effect modified assessed in the IPD dataset, A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion)
10.1007/s40744-018-0106-6	methodology	3	NA	pf_yn	Yes
10.1007/s40744-018-0106-6	methodology	3	NA	tem_yn	Yes
10.1007/s40744-018-0106-6	methodology	3	NA	adjustment_model_details_yn	Yes
10.1007/s40744-018-0106-6	methodology	3	NA	scale_choice_yn	No
10.1007/s40744-018-0106-6	methodology	4	NA	outcome_name	acr 20 response rate at week 16
10.1007/s40744-018-0106-6	methodology	4	NA	outcome_short_name	ACR Response Rate
10.1007/s40744-018-0106-6	methodology	4	NA	outcome_variable_type	Binary (eg rates)
10.1007/s40744-018-0106-6	methodology	4	NA	treatment_name_ipd	secukinumab 300 mg
10.1007/s40744-018-0106-6	methodology	4	NA	studies_number_ipd	1
10.1007/s40744-018-0106-6	methodology	4	NA	treatment_name_nonipd	adalimumab
10.1007/s40744-018-0106-6	methodology	4	NA	studies_number_nonipd	2
10.1007/s40744-018-0106-6	methodology	4	NA	paic_type	MAIC
10.1007/s40744-018-0106-6	methodology	4	NA	anchored_yn	No
10.1007/s40744-018-0106-6	methodology	4	NA	paic_form	Simple (ie treatments effects extracted from two studies)
10.1007/s40744-018-0106-6	methodology	4	NA	primary_outcome_yn	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.1007/s40744-018-0106-6	methodology	4	NA	variables_selection_justification	Status of prognostic factor/treatment effect modified assessed in the IPD dataset, A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion)
10.1007/s40744-018-0106-6	methodology	4	NA	pf_yn	Yes
10.1007/s40744-018-0106-6	methodology	4	NA	tem_yn	Yes
10.1007/s40744-018-0106-6	methodology	4	NA	adjustment_model_details_yn	Yes
10.1007/s40744-018-0106-6	methodology	4	NA	scale_choice_yn	No
10.1007/s40744-018-0106-6	results	1	NA	contrast_effect_type	RR
10.1007/s40744-018-0106-6	results	1	NA	direction_benefit	superior
10.1007/s40744-018-0106-6	results	1	NA	ss_ttt_nonipd	151
10.1007/s40744-018-0106-6	results	1	NA	ss_ttt_ipd	100
10.1007/s40744-018-0106-6	results	1	NA	ss_adjusted_ttt_ipd	36
10.1007/s40744-018-0106-6	results	1	NA	weights_yn	Not mentioned
10.1007/s40744-018-0106-6	results	1	NA	covariates_yn	Yes
10.1007/s40744-018-0106-6	results	1	NA	covariates_n	11
10.1007/s40744-018-0106-6	results	1	NA	covariates_names	Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Race/ethnicity, Past treatments for the disease of interest, Other(s)
10.1007/s40744-018-0106-6	results	1	NA	contrast_effect_direction	Numerator if ratio, or left side if difference
10.1007/s40744-018-0106-6	results	1	NA	contrast_effect_unadjusted_value	NA
10.1007/s40744-018-0106-6	results	1	NA	contrast_effect_unadjusted_pvalci	NA
10.1007/s40744-018-0106-6	results	1	NA	contrast_effect_adjusted_value	0.69
10.1007/s40744-018-0106-6	results	1	NA	contrast_effect_adjusted_pvalci	[0.34;1.43]
10.1007/s40744-018-0106-6	results	1	NA	adjustment_geographical	No
10.1007/s40744-018-0106-6	results	1	NA	ss_total_ipd	NA
10.1007/s40744-018-0106-6	results	1	NA	ss_adjusted_total_ipd	NA
10.1007/s40744-018-0106-6	results	1	NA	ss_total_nonipd	NA
10.1007/s40744-018-0106-6	results	1	NA	ss_anchor_nonipd	162
10.1007/s40744-018-0106-6	results	1	NA	ss_anchor_ipd	98
10.1007/s40744-018-0106-6	results	1	NA	ss_adjusted_anchor_ipd	27
10.1007/s40744-018-0106-6	results	1	NA	effect_cutoff	1
10.1007/s40744-018-0106-6	results	1	NA	adjusted_lb_ci	0.34
10.1007/s40744-018-0106-6	results	1	NA	adjusted_ub_ci	1.43
10.1007/s40744-018-0106-6	results	1	NA	adjusted_significant	FALSE
10.1007/s40744-018-0106-6	results	2	NA	contrast_effect_type	RR
10.1007/s40744-018-0106-6	results	2	NA	direction_benefit	superior
10.1007/s40744-018-0106-6	results	2	NA	ss_ttt_nonipd	151
10.1007/s40744-018-0106-6	results	2	NA	ss_ttt_ipd	100
10.1007/s40744-018-0106-6	results	2	NA	ss_adjusted_ttt_ipd	38
10.1007/s40744-018-0106-6	results	2	NA	weights_yn	Not mentioned
10.1007/s40744-018-0106-6	results	2	NA	covariates_yn	Yes
10.1007/s40744-018-0106-6	results	2	NA	covariates_n	11
10.1007/s40744-018-0106-6	results	2	NA	covariates_names	Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Race/ethnicity, Past treatments for the disease of interest, Other(s)
10.1007/s40744-018-0106-6	results	2	NA	contrast_effect_direction	Numerator if ratio, or left side if difference
10.1007/s40744-018-0106-6	results	2	NA	contrast_effect_unadjusted_value	NA
10.1007/s40744-018-0106-6	results	2	NA	contrast_effect_unadjusted_pvalci	NA
10.1007/s40744-018-0106-6	results	2	NA	contrast_effect_adjusted_value	0.61
10.1007/s40744-018-0106-6	results	2	NA	contrast_effect_adjusted_pvalci	[0.29;1.27]
10.1007/s40744-018-0106-6	results	2	NA	adjustment_geographical	No
10.1007/s40744-018-0106-6	results	2	NA	ss_total_ipd	NA
10.1007/s40744-018-0106-6	results	2	NA	ss_adjusted_total_ipd	NA
10.1007/s40744-018-0106-6	results	2	NA	ss_total_nonipd	NA
10.1007/s40744-018-0106-6	results	2	NA	ss_anchor_nonipd	162
10.1007/s40744-018-0106-6	results	2	NA	ss_anchor_ipd	98
10.1007/s40744-018-0106-6	results	2	NA	ss_adjusted_anchor_ipd	27
10.1007/s40744-018-0106-6	results	2	NA	effect_cutoff	1
10.1007/s40744-018-0106-6	results	2	NA	adjusted_lb_ci	0.29
10.1007/s40744-018-0106-6	results	2	NA	adjusted_ub_ci	1.27
10.1007/s40744-018-0106-6	results	2	NA	adjusted_significant	FALSE
10.1007/s40744-018-0106-6	results	3	NA	contrast_effect_type	RR
10.1007/s40744-018-0106-6	results	3	NA	direction_benefit	superior
10.1007/s40744-018-0106-6	results	3	NA	ss_ttt_nonipd	151
10.1007/s40744-018-0106-6	results	3	NA	ss_ttt_ipd	100
10.1007/s40744-018-0106-6	results	3	NA	ss_adjusted_ttt_ipd	36
10.1007/s40744-018-0106-6	results	3	NA	weights_yn	Not mentioned
10.1007/s40744-018-0106-6	results	3	NA	covariates_yn	Yes
10.1007/s40744-018-0106-6	results	3	NA	covariates_n	11
10.1007/s40744-018-0106-6	results	3	NA	covariates_names	Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Race/ethnicity, Past treatments for the disease of interest, Other(s)
10.1007/s40744-018-0106-6	results	3	NA	contrast_effect_direction	Numerator if ratio, or left side if difference
10.1007/s40744-018-0106-6	results	3	NA	contrast_effect_unadjusted_value	NA
10.1007/s40744-018-0106-6	results	3	NA	contrast_effect_unadjusted_pvalci	NA
10.1007/s40744-018-0106-6	results	3	NA	contrast_effect_adjusted_value	1.34
10.1007/s40744-018-0106-6	results	3	NA	contrast_effect_adjusted_pvalci	[1.05;1.70]
10.1007/s40744-018-0106-6	results	3	NA	adjustment_geographical	No
10.1007/s40744-018-0106-6	results	3	NA	ss_total_ipd	NA
10.1007/s40744-018-0106-6	results	3	NA	ss_adjusted_total_ipd	NA
10.1007/s40744-018-0106-6	results	3	NA	ss_total_nonipd	NA
10.1007/s40744-018-0106-6	results	3	NA	ss_anchor_nonipd	NA
10.1007/s40744-018-0106-6	results	3	NA	ss_anchor_ipd	NA
10.1007/s40744-018-0106-6	results	3	NA	ss_adjusted_anchor_ipd	NA
10.1007/s40744-018-0106-6	results	3	NA	effect_cutoff	1
10.1007/s40744-018-0106-6	results	3	NA	adjusted_lb_ci	1.05
10.1007/s40744-018-0106-6	results	3	NA	adjusted_ub_ci	1.7
10.1007/s40744-018-0106-6	results	3	NA	adjusted_significant	TRUE
10.1007/s40744-018-0106-6	results	4	NA	contrast_effect_type	RR
10.1007/s40744-018-0106-6	results	4	NA	direction_benefit	superior
10.1007/s40744-018-0106-6	results	4	NA	ss_ttt_nonipd	151
10.1007/s40744-018-0106-6	results	4	NA	ss_ttt_ipd	100
10.1007/s40744-018-0106-6	results	4	NA	ss_adjusted_ttt_ipd	38
10.1007/s40744-018-0106-6	results	4	NA	weights_yn	Not mentioned
10.1007/s40744-018-0106-6	results	4	NA	covariates_yn	Yes
10.1007/s40744-018-0106-6	results	4	NA	covariates_n	11
10.1007/s40744-018-0106-6	results	4	NA	covariates_names	Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Race/ethnicity, Past treatments for the disease of interest, Other(s)
10.1007/s40744-018-0106-6	results	4	NA	contrast_effect_direction	Numerator if ratio, or left side if difference
10.1007/s40744-018-0106-6	results	4	NA	contrast_effect_unadjusted_value	NA
10.1007/s40744-018-0106-6	results	4	NA	contrast_effect_unadjusted_pvalci	NA
10.1007/s40744-018-0106-6	results	4	NA	contrast_effect_adjusted_value	1.18
10.1007/s40744-018-0106-6	results	4	NA	contrast_effect_adjusted_pvalci	[0.90;1.54]
10.1007/s40744-018-0106-6	results	4	NA	adjustment_geographical	NA
10.1007/s40744-018-0106-6	results	4	NA	ss_total_ipd	NA
10.1007/s40744-018-0106-6	results	4	NA	ss_adjusted_total_ipd	NA
10.1007/s40744-018-0106-6	results	4	NA	ss_total_nonipd	NA
10.1007/s40744-018-0106-6	results	4	NA	ss_anchor_nonipd	NA
10.1007/s40744-018-0106-6	results	4	NA	ss_anchor_ipd	NA
10.1007/s40744-018-0106-6	results	4	NA	ss_adjusted_anchor_ipd	NA
10.1007/s40744-018-0106-6	results	4	NA	effect_cutoff	1
10.1007/s40744-018-0106-6	results	4	NA	adjusted_lb_ci	0.9
10.1007/s40744-018-0106-6	results	4	NA	adjusted_ub_ci	1.54
10.1007/s40744-018-0106-6	results	4	NA	adjusted_significant	FALSE
10.1007/s40744-018-0106-6	study_information	NA	1	ipd_yn	Yes
10.1007/s40744-018-0106-6	study_information	NA	1	ct_yn	Yes
10.1007/s40744-018-0106-6	study_information	NA	1	nct	NCT01752634
10.1007/s40744-018-0106-6	study_information	NA	1	country_study	international
10.1007/s40744-018-0106-6	study_information	NA	1	ct_phase	3
10.1007/s40744-018-0106-6	study_information	NA	1	ct_arms	2 or more
10.1007/s40744-018-0106-6	study_information	NA	2	ipd_yn	No
10.1007/s40744-018-0106-6	study_information	NA	2	ct_yn	Yes
10.1007/s40744-018-0106-6	study_information	NA	2	nct	NCT00195689
10.1007/s40744-018-0106-6	study_information	NA	2	country_study	usa
10.1007/s40744-018-0106-6	study_information	NA	2	ct_phase	3
10.1007/s40744-018-0106-6	study_information	NA	2	ct_arms	2 or more
10.1007/s40744-020-00257-w	general_information	NA	NA	condition_name	moderate-to-severe rheumatoid arthritis
10.1007/s40744-020-00257-w	general_information	NA	NA	country_first_author	uk
10.1007/s40744-020-00257-w	general_information	NA	NA	country_last_author	usa
10.1007/s40744-020-00257-w	general_information	NA	NA	positions	Academic, Pharmaceutical Industry, Private Data Analysis Company
10.1007/s40744-020-00257-w	general_information	NA	NA	methodologist_yn	Yes
10.1007/s40744-020-00257-w	general_information	NA	NA	funding_source	Pharmaceutical Industry
10.1007/s40744-020-00257-w	general_information	NA	NA	pharmaceutical_ties_yn	Yes
10.1007/s40744-020-00257-w	general_information	NA	NA	systematic_review_yn	Yes
10.1007/s40744-020-00257-w	methodology	1	NA	outcome_name	proportions of patients achieving 70 improvement in the acr criteria (acr70) at month 3
10.1007/s40744-020-00257-w	methodology	1	NA	outcome_short_name	ACR Response Rate
10.1007/s40744-020-00257-w	methodology	1	NA	outcome_variable_type	Binary (eg rates)
10.1007/s40744-020-00257-w	methodology	1	NA	treatment_name_ipd	upadacitinib monotherapy
10.1007/s40744-020-00257-w	methodology	1	NA	studies_number_ipd	1
10.1007/s40744-020-00257-w	methodology	1	NA	treatment_name_nonipd	tofacitinib + methotrexate
10.1007/s40744-020-00257-w	methodology	1	NA	studies_number_nonipd	3
10.1007/s40744-020-00257-w	methodology	1	NA	paic_type	MAIC
10.1007/s40744-020-00257-w	methodology	1	NA	anchored_yn	Yes
10.1007/s40744-020-00257-w	methodology	1	NA	paic_form	Simple (ie treatments effects extracted from two studies)
10.1007/s40744-020-00257-w	methodology	1	NA	primary_outcome_yn	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.1007/s40744-020-00257-w	methodology	1	NA	variables_selection_justification	A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion)
10.1007/s40744-020-00257-w	methodology	1	NA	pf_yn	No discussion (in the main text) of the status of prognostic factors of the variables
10.1007/s40744-020-00257-w	methodology	1	NA	tem_yn	No discussion (in the main text) of the status of treatment-effect modifiers of the variables
10.1007/s40744-020-00257-w	methodology	1	NA	adjustment_model_details_yn	No
10.1007/s40744-020-00257-w	methodology	1	NA	scale_choice_yn	No
10.1007/s40744-020-00257-w	methodology	2	NA	outcome_name	proportions of patients achieving 50 improvement in the acr criteria (acr50)at month 3,
10.1007/s40744-020-00257-w	methodology	2	NA	outcome_short_name	ACR Response Rate
10.1007/s40744-020-00257-w	methodology	2	NA	outcome_variable_type	Binary (eg rates)
10.1007/s40744-020-00257-w	methodology	2	NA	treatment_name_ipd	upadacitinib + methotrexate
10.1007/s40744-020-00257-w	methodology	2	NA	studies_number_ipd	2
10.1007/s40744-020-00257-w	methodology	2	NA	treatment_name_nonipd	tofacitinib + methotrexate
10.1007/s40744-020-00257-w	methodology	2	NA	studies_number_nonipd	4
10.1007/s40744-020-00257-w	methodology	2	NA	paic_type	MAIC
10.1007/s40744-020-00257-w	methodology	2	NA	anchored_yn	Yes
10.1007/s40744-020-00257-w	methodology	2	NA	paic_form	Simple (ie treatments effects extracted from two studies)
10.1007/s40744-020-00257-w	methodology	2	NA	primary_outcome_yn	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.1007/s40744-020-00257-w	methodology	2	NA	variables_selection_justification	A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion)
10.1007/s40744-020-00257-w	methodology	2	NA	pf_yn	No discussion (in the main text) of the status of prognostic factors of the variables
10.1007/s40744-020-00257-w	methodology	2	NA	tem_yn	No discussion (in the main text) of the status of treatment-effect modifiers of the variables
10.1007/s40744-020-00257-w	methodology	2	NA	adjustment_model_details_yn	No
10.1007/s40744-020-00257-w	methodology	2	NA	scale_choice_yn	No
10.1007/s40744-020-00257-w	results	1	NA	contrast_effect_type	Proportion difference
10.1007/s40744-020-00257-w	results	1	NA	direction_benefit	superior
10.1007/s40744-020-00257-w	results	1	NA	ss_ttt_nonipd	204
10.1007/s40744-020-00257-w	results	1	NA	ss_ttt_ipd	217
10.1007/s40744-020-00257-w	results	1	NA	ss_adjusted_ttt_ipd	173
10.1007/s40744-020-00257-w	results	1	NA	weights_yn	Not mentioned
10.1007/s40744-020-00257-w	results	1	NA	covariates_yn	Yes
10.1007/s40744-020-00257-w	results	1	NA	covariates_n	7
10.1007/s40744-020-00257-w	results	1	NA	covariates_names	Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Race/ethnicity
10.1007/s40744-020-00257-w	results	1	NA	contrast_effect_direction	Numerator if ratio, or left side if difference
10.1007/s40744-020-00257-w	results	1	NA	contrast_effect_unadjusted_value	0.096
10.1007/s40744-020-00257-w	results	1	NA	contrast_effect_unadjusted_pvalci	0.018
10.1007/s40744-020-00257-w	results	1	NA	contrast_effect_adjusted_value	0.099
10.1007/s40744-020-00257-w	results	1	NA	contrast_effect_adjusted_pvalci	0.019
10.1007/s40744-020-00257-w	results	1	NA	adjustment_geographical	NA
10.1007/s40744-020-00257-w	results	1	NA	ss_total_ipd	NA
10.1007/s40744-020-00257-w	results	1	NA	ss_adjusted_total_ipd	NA
10.1007/s40744-020-00257-w	results	1	NA	ss_total_nonipd	NA
10.1007/s40744-020-00257-w	results	1	NA	ss_anchor_nonipd	108
10.1007/s40744-020-00257-w	results	1	NA	ss_anchor_ipd	216
10.1007/s40744-020-00257-w	results	1	NA	ss_adjusted_anchor_ipd	158
10.1007/s40744-020-00257-w	results	1	NA	effect_cutoff	0
10.1007/s40744-020-00257-w	results	1	NA	unadjusted_pval	0.018
10.1007/s40744-020-00257-w	results	1	NA	unadjusted_num_pval	0.018
10.1007/s40744-020-00257-w	results	1	NA	unadjusted_significant	TRUE
10.1007/s40744-020-00257-w	results	1	NA	adjusted_pval	0.019
10.1007/s40744-020-00257-w	results	1	NA	adjusted_num_pval	0.019
10.1007/s40744-020-00257-w	results	1	NA	adjusted_significant	TRUE
10.1007/s40744-020-00257-w	results	2	NA	contrast_effect_type	Proportion difference
10.1007/s40744-020-00257-w	results	2	NA	direction_benefit	superior
10.1007/s40744-020-00257-w	results	2	NA	ss_ttt_nonipd	376
10.1007/s40744-020-00257-w	results	2	NA	ss_ttt_ipd	647
10.1007/s40744-020-00257-w	results	2	NA	ss_adjusted_ttt_ipd	480
10.1007/s40744-020-00257-w	results	2	NA	weights_yn	Not mentioned
10.1007/s40744-020-00257-w	results	2	NA	covariates_yn	Yes
10.1007/s40744-020-00257-w	results	2	NA	covariates_n	7
10.1007/s40744-020-00257-w	results	2	NA	covariates_names	Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Race/ethnicity
10.1007/s40744-020-00257-w	results	2	NA	contrast_effect_direction	Numerator if ratio, or left side if difference
10.1007/s40744-020-00257-w	results	2	NA	contrast_effect_unadjusted_value	0.127
10.1007/s40744-020-00257-w	results	2	NA	contrast_effect_unadjusted_pvalci	0.008
10.1007/s40744-020-00257-w	results	2	NA	contrast_effect_adjusted_value	0.129
10.1007/s40744-020-00257-w	results	2	NA	contrast_effect_adjusted_pvalci	0.011
10.1007/s40744-020-00257-w	results	2	NA	adjustment_geographical	NA
10.1007/s40744-020-00257-w	results	2	NA	ss_total_ipd	NA
10.1007/s40744-020-00257-w	results	2	NA	ss_adjusted_total_ipd	NA
10.1007/s40744-020-00257-w	results	2	NA	ss_total_nonipd	NA
10.1007/s40744-020-00257-w	results	2	NA	ss_anchor_nonipd	386
10.1007/s40744-020-00257-w	results	2	NA	ss_anchor_ipd	324
10.1007/s40744-020-00257-w	results	2	NA	ss_adjusted_anchor_ipd	228
10.1007/s40744-020-00257-w	results	2	NA	effect_cutoff	0
10.1007/s40744-020-00257-w	results	2	NA	unadjusted_pval	0.008
10.1007/s40744-020-00257-w	results	2	NA	unadjusted_num_pval	0.008
10.1007/s40744-020-00257-w	results	2	NA	unadjusted_significant	TRUE
10.1007/s40744-020-00257-w	results	2	NA	adjusted_pval	0.011
10.1007/s40744-020-00257-w	results	2	NA	adjusted_num_pval	0.011
10.1007/s40744-020-00257-w	results	2	NA	adjusted_significant	TRUE
10.1007/s40744-020-00257-w	study_information	NA	1	ipd_yn	Yes
10.1007/s40744-020-00257-w	study_information	NA	1	ct_yn	Yes
10.1007/s40744-020-00257-w	study_information	NA	1	nct	NCT02706951
10.1007/s40744-020-00257-w	study_information	NA	1	country_study	international
10.1007/s40744-020-00257-w	study_information	NA	1	ct_phase	3
10.1007/s40744-020-00257-w	study_information	NA	1	ct_arms	2 or more
10.1007/s40744-020-00257-w	study_information	NA	2	ipd_yn	Yes
10.1007/s40744-020-00257-w	study_information	NA	2	ct_yn	Yes
10.1007/s40744-020-00257-w	study_information	NA	2	nct	NCT02629159
10.1007/s40744-020-00257-w	study_information	NA	2	country_study	international
10.1007/s40744-020-00257-w	study_information	NA	2	ct_phase	3
10.1007/s40744-020-00257-w	study_information	NA	2	ct_arms	2 or more
10.1007/s40744-020-00257-w	study_information	NA	3	ipd_yn	No
10.1007/s40744-020-00257-w	study_information	NA	3	ct_yn	Yes
10.1007/s40744-020-00257-w	study_information	NA	3	nct	NCT00853385
10.1007/s40744-020-00257-w	study_information	NA	3	country_study	international
10.1007/s40744-020-00257-w	study_information	NA	3	ct_phase	3
10.1007/s40744-020-00257-w	study_information	NA	3	ct_arms	2 or more
10.1007/s40744-020-00257-w	study_information	NA	4	ipd_yn	No
10.1007/s40744-020-00257-w	study_information	NA	4	ct_yn	Yes
10.1007/s40744-020-00257-w	study_information	NA	4	nct	NCT02187055
10.1007/s40744-020-00257-w	study_information	NA	4	country_study	international
10.1007/s40744-020-00257-w	study_information	NA	4	ct_phase	3, 4
10.1007/s40744-020-00257-w	study_information	NA	4	ct_arms	2 or more
10.1016/j.bbmt.2020.06.008	general_information	NA	NA	condition_name	relapsed/refractory large b cell lymphoma
10.1016/j.bbmt.2020.06.008	general_information	NA	NA	country_first_author	usa
10.1016/j.bbmt.2020.06.008	general_information	NA	NA	country_last_author	usa
10.1016/j.bbmt.2020.06.008	general_information	NA	NA	positions	Academic, Pharmaceutical Industry, Private Data Analysis Company
10.1016/j.bbmt.2020.06.008	general_information	NA	NA	methodologist_yn	Yes
10.1016/j.bbmt.2020.06.008	general_information	NA	NA	funding_source	Pharmaceutical Industry
10.1016/j.bbmt.2020.06.008	general_information	NA	NA	pharmaceutical_ties_yn	Yes
10.1016/j.bbmt.2020.06.008	general_information	NA	NA	systematic_review_yn	No
10.1016/j.bbmt.2020.06.008	methodology	1	NA	outcome_name	Overall Survival
10.1016/j.bbmt.2020.06.008	methodology	1	NA	outcome_short_name	Overall Survival
10.1016/j.bbmt.2020.06.008	methodology	1	NA	outcome_variable_type	Time-to-event
10.1016/j.bbmt.2020.06.008	methodology	1	NA	treatment_name_ipd	axicabtagene ciloleucel
10.1016/j.bbmt.2020.06.008	methodology	1	NA	studies_number_ipd	1
10.1016/j.bbmt.2020.06.008	methodology	1	NA	treatment_name_nonipd	tisagenlecleucel
10.1016/j.bbmt.2020.06.008	methodology	1	NA	studies_number_nonipd	2
10.1016/j.bbmt.2020.06.008	methodology	1	NA	paic_type	MAIC
10.1016/j.bbmt.2020.06.008	methodology	1	NA	anchored_yn	No
10.1016/j.bbmt.2020.06.008	methodology	1	NA	paic_form	Simple (ie treatments effects extracted from two studies)
10.1016/j.bbmt.2020.06.008	methodology	1	NA	primary_outcome_yn	Yes
10.1016/j.bbmt.2020.06.008	methodology	1	NA	variables_selection_justification	A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion)
10.1016/j.bbmt.2020.06.008	methodology	1	NA	pf_yn	Yes
10.1016/j.bbmt.2020.06.008	methodology	1	NA	tem_yn	Yes
10.1016/j.bbmt.2020.06.008	methodology	1	NA	adjustment_model_details_yn	No
10.1016/j.bbmt.2020.06.008	methodology	1	NA	scale_choice_yn	No
10.1016/j.bbmt.2020.06.008	results	1	NA	contrast_effect_type	HR
10.1016/j.bbmt.2020.06.008	results	1	NA	direction_benefit	inferior
10.1016/j.bbmt.2020.06.008	results	1	NA	ss_ttt_nonipd	115
10.1016/j.bbmt.2020.06.008	results	1	NA	ss_ttt_ipd	101
10.1016/j.bbmt.2020.06.008	results	1	NA	ss_adjusted_ttt_ipd	39.59
10.1016/j.bbmt.2020.06.008	results	1	NA	weights_yn	Not mentioned
10.1016/j.bbmt.2020.06.008	results	1	NA	covariates_yn	Yes
10.1016/j.bbmt.2020.06.008	results	1	NA	covariates_n	7
10.1016/j.bbmt.2020.06.008	results	1	NA	covariates_names	Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Past treatments for the disease of interest
10.1016/j.bbmt.2020.06.008	results	1	NA	contrast_effect_direction	Numerator if ratio, or left side if difference
10.1016/j.bbmt.2020.06.008	results	1	NA	contrast_effect_unadjusted_value	0.68
10.1016/j.bbmt.2020.06.008	results	1	NA	contrast_effect_unadjusted_pvalci	[0.47;0.98]
10.1016/j.bbmt.2020.06.008	results	1	NA	contrast_effect_adjusted_value	0.51
10.1016/j.bbmt.2020.06.008	results	1	NA	contrast_effect_adjusted_pvalci	[0.31;0.83]
10.1016/j.bbmt.2020.06.008	results	1	NA	adjustment_geographical	NA
10.1016/j.bbmt.2020.06.008	results	1	NA	ss_total_ipd	NA
10.1016/j.bbmt.2020.06.008	results	1	NA	ss_adjusted_total_ipd	NA
10.1016/j.bbmt.2020.06.008	results	1	NA	ss_total_nonipd	NA
10.1016/j.bbmt.2020.06.008	results	1	NA	ss_anchor_nonipd	NA
10.1016/j.bbmt.2020.06.008	results	1	NA	ss_anchor_ipd	NA
10.1016/j.bbmt.2020.06.008	results	1	NA	ss_adjusted_anchor_ipd	NA
10.1016/j.bbmt.2020.06.008	results	1	NA	effect_cutoff	1
10.1016/j.bbmt.2020.06.008	results	1	NA	unadjusted_lb_ci	0.47
10.1016/j.bbmt.2020.06.008	results	1	NA	unadjusted_ub_ci	0.98
10.1016/j.bbmt.2020.06.008	results	1	NA	unadjusted_significant	TRUE
10.1016/j.bbmt.2020.06.008	results	1	NA	adjusted_lb_ci	0.31
10.1016/j.bbmt.2020.06.008	results	1	NA	adjusted_ub_ci	0.83
10.1016/j.bbmt.2020.06.008	results	1	NA	adjusted_significant	TRUE
10.1016/j.bbmt.2020.06.008	study_information	NA	1	ipd_yn	Yes
10.1016/j.bbmt.2020.06.008	study_information	NA	1	ct_yn	Yes
10.1016/j.bbmt.2020.06.008	study_information	NA	1	nct	NCT02348216
10.1016/j.bbmt.2020.06.008	study_information	NA	1	country_study	international
10.1016/j.bbmt.2020.06.008	study_information	NA	1	ct_phase	1, 2
10.1016/j.bbmt.2020.06.008	study_information	NA	1	ct_arms	1
10.1016/j.bbmt.2020.06.008	study_information	NA	2	ipd_yn	No
10.1016/j.bbmt.2020.06.008	study_information	NA	2	ct_yn	Yes
10.1016/j.bbmt.2020.06.008	study_information	NA	2	nct	NCT02445248
10.1016/j.bbmt.2020.06.008	study_information	NA	2	country_study	international
10.1016/j.bbmt.2020.06.008	study_information	NA	2	ct_phase	2
10.1016/j.bbmt.2020.06.008	study_information	NA	2	ct_arms	1
10.1016/j.clgc.2020.07.006	general_information	NA	NA	condition_name	locally advanced or metastatic urothelial carcinoma
10.1016/j.clgc.2020.07.006	general_information	NA	NA	country_first_author	uk
10.1016/j.clgc.2020.07.006	general_information	NA	NA	country_last_author	usa
10.1016/j.clgc.2020.07.006	general_information	NA	NA	positions	Academic, Pharmaceutical Industry, Private Data Analysis Company
10.1016/j.clgc.2020.07.006	general_information	NA	NA	methodologist_yn	Yes
10.1016/j.clgc.2020.07.006	general_information	NA	NA	funding_source	Pharmaceutical Industry
10.1016/j.clgc.2020.07.006	general_information	NA	NA	pharmaceutical_ties_yn	Yes
10.1016/j.clgc.2020.07.006	general_information	NA	NA	systematic_review_yn	No
10.1016/j.clgc.2020.07.006	methodology	1	NA	outcome_name	overall survival
10.1016/j.clgc.2020.07.006	methodology	1	NA	outcome_short_name	Overall Survival
10.1016/j.clgc.2020.07.006	methodology	1	NA	outcome_variable_type	Time-to-event
10.1016/j.clgc.2020.07.006	methodology	1	NA	treatment_name_ipd	pembrolizumab
10.1016/j.clgc.2020.07.006	methodology	1	NA	studies_number_ipd	1
10.1016/j.clgc.2020.07.006	methodology	1	NA	treatment_name_nonipd	carboplatin + gemcitabine
10.1016/j.clgc.2020.07.006	methodology	1	NA	studies_number_nonipd	2;3;4;5
10.1016/j.clgc.2020.07.006	methodology	1	NA	paic_type	STC
10.1016/j.clgc.2020.07.006	methodology	1	NA	anchored_yn	No
10.1016/j.clgc.2020.07.006	methodology	1	NA	paic_form	Aggregation of multiple studies to estimate individual treatment effects (e.g. meta-analysis in a first step to estimate treatment A effect, then population adjusted indirect comparison using treatment A effect estimate)
10.1016/j.clgc.2020.07.006	methodology	1	NA	primary_outcome_yn	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.1016/j.clgc.2020.07.006	methodology	1	NA	variables_selection_justification	Nothing mentioned, not reported
10.1016/j.clgc.2020.07.006	methodology	1	NA	pf_yn	No discussion (in the main text) of the status of prognostic factors of the variables
10.1016/j.clgc.2020.07.006	methodology	1	NA	tem_yn	No discussion (in the main text) of the status of treatment-effect modifiers of the variables
10.1016/j.clgc.2020.07.006	methodology	1	NA	adjustment_model_details_yn	No
10.1016/j.clgc.2020.07.006	methodology	1	NA	scale_choice_yn	No
10.1016/j.clgc.2020.07.006	results	1	NA	contrast_effect_type	HR
10.1016/j.clgc.2020.07.006	results	1	NA	direction_benefit	inferior
10.1016/j.clgc.2020.07.006	results	1	NA	ss_ttt_nonipd	NA
10.1016/j.clgc.2020.07.006	results	1	NA	ss_ttt_ipd	NA
10.1016/j.clgc.2020.07.006	results	1	NA	ss_adjusted_ttt_ipd	NA
10.1016/j.clgc.2020.07.006	results	1	NA	weights_yn	NA
10.1016/j.clgc.2020.07.006	results	1	NA	covariates_yn	No
10.1016/j.clgc.2020.07.006	results	1	NA	covariates_n	NA
10.1016/j.clgc.2020.07.006	results	1	NA	covariates_names	NA
10.1016/j.clgc.2020.07.006	results	1	NA	contrast_effect_direction	Denominator if ratio, or rightside if difference
10.1016/j.clgc.2020.07.006	results	1	NA	contrast_effect_unadjusted_value	NA
10.1016/j.clgc.2020.07.006	results	1	NA	contrast_effect_unadjusted_pvalci	NA
10.1016/j.clgc.2020.07.006	results	1	NA	contrast_effect_adjusted_value	2.34
10.1016/j.clgc.2020.07.006	results	1	NA	contrast_effect_adjusted_pvalci	[1.92;2.85]
10.1016/j.clgc.2020.07.006	results	1	NA	adjustment_geographical	NA
10.1016/j.clgc.2020.07.006	results	1	NA	ss_total_ipd	NA
10.1016/j.clgc.2020.07.006	results	1	NA	ss_adjusted_total_ipd	NA
10.1016/j.clgc.2020.07.006	results	1	NA	ss_total_nonipd	NA
10.1016/j.clgc.2020.07.006	results	1	NA	ss_anchor_nonipd	NA
10.1016/j.clgc.2020.07.006	results	1	NA	ss_anchor_ipd	NA
10.1016/j.clgc.2020.07.006	results	1	NA	ss_adjusted_anchor_ipd	NA
10.1016/j.clgc.2020.07.006	results	1	NA	effect_cutoff	1
10.1016/j.clgc.2020.07.006	results	1	NA	adjusted_lb_ci	1.92
10.1016/j.clgc.2020.07.006	results	1	NA	adjusted_ub_ci	2.85
10.1016/j.clgc.2020.07.006	results	1	NA	adjusted_significant	TRUE
10.1016/j.clgc.2020.07.006	study_information	NA	1	ipd_yn	Yes
10.1016/j.clgc.2020.07.006	study_information	NA	1	ct_yn	Yes
10.1016/j.clgc.2020.07.006	study_information	NA	1	nct	NCT02335424
10.1016/j.clgc.2020.07.006	study_information	NA	1	country_study	international
10.1016/j.clgc.2020.07.006	study_information	NA	1	ct_phase	2
10.1016/j.clgc.2020.07.006	study_information	NA	1	ct_arms	1
10.1016/j.clgc.2020.07.006	study_information	NA	2	ipd_yn	No
10.1016/j.clgc.2020.07.006	study_information	NA	2	ct_yn	Yes
10.1016/j.clgc.2020.07.006	study_information	NA	2	data_source_name	bamias et al. (2007)
10.1016/j.clgc.2020.07.006	study_information	NA	2	country_study	unknown
10.1016/j.clgc.2020.07.006	study_information	NA	2	ct_arms	1
10.1016/j.clgc.2020.07.006	study_information	NA	3	ipd_yn	No
10.1016/j.clgc.2020.07.006	study_information	NA	3	ct_yn	No
10.1016/j.clgc.2020.07.006	study_information	NA	3	data_source_name	carles et al. (2000)
10.1016/j.clgc.2020.07.006	study_information	NA	3	country_study	spain
10.1016/j.clgc.2020.07.006	study_information	NA	4	ipd_yn	No
10.1016/j.clgc.2020.07.006	study_information	NA	4	ct_yn	Yes
10.1016/j.clgc.2020.07.006	study_information	NA	4	nct	NCT00014274
10.1016/j.clgc.2020.07.006	study_information	NA	4	country_study	international
10.1016/j.clgc.2020.07.006	study_information	NA	4	ct_phase	2, 3
10.1016/j.clgc.2020.07.006	study_information	NA	4	ct_arms	2 or more
10.1016/j.clgc.2020.07.006	study_information	NA	5	ipd_yn	No
10.1016/j.clgc.2020.07.006	study_information	NA	5	ct_yn	Yes
10.1016/j.clgc.2020.07.006	study_information	NA	5	data_source_name	linardou et al. (2004)
10.1016/j.clgc.2020.07.006	study_information	NA	5	country_study	greece
10.1016/j.clgc.2020.07.006	study_information	NA	5	ct_phase	2
10.1016/j.clgc.2020.07.006	study_information	NA	5	ct_arms	1
10.1016/j.clinthera.2015.09.013	general_information	NA	NA	condition_name	metastatic advanced renal cell carcinoma
10.1016/j.clinthera.2015.09.013	general_information	NA	NA	country_first_author	usa
10.1016/j.clinthera.2015.09.013	general_information	NA	NA	country_last_author	usa
10.1016/j.clinthera.2015.09.013	general_information	NA	NA	positions	Academic, Pharmaceutical Industry, Private Data Analysis Company
10.1016/j.clinthera.2015.09.013	general_information	NA	NA	methodologist_yn	Yes
10.1016/j.clinthera.2015.09.013	general_information	NA	NA	funding_source	Pharmaceutical Industry
10.1016/j.clinthera.2015.09.013	general_information	NA	NA	pharmaceutical_ties_yn	Yes
10.1016/j.clinthera.2015.09.013	general_information	NA	NA	systematic_review_yn	No
10.1016/j.clinthera.2015.09.013	methodology	1	NA	outcome_name	progression-free survival
10.1016/j.clinthera.2015.09.013	methodology	1	NA	outcome_short_name	Progression-free Survival
10.1016/j.clinthera.2015.09.013	methodology	1	NA	outcome_variable_type	Time-to-event
10.1016/j.clinthera.2015.09.013	methodology	1	NA	treatment_name_ipd	everolimus
10.1016/j.clinthera.2015.09.013	methodology	1	NA	studies_number_ipd	1
10.1016/j.clinthera.2015.09.013	methodology	1	NA	treatment_name_nonipd	axitinib
10.1016/j.clinthera.2015.09.013	methodology	1	NA	studies_number_nonipd	2
10.1016/j.clinthera.2015.09.013	methodology	1	NA	paic_type	MAIC
10.1016/j.clinthera.2015.09.013	methodology	1	NA	anchored_yn	No
10.1016/j.clinthera.2015.09.013	methodology	1	NA	paic_form	Simple (ie treatments effects extracted from two studies)
10.1016/j.clinthera.2015.09.013	methodology	1	NA	primary_outcome_yn	Yes
10.1016/j.clinthera.2015.09.013	methodology	1	NA	variables_selection_justification	Status of prognostic factor/treatment effect modified assessed in the IPD dataset
10.1016/j.clinthera.2015.09.013	methodology	1	NA	pf_yn	Yes
10.1016/j.clinthera.2015.09.013	methodology	1	NA	tem_yn	No discussion (in the main text) of the status of treatment-effect modifiers of the variables
10.1016/j.clinthera.2015.09.013	methodology	1	NA	adjustment_model_details_yn	Yes
10.1016/j.clinthera.2015.09.013	methodology	1	NA	scale_choice_yn	No
10.1016/j.clinthera.2015.09.013	results	1	NA	contrast_effect_type	NA
10.1016/j.clinthera.2015.09.013	results	1	NA	direction_benefit	NA
10.1016/j.clinthera.2015.09.013	results	1	NA	ss_ttt_nonipd	194
10.1016/j.clinthera.2015.09.013	results	1	NA	ss_ttt_ipd	43
10.1016/j.clinthera.2015.09.013	results	1	NA	ss_adjusted_ttt_ipd	43
10.1016/j.clinthera.2015.09.013	results	1	NA	weights_yn	Yes, mentions that the weights distribution has been studied, and weights distribution reported in main article or supplemental materials
10.1016/j.clinthera.2015.09.013	results	1	NA	covariates_yn	Yes
10.1016/j.clinthera.2015.09.013	results	1	NA	covariates_n	3
10.1016/j.clinthera.2015.09.013	results	1	NA	covariates_names	Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Past treatments for the disease of interest
10.1016/j.clinthera.2015.09.013	results	1	NA	contrast_effect_direction	NA
10.1016/j.clinthera.2015.09.013	results	1	NA	contrast_effect_unadjusted_value	NA
10.1016/j.clinthera.2015.09.013	results	1	NA	contrast_effect_unadjusted_pvalci	NA
10.1016/j.clinthera.2015.09.013	results	1	NA	contrast_effect_adjusted_value	NA
10.1016/j.clinthera.2015.09.013	results	1	NA	contrast_effect_adjusted_pvalci	NA
10.1016/j.clinthera.2015.09.013	results	1	NA	adjustment_geographical	NA
10.1016/j.clinthera.2015.09.013	results	1	NA	ss_total_ipd	NA
10.1016/j.clinthera.2015.09.013	results	1	NA	ss_adjusted_total_ipd	NA
10.1016/j.clinthera.2015.09.013	results	1	NA	ss_total_nonipd	NA
10.1016/j.clinthera.2015.09.013	results	1	NA	ss_anchor_nonipd	NA
10.1016/j.clinthera.2015.09.013	results	1	NA	ss_anchor_ipd	NA
10.1016/j.clinthera.2015.09.013	results	1	NA	ss_adjusted_anchor_ipd	NA
10.1016/j.clinthera.2015.09.013	results	1	NA	effect_cutoff	NA
10.1016/j.clinthera.2015.09.013	study_information	NA	1	ipd_yn	Yes
10.1016/j.clinthera.2015.09.013	study_information	NA	1	ct_yn	Yes
10.1016/j.clinthera.2015.09.013	study_information	NA	1	nct	NCT00410124
10.1016/j.clinthera.2015.09.013	study_information	NA	1	country_study	international
10.1016/j.clinthera.2015.09.013	study_information	NA	1	ct_phase	3
10.1016/j.clinthera.2015.09.013	study_information	NA	1	ct_arms	2 or more
10.1016/j.clinthera.2015.09.013	study_information	NA	2	ipd_yn	No
10.1016/j.clinthera.2015.09.013	study_information	NA	2	ct_yn	Yes
10.1016/j.clinthera.2015.09.013	study_information	NA	2	nct	NCT00678392
10.1016/j.clinthera.2015.09.013	study_information	NA	2	country_study	international
10.1016/j.clinthera.2015.09.013	study_information	NA	2	ct_phase	3
10.1016/j.clinthera.2015.09.013	study_information	NA	2	ct_arms	2 or more
10.1016/j.clinthera.2015.12.017	general_information	NA	NA	condition_name	chronic hepatitis c coinfected with hiv
10.1016/j.clinthera.2015.12.017	general_information	NA	NA	country_first_author	usa
10.1016/j.clinthera.2015.12.017	general_information	NA	NA	country_last_author	usa
10.1016/j.clinthera.2015.12.017	general_information	NA	NA	positions	Pharmaceutical Industry, Private Data Analysis Company
10.1016/j.clinthera.2015.12.017	general_information	NA	NA	methodologist_yn	Yes
10.1016/j.clinthera.2015.12.017	general_information	NA	NA	funding_source	Pharmaceutical Industry
10.1016/j.clinthera.2015.12.017	general_information	NA	NA	pharmaceutical_ties_yn	Yes
10.1016/j.clinthera.2015.12.017	general_information	NA	NA	systematic_review_yn	Yes
10.1016/j.clinthera.2015.12.017	methodology	1	NA	outcome_name	sustained virologic response at week 12 post-treatment
10.1016/j.clinthera.2015.12.017	methodology	1	NA	outcome_short_name	SVR rate
10.1016/j.clinthera.2015.12.017	methodology	1	NA	outcome_variable_type	Binary (eg rates)
10.1016/j.clinthera.2015.12.017	methodology	1	NA	treatment_name_ipd	daclatasvir + sofosbuvir
10.1016/j.clinthera.2015.12.017	methodology	1	NA	studies_number_ipd	1
10.1016/j.clinthera.2015.12.017	methodology	1	NA	treatment_name_nonipd	sofosbuvir + ribavirin
10.1016/j.clinthera.2015.12.017	methodology	1	NA	studies_number_nonipd	2;3
10.1016/j.clinthera.2015.12.017	methodology	1	NA	paic_type	MAIC
10.1016/j.clinthera.2015.12.017	methodology	1	NA	anchored_yn	No
10.1016/j.clinthera.2015.12.017	methodology	1	NA	paic_form	Aggregation of multiple studies to estimate individual treatment effects (e.g. meta-analysis in a first step to estimate treatment A effect, then population adjusted indirect comparison using treatment A effect estimate)
10.1016/j.clinthera.2015.12.017	methodology	1	NA	primary_outcome_yn	Yes
10.1016/j.clinthera.2015.12.017	methodology	1	NA	variables_selection_justification	Nothing mentioned, not reported
10.1016/j.clinthera.2015.12.017	methodology	1	NA	pf_yn	No discussion (in the main text) of the status of prognostic factors of the variables
10.1016/j.clinthera.2015.12.017	methodology	1	NA	tem_yn	No discussion (in the main text) of the status of treatment-effect modifiers of the variables
10.1016/j.clinthera.2015.12.017	methodology	1	NA	adjustment_model_details_yn	No
10.1016/j.clinthera.2015.12.017	methodology	1	NA	scale_choice_yn	No
10.1016/j.clinthera.2015.12.017	results	1	NA	contrast_effect_type	Rate difference
10.1016/j.clinthera.2015.12.017	results	1	NA	direction_benefit	superior
10.1016/j.clinthera.2015.12.017	results	1	NA	ss_ttt_nonipd	455
10.1016/j.clinthera.2015.12.017	results	1	NA	ss_ttt_ipd	91
10.1016/j.clinthera.2015.12.017	results	1	NA	ss_adjusted_ttt_ipd	NA
10.1016/j.clinthera.2015.12.017	results	1	NA	weights_yn	Not mentioned
10.1016/j.clinthera.2015.12.017	results	1	NA	covariates_yn	Yes
10.1016/j.clinthera.2015.12.017	results	1	NA	covariates_n	11
10.1016/j.clinthera.2015.12.017	results	1	NA	covariates_names	Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Race/ethnicity, Past treatments for the disease of interest, Other(s)
10.1016/j.clinthera.2015.12.017	results	1	NA	contrast_effect_direction	Numerator if ratio, or left side if difference
10.1016/j.clinthera.2015.12.017	results	1	NA	contrast_effect_unadjusted_value	0.12
10.1016/j.clinthera.2015.12.017	results	1	NA	contrast_effect_unadjusted_pvalci	0.002
10.1016/j.clinthera.2015.12.017	results	1	NA	contrast_effect_adjusted_value	0.15
10.1016/j.clinthera.2015.12.017	results	1	NA	contrast_effect_adjusted_pvalci	<0.001
10.1016/j.clinthera.2015.12.017	results	1	NA	adjustment_geographical	No
10.1016/j.clinthera.2015.12.017	results	1	NA	ss_total_ipd	NA
10.1016/j.clinthera.2015.12.017	results	1	NA	ss_adjusted_total_ipd	NA
10.1016/j.clinthera.2015.12.017	results	1	NA	ss_total_nonipd	NA
10.1016/j.clinthera.2015.12.017	results	1	NA	ss_anchor_nonipd	NA
10.1016/j.clinthera.2015.12.017	results	1	NA	ss_anchor_ipd	NA
10.1016/j.clinthera.2015.12.017	results	1	NA	ss_adjusted_anchor_ipd	NA
10.1016/j.clinthera.2015.12.017	results	1	NA	effect_cutoff	0
10.1016/j.clinthera.2015.12.017	results	1	NA	unadjusted_pval	0.002
10.1016/j.clinthera.2015.12.017	results	1	NA	unadjusted_num_pval	0.002
10.1016/j.clinthera.2015.12.017	results	1	NA	unadjusted_significant	TRUE
10.1016/j.clinthera.2015.12.017	results	1	NA	adjusted_pval	<0.001
10.1016/j.clinthera.2015.12.017	results	1	NA	adjusted_significant	TRUE
10.1016/j.clinthera.2015.12.017	study_information	NA	1	ipd_yn	Yes
10.1016/j.clinthera.2015.12.017	study_information	NA	1	ct_yn	Yes
10.1016/j.clinthera.2015.12.017	study_information	NA	1	nct	NCT02032888
10.1016/j.clinthera.2015.12.017	study_information	NA	1	country_study	usa
10.1016/j.clinthera.2015.12.017	study_information	NA	1	ct_phase	3
10.1016/j.clinthera.2015.12.017	study_information	NA	1	ct_arms	1
10.1016/j.clinthera.2015.12.017	study_information	NA	2	ipd_yn	No
10.1016/j.clinthera.2015.12.017	study_information	NA	2	ct_yn	Yes
10.1016/j.clinthera.2015.12.017	study_information	NA	2	nct	NCT01667731
10.1016/j.clinthera.2015.12.017	study_information	NA	2	country_study	international
10.1016/j.clinthera.2015.12.017	study_information	NA	2	ct_phase	3
10.1016/j.clinthera.2015.12.017	study_information	NA	2	ct_arms	1
10.1016/j.clinthera.2015.12.017	study_information	NA	3	ipd_yn	No
10.1016/j.clinthera.2015.12.017	study_information	NA	3	ct_yn	Yes
10.1016/j.clinthera.2015.12.017	study_information	NA	3	nct	NCT01783678
10.1016/j.clinthera.2015.12.017	study_information	NA	3	country_study	international
10.1016/j.clinthera.2015.12.017	study_information	NA	3	ct_phase	3
10.1016/j.clinthera.2015.12.017	study_information	NA	3	ct_arms	1
10.1016/j.clinthera.2017.08.010	general_information	NA	NA	condition_name	relapsed-refractory multiple myeloma
10.1016/j.clinthera.2017.08.010	general_information	NA	NA	country_first_author	usa
10.1016/j.clinthera.2017.08.010	general_information	NA	NA	country_last_author	usa
10.1016/j.clinthera.2017.08.010	general_information	NA	NA	positions	Academic, Pharmaceutical Industry, Private Data Analysis Company
10.1016/j.clinthera.2017.08.010	general_information	NA	NA	methodologist_yn	Yes
10.1016/j.clinthera.2017.08.010	general_information	NA	NA	funding_source	Pharmaceutical Industry
10.1016/j.clinthera.2017.08.010	general_information	NA	NA	pharmaceutical_ties_yn	Yes
10.1016/j.clinthera.2017.08.010	general_information	NA	NA	systematic_review_yn	No
10.1016/j.clinthera.2017.08.010	methodology	1	NA	outcome_name	progression-free survival
10.1016/j.clinthera.2017.08.010	methodology	1	NA	outcome_short_name	Progression-free Survival
10.1016/j.clinthera.2017.08.010	methodology	1	NA	outcome_variable_type	Time-to-event
10.1016/j.clinthera.2017.08.010	methodology	1	NA	treatment_name_ipd	pomalidomide + dexamethasone
10.1016/j.clinthera.2017.08.010	methodology	1	NA	studies_number_ipd	1
10.1016/j.clinthera.2017.08.010	methodology	1	NA	treatment_name_nonipd	daratumumab
10.1016/j.clinthera.2017.08.010	methodology	1	NA	studies_number_nonipd	2
10.1016/j.clinthera.2017.08.010	methodology	1	NA	paic_type	MAIC
10.1016/j.clinthera.2017.08.010	methodology	1	NA	anchored_yn	No
10.1016/j.clinthera.2017.08.010	methodology	1	NA	paic_form	Simple (ie treatments effects extracted from two studies)
10.1016/j.clinthera.2017.08.010	methodology	1	NA	primary_outcome_yn	Yes
10.1016/j.clinthera.2017.08.010	methodology	1	NA	variables_selection_justification	Status of prognostic factor/treatment effect modified assessed in the IPD dataset
10.1016/j.clinthera.2017.08.010	methodology	1	NA	pf_yn	No discussion (in the main text) of the status of prognostic factors of the variables
10.1016/j.clinthera.2017.08.010	methodology	1	NA	tem_yn	No discussion (in the main text) of the status of treatment-effect modifiers of the variables
10.1016/j.clinthera.2017.08.010	methodology	1	NA	adjustment_model_details_yn	No
10.1016/j.clinthera.2017.08.010	methodology	1	NA	scale_choice_yn	No
10.1016/j.clinthera.2017.08.010	methodology	2	NA	outcome_name	progression-free survival
10.1016/j.clinthera.2017.08.010	methodology	2	NA	outcome_short_name	Progression-free Survival
10.1016/j.clinthera.2017.08.010	methodology	2	NA	outcome_variable_type	Time-to-event
10.1016/j.clinthera.2017.08.010	methodology	2	NA	treatment_name_ipd	pomalidomide + dexamethasone
10.1016/j.clinthera.2017.08.010	methodology	2	NA	studies_number_ipd	1
10.1016/j.clinthera.2017.08.010	methodology	2	NA	treatment_name_nonipd	carfilzomib
10.1016/j.clinthera.2017.08.010	methodology	2	NA	studies_number_nonipd	3
10.1016/j.clinthera.2017.08.010	methodology	2	NA	paic_type	MAIC
10.1016/j.clinthera.2017.08.010	methodology	2	NA	anchored_yn	No
10.1016/j.clinthera.2017.08.010	methodology	2	NA	paic_form	Simple (ie treatments effects extracted from two studies)
10.1016/j.clinthera.2017.08.010	methodology	2	NA	primary_outcome_yn	Yes
10.1016/j.clinthera.2017.08.010	methodology	2	NA	variables_selection_justification	Status of prognostic factor/treatment effect modified assessed in the IPD dataset
10.1016/j.clinthera.2017.08.010	methodology	2	NA	pf_yn	No discussion (in the main text) of the status of prognostic factors of the variables
10.1016/j.clinthera.2017.08.010	methodology	2	NA	tem_yn	No discussion (in the main text) of the status of treatment-effect modifiers of the variables
10.1016/j.clinthera.2017.08.010	methodology	2	NA	adjustment_model_details_yn	No
10.1016/j.clinthera.2017.08.010	methodology	2	NA	scale_choice_yn	No
10.1016/j.clinthera.2017.08.010	results	1	NA	contrast_effect_type	HR
10.1016/j.clinthera.2017.08.010	results	1	NA	direction_benefit	inferior
10.1016/j.clinthera.2017.08.010	results	1	NA	ss_ttt_nonipd	NA
10.1016/j.clinthera.2017.08.010	results	1	NA	ss_ttt_ipd	NA
10.1016/j.clinthera.2017.08.010	results	1	NA	ss_adjusted_ttt_ipd	NA
10.1016/j.clinthera.2017.08.010	results	1	NA	weights_yn	Not mentioned
10.1016/j.clinthera.2017.08.010	results	1	NA	covariates_yn	Yes
10.1016/j.clinthera.2017.08.010	results	1	NA	covariates_n	8
10.1016/j.clinthera.2017.08.010	results	1	NA	covariates_names	Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Race/ethnicity, Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Past treatments for the disease of interest, Comorbidities and medical history (beside pathology/disease of interest in the comparison)
10.1016/j.clinthera.2017.08.010	results	1	NA	contrast_effect_direction	Numerator if ratio, or left side if difference
10.1016/j.clinthera.2017.08.010	results	1	NA	contrast_effect_unadjusted_value	NA
10.1016/j.clinthera.2017.08.010	results	1	NA	contrast_effect_unadjusted_pvalci	NA
10.1016/j.clinthera.2017.08.010	results	1	NA	contrast_effect_adjusted_value	0.945
10.1016/j.clinthera.2017.08.010	results	1	NA	contrast_effect_adjusted_pvalci	0.749
10.1016/j.clinthera.2017.08.010	results	1	NA	adjustment_geographical	NA
10.1016/j.clinthera.2017.08.010	results	1	NA	ss_total_ipd	NA
10.1016/j.clinthera.2017.08.010	results	1	NA	ss_adjusted_total_ipd	NA
10.1016/j.clinthera.2017.08.010	results	1	NA	ss_total_nonipd	NA
10.1016/j.clinthera.2017.08.010	results	1	NA	ss_anchor_nonipd	NA
10.1016/j.clinthera.2017.08.010	results	1	NA	ss_anchor_ipd	NA
10.1016/j.clinthera.2017.08.010	results	1	NA	ss_adjusted_anchor_ipd	NA
10.1016/j.clinthera.2017.08.010	results	1	NA	effect_cutoff	1
10.1016/j.clinthera.2017.08.010	results	1	NA	adjusted_pval	0.749
10.1016/j.clinthera.2017.08.010	results	1	NA	adjusted_num_pval	0.749
10.1016/j.clinthera.2017.08.010	results	1	NA	adjusted_significant	FALSE
10.1016/j.clinthera.2017.08.010	results	2	NA	contrast_effect_type	HR
10.1016/j.clinthera.2017.08.010	results	2	NA	direction_benefit	inferior
10.1016/j.clinthera.2017.08.010	results	2	NA	ss_ttt_nonipd	NA
10.1016/j.clinthera.2017.08.010	results	2	NA	ss_ttt_ipd	NA
10.1016/j.clinthera.2017.08.010	results	2	NA	ss_adjusted_ttt_ipd	NA
10.1016/j.clinthera.2017.08.010	results	2	NA	weights_yn	Not mentioned
10.1016/j.clinthera.2017.08.010	results	2	NA	covariates_yn	Yes
10.1016/j.clinthera.2017.08.010	results	2	NA	covariates_n	8
10.1016/j.clinthera.2017.08.010	results	2	NA	covariates_names	Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Race/ethnicity, Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Past treatments for the disease of interest, Comorbidities and medical history (beside pathology/disease of interest in the comparison)
10.1016/j.clinthera.2017.08.010	results	2	NA	contrast_effect_direction	Numerator if ratio, or left side if difference
10.1016/j.clinthera.2017.08.010	results	2	NA	contrast_effect_unadjusted_value	NA
10.1016/j.clinthera.2017.08.010	results	2	NA	contrast_effect_unadjusted_pvalci	NA
10.1016/j.clinthera.2017.08.010	results	2	NA	contrast_effect_adjusted_value	0.833
10.1016/j.clinthera.2017.08.010	results	2	NA	contrast_effect_adjusted_pvalci	0.238
10.1016/j.clinthera.2017.08.010	results	2	NA	adjustment_geographical	NA
10.1016/j.clinthera.2017.08.010	results	2	NA	ss_total_ipd	NA
10.1016/j.clinthera.2017.08.010	results	2	NA	ss_adjusted_total_ipd	NA
10.1016/j.clinthera.2017.08.010	results	2	NA	ss_total_nonipd	NA
10.1016/j.clinthera.2017.08.010	results	2	NA	ss_anchor_nonipd	NA
10.1016/j.clinthera.2017.08.010	results	2	NA	ss_anchor_ipd	NA
10.1016/j.clinthera.2017.08.010	results	2	NA	ss_adjusted_anchor_ipd	NA
10.1016/j.clinthera.2017.08.010	results	2	NA	effect_cutoff	1
10.1016/j.clinthera.2017.08.010	results	2	NA	adjusted_pval	0.238
10.1016/j.clinthera.2017.08.010	results	2	NA	adjusted_num_pval	0.238
10.1016/j.clinthera.2017.08.010	results	2	NA	adjusted_significant	FALSE
10.1016/j.clinthera.2017.08.010	study_information	NA	1	ipd_yn	Yes
10.1016/j.clinthera.2017.08.010	study_information	NA	1	ct_yn	Yes
10.1016/j.clinthera.2017.08.010	study_information	NA	1	nct	NCT00833833
10.1016/j.clinthera.2017.08.010	study_information	NA	1	country_study	international
10.1016/j.clinthera.2017.08.010	study_information	NA	1	ct_phase	1, 2
10.1016/j.clinthera.2017.08.010	study_information	NA	1	ct_arms	2 or more
10.1016/j.clinthera.2017.08.010	study_information	NA	2	ipd_yn	No
10.1016/j.clinthera.2017.08.010	study_information	NA	2	ct_yn	Yes
10.1016/j.clinthera.2017.08.010	study_information	NA	2	nct	NCT01985126
10.1016/j.clinthera.2017.08.010	study_information	NA	2	country_study	international
10.1016/j.clinthera.2017.08.010	study_information	NA	2	ct_phase	2
10.1016/j.clinthera.2017.08.010	study_information	NA	2	ct_arms	1
10.1016/j.clinthera.2017.08.010	study_information	NA	3	ipd_yn	No
10.1016/j.clinthera.2017.08.010	study_information	NA	3	ct_yn	Yes
10.1016/j.clinthera.2017.08.010	study_information	NA	3	nct	NCT00511238
10.1016/j.clinthera.2017.08.010	study_information	NA	3	country_study	international
10.1016/j.clinthera.2017.08.010	study_information	NA	3	ct_phase	2
10.1016/j.clinthera.2017.08.010	study_information	NA	3	ct_arms	1
10.1016/j.clinthera.2019.09.012	general_information	NA	NA	condition_name	relapsed/refractory mantle cell lymphoma
10.1016/j.clinthera.2019.09.012	general_information	NA	NA	country_first_author	usa
10.1016/j.clinthera.2019.09.012	general_information	NA	NA	country_last_author	usa
10.1016/j.clinthera.2019.09.012	general_information	NA	NA	positions	Pharmaceutical Industry, Private Data Analysis Company
10.1016/j.clinthera.2019.09.012	general_information	NA	NA	methodologist_yn	Yes
10.1016/j.clinthera.2019.09.012	general_information	NA	NA	funding_source	Pharmaceutical Industry
10.1016/j.clinthera.2019.09.012	general_information	NA	NA	pharmaceutical_ties_yn	Yes
10.1016/j.clinthera.2019.09.012	general_information	NA	NA	systematic_review_yn	Yes
10.1016/j.clinthera.2019.09.012	methodology	1	NA	outcome_name	overall response rate
10.1016/j.clinthera.2019.09.012	methodology	1	NA	outcome_short_name	Overall Response Rate
10.1016/j.clinthera.2019.09.012	methodology	1	NA	outcome_variable_type	Binary (eg rates)
10.1016/j.clinthera.2019.09.012	methodology	1	NA	treatment_name_ipd	acalabrutinib
10.1016/j.clinthera.2019.09.012	methodology	1	NA	studies_number_ipd	1
10.1016/j.clinthera.2019.09.012	methodology	1	NA	treatment_name_nonipd	ibrutinib
10.1016/j.clinthera.2019.09.012	methodology	1	NA	studies_number_nonipd	2;3;4
10.1016/j.clinthera.2019.09.012	methodology	1	NA	paic_type	MAIC
10.1016/j.clinthera.2019.09.012	methodology	1	NA	anchored_yn	No
10.1016/j.clinthera.2019.09.012	methodology	1	NA	paic_form	Aggregation of multiple studies to estimate individual treatment effects (e.g. meta-analysis in a first step to estimate treatment A effect, then population adjusted indirect comparison using treatment A effect estimate)
10.1016/j.clinthera.2019.09.012	methodology	1	NA	primary_outcome_yn	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.1016/j.clinthera.2019.09.012	methodology	1	NA	variables_selection_justification	A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion)
10.1016/j.clinthera.2019.09.012	methodology	1	NA	pf_yn	No discussion (in the main text) of the status of prognostic factors of the variables
10.1016/j.clinthera.2019.09.012	methodology	1	NA	tem_yn	No discussion (in the main text) of the status of treatment-effect modifiers of the variables
10.1016/j.clinthera.2019.09.012	methodology	1	NA	adjustment_model_details_yn	No
10.1016/j.clinthera.2019.09.012	methodology	1	NA	scale_choice_yn	No
10.1016/j.clinthera.2019.09.012	methodology	2	NA	outcome_name	overall response rate
10.1016/j.clinthera.2019.09.012	methodology	2	NA	outcome_short_name	Overall Response Rate
10.1016/j.clinthera.2019.09.012	methodology	2	NA	outcome_variable_type	Binary (eg rates)
10.1016/j.clinthera.2019.09.012	methodology	2	NA	treatment_name_ipd	acalabrutinib
10.1016/j.clinthera.2019.09.012	methodology	2	NA	studies_number_ipd	1
10.1016/j.clinthera.2019.09.012	methodology	2	NA	treatment_name_nonipd	bortezomib
10.1016/j.clinthera.2019.09.012	methodology	2	NA	studies_number_nonipd	5
10.1016/j.clinthera.2019.09.012	methodology	2	NA	paic_type	MAIC
10.1016/j.clinthera.2019.09.012	methodology	2	NA	anchored_yn	No
10.1016/j.clinthera.2019.09.012	methodology	2	NA	paic_form	Simple (ie treatments effects extracted from two studies)
10.1016/j.clinthera.2019.09.012	methodology	2	NA	primary_outcome_yn	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.1016/j.clinthera.2019.09.012	methodology	2	NA	variables_selection_justification	A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion)
10.1016/j.clinthera.2019.09.012	methodology	2	NA	pf_yn	No discussion (in the main text) of the status of prognostic factors of the variables
10.1016/j.clinthera.2019.09.012	methodology	2	NA	tem_yn	No discussion (in the main text) of the status of treatment-effect modifiers of the variables
10.1016/j.clinthera.2019.09.012	methodology	2	NA	adjustment_model_details_yn	No
10.1016/j.clinthera.2019.09.012	methodology	2	NA	scale_choice_yn	No
10.1016/j.clinthera.2019.09.012	methodology	3	NA	outcome_name	overall response rate
10.1016/j.clinthera.2019.09.012	methodology	3	NA	outcome_short_name	Overall Response Rate
10.1016/j.clinthera.2019.09.012	methodology	3	NA	outcome_variable_type	Binary (eg rates)
10.1016/j.clinthera.2019.09.012	methodology	3	NA	treatment_name_ipd	acalabrutinib
10.1016/j.clinthera.2019.09.012	methodology	3	NA	studies_number_ipd	1
10.1016/j.clinthera.2019.09.012	methodology	3	NA	treatment_name_nonipd	lenalidomide
10.1016/j.clinthera.2019.09.012	methodology	3	NA	studies_number_nonipd	6;7
10.1016/j.clinthera.2019.09.012	methodology	3	NA	paic_type	MAIC
10.1016/j.clinthera.2019.09.012	methodology	3	NA	anchored_yn	No
10.1016/j.clinthera.2019.09.012	methodology	3	NA	paic_form	Aggregation of multiple studies to estimate individual treatment effects (e.g. meta-analysis in a first step to estimate treatment A effect, then population adjusted indirect comparison using treatment A effect estimate)
10.1016/j.clinthera.2019.09.012	methodology	3	NA	primary_outcome_yn	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.1016/j.clinthera.2019.09.012	methodology	3	NA	variables_selection_justification	A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion)
10.1016/j.clinthera.2019.09.012	methodology	3	NA	pf_yn	No discussion (in the main text) of the status of prognostic factors of the variables
10.1016/j.clinthera.2019.09.012	methodology	3	NA	tem_yn	No discussion (in the main text) of the status of treatment-effect modifiers of the variables
10.1016/j.clinthera.2019.09.012	methodology	3	NA	adjustment_model_details_yn	No
10.1016/j.clinthera.2019.09.012	methodology	3	NA	scale_choice_yn	No
10.1016/j.clinthera.2019.09.012	methodology	4	NA	outcome_name	overall response rate
10.1016/j.clinthera.2019.09.012	methodology	4	NA	outcome_short_name	Overall Response Rate
10.1016/j.clinthera.2019.09.012	methodology	4	NA	outcome_variable_type	Binary (eg rates)
10.1016/j.clinthera.2019.09.012	methodology	4	NA	treatment_name_ipd	acalabrutinib
10.1016/j.clinthera.2019.09.012	methodology	4	NA	studies_number_ipd	1
10.1016/j.clinthera.2019.09.012	methodology	4	NA	treatment_name_nonipd	temsirolimus
10.1016/j.clinthera.2019.09.012	methodology	4	NA	studies_number_nonipd	2;8;9
10.1016/j.clinthera.2019.09.012	methodology	4	NA	paic_type	MAIC
10.1016/j.clinthera.2019.09.012	methodology	4	NA	anchored_yn	No
10.1016/j.clinthera.2019.09.012	methodology	4	NA	paic_form	Aggregation of multiple studies to estimate individual treatment effects (e.g. meta-analysis in a first step to estimate treatment A effect, then population adjusted indirect comparison using treatment A effect estimate)
10.1016/j.clinthera.2019.09.012	methodology	4	NA	primary_outcome_yn	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.1016/j.clinthera.2019.09.012	methodology	4	NA	variables_selection_justification	A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion)
10.1016/j.clinthera.2019.09.012	methodology	4	NA	pf_yn	No discussion (in the main text) of the status of prognostic factors of the variables
10.1016/j.clinthera.2019.09.012	methodology	4	NA	tem_yn	No discussion (in the main text) of the status of treatment-effect modifiers of the variables
10.1016/j.clinthera.2019.09.012	methodology	4	NA	adjustment_model_details_yn	No
10.1016/j.clinthera.2019.09.012	methodology	4	NA	scale_choice_yn	No
10.1016/j.clinthera.2019.09.012	methodology	5	NA	outcome_name	overall response rate
10.1016/j.clinthera.2019.09.012	methodology	5	NA	outcome_short_name	Overall Response Rate
10.1016/j.clinthera.2019.09.012	methodology	5	NA	outcome_variable_type	Binary (eg rates)
10.1016/j.clinthera.2019.09.012	methodology	5	NA	treatment_name_ipd	acalabrutinib
10.1016/j.clinthera.2019.09.012	methodology	5	NA	studies_number_ipd	1
10.1016/j.clinthera.2019.09.012	methodology	5	NA	treatment_name_nonipd	ibrutinib + rituximab
10.1016/j.clinthera.2019.09.012	methodology	5	NA	studies_number_nonipd	10
10.1016/j.clinthera.2019.09.012	methodology	5	NA	paic_type	MAIC
10.1016/j.clinthera.2019.09.012	methodology	5	NA	anchored_yn	No
10.1016/j.clinthera.2019.09.012	methodology	5	NA	paic_form	Simple (ie treatments effects extracted from two studies)
10.1016/j.clinthera.2019.09.012	methodology	5	NA	primary_outcome_yn	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.1016/j.clinthera.2019.09.012	methodology	5	NA	variables_selection_justification	A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion)
10.1016/j.clinthera.2019.09.012	methodology	5	NA	pf_yn	No discussion (in the main text) of the status of prognostic factors of the variables
10.1016/j.clinthera.2019.09.012	methodology	5	NA	tem_yn	No discussion (in the main text) of the status of treatment-effect modifiers of the variables
10.1016/j.clinthera.2019.09.012	methodology	5	NA	adjustment_model_details_yn	No
10.1016/j.clinthera.2019.09.012	methodology	5	NA	scale_choice_yn	No
10.1016/j.clinthera.2019.09.012	methodology	6	NA	outcome_name	overall response rate
10.1016/j.clinthera.2019.09.012	methodology	6	NA	outcome_short_name	Overall Response Rate
10.1016/j.clinthera.2019.09.012	methodology	6	NA	outcome_variable_type	Binary (eg rates)
10.1016/j.clinthera.2019.09.012	methodology	6	NA	treatment_name_ipd	acalabrutinib
10.1016/j.clinthera.2019.09.012	methodology	6	NA	studies_number_ipd	1
10.1016/j.clinthera.2019.09.012	methodology	6	NA	treatment_name_nonipd	bendamustine + rituximab
10.1016/j.clinthera.2019.09.012	methodology	6	NA	studies_number_nonipd	11
10.1016/j.clinthera.2019.09.012	methodology	6	NA	paic_type	MAIC
10.1016/j.clinthera.2019.09.012	methodology	6	NA	anchored_yn	No
10.1016/j.clinthera.2019.09.012	methodology	6	NA	paic_form	Simple (ie treatments effects extracted from two studies)
10.1016/j.clinthera.2019.09.012	methodology	6	NA	primary_outcome_yn	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.1016/j.clinthera.2019.09.012	methodology	6	NA	variables_selection_justification	A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion)
10.1016/j.clinthera.2019.09.012	methodology	6	NA	pf_yn	No discussion (in the main text) of the status of prognostic factors of the variables
10.1016/j.clinthera.2019.09.012	methodology	6	NA	tem_yn	No discussion (in the main text) of the status of treatment-effect modifiers of the variables
10.1016/j.clinthera.2019.09.012	methodology	6	NA	adjustment_model_details_yn	No
10.1016/j.clinthera.2019.09.012	methodology	6	NA	scale_choice_yn	No
10.1016/j.clinthera.2019.09.012	methodology	7	NA	outcome_name	overall response rate
10.1016/j.clinthera.2019.09.012	methodology	7	NA	outcome_short_name	Overall Response Rate
10.1016/j.clinthera.2019.09.012	methodology	7	NA	outcome_variable_type	Binary (eg rates)
10.1016/j.clinthera.2019.09.012	methodology	7	NA	treatment_name_ipd	acalabrutinib
10.1016/j.clinthera.2019.09.012	methodology	7	NA	studies_number_ipd	1
10.1016/j.clinthera.2019.09.012	methodology	7	NA	treatment_name_nonipd	lenalidomide + rituximab
10.1016/j.clinthera.2019.09.012	methodology	7	NA	studies_number_nonipd	12
10.1016/j.clinthera.2019.09.012	methodology	7	NA	paic_type	MAIC
10.1016/j.clinthera.2019.09.012	methodology	7	NA	anchored_yn	No
10.1016/j.clinthera.2019.09.012	methodology	7	NA	paic_form	Simple (ie treatments effects extracted from two studies)
10.1016/j.clinthera.2019.09.012	methodology	7	NA	primary_outcome_yn	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.1016/j.clinthera.2019.09.012	methodology	7	NA	variables_selection_justification	A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion)
10.1016/j.clinthera.2019.09.012	methodology	7	NA	pf_yn	No discussion (in the main text) of the status of prognostic factors of the variables
10.1016/j.clinthera.2019.09.012	methodology	7	NA	tem_yn	No discussion (in the main text) of the status of treatment-effect modifiers of the variables
10.1016/j.clinthera.2019.09.012	methodology	7	NA	adjustment_model_details_yn	No
10.1016/j.clinthera.2019.09.012	methodology	7	NA	scale_choice_yn	No
10.1016/j.clinthera.2019.09.012	results	1	NA	contrast_effect_type	Rate difference
10.1016/j.clinthera.2019.09.012	results	1	NA	direction_benefit	superior
10.1016/j.clinthera.2019.09.012	results	1	NA	ss_ttt_nonipd	370
10.1016/j.clinthera.2019.09.012	results	1	NA	ss_ttt_ipd	123
10.1016/j.clinthera.2019.09.012	results	1	NA	ss_adjusted_ttt_ipd	45
10.1016/j.clinthera.2019.09.012	results	1	NA	weights_yn	Not mentioned
10.1016/j.clinthera.2019.09.012	results	1	NA	covariates_yn	Yes
10.1016/j.clinthera.2019.09.012	results	1	NA	covariates_n	10
10.1016/j.clinthera.2019.09.012	results	1	NA	covariates_names	Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Race/ethnicity, Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Past treatments for the disease of interest
10.1016/j.clinthera.2019.09.012	results	1	NA	contrast_effect_direction	Numerator if ratio, or left side if difference
10.1016/j.clinthera.2019.09.012	results	1	NA	contrast_effect_unadjusted_value	10.2
10.1016/j.clinthera.2019.09.012	results	1	NA	contrast_effect_unadjusted_pvalci	<0.05
10.1016/j.clinthera.2019.09.012	results	1	NA	contrast_effect_adjusted_value	9.3
10.1016/j.clinthera.2019.09.012	results	1	NA	contrast_effect_adjusted_pvalci	<0.05
10.1016/j.clinthera.2019.09.012	results	1	NA	adjustment_geographical	NA
10.1016/j.clinthera.2019.09.012	results	1	NA	ss_total_ipd	NA
10.1016/j.clinthera.2019.09.012	results	1	NA	ss_adjusted_total_ipd	NA
10.1016/j.clinthera.2019.09.012	results	1	NA	ss_total_nonipd	NA
10.1016/j.clinthera.2019.09.012	results	1	NA	ss_anchor_nonipd	NA
10.1016/j.clinthera.2019.09.012	results	1	NA	ss_anchor_ipd	NA
10.1016/j.clinthera.2019.09.012	results	1	NA	ss_adjusted_anchor_ipd	NA
10.1016/j.clinthera.2019.09.012	results	1	NA	effect_cutoff	0
10.1016/j.clinthera.2019.09.012	results	1	NA	unadjusted_pval	<0.05
10.1016/j.clinthera.2019.09.012	results	1	NA	unadjusted_significant	TRUE
10.1016/j.clinthera.2019.09.012	results	1	NA	adjusted_pval	<0.05
10.1016/j.clinthera.2019.09.012	results	1	NA	adjusted_significant	TRUE
10.1016/j.clinthera.2019.09.012	results	2	NA	contrast_effect_type	Rate difference
10.1016/j.clinthera.2019.09.012	results	2	NA	direction_benefit	superior
10.1016/j.clinthera.2019.09.012	results	2	NA	ss_ttt_nonipd	155
10.1016/j.clinthera.2019.09.012	results	2	NA	ss_ttt_ipd	124
10.1016/j.clinthera.2019.09.012	results	2	NA	ss_adjusted_ttt_ipd	61
10.1016/j.clinthera.2019.09.012	results	2	NA	weights_yn	Not mentioned
10.1016/j.clinthera.2019.09.012	results	2	NA	covariates_yn	Yes
10.1016/j.clinthera.2019.09.012	results	2	NA	covariates_n	9
10.1016/j.clinthera.2019.09.012	results	2	NA	covariates_names	Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Race/ethnicity, Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Past treatments for the disease of interest
10.1016/j.clinthera.2019.09.012	results	2	NA	contrast_effect_direction	Numerator if ratio, or left side if difference
10.1016/j.clinthera.2019.09.012	results	2	NA	contrast_effect_unadjusted_value	46
10.1016/j.clinthera.2019.09.012	results	2	NA	contrast_effect_unadjusted_pvalci	<0.001
10.1016/j.clinthera.2019.09.012	results	2	NA	contrast_effect_adjusted_value	50.6
10.1016/j.clinthera.2019.09.012	results	2	NA	contrast_effect_adjusted_pvalci	<0.001
10.1016/j.clinthera.2019.09.012	results	2	NA	adjustment_geographical	NA
10.1016/j.clinthera.2019.09.012	results	2	NA	ss_total_ipd	NA
10.1016/j.clinthera.2019.09.012	results	2	NA	ss_adjusted_total_ipd	NA
10.1016/j.clinthera.2019.09.012	results	2	NA	ss_total_nonipd	NA
10.1016/j.clinthera.2019.09.012	results	2	NA	ss_anchor_nonipd	NA
10.1016/j.clinthera.2019.09.012	results	2	NA	ss_anchor_ipd	NA
10.1016/j.clinthera.2019.09.012	results	2	NA	ss_adjusted_anchor_ipd	NA
10.1016/j.clinthera.2019.09.012	results	2	NA	effect_cutoff	0
10.1016/j.clinthera.2019.09.012	results	2	NA	unadjusted_pval	<0.001
10.1016/j.clinthera.2019.09.012	results	2	NA	unadjusted_significant	TRUE
10.1016/j.clinthera.2019.09.012	results	2	NA	adjusted_pval	<0.001
10.1016/j.clinthera.2019.09.012	results	2	NA	adjusted_significant	TRUE
10.1016/j.clinthera.2019.09.012	results	3	NA	contrast_effect_type	Rate difference
10.1016/j.clinthera.2019.09.012	results	3	NA	direction_benefit	superior
10.1016/j.clinthera.2019.09.012	results	3	NA	ss_ttt_nonipd	304
10.1016/j.clinthera.2019.09.012	results	3	NA	ss_ttt_ipd	122
10.1016/j.clinthera.2019.09.012	results	3	NA	ss_adjusted_ttt_ipd	28
10.1016/j.clinthera.2019.09.012	results	3	NA	weights_yn	Not mentioned
10.1016/j.clinthera.2019.09.012	results	3	NA	covariates_yn	Yes
10.1016/j.clinthera.2019.09.012	results	3	NA	covariates_n	12
10.1016/j.clinthera.2019.09.012	results	3	NA	covariates_names	Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Past treatments for the disease of interest
10.1016/j.clinthera.2019.09.012	results	3	NA	contrast_effect_direction	Numerator if ratio, or left side if difference
10.1016/j.clinthera.2019.09.012	results	3	NA	contrast_effect_unadjusted_value	39.7
10.1016/j.clinthera.2019.09.012	results	3	NA	contrast_effect_unadjusted_pvalci	<0.001
10.1016/j.clinthera.2019.09.012	results	3	NA	contrast_effect_adjusted_value	38.1
10.1016/j.clinthera.2019.09.012	results	3	NA	contrast_effect_adjusted_pvalci	<0.001
10.1016/j.clinthera.2019.09.012	results	3	NA	adjustment_geographical	NA
10.1016/j.clinthera.2019.09.012	results	3	NA	ss_total_ipd	NA
10.1016/j.clinthera.2019.09.012	results	3	NA	ss_adjusted_total_ipd	NA
10.1016/j.clinthera.2019.09.012	results	3	NA	ss_total_nonipd	NA
10.1016/j.clinthera.2019.09.012	results	3	NA	ss_anchor_nonipd	NA
10.1016/j.clinthera.2019.09.012	results	3	NA	ss_anchor_ipd	NA
10.1016/j.clinthera.2019.09.012	results	3	NA	ss_adjusted_anchor_ipd	NA
10.1016/j.clinthera.2019.09.012	results	3	NA	effect_cutoff	0
10.1016/j.clinthera.2019.09.012	results	3	NA	unadjusted_pval	<0.001
10.1016/j.clinthera.2019.09.012	results	3	NA	unadjusted_significant	TRUE
10.1016/j.clinthera.2019.09.012	results	3	NA	adjusted_pval	<0.001
10.1016/j.clinthera.2019.09.012	results	3	NA	adjusted_significant	TRUE
10.1016/j.clinthera.2019.09.012	results	4	NA	contrast_effect_type	Rate difference
10.1016/j.clinthera.2019.09.012	results	4	NA	direction_benefit	superior
10.1016/j.clinthera.2019.09.012	results	4	NA	ss_ttt_nonipd	242
10.1016/j.clinthera.2019.09.012	results	4	NA	ss_ttt_ipd	123
10.1016/j.clinthera.2019.09.012	results	4	NA	ss_adjusted_ttt_ipd	120
10.1016/j.clinthera.2019.09.012	results	4	NA	weights_yn	Not mentioned
10.1016/j.clinthera.2019.09.012	results	4	NA	covariates_yn	Yes
10.1016/j.clinthera.2019.09.012	results	4	NA	covariates_n	3
10.1016/j.clinthera.2019.09.012	results	4	NA	covariates_names	Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...)
10.1016/j.clinthera.2019.09.012	results	4	NA	contrast_effect_direction	Numerator if ratio, or left side if difference
10.1016/j.clinthera.2019.09.012	results	4	NA	contrast_effect_unadjusted_value	40.9
10.1016/j.clinthera.2019.09.012	results	4	NA	contrast_effect_unadjusted_pvalci	<0.001
10.1016/j.clinthera.2019.09.012	results	4	NA	contrast_effect_adjusted_value	40.7
10.1016/j.clinthera.2019.09.012	results	4	NA	contrast_effect_adjusted_pvalci	<0.001
10.1016/j.clinthera.2019.09.012	results	4	NA	adjustment_geographical	NA
10.1016/j.clinthera.2019.09.012	results	4	NA	ss_total_ipd	NA
10.1016/j.clinthera.2019.09.012	results	4	NA	ss_adjusted_total_ipd	NA
10.1016/j.clinthera.2019.09.012	results	4	NA	ss_total_nonipd	NA
10.1016/j.clinthera.2019.09.012	results	4	NA	ss_anchor_nonipd	NA
10.1016/j.clinthera.2019.09.012	results	4	NA	ss_anchor_ipd	NA
10.1016/j.clinthera.2019.09.012	results	4	NA	ss_adjusted_anchor_ipd	NA
10.1016/j.clinthera.2019.09.012	results	4	NA	effect_cutoff	0
10.1016/j.clinthera.2019.09.012	results	4	NA	unadjusted_pval	<0.001
10.1016/j.clinthera.2019.09.012	results	4	NA	unadjusted_significant	TRUE
10.1016/j.clinthera.2019.09.012	results	4	NA	adjusted_pval	<0.001
10.1016/j.clinthera.2019.09.012	results	4	NA	adjusted_significant	TRUE
10.1016/j.clinthera.2019.09.012	results	5	NA	contrast_effect_type	Rate difference
10.1016/j.clinthera.2019.09.012	results	5	NA	direction_benefit	superior
10.1016/j.clinthera.2019.09.012	results	5	NA	ss_ttt_nonipd	50
10.1016/j.clinthera.2019.09.012	results	5	NA	ss_ttt_ipd	84
10.1016/j.clinthera.2019.09.012	results	5	NA	ss_adjusted_ttt_ipd	16
10.1016/j.clinthera.2019.09.012	results	5	NA	weights_yn	Not mentioned
10.1016/j.clinthera.2019.09.012	results	5	NA	covariates_yn	Yes
10.1016/j.clinthera.2019.09.012	results	5	NA	covariates_n	8
10.1016/j.clinthera.2019.09.012	results	5	NA	covariates_names	Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Past treatments for the disease of interest
10.1016/j.clinthera.2019.09.012	results	5	NA	contrast_effect_direction	Numerator if ratio, or left side if difference
10.1016/j.clinthera.2019.09.012	results	5	NA	contrast_effect_unadjusted_value	-14.2
10.1016/j.clinthera.2019.09.012	results	5	NA	contrast_effect_unadjusted_pvalci	<0.05
10.1016/j.clinthera.2019.09.012	results	5	NA	contrast_effect_adjusted_value	-10.6
10.1016/j.clinthera.2019.09.012	results	5	NA	contrast_effect_adjusted_pvalci	0.09
10.1016/j.clinthera.2019.09.012	results	5	NA	adjustment_geographical	NA
10.1016/j.clinthera.2019.09.012	results	5	NA	ss_total_ipd	NA
10.1016/j.clinthera.2019.09.012	results	5	NA	ss_adjusted_total_ipd	NA
10.1016/j.clinthera.2019.09.012	results	5	NA	ss_total_nonipd	NA
10.1016/j.clinthera.2019.09.012	results	5	NA	ss_anchor_nonipd	NA
10.1016/j.clinthera.2019.09.012	results	5	NA	ss_anchor_ipd	NA
10.1016/j.clinthera.2019.09.012	results	5	NA	ss_adjusted_anchor_ipd	NA
10.1016/j.clinthera.2019.09.012	results	5	NA	effect_cutoff	0
10.1016/j.clinthera.2019.09.012	results	5	NA	unadjusted_pval	<0.05
10.1016/j.clinthera.2019.09.012	results	5	NA	unadjusted_significant	TRUE
10.1016/j.clinthera.2019.09.012	results	5	NA	adjusted_pval	0.09
10.1016/j.clinthera.2019.09.012	results	5	NA	adjusted_num_pval	0.09
10.1016/j.clinthera.2019.09.012	results	5	NA	adjusted_significant	FALSE
10.1016/j.clinthera.2019.09.012	results	6	NA	contrast_effect_type	Rate difference
10.1016/j.clinthera.2019.09.012	results	6	NA	direction_benefit	superior
10.1016/j.clinthera.2019.09.012	results	6	NA	ss_ttt_nonipd	45
10.1016/j.clinthera.2019.09.012	results	6	NA	ss_ttt_ipd	121
10.1016/j.clinthera.2019.09.012	results	6	NA	ss_adjusted_ttt_ipd	56
10.1016/j.clinthera.2019.09.012	results	6	NA	weights_yn	Not mentioned
10.1016/j.clinthera.2019.09.012	results	6	NA	covariates_yn	Yes
10.1016/j.clinthera.2019.09.012	results	6	NA	covariates_n	5
10.1016/j.clinthera.2019.09.012	results	6	NA	covariates_names	Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease)
10.1016/j.clinthera.2019.09.012	results	6	NA	contrast_effect_direction	Numerator if ratio, or left side if difference
10.1016/j.clinthera.2019.09.012	results	6	NA	contrast_effect_unadjusted_value	-7
10.1016/j.clinthera.2019.09.012	results	6	NA	contrast_effect_unadjusted_pvalci	0.31
10.1016/j.clinthera.2019.09.012	results	6	NA	contrast_effect_adjusted_value	-9.8
10.1016/j.clinthera.2019.09.012	results	6	NA	contrast_effect_adjusted_pvalci	0.22
10.1016/j.clinthera.2019.09.012	results	6	NA	adjustment_geographical	NA
10.1016/j.clinthera.2019.09.012	results	6	NA	ss_total_ipd	NA
10.1016/j.clinthera.2019.09.012	results	6	NA	ss_adjusted_total_ipd	NA
10.1016/j.clinthera.2019.09.012	results	6	NA	ss_total_nonipd	NA
10.1016/j.clinthera.2019.09.012	results	6	NA	ss_anchor_nonipd	NA
10.1016/j.clinthera.2019.09.012	results	6	NA	ss_anchor_ipd	NA
10.1016/j.clinthera.2019.09.012	results	6	NA	ss_adjusted_anchor_ipd	NA
10.1016/j.clinthera.2019.09.012	results	6	NA	effect_cutoff	0
10.1016/j.clinthera.2019.09.012	results	6	NA	unadjusted_pval	0.31
10.1016/j.clinthera.2019.09.012	results	6	NA	unadjusted_num_pval	0.31
10.1016/j.clinthera.2019.09.012	results	6	NA	unadjusted_significant	FALSE
10.1016/j.clinthera.2019.09.012	results	6	NA	adjusted_pval	0.22
10.1016/j.clinthera.2019.09.012	results	6	NA	adjusted_num_pval	0.22
10.1016/j.clinthera.2019.09.012	results	6	NA	adjusted_significant	FALSE
10.1016/j.clinthera.2019.09.012	results	7	NA	contrast_effect_type	Rate difference
10.1016/j.clinthera.2019.09.012	results	7	NA	direction_benefit	superior
10.1016/j.clinthera.2019.09.012	results	7	NA	ss_ttt_nonipd	44
10.1016/j.clinthera.2019.09.012	results	7	NA	ss_ttt_ipd	93
10.1016/j.clinthera.2019.09.012	results	7	NA	ss_adjusted_ttt_ipd	64
10.1016/j.clinthera.2019.09.012	results	7	NA	weights_yn	Not mentioned
10.1016/j.clinthera.2019.09.012	results	7	NA	covariates_yn	Yes
10.1016/j.clinthera.2019.09.012	results	7	NA	covariates_n	7
10.1016/j.clinthera.2019.09.012	results	7	NA	covariates_names	Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Past treatments for the disease of interest
10.1016/j.clinthera.2019.09.012	results	7	NA	contrast_effect_direction	Numerator if ratio, or left side if difference
10.1016/j.clinthera.2019.09.012	results	7	NA	contrast_effect_unadjusted_value	16.3
10.1016/j.clinthera.2019.09.012	results	7	NA	contrast_effect_unadjusted_pvalci	0.06
10.1016/j.clinthera.2019.09.012	results	7	NA	contrast_effect_adjusted_value	14.1
10.1016/j.clinthera.2019.09.012	results	7	NA	contrast_effect_adjusted_pvalci	0.13
10.1016/j.clinthera.2019.09.012	results	7	NA	adjustment_geographical	NA
10.1016/j.clinthera.2019.09.012	results	7	NA	ss_total_ipd	NA
10.1016/j.clinthera.2019.09.012	results	7	NA	ss_adjusted_total_ipd	NA
10.1016/j.clinthera.2019.09.012	results	7	NA	ss_total_nonipd	NA
10.1016/j.clinthera.2019.09.012	results	7	NA	ss_anchor_nonipd	NA
10.1016/j.clinthera.2019.09.012	results	7	NA	ss_anchor_ipd	NA
10.1016/j.clinthera.2019.09.012	results	7	NA	ss_adjusted_anchor_ipd	NA
10.1016/j.clinthera.2019.09.012	results	7	NA	effect_cutoff	0
10.1016/j.clinthera.2019.09.012	results	7	NA	unadjusted_pval	0.06
10.1016/j.clinthera.2019.09.012	results	7	NA	unadjusted_num_pval	0.06
10.1016/j.clinthera.2019.09.012	results	7	NA	unadjusted_significant	FALSE
10.1016/j.clinthera.2019.09.012	results	7	NA	adjusted_pval	0.13
10.1016/j.clinthera.2019.09.012	results	7	NA	adjusted_num_pval	0.13
10.1016/j.clinthera.2019.09.012	results	7	NA	adjusted_significant	FALSE
10.1016/j.clinthera.2019.09.012	study_information	NA	1	ipd_yn	Yes
10.1016/j.clinthera.2019.09.012	study_information	NA	1	ct_yn	Yes
10.1016/j.clinthera.2019.09.012	study_information	NA	1	nct	NCT02213926
10.1016/j.clinthera.2019.09.012	study_information	NA	1	country_study	international
10.1016/j.clinthera.2019.09.012	study_information	NA	1	ct_phase	2
10.1016/j.clinthera.2019.09.012	study_information	NA	1	ct_arms	1
10.1016/j.clinthera.2019.09.012	study_information	NA	10	ipd_yn	No
10.1016/j.clinthera.2019.09.012	study_information	NA	10	ct_yn	Yes
10.1016/j.clinthera.2019.09.012	study_information	NA	10	nct	NCT01880567
10.1016/j.clinthera.2019.09.012	study_information	NA	10	country_study	usa
10.1016/j.clinthera.2019.09.012	study_information	NA	10	ct_phase	2
10.1016/j.clinthera.2019.09.012	study_information	NA	10	ct_arms	1
10.1016/j.clinthera.2019.09.012	study_information	NA	11	ipd_yn	no
10.1016/j.clinthera.2019.09.012	study_information	NA	11	ct_yn	yes
10.1016/j.clinthera.2019.09.012	study_information	NA	11	data_source_name	czuczman 2015
10.1016/j.clinthera.2019.09.012	study_information	NA	11	ct_phase	2
10.1016/j.clinthera.2019.09.012	study_information	NA	11	ct_arms	1
10.1016/j.clinthera.2019.09.012	study_information	NA	11	country_study	unknown
10.1016/j.clinthera.2019.09.012	study_information	NA	12	ipd_yn	no
10.1016/j.clinthera.2019.09.012	study_information	NA	12	ct_yn	yes
10.1016/j.clinthera.2019.09.012	study_information	NA	12	nct	NCT00294632
10.1016/j.clinthera.2019.09.012	study_information	NA	12	country_study	usa
10.1016/j.clinthera.2019.09.012	study_information	NA	12	ct_phase	1, 2
10.1016/j.clinthera.2019.09.012	study_information	NA	12	ct_arms	1
10.1016/j.clinthera.2019.09.012	study_information	NA	2	ipd_yn	No
10.1016/j.clinthera.2019.09.012	study_information	NA	2	ct_yn	Yes
10.1016/j.clinthera.2019.09.012	study_information	NA	2	nct	NCT01646021
10.1016/j.clinthera.2019.09.012	study_information	NA	2	country_study	international
10.1016/j.clinthera.2019.09.012	study_information	NA	2	ct_phase	3
10.1016/j.clinthera.2019.09.012	study_information	NA	2	ct_arms	2 or more
10.1016/j.clinthera.2019.09.012	study_information	NA	3	ipd_yn	No
10.1016/j.clinthera.2019.09.012	study_information	NA	3	ct_yn	Yes
10.1016/j.clinthera.2019.09.012	study_information	NA	3	nct	NCT01236391
10.1016/j.clinthera.2019.09.012	study_information	NA	3	country_study	international
10.1016/j.clinthera.2019.09.012	study_information	NA	3	ct_phase	2
10.1016/j.clinthera.2019.09.012	study_information	NA	3	ct_arms	1
10.1016/j.clinthera.2019.09.012	study_information	NA	4	ipd_yn	No
10.1016/j.clinthera.2019.09.012	study_information	NA	4	ct_yn	Yes
10.1016/j.clinthera.2019.09.012	study_information	NA	4	nct	NCT01599949
10.1016/j.clinthera.2019.09.012	study_information	NA	4	country_study	international
10.1016/j.clinthera.2019.09.012	study_information	NA	4	ct_phase	2
10.1016/j.clinthera.2019.09.012	study_information	NA	4	ct_arms	1
10.1016/j.clinthera.2019.09.012	study_information	NA	5	ipd_yn	No
10.1016/j.clinthera.2019.09.012	study_information	NA	5	ct_yn	Yes
10.1016/j.clinthera.2019.09.012	study_information	NA	5	data_source_name	pinnacle
10.1016/j.clinthera.2019.09.012	study_information	NA	5	country_study	international
10.1016/j.clinthera.2019.09.012	study_information	NA	5	ct_phase	2
10.1016/j.clinthera.2019.09.012	study_information	NA	5	ct_arms	1
10.1016/j.clinthera.2019.09.012	study_information	NA	6	ipd_yn	No
10.1016/j.clinthera.2019.09.012	study_information	NA	6	ct_yn	Yes
10.1016/j.clinthera.2019.09.012	study_information	NA	6	nct	NCT00875667
10.1016/j.clinthera.2019.09.012	study_information	NA	6	country_study	international
10.1016/j.clinthera.2019.09.012	study_information	NA	6	ct_phase	2
10.1016/j.clinthera.2019.09.012	study_information	NA	6	ct_arms	2 or more
10.1016/j.clinthera.2019.09.012	study_information	NA	7	ipd_yn	No
10.1016/j.clinthera.2019.09.012	study_information	NA	7	ct_yn	Yes
10.1016/j.clinthera.2019.09.012	study_information	NA	7	nct	NCT00737529
10.1016/j.clinthera.2019.09.012	study_information	NA	7	country_study	international
10.1016/j.clinthera.2019.09.012	study_information	NA	7	ct_phase	2
10.1016/j.clinthera.2019.09.012	study_information	NA	7	ct_arms	1
10.1016/j.clinthera.2019.09.012	study_information	NA	8	ipd_yn	No
10.1016/j.clinthera.2019.09.012	study_information	NA	8	ct_yn	Yes
10.1016/j.clinthera.2019.09.012	study_information	NA	8	nct	NCT00117598
10.1016/j.clinthera.2019.09.012	study_information	NA	8	country_study	international
10.1016/j.clinthera.2019.09.012	study_information	NA	8	ct_phase	3
10.1016/j.clinthera.2019.09.012	study_information	NA	8	ct_arms	2 or more
10.1016/j.clinthera.2019.09.012	study_information	NA	9	ipd_yn	No
10.1016/j.clinthera.2019.09.012	study_information	NA	9	ct_yn	Yes
10.1016/j.clinthera.2019.09.012	study_information	NA	9	nct	NCT01180049
10.1016/j.clinthera.2019.09.012	study_information	NA	9	country_study	international
10.1016/j.clinthera.2019.09.012	study_information	NA	9	ct_phase	4
10.1016/j.clinthera.2019.09.012	study_information	NA	9	ct_arms	2 or more
10.1016/j.ejcsup.2021.06.002	general_information	NA	NA	condition_name	advanced, unresectable gastroenteropancreatic neuroendocrine tumours
10.1016/j.ejcsup.2021.06.002	general_information	NA	NA	country_first_author	uk
10.1016/j.ejcsup.2021.06.002	general_information	NA	NA	country_last_author	germany
10.1016/j.ejcsup.2021.06.002	general_information	NA	NA	positions	Academic, Private Data Analysis Company
10.1016/j.ejcsup.2021.06.002	general_information	NA	NA	methodologist_yn	Yes
10.1016/j.ejcsup.2021.06.002	general_information	NA	NA	funding_source	Pharmaceutical Industry
10.1016/j.ejcsup.2021.06.002	general_information	NA	NA	pharmaceutical_ties_yn	Yes
10.1016/j.ejcsup.2021.06.002	general_information	NA	NA	systematic_review_yn	No
10.1016/j.ejcsup.2021.06.002	methodology	1	NA	outcome_name	progression-free survival
10.1016/j.ejcsup.2021.06.002	methodology	1	NA	outcome_short_name	Progression-free Survival
10.1016/j.ejcsup.2021.06.002	methodology	1	NA	outcome_variable_type	Time-to-event
10.1016/j.ejcsup.2021.06.002	methodology	1	NA	treatment_name_ipd	[177lu]lu-dota-tate
10.1016/j.ejcsup.2021.06.002	methodology	1	NA	studies_number_ipd	1
10.1016/j.ejcsup.2021.06.002	methodology	1	NA	treatment_name_nonipd	everolimus
10.1016/j.ejcsup.2021.06.002	methodology	1	NA	studies_number_nonipd	2
10.1016/j.ejcsup.2021.06.002	methodology	1	NA	paic_type	MAIC
10.1016/j.ejcsup.2021.06.002	methodology	1	NA	anchored_yn	No
10.1016/j.ejcsup.2021.06.002	methodology	1	NA	paic_form	Simple (ie treatments effects extracted from two studies)
10.1016/j.ejcsup.2021.06.002	methodology	1	NA	primary_outcome_yn	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.1016/j.ejcsup.2021.06.002	methodology	1	NA	variables_selection_justification	Status of prognostic factor/treatment effect modified assessed in the IPD dataset
10.1016/j.ejcsup.2021.06.002	methodology	1	NA	pf_yn	Yes
10.1016/j.ejcsup.2021.06.002	methodology	1	NA	tem_yn	No discussion (in the main text) of the status of treatment-effect modifiers of the variables
10.1016/j.ejcsup.2021.06.002	methodology	1	NA	adjustment_model_details_yn	No
10.1016/j.ejcsup.2021.06.002	methodology	1	NA	scale_choice_yn	No
10.1016/j.ejcsup.2021.06.002	methodology	2	NA	outcome_name	progression-free survival
10.1016/j.ejcsup.2021.06.002	methodology	2	NA	outcome_short_name	Progression-free Survival
10.1016/j.ejcsup.2021.06.002	methodology	2	NA	outcome_variable_type	Time-to-event
10.1016/j.ejcsup.2021.06.002	methodology	2	NA	treatment_name_ipd	[177lu]lu-dota-tate
10.1016/j.ejcsup.2021.06.002	methodology	2	NA	studies_number_ipd	1
10.1016/j.ejcsup.2021.06.002	methodology	2	NA	treatment_name_nonipd	best supportive care (bsc)
10.1016/j.ejcsup.2021.06.002	methodology	2	NA	studies_number_nonipd	2
10.1016/j.ejcsup.2021.06.002	methodology	2	NA	paic_type	MAIC
10.1016/j.ejcsup.2021.06.002	methodology	2	NA	anchored_yn	No
10.1016/j.ejcsup.2021.06.002	methodology	2	NA	paic_form	Simple (ie treatments effects extracted from two studies)
10.1016/j.ejcsup.2021.06.002	methodology	2	NA	primary_outcome_yn	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.1016/j.ejcsup.2021.06.002	methodology	2	NA	variables_selection_justification	Status of prognostic factor/treatment effect modified assessed in the IPD dataset
10.1016/j.ejcsup.2021.06.002	methodology	2	NA	pf_yn	Yes
10.1016/j.ejcsup.2021.06.002	methodology	2	NA	tem_yn	No discussion (in the main text) of the status of treatment-effect modifiers of the variables
10.1016/j.ejcsup.2021.06.002	methodology	2	NA	adjustment_model_details_yn	No
10.1016/j.ejcsup.2021.06.002	methodology	2	NA	scale_choice_yn	No
10.1016/j.ejcsup.2021.06.002	methodology	3	NA	outcome_name	progression-free survival
10.1016/j.ejcsup.2021.06.002	methodology	3	NA	outcome_short_name	Progression-free Survival
10.1016/j.ejcsup.2021.06.002	methodology	3	NA	outcome_variable_type	Time-to-event
10.1016/j.ejcsup.2021.06.002	methodology	3	NA	treatment_name_ipd	[177lu]lu-dota-tate
10.1016/j.ejcsup.2021.06.002	methodology	3	NA	studies_number_ipd	1
10.1016/j.ejcsup.2021.06.002	methodology	3	NA	treatment_name_nonipd	sunitinib
10.1016/j.ejcsup.2021.06.002	methodology	3	NA	studies_number_nonipd	4
10.1016/j.ejcsup.2021.06.002	methodology	3	NA	paic_type	MAIC
10.1016/j.ejcsup.2021.06.002	methodology	3	NA	anchored_yn	No
10.1016/j.ejcsup.2021.06.002	methodology	3	NA	paic_form	Simple (ie treatments effects extracted from two studies)
10.1016/j.ejcsup.2021.06.002	methodology	3	NA	primary_outcome_yn	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.1016/j.ejcsup.2021.06.002	methodology	3	NA	variables_selection_justification	Status of prognostic factor/treatment effect modified assessed in the IPD dataset
10.1016/j.ejcsup.2021.06.002	methodology	3	NA	pf_yn	Yes
10.1016/j.ejcsup.2021.06.002	methodology	3	NA	tem_yn	No discussion (in the main text) of the status of treatment-effect modifiers of the variables
10.1016/j.ejcsup.2021.06.002	methodology	3	NA	adjustment_model_details_yn	No
10.1016/j.ejcsup.2021.06.002	methodology	3	NA	scale_choice_yn	No
10.1016/j.ejcsup.2021.06.002	methodology	4	NA	outcome_name	progression-free survival
10.1016/j.ejcsup.2021.06.002	methodology	4	NA	outcome_short_name	Progression-free Survival
10.1016/j.ejcsup.2021.06.002	methodology	4	NA	outcome_variable_type	Time-to-event
10.1016/j.ejcsup.2021.06.002	methodology	4	NA	treatment_name_ipd	[177lu]lu-dota-tate
10.1016/j.ejcsup.2021.06.002	methodology	4	NA	studies_number_ipd	1
10.1016/j.ejcsup.2021.06.002	methodology	4	NA	treatment_name_nonipd	best supportive care
10.1016/j.ejcsup.2021.06.002	methodology	4	NA	studies_number_nonipd	4
10.1016/j.ejcsup.2021.06.002	methodology	4	NA	paic_type	MAIC
10.1016/j.ejcsup.2021.06.002	methodology	4	NA	anchored_yn	No
10.1016/j.ejcsup.2021.06.002	methodology	4	NA	paic_form	Simple (ie treatments effects extracted from two studies)
10.1016/j.ejcsup.2021.06.002	methodology	4	NA	primary_outcome_yn	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.1016/j.ejcsup.2021.06.002	methodology	4	NA	variables_selection_justification	Status of prognostic factor/treatment effect modified assessed in the IPD dataset
10.1016/j.ejcsup.2021.06.002	methodology	4	NA	pf_yn	Yes
10.1016/j.ejcsup.2021.06.002	methodology	4	NA	tem_yn	No discussion (in the main text) of the status of treatment-effect modifiers of the variables
10.1016/j.ejcsup.2021.06.002	methodology	4	NA	adjustment_model_details_yn	No
10.1016/j.ejcsup.2021.06.002	methodology	4	NA	scale_choice_yn	No
10.1016/j.ejcsup.2021.06.002	methodology	5	NA	outcome_name	progression-free survival
10.1016/j.ejcsup.2021.06.002	methodology	5	NA	outcome_short_name	Progression-free Survival
10.1016/j.ejcsup.2021.06.002	methodology	5	NA	outcome_variable_type	Time-to-event
10.1016/j.ejcsup.2021.06.002	methodology	5	NA	treatment_name_ipd	[177lu]lu-dota-tate
10.1016/j.ejcsup.2021.06.002	methodology	5	NA	studies_number_ipd	1
10.1016/j.ejcsup.2021.06.002	methodology	5	NA	treatment_name_nonipd	everolimus
10.1016/j.ejcsup.2021.06.002	methodology	5	NA	studies_number_nonipd	3
10.1016/j.ejcsup.2021.06.002	methodology	5	NA	paic_type	MAIC
10.1016/j.ejcsup.2021.06.002	methodology	5	NA	anchored_yn	No
10.1016/j.ejcsup.2021.06.002	methodology	5	NA	paic_form	Simple (ie treatments effects extracted from two studies)
10.1016/j.ejcsup.2021.06.002	methodology	5	NA	primary_outcome_yn	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.1016/j.ejcsup.2021.06.002	methodology	5	NA	variables_selection_justification	Status of prognostic factor/treatment effect modified assessed in the IPD dataset
10.1016/j.ejcsup.2021.06.002	methodology	5	NA	pf_yn	Yes
10.1016/j.ejcsup.2021.06.002	methodology	5	NA	tem_yn	No discussion (in the main text) of the status of treatment-effect modifiers of the variables
10.1016/j.ejcsup.2021.06.002	methodology	5	NA	adjustment_model_details_yn	No
10.1016/j.ejcsup.2021.06.002	methodology	5	NA	scale_choice_yn	No
10.1016/j.ejcsup.2021.06.002	methodology	6	NA	outcome_name	progression-free survival
10.1016/j.ejcsup.2021.06.002	methodology	6	NA	outcome_short_name	Progression-free Survival
10.1016/j.ejcsup.2021.06.002	methodology	6	NA	outcome_variable_type	Time-to-event
10.1016/j.ejcsup.2021.06.002	methodology	6	NA	treatment_name_ipd	[177lu]lu-dota-tate
10.1016/j.ejcsup.2021.06.002	methodology	6	NA	studies_number_ipd	1
10.1016/j.ejcsup.2021.06.002	methodology	6	NA	treatment_name_nonipd	best supportive care
10.1016/j.ejcsup.2021.06.002	methodology	6	NA	studies_number_nonipd	3
10.1016/j.ejcsup.2021.06.002	methodology	6	NA	paic_type	MAIC
10.1016/j.ejcsup.2021.06.002	methodology	6	NA	anchored_yn	No
10.1016/j.ejcsup.2021.06.002	methodology	6	NA	paic_form	Simple (ie treatments effects extracted from two studies)
10.1016/j.ejcsup.2021.06.002	methodology	6	NA	primary_outcome_yn	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.1016/j.ejcsup.2021.06.002	methodology	6	NA	variables_selection_justification	Status of prognostic factor/treatment effect modified assessed in the IPD dataset
10.1016/j.ejcsup.2021.06.002	methodology	6	NA	pf_yn	Yes
10.1016/j.ejcsup.2021.06.002	methodology	6	NA	tem_yn	No discussion (in the main text) of the status of treatment-effect modifiers of the variables
10.1016/j.ejcsup.2021.06.002	methodology	6	NA	adjustment_model_details_yn	No
10.1016/j.ejcsup.2021.06.002	methodology	6	NA	scale_choice_yn	No
10.1016/j.ejcsup.2021.06.002	results	1	NA	contrast_effect_type	HR
10.1016/j.ejcsup.2021.06.002	results	1	NA	direction_benefit	inferior
10.1016/j.ejcsup.2021.06.002	results	1	NA	ss_ttt_nonipd	118
10.1016/j.ejcsup.2021.06.002	results	1	NA	ss_ttt_ipd	111
10.1016/j.ejcsup.2021.06.002	results	1	NA	ss_adjusted_ttt_ipd	105
10.1016/j.ejcsup.2021.06.002	results	1	NA	weights_yn	Yes, mentions that the weights distribution has been studied, and weights distribution reported in main article or supplemental materials
10.1016/j.ejcsup.2021.06.002	results	1	NA	covariates_yn	Yes
10.1016/j.ejcsup.2021.06.002	results	1	NA	covariates_n	1
10.1016/j.ejcsup.2021.06.002	results	1	NA	covariates_names	Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...)
10.1016/j.ejcsup.2021.06.002	results	1	NA	contrast_effect_direction	Numerator if ratio, or left side if difference
10.1016/j.ejcsup.2021.06.002	results	1	NA	contrast_effect_unadjusted_value	NA
10.1016/j.ejcsup.2021.06.002	results	1	NA	contrast_effect_unadjusted_pvalci	NA
10.1016/j.ejcsup.2021.06.002	results	1	NA	contrast_effect_adjusted_value	0.38
10.1016/j.ejcsup.2021.06.002	results	1	NA	contrast_effect_adjusted_pvalci	[0.25;0.58]
10.1016/j.ejcsup.2021.06.002	results	1	NA	adjustment_geographical	NA
10.1016/j.ejcsup.2021.06.002	results	1	NA	ss_total_ipd	NA
10.1016/j.ejcsup.2021.06.002	results	1	NA	ss_adjusted_total_ipd	NA
10.1016/j.ejcsup.2021.06.002	results	1	NA	ss_total_nonipd	NA
10.1016/j.ejcsup.2021.06.002	results	1	NA	ss_anchor_nonipd	NA
10.1016/j.ejcsup.2021.06.002	results	1	NA	ss_anchor_ipd	NA
10.1016/j.ejcsup.2021.06.002	results	1	NA	ss_adjusted_anchor_ipd	NA
10.1016/j.ejcsup.2021.06.002	results	1	NA	effect_cutoff	1
10.1016/j.ejcsup.2021.06.002	results	1	NA	adjusted_lb_ci	0.25
10.1016/j.ejcsup.2021.06.002	results	1	NA	adjusted_ub_ci	0.58
10.1016/j.ejcsup.2021.06.002	results	1	NA	adjusted_significant	TRUE
10.1016/j.ejcsup.2021.06.002	results	2	NA	contrast_effect_type	HR
10.1016/j.ejcsup.2021.06.002	results	2	NA	direction_benefit	inferior
10.1016/j.ejcsup.2021.06.002	results	2	NA	ss_ttt_nonipd	57
10.1016/j.ejcsup.2021.06.002	results	2	NA	ss_ttt_ipd	111
10.1016/j.ejcsup.2021.06.002	results	2	NA	ss_adjusted_ttt_ipd	95
10.1016/j.ejcsup.2021.06.002	results	2	NA	weights_yn	Yes, mentions that the weights distribution has been studied, and weights distribution reported in main article or supplemental materials
10.1016/j.ejcsup.2021.06.002	results	2	NA	covariates_yn	Yes
10.1016/j.ejcsup.2021.06.002	results	2	NA	covariates_n	1
10.1016/j.ejcsup.2021.06.002	results	2	NA	covariates_names	Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...)
10.1016/j.ejcsup.2021.06.002	results	2	NA	contrast_effect_direction	Numerator if ratio, or left side if difference
10.1016/j.ejcsup.2021.06.002	results	2	NA	contrast_effect_unadjusted_value	NA
10.1016/j.ejcsup.2021.06.002	results	2	NA	contrast_effect_unadjusted_pvalci	NA
10.1016/j.ejcsup.2021.06.002	results	2	NA	contrast_effect_adjusted_value	0.35
10.1016/j.ejcsup.2021.06.002	results	2	NA	contrast_effect_adjusted_pvalci	[0.21;0.59]
10.1016/j.ejcsup.2021.06.002	results	2	NA	adjustment_geographical	NA
10.1016/j.ejcsup.2021.06.002	results	2	NA	ss_total_ipd	NA
10.1016/j.ejcsup.2021.06.002	results	2	NA	ss_adjusted_total_ipd	NA
10.1016/j.ejcsup.2021.06.002	results	2	NA	ss_total_nonipd	NA
10.1016/j.ejcsup.2021.06.002	results	2	NA	ss_anchor_nonipd	NA
10.1016/j.ejcsup.2021.06.002	results	2	NA	ss_anchor_ipd	NA
10.1016/j.ejcsup.2021.06.002	results	2	NA	ss_adjusted_anchor_ipd	NA
10.1016/j.ejcsup.2021.06.002	results	2	NA	effect_cutoff	1
10.1016/j.ejcsup.2021.06.002	results	2	NA	adjusted_lb_ci	0.21
10.1016/j.ejcsup.2021.06.002	results	2	NA	adjusted_ub_ci	0.59
10.1016/j.ejcsup.2021.06.002	results	2	NA	adjusted_significant	TRUE
10.1016/j.ejcsup.2021.06.002	results	3	NA	contrast_effect_type	HR
10.1016/j.ejcsup.2021.06.002	results	3	NA	direction_benefit	inferior
10.1016/j.ejcsup.2021.06.002	results	3	NA	ss_ttt_nonipd	86
10.1016/j.ejcsup.2021.06.002	results	3	NA	ss_ttt_ipd	62
10.1016/j.ejcsup.2021.06.002	results	3	NA	ss_adjusted_ttt_ipd	48
10.1016/j.ejcsup.2021.06.002	results	3	NA	weights_yn	Yes, mentions that the weights distribution has been studied, and weights distribution reported in main article or supplemental materials
10.1016/j.ejcsup.2021.06.002	results	3	NA	covariates_yn	Yes
10.1016/j.ejcsup.2021.06.002	results	3	NA	covariates_n	4
10.1016/j.ejcsup.2021.06.002	results	3	NA	covariates_names	Age, Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Past treatments for the disease of interest
10.1016/j.ejcsup.2021.06.002	results	3	NA	contrast_effect_direction	Numerator if ratio, or left side if difference
10.1016/j.ejcsup.2021.06.002	results	3	NA	contrast_effect_unadjusted_value	NA
10.1016/j.ejcsup.2021.06.002	results	3	NA	contrast_effect_unadjusted_pvalci	NA
10.1016/j.ejcsup.2021.06.002	results	3	NA	contrast_effect_adjusted_value	0.36
10.1016/j.ejcsup.2021.06.002	results	3	NA	contrast_effect_adjusted_pvalci	[0.18;0.70]
10.1016/j.ejcsup.2021.06.002	results	3	NA	adjustment_geographical	NA
10.1016/j.ejcsup.2021.06.002	results	3	NA	ss_total_ipd	NA
10.1016/j.ejcsup.2021.06.002	results	3	NA	ss_adjusted_total_ipd	NA
10.1016/j.ejcsup.2021.06.002	results	3	NA	ss_total_nonipd	NA
10.1016/j.ejcsup.2021.06.002	results	3	NA	ss_anchor_nonipd	NA
10.1016/j.ejcsup.2021.06.002	results	3	NA	ss_anchor_ipd	NA
10.1016/j.ejcsup.2021.06.002	results	3	NA	ss_adjusted_anchor_ipd	NA
10.1016/j.ejcsup.2021.06.002	results	3	NA	effect_cutoff	1
10.1016/j.ejcsup.2021.06.002	results	3	NA	adjusted_lb_ci	0.18
10.1016/j.ejcsup.2021.06.002	results	3	NA	adjusted_ub_ci	0.7
10.1016/j.ejcsup.2021.06.002	results	3	NA	adjusted_significant	TRUE
10.1016/j.ejcsup.2021.06.002	results	4	NA	contrast_effect_type	HR
10.1016/j.ejcsup.2021.06.002	results	4	NA	direction_benefit	inferior
10.1016/j.ejcsup.2021.06.002	results	4	NA	ss_ttt_nonipd	85
10.1016/j.ejcsup.2021.06.002	results	4	NA	ss_ttt_ipd	62
10.1016/j.ejcsup.2021.06.002	results	4	NA	ss_adjusted_ttt_ipd	35
10.1016/j.ejcsup.2021.06.002	results	4	NA	weights_yn	Yes, mentions that the weights distribution has been studied, and weights distribution reported in main article or supplemental materials
10.1016/j.ejcsup.2021.06.002	results	4	NA	covariates_yn	Yes
10.1016/j.ejcsup.2021.06.002	results	4	NA	covariates_n	4
10.1016/j.ejcsup.2021.06.002	results	4	NA	covariates_names	Age, Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Past treatments for the disease of interest
10.1016/j.ejcsup.2021.06.002	results	4	NA	contrast_effect_direction	Numerator if ratio, or left side if difference
10.1016/j.ejcsup.2021.06.002	results	4	NA	contrast_effect_unadjusted_value	NA
10.1016/j.ejcsup.2021.06.002	results	4	NA	contrast_effect_unadjusted_pvalci	NA
10.1016/j.ejcsup.2021.06.002	results	4	NA	contrast_effect_adjusted_value	0.13
10.1016/j.ejcsup.2021.06.002	results	4	NA	contrast_effect_adjusted_pvalci	[0.08;0.22]
10.1016/j.ejcsup.2021.06.002	results	4	NA	adjustment_geographical	NA
10.1016/j.ejcsup.2021.06.002	results	4	NA	ss_total_ipd	NA
10.1016/j.ejcsup.2021.06.002	results	4	NA	ss_adjusted_total_ipd	NA
10.1016/j.ejcsup.2021.06.002	results	4	NA	ss_total_nonipd	NA
10.1016/j.ejcsup.2021.06.002	results	4	NA	ss_anchor_nonipd	NA
10.1016/j.ejcsup.2021.06.002	results	4	NA	ss_anchor_ipd	NA
10.1016/j.ejcsup.2021.06.002	results	4	NA	ss_adjusted_anchor_ipd	NA
10.1016/j.ejcsup.2021.06.002	results	4	NA	effect_cutoff	1
10.1016/j.ejcsup.2021.06.002	results	4	NA	adjusted_lb_ci	0.08
10.1016/j.ejcsup.2021.06.002	results	4	NA	adjusted_ub_ci	0.22
10.1016/j.ejcsup.2021.06.002	results	4	NA	adjusted_significant	TRUE
10.1016/j.ejcsup.2021.06.002	results	5	NA	contrast_effect_type	HR
10.1016/j.ejcsup.2021.06.002	results	5	NA	direction_benefit	inferior
10.1016/j.ejcsup.2021.06.002	results	5	NA	ss_ttt_nonipd	207
10.1016/j.ejcsup.2021.06.002	results	5	NA	ss_ttt_ipd	62
10.1016/j.ejcsup.2021.06.002	results	5	NA	ss_adjusted_ttt_ipd	22
10.1016/j.ejcsup.2021.06.002	results	5	NA	weights_yn	Yes, mentions that the weights distribution has been studied, and weights distribution reported in main article or supplemental materials
10.1016/j.ejcsup.2021.06.002	results	5	NA	covariates_yn	Yes
10.1016/j.ejcsup.2021.06.002	results	5	NA	covariates_n	4
10.1016/j.ejcsup.2021.06.002	results	5	NA	covariates_names	Age, Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Past treatments for the disease of interest
10.1016/j.ejcsup.2021.06.002	results	5	NA	contrast_effect_direction	Numerator if ratio, or left side if difference
10.1016/j.ejcsup.2021.06.002	results	5	NA	contrast_effect_unadjusted_value	NA
10.1016/j.ejcsup.2021.06.002	results	5	NA	contrast_effect_unadjusted_pvalci	NA
10.1016/j.ejcsup.2021.06.002	results	5	NA	contrast_effect_adjusted_value	0.46
10.1016/j.ejcsup.2021.06.002	results	5	NA	contrast_effect_adjusted_pvalci	[0.30;0.71]
10.1016/j.ejcsup.2021.06.002	results	5	NA	adjustment_geographical	NA
10.1016/j.ejcsup.2021.06.002	results	5	NA	ss_total_ipd	NA
10.1016/j.ejcsup.2021.06.002	results	5	NA	ss_adjusted_total_ipd	NA
10.1016/j.ejcsup.2021.06.002	results	5	NA	ss_total_nonipd	NA
10.1016/j.ejcsup.2021.06.002	results	5	NA	ss_anchor_nonipd	NA
10.1016/j.ejcsup.2021.06.002	results	5	NA	ss_anchor_ipd	NA
10.1016/j.ejcsup.2021.06.002	results	5	NA	ss_adjusted_anchor_ipd	NA
10.1016/j.ejcsup.2021.06.002	results	5	NA	effect_cutoff	1
10.1016/j.ejcsup.2021.06.002	results	5	NA	adjusted_lb_ci	0.3
10.1016/j.ejcsup.2021.06.002	results	5	NA	adjusted_ub_ci	0.71
10.1016/j.ejcsup.2021.06.002	results	5	NA	adjusted_significant	TRUE
10.1016/j.ejcsup.2021.06.002	results	6	NA	contrast_effect_type	HR
10.1016/j.ejcsup.2021.06.002	results	6	NA	direction_benefit	inferior
10.1016/j.ejcsup.2021.06.002	results	6	NA	ss_ttt_nonipd	203
10.1016/j.ejcsup.2021.06.002	results	6	NA	ss_ttt_ipd	62
10.1016/j.ejcsup.2021.06.002	results	6	NA	ss_adjusted_ttt_ipd	18
10.1016/j.ejcsup.2021.06.002	results	6	NA	weights_yn	Yes, mentions that the weights distribution has been studied, and weights distribution reported in main article or supplemental materials
10.1016/j.ejcsup.2021.06.002	results	6	NA	covariates_yn	Yes
10.1016/j.ejcsup.2021.06.002	results	6	NA	covariates_n	4
10.1016/j.ejcsup.2021.06.002	results	6	NA	covariates_names	Age, Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Past treatments for the disease of interest
10.1016/j.ejcsup.2021.06.002	results	6	NA	contrast_effect_direction	Numerator if ratio, or left side if difference
10.1016/j.ejcsup.2021.06.002	results	6	NA	contrast_effect_unadjusted_value	NA
10.1016/j.ejcsup.2021.06.002	results	6	NA	contrast_effect_unadjusted_pvalci	NA
10.1016/j.ejcsup.2021.06.002	results	6	NA	contrast_effect_adjusted_value	0.21
10.1016/j.ejcsup.2021.06.002	results	6	NA	contrast_effect_adjusted_pvalci	[0.13;0.32]
10.1016/j.ejcsup.2021.06.002	results	6	NA	adjustment_geographical	NA
10.1016/j.ejcsup.2021.06.002	results	6	NA	ss_total_ipd	NA
10.1016/j.ejcsup.2021.06.002	results	6	NA	ss_adjusted_total_ipd	NA
10.1016/j.ejcsup.2021.06.002	results	6	NA	ss_total_nonipd	NA
10.1016/j.ejcsup.2021.06.002	results	6	NA	ss_anchor_nonipd	NA
10.1016/j.ejcsup.2021.06.002	results	6	NA	ss_anchor_ipd	NA
10.1016/j.ejcsup.2021.06.002	results	6	NA	ss_adjusted_anchor_ipd	NA
10.1016/j.ejcsup.2021.06.002	results	6	NA	effect_cutoff	1
10.1016/j.ejcsup.2021.06.002	results	6	NA	adjusted_lb_ci	0.13
10.1016/j.ejcsup.2021.06.002	results	6	NA	adjusted_ub_ci	0.32
10.1016/j.ejcsup.2021.06.002	results	6	NA	adjusted_significant	TRUE
10.1016/j.ejcsup.2021.06.002	study_information	NA	1	ipd_yn	Yes
10.1016/j.ejcsup.2021.06.002	study_information	NA	1	ct_yn	Yes
10.1016/j.ejcsup.2021.06.002	study_information	NA	1	data_source_name	erasmus study
10.1016/j.ejcsup.2021.06.002	study_information	NA	1	country_study	the netherlands
10.1016/j.ejcsup.2021.06.002	study_information	NA	1	ct_arms	1
10.1016/j.ejcsup.2021.06.002	study_information	NA	2	ipd_yn	No
10.1016/j.ejcsup.2021.06.002	study_information	NA	2	ct_yn	Yes
10.1016/j.ejcsup.2021.06.002	study_information	NA	2	nct	NCT01524783
10.1016/j.ejcsup.2021.06.002	study_information	NA	2	country_study	international
10.1016/j.ejcsup.2021.06.002	study_information	NA	2	ct_phase	3
10.1016/j.ejcsup.2021.06.002	study_information	NA	2	ct_arms	2 or more
10.1016/j.ejcsup.2021.06.002	study_information	NA	3	ipd_yn	No
10.1016/j.ejcsup.2021.06.002	study_information	NA	3	ct_yn	Yes
10.1016/j.ejcsup.2021.06.002	study_information	NA	3	nct	NCT00510068
10.1016/j.ejcsup.2021.06.002	study_information	NA	3	country_study	international
10.1016/j.ejcsup.2021.06.002	study_information	NA	3	ct_phase	3
10.1016/j.ejcsup.2021.06.002	study_information	NA	3	ct_arms	2 or more
10.1016/j.ejcsup.2021.06.002	study_information	NA	4	ipd_yn	No
10.1016/j.ejcsup.2021.06.002	study_information	NA	4	ct_yn	Yes
10.1016/j.ejcsup.2021.06.002	study_information	NA	4	nct	NCT00428597
10.1016/j.ejcsup.2021.06.002	study_information	NA	4	country_study	international
10.1016/j.ejcsup.2021.06.002	study_information	NA	4	ct_phase	3
10.1016/j.ejcsup.2021.06.002	study_information	NA	4	ct_arms	2 or more
10.1016/j.esmoop.2021.100050	general_information	NA	NA	condition_name	braf-mutant advanced melanoma
10.1016/j.esmoop.2021.100050	general_information	NA	NA	country_first_author	usa
10.1016/j.esmoop.2021.100050	general_information	NA	NA	country_last_author	usa
10.1016/j.esmoop.2021.100050	general_information	NA	NA	positions	Academic, Pharmaceutical Industry, Private Data Analysis Company
10.1016/j.esmoop.2021.100050	general_information	NA	NA	methodologist_yn	Yes
10.1016/j.esmoop.2021.100050	general_information	NA	NA	funding_source	Pharmaceutical Industry
10.1016/j.esmoop.2021.100050	general_information	NA	NA	pharmaceutical_ties_yn	Yes
10.1016/j.esmoop.2021.100050	general_information	NA	NA	systematic_review_yn	Yes
10.1016/j.esmoop.2021.100050	methodology	1	NA	outcome_name	overall survival
10.1016/j.esmoop.2021.100050	methodology	1	NA	outcome_short_name	Overall Survival
10.1016/j.esmoop.2021.100050	methodology	1	NA	outcome_variable_type	Time-to-event
10.1016/j.esmoop.2021.100050	methodology	1	NA	treatment_name_ipd	nivolumab + ipilimumab
10.1016/j.esmoop.2021.100050	methodology	1	NA	studies_number_ipd	1
10.1016/j.esmoop.2021.100050	methodology	1	NA	treatment_name_nonipd	dabrafenib + trametinib
10.1016/j.esmoop.2021.100050	methodology	1	NA	studies_number_nonipd	2;3
10.1016/j.esmoop.2021.100050	methodology	1	NA	paic_type	MAIC
10.1016/j.esmoop.2021.100050	methodology	1	NA	anchored_yn	No
10.1016/j.esmoop.2021.100050	methodology	1	NA	paic_form	Aggregation of multiple studies to estimate individual treatment effects (e.g. meta-analysis in a first step to estimate treatment A effect, then population adjusted indirect comparison using treatment A effect estimate)
10.1016/j.esmoop.2021.100050	methodology	1	NA	primary_outcome_yn	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.1016/j.esmoop.2021.100050	methodology	1	NA	variables_selection_justification	Nothing mentioned, not reported
10.1016/j.esmoop.2021.100050	methodology	1	NA	pf_yn	No
10.1016/j.esmoop.2021.100050	methodology	1	NA	tem_yn	Yes
10.1016/j.esmoop.2021.100050	methodology	1	NA	adjustment_model_details_yn	No
10.1016/j.esmoop.2021.100050	methodology	1	NA	scale_choice_yn	No
10.1016/j.esmoop.2021.100050	methodology	2	NA	outcome_name	overall survival
10.1016/j.esmoop.2021.100050	methodology	2	NA	outcome_short_name	Overall Survival
10.1016/j.esmoop.2021.100050	methodology	2	NA	outcome_variable_type	Time-to-event
10.1016/j.esmoop.2021.100050	methodology	2	NA	treatment_name_ipd	nivolumab + ipilimumab
10.1016/j.esmoop.2021.100050	methodology	2	NA	studies_number_ipd	1
10.1016/j.esmoop.2021.100050	methodology	2	NA	treatment_name_nonipd	encorafenib + binimetinib
10.1016/j.esmoop.2021.100050	methodology	2	NA	studies_number_nonipd	4
10.1016/j.esmoop.2021.100050	methodology	2	NA	paic_type	MAIC
10.1016/j.esmoop.2021.100050	methodology	2	NA	anchored_yn	No
10.1016/j.esmoop.2021.100050	methodology	2	NA	paic_form	Simple (ie treatments effects extracted from two studies)
10.1016/j.esmoop.2021.100050	methodology	2	NA	primary_outcome_yn	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.1016/j.esmoop.2021.100050	methodology	2	NA	variables_selection_justification	Nothing mentioned, not reported
10.1016/j.esmoop.2021.100050	methodology	2	NA	pf_yn	No
10.1016/j.esmoop.2021.100050	methodology	2	NA	tem_yn	Yes
10.1016/j.esmoop.2021.100050	methodology	2	NA	adjustment_model_details_yn	No
10.1016/j.esmoop.2021.100050	methodology	2	NA	scale_choice_yn	No
10.1016/j.esmoop.2021.100050	methodology	3	NA	outcome_name	overall survival
10.1016/j.esmoop.2021.100050	methodology	3	NA	outcome_short_name	Overall Survival
10.1016/j.esmoop.2021.100050	methodology	3	NA	outcome_variable_type	Time-to-event
10.1016/j.esmoop.2021.100050	methodology	3	NA	treatment_name_ipd	nivolumab + ipilimumab
10.1016/j.esmoop.2021.100050	methodology	3	NA	studies_number_ipd	1
10.1016/j.esmoop.2021.100050	methodology	3	NA	treatment_name_nonipd	vemurafenib + cobimetinib
10.1016/j.esmoop.2021.100050	methodology	3	NA	studies_number_nonipd	5
10.1016/j.esmoop.2021.100050	methodology	3	NA	paic_type	MAIC
10.1016/j.esmoop.2021.100050	methodology	3	NA	anchored_yn	No
10.1016/j.esmoop.2021.100050	methodology	3	NA	paic_form	Simple (ie treatments effects extracted from two studies)
10.1016/j.esmoop.2021.100050	methodology	3	NA	primary_outcome_yn	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.1016/j.esmoop.2021.100050	methodology	3	NA	variables_selection_justification	Nothing mentioned, not reported
10.1016/j.esmoop.2021.100050	methodology	3	NA	pf_yn	No
10.1016/j.esmoop.2021.100050	methodology	3	NA	tem_yn	Yes
10.1016/j.esmoop.2021.100050	methodology	3	NA	adjustment_model_details_yn	No
10.1016/j.esmoop.2021.100050	methodology	3	NA	scale_choice_yn	No
10.1016/j.esmoop.2021.100050	results	1	NA	contrast_effect_type	HR
10.1016/j.esmoop.2021.100050	results	1	NA	direction_benefit	inferior
10.1016/j.esmoop.2021.100050	results	1	NA	ss_ttt_nonipd	563
10.1016/j.esmoop.2021.100050	results	1	NA	ss_ttt_ipd	103
10.1016/j.esmoop.2021.100050	results	1	NA	ss_adjusted_ttt_ipd	91.68
10.1016/j.esmoop.2021.100050	results	1	NA	weights_yn	Not mentioned
10.1016/j.esmoop.2021.100050	results	1	NA	covariates_yn	Yes
10.1016/j.esmoop.2021.100050	results	1	NA	covariates_n	5
10.1016/j.esmoop.2021.100050	results	1	NA	covariates_names	Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...)
10.1016/j.esmoop.2021.100050	results	1	NA	contrast_effect_direction	Numerator if ratio, or left side if difference
10.1016/j.esmoop.2021.100050	results	1	NA	contrast_effect_unadjusted_value	NA
10.1016/j.esmoop.2021.100050	results	1	NA	contrast_effect_unadjusted_pvalci	NA
10.1016/j.esmoop.2021.100050	results	1	NA	contrast_effect_adjusted_value	0.53
10.1016/j.esmoop.2021.100050	results	1	NA	contrast_effect_adjusted_pvalci	[0.39;0.73]
10.1016/j.esmoop.2021.100050	results	1	NA	adjustment_geographical	NA
10.1016/j.esmoop.2021.100050	results	1	NA	ss_total_ipd	NA
10.1016/j.esmoop.2021.100050	results	1	NA	ss_adjusted_total_ipd	NA
10.1016/j.esmoop.2021.100050	results	1	NA	ss_total_nonipd	NA
10.1016/j.esmoop.2021.100050	results	1	NA	ss_anchor_nonipd	NA
10.1016/j.esmoop.2021.100050	results	1	NA	ss_anchor_ipd	NA
10.1016/j.esmoop.2021.100050	results	1	NA	ss_adjusted_anchor_ipd	NA
10.1016/j.esmoop.2021.100050	results	1	NA	effect_cutoff	1
10.1016/j.esmoop.2021.100050	results	1	NA	adjusted_lb_ci	0.39
10.1016/j.esmoop.2021.100050	results	1	NA	adjusted_ub_ci	0.73
10.1016/j.esmoop.2021.100050	results	1	NA	adjusted_significant	TRUE
10.1016/j.esmoop.2021.100050	results	2	NA	contrast_effect_type	HR
10.1016/j.esmoop.2021.100050	results	2	NA	direction_benefit	inferior
10.1016/j.esmoop.2021.100050	results	2	NA	ss_ttt_nonipd	192
10.1016/j.esmoop.2021.100050	results	2	NA	ss_ttt_ipd	103
10.1016/j.esmoop.2021.100050	results	2	NA	ss_adjusted_ttt_ipd	93.81
10.1016/j.esmoop.2021.100050	results	2	NA	weights_yn	Not mentioned
10.1016/j.esmoop.2021.100050	results	2	NA	covariates_yn	Yes
10.1016/j.esmoop.2021.100050	results	2	NA	covariates_n	5
10.1016/j.esmoop.2021.100050	results	2	NA	covariates_names	Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...)
10.1016/j.esmoop.2021.100050	results	2	NA	contrast_effect_direction	Numerator if ratio, or left side if difference
10.1016/j.esmoop.2021.100050	results	2	NA	contrast_effect_unadjusted_value	NA
10.1016/j.esmoop.2021.100050	results	2	NA	contrast_effect_unadjusted_pvalci	NA
10.1016/j.esmoop.2021.100050	results	2	NA	contrast_effect_adjusted_value	0.6
10.1016/j.esmoop.2021.100050	results	2	NA	contrast_effect_adjusted_pvalci	[0.42;0.85]
10.1016/j.esmoop.2021.100050	results	2	NA	adjustment_geographical	NA
10.1016/j.esmoop.2021.100050	results	2	NA	ss_total_ipd	NA
10.1016/j.esmoop.2021.100050	results	2	NA	ss_adjusted_total_ipd	NA
10.1016/j.esmoop.2021.100050	results	2	NA	ss_total_nonipd	NA
10.1016/j.esmoop.2021.100050	results	2	NA	ss_anchor_nonipd	NA
10.1016/j.esmoop.2021.100050	results	2	NA	ss_anchor_ipd	NA
10.1016/j.esmoop.2021.100050	results	2	NA	ss_adjusted_anchor_ipd	NA
10.1016/j.esmoop.2021.100050	results	2	NA	effect_cutoff	1
10.1016/j.esmoop.2021.100050	results	2	NA	adjusted_lb_ci	0.42
10.1016/j.esmoop.2021.100050	results	2	NA	adjusted_ub_ci	0.85
10.1016/j.esmoop.2021.100050	results	2	NA	adjusted_significant	TRUE
10.1016/j.esmoop.2021.100050	results	3	NA	contrast_effect_type	HR
10.1016/j.esmoop.2021.100050	results	3	NA	direction_benefit	inferior
10.1016/j.esmoop.2021.100050	results	3	NA	ss_ttt_nonipd	247
10.1016/j.esmoop.2021.100050	results	3	NA	ss_ttt_ipd	103
10.1016/j.esmoop.2021.100050	results	3	NA	ss_adjusted_ttt_ipd	91.69
10.1016/j.esmoop.2021.100050	results	3	NA	weights_yn	Not mentioned
10.1016/j.esmoop.2021.100050	results	3	NA	covariates_yn	Yes
10.1016/j.esmoop.2021.100050	results	3	NA	covariates_n	5
10.1016/j.esmoop.2021.100050	results	3	NA	covariates_names	Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...)
10.1016/j.esmoop.2021.100050	results	3	NA	contrast_effect_direction	Numerator if ratio, or left side if difference
10.1016/j.esmoop.2021.100050	results	3	NA	contrast_effect_unadjusted_value	NA
10.1016/j.esmoop.2021.100050	results	3	NA	contrast_effect_unadjusted_pvalci	NA
10.1016/j.esmoop.2021.100050	results	3	NA	contrast_effect_adjusted_value	0.5
10.1016/j.esmoop.2021.100050	results	3	NA	contrast_effect_adjusted_pvalci	[0.36;0.70]
10.1016/j.esmoop.2021.100050	results	3	NA	adjustment_geographical	NA
10.1016/j.esmoop.2021.100050	results	3	NA	ss_total_ipd	NA
10.1016/j.esmoop.2021.100050	results	3	NA	ss_adjusted_total_ipd	NA
10.1016/j.esmoop.2021.100050	results	3	NA	ss_total_nonipd	NA
10.1016/j.esmoop.2021.100050	results	3	NA	ss_anchor_nonipd	NA
10.1016/j.esmoop.2021.100050	results	3	NA	ss_anchor_ipd	NA
10.1016/j.esmoop.2021.100050	results	3	NA	ss_adjusted_anchor_ipd	NA
10.1016/j.esmoop.2021.100050	results	3	NA	effect_cutoff	1
10.1016/j.esmoop.2021.100050	results	3	NA	adjusted_lb_ci	0.36
10.1016/j.esmoop.2021.100050	results	3	NA	adjusted_ub_ci	0.7
10.1016/j.esmoop.2021.100050	results	3	NA	adjusted_significant	TRUE
10.1016/j.esmoop.2021.100050	study_information	NA	1	ipd_yn	Yes
10.1016/j.esmoop.2021.100050	study_information	NA	1	ct_yn	Yes
10.1016/j.esmoop.2021.100050	study_information	NA	1	nct	NCT01844505
10.1016/j.esmoop.2021.100050	study_information	NA	1	country_study	international
10.1016/j.esmoop.2021.100050	study_information	NA	1	ct_phase	3
10.1016/j.esmoop.2021.100050	study_information	NA	1	ct_arms	2 or more
10.1016/j.esmoop.2021.100050	study_information	NA	2	ipd_yn	No
10.1016/j.esmoop.2021.100050	study_information	NA	2	ct_yn	Yes
10.1016/j.esmoop.2021.100050	study_information	NA	2	nct	NCT01584648
10.1016/j.esmoop.2021.100050	study_information	NA	2	country_study	international
10.1016/j.esmoop.2021.100050	study_information	NA	2	ct_phase	3
10.1016/j.esmoop.2021.100050	study_information	NA	2	ct_arms	2 or more
10.1016/j.esmoop.2021.100050	study_information	NA	3	ipd_yn	No
10.1016/j.esmoop.2021.100050	study_information	NA	3	ct_yn	Yes
10.1016/j.esmoop.2021.100050	study_information	NA	3	nct	NCT01597908
10.1016/j.esmoop.2021.100050	study_information	NA	3	country_study	international
10.1016/j.esmoop.2021.100050	study_information	NA	3	ct_phase	3
10.1016/j.esmoop.2021.100050	study_information	NA	3	ct_arms	2 or more
10.1016/j.esmoop.2021.100050	study_information	NA	4	ipd_yn	No
10.1016/j.esmoop.2021.100050	study_information	NA	4	ct_yn	Yes
10.1016/j.esmoop.2021.100050	study_information	NA	4	nct	NCT01909453
10.1016/j.esmoop.2021.100050	study_information	NA	4	country_study	international
10.1016/j.esmoop.2021.100050	study_information	NA	4	ct_phase	3
10.1016/j.esmoop.2021.100050	study_information	NA	4	ct_arms	2 or more
10.1016/j.esmoop.2021.100050	study_information	NA	5	ipd_yn	No
10.1016/j.esmoop.2021.100050	study_information	NA	5	ct_yn	Yes
10.1016/j.esmoop.2021.100050	study_information	NA	5	nct	NCT01689519
10.1016/j.esmoop.2021.100050	study_information	NA	5	country_study	international
10.1016/j.esmoop.2021.100050	study_information	NA	5	ct_phase	3
10.1016/j.esmoop.2021.100050	study_information	NA	5	ct_arms	2 or more
10.1016/j.euo.2018.09.009	general_information	NA	NA	condition_name	advanced, unresectable, or metastatic urothelial cancer
10.1016/j.euo.2018.09.009	general_information	NA	NA	country_first_author	uk
10.1016/j.euo.2018.09.009	general_information	NA	NA	country_last_author	the netherlands
10.1016/j.euo.2018.09.009	general_information	NA	NA	positions	Academic, Pharmaceutical Industry, Private Data Analysis Company
10.1016/j.euo.2018.09.009	general_information	NA	NA	methodologist_yn	Yes
10.1016/j.euo.2018.09.009	general_information	NA	NA	funding_source	Pharmaceutical Industry
10.1016/j.euo.2018.09.009	general_information	NA	NA	pharmaceutical_ties_yn	Yes
10.1016/j.euo.2018.09.009	general_information	NA	NA	systematic_review_yn	Yes
10.1016/j.euo.2018.09.009	methodology	1	NA	outcome_name	overall survival
10.1016/j.euo.2018.09.009	methodology	1	NA	outcome_short_name	Overall Survival
10.1016/j.euo.2018.09.009	methodology	1	NA	outcome_variable_type	Time-to-event
10.1016/j.euo.2018.09.009	methodology	1	NA	treatment_name_ipd	pembrolizumab
10.1016/j.euo.2018.09.009	methodology	1	NA	studies_number_ipd	1
10.1016/j.euo.2018.09.009	methodology	1	NA	treatment_name_nonipd	carboplatin + gemcitabine
10.1016/j.euo.2018.09.009	methodology	1	NA	studies_number_nonipd	2;4;5;6
10.1016/j.euo.2018.09.009	methodology	1	NA	paic_type	STC
10.1016/j.euo.2018.09.009	methodology	1	NA	anchored_yn	No
10.1016/j.euo.2018.09.009	methodology	1	NA	paic_form	Aggregation of multiple studies to estimate individual treatment effects (e.g. meta-analysis in a first step to estimate treatment A effect, then population adjusted indirect comparison using treatment A effect estimate)
10.1016/j.euo.2018.09.009	methodology	1	NA	primary_outcome_yn	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.1016/j.euo.2018.09.009	methodology	1	NA	variables_selection_justification	Nothing mentioned, not reported
10.1016/j.euo.2018.09.009	methodology	1	NA	pf_yn	Yes
10.1016/j.euo.2018.09.009	methodology	1	NA	tem_yn	No discussion (in the main text) of the status of treatment-effect modifiers of the variables
10.1016/j.euo.2018.09.009	methodology	1	NA	adjustment_model_details_yn	No
10.1016/j.euo.2018.09.009	methodology	1	NA	scale_choice_yn	No
10.1016/j.euo.2018.09.009	methodology	2	NA	outcome_name	overall survival
10.1016/j.euo.2018.09.009	methodology	2	NA	outcome_short_name	Overall Survival
10.1016/j.euo.2018.09.009	methodology	2	NA	outcome_variable_type	Time-to-event
10.1016/j.euo.2018.09.009	methodology	2	NA	treatment_name_ipd	pembrolizumab
10.1016/j.euo.2018.09.009	methodology	2	NA	studies_number_ipd	1
10.1016/j.euo.2018.09.009	methodology	2	NA	treatment_name_nonipd	gemcitabine
10.1016/j.euo.2018.09.009	methodology	2	NA	studies_number_nonipd	3
10.1016/j.euo.2018.09.009	methodology	2	NA	paic_type	STC
10.1016/j.euo.2018.09.009	methodology	2	NA	anchored_yn	No
10.1016/j.euo.2018.09.009	methodology	2	NA	paic_form	Simple (ie treatments effects extracted from two studies)
10.1016/j.euo.2018.09.009	methodology	2	NA	primary_outcome_yn	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.1016/j.euo.2018.09.009	methodology	2	NA	variables_selection_justification	Nothing mentioned, not reported
10.1016/j.euo.2018.09.009	methodology	2	NA	pf_yn	Yes
10.1016/j.euo.2018.09.009	methodology	2	NA	tem_yn	No discussion (in the main text) of the status of treatment-effect modifiers of the variables
10.1016/j.euo.2018.09.009	methodology	2	NA	adjustment_model_details_yn	No
10.1016/j.euo.2018.09.009	methodology	2	NA	scale_choice_yn	No
10.1016/j.euo.2018.09.009	results	1	NA	contrast_effect_type	HR
10.1016/j.euo.2018.09.009	results	1	NA	direction_benefit	inferior
10.1016/j.euo.2018.09.009	results	1	NA	ss_ttt_nonipd	NA
10.1016/j.euo.2018.09.009	results	1	NA	ss_ttt_ipd	NA
10.1016/j.euo.2018.09.009	results	1	NA	ss_adjusted_ttt_ipd	NA
10.1016/j.euo.2018.09.009	results	1	NA	weights_yn	NA
10.1016/j.euo.2018.09.009	results	1	NA	covariates_yn	Yes
10.1016/j.euo.2018.09.009	results	1	NA	covariates_n	3
10.1016/j.euo.2018.09.009	results	1	NA	covariates_names	Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Comorbidities and medical history (beside pathology/disease of interest in the comparison)
10.1016/j.euo.2018.09.009	results	1	NA	contrast_effect_direction	Denominator if ratio, or rightside if difference
10.1016/j.euo.2018.09.009	results	1	NA	contrast_effect_unadjusted_value	NA
10.1016/j.euo.2018.09.009	results	1	NA	contrast_effect_unadjusted_pvalci	NA
10.1016/j.euo.2018.09.009	results	1	NA	contrast_effect_adjusted_value	2.78
10.1016/j.euo.2018.09.009	results	1	NA	contrast_effect_adjusted_pvalci	[2.29;3.38]
10.1016/j.euo.2018.09.009	results	1	NA	adjustment_geographical	NA
10.1016/j.euo.2018.09.009	results	1	NA	ss_total_ipd	NA
10.1016/j.euo.2018.09.009	results	1	NA	ss_adjusted_total_ipd	NA
10.1016/j.euo.2018.09.009	results	1	NA	ss_total_nonipd	NA
10.1016/j.euo.2018.09.009	results	1	NA	ss_anchor_nonipd	NA
10.1016/j.euo.2018.09.009	results	1	NA	ss_anchor_ipd	NA
10.1016/j.euo.2018.09.009	results	1	NA	ss_adjusted_anchor_ipd	NA
10.1016/j.euo.2018.09.009	results	1	NA	effect_cutoff	1
10.1016/j.euo.2018.09.009	results	1	NA	adjusted_lb_ci	2.29
10.1016/j.euo.2018.09.009	results	1	NA	adjusted_ub_ci	3.38
10.1016/j.euo.2018.09.009	results	1	NA	adjusted_significant	TRUE
10.1016/j.euo.2018.09.009	results	2	NA	contrast_effect_type	HR
10.1016/j.euo.2018.09.009	results	2	NA	direction_benefit	inferior
10.1016/j.euo.2018.09.009	results	2	NA	ss_ttt_nonipd	NA
10.1016/j.euo.2018.09.009	results	2	NA	ss_ttt_ipd	NA
10.1016/j.euo.2018.09.009	results	2	NA	ss_adjusted_ttt_ipd	NA
10.1016/j.euo.2018.09.009	results	2	NA	weights_yn	NA
10.1016/j.euo.2018.09.009	results	2	NA	covariates_yn	Yes
10.1016/j.euo.2018.09.009	results	2	NA	covariates_n	3
10.1016/j.euo.2018.09.009	results	2	NA	covariates_names	Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Comorbidities and medical history (beside pathology/disease of interest in the comparison)
10.1016/j.euo.2018.09.009	results	2	NA	contrast_effect_direction	Denominator if ratio, or rightside if difference
10.1016/j.euo.2018.09.009	results	2	NA	contrast_effect_unadjusted_value	NA
10.1016/j.euo.2018.09.009	results	2	NA	contrast_effect_unadjusted_pvalci	NA
10.1016/j.euo.2018.09.009	results	2	NA	contrast_effect_adjusted_value	2.94
10.1016/j.euo.2018.09.009	results	2	NA	contrast_effect_adjusted_pvalci	[2.42;3.57]
10.1016/j.euo.2018.09.009	results	2	NA	adjustment_geographical	NA
10.1016/j.euo.2018.09.009	results	2	NA	ss_total_ipd	NA
10.1016/j.euo.2018.09.009	results	2	NA	ss_adjusted_total_ipd	NA
10.1016/j.euo.2018.09.009	results	2	NA	ss_total_nonipd	NA
10.1016/j.euo.2018.09.009	results	2	NA	ss_anchor_nonipd	NA
10.1016/j.euo.2018.09.009	results	2	NA	ss_anchor_ipd	NA
10.1016/j.euo.2018.09.009	results	2	NA	ss_adjusted_anchor_ipd	NA
10.1016/j.euo.2018.09.009	results	2	NA	effect_cutoff	1
10.1016/j.euo.2018.09.009	results	2	NA	adjusted_lb_ci	2.42
10.1016/j.euo.2018.09.009	results	2	NA	adjusted_ub_ci	3.57
10.1016/j.euo.2018.09.009	results	2	NA	adjusted_significant	TRUE
10.1016/j.euo.2018.09.009	study_information	NA	1	ipd_yn	Yes
10.1016/j.euo.2018.09.009	study_information	NA	1	ct_yn	Yes
10.1016/j.euo.2018.09.009	study_information	NA	1	nct	NCT02335424
10.1016/j.euo.2018.09.009	study_information	NA	1	country_study	unknown
10.1016/j.euo.2018.09.009	study_information	NA	1	ct_phase	2
10.1016/j.euo.2018.09.009	study_information	NA	1	ct_arms	1
10.1016/j.euo.2018.09.009	study_information	NA	2	ipd_yn	No
10.1016/j.euo.2018.09.009	study_information	NA	2	ct_yn	Yes
10.1016/j.euo.2018.09.009	study_information	NA	2	nct	NCT00014274
10.1016/j.euo.2018.09.009	study_information	NA	2	country_study	international
10.1016/j.euo.2018.09.009	study_information	NA	2	ct_phase	2, 3
10.1016/j.euo.2018.09.009	study_information	NA	2	ct_arms	2 or more
10.1016/j.euo.2018.09.009	study_information	NA	3	ipd_yn	No
10.1016/j.euo.2018.09.009	study_information	NA	3	ct_yn	Yes
10.1016/j.euo.2018.09.009	study_information	NA	3	data_source_name	getug v01
10.1016/j.euo.2018.09.009	study_information	NA	3	country_study	france
10.1016/j.euo.2018.09.009	study_information	NA	3	ct_phase	1, 2
10.1016/j.euo.2018.09.009	study_information	NA	3	ct_arms	2 or more
10.1016/j.euo.2018.09.009	study_information	NA	4	ipd_yn	No
10.1016/j.euo.2018.09.009	study_information	NA	4	ct_yn	Yes
10.1016/j.euo.2018.09.009	study_information	NA	4	data_source_name	bamias et al. (2007)
10.1016/j.euo.2018.09.009	study_information	NA	4	country_study	greece
10.1016/j.euo.2018.09.009	study_information	NA	4	ct_arms	1
10.1016/j.euo.2018.09.009	study_information	NA	5	ipd_yn	No
10.1016/j.euo.2018.09.009	study_information	NA	5	ct_yn	Yes
10.1016/j.euo.2018.09.009	study_information	NA	5	data_source_name	carles et al. (2000)
10.1016/j.euo.2018.09.009	study_information	NA	5	country_study	spain
10.1016/j.euo.2018.09.009	study_information	NA	5	ct_arms	1
10.1016/j.euo.2018.09.009	study_information	NA	6	ipd_yn	No
10.1016/j.euo.2018.09.009	study_information	NA	6	ct_yn	Yes
10.1016/j.euo.2018.09.009	study_information	NA	6	data_source_name	linardou et al. (2003)
10.1016/j.euo.2018.09.009	study_information	NA	6	country_study	greece
10.1016/j.euo.2018.09.009	study_information	NA	6	ct_phase	2
10.1016/j.euo.2018.09.009	study_information	NA	6	ct_arms	1
10.1016/j.jtho.2016.05.029	general_information	NA	NA	condition_name	advanced or metastatic non-small cell lung cancer
10.1016/j.jtho.2016.05.029	general_information	NA	NA	country_first_author	singapore
10.1016/j.jtho.2016.05.029	general_information	NA	NA	country_last_author	canada
10.1016/j.jtho.2016.05.029	general_information	NA	NA	positions	Academic, Pharmaceutical Industry, Private Data Analysis Company
10.1016/j.jtho.2016.05.029	general_information	NA	NA	methodologist_yn	Yes
10.1016/j.jtho.2016.05.029	general_information	NA	NA	funding_source	Pharmaceutical Industry
10.1016/j.jtho.2016.05.029	general_information	NA	NA	pharmaceutical_ties_yn	Yes
10.1016/j.jtho.2016.05.029	general_information	NA	NA	systematic_review_yn	No
10.1016/j.jtho.2016.05.029	methodology	1	NA	outcome_name	overall survival
10.1016/j.jtho.2016.05.029	methodology	1	NA	outcome_short_name	Overall Survival
10.1016/j.jtho.2016.05.029	methodology	1	NA	outcome_variable_type	Time-to-event
10.1016/j.jtho.2016.05.029	methodology	1	NA	treatment_name_ipd	ceritinib
10.1016/j.jtho.2016.05.029	methodology	1	NA	studies_number_ipd	1;2
10.1016/j.jtho.2016.05.029	methodology	1	NA	treatment_name_nonipd	crizotinib
10.1016/j.jtho.2016.05.029	methodology	1	NA	studies_number_nonipd	3;4;5
10.1016/j.jtho.2016.05.029	methodology	1	NA	paic_type	MAIC
10.1016/j.jtho.2016.05.029	methodology	1	NA	anchored_yn	No
10.1016/j.jtho.2016.05.029	methodology	1	NA	paic_form	Aggregation of multiple studies to estimate individual treatment effects (e.g. meta-analysis in a first step to estimate treatment A effect, then population adjusted indirect comparison using treatment A effect estimate)
10.1016/j.jtho.2016.05.029	methodology	1	NA	primary_outcome_yn	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.1016/j.jtho.2016.05.029	methodology	1	NA	variables_selection_justification	A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion), Literature based (clinically or methodologically relevant to adjust on these variables based on the literature search conducted for this specific purpose)
10.1016/j.jtho.2016.05.029	methodology	1	NA	pf_yn	Yes
10.1016/j.jtho.2016.05.029	methodology	1	NA	tem_yn	Yes
10.1016/j.jtho.2016.05.029	methodology	1	NA	adjustment_model_details_yn	No
10.1016/j.jtho.2016.05.029	methodology	1	NA	scale_choice_yn	No
10.1016/j.jtho.2016.05.029	results	1	NA	contrast_effect_type	HR
10.1016/j.jtho.2016.05.029	results	1	NA	direction_benefit	inferior
10.1016/j.jtho.2016.05.029	results	1	NA	ss_ttt_nonipd	557
10.1016/j.jtho.2016.05.029	results	1	NA	ss_ttt_ipd	189
10.1016/j.jtho.2016.05.029	results	1	NA	ss_adjusted_ttt_ipd	143
10.1016/j.jtho.2016.05.029	results	1	NA	weights_yn	Not mentioned
10.1016/j.jtho.2016.05.029	results	1	NA	covariates_yn	Yes
10.1016/j.jtho.2016.05.029	results	1	NA	covariates_n	6
10.1016/j.jtho.2016.05.029	results	1	NA	covariates_names	Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Race/ethnicity, Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Past treatments for the disease of interest
10.1016/j.jtho.2016.05.029	results	1	NA	contrast_effect_direction	Numerator if ratio, or left side if difference
10.1016/j.jtho.2016.05.029	results	1	NA	contrast_effect_unadjusted_value	0.49
10.1016/j.jtho.2016.05.029	results	1	NA	contrast_effect_unadjusted_pvalci	[0.33;0.74]
10.1016/j.jtho.2016.05.029	results	1	NA	contrast_effect_adjusted_value	0.59
10.1016/j.jtho.2016.05.029	results	1	NA	contrast_effect_adjusted_pvalci	[0.46;0.75]
10.1016/j.jtho.2016.05.029	results	1	NA	adjustment_geographical	NA
10.1016/j.jtho.2016.05.029	results	1	NA	ss_total_ipd	NA
10.1016/j.jtho.2016.05.029	results	1	NA	ss_adjusted_total_ipd	NA
10.1016/j.jtho.2016.05.029	results	1	NA	ss_total_nonipd	NA
10.1016/j.jtho.2016.05.029	results	1	NA	ss_anchor_nonipd	NA
10.1016/j.jtho.2016.05.029	results	1	NA	ss_anchor_ipd	NA
10.1016/j.jtho.2016.05.029	results	1	NA	ss_adjusted_anchor_ipd	NA
10.1016/j.jtho.2016.05.029	results	1	NA	effect_cutoff	1
10.1016/j.jtho.2016.05.029	results	1	NA	unadjusted_lb_ci	0.33
10.1016/j.jtho.2016.05.029	results	1	NA	unadjusted_ub_ci	0.74
10.1016/j.jtho.2016.05.029	results	1	NA	unadjusted_significant	TRUE
10.1016/j.jtho.2016.05.029	results	1	NA	adjusted_lb_ci	0.46
10.1016/j.jtho.2016.05.029	results	1	NA	adjusted_ub_ci	0.75
10.1016/j.jtho.2016.05.029	results	1	NA	adjusted_significant	TRUE
10.1016/j.jtho.2016.05.029	study_information	NA	1	ipd_yn	Yes
10.1016/j.jtho.2016.05.029	study_information	NA	1	ct_yn	Yes
10.1016/j.jtho.2016.05.029	study_information	NA	1	nct	NCT01283516
10.1016/j.jtho.2016.05.029	study_information	NA	1	country_study	international
10.1016/j.jtho.2016.05.029	study_information	NA	1	ct_phase	1
10.1016/j.jtho.2016.05.029	study_information	NA	1	ct_arms	1
10.1016/j.jtho.2016.05.029	study_information	NA	2	ipd_yn	Yes
10.1016/j.jtho.2016.05.029	study_information	NA	2	ct_yn	Yes
10.1016/j.jtho.2016.05.029	study_information	NA	2	nct	NCT01685138
10.1016/j.jtho.2016.05.029	study_information	NA	2	country_study	international
10.1016/j.jtho.2016.05.029	study_information	NA	2	ct_phase	2
10.1016/j.jtho.2016.05.029	study_information	NA	2	ct_arms	1
10.1016/j.jtho.2016.05.029	study_information	NA	3	ipd_yn	No
10.1016/j.jtho.2016.05.029	study_information	NA	3	ct_yn	Yes
10.1016/j.jtho.2016.05.029	study_information	NA	3	nct	NCT00585195
10.1016/j.jtho.2016.05.029	study_information	NA	3	country_study	international
10.1016/j.jtho.2016.05.029	study_information	NA	3	ct_phase	1
10.1016/j.jtho.2016.05.029	study_information	NA	3	ct_arms	1
10.1016/j.jtho.2016.05.029	study_information	NA	4	ipd_yn	No
10.1016/j.jtho.2016.05.029	study_information	NA	4	ct_yn	Yes
10.1016/j.jtho.2016.05.029	study_information	NA	4	nct	NCT00932451
10.1016/j.jtho.2016.05.029	study_information	NA	4	country_study	international
10.1016/j.jtho.2016.05.029	study_information	NA	4	ct_phase	2
10.1016/j.jtho.2016.05.029	study_information	NA	4	ct_arms	1
10.1016/j.jtho.2016.05.029	study_information	NA	5	ipd_yn	No
10.1016/j.jtho.2016.05.029	study_information	NA	5	ct_yn	Yes
10.1016/j.jtho.2016.05.029	study_information	NA	5	nct	NCT00932893
10.1016/j.jtho.2016.05.029	study_information	NA	5	country_study	international
10.1016/j.jtho.2016.05.029	study_information	NA	5	ct_phase	3
10.1016/j.jtho.2016.05.029	study_information	NA	5	ct_arms	2 or more
10.1016/j.jval.2018.03.015	general_information	NA	NA	condition_name	tremor
10.1016/j.jval.2018.03.015	general_information	NA	NA	country_first_author	uk
10.1016/j.jval.2018.03.015	general_information	NA	NA	country_last_author	israel
10.1016/j.jval.2018.03.015	general_information	NA	NA	positions	Pharmaceutical Industry, Private Data Analysis Company
10.1016/j.jval.2018.03.015	general_information	NA	NA	methodologist_yn	Yes
10.1016/j.jval.2018.03.015	general_information	NA	NA	funding_source	Pharmaceutical Industry
10.1016/j.jval.2018.03.015	general_information	NA	NA	pharmaceutical_ties_yn	Yes
10.1016/j.jval.2018.03.015	general_information	NA	NA	systematic_review_yn	Yes
10.1016/j.jval.2018.03.015	methodology	1	NA	outcome_name	clinical rating scale for tremor part c at 1 month
10.1016/j.jval.2018.03.015	methodology	1	NA	outcome_short_name	Clinical Rating Scale for Tremor
10.1016/j.jval.2018.03.015	methodology	1	NA	outcome_variable_type	Continuous (count, mean, ...)
10.1016/j.jval.2018.03.015	methodology	1	NA	treatment_name_ipd	magnetic resonance-guided focused ultrasound
10.1016/j.jval.2018.03.015	methodology	1	NA	studies_number_ipd	1
10.1016/j.jval.2018.03.015	methodology	1	NA	treatment_name_nonipd	unilateral deep brain stimulation
10.1016/j.jval.2018.03.015	methodology	1	NA	studies_number_nonipd	2
10.1016/j.jval.2018.03.015	methodology	1	NA	paic_type	MAIC
10.1016/j.jval.2018.03.015	methodology	1	NA	anchored_yn	No
10.1016/j.jval.2018.03.015	methodology	1	NA	paic_form	Simple (ie treatments effects extracted from two studies)
10.1016/j.jval.2018.03.015	methodology	1	NA	primary_outcome_yn	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.1016/j.jval.2018.03.015	methodology	1	NA	variables_selection_justification	A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion)
10.1016/j.jval.2018.03.015	methodology	1	NA	pf_yn	Yes
10.1016/j.jval.2018.03.015	methodology	1	NA	tem_yn	No discussion (in the main text) of the status of treatment-effect modifiers of the variables
10.1016/j.jval.2018.03.015	methodology	1	NA	adjustment_model_details_yn	No
10.1016/j.jval.2018.03.015	methodology	1	NA	scale_choice_yn	No
10.1016/j.jval.2018.03.015	methodology	2	NA	outcome_name	clinical rating scale for tremor part c at 1 month
10.1016/j.jval.2018.03.015	methodology	2	NA	outcome_short_name	Clinical Rating Scale for Tremor
10.1016/j.jval.2018.03.015	methodology	2	NA	outcome_variable_type	Continuous (count, mean, ...)
10.1016/j.jval.2018.03.015	methodology	2	NA	treatment_name_ipd	magnetic resonance-guided focused ultrasound
10.1016/j.jval.2018.03.015	methodology	2	NA	studies_number_ipd	1
10.1016/j.jval.2018.03.015	methodology	2	NA	treatment_name_nonipd	unilateral deep brain stimulation (dbs)
10.1016/j.jval.2018.03.015	methodology	2	NA	studies_number_nonipd	2
10.1016/j.jval.2018.03.015	methodology	2	NA	paic_type	STC
10.1016/j.jval.2018.03.015	methodology	2	NA	anchored_yn	No
10.1016/j.jval.2018.03.015	methodology	2	NA	paic_form	Simple (ie treatments effects extracted from two studies)
10.1016/j.jval.2018.03.015	methodology	2	NA	primary_outcome_yn	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.1016/j.jval.2018.03.015	methodology	2	NA	variables_selection_justification	A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion)
10.1016/j.jval.2018.03.015	methodology	2	NA	pf_yn	Yes
10.1016/j.jval.2018.03.015	methodology	2	NA	tem_yn	No discussion (in the main text) of the status of treatment-effect modifiers of the variables
10.1016/j.jval.2018.03.015	methodology	2	NA	adjustment_model_details_yn	Yes
10.1016/j.jval.2018.03.015	methodology	2	NA	scale_choice_yn	No
10.1016/j.jval.2018.03.015	results	1	NA	contrast_effect_type	Means difference
10.1016/j.jval.2018.03.015	results	1	NA	direction_benefit	inferior
10.1016/j.jval.2018.03.015	results	1	NA	ss_ttt_nonipd	22
10.1016/j.jval.2018.03.015	results	1	NA	ss_ttt_ipd	56
10.1016/j.jval.2018.03.015	results	1	NA	ss_adjusted_ttt_ipd	35.8
10.1016/j.jval.2018.03.015	results	1	NA	weights_yn	Not mentioned
10.1016/j.jval.2018.03.015	results	1	NA	covariates_yn	Yes
10.1016/j.jval.2018.03.015	results	1	NA	covariates_n	3
10.1016/j.jval.2018.03.015	results	1	NA	covariates_names	Age, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease)
10.1016/j.jval.2018.03.015	results	1	NA	contrast_effect_direction	Numerator if ratio, or left side if difference
10.1016/j.jval.2018.03.015	results	1	NA	contrast_effect_unadjusted_value	0.35
10.1016/j.jval.2018.03.015	results	1	NA	contrast_effect_unadjusted_pvalci	[-2.17;2.87]
10.1016/j.jval.2018.03.015	results	1	NA	contrast_effect_adjusted_value	1.92
10.1016/j.jval.2018.03.015	results	1	NA	contrast_effect_adjusted_pvalci	[-0.94;4.79]
10.1016/j.jval.2018.03.015	results	1	NA	adjustment_geographical	NA
10.1016/j.jval.2018.03.015	results	1	NA	ss_total_ipd	NA
10.1016/j.jval.2018.03.015	results	1	NA	ss_adjusted_total_ipd	NA
10.1016/j.jval.2018.03.015	results	1	NA	ss_total_nonipd	NA
10.1016/j.jval.2018.03.015	results	1	NA	ss_anchor_nonipd	NA
10.1016/j.jval.2018.03.015	results	1	NA	ss_anchor_ipd	NA
10.1016/j.jval.2018.03.015	results	1	NA	ss_adjusted_anchor_ipd	NA
10.1016/j.jval.2018.03.015	results	1	NA	effect_cutoff	0
10.1016/j.jval.2018.03.015	results	1	NA	unadjusted_lb_ci	-2.17
10.1016/j.jval.2018.03.015	results	1	NA	unadjusted_ub_ci	2.87
10.1016/j.jval.2018.03.015	results	1	NA	unadjusted_significant	FALSE
10.1016/j.jval.2018.03.015	results	1	NA	adjusted_lb_ci	-0.94
10.1016/j.jval.2018.03.015	results	1	NA	adjusted_ub_ci	4.79
10.1016/j.jval.2018.03.015	results	1	NA	adjusted_significant	FALSE
10.1016/j.jval.2018.03.015	results	2	NA	contrast_effect_type	Means difference
10.1016/j.jval.2018.03.015	results	2	NA	direction_benefit	inferior
10.1016/j.jval.2018.03.015	results	2	NA	ss_ttt_nonipd	22
10.1016/j.jval.2018.03.015	results	2	NA	ss_ttt_ipd	56
10.1016/j.jval.2018.03.015	results	2	NA	ss_adjusted_ttt_ipd	56
10.1016/j.jval.2018.03.015	results	2	NA	weights_yn	NA
10.1016/j.jval.2018.03.015	results	2	NA	covariates_yn	Yes
10.1016/j.jval.2018.03.015	results	2	NA	covariates_n	3
10.1016/j.jval.2018.03.015	results	2	NA	covariates_names	Age, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease)
10.1016/j.jval.2018.03.015	results	2	NA	contrast_effect_direction	Numerator if ratio, or left side if difference
10.1016/j.jval.2018.03.015	results	2	NA	contrast_effect_unadjusted_value	0.35
10.1016/j.jval.2018.03.015	results	2	NA	contrast_effect_unadjusted_pvalci	[-2.17;2.87]
10.1016/j.jval.2018.03.015	results	2	NA	contrast_effect_adjusted_value	1.67
10.1016/j.jval.2018.03.015	results	2	NA	contrast_effect_adjusted_pvalci	[-0.74;4.08]
10.1016/j.jval.2018.03.015	results	2	NA	adjustment_geographical	NA
10.1016/j.jval.2018.03.015	results	2	NA	ss_total_ipd	NA
10.1016/j.jval.2018.03.015	results	2	NA	ss_adjusted_total_ipd	NA
10.1016/j.jval.2018.03.015	results	2	NA	ss_total_nonipd	NA
10.1016/j.jval.2018.03.015	results	2	NA	ss_anchor_nonipd	NA
10.1016/j.jval.2018.03.015	results	2	NA	ss_anchor_ipd	NA
10.1016/j.jval.2018.03.015	results	2	NA	ss_adjusted_anchor_ipd	NA
10.1016/j.jval.2018.03.015	results	2	NA	effect_cutoff	0
10.1016/j.jval.2018.03.015	results	2	NA	unadjusted_lb_ci	-2.17
10.1016/j.jval.2018.03.015	results	2	NA	unadjusted_ub_ci	2.87
10.1016/j.jval.2018.03.015	results	2	NA	unadjusted_significant	FALSE
10.1016/j.jval.2018.03.015	results	2	NA	adjusted_lb_ci	-0.74
10.1016/j.jval.2018.03.015	results	2	NA	adjusted_ub_ci	4.08
10.1016/j.jval.2018.03.015	results	2	NA	adjusted_significant	FALSE
10.1016/j.jval.2018.03.015	study_information	NA	1	ipd_yn	Yes
10.1016/j.jval.2018.03.015	study_information	NA	1	ct_yn	Yes
10.1016/j.jval.2018.03.015	study_information	NA	1	nct	NCT01827904
10.1016/j.jval.2018.03.015	study_information	NA	1	country_study	international
10.1016/j.jval.2018.03.015	study_information	NA	1	ct_arms	2 or more
10.1016/j.jval.2018.03.015	study_information	NA	2	ipd_yn	No
10.1016/j.jval.2018.03.015	study_information	NA	2	ct_yn	No
10.1016/j.jval.2018.03.015	study_information	NA	2	data_source_name	putzke et al. (2005)
10.1016/j.jval.2018.03.015	study_information	NA	2	country_study	unknown
10.1016/j.lungcan.2021.03.020	general_information	NA	NA	condition_name	non-squamous non-small cell lung cancer
10.1016/j.lungcan.2021.03.020	general_information	NA	NA	country_first_author	usa
10.1016/j.lungcan.2021.03.020	general_information	NA	NA	country_last_author	usa
10.1016/j.lungcan.2021.03.020	general_information	NA	NA	positions	Academic, Pharmaceutical Industry, Private Data Analysis Company
10.1016/j.lungcan.2021.03.020	general_information	NA	NA	methodologist_yn	Yes
10.1016/j.lungcan.2021.03.020	general_information	NA	NA	funding_source	Pharmaceutical Industry
10.1016/j.lungcan.2021.03.020	general_information	NA	NA	pharmaceutical_ties_yn	Yes
10.1016/j.lungcan.2021.03.020	general_information	NA	NA	systematic_review_yn	Yes
10.1016/j.lungcan.2021.03.020	methodology	1	NA	outcome_name	overall survival
10.1016/j.lungcan.2021.03.020	methodology	1	NA	outcome_short_name	Overall Survival
10.1016/j.lungcan.2021.03.020	methodology	1	NA	outcome_variable_type	Time-to-event
10.1016/j.lungcan.2021.03.020	methodology	1	NA	treatment_name_ipd	pembrolizumab + chemotherapy
10.1016/j.lungcan.2021.03.020	methodology	1	NA	studies_number_ipd	1;2
10.1016/j.lungcan.2021.03.020	methodology	1	NA	treatment_name_nonipd	atezolizumab + chemotherapy
10.1016/j.lungcan.2021.03.020	methodology	1	NA	studies_number_nonipd	3;4
10.1016/j.lungcan.2021.03.020	methodology	1	NA	paic_type	MAIC
10.1016/j.lungcan.2021.03.020	methodology	1	NA	anchored_yn	No
10.1016/j.lungcan.2021.03.020	methodology	1	NA	paic_form	Aggregation of multiple studies to estimate individual treatment effects (e.g. meta-analysis in a first step to estimate treatment A effect, then population adjusted indirect comparison using treatment A effect estimate)
10.1016/j.lungcan.2021.03.020	methodology	1	NA	primary_outcome_yn	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.1016/j.lungcan.2021.03.020	methodology	1	NA	variables_selection_justification	Statistical imbalanced between treatment groups (independently of the status of prognostic/effect modifier), A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion), Literature based (clinically or methodologically relevant to adjust on these variables based on the literature search conducted for this specific purpose)
10.1016/j.lungcan.2021.03.020	methodology	1	NA	pf_yn	Yes
10.1016/j.lungcan.2021.03.020	methodology	1	NA	tem_yn	Yes
10.1016/j.lungcan.2021.03.020	methodology	1	NA	adjustment_model_details_yn	No
10.1016/j.lungcan.2021.03.020	methodology	1	NA	scale_choice_yn	No
10.1016/j.lungcan.2021.03.020	methodology	2	NA	outcome_name	overall survival
10.1016/j.lungcan.2021.03.020	methodology	2	NA	outcome_short_name	Overall Survival
10.1016/j.lungcan.2021.03.020	methodology	2	NA	outcome_variable_type	Time-to-event
10.1016/j.lungcan.2021.03.020	methodology	2	NA	treatment_name_ipd	pembrolizumab + chemotherapy
10.1016/j.lungcan.2021.03.020	methodology	2	NA	studies_number_ipd	1;2
10.1016/j.lungcan.2021.03.020	methodology	2	NA	treatment_name_nonipd	atezolizumab + bevacizumab + chemotherapy
10.1016/j.lungcan.2021.03.020	methodology	2	NA	studies_number_nonipd	4
10.1016/j.lungcan.2021.03.020	methodology	2	NA	paic_type	MAIC
10.1016/j.lungcan.2021.03.020	methodology	2	NA	anchored_yn	No
10.1016/j.lungcan.2021.03.020	methodology	2	NA	paic_form	Aggregation of multiple studies to estimate individual treatment effects (e.g. meta-analysis in a first step to estimate treatment A effect, then population adjusted indirect comparison using treatment A effect estimate)
10.1016/j.lungcan.2021.03.020	methodology	2	NA	primary_outcome_yn	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.1016/j.lungcan.2021.03.020	methodology	2	NA	variables_selection_justification	Statistical imbalanced between treatment groups (independently of the status of prognostic/effect modifier), A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion), Literature based (clinically or methodologically relevant to adjust on these variables based on the literature search conducted for this specific purpose)
10.1016/j.lungcan.2021.03.020	methodology	2	NA	pf_yn	Yes
10.1016/j.lungcan.2021.03.020	methodology	2	NA	tem_yn	Yes
10.1016/j.lungcan.2021.03.020	methodology	2	NA	adjustment_model_details_yn	No
10.1016/j.lungcan.2021.03.020	methodology	2	NA	scale_choice_yn	No
10.1016/j.lungcan.2021.03.020	results	1	NA	contrast_effect_type	HR
10.1016/j.lungcan.2021.03.020	results	1	NA	direction_benefit	inferior
10.1016/j.lungcan.2021.03.020	results	1	NA	ss_ttt_nonipd	451
10.1016/j.lungcan.2021.03.020	results	1	NA	ss_ttt_ipd	469
10.1016/j.lungcan.2021.03.020	results	1	NA	ss_adjusted_ttt_ipd	428
10.1016/j.lungcan.2021.03.020	results	1	NA	weights_yn	Not mentioned
10.1016/j.lungcan.2021.03.020	results	1	NA	covariates_yn	Yes
10.1016/j.lungcan.2021.03.020	results	1	NA	covariates_n	6
10.1016/j.lungcan.2021.03.020	results	1	NA	covariates_names	Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Race/ethnicity, Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Other(s)
10.1016/j.lungcan.2021.03.020	results	1	NA	contrast_effect_direction	Numerator if ratio, or left side if difference
10.1016/j.lungcan.2021.03.020	results	1	NA	contrast_effect_unadjusted_value	0.8
10.1016/j.lungcan.2021.03.020	results	1	NA	contrast_effect_unadjusted_pvalci	0.009
10.1016/j.lungcan.2021.03.020	results	1	NA	contrast_effect_adjusted_value	0.8
10.1016/j.lungcan.2021.03.020	results	1	NA	contrast_effect_adjusted_pvalci	0.012
10.1016/j.lungcan.2021.03.020	results	1	NA	adjustment_geographical	No
10.1016/j.lungcan.2021.03.020	results	1	NA	ss_total_ipd	NA
10.1016/j.lungcan.2021.03.020	results	1	NA	ss_adjusted_total_ipd	NA
10.1016/j.lungcan.2021.03.020	results	1	NA	ss_total_nonipd	NA
10.1016/j.lungcan.2021.03.020	results	1	NA	ss_anchor_nonipd	NA
10.1016/j.lungcan.2021.03.020	results	1	NA	ss_anchor_ipd	NA
10.1016/j.lungcan.2021.03.020	results	1	NA	ss_adjusted_anchor_ipd	NA
10.1016/j.lungcan.2021.03.020	results	1	NA	effect_cutoff	1
10.1016/j.lungcan.2021.03.020	results	1	NA	unadjusted_pval	0.009
10.1016/j.lungcan.2021.03.020	results	1	NA	unadjusted_num_pval	0.009
10.1016/j.lungcan.2021.03.020	results	1	NA	unadjusted_significant	TRUE
10.1016/j.lungcan.2021.03.020	results	1	NA	adjusted_pval	0.012
10.1016/j.lungcan.2021.03.020	results	1	NA	adjusted_num_pval	0.012
10.1016/j.lungcan.2021.03.020	results	1	NA	adjusted_significant	TRUE
10.1016/j.lungcan.2021.03.020	results	2	NA	contrast_effect_type	HR
10.1016/j.lungcan.2021.03.020	results	2	NA	direction_benefit	inferior
10.1016/j.lungcan.2021.03.020	results	2	NA	ss_ttt_nonipd	356
10.1016/j.lungcan.2021.03.020	results	2	NA	ss_ttt_ipd	469
10.1016/j.lungcan.2021.03.020	results	2	NA	ss_adjusted_ttt_ipd	389
10.1016/j.lungcan.2021.03.020	results	2	NA	weights_yn	Not mentioned
10.1016/j.lungcan.2021.03.020	results	2	NA	covariates_yn	Yes
10.1016/j.lungcan.2021.03.020	results	2	NA	covariates_n	6
10.1016/j.lungcan.2021.03.020	results	2	NA	covariates_names	Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Race/ethnicity, Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Other(s)
10.1016/j.lungcan.2021.03.020	results	2	NA	contrast_effect_direction	Numerator if ratio, or left side if difference
10.1016/j.lungcan.2021.03.020	results	2	NA	contrast_effect_unadjusted_value	0.84
10.1016/j.lungcan.2021.03.020	results	2	NA	contrast_effect_unadjusted_pvalci	0.04
10.1016/j.lungcan.2021.03.020	results	2	NA	contrast_effect_adjusted_value	0.86
10.1016/j.lungcan.2021.03.020	results	2	NA	contrast_effect_adjusted_pvalci	0.099
10.1016/j.lungcan.2021.03.020	results	2	NA	adjustment_geographical	No
10.1016/j.lungcan.2021.03.020	results	2	NA	ss_total_ipd	NA
10.1016/j.lungcan.2021.03.020	results	2	NA	ss_adjusted_total_ipd	NA
10.1016/j.lungcan.2021.03.020	results	2	NA	ss_total_nonipd	NA
10.1016/j.lungcan.2021.03.020	results	2	NA	ss_anchor_nonipd	NA
10.1016/j.lungcan.2021.03.020	results	2	NA	ss_anchor_ipd	NA
10.1016/j.lungcan.2021.03.020	results	2	NA	ss_adjusted_anchor_ipd	NA
10.1016/j.lungcan.2021.03.020	results	2	NA	effect_cutoff	1
10.1016/j.lungcan.2021.03.020	results	2	NA	unadjusted_pval	0.04
10.1016/j.lungcan.2021.03.020	results	2	NA	unadjusted_num_pval	0.04
10.1016/j.lungcan.2021.03.020	results	2	NA	unadjusted_significant	TRUE
10.1016/j.lungcan.2021.03.020	results	2	NA	adjusted_pval	0.099
10.1016/j.lungcan.2021.03.020	results	2	NA	adjusted_num_pval	0.099
10.1016/j.lungcan.2021.03.020	results	2	NA	adjusted_significant	FALSE
10.1016/j.lungcan.2021.03.020	study_information	NA	1	ipd_yn	Yes
10.1016/j.lungcan.2021.03.020	study_information	NA	1	ct_yn	Yes
10.1016/j.lungcan.2021.03.020	study_information	NA	1	nct	NCT02039674
10.1016/j.lungcan.2021.03.020	study_information	NA	1	ct_phase	1, 2
10.1016/j.lungcan.2021.03.020	study_information	NA	1	ct_arms	2 or more
10.1016/j.lungcan.2021.03.020	study_information	NA	1	country_study	International
10.1016/j.lungcan.2021.03.020	study_information	NA	2	ipd_yn	Yes
10.1016/j.lungcan.2021.03.020	study_information	NA	2	ct_yn	Yes
10.1016/j.lungcan.2021.03.020	study_information	NA	2	nct	NCT02578680
10.1016/j.lungcan.2021.03.020	study_information	NA	2	ct_phase	3
10.1016/j.lungcan.2021.03.020	study_information	NA	2	ct_arms	2 or more
10.1016/j.lungcan.2021.03.020	study_information	NA	2	country_study	unknown
10.1016/j.lungcan.2021.03.020	study_information	NA	3	ipd_yn	No
10.1016/j.lungcan.2021.03.020	study_information	NA	3	ct_yn	Yes
10.1016/j.lungcan.2021.03.020	study_information	NA	3	nct	NCT02367781
10.1016/j.lungcan.2021.03.020	study_information	NA	3	country_study	international
10.1016/j.lungcan.2021.03.020	study_information	NA	3	ct_phase	3
10.1016/j.lungcan.2021.03.020	study_information	NA	3	ct_arms	2 or more
10.1016/j.lungcan.2021.03.020	study_information	NA	4	ipd_yn	No
10.1016/j.lungcan.2021.03.020	study_information	NA	4	ct_yn	Yes
10.1016/j.lungcan.2021.03.020	study_information	NA	4	nct	NCT02366143
10.1016/j.lungcan.2021.03.020	study_information	NA	4	country_study	international
10.1016/j.lungcan.2021.03.020	study_information	NA	4	ct_phase	3
10.1016/j.lungcan.2021.03.020	study_information	NA	4	ct_arms	2 or more
10.1016/j.msard.2021.102972	general_information	NA	NA	condition_name	relapsing multiple sclerosis
10.1016/j.msard.2021.102972	general_information	NA	NA	country_first_author	usa
10.1016/j.msard.2021.102972	general_information	NA	NA	country_last_author	usa
10.1016/j.msard.2021.102972	general_information	NA	NA	positions	Academic, Pharmaceutical Industry, Private Data Analysis Company
10.1016/j.msard.2021.102972	general_information	NA	NA	methodologist_yn	Yes
10.1016/j.msard.2021.102972	general_information	NA	NA	funding_source	Pharmaceutical Industry
10.1016/j.msard.2021.102972	general_information	NA	NA	pharmaceutical_ties_yn	Yes
10.1016/j.msard.2021.102972	general_information	NA	NA	systematic_review_yn	Yes
10.1016/j.msard.2021.102972	methodology	1	NA	outcome_name	annualized relapse rate
10.1016/j.msard.2021.102972	methodology	1	NA	outcome_short_name	Annualized Relapse Rate
10.1016/j.msard.2021.102972	methodology	1	NA	outcome_variable_type	Binary (eg rates)
10.1016/j.msard.2021.102972	methodology	1	NA	treatment_name_ipd	ozanimod
10.1016/j.msard.2021.102972	methodology	1	NA	studies_number_ipd	1;2
10.1016/j.msard.2021.102972	methodology	1	NA	treatment_name_nonipd	teriflunomide
10.1016/j.msard.2021.102972	methodology	1	NA	studies_number_nonipd	3;4;5;6;7;8
10.1016/j.msard.2021.102972	methodology	1	NA	paic_type	MAIC
10.1016/j.msard.2021.102972	methodology	1	NA	anchored_yn	No
10.1016/j.msard.2021.102972	methodology	1	NA	paic_form	Aggregation of multiple studies to estimate individual treatment effects (e.g. meta-analysis in a first step to estimate treatment A effect, then population adjusted indirect comparison using treatment A effect estimate)
10.1016/j.msard.2021.102972	methodology	1	NA	primary_outcome_yn	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.1016/j.msard.2021.102972	methodology	1	NA	variables_selection_justification	Statistical imbalanced between treatment groups (independently of the status of prognostic/effect modifier), A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion), Literature based (clinically or methodologically relevant to adjust on these variables based on the literature search conducted for this specific purpose)
10.1016/j.msard.2021.102972	methodology	1	NA	pf_yn	Yes
10.1016/j.msard.2021.102972	methodology	1	NA	tem_yn	Yes
10.1016/j.msard.2021.102972	methodology	1	NA	adjustment_model_details_yn	No
10.1016/j.msard.2021.102972	methodology	1	NA	scale_choice_yn	No
10.1016/j.msard.2021.102972	results	1	NA	contrast_effect_type	OR
10.1016/j.msard.2021.102972	results	1	NA	direction_benefit	inferior
10.1016/j.msard.2021.102972	results	1	NA	ss_ttt_nonipd	2290
10.1016/j.msard.2021.102972	results	1	NA	ss_ttt_ipd	880
10.1016/j.msard.2021.102972	results	1	NA	ss_adjusted_ttt_ipd	663.53
10.1016/j.msard.2021.102972	results	1	NA	weights_yn	Yes, mentions that the weights distribution has been studied, but weights distribution not reported
10.1016/j.msard.2021.102972	results	1	NA	covariates_yn	Yes
10.1016/j.msard.2021.102972	results	1	NA	covariates_n	9
10.1016/j.msard.2021.102972	results	1	NA	covariates_names	Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Race/ethnicity, Past treatments for the disease of interest, Other(s)
10.1016/j.msard.2021.102972	results	1	NA	contrast_effect_direction	Numerator if ratio, or left side if difference
10.1016/j.msard.2021.102972	results	1	NA	contrast_effect_unadjusted_value	NA
10.1016/j.msard.2021.102972	results	1	NA	contrast_effect_unadjusted_pvalci	NA
10.1016/j.msard.2021.102972	results	1	NA	contrast_effect_adjusted_value	0.73
10.1016/j.msard.2021.102972	results	1	NA	contrast_effect_adjusted_pvalci	[0.62;0.84]
10.1016/j.msard.2021.102972	results	1	NA	adjustment_geographical	No
10.1016/j.msard.2021.102972	results	1	NA	ss_total_ipd	NA
10.1016/j.msard.2021.102972	results	1	NA	ss_adjusted_total_ipd	NA
10.1016/j.msard.2021.102972	results	1	NA	ss_total_nonipd	NA
10.1016/j.msard.2021.102972	results	1	NA	ss_anchor_nonipd	NA
10.1016/j.msard.2021.102972	results	1	NA	ss_anchor_ipd	NA
10.1016/j.msard.2021.102972	results	1	NA	ss_adjusted_anchor_ipd	NA
10.1016/j.msard.2021.102972	results	1	NA	effect_cutoff	1
10.1016/j.msard.2021.102972	results	1	NA	adjusted_lb_ci	0.62
10.1016/j.msard.2021.102972	results	1	NA	adjusted_ub_ci	0.84
10.1016/j.msard.2021.102972	results	1	NA	adjusted_significant	TRUE
10.1016/j.msard.2021.102972	study_information	NA	1	ipd_yn	Yes
10.1016/j.msard.2021.102972	study_information	NA	1	ct_yn	Yes
10.1016/j.msard.2021.102972	study_information	NA	1	nct	NCT02047734
10.1016/j.msard.2021.102972	study_information	NA	1	country_study	international
10.1016/j.msard.2021.102972	study_information	NA	1	ct_phase	3
10.1016/j.msard.2021.102972	study_information	NA	1	ct_arms	2 or more
10.1016/j.msard.2021.102972	study_information	NA	2	ipd_yn	Yes
10.1016/j.msard.2021.102972	study_information	NA	2	ct_yn	Yes
10.1016/j.msard.2021.102972	study_information	NA	2	nct	NCT02294058
10.1016/j.msard.2021.102972	study_information	NA	2	country_study	international
10.1016/j.msard.2021.102972	study_information	NA	2	ct_phase	3
10.1016/j.msard.2021.102972	study_information	NA	2	ct_arms	2 or more
10.1016/j.msard.2021.102972	study_information	NA	3	ipd_yn	No
10.1016/j.msard.2021.102972	study_information	NA	3	ct_yn	Yes
10.1016/j.msard.2021.102972	study_information	NA	3	nct	NCT02792218
10.1016/j.msard.2021.102972	study_information	NA	3	country_study	international
10.1016/j.msard.2021.102972	study_information	NA	3	ct_phase	3
10.1016/j.msard.2021.102972	study_information	NA	3	ct_arms	2 or more
10.1016/j.msard.2021.102972	study_information	NA	4	ipd_yn	No
10.1016/j.msard.2021.102972	study_information	NA	4	ct_yn	Yes
10.1016/j.msard.2021.102972	study_information	NA	4	nct	NCT02792231
10.1016/j.msard.2021.102972	study_information	NA	4	country_study	international
10.1016/j.msard.2021.102972	study_information	NA	4	ct_phase	3
10.1016/j.msard.2021.102972	study_information	NA	4	ct_arms	2 or more
10.1016/j.msard.2021.102972	study_information	NA	5	ipd_yn	No
10.1016/j.msard.2021.102972	study_information	NA	5	ct_yn	Yes
10.1016/j.msard.2021.102972	study_information	NA	5	nct	NCT00751881
10.1016/j.msard.2021.102972	study_information	NA	5	country_study	international
10.1016/j.msard.2021.102972	study_information	NA	5	ct_phase	3
10.1016/j.msard.2021.102972	study_information	NA	5	ct_arms	2 or more
10.1016/j.msard.2021.102972	study_information	NA	6	ipd_yn	No
10.1016/j.msard.2021.102972	study_information	NA	6	ct_yn	Yes
10.1016/j.msard.2021.102972	study_information	NA	6	nct	NCT02425644
10.1016/j.msard.2021.102972	study_information	NA	6	country_study	international
10.1016/j.msard.2021.102972	study_information	NA	6	ct_phase	3
10.1016/j.msard.2021.102972	study_information	NA	6	ct_arms	2 or more
10.1016/j.msard.2021.102972	study_information	NA	7	ipd_yn	No
10.1016/j.msard.2021.102972	study_information	NA	7	ct_yn	Yes
10.1016/j.msard.2021.102972	study_information	NA	7	nct	NCT00134563
10.1016/j.msard.2021.102972	study_information	NA	7	country_study	international
10.1016/j.msard.2021.102972	study_information	NA	7	ct_phase	3
10.1016/j.msard.2021.102972	study_information	NA	7	ct_arms	2 or more
10.1016/j.msard.2021.102972	study_information	NA	8	ipd_yn	No
10.1016/j.msard.2021.102972	study_information	NA	8	ct_yn	Yes
10.1016/j.msard.2021.102972	study_information	NA	8	nct	NCT00883337
10.1016/j.msard.2021.102972	study_information	NA	8	country_study	international
10.1016/j.msard.2021.102972	study_information	NA	8	ct_phase	3
10.1016/j.msard.2021.102972	study_information	NA	8	ct_arms	2 or more
10.1080/03007995.2016.1248380	general_information	NA	NA	condition_name	multiple sclerosis
10.1080/03007995.2016.1248380	general_information	NA	NA	country_first_author	usa
10.1080/03007995.2016.1248380	general_information	NA	NA	country_last_author	usa
10.1080/03007995.2016.1248380	general_information	NA	NA	positions	Academic, Pharmaceutical Industry
10.1080/03007995.2016.1248380	general_information	NA	NA	methodologist_yn	Not mentioned
10.1080/03007995.2016.1248380	general_information	NA	NA	funding_source	Pharmaceutical Industry
10.1080/03007995.2016.1248380	general_information	NA	NA	pharmaceutical_ties_yn	Yes
10.1080/03007995.2016.1248380	general_information	NA	NA	systematic_review_yn	No
10.1080/03007995.2016.1248380	methodology	1	NA	outcome_name	annualized relapse rate
10.1080/03007995.2016.1248380	methodology	1	NA	outcome_short_name	Annualized Relapse Rate
10.1080/03007995.2016.1248380	methodology	1	NA	outcome_variable_type	Binary (eg rates)
10.1080/03007995.2016.1248380	methodology	1	NA	treatment_name_ipd	dimethyl fumarate
10.1080/03007995.2016.1248380	methodology	1	NA	studies_number_ipd	1;2
10.1080/03007995.2016.1248380	methodology	1	NA	treatment_name_nonipd	fingolimod
10.1080/03007995.2016.1248380	methodology	1	NA	studies_number_nonipd	3;4
10.1080/03007995.2016.1248380	methodology	1	NA	paic_type	MAIC
10.1080/03007995.2016.1248380	methodology	1	NA	anchored_yn	Yes
10.1080/03007995.2016.1248380	methodology	1	NA	paic_form	Aggregation of multiple studies to estimate individual treatment effects (e.g. meta-analysis in a first step to estimate treatment A effect, then population adjusted indirect comparison using treatment A effect estimate)
10.1080/03007995.2016.1248380	methodology	1	NA	primary_outcome_yn	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.1080/03007995.2016.1248380	methodology	1	NA	variables_selection_justification	Nothing mentioned, not reported
10.1080/03007995.2016.1248380	methodology	1	NA	pf_yn	No discussion (in the main text) of the status of prognostic factors of the variables
10.1080/03007995.2016.1248380	methodology	1	NA	tem_yn	No discussion (in the main text) of the status of treatment-effect modifiers of the variables
10.1080/03007995.2016.1248380	methodology	1	NA	adjustment_model_details_yn	No
10.1080/03007995.2016.1248380	methodology	1	NA	scale_choice_yn	No
10.1080/03007995.2016.1248380	results	1	NA	contrast_effect_type	RR
10.1080/03007995.2016.1248380	results	1	NA	direction_benefit	inferior
10.1080/03007995.2016.1248380	results	1	NA	ss_ttt_nonipd	783
10.1080/03007995.2016.1248380	results	1	NA	ss_ttt_ipd	769
10.1080/03007995.2016.1248380	results	1	NA	ss_adjusted_ttt_ipd	587
10.1080/03007995.2016.1248380	results	1	NA	weights_yn	Not mentioned
10.1080/03007995.2016.1248380	results	1	NA	covariates_yn	Yes
10.1080/03007995.2016.1248380	results	1	NA	covariates_n	6
10.1080/03007995.2016.1248380	results	1	NA	covariates_names	Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Past treatments for the disease of interest
10.1080/03007995.2016.1248380	results	1	NA	contrast_effect_direction	Numerator if ratio, or left side if difference
10.1080/03007995.2016.1248380	results	1	NA	contrast_effect_unadjusted_value	1.07
10.1080/03007995.2016.1248380	results	1	NA	contrast_effect_unadjusted_pvalci	0.5501
10.1080/03007995.2016.1248380	results	1	NA	contrast_effect_adjusted_value	1.11
10.1080/03007995.2016.1248380	results	1	NA	contrast_effect_adjusted_pvalci	0.3893
10.1080/03007995.2016.1248380	results	1	NA	adjustment_geographical	NA
10.1080/03007995.2016.1248380	results	1	NA	ss_total_ipd	NA
10.1080/03007995.2016.1248380	results	1	NA	ss_adjusted_total_ipd	NA
10.1080/03007995.2016.1248380	results	1	NA	ss_total_nonipd	NA
10.1080/03007995.2016.1248380	results	1	NA	ss_anchor_nonipd	773
10.1080/03007995.2016.1248380	results	1	NA	ss_anchor_ipd	771
10.1080/03007995.2016.1248380	results	1	NA	ss_adjusted_anchor_ipd	599
10.1080/03007995.2016.1248380	results	1	NA	effect_cutoff	1
10.1080/03007995.2016.1248380	results	1	NA	unadjusted_pval	0.5501
10.1080/03007995.2016.1248380	results	1	NA	unadjusted_num_pval	0.5501
10.1080/03007995.2016.1248380	results	1	NA	unadjusted_significant	FALSE
10.1080/03007995.2016.1248380	results	1	NA	adjusted_pval	0.3893
10.1080/03007995.2016.1248380	results	1	NA	adjusted_num_pval	0.3893
10.1080/03007995.2016.1248380	results	1	NA	adjusted_significant	FALSE
10.1080/03007995.2016.1248380	study_information	NA	1	ipd_yn	Yes
10.1080/03007995.2016.1248380	study_information	NA	1	ct_yn	Yes
10.1080/03007995.2016.1248380	study_information	NA	1	nct	NCT00420212
10.1080/03007995.2016.1248380	study_information	NA	1	country_study	international
10.1080/03007995.2016.1248380	study_information	NA	1	ct_phase	3
10.1080/03007995.2016.1248380	study_information	NA	1	ct_arms	2 or more
10.1080/03007995.2016.1248380	study_information	NA	2	ipd_yn	Yes
10.1080/03007995.2016.1248380	study_information	NA	2	ct_yn	Yes
10.1080/03007995.2016.1248380	study_information	NA	2	nct	NCT00451451
10.1080/03007995.2016.1248380	study_information	NA	2	country_study	international
10.1080/03007995.2016.1248380	study_information	NA	2	ct_phase	3
10.1080/03007995.2016.1248380	study_information	NA	2	ct_arms	2 or more
10.1080/03007995.2016.1248380	study_information	NA	3	ipd_yn	No
10.1080/03007995.2016.1248380	study_information	NA	3	ct_yn	Yes
10.1080/03007995.2016.1248380	study_information	NA	3	nct	NCT00289978
10.1080/03007995.2016.1248380	study_information	NA	3	country_study	international
10.1080/03007995.2016.1248380	study_information	NA	3	ct_phase	3
10.1080/03007995.2016.1248380	study_information	NA	3	ct_arms	2 or more
10.1080/03007995.2016.1248380	study_information	NA	4	ipd_yn	No
10.1080/03007995.2016.1248380	study_information	NA	4	ct_yn	Yes
10.1080/03007995.2016.1248380	study_information	NA	4	nct	NCT00355134
10.1080/03007995.2016.1248380	study_information	NA	4	country_study	international
10.1080/03007995.2016.1248380	study_information	NA	4	ct_phase	3
10.1080/03007995.2016.1248380	study_information	NA	4	ct_arms	2 or more
10.1080/03007995.2018.1510225	general_information	NA	NA	condition_name	chronic phase chronic myeloid leukemia
10.1080/03007995.2018.1510225	general_information	NA	NA	country_first_author	usa
10.1080/03007995.2018.1510225	general_information	NA	NA	country_last_author	italy
10.1080/03007995.2018.1510225	general_information	NA	NA	positions	Academic, Pharmaceutical Industry, Private Data Analysis Company
10.1080/03007995.2018.1510225	general_information	NA	NA	methodologist_yn	Yes
10.1080/03007995.2018.1510225	general_information	NA	NA	funding_source	Pharmaceutical Industry
10.1080/03007995.2018.1510225	general_information	NA	NA	pharmaceutical_ties_yn	Yes
10.1080/03007995.2018.1510225	general_information	NA	NA	systematic_review_yn	No
10.1080/03007995.2018.1510225	methodology	1	NA	outcome_name	cytogenetic response rate
10.1080/03007995.2018.1510225	methodology	1	NA	outcome_short_name	Cytogenetic Response Rate
10.1080/03007995.2018.1510225	methodology	1	NA	outcome_variable_type	Binary (eg rates)
10.1080/03007995.2018.1510225	methodology	1	NA	treatment_name_ipd	ponatinib
10.1080/03007995.2018.1510225	methodology	1	NA	studies_number_ipd	1
10.1080/03007995.2018.1510225	methodology	1	NA	treatment_name_nonipd	bosutinib
10.1080/03007995.2018.1510225	methodology	1	NA	studies_number_nonipd	2
10.1080/03007995.2018.1510225	methodology	1	NA	paic_type	MAIC
10.1080/03007995.2018.1510225	methodology	1	NA	anchored_yn	No
10.1080/03007995.2018.1510225	methodology	1	NA	paic_form	Simple (ie treatments effects extracted from two studies)
10.1080/03007995.2018.1510225	methodology	1	NA	primary_outcome_yn	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.1080/03007995.2018.1510225	methodology	1	NA	variables_selection_justification	Nothing mentioned, not reported
10.1080/03007995.2018.1510225	methodology	1	NA	pf_yn	No discussion (in the main text) of the status of prognostic factors of the variables
10.1080/03007995.2018.1510225	methodology	1	NA	tem_yn	No discussion (in the main text) of the status of treatment-effect modifiers of the variables
10.1080/03007995.2018.1510225	methodology	1	NA	adjustment_model_details_yn	No
10.1080/03007995.2018.1510225	methodology	1	NA	scale_choice_yn	No
10.1080/03007995.2018.1510225	results	1	NA	contrast_effect_type	NA
10.1080/03007995.2018.1510225	results	1	NA	direction_benefit	superior
10.1080/03007995.2018.1510225	results	1	NA	ss_ttt_nonipd	119
10.1080/03007995.2018.1510225	results	1	NA	ss_ttt_ipd	97
10.1080/03007995.2018.1510225	results	1	NA	ss_adjusted_ttt_ipd	70
10.1080/03007995.2018.1510225	results	1	NA	weights_yn	Not mentioned
10.1080/03007995.2018.1510225	results	1	NA	covariates_yn	Yes
10.1080/03007995.2018.1510225	results	1	NA	covariates_n	6
10.1080/03007995.2018.1510225	results	1	NA	covariates_names	Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Race/ethnicity, Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...)
10.1080/03007995.2018.1510225	results	1	NA	contrast_effect_direction	NA
10.1080/03007995.2018.1510225	results	1	NA	contrast_effect_unadjusted_value	NA
10.1080/03007995.2018.1510225	results	1	NA	contrast_effect_unadjusted_pvalci	NA
10.1080/03007995.2018.1510225	results	1	NA	contrast_effect_adjusted_value	NA
10.1080/03007995.2018.1510225	results	1	NA	contrast_effect_adjusted_pvalci	NA
10.1080/03007995.2018.1510225	results	1	NA	adjustment_geographical	NA
10.1080/03007995.2018.1510225	results	1	NA	ss_total_ipd	NA
10.1080/03007995.2018.1510225	results	1	NA	ss_adjusted_total_ipd	NA
10.1080/03007995.2018.1510225	results	1	NA	ss_total_nonipd	NA
10.1080/03007995.2018.1510225	results	1	NA	ss_anchor_nonipd	NA
10.1080/03007995.2018.1510225	results	1	NA	ss_anchor_ipd	NA
10.1080/03007995.2018.1510225	results	1	NA	ss_adjusted_anchor_ipd	NA
10.1080/03007995.2018.1510225	results	1	NA	effect_cutoff	NA
10.1080/03007995.2018.1510225	study_information	NA	1	ipd_yn	Yes
10.1080/03007995.2018.1510225	study_information	NA	1	ct_yn	Yes
10.1080/03007995.2018.1510225	study_information	NA	1	nct	NCT01207440
10.1080/03007995.2018.1510225	study_information	NA	1	country_study	international
10.1080/03007995.2018.1510225	study_information	NA	1	ct_phase	2
10.1080/03007995.2018.1510225	study_information	NA	1	ct_arms	1
10.1080/03007995.2018.1510225	study_information	NA	2	ipd_yn	No
10.1080/03007995.2018.1510225	study_information	NA	2	ct_yn	Yes
10.1080/03007995.2018.1510225	study_information	NA	2	nct	NCT00261846
10.1080/03007995.2018.1510225	study_information	NA	2	country_study	international
10.1080/03007995.2018.1510225	study_information	NA	2	ct_phase	1, 2
10.1080/03007995.2018.1510225	study_information	NA	2	ct_arms	1
10.1080/03007995.2018.1520696	general_information	NA	NA	condition_name	anaplastic lymphoma kinase-positive non-small cell lung cancer
10.1080/03007995.2018.1520696	general_information	NA	NA	country_first_author	usa
10.1080/03007995.2018.1520696	general_information	NA	NA	country_last_author	usa
10.1080/03007995.2018.1520696	general_information	NA	NA	positions	Academic, Pharmaceutical Industry, Private Data Analysis Company
10.1080/03007995.2018.1520696	general_information	NA	NA	methodologist_yn	Yes
10.1080/03007995.2018.1520696	general_information	NA	NA	funding_source	Pharmaceutical Industry
10.1080/03007995.2018.1520696	general_information	NA	NA	pharmaceutical_ties_yn	Yes
10.1080/03007995.2018.1520696	general_information	NA	NA	systematic_review_yn	No
10.1080/03007995.2018.1520696	methodology	1	NA	outcome_name	objective response rate
10.1080/03007995.2018.1520696	methodology	1	NA	outcome_short_name	Objective Response Rate
10.1080/03007995.2018.1520696	methodology	1	NA	outcome_variable_type	Binary (eg rates)
10.1080/03007995.2018.1520696	methodology	1	NA	treatment_name_ipd	brigatinib
10.1080/03007995.2018.1520696	methodology	1	NA	studies_number_ipd	1
10.1080/03007995.2018.1520696	methodology	1	NA	treatment_name_nonipd	ceritinib
10.1080/03007995.2018.1520696	methodology	1	NA	studies_number_nonipd	2
10.1080/03007995.2018.1520696	methodology	1	NA	paic_type	MAIC
10.1080/03007995.2018.1520696	methodology	1	NA	anchored_yn	No
10.1080/03007995.2018.1520696	methodology	1	NA	paic_form	Simple (ie treatments effects extracted from two studies)
10.1080/03007995.2018.1520696	methodology	1	NA	primary_outcome_yn	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.1080/03007995.2018.1520696	methodology	1	NA	variables_selection_justification	A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion), Literature based (clinically or methodologically relevant to adjust on these variables based on the literature search conducted for this specific purpose)
10.1080/03007995.2018.1520696	methodology	1	NA	pf_yn	Yes
10.1080/03007995.2018.1520696	methodology	1	NA	tem_yn	Yes
10.1080/03007995.2018.1520696	methodology	1	NA	adjustment_model_details_yn	No
10.1080/03007995.2018.1520696	methodology	1	NA	scale_choice_yn	No
10.1080/03007995.2018.1520696	methodology	2	NA	outcome_name	objective response rate
10.1080/03007995.2018.1520696	methodology	2	NA	outcome_short_name	Objective Response Rate
10.1080/03007995.2018.1520696	methodology	2	NA	outcome_variable_type	Binary (eg rates)
10.1080/03007995.2018.1520696	methodology	2	NA	treatment_name_ipd	brigatinib
10.1080/03007995.2018.1520696	methodology	2	NA	studies_number_ipd	1
10.1080/03007995.2018.1520696	methodology	2	NA	treatment_name_nonipd	ceritinib
10.1080/03007995.2018.1520696	methodology	2	NA	studies_number_nonipd	3
10.1080/03007995.2018.1520696	methodology	2	NA	paic_type	MAIC
10.1080/03007995.2018.1520696	methodology	2	NA	anchored_yn	No
10.1080/03007995.2018.1520696	methodology	2	NA	paic_form	Simple (ie treatments effects extracted from two studies)
10.1080/03007995.2018.1520696	methodology	2	NA	primary_outcome_yn	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.1080/03007995.2018.1520696	methodology	2	NA	variables_selection_justification	A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion), Literature based (clinically or methodologically relevant to adjust on these variables based on the literature search conducted for this specific purpose)
10.1080/03007995.2018.1520696	methodology	2	NA	pf_yn	Yes
10.1080/03007995.2018.1520696	methodology	2	NA	tem_yn	Yes
10.1080/03007995.2018.1520696	methodology	2	NA	adjustment_model_details_yn	No
10.1080/03007995.2018.1520696	methodology	2	NA	scale_choice_yn	No
10.1080/03007995.2018.1520696	methodology	3	NA	outcome_name	objective response rate
10.1080/03007995.2018.1520696	methodology	3	NA	outcome_short_name	Objective Response Rate
10.1080/03007995.2018.1520696	methodology	3	NA	outcome_variable_type	Binary (eg rates)
10.1080/03007995.2018.1520696	methodology	3	NA	treatment_name_ipd	brigatinib
10.1080/03007995.2018.1520696	methodology	3	NA	studies_number_ipd	1
10.1080/03007995.2018.1520696	methodology	3	NA	treatment_name_nonipd	alectinib
10.1080/03007995.2018.1520696	methodology	3	NA	studies_number_nonipd	4
10.1080/03007995.2018.1520696	methodology	3	NA	paic_type	MAIC
10.1080/03007995.2018.1520696	methodology	3	NA	anchored_yn	No
10.1080/03007995.2018.1520696	methodology	3	NA	paic_form	Simple (ie treatments effects extracted from two studies)
10.1080/03007995.2018.1520696	methodology	3	NA	primary_outcome_yn	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.1080/03007995.2018.1520696	methodology	3	NA	variables_selection_justification	A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion), Literature based (clinically or methodologically relevant to adjust on these variables based on the literature search conducted for this specific purpose)
10.1080/03007995.2018.1520696	methodology	3	NA	pf_yn	Yes
10.1080/03007995.2018.1520696	methodology	3	NA	tem_yn	Yes
10.1080/03007995.2018.1520696	methodology	3	NA	adjustment_model_details_yn	No
10.1080/03007995.2018.1520696	methodology	3	NA	scale_choice_yn	No
10.1080/03007995.2018.1520696	methodology	4	NA	outcome_name	objective response rate
10.1080/03007995.2018.1520696	methodology	4	NA	outcome_short_name	Objective Response Rate
10.1080/03007995.2018.1520696	methodology	4	NA	outcome_variable_type	Binary (eg rates)
10.1080/03007995.2018.1520696	methodology	4	NA	treatment_name_ipd	brigatinib
10.1080/03007995.2018.1520696	methodology	4	NA	studies_number_ipd	1
10.1080/03007995.2018.1520696	methodology	4	NA	treatment_name_nonipd	alectinib
10.1080/03007995.2018.1520696	methodology	4	NA	studies_number_nonipd	5
10.1080/03007995.2018.1520696	methodology	4	NA	paic_type	MAIC
10.1080/03007995.2018.1520696	methodology	4	NA	anchored_yn	No
10.1080/03007995.2018.1520696	methodology	4	NA	paic_form	Simple (ie treatments effects extracted from two studies)
10.1080/03007995.2018.1520696	methodology	4	NA	primary_outcome_yn	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.1080/03007995.2018.1520696	methodology	4	NA	variables_selection_justification	A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion), Literature based (clinically or methodologically relevant to adjust on these variables based on the literature search conducted for this specific purpose)
10.1080/03007995.2018.1520696	methodology	4	NA	pf_yn	Yes
10.1080/03007995.2018.1520696	methodology	4	NA	tem_yn	Yes
10.1080/03007995.2018.1520696	methodology	4	NA	adjustment_model_details_yn	No
10.1080/03007995.2018.1520696	methodology	4	NA	scale_choice_yn	No
10.1080/03007995.2018.1520696	results	1	NA	contrast_effect_type	OR
10.1080/03007995.2018.1520696	results	1	NA	direction_benefit	superior
10.1080/03007995.2018.1520696	results	1	NA	ss_ttt_nonipd	163
10.1080/03007995.2018.1520696	results	1	NA	ss_ttt_ipd	110
10.1080/03007995.2018.1520696	results	1	NA	ss_adjusted_ttt_ipd	75.8
10.1080/03007995.2018.1520696	results	1	NA	weights_yn	Yes, mentions that the weights distribution has been studied, but weights distribution not reported
10.1080/03007995.2018.1520696	results	1	NA	covariates_yn	Yes
10.1080/03007995.2018.1520696	results	1	NA	covariates_n	7
10.1080/03007995.2018.1520696	results	1	NA	covariates_names	Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Race/ethnicity, Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Past treatments for the disease of interest, Other(s)
10.1080/03007995.2018.1520696	results	1	NA	contrast_effect_direction	Numerator if ratio, or left side if difference
10.1080/03007995.2018.1520696	results	1	NA	contrast_effect_unadjusted_value	0.96
10.1080/03007995.2018.1520696	results	1	NA	contrast_effect_unadjusted_pvalci	0.872
10.1080/03007995.2018.1520696	results	1	NA	contrast_effect_adjusted_value	0.88
10.1080/03007995.2018.1520696	results	1	NA	contrast_effect_adjusted_pvalci	0.659
10.1080/03007995.2018.1520696	results	1	NA	adjustment_geographical	No
10.1080/03007995.2018.1520696	results	1	NA	ss_total_ipd	NA
10.1080/03007995.2018.1520696	results	1	NA	ss_adjusted_total_ipd	NA
10.1080/03007995.2018.1520696	results	1	NA	ss_total_nonipd	NA
10.1080/03007995.2018.1520696	results	1	NA	ss_anchor_nonipd	NA
10.1080/03007995.2018.1520696	results	1	NA	ss_anchor_ipd	NA
10.1080/03007995.2018.1520696	results	1	NA	ss_adjusted_anchor_ipd	NA
10.1080/03007995.2018.1520696	results	1	NA	effect_cutoff	1
10.1080/03007995.2018.1520696	results	1	NA	unadjusted_pval	0.872
10.1080/03007995.2018.1520696	results	1	NA	unadjusted_num_pval	0.872
10.1080/03007995.2018.1520696	results	1	NA	unadjusted_significant	FALSE
10.1080/03007995.2018.1520696	results	1	NA	adjusted_pval	0.659
10.1080/03007995.2018.1520696	results	1	NA	adjusted_num_pval	0.659
10.1080/03007995.2018.1520696	results	1	NA	adjusted_significant	FALSE
10.1080/03007995.2018.1520696	results	2	NA	contrast_effect_type	OR
10.1080/03007995.2018.1520696	results	2	NA	direction_benefit	superior
10.1080/03007995.2018.1520696	results	2	NA	ss_ttt_nonipd	140
10.1080/03007995.2018.1520696	results	2	NA	ss_ttt_ipd	110
10.1080/03007995.2018.1520696	results	2	NA	ss_adjusted_ttt_ipd	50.8
10.1080/03007995.2018.1520696	results	2	NA	weights_yn	Yes, mentions that the weights distribution has been studied, but weights distribution not reported
10.1080/03007995.2018.1520696	results	2	NA	covariates_yn	Yes
10.1080/03007995.2018.1520696	results	2	NA	covariates_n	7
10.1080/03007995.2018.1520696	results	2	NA	covariates_names	Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Race/ethnicity, Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Past treatments for the disease of interest
10.1080/03007995.2018.1520696	results	2	NA	contrast_effect_direction	Numerator if ratio, or left side if difference
10.1080/03007995.2018.1520696	results	2	NA	contrast_effect_unadjusted_value	2.16
10.1080/03007995.2018.1520696	results	2	NA	contrast_effect_unadjusted_pvalci	0.003
10.1080/03007995.2018.1520696	results	2	NA	contrast_effect_adjusted_value	2.17
10.1080/03007995.2018.1520696	results	2	NA	contrast_effect_adjusted_pvalci	0.02
10.1080/03007995.2018.1520696	results	2	NA	adjustment_geographical	NA
10.1080/03007995.2018.1520696	results	2	NA	ss_total_ipd	NA
10.1080/03007995.2018.1520696	results	2	NA	ss_adjusted_total_ipd	NA
10.1080/03007995.2018.1520696	results	2	NA	ss_total_nonipd	NA
10.1080/03007995.2018.1520696	results	2	NA	ss_anchor_nonipd	NA
10.1080/03007995.2018.1520696	results	2	NA	ss_anchor_ipd	NA
10.1080/03007995.2018.1520696	results	2	NA	ss_adjusted_anchor_ipd	NA
10.1080/03007995.2018.1520696	results	2	NA	effect_cutoff	1
10.1080/03007995.2018.1520696	results	2	NA	unadjusted_pval	0.003
10.1080/03007995.2018.1520696	results	2	NA	unadjusted_num_pval	0.003
10.1080/03007995.2018.1520696	results	2	NA	unadjusted_significant	TRUE
10.1080/03007995.2018.1520696	results	2	NA	adjusted_pval	0.02
10.1080/03007995.2018.1520696	results	2	NA	adjusted_num_pval	0.02
10.1080/03007995.2018.1520696	results	2	NA	adjusted_significant	TRUE
10.1080/03007995.2018.1520696	results	3	NA	contrast_effect_type	OR
10.1080/03007995.2018.1520696	results	3	NA	direction_benefit	superior
10.1080/03007995.2018.1520696	results	3	NA	ss_ttt_nonipd	87
10.1080/03007995.2018.1520696	results	3	NA	ss_ttt_ipd	110
10.1080/03007995.2018.1520696	results	3	NA	ss_adjusted_ttt_ipd	77.5
10.1080/03007995.2018.1520696	results	3	NA	weights_yn	Yes, mentions that the weights distribution has been studied, but weights distribution not reported
10.1080/03007995.2018.1520696	results	3	NA	covariates_yn	Yes
10.1080/03007995.2018.1520696	results	3	NA	covariates_n	7
10.1080/03007995.2018.1520696	results	3	NA	covariates_names	Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Race/ethnicity, Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Past treatments for the disease of interest, Other(s)
10.1080/03007995.2018.1520696	results	3	NA	contrast_effect_direction	Numerator if ratio, or left side if difference
10.1080/03007995.2018.1520696	results	3	NA	contrast_effect_unadjusted_value	1.78
10.1080/03007995.2018.1520696	results	3	NA	contrast_effect_unadjusted_pvalci	0.047
10.1080/03007995.2018.1520696	results	3	NA	contrast_effect_adjusted_value	1.69
10.1080/03007995.2018.1520696	results	3	NA	contrast_effect_adjusted_pvalci	0.096
10.1080/03007995.2018.1520696	results	3	NA	adjustment_geographical	No
10.1080/03007995.2018.1520696	results	3	NA	ss_total_ipd	NA
10.1080/03007995.2018.1520696	results	3	NA	ss_adjusted_total_ipd	NA
10.1080/03007995.2018.1520696	results	3	NA	ss_total_nonipd	NA
10.1080/03007995.2018.1520696	results	3	NA	ss_anchor_nonipd	NA
10.1080/03007995.2018.1520696	results	3	NA	ss_anchor_ipd	NA
10.1080/03007995.2018.1520696	results	3	NA	ss_adjusted_anchor_ipd	NA
10.1080/03007995.2018.1520696	results	3	NA	effect_cutoff	1
10.1080/03007995.2018.1520696	results	3	NA	unadjusted_pval	0.047
10.1080/03007995.2018.1520696	results	3	NA	unadjusted_num_pval	0.047
10.1080/03007995.2018.1520696	results	3	NA	unadjusted_significant	TRUE
10.1080/03007995.2018.1520696	results	3	NA	adjusted_pval	0.096
10.1080/03007995.2018.1520696	results	3	NA	adjusted_num_pval	0.096
10.1080/03007995.2018.1520696	results	3	NA	adjusted_significant	FALSE
10.1080/03007995.2018.1520696	results	4	NA	contrast_effect_type	OR
10.1080/03007995.2018.1520696	results	4	NA	direction_benefit	superior
10.1080/03007995.2018.1520696	results	4	NA	ss_ttt_nonipd	138
10.1080/03007995.2018.1520696	results	4	NA	ss_ttt_ipd	110
10.1080/03007995.2018.1520696	results	4	NA	ss_adjusted_ttt_ipd	70.7
10.1080/03007995.2018.1520696	results	4	NA	weights_yn	Yes, mentions that the weights distribution has been studied, but weights distribution not reported
10.1080/03007995.2018.1520696	results	4	NA	covariates_yn	Yes
10.1080/03007995.2018.1520696	results	4	NA	covariates_n	8
10.1080/03007995.2018.1520696	results	4	NA	covariates_names	Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Race/ethnicity, Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Past treatments for the disease of interest, Other(s)
10.1080/03007995.2018.1520696	results	4	NA	contrast_effect_direction	Numerator if ratio, or left side if difference
10.1080/03007995.2018.1520696	results	4	NA	contrast_effect_unadjusted_value	1.47
10.1080/03007995.2018.1520696	results	4	NA	contrast_effect_unadjusted_pvalci	0.133
10.1080/03007995.2018.1520696	results	4	NA	contrast_effect_adjusted_value	1.44
10.1080/03007995.2018.1520696	results	4	NA	contrast_effect_adjusted_pvalci	0.212
10.1080/03007995.2018.1520696	results	4	NA	adjustment_geographical	No
10.1080/03007995.2018.1520696	results	4	NA	ss_total_ipd	NA
10.1080/03007995.2018.1520696	results	4	NA	ss_adjusted_total_ipd	NA
10.1080/03007995.2018.1520696	results	4	NA	ss_total_nonipd	NA
10.1080/03007995.2018.1520696	results	4	NA	ss_anchor_nonipd	NA
10.1080/03007995.2018.1520696	results	4	NA	ss_anchor_ipd	NA
10.1080/03007995.2018.1520696	results	4	NA	ss_adjusted_anchor_ipd	NA
10.1080/03007995.2018.1520696	results	4	NA	effect_cutoff	1
10.1080/03007995.2018.1520696	results	4	NA	unadjusted_pval	0.133
10.1080/03007995.2018.1520696	results	4	NA	unadjusted_num_pval	0.133
10.1080/03007995.2018.1520696	results	4	NA	unadjusted_significant	FALSE
10.1080/03007995.2018.1520696	results	4	NA	adjusted_pval	0.212
10.1080/03007995.2018.1520696	results	4	NA	adjusted_num_pval	0.212
10.1080/03007995.2018.1520696	results	4	NA	adjusted_significant	FALSE
10.1080/03007995.2018.1520696	study_information	NA	1	ipd_yn	Yes
10.1080/03007995.2018.1520696	study_information	NA	1	ct_yn	Yes
10.1080/03007995.2018.1520696	study_information	NA	1	nct	NCT02094573
10.1080/03007995.2018.1520696	study_information	NA	1	country_study	international
10.1080/03007995.2018.1520696	study_information	NA	1	ct_phase	2
10.1080/03007995.2018.1520696	study_information	NA	1	ct_arms	1
10.1080/03007995.2018.1520696	study_information	NA	2	ipd_yn	No
10.1080/03007995.2018.1520696	study_information	NA	2	ct_yn	Yes
10.1080/03007995.2018.1520696	study_information	NA	2	nct	NCT01283516
10.1080/03007995.2018.1520696	study_information	NA	2	country_study	international
10.1080/03007995.2018.1520696	study_information	NA	2	ct_phase	1
10.1080/03007995.2018.1520696	study_information	NA	2	ct_arms	1
10.1080/03007995.2018.1520696	study_information	NA	3	ipd_yn	No
10.1080/03007995.2018.1520696	study_information	NA	3	ct_yn	Yes
10.1080/03007995.2018.1520696	study_information	NA	3	nct	NCT01685060
10.1080/03007995.2018.1520696	study_information	NA	3	country_study	international
10.1080/03007995.2018.1520696	study_information	NA	3	ct_phase	2
10.1080/03007995.2018.1520696	study_information	NA	3	ct_arms	1
10.1080/03007995.2018.1520696	study_information	NA	4	ipd_yn	No
10.1080/03007995.2018.1520696	study_information	NA	4	ct_yn	Yes
10.1080/03007995.2018.1520696	study_information	NA	4	nct	NCT01871805
10.1080/03007995.2018.1520696	study_information	NA	4	country_study	international
10.1080/03007995.2018.1520696	study_information	NA	4	ct_phase	1, 2
10.1080/03007995.2018.1520696	study_information	NA	4	ct_arms	1
10.1080/03007995.2018.1520696	study_information	NA	5	ipd_yn	No
10.1080/03007995.2018.1520696	study_information	NA	5	ct_yn	Yes
10.1080/03007995.2018.1520696	study_information	NA	5	nct	NCT01801111
10.1080/03007995.2018.1520696	study_information	NA	5	country_study	international
10.1080/03007995.2018.1520696	study_information	NA	5	ct_phase	1, 2
10.1080/03007995.2018.1520696	study_information	NA	5	ct_arms	1
10.1080/03007995.2018.1541443	general_information	NA	NA	condition_name	advanced anaplastic lymphoma kinase (alk)-positive non-small cell lung cancer
10.1080/03007995.2018.1541443	general_information	NA	NA	country_first_author	usa
10.1080/03007995.2018.1541443	general_information	NA	NA	country_last_author	usa
10.1080/03007995.2018.1541443	general_information	NA	NA	positions	Pharmaceutical Industry, Private Data Analysis Company
10.1080/03007995.2018.1541443	general_information	NA	NA	methodologist_yn	Yes
10.1080/03007995.2018.1541443	general_information	NA	NA	funding_source	Pharmaceutical Industry
10.1080/03007995.2018.1541443	general_information	NA	NA	pharmaceutical_ties_yn	Yes
10.1080/03007995.2018.1541443	general_information	NA	NA	systematic_review_yn	No
10.1080/03007995.2018.1541443	methodology	1	NA	outcome_name	progression-free survival
10.1080/03007995.2018.1541443	methodology	1	NA	outcome_short_name	Progression-free Survival
10.1080/03007995.2018.1541443	methodology	1	NA	outcome_variable_type	Time-to-event
10.1080/03007995.2018.1541443	methodology	1	NA	treatment_name_ipd	ceritinib
10.1080/03007995.2018.1541443	methodology	1	NA	studies_number_ipd	1
10.1080/03007995.2018.1541443	methodology	1	NA	treatment_name_nonipd	crizotinib
10.1080/03007995.2018.1541443	methodology	1	NA	studies_number_nonipd	2
10.1080/03007995.2018.1541443	methodology	1	NA	paic_type	MAIC
10.1080/03007995.2018.1541443	methodology	1	NA	anchored_yn	No
10.1080/03007995.2018.1541443	methodology	1	NA	paic_form	Simple (ie treatments effects extracted from two studies)
10.1080/03007995.2018.1541443	methodology	1	NA	primary_outcome_yn	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.1080/03007995.2018.1541443	methodology	1	NA	variables_selection_justification	Nothing mentioned, not reported
10.1080/03007995.2018.1541443	methodology	1	NA	pf_yn	Yes
10.1080/03007995.2018.1541443	methodology	1	NA	tem_yn	No discussion (in the main text) of the status of treatment-effect modifiers of the variables
10.1080/03007995.2018.1541443	methodology	1	NA	adjustment_model_details_yn	No
10.1080/03007995.2018.1541443	methodology	1	NA	scale_choice_yn	No
10.1080/03007995.2018.1541443	results	1	NA	contrast_effect_type	HR
10.1080/03007995.2018.1541443	results	1	NA	direction_benefit	inferior
10.1080/03007995.2018.1541443	results	1	NA	ss_ttt_nonipd	172
10.1080/03007995.2018.1541443	results	1	NA	ss_ttt_ipd	189
10.1080/03007995.2018.1541443	results	1	NA	ss_adjusted_ttt_ipd	NA
10.1080/03007995.2018.1541443	results	1	NA	weights_yn	Yes, mentions that the weights distribution has been studied, and weights distribution reported in main article or supplemental materials
10.1080/03007995.2018.1541443	results	1	NA	covariates_yn	Yes
10.1080/03007995.2018.1541443	results	1	NA	covariates_n	8
10.1080/03007995.2018.1541443	results	1	NA	covariates_names	Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Race/ethnicity, Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Comorbidities and medical history (beside pathology/disease of interest in the comparison)
10.1080/03007995.2018.1541443	results	1	NA	contrast_effect_direction	Numerator if ratio, or left side if difference
10.1080/03007995.2018.1541443	results	1	NA	contrast_effect_unadjusted_value	0.68
10.1080/03007995.2018.1541443	results	1	NA	contrast_effect_unadjusted_pvalci	0.01
10.1080/03007995.2018.1541443	results	1	NA	contrast_effect_adjusted_value	0.64
10.1080/03007995.2018.1541443	results	1	NA	contrast_effect_adjusted_pvalci	0.004
10.1080/03007995.2018.1541443	results	1	NA	adjustment_geographical	NA
10.1080/03007995.2018.1541443	results	1	NA	ss_total_ipd	NA
10.1080/03007995.2018.1541443	results	1	NA	ss_adjusted_total_ipd	NA
10.1080/03007995.2018.1541443	results	1	NA	ss_total_nonipd	NA
10.1080/03007995.2018.1541443	results	1	NA	ss_anchor_nonipd	NA
10.1080/03007995.2018.1541443	results	1	NA	ss_anchor_ipd	NA
10.1080/03007995.2018.1541443	results	1	NA	ss_adjusted_anchor_ipd	NA
10.1080/03007995.2018.1541443	results	1	NA	effect_cutoff	1
10.1080/03007995.2018.1541443	results	1	NA	unadjusted_pval	0.01
10.1080/03007995.2018.1541443	results	1	NA	unadjusted_num_pval	0.01
10.1080/03007995.2018.1541443	results	1	NA	unadjusted_significant	TRUE
10.1080/03007995.2018.1541443	results	1	NA	adjusted_pval	0.004
10.1080/03007995.2018.1541443	results	1	NA	adjusted_num_pval	0.004
10.1080/03007995.2018.1541443	results	1	NA	adjusted_significant	TRUE
10.1080/03007995.2018.1541443	study_information	NA	1	ipd_yn	Yes
10.1080/03007995.2018.1541443	study_information	NA	1	ct_yn	Yes
10.1080/03007995.2018.1541443	study_information	NA	1	nct	NCT01828099
10.1080/03007995.2018.1541443	study_information	NA	1	country_study	international
10.1080/03007995.2018.1541443	study_information	NA	1	ct_phase	3
10.1080/03007995.2018.1541443	study_information	NA	1	ct_arms	2 or more
10.1080/03007995.2018.1541443	study_information	NA	2	ipd_yn	No
10.1080/03007995.2018.1541443	study_information	NA	2	ct_yn	Yes
10.1080/03007995.2018.1541443	study_information	NA	2	nct	NCT01154140
10.1080/03007995.2018.1541443	study_information	NA	2	country_study	international
10.1080/03007995.2018.1541443	study_information	NA	2	ct_phase	3
10.1080/03007995.2018.1541443	study_information	NA	2	ct_arms	2 or more
10.1080/03007995.2019.1585779	general_information	NA	NA	condition_name	active relapsing-remitting multiple sclerosis
10.1080/03007995.2019.1585779	general_information	NA	NA	country_first_author	uk
10.1080/03007995.2019.1585779	general_information	NA	NA	country_last_author	usa
10.1080/03007995.2019.1585779	general_information	NA	NA	positions	Pharmaceutical Industry, Private Data Analysis Company
10.1080/03007995.2019.1585779	general_information	NA	NA	methodologist_yn	Yes
10.1080/03007995.2019.1585779	general_information	NA	NA	funding_source	Pharmaceutical Industry
10.1080/03007995.2019.1585779	general_information	NA	NA	pharmaceutical_ties_yn	Yes
10.1080/03007995.2019.1585779	general_information	NA	NA	systematic_review_yn	Yes
10.1080/03007995.2019.1585779	methodology	1	NA	outcome_name	confirmed disability progression
10.1080/03007995.2019.1585779	methodology	1	NA	outcome_short_name	Confirmed Disability Progression
10.1080/03007995.2019.1585779	methodology	1	NA	outcome_variable_type	Time-to-event
10.1080/03007995.2019.1585779	methodology	1	NA	treatment_name_ipd	cladribine
10.1080/03007995.2019.1585779	methodology	1	NA	studies_number_ipd	1
10.1080/03007995.2019.1585779	methodology	1	NA	treatment_name_nonipd	alemtuzumab
10.1080/03007995.2019.1585779	methodology	1	NA	studies_number_nonipd	2
10.1080/03007995.2019.1585779	methodology	1	NA	paic_type	MAIC
10.1080/03007995.2019.1585779	methodology	1	NA	anchored_yn	No
10.1080/03007995.2019.1585779	methodology	1	NA	paic_form	Simple (ie treatments effects extracted from two studies)
10.1080/03007995.2019.1585779	methodology	1	NA	primary_outcome_yn	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.1080/03007995.2019.1585779	methodology	1	NA	variables_selection_justification	Nothing mentioned, not reported
10.1080/03007995.2019.1585779	methodology	1	NA	pf_yn	No discussion (in the main text) of the status of prognostic factors of the variables
10.1080/03007995.2019.1585779	methodology	1	NA	tem_yn	No discussion (in the main text) of the status of treatment-effect modifiers of the variables
10.1080/03007995.2019.1585779	methodology	1	NA	adjustment_model_details_yn	No
10.1080/03007995.2019.1585779	methodology	1	NA	scale_choice_yn	No
10.1080/03007995.2019.1585779	results	1	NA	contrast_effect_type	HR
10.1080/03007995.2019.1585779	results	1	NA	direction_benefit	inferior
10.1080/03007995.2019.1585779	results	1	NA	ss_ttt_nonipd	426
10.1080/03007995.2019.1585779	results	1	NA	ss_ttt_ipd	113
10.1080/03007995.2019.1585779	results	1	NA	ss_adjusted_ttt_ipd	41
10.1080/03007995.2019.1585779	results	1	NA	weights_yn	Yes, mentions that the weights distribution has been studied, but weights distribution not reported
10.1080/03007995.2019.1585779	results	1	NA	covariates_yn	Yes
10.1080/03007995.2019.1585779	results	1	NA	covariates_n	6
10.1080/03007995.2019.1585779	results	1	NA	covariates_names	Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Past treatments for the disease of interest
10.1080/03007995.2019.1585779	results	1	NA	contrast_effect_direction	Numerator if ratio, or left side if difference
10.1080/03007995.2019.1585779	results	1	NA	contrast_effect_unadjusted_value	0.96
10.1080/03007995.2019.1585779	results	1	NA	contrast_effect_unadjusted_pvalci	[0.51;1.80]
10.1080/03007995.2019.1585779	results	1	NA	contrast_effect_adjusted_value	1
10.1080/03007995.2019.1585779	results	1	NA	contrast_effect_adjusted_pvalci	[0.44;2.27]
10.1080/03007995.2019.1585779	results	1	NA	adjustment_geographical	NA
10.1080/03007995.2019.1585779	results	1	NA	ss_total_ipd	NA
10.1080/03007995.2019.1585779	results	1	NA	ss_adjusted_total_ipd	NA
10.1080/03007995.2019.1585779	results	1	NA	ss_total_nonipd	NA
10.1080/03007995.2019.1585779	results	1	NA	ss_anchor_nonipd	NA
10.1080/03007995.2019.1585779	results	1	NA	ss_anchor_ipd	NA
10.1080/03007995.2019.1585779	results	1	NA	ss_adjusted_anchor_ipd	NA
10.1080/03007995.2019.1585779	results	1	NA	effect_cutoff	1
10.1080/03007995.2019.1585779	results	1	NA	unadjusted_lb_ci	0.51
10.1080/03007995.2019.1585779	results	1	NA	unadjusted_ub_ci	1.8
10.1080/03007995.2019.1585779	results	1	NA	unadjusted_significant	FALSE
10.1080/03007995.2019.1585779	results	1	NA	adjusted_lb_ci	0.44
10.1080/03007995.2019.1585779	results	1	NA	adjusted_ub_ci	2.27
10.1080/03007995.2019.1585779	results	1	NA	adjusted_significant	FALSE
10.1080/03007995.2019.1585779	study_information	NA	1	ipd_yn	Yes
10.1080/03007995.2019.1585779	study_information	NA	1	ct_yn	Yes
10.1080/03007995.2019.1585779	study_information	NA	1	nct	NCT00213135
10.1080/03007995.2019.1585779	study_information	NA	1	ct_phase	3
10.1080/03007995.2019.1585779	study_information	NA	1	ct_arms	2 or more
10.1080/03007995.2019.1585779	study_information	NA	1	country_study	international
10.1080/03007995.2019.1585779	study_information	NA	2	ipd_yn	No
10.1080/03007995.2019.1585779	study_information	NA	2	ct_yn	Yes
10.1080/03007995.2019.1585779	study_information	NA	2	nct	NCT00548405
10.1080/03007995.2019.1585779	study_information	NA	2	country_study	international
10.1080/03007995.2019.1585779	study_information	NA	2	ct_phase	3
10.1080/03007995.2019.1585779	study_information	NA	2	ct_arms	2 or more
10.1080/03007995.2019.1605239	general_information	NA	NA	condition_name	chronic phase chronic myeloid leukemia
10.1080/03007995.2019.1605239	general_information	NA	NA	country_first_author	usa
10.1080/03007995.2019.1605239	general_information	NA	NA	country_last_author	usa
10.1080/03007995.2019.1605239	general_information	NA	NA	positions	Academic, Pharmaceutical Industry, Private Data Analysis Company
10.1080/03007995.2019.1605239	general_information	NA	NA	methodologist_yn	Yes
10.1080/03007995.2019.1605239	general_information	NA	NA	funding_source	Pharmaceutical Industry
10.1080/03007995.2019.1605239	general_information	NA	NA	pharmaceutical_ties_yn	Yes
10.1080/03007995.2019.1605239	general_information	NA	NA	systematic_review_yn	Yes
10.1080/03007995.2019.1605239	methodology	1	NA	outcome_name	overall survival
10.1080/03007995.2019.1605239	methodology	1	NA	outcome_short_name	Overall Survival
10.1080/03007995.2019.1605239	methodology	1	NA	outcome_variable_type	Time-to-event
10.1080/03007995.2019.1605239	methodology	1	NA	treatment_name_ipd	bosutinib
10.1080/03007995.2019.1605239	methodology	1	NA	studies_number_ipd	1
10.1080/03007995.2019.1605239	methodology	1	NA	treatment_name_nonipd	dasatinib
10.1080/03007995.2019.1605239	methodology	1	NA	studies_number_nonipd	2
10.1080/03007995.2019.1605239	methodology	1	NA	paic_type	MAIC
10.1080/03007995.2019.1605239	methodology	1	NA	anchored_yn	No
10.1080/03007995.2019.1605239	methodology	1	NA	paic_form	Simple (ie treatments effects extracted from two studies)
10.1080/03007995.2019.1605239	methodology	1	NA	primary_outcome_yn	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.1080/03007995.2019.1605239	methodology	1	NA	variables_selection_justification	Status of prognostic factor/treatment effect modified assessed in the IPD dataset
10.1080/03007995.2019.1605239	methodology	1	NA	pf_yn	No discussion (in the main text) of the status of prognostic factors of the variables
10.1080/03007995.2019.1605239	methodology	1	NA	tem_yn	No discussion (in the main text) of the status of treatment-effect modifiers of the variables
10.1080/03007995.2019.1605239	methodology	1	NA	adjustment_model_details_yn	No
10.1080/03007995.2019.1605239	methodology	1	NA	scale_choice_yn	Yes
10.1080/03007995.2019.1605239	methodology	2	NA	outcome_name	overall survival
10.1080/03007995.2019.1605239	methodology	2	NA	outcome_short_name	Overall Survival
10.1080/03007995.2019.1605239	methodology	2	NA	outcome_variable_type	Time-to-event
10.1080/03007995.2019.1605239	methodology	2	NA	treatment_name_ipd	bosutinib
10.1080/03007995.2019.1605239	methodology	2	NA	studies_number_ipd	1
10.1080/03007995.2019.1605239	methodology	2	NA	treatment_name_nonipd	nilotinib
10.1080/03007995.2019.1605239	methodology	2	NA	studies_number_nonipd	3
10.1080/03007995.2019.1605239	methodology	2	NA	paic_type	MAIC
10.1080/03007995.2019.1605239	methodology	2	NA	anchored_yn	No
10.1080/03007995.2019.1605239	methodology	2	NA	paic_form	Simple (ie treatments effects extracted from two studies)
10.1080/03007995.2019.1605239	methodology	2	NA	primary_outcome_yn	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.1080/03007995.2019.1605239	methodology	2	NA	variables_selection_justification	Status of prognostic factor/treatment effect modified assessed in the IPD dataset
10.1080/03007995.2019.1605239	methodology	2	NA	pf_yn	No discussion (in the main text) of the status of prognostic factors of the variables
10.1080/03007995.2019.1605239	methodology	2	NA	tem_yn	No discussion (in the main text) of the status of treatment-effect modifiers of the variables
10.1080/03007995.2019.1605239	methodology	2	NA	adjustment_model_details_yn	No
10.1080/03007995.2019.1605239	methodology	2	NA	scale_choice_yn	Yes
10.1080/03007995.2019.1605239	results	1	NA	contrast_effect_type	HR
10.1080/03007995.2019.1605239	results	1	NA	direction_benefit	inferior
10.1080/03007995.2019.1605239	results	1	NA	ss_ttt_nonipd	167
10.1080/03007995.2019.1605239	results	1	NA	ss_ttt_ipd	283
10.1080/03007995.2019.1605239	results	1	NA	ss_adjusted_ttt_ipd	NA
10.1080/03007995.2019.1605239	results	1	NA	weights_yn	Not mentioned
10.1080/03007995.2019.1605239	results	1	NA	covariates_yn	Yes
10.1080/03007995.2019.1605239	results	1	NA	covariates_n	4
10.1080/03007995.2019.1605239	results	1	NA	covariates_names	Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Past treatments for the disease of interest
10.1080/03007995.2019.1605239	results	1	NA	contrast_effect_direction	Numerator if ratio, or left side if difference
10.1080/03007995.2019.1605239	results	1	NA	contrast_effect_unadjusted_value	NA
10.1080/03007995.2019.1605239	results	1	NA	contrast_effect_unadjusted_pvalci	NA
10.1080/03007995.2019.1605239	results	1	NA	contrast_effect_adjusted_value	0.82
10.1080/03007995.2019.1605239	results	1	NA	contrast_effect_adjusted_pvalci	0.37
10.1080/03007995.2019.1605239	results	1	NA	adjustment_geographical	No
10.1080/03007995.2019.1605239	results	1	NA	ss_total_ipd	NA
10.1080/03007995.2019.1605239	results	1	NA	ss_adjusted_total_ipd	NA
10.1080/03007995.2019.1605239	results	1	NA	ss_total_nonipd	NA
10.1080/03007995.2019.1605239	results	1	NA	ss_anchor_nonipd	NA
10.1080/03007995.2019.1605239	results	1	NA	ss_anchor_ipd	NA
10.1080/03007995.2019.1605239	results	1	NA	ss_adjusted_anchor_ipd	NA
10.1080/03007995.2019.1605239	results	1	NA	effect_cutoff	1
10.1080/03007995.2019.1605239	results	1	NA	adjusted_pval	0.37
10.1080/03007995.2019.1605239	results	1	NA	adjusted_num_pval	0.37
10.1080/03007995.2019.1605239	results	1	NA	adjusted_significant	FALSE
10.1080/03007995.2019.1605239	results	2	NA	contrast_effect_type	HR
10.1080/03007995.2019.1605239	results	2	NA	direction_benefit	inferior
10.1080/03007995.2019.1605239	results	2	NA	ss_ttt_nonipd	321
10.1080/03007995.2019.1605239	results	2	NA	ss_ttt_ipd	283
10.1080/03007995.2019.1605239	results	2	NA	ss_adjusted_ttt_ipd	NA
10.1080/03007995.2019.1605239	results	2	NA	weights_yn	Not mentioned
10.1080/03007995.2019.1605239	results	2	NA	covariates_yn	Yes
10.1080/03007995.2019.1605239	results	2	NA	covariates_n	3
10.1080/03007995.2019.1605239	results	2	NA	covariates_names	Age, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Past treatments for the disease of interest
10.1080/03007995.2019.1605239	results	2	NA	contrast_effect_direction	Numerator if ratio, or left side if difference
10.1080/03007995.2019.1605239	results	2	NA	contrast_effect_unadjusted_value	NA
10.1080/03007995.2019.1605239	results	2	NA	contrast_effect_unadjusted_pvalci	NA
10.1080/03007995.2019.1605239	results	2	NA	contrast_effect_adjusted_value	0.72
10.1080/03007995.2019.1605239	results	2	NA	contrast_effect_adjusted_pvalci	0.16
10.1080/03007995.2019.1605239	results	2	NA	adjustment_geographical	No
10.1080/03007995.2019.1605239	results	2	NA	ss_total_ipd	NA
10.1080/03007995.2019.1605239	results	2	NA	ss_adjusted_total_ipd	NA
10.1080/03007995.2019.1605239	results	2	NA	ss_total_nonipd	NA
10.1080/03007995.2019.1605239	results	2	NA	ss_anchor_nonipd	NA
10.1080/03007995.2019.1605239	results	2	NA	ss_anchor_ipd	NA
10.1080/03007995.2019.1605239	results	2	NA	ss_adjusted_anchor_ipd	NA
10.1080/03007995.2019.1605239	results	2	NA	effect_cutoff	1
10.1080/03007995.2019.1605239	results	2	NA	adjusted_pval	0.16
10.1080/03007995.2019.1605239	results	2	NA	adjusted_num_pval	0.16
10.1080/03007995.2019.1605239	results	2	NA	adjusted_significant	FALSE
10.1080/03007995.2019.1605239	study_information	NA	1	ipd_yn	Yes
10.1080/03007995.2019.1605239	study_information	NA	1	ct_yn	Yes
10.1080/03007995.2019.1605239	study_information	NA	1	nct	NCT00261846
10.1080/03007995.2019.1605239	study_information	NA	1	country_study	international
10.1080/03007995.2019.1605239	study_information	NA	1	ct_phase	1, 2
10.1080/03007995.2019.1605239	study_information	NA	1	ct_arms	1
10.1080/03007995.2019.1605239	study_information	NA	2	ipd_yn	No
10.1080/03007995.2019.1605239	study_information	NA	2	ct_yn	Yes
10.1080/03007995.2019.1605239	study_information	NA	2	nct	NCT00123474
10.1080/03007995.2019.1605239	study_information	NA	2	country_study	international
10.1080/03007995.2019.1605239	study_information	NA	2	ct_phase	3
10.1080/03007995.2019.1605239	study_information	NA	2	ct_arms	1
10.1080/03007995.2019.1605239	study_information	NA	3	ipd_yn	No
10.1080/03007995.2019.1605239	study_information	NA	3	ct_yn	Yes
10.1080/03007995.2019.1605239	study_information	NA	3	nct	NCT00109707
10.1080/03007995.2019.1605239	study_information	NA	3	country_study	international
10.1080/03007995.2019.1605239	study_information	NA	3	ct_phase	1, 2
10.1080/03007995.2019.1605239	study_information	NA	3	ct_arms	1
10.1080/03007995.2020.1747999	general_information	NA	NA	condition_name	secondary progressive multiple sclerosis
10.1080/03007995.2020.1747999	general_information	NA	NA	country_first_author	canada
10.1080/03007995.2020.1747999	general_information	NA	NA	country_last_author	switzerland
10.1080/03007995.2020.1747999	general_information	NA	NA	positions	Academic, Pharmaceutical Industry, Private Data Analysis Company
10.1080/03007995.2020.1747999	general_information	NA	NA	methodologist_yn	Yes
10.1080/03007995.2020.1747999	general_information	NA	NA	funding_source	Pharmaceutical Industry
10.1080/03007995.2020.1747999	general_information	NA	NA	pharmaceutical_ties_yn	Yes
10.1080/03007995.2020.1747999	general_information	NA	NA	systematic_review_yn	Yes
10.1080/03007995.2020.1747999	methodology	1	NA	outcome_name	time to confirmed disability progression at six months (cdp-6)
10.1080/03007995.2020.1747999	methodology	1	NA	outcome_short_name	Confirmed Disability Progression
10.1080/03007995.2020.1747999	methodology	1	NA	outcome_variable_type	Time-to-event
10.1080/03007995.2020.1747999	methodology	1	NA	treatment_name_ipd	siponimod
10.1080/03007995.2020.1747999	methodology	1	NA	studies_number_ipd	1
10.1080/03007995.2020.1747999	methodology	1	NA	treatment_name_nonipd	ifn-1b 250 g once every other day (q2d)
10.1080/03007995.2020.1747999	methodology	1	NA	studies_number_nonipd	4
10.1080/03007995.2020.1747999	methodology	1	NA	paic_type	MAIC
10.1080/03007995.2020.1747999	methodology	1	NA	anchored_yn	Yes
10.1080/03007995.2020.1747999	methodology	1	NA	paic_form	Simple (ie treatments effects extracted from two studies)
10.1080/03007995.2020.1747999	methodology	1	NA	primary_outcome_yn	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.1080/03007995.2020.1747999	methodology	1	NA	variables_selection_justification	Status of prognostic factor/treatment effect modified assessed in the IPD dataset, A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion)
10.1080/03007995.2020.1747999	methodology	1	NA	pf_yn	No
10.1080/03007995.2020.1747999	methodology	1	NA	tem_yn	Yes
10.1080/03007995.2020.1747999	methodology	1	NA	adjustment_model_details_yn	No
10.1080/03007995.2020.1747999	methodology	1	NA	scale_choice_yn	No
10.1080/03007995.2020.1747999	methodology	2	NA	outcome_name	time to confirmed disability progression at six months (cdp-6)
10.1080/03007995.2020.1747999	methodology	2	NA	outcome_short_name	Confirmed Disability Progression
10.1080/03007995.2020.1747999	methodology	2	NA	outcome_variable_type	Time-to-event
10.1080/03007995.2020.1747999	methodology	2	NA	treatment_name_ipd	siponimod
10.1080/03007995.2020.1747999	methodology	2	NA	studies_number_ipd	1
10.1080/03007995.2020.1747999	methodology	2	NA	treatment_name_nonipd	ifn-1a 22 g once weekly (qw)
10.1080/03007995.2020.1747999	methodology	2	NA	studies_number_nonipd	3
10.1080/03007995.2020.1747999	methodology	2	NA	paic_type	MAIC
10.1080/03007995.2020.1747999	methodology	2	NA	anchored_yn	Yes
10.1080/03007995.2020.1747999	methodology	2	NA	paic_form	Simple (ie treatments effects extracted from two studies)
10.1080/03007995.2020.1747999	methodology	2	NA	primary_outcome_yn	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.1080/03007995.2020.1747999	methodology	2	NA	variables_selection_justification	Status of prognostic factor/treatment effect modified assessed in the IPD dataset, A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion)
10.1080/03007995.2020.1747999	methodology	2	NA	pf_yn	No
10.1080/03007995.2020.1747999	methodology	2	NA	tem_yn	Yes
10.1080/03007995.2020.1747999	methodology	2	NA	adjustment_model_details_yn	No
10.1080/03007995.2020.1747999	methodology	2	NA	scale_choice_yn	No
10.1080/03007995.2020.1747999	methodology	3	NA	outcome_name	the proportion of patients who experienced cdp-6 (confirmed disability progression at six months) by 96 weeks based on an increase in edss alone
10.1080/03007995.2020.1747999	methodology	3	NA	outcome_short_name	Confirmed Disability Progression
10.1080/03007995.2020.1747999	methodology	3	NA	outcome_variable_type	Binary (eg rates)
10.1080/03007995.2020.1747999	methodology	3	NA	treatment_name_ipd	siponimod
10.1080/03007995.2020.1747999	methodology	3	NA	studies_number_ipd	1
10.1080/03007995.2020.1747999	methodology	3	NA	treatment_name_nonipd	natalizumab
10.1080/03007995.2020.1747999	methodology	3	NA	studies_number_nonipd	2
10.1080/03007995.2020.1747999	methodology	3	NA	paic_type	MAIC
10.1080/03007995.2020.1747999	methodology	3	NA	anchored_yn	Yes
10.1080/03007995.2020.1747999	methodology	3	NA	paic_form	Simple (ie treatments effects extracted from two studies)
10.1080/03007995.2020.1747999	methodology	3	NA	primary_outcome_yn	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.1080/03007995.2020.1747999	methodology	3	NA	variables_selection_justification	Status of prognostic factor/treatment effect modified assessed in the IPD dataset, A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion)
10.1080/03007995.2020.1747999	methodology	3	NA	pf_yn	No
10.1080/03007995.2020.1747999	methodology	3	NA	tem_yn	Yes
10.1080/03007995.2020.1747999	methodology	3	NA	adjustment_model_details_yn	No
10.1080/03007995.2020.1747999	methodology	3	NA	scale_choice_yn	No
10.1080/03007995.2020.1747999	methodology	4	NA	outcome_name	time to confirmed disability progression at three months (cdp-3)
10.1080/03007995.2020.1747999	methodology	4	NA	outcome_short_name	Confirmed Disability Progression
10.1080/03007995.2020.1747999	methodology	4	NA	outcome_variable_type	Time-to-event
10.1080/03007995.2020.1747999	methodology	4	NA	treatment_name_ipd	siponimod
10.1080/03007995.2020.1747999	methodology	4	NA	studies_number_ipd	1
10.1080/03007995.2020.1747999	methodology	4	NA	treatment_name_nonipd	sc ifn-1a 22 g three times weekly
10.1080/03007995.2020.1747999	methodology	4	NA	studies_number_nonipd	6
10.1080/03007995.2020.1747999	methodology	4	NA	paic_type	MAIC
10.1080/03007995.2020.1747999	methodology	4	NA	anchored_yn	Yes
10.1080/03007995.2020.1747999	methodology	4	NA	paic_form	Simple (ie treatments effects extracted from two studies)
10.1080/03007995.2020.1747999	methodology	4	NA	primary_outcome_yn	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.1080/03007995.2020.1747999	methodology	4	NA	variables_selection_justification	Status of prognostic factor/treatment effect modified assessed in the IPD dataset, A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion)
10.1080/03007995.2020.1747999	methodology	4	NA	pf_yn	No
10.1080/03007995.2020.1747999	methodology	4	NA	tem_yn	Yes
10.1080/03007995.2020.1747999	methodology	4	NA	adjustment_model_details_yn	No
10.1080/03007995.2020.1747999	methodology	4	NA	scale_choice_yn	No
10.1080/03007995.2020.1747999	methodology	5	NA	outcome_name	time to confirmed disability progression at three months (cdp-3)
10.1080/03007995.2020.1747999	methodology	5	NA	outcome_short_name	Confirmed Disability Progression
10.1080/03007995.2020.1747999	methodology	5	NA	outcome_variable_type	Time-to-event
10.1080/03007995.2020.1747999	methodology	5	NA	treatment_name_ipd	siponimod
10.1080/03007995.2020.1747999	methodology	5	NA	studies_number_ipd	1
10.1080/03007995.2020.1747999	methodology	5	NA	treatment_name_nonipd	sc ifn-1a 44 g three times weekly
10.1080/03007995.2020.1747999	methodology	5	NA	studies_number_nonipd	6
10.1080/03007995.2020.1747999	methodology	5	NA	paic_type	MAIC
10.1080/03007995.2020.1747999	methodology	5	NA	anchored_yn	Yes
10.1080/03007995.2020.1747999	methodology	5	NA	paic_form	Simple (ie treatments effects extracted from two studies)
10.1080/03007995.2020.1747999	methodology	5	NA	primary_outcome_yn	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.1080/03007995.2020.1747999	methodology	5	NA	variables_selection_justification	Status of prognostic factor/treatment effect modified assessed in the IPD dataset, A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion)
10.1080/03007995.2020.1747999	methodology	5	NA	pf_yn	No
10.1080/03007995.2020.1747999	methodology	5	NA	tem_yn	Yes
10.1080/03007995.2020.1747999	methodology	5	NA	adjustment_model_details_yn	No
10.1080/03007995.2020.1747999	methodology	5	NA	scale_choice_yn	No
10.1080/03007995.2020.1747999	methodology	6	NA	outcome_name	time to confirmed disability progression at three months (cdp-3)
10.1080/03007995.2020.1747999	methodology	6	NA	outcome_short_name	Confirmed Disability Progression
10.1080/03007995.2020.1747999	methodology	6	NA	outcome_variable_type	Time-to-event
10.1080/03007995.2020.1747999	methodology	6	NA	treatment_name_ipd	siponimod
10.1080/03007995.2020.1747999	methodology	6	NA	studies_number_ipd	1
10.1080/03007995.2020.1747999	methodology	6	NA	treatment_name_nonipd	ifn-1b 8 miu once every other day
10.1080/03007995.2020.1747999	methodology	6	NA	studies_number_nonipd	7
10.1080/03007995.2020.1747999	methodology	6	NA	paic_type	MAIC
10.1080/03007995.2020.1747999	methodology	6	NA	anchored_yn	Yes
10.1080/03007995.2020.1747999	methodology	6	NA	paic_form	Simple (ie treatments effects extracted from two studies)
10.1080/03007995.2020.1747999	methodology	6	NA	primary_outcome_yn	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.1080/03007995.2020.1747999	methodology	6	NA	variables_selection_justification	Status of prognostic factor/treatment effect modified assessed in the IPD dataset, A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion)
10.1080/03007995.2020.1747999	methodology	6	NA	pf_yn	No
10.1080/03007995.2020.1747999	methodology	6	NA	tem_yn	Yes
10.1080/03007995.2020.1747999	methodology	6	NA	adjustment_model_details_yn	No
10.1080/03007995.2020.1747999	methodology	6	NA	scale_choice_yn	No
10.1080/03007995.2020.1747999	methodology	7	NA	outcome_name	time to confirmed disability progression at three months (cdp-3)
10.1080/03007995.2020.1747999	methodology	7	NA	outcome_short_name	Confirmed Disability Progression
10.1080/03007995.2020.1747999	methodology	7	NA	outcome_variable_type	Time-to-event
10.1080/03007995.2020.1747999	methodology	7	NA	treatment_name_ipd	siponimod
10.1080/03007995.2020.1747999	methodology	7	NA	studies_number_ipd	1
10.1080/03007995.2020.1747999	methodology	7	NA	treatment_name_nonipd	im ifn-1a 60 g once weekly
10.1080/03007995.2020.1747999	methodology	7	NA	studies_number_nonipd	5
10.1080/03007995.2020.1747999	methodology	7	NA	paic_type	MAIC
10.1080/03007995.2020.1747999	methodology	7	NA	anchored_yn	Yes
10.1080/03007995.2020.1747999	methodology	7	NA	paic_form	Simple (ie treatments effects extracted from two studies)
10.1080/03007995.2020.1747999	methodology	7	NA	primary_outcome_yn	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.1080/03007995.2020.1747999	methodology	7	NA	variables_selection_justification	Status of prognostic factor/treatment effect modified assessed in the IPD dataset, A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion)
10.1080/03007995.2020.1747999	methodology	7	NA	pf_yn	No
10.1080/03007995.2020.1747999	methodology	7	NA	tem_yn	Yes
10.1080/03007995.2020.1747999	methodology	7	NA	adjustment_model_details_yn	No
10.1080/03007995.2020.1747999	methodology	7	NA	scale_choice_yn	No
10.1080/03007995.2020.1747999	results	1	NA	contrast_effect_type	HR
10.1080/03007995.2020.1747999	results	1	NA	direction_benefit	inferior
10.1080/03007995.2020.1747999	results	1	NA	ss_ttt_nonipd	NA
10.1080/03007995.2020.1747999	results	1	NA	ss_ttt_ipd	NA
10.1080/03007995.2020.1747999	results	1	NA	ss_adjusted_ttt_ipd	NA
10.1080/03007995.2020.1747999	results	1	NA	weights_yn	Not mentioned
10.1080/03007995.2020.1747999	results	1	NA	covariates_yn	Yes
10.1080/03007995.2020.1747999	results	1	NA	covariates_n	10
10.1080/03007995.2020.1747999	results	1	NA	covariates_names	Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Past treatments for the disease of interest
10.1080/03007995.2020.1747999	results	1	NA	contrast_effect_direction	Numerator if ratio, or left side if difference
10.1080/03007995.2020.1747999	results	1	NA	contrast_effect_unadjusted_value	NA
10.1080/03007995.2020.1747999	results	1	NA	contrast_effect_unadjusted_pvalci	NA
10.1080/03007995.2020.1747999	results	1	NA	contrast_effect_adjusted_value	0.55
10.1080/03007995.2020.1747999	results	1	NA	contrast_effect_adjusted_pvalci	[0.33;0.91]
10.1080/03007995.2020.1747999	results	1	NA	adjustment_geographical	NA
10.1080/03007995.2020.1747999	results	1	NA	ss_total_ipd	543
10.1080/03007995.2020.1747999	results	1	NA	ss_adjusted_total_ipd	410
10.1080/03007995.2020.1747999	results	1	NA	ss_total_nonipd	939
10.1080/03007995.2020.1747999	results	1	NA	ss_anchor_nonipd	NA
10.1080/03007995.2020.1747999	results	1	NA	ss_anchor_ipd	NA
10.1080/03007995.2020.1747999	results	1	NA	ss_adjusted_anchor_ipd	NA
10.1080/03007995.2020.1747999	results	1	NA	effect_cutoff	1
10.1080/03007995.2020.1747999	results	1	NA	adjusted_lb_ci	0.33
10.1080/03007995.2020.1747999	results	1	NA	adjusted_ub_ci	0.91
10.1080/03007995.2020.1747999	results	1	NA	adjusted_significant	TRUE
10.1080/03007995.2020.1747999	results	2	NA	contrast_effect_type	HR
10.1080/03007995.2020.1747999	results	2	NA	direction_benefit	inferior
10.1080/03007995.2020.1747999	results	2	NA	ss_ttt_nonipd	NA
10.1080/03007995.2020.1747999	results	2	NA	ss_ttt_ipd	NA
10.1080/03007995.2020.1747999	results	2	NA	ss_adjusted_ttt_ipd	NA
10.1080/03007995.2020.1747999	results	2	NA	weights_yn	Not mentioned
10.1080/03007995.2020.1747999	results	2	NA	covariates_yn	Yes
10.1080/03007995.2020.1747999	results	2	NA	covariates_n	10
10.1080/03007995.2020.1747999	results	2	NA	covariates_names	Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Past treatments for the disease of interest
10.1080/03007995.2020.1747999	results	2	NA	contrast_effect_direction	Numerator if ratio, or left side if difference
10.1080/03007995.2020.1747999	results	2	NA	contrast_effect_unadjusted_value	NA
10.1080/03007995.2020.1747999	results	2	NA	contrast_effect_unadjusted_pvalci	NA
10.1080/03007995.2020.1747999	results	2	NA	contrast_effect_adjusted_value	0.43
10.1080/03007995.2020.1747999	results	2	NA	contrast_effect_adjusted_pvalci	[0.20;0.93]
10.1080/03007995.2020.1747999	results	2	NA	adjustment_geographical	NA
10.1080/03007995.2020.1747999	results	2	NA	ss_total_ipd	578
10.1080/03007995.2020.1747999	results	2	NA	ss_adjusted_total_ipd	157
10.1080/03007995.2020.1747999	results	2	NA	ss_total_nonipd	364
10.1080/03007995.2020.1747999	results	2	NA	ss_anchor_nonipd	NA
10.1080/03007995.2020.1747999	results	2	NA	ss_anchor_ipd	NA
10.1080/03007995.2020.1747999	results	2	NA	ss_adjusted_anchor_ipd	NA
10.1080/03007995.2020.1747999	results	2	NA	effect_cutoff	1
10.1080/03007995.2020.1747999	results	2	NA	adjusted_lb_ci	0.2
10.1080/03007995.2020.1747999	results	2	NA	adjusted_ub_ci	0.93
10.1080/03007995.2020.1747999	results	2	NA	adjusted_significant	TRUE
10.1080/03007995.2020.1747999	results	3	NA	contrast_effect_type	OR
10.1080/03007995.2020.1747999	results	3	NA	direction_benefit	inferior
10.1080/03007995.2020.1747999	results	3	NA	ss_ttt_nonipd	NA
10.1080/03007995.2020.1747999	results	3	NA	ss_ttt_ipd	NA
10.1080/03007995.2020.1747999	results	3	NA	ss_adjusted_ttt_ipd	NA
10.1080/03007995.2020.1747999	results	3	NA	weights_yn	Not mentioned
10.1080/03007995.2020.1747999	results	3	NA	covariates_yn	Yes
10.1080/03007995.2020.1747999	results	3	NA	covariates_n	10
10.1080/03007995.2020.1747999	results	3	NA	covariates_names	Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Past treatments for the disease of interest
10.1080/03007995.2020.1747999	results	3	NA	contrast_effect_direction	Numerator if ratio, or left side if difference
10.1080/03007995.2020.1747999	results	3	NA	contrast_effect_unadjusted_value	NA
10.1080/03007995.2020.1747999	results	3	NA	contrast_effect_unadjusted_pvalci	NA
10.1080/03007995.2020.1747999	results	3	NA	contrast_effect_adjusted_value	0.76
10.1080/03007995.2020.1747999	results	3	NA	contrast_effect_adjusted_pvalci	[0.44;1.30]
10.1080/03007995.2020.1747999	results	3	NA	adjustment_geographical	No
10.1080/03007995.2020.1747999	results	3	NA	ss_total_ipd	608
10.1080/03007995.2020.1747999	results	3	NA	ss_adjusted_total_ipd	516
10.1080/03007995.2020.1747999	results	3	NA	ss_total_nonipd	887
10.1080/03007995.2020.1747999	results	3	NA	ss_anchor_nonipd	NA
10.1080/03007995.2020.1747999	results	3	NA	ss_anchor_ipd	NA
10.1080/03007995.2020.1747999	results	3	NA	ss_adjusted_anchor_ipd	NA
10.1080/03007995.2020.1747999	results	3	NA	effect_cutoff	1
10.1080/03007995.2020.1747999	results	3	NA	adjusted_lb_ci	0.44
10.1080/03007995.2020.1747999	results	3	NA	adjusted_ub_ci	1.3
10.1080/03007995.2020.1747999	results	3	NA	adjusted_significant	FALSE
10.1080/03007995.2020.1747999	results	4	NA	contrast_effect_type	HR
10.1080/03007995.2020.1747999	results	4	NA	direction_benefit	inferior
10.1080/03007995.2020.1747999	results	4	NA	ss_ttt_nonipd	NA
10.1080/03007995.2020.1747999	results	4	NA	ss_ttt_ipd	NA
10.1080/03007995.2020.1747999	results	4	NA	ss_adjusted_ttt_ipd	NA
10.1080/03007995.2020.1747999	results	4	NA	weights_yn	Not mentioned
10.1080/03007995.2020.1747999	results	4	NA	covariates_yn	Yes
10.1080/03007995.2020.1747999	results	4	NA	covariates_n	10
10.1080/03007995.2020.1747999	results	4	NA	covariates_names	Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Past treatments for the disease of interest
10.1080/03007995.2020.1747999	results	4	NA	contrast_effect_direction	Numerator if ratio, or left side if difference
10.1080/03007995.2020.1747999	results	4	NA	contrast_effect_unadjusted_value	NA
10.1080/03007995.2020.1747999	results	4	NA	contrast_effect_unadjusted_pvalci	NA
10.1080/03007995.2020.1747999	results	4	NA	contrast_effect_adjusted_value	0.8
10.1080/03007995.2020.1747999	results	4	NA	contrast_effect_adjusted_pvalci	[0.46;1.38]
10.1080/03007995.2020.1747999	results	4	NA	adjustment_geographical	NA
10.1080/03007995.2020.1747999	results	4	NA	ss_total_ipd	455
10.1080/03007995.2020.1747999	results	4	NA	ss_adjusted_total_ipd	237
10.1080/03007995.2020.1747999	results	4	NA	ss_total_nonipd	618
10.1080/03007995.2020.1747999	results	4	NA	ss_anchor_nonipd	NA
10.1080/03007995.2020.1747999	results	4	NA	ss_anchor_ipd	NA
10.1080/03007995.2020.1747999	results	4	NA	ss_adjusted_anchor_ipd	NA
10.1080/03007995.2020.1747999	results	4	NA	effect_cutoff	1
10.1080/03007995.2020.1747999	results	4	NA	adjusted_lb_ci	0.46
10.1080/03007995.2020.1747999	results	4	NA	adjusted_ub_ci	1.38
10.1080/03007995.2020.1747999	results	4	NA	adjusted_significant	FALSE
10.1080/03007995.2020.1747999	results	5	NA	contrast_effect_type	HR
10.1080/03007995.2020.1747999	results	5	NA	direction_benefit	inferior
10.1080/03007995.2020.1747999	results	5	NA	ss_ttt_nonipd	NA
10.1080/03007995.2020.1747999	results	5	NA	ss_ttt_ipd	NA
10.1080/03007995.2020.1747999	results	5	NA	ss_adjusted_ttt_ipd	NA
10.1080/03007995.2020.1747999	results	5	NA	weights_yn	Not mentioned
10.1080/03007995.2020.1747999	results	5	NA	covariates_yn	Yes
10.1080/03007995.2020.1747999	results	5	NA	covariates_n	10
10.1080/03007995.2020.1747999	results	5	NA	covariates_names	Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Past treatments for the disease of interest
10.1080/03007995.2020.1747999	results	5	NA	contrast_effect_direction	Numerator if ratio, or left side if difference
10.1080/03007995.2020.1747999	results	5	NA	contrast_effect_unadjusted_value	NA
10.1080/03007995.2020.1747999	results	5	NA	contrast_effect_unadjusted_pvalci	NA
10.1080/03007995.2020.1747999	results	5	NA	contrast_effect_adjusted_value	0.84
10.1080/03007995.2020.1747999	results	5	NA	contrast_effect_adjusted_pvalci	[0.49;1.47]
10.1080/03007995.2020.1747999	results	5	NA	adjustment_geographical	NA
10.1080/03007995.2020.1747999	results	5	NA	ss_total_ipd	455
10.1080/03007995.2020.1747999	results	5	NA	ss_adjusted_total_ipd	237
10.1080/03007995.2020.1747999	results	5	NA	ss_total_nonipd	618
10.1080/03007995.2020.1747999	results	5	NA	ss_anchor_nonipd	NA
10.1080/03007995.2020.1747999	results	5	NA	ss_anchor_ipd	NA
10.1080/03007995.2020.1747999	results	5	NA	ss_adjusted_anchor_ipd	NA
10.1080/03007995.2020.1747999	results	5	NA	effect_cutoff	1
10.1080/03007995.2020.1747999	results	5	NA	adjusted_lb_ci	0.49
10.1080/03007995.2020.1747999	results	5	NA	adjusted_ub_ci	1.47
10.1080/03007995.2020.1747999	results	5	NA	adjusted_significant	FALSE
10.1080/03007995.2020.1747999	results	6	NA	contrast_effect_type	HR
10.1080/03007995.2020.1747999	results	6	NA	direction_benefit	inferior
10.1080/03007995.2020.1747999	results	6	NA	ss_ttt_nonipd	NA
10.1080/03007995.2020.1747999	results	6	NA	ss_ttt_ipd	NA
10.1080/03007995.2020.1747999	results	6	NA	ss_adjusted_ttt_ipd	NA
10.1080/03007995.2020.1747999	results	6	NA	weights_yn	Not mentioned
10.1080/03007995.2020.1747999	results	6	NA	covariates_yn	Yes
10.1080/03007995.2020.1747999	results	6	NA	covariates_n	10
10.1080/03007995.2020.1747999	results	6	NA	covariates_names	Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Past treatments for the disease of interest
10.1080/03007995.2020.1747999	results	6	NA	contrast_effect_direction	Numerator if ratio, or left side if difference
10.1080/03007995.2020.1747999	results	6	NA	contrast_effect_unadjusted_value	NA
10.1080/03007995.2020.1747999	results	6	NA	contrast_effect_unadjusted_pvalci	NA
10.1080/03007995.2020.1747999	results	6	NA	contrast_effect_adjusted_value	0.82
10.1080/03007995.2020.1747999	results	6	NA	contrast_effect_adjusted_pvalci	[0.42;1.63]
10.1080/03007995.2020.1747999	results	6	NA	adjustment_geographical	NA
10.1080/03007995.2020.1747999	results	6	NA	ss_total_ipd	455
10.1080/03007995.2020.1747999	results	6	NA	ss_adjusted_total_ipd	140
10.1080/03007995.2020.1747999	results	6	NA	ss_total_nonipd	718
10.1080/03007995.2020.1747999	results	6	NA	ss_anchor_nonipd	NA
10.1080/03007995.2020.1747999	results	6	NA	ss_anchor_ipd	NA
10.1080/03007995.2020.1747999	results	6	NA	ss_adjusted_anchor_ipd	NA
10.1080/03007995.2020.1747999	results	6	NA	effect_cutoff	1
10.1080/03007995.2020.1747999	results	6	NA	adjusted_lb_ci	0.42
10.1080/03007995.2020.1747999	results	6	NA	adjusted_ub_ci	1.63
10.1080/03007995.2020.1747999	results	6	NA	adjusted_significant	FALSE
10.1080/03007995.2020.1747999	results	7	NA	contrast_effect_type	HR
10.1080/03007995.2020.1747999	results	7	NA	direction_benefit	inferior
10.1080/03007995.2020.1747999	results	7	NA	ss_ttt_nonipd	NA
10.1080/03007995.2020.1747999	results	7	NA	ss_ttt_ipd	NA
10.1080/03007995.2020.1747999	results	7	NA	ss_adjusted_ttt_ipd	NA
10.1080/03007995.2020.1747999	results	7	NA	weights_yn	Not mentioned
10.1080/03007995.2020.1747999	results	7	NA	covariates_yn	Yes
10.1080/03007995.2020.1747999	results	7	NA	covariates_n	10
10.1080/03007995.2020.1747999	results	7	NA	covariates_names	Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Past treatments for the disease of interest
10.1080/03007995.2020.1747999	results	7	NA	contrast_effect_direction	Numerator if ratio, or left side if difference
10.1080/03007995.2020.1747999	results	7	NA	contrast_effect_unadjusted_value	NA
10.1080/03007995.2020.1747999	results	7	NA	contrast_effect_unadjusted_pvalci	NA
10.1080/03007995.2020.1747999	results	7	NA	contrast_effect_adjusted_value	0.42
10.1080/03007995.2020.1747999	results	7	NA	contrast_effect_adjusted_pvalci	[0.20;0.88]
10.1080/03007995.2020.1747999	results	7	NA	adjustment_geographical	NA
10.1080/03007995.2020.1747999	results	7	NA	ss_total_ipd	563
10.1080/03007995.2020.1747999	results	7	NA	ss_adjusted_total_ipd	113
10.1080/03007995.2020.1747999	results	7	NA	ss_total_nonipd	436
10.1080/03007995.2020.1747999	results	7	NA	ss_anchor_nonipd	NA
10.1080/03007995.2020.1747999	results	7	NA	ss_anchor_ipd	NA
10.1080/03007995.2020.1747999	results	7	NA	ss_adjusted_anchor_ipd	NA
10.1080/03007995.2020.1747999	results	7	NA	effect_cutoff	1
10.1080/03007995.2020.1747999	results	7	NA	adjusted_lb_ci	0.2
10.1080/03007995.2020.1747999	results	7	NA	adjusted_ub_ci	0.88
10.1080/03007995.2020.1747999	results	7	NA	adjusted_significant	TRUE
10.1080/03007995.2020.1747999	study_information	NA	1	ipd_yn	Yes
10.1080/03007995.2020.1747999	study_information	NA	1	ct_yn	Yes
10.1080/03007995.2020.1747999	study_information	NA	1	nct	NCT01665144
10.1080/03007995.2020.1747999	study_information	NA	1	country_study	international
10.1080/03007995.2020.1747999	study_information	NA	1	ct_phase	3
10.1080/03007995.2020.1747999	study_information	NA	1	ct_arms	2 or more
10.1080/03007995.2020.1747999	study_information	NA	2	ipd_yn	No
10.1080/03007995.2020.1747999	study_information	NA	2	ct_yn	Yes
10.1080/03007995.2020.1747999	study_information	NA	2	nct	NCT01416181
10.1080/03007995.2020.1747999	study_information	NA	2	country_study	international
10.1080/03007995.2020.1747999	study_information	NA	2	ct_phase	3
10.1080/03007995.2020.1747999	study_information	NA	2	ct_arms	2 or more
10.1080/03007995.2020.1747999	study_information	NA	3	ipd_yn	No
10.1080/03007995.2020.1747999	study_information	NA	3	ct_yn	Yes
10.1080/03007995.2020.1747999	study_information	NA	3	data_source_name	nordic spms study
10.1080/03007995.2020.1747999	study_information	NA	3	country_study	international
10.1080/03007995.2020.1747999	study_information	NA	3	ct_arms	2 or more
10.1080/03007995.2020.1747999	study_information	NA	3	ct_phase	3
10.1080/03007995.2020.1747999	study_information	NA	4	ipd_yn	No
10.1080/03007995.2020.1747999	study_information	NA	4	ct_yn	Yes
10.1080/03007995.2020.1747999	study_information	NA	4	data_source_name	panitch et al. (2004) (north american study)
10.1080/03007995.2020.1747999	study_information	NA	4	country_study	international
10.1080/03007995.2020.1747999	study_information	NA	4	ct_arms	2 or more
10.1080/03007995.2020.1747999	study_information	NA	5	ipd_yn	No
10.1080/03007995.2020.1747999	study_information	NA	5	ct_yn	Yes
10.1080/03007995.2020.1747999	study_information	NA	5	data_source_name	cohen et al. (2002) (impact)
10.1080/03007995.2020.1747999	study_information	NA	5	ct_arms	2 or more
10.1080/03007995.2020.1747999	study_information	NA	5	country_study	international
10.1080/03007995.2020.1747999	study_information	NA	6	ipd_yn	No
10.1080/03007995.2020.1747999	study_information	NA	6	ct_yn	Yes
10.1080/03007995.2020.1747999	study_information	NA	6	data_source_name	spectrims study group (2001) li et al. (2001)
10.1080/03007995.2020.1747999	study_information	NA	6	ct_arms	2 or more
10.1080/03007995.2020.1747999	study_information	NA	6	country_study	international
10.1080/03007995.2020.1747999	study_information	NA	7	ipd_yn	No
10.1080/03007995.2020.1747999	study_information	NA	7	ct_yn	Yes
10.1080/03007995.2020.1747999	study_information	NA	7	data_source_name	european study group (1998) kappos et al. (2001)
10.1080/03007995.2020.1747999	study_information	NA	7	country_study	international
10.1080/03007995.2020.1747999	study_information	NA	7	ct_arms	2 or more
10.1080/03007995.2021.1896489	general_information	NA	NA	condition_name	chronic phase chronic myeloid leukemia
10.1080/03007995.2021.1896489	general_information	NA	NA	country_first_author	the netherlands
10.1080/03007995.2021.1896489	general_information	NA	NA	country_last_author	the netherlands
10.1080/03007995.2021.1896489	general_information	NA	NA	positions	Pharmaceutical Industry, Private Data Analysis Company
10.1080/03007995.2021.1896489	general_information	NA	NA	methodologist_yn	Yes
10.1080/03007995.2021.1896489	general_information	NA	NA	funding_source	Pharmaceutical Industry
10.1080/03007995.2021.1896489	general_information	NA	NA	pharmaceutical_ties_yn	Yes
10.1080/03007995.2021.1896489	general_information	NA	NA	systematic_review_yn	No
10.1080/03007995.2021.1896489	methodology	1	NA	outcome_name	major molecular response at 24 months
10.1080/03007995.2021.1896489	methodology	1	NA	outcome_short_name	Major Molecular Response
10.1080/03007995.2021.1896489	methodology	1	NA	outcome_variable_type	Binary (eg rates)
10.1080/03007995.2021.1896489	methodology	1	NA	treatment_name_ipd	bosutinib
10.1080/03007995.2021.1896489	methodology	1	NA	studies_number_ipd	1
10.1080/03007995.2021.1896489	methodology	1	NA	treatment_name_nonipd	nilotinib
10.1080/03007995.2021.1896489	methodology	1	NA	studies_number_nonipd	2
10.1080/03007995.2021.1896489	methodology	1	NA	paic_type	MAIC
10.1080/03007995.2021.1896489	methodology	1	NA	anchored_yn	No
10.1080/03007995.2021.1896489	methodology	1	NA	paic_form	Simple (ie treatments effects extracted from two studies)
10.1080/03007995.2021.1896489	methodology	1	NA	primary_outcome_yn	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.1080/03007995.2021.1896489	methodology	1	NA	variables_selection_justification	Status of prognostic factor/treatment effect modified assessed in the IPD dataset
10.1080/03007995.2021.1896489	methodology	1	NA	pf_yn	Yes
10.1080/03007995.2021.1896489	methodology	1	NA	tem_yn	Yes
10.1080/03007995.2021.1896489	methodology	1	NA	adjustment_model_details_yn	No
10.1080/03007995.2021.1896489	methodology	1	NA	scale_choice_yn	Yes
10.1080/03007995.2021.1896489	methodology	2	NA	outcome_name	major molecular response by 24 months
10.1080/03007995.2021.1896489	methodology	2	NA	outcome_short_name	Major Molecular Response
10.1080/03007995.2021.1896489	methodology	2	NA	outcome_variable_type	Binary (eg rates)
10.1080/03007995.2021.1896489	methodology	2	NA	treatment_name_ipd	bosutinib
10.1080/03007995.2021.1896489	methodology	2	NA	studies_number_ipd	1
10.1080/03007995.2021.1896489	methodology	2	NA	treatment_name_nonipd	dasatinib
10.1080/03007995.2021.1896489	methodology	2	NA	studies_number_nonipd	3
10.1080/03007995.2021.1896489	methodology	2	NA	paic_type	MAIC
10.1080/03007995.2021.1896489	methodology	2	NA	anchored_yn	No
10.1080/03007995.2021.1896489	methodology	2	NA	paic_form	Simple (ie treatments effects extracted from two studies)
10.1080/03007995.2021.1896489	methodology	2	NA	primary_outcome_yn	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.1080/03007995.2021.1896489	methodology	2	NA	variables_selection_justification	Status of prognostic factor/treatment effect modified assessed in the IPD dataset
10.1080/03007995.2021.1896489	methodology	2	NA	pf_yn	Yes
10.1080/03007995.2021.1896489	methodology	2	NA	tem_yn	Yes
10.1080/03007995.2021.1896489	methodology	2	NA	adjustment_model_details_yn	No
10.1080/03007995.2021.1896489	methodology	2	NA	scale_choice_yn	Yes
10.1080/03007995.2021.1896489	results	1	NA	contrast_effect_type	OR
10.1080/03007995.2021.1896489	results	1	NA	direction_benefit	superior
10.1080/03007995.2021.1896489	results	1	NA	ss_ttt_nonipd	282
10.1080/03007995.2021.1896489	results	1	NA	ss_ttt_ipd	248
10.1080/03007995.2021.1896489	results	1	NA	ss_adjusted_ttt_ipd	190
10.1080/03007995.2021.1896489	results	1	NA	weights_yn	Not mentioned
10.1080/03007995.2021.1896489	results	1	NA	covariates_yn	Yes
10.1080/03007995.2021.1896489	results	1	NA	covariates_n	3
10.1080/03007995.2021.1896489	results	1	NA	covariates_names	Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Race/ethnicity
10.1080/03007995.2021.1896489	results	1	NA	contrast_effect_direction	Denominator if ratio, or rightside if difference
10.1080/03007995.2021.1896489	results	1	NA	contrast_effect_unadjusted_value	NA
10.1080/03007995.2021.1896489	results	1	NA	contrast_effect_unadjusted_pvalci	NA
10.1080/03007995.2021.1896489	results	1	NA	contrast_effect_adjusted_value	1.01
10.1080/03007995.2021.1896489	results	1	NA	contrast_effect_adjusted_pvalci	[0.70;1.45]
10.1080/03007995.2021.1896489	results	1	NA	adjustment_geographical	NA
10.1080/03007995.2021.1896489	results	1	NA	ss_total_ipd	NA
10.1080/03007995.2021.1896489	results	1	NA	ss_adjusted_total_ipd	NA
10.1080/03007995.2021.1896489	results	1	NA	ss_total_nonipd	NA
10.1080/03007995.2021.1896489	results	1	NA	ss_anchor_nonipd	NA
10.1080/03007995.2021.1896489	results	1	NA	ss_anchor_ipd	NA
10.1080/03007995.2021.1896489	results	1	NA	ss_adjusted_anchor_ipd	NA
10.1080/03007995.2021.1896489	results	1	NA	effect_cutoff	1
10.1080/03007995.2021.1896489	results	1	NA	adjusted_lb_ci	0.7
10.1080/03007995.2021.1896489	results	1	NA	adjusted_ub_ci	1.45
10.1080/03007995.2021.1896489	results	1	NA	adjusted_significant	FALSE
10.1080/03007995.2021.1896489	results	2	NA	contrast_effect_type	OR
10.1080/03007995.2021.1896489	results	2	NA	direction_benefit	superior
10.1080/03007995.2021.1896489	results	2	NA	ss_ttt_nonipd	259
10.1080/03007995.2021.1896489	results	2	NA	ss_ttt_ipd	244
10.1080/03007995.2021.1896489	results	2	NA	ss_adjusted_ttt_ipd	118
10.1080/03007995.2021.1896489	results	2	NA	weights_yn	Not mentioned
10.1080/03007995.2021.1896489	results	2	NA	covariates_yn	Yes
10.1080/03007995.2021.1896489	results	2	NA	covariates_n	5
10.1080/03007995.2021.1896489	results	2	NA	covariates_names	Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Race/ethnicity, Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...)
10.1080/03007995.2021.1896489	results	2	NA	contrast_effect_direction	Denominator if ratio, or rightside if difference
10.1080/03007995.2021.1896489	results	2	NA	contrast_effect_unadjusted_value	NA
10.1080/03007995.2021.1896489	results	2	NA	contrast_effect_unadjusted_pvalci	NA
10.1080/03007995.2021.1896489	results	2	NA	contrast_effect_adjusted_value	0.81
10.1080/03007995.2021.1896489	results	2	NA	contrast_effect_adjusted_pvalci	[0.54;1.22]
10.1080/03007995.2021.1896489	results	2	NA	adjustment_geographical	NA
10.1080/03007995.2021.1896489	results	2	NA	ss_total_ipd	NA
10.1080/03007995.2021.1896489	results	2	NA	ss_adjusted_total_ipd	NA
10.1080/03007995.2021.1896489	results	2	NA	ss_total_nonipd	NA
10.1080/03007995.2021.1896489	results	2	NA	ss_anchor_nonipd	NA
10.1080/03007995.2021.1896489	results	2	NA	ss_anchor_ipd	NA
10.1080/03007995.2021.1896489	results	2	NA	ss_adjusted_anchor_ipd	NA
10.1080/03007995.2021.1896489	results	2	NA	effect_cutoff	1
10.1080/03007995.2021.1896489	results	2	NA	adjusted_lb_ci	0.54
10.1080/03007995.2021.1896489	results	2	NA	adjusted_ub_ci	1.22
10.1080/03007995.2021.1896489	results	2	NA	adjusted_significant	FALSE
10.1080/03007995.2021.1896489	study_information	NA	1	ipd_yn	Yes
10.1080/03007995.2021.1896489	study_information	NA	1	ct_yn	Yes
10.1080/03007995.2021.1896489	study_information	NA	1	nct	NCT02130557
10.1080/03007995.2021.1896489	study_information	NA	1	country_study	international
10.1080/03007995.2021.1896489	study_information	NA	1	ct_phase	3
10.1080/03007995.2021.1896489	study_information	NA	1	ct_arms	2 or more
10.1080/03007995.2021.1896489	study_information	NA	2	ipd_yn	No
10.1080/03007995.2021.1896489	study_information	NA	2	ct_yn	Yes
10.1080/03007995.2021.1896489	study_information	NA	2	nct	NCT00471497
10.1080/03007995.2021.1896489	study_information	NA	2	country_study	international
10.1080/03007995.2021.1896489	study_information	NA	2	ct_phase	3
10.1080/03007995.2021.1896489	study_information	NA	2	ct_arms	2 or more
10.1080/03007995.2021.1896489	study_information	NA	3	ipd_yn	No
10.1080/03007995.2021.1896489	study_information	NA	3	ct_yn	Yes
10.1080/03007995.2021.1896489	study_information	NA	3	nct	NCT00481247
10.1080/03007995.2021.1896489	study_information	NA	3	country_study	international
10.1080/03007995.2021.1896489	study_information	NA	3	ct_phase	3
10.1080/03007995.2021.1896489	study_information	NA	3	ct_arms	2 or more
10.1080/03007995.2021.1947216	general_information	NA	NA	condition_name	spinal muscular atrophy type 1
10.1080/03007995.2021.1947216	general_information	NA	NA	country_first_author	switzerland
10.1080/03007995.2021.1947216	general_information	NA	NA	country_last_author	usa
10.1080/03007995.2021.1947216	general_information	NA	NA	positions	Pharmaceutical Industry, Private Data Analysis Company
10.1080/03007995.2021.1947216	general_information	NA	NA	methodologist_yn	Yes
10.1080/03007995.2021.1947216	general_information	NA	NA	funding_source	Pharmaceutical Industry
10.1080/03007995.2021.1947216	general_information	NA	NA	pharmaceutical_ties_yn	Yes
10.1080/03007995.2021.1947216	general_information	NA	NA	systematic_review_yn	Yes
10.1080/03007995.2021.1947216	methodology	1	NA	outcome_name	event-free survival
10.1080/03007995.2021.1947216	methodology	1	NA	outcome_short_name	Event-free Survival
10.1080/03007995.2021.1947216	methodology	1	NA	outcome_variable_type	Time-to-event
10.1080/03007995.2021.1947216	methodology	1	NA	treatment_name_ipd	onasemnogene abeparvovec
10.1080/03007995.2021.1947216	methodology	1	NA	studies_number_ipd	1;2
10.1080/03007995.2021.1947216	methodology	1	NA	treatment_name_nonipd	nusinersen
10.1080/03007995.2021.1947216	methodology	1	NA	studies_number_nonipd	3
10.1080/03007995.2021.1947216	methodology	1	NA	paic_type	MAIC
10.1080/03007995.2021.1947216	methodology	1	NA	anchored_yn	No
10.1080/03007995.2021.1947216	methodology	1	NA	paic_form	Aggregation of multiple studies to estimate individual treatment effects (e.g. meta-analysis in a first step to estimate treatment A effect, then population adjusted indirect comparison using treatment A effect estimate)
10.1080/03007995.2021.1947216	methodology	1	NA	primary_outcome_yn	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.1080/03007995.2021.1947216	methodology	1	NA	variables_selection_justification	A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion)
10.1080/03007995.2021.1947216	methodology	1	NA	pf_yn	Yes
10.1080/03007995.2021.1947216	methodology	1	NA	tem_yn	Yes
10.1080/03007995.2021.1947216	methodology	1	NA	adjustment_model_details_yn	Yes
10.1080/03007995.2021.1947216	methodology	1	NA	scale_choice_yn	No
10.1080/03007995.2021.1947216	results	1	NA	contrast_effect_type	HR
10.1080/03007995.2021.1947216	results	1	NA	direction_benefit	inferior
10.1080/03007995.2021.1947216	results	1	NA	ss_ttt_nonipd	81
10.1080/03007995.2021.1947216	results	1	NA	ss_ttt_ipd	34
10.1080/03007995.2021.1947216	results	1	NA	ss_adjusted_ttt_ipd	24.6
10.1080/03007995.2021.1947216	results	1	NA	weights_yn	Not mentioned
10.1080/03007995.2021.1947216	results	1	NA	covariates_yn	Yes
10.1080/03007995.2021.1947216	results	1	NA	covariates_n	2
10.1080/03007995.2021.1947216	results	1	NA	covariates_names	Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease)
10.1080/03007995.2021.1947216	results	1	NA	contrast_effect_direction	Numerator if ratio, or left side if difference
10.1080/03007995.2021.1947216	results	1	NA	contrast_effect_unadjusted_value	NA
10.1080/03007995.2021.1947216	results	1	NA	contrast_effect_unadjusted_pvalci	NA
10.1080/03007995.2021.1947216	results	1	NA	contrast_effect_adjusted_value	0.19
10.1080/03007995.2021.1947216	results	1	NA	contrast_effect_adjusted_pvalci	[0.07;0.54]
10.1080/03007995.2021.1947216	results	1	NA	adjustment_geographical	NA
10.1080/03007995.2021.1947216	results	1	NA	ss_total_ipd	NA
10.1080/03007995.2021.1947216	results	1	NA	ss_adjusted_total_ipd	NA
10.1080/03007995.2021.1947216	results	1	NA	ss_total_nonipd	NA
10.1080/03007995.2021.1947216	results	1	NA	ss_anchor_nonipd	NA
10.1080/03007995.2021.1947216	results	1	NA	ss_anchor_ipd	NA
10.1080/03007995.2021.1947216	results	1	NA	ss_adjusted_anchor_ipd	NA
10.1080/03007995.2021.1947216	results	1	NA	effect_cutoff	1
10.1080/03007995.2021.1947216	results	1	NA	adjusted_lb_ci	0.07
10.1080/03007995.2021.1947216	results	1	NA	adjusted_ub_ci	0.54
10.1080/03007995.2021.1947216	results	1	NA	adjusted_significant	TRUE
10.1080/03007995.2021.1947216	study_information	NA	1	ipd_yn	Yes
10.1080/03007995.2021.1947216	study_information	NA	1	ct_yn	Yes
10.1080/03007995.2021.1947216	study_information	NA	1	nct	NCT02122952
10.1080/03007995.2021.1947216	study_information	NA	1	country_study	usa
10.1080/03007995.2021.1947216	study_information	NA	1	ct_phase	1
10.1080/03007995.2021.1947216	study_information	NA	1	ct_arms	1
10.1080/03007995.2021.1947216	study_information	NA	2	ipd_yn	Yes
10.1080/03007995.2021.1947216	study_information	NA	2	ct_yn	Yes
10.1080/03007995.2021.1947216	study_information	NA	2	nct	NCT03306277
10.1080/03007995.2021.1947216	study_information	NA	2	country_study	usa
10.1080/03007995.2021.1947216	study_information	NA	2	ct_phase	3
10.1080/03007995.2021.1947216	study_information	NA	2	ct_arms	1
10.1080/03007995.2021.1947216	study_information	NA	3	ipd_yn	No
10.1080/03007995.2021.1947216	study_information	NA	3	ct_yn	Yes
10.1080/03007995.2021.1947216	study_information	NA	3	nct	NCT02594124
10.1080/03007995.2021.1947216	study_information	NA	3	country_study	international
10.1080/03007995.2021.1947216	study_information	NA	3	ct_phase	3
10.1080/03007995.2021.1947216	study_information	NA	3	ct_arms	1
10.1080/03007995.2021.1953456	general_information	NA	NA	condition_name	relapsed or refractory multiple myeloma
10.1080/03007995.2021.1953456	general_information	NA	NA	country_first_author	usa
10.1080/03007995.2021.1953456	general_information	NA	NA	country_last_author	canada
10.1080/03007995.2021.1953456	general_information	NA	NA	positions	Academic, Pharmaceutical Industry, Private Data Analysis Company
10.1080/03007995.2021.1953456	general_information	NA	NA	methodologist_yn	Yes
10.1080/03007995.2021.1953456	general_information	NA	NA	funding_source	Pharmaceutical Industry
10.1080/03007995.2021.1953456	general_information	NA	NA	pharmaceutical_ties_yn	Yes
10.1080/03007995.2021.1953456	general_information	NA	NA	systematic_review_yn	No
10.1080/03007995.2021.1953456	methodology	1	NA	outcome_name	overall response rate
10.1080/03007995.2021.1953456	methodology	1	NA	outcome_short_name	Overall Response Rate
10.1080/03007995.2021.1953456	methodology	1	NA	outcome_variable_type	Binary (eg rates)
10.1080/03007995.2021.1953456	methodology	1	NA	treatment_name_ipd	ciltacabtagene autoleucel
10.1080/03007995.2021.1953456	methodology	1	NA	studies_number_ipd	1
10.1080/03007995.2021.1953456	methodology	1	NA	treatment_name_nonipd	idecabtagene vicleucel
10.1080/03007995.2021.1953456	methodology	1	NA	studies_number_nonipd	2
10.1080/03007995.2021.1953456	methodology	1	NA	paic_type	MAIC
10.1080/03007995.2021.1953456	methodology	1	NA	anchored_yn	No
10.1080/03007995.2021.1953456	methodology	1	NA	paic_form	Simple (ie treatments effects extracted from two studies)
10.1080/03007995.2021.1953456	methodology	1	NA	primary_outcome_yn	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.1080/03007995.2021.1953456	methodology	1	NA	variables_selection_justification	A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion), Literature based (clinically or methodologically relevant to adjust on these variables based on the literature search conducted for this specific purpose)
10.1080/03007995.2021.1953456	methodology	1	NA	pf_yn	Yes
10.1080/03007995.2021.1953456	methodology	1	NA	tem_yn	No discussion (in the main text) of the status of treatment-effect modifiers of the variables
10.1080/03007995.2021.1953456	methodology	1	NA	adjustment_model_details_yn	No
10.1080/03007995.2021.1953456	methodology	1	NA	scale_choice_yn	No
10.1080/03007995.2021.1953456	results	1	NA	contrast_effect_type	OR
10.1080/03007995.2021.1953456	results	1	NA	direction_benefit	superior
10.1080/03007995.2021.1953456	results	1	NA	ss_ttt_nonipd	124
10.1080/03007995.2021.1953456	results	1	NA	ss_ttt_ipd	97
10.1080/03007995.2021.1953456	results	1	NA	ss_adjusted_ttt_ipd	52
10.1080/03007995.2021.1953456	results	1	NA	weights_yn	Yes, mentions that the weights distribution has been studied, and weights distribution reported in main article or supplemental materials
10.1080/03007995.2021.1953456	results	1	NA	covariates_yn	Yes
10.1080/03007995.2021.1953456	results	1	NA	covariates_n	4
10.1080/03007995.2021.1953456	results	1	NA	covariates_names	Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease)
10.1080/03007995.2021.1953456	results	1	NA	contrast_effect_direction	Numerator if ratio, or left side if difference
10.1080/03007995.2021.1953456	results	1	NA	contrast_effect_unadjusted_value	16.52
10.1080/03007995.2021.1953456	results	1	NA	contrast_effect_unadjusted_pvalci	0.0002
10.1080/03007995.2021.1953456	results	1	NA	contrast_effect_adjusted_value	94.93
10.1080/03007995.2021.1953456	results	1	NA	contrast_effect_adjusted_pvalci	<0.0001
10.1080/03007995.2021.1953456	results	1	NA	adjustment_geographical	NA
10.1080/03007995.2021.1953456	results	1	NA	ss_total_ipd	NA
10.1080/03007995.2021.1953456	results	1	NA	ss_adjusted_total_ipd	NA
10.1080/03007995.2021.1953456	results	1	NA	ss_total_nonipd	NA
10.1080/03007995.2021.1953456	results	1	NA	ss_anchor_nonipd	NA
10.1080/03007995.2021.1953456	results	1	NA	ss_anchor_ipd	NA
10.1080/03007995.2021.1953456	results	1	NA	ss_adjusted_anchor_ipd	NA
10.1080/03007995.2021.1953456	results	1	NA	effect_cutoff	1
10.1080/03007995.2021.1953456	results	1	NA	unadjusted_pval	0.0002
10.1080/03007995.2021.1953456	results	1	NA	unadjusted_num_pval	2e-04
10.1080/03007995.2021.1953456	results	1	NA	unadjusted_significant	TRUE
10.1080/03007995.2021.1953456	results	1	NA	adjusted_pval	<0.0001
10.1080/03007995.2021.1953456	results	1	NA	adjusted_significant	TRUE
10.1080/03007995.2021.1953456	study_information	NA	1	ipd_yn	Yes
10.1080/03007995.2021.1953456	study_information	NA	1	ct_yn	Yes
10.1080/03007995.2021.1953456	study_information	NA	1	nct	NCT03548207
10.1080/03007995.2021.1953456	study_information	NA	1	country_study	international
10.1080/03007995.2021.1953456	study_information	NA	1	ct_phase	1, 2
10.1080/03007995.2021.1953456	study_information	NA	1	ct_arms	1
10.1080/03007995.2021.1953456	study_information	NA	2	ipd_yn	No
10.1080/03007995.2021.1953456	study_information	NA	2	ct_yn	Yes
10.1080/03007995.2021.1953456	study_information	NA	2	nct	NCT03361748
10.1080/03007995.2021.1953456	study_information	NA	2	country_study	international
10.1080/03007995.2021.1953456	study_information	NA	2	ct_phase	2
10.1080/03007995.2021.1953456	study_information	NA	2	ct_arms	1
10.1080/03007995.2021.1971182	general_information	NA	NA	condition_name	paroxysmal nocturnal hemoglobinuria
10.1080/03007995.2021.1971182	general_information	NA	NA	country_first_author	usa
10.1080/03007995.2021.1971182	general_information	NA	NA	country_last_author	usa
10.1080/03007995.2021.1971182	general_information	NA	NA	positions	Pharmaceutical Industry, Private Data Analysis Company
10.1080/03007995.2021.1971182	general_information	NA	NA	methodologist_yn	Yes
10.1080/03007995.2021.1971182	general_information	NA	NA	funding_source	Pharmaceutical Industry
10.1080/03007995.2021.1971182	general_information	NA	NA	pharmaceutical_ties_yn	Yes
10.1080/03007995.2021.1971182	general_information	NA	NA	systematic_review_yn	No
10.1080/03007995.2021.1971182	methodology	1	NA	outcome_name	proportion of patients with transfusion avoidance
10.1080/03007995.2021.1971182	methodology	1	NA	outcome_short_name	Transfusion avoidance
10.1080/03007995.2021.1971182	methodology	1	NA	outcome_variable_type	Binary (eg rates)
10.1080/03007995.2021.1971182	methodology	1	NA	treatment_name_ipd	pegcetacoplan
10.1080/03007995.2021.1971182	methodology	1	NA	studies_number_ipd	1
10.1080/03007995.2021.1971182	methodology	1	NA	treatment_name_nonipd	ravulizumab
10.1080/03007995.2021.1971182	methodology	1	NA	studies_number_nonipd	2
10.1080/03007995.2021.1971182	methodology	1	NA	paic_type	MAIC
10.1080/03007995.2021.1971182	methodology	1	NA	anchored_yn	Yes
10.1080/03007995.2021.1971182	methodology	1	NA	paic_form	Simple (ie treatments effects extracted from two studies)
10.1080/03007995.2021.1971182	methodology	1	NA	primary_outcome_yn	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.1080/03007995.2021.1971182	methodology	1	NA	variables_selection_justification	A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion)
10.1080/03007995.2021.1971182	methodology	1	NA	pf_yn	No
10.1080/03007995.2021.1971182	methodology	1	NA	tem_yn	Yes
10.1080/03007995.2021.1971182	methodology	1	NA	adjustment_model_details_yn	No
10.1080/03007995.2021.1971182	methodology	1	NA	scale_choice_yn	No
10.1080/03007995.2021.1971182	results	1	NA	contrast_effect_type	Proportions difference
10.1080/03007995.2021.1971182	results	1	NA	direction_benefit	superior
10.1080/03007995.2021.1971182	results	1	NA	ss_ttt_nonipd	97
10.1080/03007995.2021.1971182	results	1	NA	ss_ttt_ipd	36
10.1080/03007995.2021.1971182	results	1	NA	ss_adjusted_ttt_ipd	24
10.1080/03007995.2021.1971182	results	1	NA	weights_yn	Yes, mentions that the weights distribution has been studied, but weights distribution not reported
10.1080/03007995.2021.1971182	results	1	NA	covariates_yn	Yes
10.1080/03007995.2021.1971182	results	1	NA	covariates_n	5
10.1080/03007995.2021.1971182	results	1	NA	covariates_names	Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Race/ethnicity
10.1080/03007995.2021.1971182	results	1	NA	contrast_effect_direction	Numerator if ratio, or left side if difference
10.1080/03007995.2021.1971182	results	1	NA	contrast_effect_unadjusted_value	NA
10.1080/03007995.2021.1971182	results	1	NA	contrast_effect_unadjusted_pvalci	NA
10.1080/03007995.2021.1971182	results	1	NA	contrast_effect_adjusted_value	0.00714
10.1080/03007995.2021.1971182	results	1	NA	contrast_effect_adjusted_pvalci	<0.0001
10.1080/03007995.2021.1971182	results	1	NA	adjustment_geographical	NA
10.1080/03007995.2021.1971182	results	1	NA	ss_total_ipd	NA
10.1080/03007995.2021.1971182	results	1	NA	ss_adjusted_total_ipd	NA
10.1080/03007995.2021.1971182	results	1	NA	ss_total_nonipd	NA
10.1080/03007995.2021.1971182	results	1	NA	ss_anchor_nonipd	98
10.1080/03007995.2021.1971182	results	1	NA	ss_anchor_ipd	32
10.1080/03007995.2021.1971182	results	1	NA	ss_adjusted_anchor_ipd	12
10.1080/03007995.2021.1971182	results	1	NA	effect_cutoff	0
10.1080/03007995.2021.1971182	results	1	NA	adjusted_pval	<0.0001
10.1080/03007995.2021.1971182	results	1	NA	adjusted_significant	TRUE
10.1080/03007995.2021.1971182	study_information	NA	1	ipd_yn	Yes
10.1080/03007995.2021.1971182	study_information	NA	1	ct_yn	Yes
10.1080/03007995.2021.1971182	study_information	NA	1	nct	NCT03500549
10.1080/03007995.2021.1971182	study_information	NA	1	country_study	international
10.1080/03007995.2021.1971182	study_information	NA	1	ct_phase	3
10.1080/03007995.2021.1971182	study_information	NA	1	ct_arms	2 or more
10.1080/03007995.2021.1971182	study_information	NA	2	ipd_yn	No
10.1080/03007995.2021.1971182	study_information	NA	2	ct_yn	Yes
10.1080/03007995.2021.1971182	study_information	NA	2	nct	NCT03056040
10.1080/03007995.2021.1971182	study_information	NA	2	country_study	international
10.1080/03007995.2021.1971182	study_information	NA	2	ct_phase	3
10.1080/03007995.2021.1971182	study_information	NA	2	ct_arms	2 or more
10.1080/03007995.2022.2030112	general_information	NA	NA	condition_name	uncontrolled hypertension
10.1080/03007995.2022.2030112	general_information	NA	NA	country_first_author	germany
10.1080/03007995.2022.2030112	general_information	NA	NA	country_last_author	germany
10.1080/03007995.2022.2030112	general_information	NA	NA	positions	Pharmaceutical Industry
10.1080/03007995.2022.2030112	general_information	NA	NA	methodologist_yn	Yes
10.1080/03007995.2022.2030112	general_information	NA	NA	funding_source	Pharmaceutical Industry
10.1080/03007995.2022.2030112	general_information	NA	NA	pharmaceutical_ties_yn	Yes
10.1080/03007995.2022.2030112	general_information	NA	NA	systematic_review_yn	Yes
10.1080/03007995.2022.2030112	methodology	1	NA	outcome_name	change in systolic blood pressures from baseline to following 8 weeks of treatment
10.1080/03007995.2022.2030112	methodology	1	NA	outcome_short_name	Systolic blood pressure change
10.1080/03007995.2022.2030112	methodology	1	NA	outcome_variable_type	Continuous (count, mean, ...)
10.1080/03007995.2022.2030112	methodology	1	NA	treatment_name_ipd	amlodipine 5 mg + bisoprolol 5 mg
10.1080/03007995.2022.2030112	methodology	1	NA	studies_number_ipd	1
10.1080/03007995.2022.2030112	methodology	1	NA	treatment_name_nonipd	amlodipine 10mg,
10.1080/03007995.2022.2030112	methodology	1	NA	studies_number_nonipd	2
10.1080/03007995.2022.2030112	methodology	1	NA	paic_type	STC
10.1080/03007995.2022.2030112	methodology	1	NA	anchored_yn	Yes
10.1080/03007995.2022.2030112	methodology	1	NA	paic_form	Simple (ie treatments effects extracted from two studies)
10.1080/03007995.2022.2030112	methodology	1	NA	primary_outcome_yn	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.1080/03007995.2022.2030112	methodology	1	NA	variables_selection_justification	Literature based (clinically or methodologically relevant to adjust on these variables based on the literature search conducted for this specific purpose)
10.1080/03007995.2022.2030112	methodology	1	NA	pf_yn	Yes
10.1080/03007995.2022.2030112	methodology	1	NA	tem_yn	Yes
10.1080/03007995.2022.2030112	methodology	1	NA	adjustment_model_details_yn	No
10.1080/03007995.2022.2030112	methodology	1	NA	scale_choice_yn	No
10.1080/03007995.2022.2030112	results	1	NA	contrast_effect_type	Means difference
10.1080/03007995.2022.2030112	results	1	NA	direction_benefit	inferior
10.1080/03007995.2022.2030112	results	1	NA	ss_ttt_nonipd	261
10.1080/03007995.2022.2030112	results	1	NA	ss_ttt_ipd	178
10.1080/03007995.2022.2030112	results	1	NA	ss_adjusted_ttt_ipd	178
10.1080/03007995.2022.2030112	results	1	NA	weights_yn	Not mentioned
10.1080/03007995.2022.2030112	results	1	NA	covariates_yn	Yes
10.1080/03007995.2022.2030112	results	1	NA	covariates_n	7
10.1080/03007995.2022.2030112	results	1	NA	covariates_names	Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Comorbidities and medical history (beside pathology/disease of interest in the comparison), Other(s)
10.1080/03007995.2022.2030112	results	1	NA	contrast_effect_direction	Numerator if ratio, or left side if difference
10.1080/03007995.2022.2030112	results	1	NA	contrast_effect_unadjusted_value	-0.3
10.1080/03007995.2022.2030112	results	1	NA	contrast_effect_unadjusted_pvalci	NA
10.1080/03007995.2022.2030112	results	1	NA	contrast_effect_adjusted_value	-1.6
10.1080/03007995.2022.2030112	results	1	NA	contrast_effect_adjusted_pvalci	[-5.3;2.2]
10.1080/03007995.2022.2030112	results	1	NA	adjustment_geographical	No
10.1080/03007995.2022.2030112	results	1	NA	ss_total_ipd	NA
10.1080/03007995.2022.2030112	results	1	NA	ss_adjusted_total_ipd	NA
10.1080/03007995.2022.2030112	results	1	NA	ss_total_nonipd	NA
10.1080/03007995.2022.2030112	results	1	NA	ss_anchor_nonipd	255
10.1080/03007995.2022.2030112	results	1	NA	ss_anchor_ipd	179
10.1080/03007995.2022.2030112	results	1	NA	ss_adjusted_anchor_ipd	179
10.1080/03007995.2022.2030112	results	1	NA	effect_cutoff	0
10.1080/03007995.2022.2030112	results	1	NA	adjusted_lb_ci	-5.3
10.1080/03007995.2022.2030112	results	1	NA	adjusted_ub_ci	2.2
10.1080/03007995.2022.2030112	results	1	NA	adjusted_significant	FALSE
10.1080/03007995.2022.2030112	study_information	NA	1	ipd_yn	Yes
10.1080/03007995.2022.2030112	study_information	NA	1	ct_yn	Yes
10.1080/03007995.2022.2030112	study_information	NA	1	eudract	2019-000751-13
10.1080/03007995.2022.2030112	study_information	NA	1	country_study	poland
10.1080/03007995.2022.2030112	study_information	NA	1	ct_phase	3
10.1080/03007995.2022.2030112	study_information	NA	1	ct_arms	2 or more
10.1080/03007995.2022.2030112	study_information	NA	2	ipd_yn	No
10.1080/03007995.2022.2030112	study_information	NA	2	ct_yn	Yes
10.1080/03007995.2022.2030112	study_information	NA	2	nct	NCT00558428
10.1080/03007995.2022.2030112	study_information	NA	2	country_study	international
10.1080/03007995.2022.2030112	study_information	NA	2	ct_phase	3
10.1080/03007995.2022.2030112	study_information	NA	2	ct_arms	2 or more
10.1080/09546634.2020.1747592	general_information	NA	NA	condition_name	moderate-to-severe plaque psoriasis
10.1080/09546634.2020.1747592	general_information	NA	NA	country_first_author	usa
10.1080/09546634.2020.1747592	general_information	NA	NA	country_last_author	germany
10.1080/09546634.2020.1747592	general_information	NA	NA	positions	Academic, Pharmaceutical Industry
10.1080/09546634.2020.1747592	general_information	NA	NA	methodologist_yn	Not mentioned
10.1080/09546634.2020.1747592	general_information	NA	NA	funding_source	Pharmaceutical Industry
10.1080/09546634.2020.1747592	general_information	NA	NA	pharmaceutical_ties_yn	Yes
10.1080/09546634.2020.1747592	general_information	NA	NA	systematic_review_yn	No
10.1080/09546634.2020.1747592	methodology	1	NA	outcome_name	rate of psoriasis area severity index (pasi) 75 improvement responders
10.1080/09546634.2020.1747592	methodology	1	NA	outcome_short_name	PASI 75 Responders Rate
10.1080/09546634.2020.1747592	methodology	1	NA	outcome_variable_type	Binary (eg rates)
10.1080/09546634.2020.1747592	methodology	1	NA	treatment_name_ipd	ixekizumab
10.1080/09546634.2020.1747592	methodology	1	NA	studies_number_ipd	1;2;3
10.1080/09546634.2020.1747592	methodology	1	NA	treatment_name_nonipd	guselkumab
10.1080/09546634.2020.1747592	methodology	1	NA	studies_number_nonipd	5
10.1080/09546634.2020.1747592	methodology	1	NA	paic_type	MAIC
10.1080/09546634.2020.1747592	methodology	1	NA	anchored_yn	Yes
10.1080/09546634.2020.1747592	methodology	1	NA	paic_form	Aggregation of multiple studies to estimate individual treatment effects (e.g. meta-analysis in a first step to estimate treatment A effect, then population adjusted indirect comparison using treatment A effect estimate)
10.1080/09546634.2020.1747592	methodology	1	NA	primary_outcome_yn	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.1080/09546634.2020.1747592	methodology	1	NA	variables_selection_justification	Nothing mentioned, not reported
10.1080/09546634.2020.1747592	methodology	1	NA	pf_yn	Yes
10.1080/09546634.2020.1747592	methodology	1	NA	tem_yn	Yes
10.1080/09546634.2020.1747592	methodology	1	NA	adjustment_model_details_yn	No
10.1080/09546634.2020.1747592	methodology	1	NA	scale_choice_yn	No
10.1080/09546634.2020.1747592	methodology	2	NA	outcome_name	rate of psoriasis area severity index (pasi) 75 improvement responders
10.1080/09546634.2020.1747592	methodology	2	NA	outcome_short_name	PASI 75 Responders Rate
10.1080/09546634.2020.1747592	methodology	2	NA	outcome_variable_type	Binary (eg rates)
10.1080/09546634.2020.1747592	methodology	2	NA	treatment_name_ipd	ixekizumab
10.1080/09546634.2020.1747592	methodology	2	NA	studies_number_ipd	1;2;3
10.1080/09546634.2020.1747592	methodology	2	NA	treatment_name_nonipd	tildrakizumab 100mg
10.1080/09546634.2020.1747592	methodology	2	NA	studies_number_nonipd	6;7
10.1080/09546634.2020.1747592	methodology	2	NA	paic_type	MAIC
10.1080/09546634.2020.1747592	methodology	2	NA	anchored_yn	Yes
10.1080/09546634.2020.1747592	methodology	2	NA	paic_form	Aggregation of multiple studies to estimate individual treatment effects (e.g. meta-analysis in a first step to estimate treatment A effect, then population adjusted indirect comparison using treatment A effect estimate)
10.1080/09546634.2020.1747592	methodology	2	NA	primary_outcome_yn	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.1080/09546634.2020.1747592	methodology	2	NA	variables_selection_justification	Nothing mentioned, not reported
10.1080/09546634.2020.1747592	methodology	2	NA	pf_yn	Yes
10.1080/09546634.2020.1747592	methodology	2	NA	tem_yn	Yes
10.1080/09546634.2020.1747592	methodology	2	NA	adjustment_model_details_yn	No
10.1080/09546634.2020.1747592	methodology	2	NA	scale_choice_yn	No
10.1080/09546634.2020.1747592	methodology	3	NA	outcome_name	rate of psoriasis area severity index (pasi) 75 improvement responders
10.1080/09546634.2020.1747592	methodology	3	NA	outcome_short_name	PASI 75 Responders Rate
10.1080/09546634.2020.1747592	methodology	3	NA	outcome_variable_type	Binary (eg rates)
10.1080/09546634.2020.1747592	methodology	3	NA	treatment_name_ipd	ixekizumab
10.1080/09546634.2020.1747592	methodology	3	NA	studies_number_ipd	1;2;3
10.1080/09546634.2020.1747592	methodology	3	NA	treatment_name_nonipd	tildrakizumab 200mg
10.1080/09546634.2020.1747592	methodology	3	NA	studies_number_nonipd	6;7
10.1080/09546634.2020.1747592	methodology	3	NA	paic_type	MAIC
10.1080/09546634.2020.1747592	methodology	3	NA	anchored_yn	Yes
10.1080/09546634.2020.1747592	methodology	3	NA	paic_form	Aggregation of multiple studies to estimate individual treatment effects (e.g. meta-analysis in a first step to estimate treatment A effect, then population adjusted indirect comparison using treatment A effect estimate)
10.1080/09546634.2020.1747592	methodology	3	NA	primary_outcome_yn	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.1080/09546634.2020.1747592	methodology	3	NA	variables_selection_justification	Nothing mentioned, not reported
10.1080/09546634.2020.1747592	methodology	3	NA	pf_yn	Yes
10.1080/09546634.2020.1747592	methodology	3	NA	tem_yn	Yes
10.1080/09546634.2020.1747592	methodology	3	NA	adjustment_model_details_yn	No
10.1080/09546634.2020.1747592	methodology	3	NA	scale_choice_yn	No
10.1080/09546634.2020.1747592	methodology	4	NA	outcome_name	rate of psoriasis area severity index (pasi) 75 improvement responders
10.1080/09546634.2020.1747592	methodology	4	NA	outcome_short_name	PASI 75 Responders Rate
10.1080/09546634.2020.1747592	methodology	4	NA	outcome_variable_type	Binary (eg rates)
10.1080/09546634.2020.1747592	methodology	4	NA	treatment_name_ipd	ixekizumab
10.1080/09546634.2020.1747592	methodology	4	NA	studies_number_ipd	2;3
10.1080/09546634.2020.1747592	methodology	4	NA	treatment_name_nonipd	tildrakizumab 100mg
10.1080/09546634.2020.1747592	methodology	4	NA	studies_number_nonipd	6;7
10.1080/09546634.2020.1747592	methodology	4	NA	paic_type	MAIC
10.1080/09546634.2020.1747592	methodology	4	NA	anchored_yn	Yes
10.1080/09546634.2020.1747592	methodology	4	NA	paic_form	Aggregation of multiple studies to estimate individual treatment effects (e.g. meta-analysis in a first step to estimate treatment A effect, then population adjusted indirect comparison using treatment A effect estimate)
10.1080/09546634.2020.1747592	methodology	4	NA	primary_outcome_yn	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.1080/09546634.2020.1747592	methodology	4	NA	variables_selection_justification	Nothing mentioned, not reported
10.1080/09546634.2020.1747592	methodology	4	NA	pf_yn	Yes
10.1080/09546634.2020.1747592	methodology	4	NA	tem_yn	Yes
10.1080/09546634.2020.1747592	methodology	4	NA	adjustment_model_details_yn	No
10.1080/09546634.2020.1747592	methodology	4	NA	scale_choice_yn	No
10.1080/09546634.2020.1747592	methodology	5	NA	outcome_name	rate of psoriasis area severity index (pasi) 75 improvement responders
10.1080/09546634.2020.1747592	methodology	5	NA	outcome_short_name	PASI 75 Responders Rate
10.1080/09546634.2020.1747592	methodology	5	NA	outcome_variable_type	Binary (eg rates)
10.1080/09546634.2020.1747592	methodology	5	NA	treatment_name_ipd	ixekizumab
10.1080/09546634.2020.1747592	methodology	5	NA	studies_number_ipd	2;3
10.1080/09546634.2020.1747592	methodology	5	NA	treatment_name_nonipd	tildrakizumab 200mg
10.1080/09546634.2020.1747592	methodology	5	NA	studies_number_nonipd	6;7
10.1080/09546634.2020.1747592	methodology	5	NA	paic_type	MAIC
10.1080/09546634.2020.1747592	methodology	5	NA	anchored_yn	Yes
10.1080/09546634.2020.1747592	methodology	5	NA	paic_form	Aggregation of multiple studies to estimate individual treatment effects (e.g. meta-analysis in a first step to estimate treatment A effect, then population adjusted indirect comparison using treatment A effect estimate)
10.1080/09546634.2020.1747592	methodology	5	NA	primary_outcome_yn	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.1080/09546634.2020.1747592	methodology	5	NA	variables_selection_justification	Nothing mentioned, not reported
10.1080/09546634.2020.1747592	methodology	5	NA	pf_yn	Yes
10.1080/09546634.2020.1747592	methodology	5	NA	tem_yn	Yes
10.1080/09546634.2020.1747592	methodology	5	NA	adjustment_model_details_yn	No
10.1080/09546634.2020.1747592	methodology	5	NA	scale_choice_yn	No
10.1080/09546634.2020.1747592	methodology	6	NA	outcome_name	rate of psoriasis area severity index (pasi) 75 improvement responders
10.1080/09546634.2020.1747592	methodology	6	NA	outcome_short_name	PASI 75 Responders Rate
10.1080/09546634.2020.1747592	methodology	6	NA	outcome_variable_type	Binary (eg rates)
10.1080/09546634.2020.1747592	methodology	6	NA	treatment_name_ipd	ixekizumab
10.1080/09546634.2020.1747592	methodology	6	NA	studies_number_ipd	1;2;3
10.1080/09546634.2020.1747592	methodology	6	NA	treatment_name_nonipd	risankizumab
10.1080/09546634.2020.1747592	methodology	6	NA	studies_number_nonipd	8
10.1080/09546634.2020.1747592	methodology	6	NA	paic_type	MAIC
10.1080/09546634.2020.1747592	methodology	6	NA	anchored_yn	Yes
10.1080/09546634.2020.1747592	methodology	6	NA	paic_form	Aggregation of multiple studies to estimate individual treatment effects (e.g. meta-analysis in a first step to estimate treatment A effect, then population adjusted indirect comparison using treatment A effect estimate)
10.1080/09546634.2020.1747592	methodology	6	NA	primary_outcome_yn	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.1080/09546634.2020.1747592	methodology	6	NA	variables_selection_justification	Nothing mentioned, not reported
10.1080/09546634.2020.1747592	methodology	6	NA	pf_yn	Yes
10.1080/09546634.2020.1747592	methodology	6	NA	tem_yn	Yes
10.1080/09546634.2020.1747592	methodology	6	NA	adjustment_model_details_yn	No
10.1080/09546634.2020.1747592	methodology	6	NA	scale_choice_yn	No
10.1080/09546634.2020.1747592	methodology	7	NA	outcome_name	rate of psoriasis area severity index (pasi) 75 improvement responders
10.1080/09546634.2020.1747592	methodology	7	NA	outcome_short_name	PASI 75 Responders Rate
10.1080/09546634.2020.1747592	methodology	7	NA	outcome_variable_type	Binary (eg rates)
10.1080/09546634.2020.1747592	methodology	7	NA	treatment_name_ipd	ixekizumab
10.1080/09546634.2020.1747592	methodology	7	NA	studies_number_ipd	4
10.1080/09546634.2020.1747592	methodology	7	NA	treatment_name_nonipd	risankizumab
10.1080/09546634.2020.1747592	methodology	7	NA	studies_number_nonipd	8;9
10.1080/09546634.2020.1747592	methodology	7	NA	paic_type	MAIC
10.1080/09546634.2020.1747592	methodology	7	NA	anchored_yn	Yes
10.1080/09546634.2020.1747592	methodology	7	NA	paic_form	Aggregation of multiple studies to estimate individual treatment effects (e.g. meta-analysis in a first step to estimate treatment A effect, then population adjusted indirect comparison using treatment A effect estimate)
10.1080/09546634.2020.1747592	methodology	7	NA	primary_outcome_yn	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.1080/09546634.2020.1747592	methodology	7	NA	variables_selection_justification	Nothing mentioned, not reported
10.1080/09546634.2020.1747592	methodology	7	NA	pf_yn	Yes
10.1080/09546634.2020.1747592	methodology	7	NA	tem_yn	Yes
10.1080/09546634.2020.1747592	methodology	7	NA	adjustment_model_details_yn	No
10.1080/09546634.2020.1747592	methodology	7	NA	scale_choice_yn	No
10.1080/09546634.2020.1747592	results	1	NA	contrast_effect_type	Risk difference
10.1080/09546634.2020.1747592	results	1	NA	direction_benefit	superior
10.1080/09546634.2020.1747592	results	1	NA	ss_ttt_nonipd	NA
10.1080/09546634.2020.1747592	results	1	NA	ss_ttt_ipd	NA
10.1080/09546634.2020.1747592	results	1	NA	ss_adjusted_ttt_ipd	NA
10.1080/09546634.2020.1747592	results	1	NA	weights_yn	Not mentioned
10.1080/09546634.2020.1747592	results	1	NA	covariates_yn	Yes
10.1080/09546634.2020.1747592	results	1	NA	covariates_n	8
10.1080/09546634.2020.1747592	results	1	NA	covariates_names	Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Past treatments for the disease of interest, Other(s)
10.1080/09546634.2020.1747592	results	1	NA	contrast_effect_direction	Numerator if ratio, or left side if difference
10.1080/09546634.2020.1747592	results	1	NA	contrast_effect_unadjusted_value	8.3
10.1080/09546634.2020.1747592	results	1	NA	contrast_effect_unadjusted_pvalci	[2.4;14.2] p<0.01
10.1080/09546634.2020.1747592	results	1	NA	contrast_effect_adjusted_value	8
10.1080/09546634.2020.1747592	results	1	NA	contrast_effect_adjusted_pvalci	[2.0;14.1] p<0.01
10.1080/09546634.2020.1747592	results	1	NA	adjustment_geographical	No
10.1080/09546634.2020.1747592	results	1	NA	ss_total_ipd	1952
10.1080/09546634.2020.1747592	results	1	NA	ss_adjusted_total_ipd	1717
10.1080/09546634.2020.1747592	results	1	NA	ss_total_nonipd	503
10.1080/09546634.2020.1747592	results	1	NA	ss_anchor_nonipd	NA
10.1080/09546634.2020.1747592	results	1	NA	ss_anchor_ipd	NA
10.1080/09546634.2020.1747592	results	1	NA	ss_adjusted_anchor_ipd	NA
10.1080/09546634.2020.1747592	results	1	NA	effect_cutoff	0
10.1080/09546634.2020.1747592	results	1	NA	unadjusted_lb_ci	2.4
10.1080/09546634.2020.1747592	results	1	NA	unadjusted_ub_ci	14.2
10.1080/09546634.2020.1747592	results	1	NA	unadjusted_pval	<0.01
10.1080/09546634.2020.1747592	results	1	NA	unadjusted_significant	TRUE
10.1080/09546634.2020.1747592	results	1	NA	adjusted_lb_ci	2
10.1080/09546634.2020.1747592	results	1	NA	adjusted_ub_ci	14.1
10.1080/09546634.2020.1747592	results	1	NA	adjusted_pval	<0.01
10.1080/09546634.2020.1747592	results	1	NA	adjusted_significant	TRUE
10.1080/09546634.2020.1747592	results	2	NA	contrast_effect_type	Risk difference
10.1080/09546634.2020.1747592	results	2	NA	direction_benefit	superior
10.1080/09546634.2020.1747592	results	2	NA	ss_ttt_nonipd	NA
10.1080/09546634.2020.1747592	results	2	NA	ss_ttt_ipd	NA
10.1080/09546634.2020.1747592	results	2	NA	ss_adjusted_ttt_ipd	NA
10.1080/09546634.2020.1747592	results	2	NA	weights_yn	Not mentioned
10.1080/09546634.2020.1747592	results	2	NA	covariates_yn	Yes
10.1080/09546634.2020.1747592	results	2	NA	covariates_n	5
10.1080/09546634.2020.1747592	results	2	NA	covariates_names	Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Past treatments for the disease of interest
10.1080/09546634.2020.1747592	results	2	NA	contrast_effect_direction	Numerator if ratio, or left side if difference
10.1080/09546634.2020.1747592	results	2	NA	contrast_effect_unadjusted_value	27.7
10.1080/09546634.2020.1747592	results	2	NA	contrast_effect_unadjusted_pvalci	[22.5;32.8] p<0.001
10.1080/09546634.2020.1747592	results	2	NA	contrast_effect_adjusted_value	27
10.1080/09546634.2020.1747592	results	2	NA	contrast_effect_adjusted_pvalci	[21.6;32.3] p<0.001
10.1080/09546634.2020.1747592	results	2	NA	adjustment_geographical	NA
10.1080/09546634.2020.1747592	results	2	NA	ss_total_ipd	1952
10.1080/09546634.2020.1747592	results	2	NA	ss_adjusted_total_ipd	1565
10.1080/09546634.2020.1747592	results	2	NA	ss_total_nonipd	927
10.1080/09546634.2020.1747592	results	2	NA	ss_anchor_nonipd	NA
10.1080/09546634.2020.1747592	results	2	NA	ss_anchor_ipd	NA
10.1080/09546634.2020.1747592	results	2	NA	ss_adjusted_anchor_ipd	NA
10.1080/09546634.2020.1747592	results	2	NA	effect_cutoff	0
10.1080/09546634.2020.1747592	results	2	NA	unadjusted_lb_ci	22.5
10.1080/09546634.2020.1747592	results	2	NA	unadjusted_ub_ci	32.8
10.1080/09546634.2020.1747592	results	2	NA	unadjusted_pval	<0.001
10.1080/09546634.2020.1747592	results	2	NA	unadjusted_significant	TRUE
10.1080/09546634.2020.1747592	results	2	NA	adjusted_lb_ci	21.6
10.1080/09546634.2020.1747592	results	2	NA	adjusted_ub_ci	32.3
10.1080/09546634.2020.1747592	results	2	NA	adjusted_pval	<0.001
10.1080/09546634.2020.1747592	results	2	NA	adjusted_significant	TRUE
10.1080/09546634.2020.1747592	results	3	NA	contrast_effect_type	Risk difference
10.1080/09546634.2020.1747592	results	3	NA	direction_benefit	superior
10.1080/09546634.2020.1747592	results	3	NA	ss_ttt_nonipd	NA
10.1080/09546634.2020.1747592	results	3	NA	ss_ttt_ipd	NA
10.1080/09546634.2020.1747592	results	3	NA	ss_adjusted_ttt_ipd	NA
10.1080/09546634.2020.1747592	results	3	NA	weights_yn	Not mentioned
10.1080/09546634.2020.1747592	results	3	NA	covariates_yn	Yes
10.1080/09546634.2020.1747592	results	3	NA	covariates_n	5
10.1080/09546634.2020.1747592	results	3	NA	covariates_names	Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Past treatments for the disease of interest
10.1080/09546634.2020.1747592	results	3	NA	contrast_effect_direction	Numerator if ratio, or left side if difference
10.1080/09546634.2020.1747592	results	3	NA	contrast_effect_unadjusted_value	26.4
10.1080/09546634.2020.1747592	results	3	NA	contrast_effect_unadjusted_pvalci	[21.3;31.5] p<0.001
10.1080/09546634.2020.1747592	results	3	NA	contrast_effect_adjusted_value	25.7
10.1080/09546634.2020.1747592	results	3	NA	contrast_effect_adjusted_pvalci	[20.4;31.0] p<0.001
10.1080/09546634.2020.1747592	results	3	NA	adjustment_geographical	NA
10.1080/09546634.2020.1747592	results	3	NA	ss_total_ipd	1952
10.1080/09546634.2020.1747592	results	3	NA	ss_adjusted_total_ipd	1588
10.1080/09546634.2020.1747592	results	3	NA	ss_total_nonipd	927
10.1080/09546634.2020.1747592	results	3	NA	ss_anchor_nonipd	NA
10.1080/09546634.2020.1747592	results	3	NA	ss_anchor_ipd	NA
10.1080/09546634.2020.1747592	results	3	NA	ss_adjusted_anchor_ipd	NA
10.1080/09546634.2020.1747592	results	3	NA	effect_cutoff	0
10.1080/09546634.2020.1747592	results	3	NA	unadjusted_lb_ci	21.3
10.1080/09546634.2020.1747592	results	3	NA	unadjusted_ub_ci	31.5
10.1080/09546634.2020.1747592	results	3	NA	unadjusted_pval	<0.001
10.1080/09546634.2020.1747592	results	3	NA	unadjusted_significant	TRUE
10.1080/09546634.2020.1747592	results	3	NA	adjusted_lb_ci	20.4
10.1080/09546634.2020.1747592	results	3	NA	adjusted_ub_ci	31
10.1080/09546634.2020.1747592	results	3	NA	adjusted_pval	<0.001
10.1080/09546634.2020.1747592	results	3	NA	adjusted_significant	TRUE
10.1080/09546634.2020.1747592	results	4	NA	contrast_effect_type	Risk difference
10.1080/09546634.2020.1747592	results	4	NA	direction_benefit	superior
10.1080/09546634.2020.1747592	results	4	NA	ss_ttt_nonipd	NA
10.1080/09546634.2020.1747592	results	4	NA	ss_ttt_ipd	NA
10.1080/09546634.2020.1747592	results	4	NA	ss_adjusted_ttt_ipd	NA
10.1080/09546634.2020.1747592	results	4	NA	weights_yn	Not mentioned
10.1080/09546634.2020.1747592	results	4	NA	covariates_yn	Yes
10.1080/09546634.2020.1747592	results	4	NA	covariates_n	5
10.1080/09546634.2020.1747592	results	4	NA	covariates_names	Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Past treatments for the disease of interest
10.1080/09546634.2020.1747592	results	4	NA	contrast_effect_direction	Numerator if ratio, or left side if difference
10.1080/09546634.2020.1747592	results	4	NA	contrast_effect_unadjusted_value	28.1
10.1080/09546634.2020.1747592	results	4	NA	contrast_effect_unadjusted_pvalci	[19.2;37.0] p<0.001
10.1080/09546634.2020.1747592	results	4	NA	contrast_effect_adjusted_value	25.7
10.1080/09546634.2020.1747592	results	4	NA	contrast_effect_adjusted_pvalci	[16.5;34.9] p<0.001
10.1080/09546634.2020.1747592	results	4	NA	adjustment_geographical	NA
10.1080/09546634.2020.1747592	results	4	NA	ss_total_ipd	1470
10.1080/09546634.2020.1747592	results	4	NA	ss_adjusted_total_ipd	1108
10.1080/09546634.2020.1747592	results	4	NA	ss_total_nonipd	463
10.1080/09546634.2020.1747592	results	4	NA	ss_anchor_nonipd	NA
10.1080/09546634.2020.1747592	results	4	NA	ss_anchor_ipd	NA
10.1080/09546634.2020.1747592	results	4	NA	ss_adjusted_anchor_ipd	NA
10.1080/09546634.2020.1747592	results	4	NA	effect_cutoff	0
10.1080/09546634.2020.1747592	results	4	NA	unadjusted_lb_ci	19.2
10.1080/09546634.2020.1747592	results	4	NA	unadjusted_ub_ci	37
10.1080/09546634.2020.1747592	results	4	NA	unadjusted_pval	<0.001
10.1080/09546634.2020.1747592	results	4	NA	unadjusted_significant	TRUE
10.1080/09546634.2020.1747592	results	4	NA	adjusted_lb_ci	16.5
10.1080/09546634.2020.1747592	results	4	NA	adjusted_ub_ci	34.9
10.1080/09546634.2020.1747592	results	4	NA	adjusted_pval	<0.001
10.1080/09546634.2020.1747592	results	4	NA	adjusted_significant	TRUE
10.1080/09546634.2020.1747592	results	5	NA	contrast_effect_type	Risk difference
10.1080/09546634.2020.1747592	results	5	NA	direction_benefit	superior
10.1080/09546634.2020.1747592	results	5	NA	ss_ttt_nonipd	NA
10.1080/09546634.2020.1747592	results	5	NA	ss_ttt_ipd	NA
10.1080/09546634.2020.1747592	results	5	NA	ss_adjusted_ttt_ipd	NA
10.1080/09546634.2020.1747592	results	5	NA	weights_yn	Not mentioned
10.1080/09546634.2020.1747592	results	5	NA	covariates_yn	Yes
10.1080/09546634.2020.1747592	results	5	NA	covariates_n	5
10.1080/09546634.2020.1747592	results	5	NA	covariates_names	Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Past treatments for the disease of interest
10.1080/09546634.2020.1747592	results	5	NA	contrast_effect_direction	Numerator if ratio, or left side if difference
10.1080/09546634.2020.1747592	results	5	NA	contrast_effect_unadjusted_value	24.1
10.1080/09546634.2020.1747592	results	5	NA	contrast_effect_unadjusted_pvalci	[15.3;32.9] p<0.001
10.1080/09546634.2020.1747592	results	5	NA	contrast_effect_adjusted_value	21.7
10.1080/09546634.2020.1747592	results	5	NA	contrast_effect_adjusted_pvalci	[12.7;30.7] p<0.001
10.1080/09546634.2020.1747592	results	5	NA	adjustment_geographical	NA
10.1080/09546634.2020.1747592	results	5	NA	ss_total_ipd	1470
10.1080/09546634.2020.1747592	results	5	NA	ss_adjusted_total_ipd	1163
10.1080/09546634.2020.1747592	results	5	NA	ss_total_nonipd	470
10.1080/09546634.2020.1747592	results	5	NA	ss_anchor_nonipd	NA
10.1080/09546634.2020.1747592	results	5	NA	ss_anchor_ipd	NA
10.1080/09546634.2020.1747592	results	5	NA	ss_adjusted_anchor_ipd	NA
10.1080/09546634.2020.1747592	results	5	NA	effect_cutoff	0
10.1080/09546634.2020.1747592	results	5	NA	unadjusted_lb_ci	15.3
10.1080/09546634.2020.1747592	results	5	NA	unadjusted_ub_ci	32.9
10.1080/09546634.2020.1747592	results	5	NA	unadjusted_pval	<0.001
10.1080/09546634.2020.1747592	results	5	NA	unadjusted_significant	TRUE
10.1080/09546634.2020.1747592	results	5	NA	adjusted_lb_ci	12.7
10.1080/09546634.2020.1747592	results	5	NA	adjusted_ub_ci	30.7
10.1080/09546634.2020.1747592	results	5	NA	adjusted_pval	<0.001
10.1080/09546634.2020.1747592	results	5	NA	adjusted_significant	TRUE
10.1080/09546634.2020.1747592	results	6	NA	contrast_effect_type	Risk difference
10.1080/09546634.2020.1747592	results	6	NA	direction_benefit	superior
10.1080/09546634.2020.1747592	results	6	NA	ss_ttt_nonipd	NA
10.1080/09546634.2020.1747592	results	6	NA	ss_ttt_ipd	NA
10.1080/09546634.2020.1747592	results	6	NA	ss_adjusted_ttt_ipd	NA
10.1080/09546634.2020.1747592	results	6	NA	weights_yn	Not mentioned
10.1080/09546634.2020.1747592	results	6	NA	covariates_yn	Yes
10.1080/09546634.2020.1747592	results	6	NA	covariates_n	8
10.1080/09546634.2020.1747592	results	6	NA	covariates_names	Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Race/ethnicity, Past treatments for the disease of interest, Other(s)
10.1080/09546634.2020.1747592	results	6	NA	contrast_effect_direction	Numerator if ratio, or left side if difference
10.1080/09546634.2020.1747592	results	6	NA	contrast_effect_unadjusted_value	5.5
10.1080/09546634.2020.1747592	results	6	NA	contrast_effect_unadjusted_pvalci	[0.2;10.8] p<0.05
10.1080/09546634.2020.1747592	results	6	NA	contrast_effect_adjusted_value	5.5
10.1080/09546634.2020.1747592	results	6	NA	contrast_effect_adjusted_pvalci	[-0.1;11.0]
10.1080/09546634.2020.1747592	results	6	NA	adjustment_geographical	No
10.1080/09546634.2020.1747592	results	6	NA	ss_total_ipd	1952
10.1080/09546634.2020.1747592	results	6	NA	ss_adjusted_total_ipd	1398
10.1080/09546634.2020.1747592	results	6	NA	ss_total_nonipd	798
10.1080/09546634.2020.1747592	results	6	NA	ss_anchor_nonipd	NA
10.1080/09546634.2020.1747592	results	6	NA	ss_anchor_ipd	NA
10.1080/09546634.2020.1747592	results	6	NA	ss_adjusted_anchor_ipd	NA
10.1080/09546634.2020.1747592	results	6	NA	effect_cutoff	0
10.1080/09546634.2020.1747592	results	6	NA	unadjusted_lb_ci	0.2
10.1080/09546634.2020.1747592	results	6	NA	unadjusted_ub_ci	10.8
10.1080/09546634.2020.1747592	results	6	NA	unadjusted_pval	<0.05
10.1080/09546634.2020.1747592	results	6	NA	unadjusted_significant	TRUE
10.1080/09546634.2020.1747592	results	6	NA	adjusted_lb_ci	-0.1
10.1080/09546634.2020.1747592	results	6	NA	adjusted_ub_ci	11
10.1080/09546634.2020.1747592	results	6	NA	adjusted_significant	FALSE
10.1080/09546634.2020.1747592	results	7	NA	contrast_effect_type	Risk difference
10.1080/09546634.2020.1747592	results	7	NA	direction_benefit	superior
10.1080/09546634.2020.1747592	results	7	NA	ss_ttt_nonipd	NA
10.1080/09546634.2020.1747592	results	7	NA	ss_ttt_ipd	NA
10.1080/09546634.2020.1747592	results	7	NA	ss_adjusted_ttt_ipd	NA
10.1080/09546634.2020.1747592	results	7	NA	weights_yn	Not mentioned
10.1080/09546634.2020.1747592	results	7	NA	covariates_yn	Yes
10.1080/09546634.2020.1747592	results	7	NA	covariates_n	8
10.1080/09546634.2020.1747592	results	7	NA	covariates_names	Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Race/ethnicity, Past treatments for the disease of interest, Other(s)
10.1080/09546634.2020.1747592	results	7	NA	contrast_effect_direction	Numerator if ratio, or left side if difference
10.1080/09546634.2020.1747592	results	7	NA	contrast_effect_unadjusted_value	0.8
10.1080/09546634.2020.1747592	results	7	NA	contrast_effect_unadjusted_pvalci	[-10.9;12.6]
10.1080/09546634.2020.1747592	results	7	NA	contrast_effect_adjusted_value	7.8
10.1080/09546634.2020.1747592	results	7	NA	contrast_effect_adjusted_pvalci	[-6.7;22.3]
10.1080/09546634.2020.1747592	results	7	NA	adjustment_geographical	No
10.1080/09546634.2020.1747592	results	7	NA	ss_total_ipd	256
10.1080/09546634.2020.1747592	results	7	NA	ss_adjusted_total_ipd	116
10.1080/09546634.2020.1747592	results	7	NA	ss_total_nonipd	797
10.1080/09546634.2020.1747592	results	7	NA	ss_anchor_nonipd	NA
10.1080/09546634.2020.1747592	results	7	NA	ss_anchor_ipd	NA
10.1080/09546634.2020.1747592	results	7	NA	ss_adjusted_anchor_ipd	NA
10.1080/09546634.2020.1747592	results	7	NA	effect_cutoff	0
10.1080/09546634.2020.1747592	results	7	NA	unadjusted_lb_ci	-10.9
10.1080/09546634.2020.1747592	results	7	NA	unadjusted_ub_ci	12.6
10.1080/09546634.2020.1747592	results	7	NA	unadjusted_significant	FALSE
10.1080/09546634.2020.1747592	results	7	NA	adjusted_lb_ci	-6.7
10.1080/09546634.2020.1747592	results	7	NA	adjusted_ub_ci	22.3
10.1080/09546634.2020.1747592	results	7	NA	adjusted_significant	FALSE
10.1080/09546634.2020.1747592	study_information	NA	1	ipd_yn	Yes
10.1080/09546634.2020.1747592	study_information	NA	1	ct_yn	Yes
10.1080/09546634.2020.1747592	study_information	NA	1	nct	NCT01474512
10.1080/09546634.2020.1747592	study_information	NA	1	country_study	international
10.1080/09546634.2020.1747592	study_information	NA	1	ct_phase	3
10.1080/09546634.2020.1747592	study_information	NA	1	ct_arms	2 or more
10.1080/09546634.2020.1747592	study_information	NA	2	ipd_yn	Yes
10.1080/09546634.2020.1747592	study_information	NA	2	ct_yn	Yes
10.1080/09546634.2020.1747592	study_information	NA	2	nct	NCT01597245
10.1080/09546634.2020.1747592	study_information	NA	2	country_study	international
10.1080/09546634.2020.1747592	study_information	NA	2	ct_phase	3
10.1080/09546634.2020.1747592	study_information	NA	2	ct_arms	2 or more
10.1080/09546634.2020.1747592	study_information	NA	3	ipd_yn	Yes
10.1080/09546634.2020.1747592	study_information	NA	3	ct_yn	Yes
10.1080/09546634.2020.1747592	study_information	NA	3	nct	NCT01646177
10.1080/09546634.2020.1747592	study_information	NA	3	country_study	international
10.1080/09546634.2020.1747592	study_information	NA	3	ct_phase	3
10.1080/09546634.2020.1747592	study_information	NA	3	ct_arms	2 or more
10.1080/09546634.2020.1747592	study_information	NA	4	ipd_yn	Yes
10.1080/09546634.2020.1747592	study_information	NA	4	ct_yn	Yes
10.1080/09546634.2020.1747592	study_information	NA	4	nct	NCT02561806
10.1080/09546634.2020.1747592	study_information	NA	4	country_study	international
10.1080/09546634.2020.1747592	study_information	NA	4	ct_phase	3
10.1080/09546634.2020.1747592	study_information	NA	4	ct_arms	2 or more
10.1080/09546634.2020.1747592	study_information	NA	5	ipd_yn	No
10.1080/09546634.2020.1747592	study_information	NA	5	ct_yn	Yes
10.1080/09546634.2020.1747592	study_information	NA	5	nct	NCT02207244
10.1080/09546634.2020.1747592	study_information	NA	5	country_study	international
10.1080/09546634.2020.1747592	study_information	NA	5	ct_phase	3
10.1080/09546634.2020.1747592	study_information	NA	5	ct_arms	2 or more
10.1080/09546634.2020.1747592	study_information	NA	6	ipd_yn	No
10.1080/09546634.2020.1747592	study_information	NA	6	ct_yn	Yes
10.1080/09546634.2020.1747592	study_information	NA	6	nct	NCT01722331
10.1080/09546634.2020.1747592	study_information	NA	6	ct_phase	3
10.1080/09546634.2020.1747592	study_information	NA	6	ct_arms	2 or more
10.1080/09546634.2020.1747592	study_information	NA	7	ipd_yn	No
10.1080/09546634.2020.1747592	study_information	NA	7	ct_yn	Yes
10.1080/09546634.2020.1747592	study_information	NA	7	nct	NCT01729754
10.1080/09546634.2020.1747592	study_information	NA	7	ct_phase	3
10.1080/09546634.2020.1747592	study_information	NA	7	ct_arms	2 or more
10.1080/09546634.2020.1747592	study_information	NA	8	ipd_yn	No
10.1080/09546634.2020.1747592	study_information	NA	8	ct_yn	Yes
10.1080/09546634.2020.1747592	study_information	NA	8	nct	NCT02684370
10.1080/09546634.2020.1747592	study_information	NA	8	ct_phase	3
10.1080/09546634.2020.1747592	study_information	NA	8	ct_arms	2 or more
10.1080/09546634.2020.1747592	study_information	NA	9	ipd_yn	No
10.1080/09546634.2020.1747592	study_information	NA	9	ct_yn	Yes
10.1080/09546634.2020.1747592	study_information	NA	9	nct	NCT02684357
10.1080/09546634.2020.1747592	study_information	NA	9	ct_phase	3
10.1080/09546634.2020.1747592	study_information	NA	9	ct_arms	2 or more
10.1080/10428194.2019.1675881	general_information	NA	NA	condition_name	transplant ineligible multiple myeloma
10.1080/10428194.2019.1675881	general_information	NA	NA	country_first_author	spain
10.1080/10428194.2019.1675881	general_information	NA	NA	country_last_author	usa
10.1080/10428194.2019.1675881	general_information	NA	NA	positions	Academic, Pharmaceutical Industry, Private Data Analysis Company
10.1080/10428194.2019.1675881	general_information	NA	NA	methodologist_yn	Yes
10.1080/10428194.2019.1675881	general_information	NA	NA	funding_source	Pharmaceutical Industry
10.1080/10428194.2019.1675881	general_information	NA	NA	pharmaceutical_ties_yn	Yes
10.1080/10428194.2019.1675881	general_information	NA	NA	systematic_review_yn	Yes
10.1080/10428194.2019.1675881	methodology	1	NA	outcome_name	progression-free survival
10.1080/10428194.2019.1675881	methodology	1	NA	outcome_short_name	Progression-free Survival
10.1080/10428194.2019.1675881	methodology	1	NA	outcome_variable_type	Time-to-event
10.1080/10428194.2019.1675881	methodology	1	NA	treatment_name_ipd	vmp (bortezomib/melphalan/prednisone)
10.1080/10428194.2019.1675881	methodology	1	NA	studies_number_ipd	1
10.1080/10428194.2019.1675881	methodology	1	NA	treatment_name_nonipd	modified vmp schedule
10.1080/10428194.2019.1675881	methodology	1	NA	studies_number_nonipd	2;3
10.1080/10428194.2019.1675881	methodology	1	NA	paic_type	MAIC
10.1080/10428194.2019.1675881	methodology	1	NA	anchored_yn	No
10.1080/10428194.2019.1675881	methodology	1	NA	paic_form	Aggregation of multiple studies to estimate individual treatment effects (e.g. meta-analysis in a first step to estimate treatment A effect, then population adjusted indirect comparison using treatment A effect estimate)
10.1080/10428194.2019.1675881	methodology	1	NA	primary_outcome_yn	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.1080/10428194.2019.1675881	methodology	1	NA	variables_selection_justification	Literature based (clinically or methodologically relevant to adjust on these variables based on the literature search conducted for this specific purpose)
10.1080/10428194.2019.1675881	methodology	1	NA	pf_yn	Yes
10.1080/10428194.2019.1675881	methodology	1	NA	tem_yn	Yes
10.1080/10428194.2019.1675881	methodology	1	NA	adjustment_model_details_yn	No
10.1080/10428194.2019.1675881	methodology	1	NA	scale_choice_yn	No
10.1080/10428194.2019.1675881	results	1	NA	contrast_effect_type	HR
10.1080/10428194.2019.1675881	results	1	NA	direction_benefit	inferior
10.1080/10428194.2019.1675881	results	1	NA	ss_ttt_nonipd	547
10.1080/10428194.2019.1675881	results	1	NA	ss_ttt_ipd	344
10.1080/10428194.2019.1675881	results	1	NA	ss_adjusted_ttt_ipd	114
10.1080/10428194.2019.1675881	results	1	NA	weights_yn	Yes, mentions that the weights distribution has been studied, and weights distribution reported in main article or supplemental materials
10.1080/10428194.2019.1675881	results	1	NA	covariates_yn	Yes
10.1080/10428194.2019.1675881	results	1	NA	covariates_n	8
10.1080/10428194.2019.1675881	results	1	NA	covariates_names	Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Comorbidities and medical history (beside pathology/disease of interest in the comparison)
10.1080/10428194.2019.1675881	results	1	NA	contrast_effect_direction	Numerator if ratio, or left side if difference
10.1080/10428194.2019.1675881	results	1	NA	contrast_effect_unadjusted_value	0.911
10.1080/10428194.2019.1675881	results	1	NA	contrast_effect_unadjusted_pvalci	0.326
10.1080/10428194.2019.1675881	results	1	NA	contrast_effect_adjusted_value	0.991
10.1080/10428194.2019.1675881	results	1	NA	contrast_effect_adjusted_pvalci	0.935
10.1080/10428194.2019.1675881	results	1	NA	adjustment_geographical	NA
10.1080/10428194.2019.1675881	results	1	NA	ss_total_ipd	NA
10.1080/10428194.2019.1675881	results	1	NA	ss_adjusted_total_ipd	NA
10.1080/10428194.2019.1675881	results	1	NA	ss_total_nonipd	NA
10.1080/10428194.2019.1675881	results	1	NA	ss_anchor_nonipd	NA
10.1080/10428194.2019.1675881	results	1	NA	ss_anchor_ipd	NA
10.1080/10428194.2019.1675881	results	1	NA	ss_adjusted_anchor_ipd	NA
10.1080/10428194.2019.1675881	results	1	NA	effect_cutoff	1
10.1080/10428194.2019.1675881	results	1	NA	unadjusted_pval	0.326
10.1080/10428194.2019.1675881	results	1	NA	unadjusted_num_pval	0.326
10.1080/10428194.2019.1675881	results	1	NA	unadjusted_significant	FALSE
10.1080/10428194.2019.1675881	results	1	NA	adjusted_pval	0.935
10.1080/10428194.2019.1675881	results	1	NA	adjusted_num_pval	0.935
10.1080/10428194.2019.1675881	results	1	NA	adjusted_significant	FALSE
10.1080/10428194.2019.1675881	study_information	NA	1	ipd_yn	Yes
10.1080/10428194.2019.1675881	study_information	NA	1	ct_yn	Yes
10.1080/10428194.2019.1675881	study_information	NA	1	nct	NCT00111319
10.1080/10428194.2019.1675881	study_information	NA	1	country_study	usa
10.1080/10428194.2019.1675881	study_information	NA	1	ct_phase	3
10.1080/10428194.2019.1675881	study_information	NA	1	ct_arms	2 or more
10.1080/10428194.2019.1675881	study_information	NA	2	ipd_yn	No
10.1080/10428194.2019.1675881	study_information	NA	2	ct_yn	Yes
10.1080/10428194.2019.1675881	study_information	NA	2	nct	NCT02195479
10.1080/10428194.2019.1675881	study_information	NA	2	country_study	international
10.1080/10428194.2019.1675881	study_information	NA	2	ct_phase	3
10.1080/10428194.2019.1675881	study_information	NA	2	ct_arms	2 or more
10.1080/10428194.2019.1675881	study_information	NA	3	ipd_yn	No
10.1080/10428194.2019.1675881	study_information	NA	3	ct_yn	Yes
10.1080/10428194.2019.1675881	study_information	NA	3	nct	NCT01063179
10.1080/10428194.2019.1675881	study_information	NA	3	country_study	italy
10.1080/10428194.2019.1675881	study_information	NA	3	ct_phase	3
10.1080/10428194.2019.1675881	study_information	NA	3	ct_arms	2 or more
10.1080/10428194.2019.1682571	general_information	NA	NA	condition_name	multiple myeloma
10.1080/10428194.2019.1682571	general_information	NA	NA	country_first_author	greece
10.1080/10428194.2019.1682571	general_information	NA	NA	country_last_author	usa
10.1080/10428194.2019.1682571	general_information	NA	NA	positions	Academic, Pharmaceutical Industry, Private Data Analysis Company
10.1080/10428194.2019.1682571	general_information	NA	NA	methodologist_yn	Yes
10.1080/10428194.2019.1682571	general_information	NA	NA	funding_source	Pharmaceutical Industry
10.1080/10428194.2019.1682571	general_information	NA	NA	pharmaceutical_ties_yn	Yes
10.1080/10428194.2019.1682571	general_information	NA	NA	systematic_review_yn	No
10.1080/10428194.2019.1682571	methodology	1	NA	outcome_name	overall survival
10.1080/10428194.2019.1682571	methodology	1	NA	outcome_short_name	Overall Survival
10.1080/10428194.2019.1682571	methodology	1	NA	outcome_variable_type	Time-to-event
10.1080/10428194.2019.1682571	methodology	1	NA	treatment_name_ipd	daratumumabbortezomibmelphalanprednisone
10.1080/10428194.2019.1682571	methodology	1	NA	studies_number_ipd	1
10.1080/10428194.2019.1682571	methodology	1	NA	treatment_name_nonipd	lenalidomidedexamethasone continuous
10.1080/10428194.2019.1682571	methodology	1	NA	studies_number_nonipd	2
10.1080/10428194.2019.1682571	methodology	1	NA	paic_type	MAIC
10.1080/10428194.2019.1682571	methodology	1	NA	anchored_yn	No
10.1080/10428194.2019.1682571	methodology	1	NA	paic_form	Simple (ie treatments effects extracted from two studies)
10.1080/10428194.2019.1682571	methodology	1	NA	primary_outcome_yn	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.1080/10428194.2019.1682571	methodology	1	NA	variables_selection_justification	Nothing mentioned, not reported
10.1080/10428194.2019.1682571	methodology	1	NA	pf_yn	No discussion (in the main text) of the status of prognostic factors of the variables
10.1080/10428194.2019.1682571	methodology	1	NA	tem_yn	No discussion (in the main text) of the status of treatment-effect modifiers of the variables
10.1080/10428194.2019.1682571	methodology	1	NA	adjustment_model_details_yn	No
10.1080/10428194.2019.1682571	methodology	1	NA	scale_choice_yn	No
10.1080/10428194.2019.1682571	methodology	2	NA	outcome_name	overall survival
10.1080/10428194.2019.1682571	methodology	2	NA	outcome_short_name	Overall Survival
10.1080/10428194.2019.1682571	methodology	2	NA	outcome_variable_type	Time-to-event
10.1080/10428194.2019.1682571	methodology	2	NA	treatment_name_ipd	daratumumabbortezomibmelphalanprednisone
10.1080/10428194.2019.1682571	methodology	2	NA	studies_number_ipd	1
10.1080/10428194.2019.1682571	methodology	2	NA	treatment_name_nonipd	lenalidomidedexamethasone 18 months (rd18)
10.1080/10428194.2019.1682571	methodology	2	NA	studies_number_nonipd	2
10.1080/10428194.2019.1682571	methodology	2	NA	paic_type	MAIC
10.1080/10428194.2019.1682571	methodology	2	NA	anchored_yn	No
10.1080/10428194.2019.1682571	methodology	2	NA	paic_form	Simple (ie treatments effects extracted from two studies)
10.1080/10428194.2019.1682571	methodology	2	NA	primary_outcome_yn	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.1080/10428194.2019.1682571	methodology	2	NA	variables_selection_justification	Nothing mentioned, not reported
10.1080/10428194.2019.1682571	methodology	2	NA	pf_yn	No discussion (in the main text) of the status of prognostic factors of the variables
10.1080/10428194.2019.1682571	methodology	2	NA	tem_yn	No discussion (in the main text) of the status of treatment-effect modifiers of the variables
10.1080/10428194.2019.1682571	methodology	2	NA	adjustment_model_details_yn	No
10.1080/10428194.2019.1682571	methodology	2	NA	scale_choice_yn	No
10.1080/10428194.2019.1682571	methodology	3	NA	outcome_name	overall survival
10.1080/10428194.2019.1682571	methodology	3	NA	outcome_short_name	Overall Survival
10.1080/10428194.2019.1682571	methodology	3	NA	outcome_variable_type	Time-to-event
10.1080/10428194.2019.1682571	methodology	3	NA	treatment_name_ipd	daratumumabbortezomibmelphalanprednisone
10.1080/10428194.2019.1682571	methodology	3	NA	studies_number_ipd	1
10.1080/10428194.2019.1682571	methodology	3	NA	treatment_name_nonipd	melphalanprednisonethalidomide
10.1080/10428194.2019.1682571	methodology	3	NA	studies_number_nonipd	2
10.1080/10428194.2019.1682571	methodology	3	NA	paic_type	MAIC
10.1080/10428194.2019.1682571	methodology	3	NA	anchored_yn	No
10.1080/10428194.2019.1682571	methodology	3	NA	paic_form	Simple (ie treatments effects extracted from two studies)
10.1080/10428194.2019.1682571	methodology	3	NA	primary_outcome_yn	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.1080/10428194.2019.1682571	methodology	3	NA	variables_selection_justification	Nothing mentioned, not reported
10.1080/10428194.2019.1682571	methodology	3	NA	pf_yn	No discussion (in the main text) of the status of prognostic factors of the variables
10.1080/10428194.2019.1682571	methodology	3	NA	tem_yn	No discussion (in the main text) of the status of treatment-effect modifiers of the variables
10.1080/10428194.2019.1682571	methodology	3	NA	adjustment_model_details_yn	No
10.1080/10428194.2019.1682571	methodology	3	NA	scale_choice_yn	No
10.1080/10428194.2019.1682571	results	1	NA	contrast_effect_type	HR
10.1080/10428194.2019.1682571	results	1	NA	direction_benefit	inferior
10.1080/10428194.2019.1682571	results	1	NA	ss_ttt_nonipd	535
10.1080/10428194.2019.1682571	results	1	NA	ss_ttt_ipd	350
10.1080/10428194.2019.1682571	results	1	NA	ss_adjusted_ttt_ipd	248
10.1080/10428194.2019.1682571	results	1	NA	weights_yn	Not mentioned
10.1080/10428194.2019.1682571	results	1	NA	covariates_yn	Yes
10.1080/10428194.2019.1682571	results	1	NA	covariates_n	7
10.1080/10428194.2019.1682571	results	1	NA	covariates_names	Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Comorbidities and medical history (beside pathology/disease of interest in the comparison)
10.1080/10428194.2019.1682571	results	1	NA	contrast_effect_direction	Numerator if ratio, or left side if difference
10.1080/10428194.2019.1682571	results	1	NA	contrast_effect_unadjusted_value	0.88
10.1080/10428194.2019.1682571	results	1	NA	contrast_effect_unadjusted_pvalci	0.51
10.1080/10428194.2019.1682571	results	1	NA	contrast_effect_adjusted_value	0.68
10.1080/10428194.2019.1682571	results	1	NA	contrast_effect_adjusted_pvalci	0.086
10.1080/10428194.2019.1682571	results	1	NA	adjustment_geographical	NA
10.1080/10428194.2019.1682571	results	1	NA	ss_total_ipd	NA
10.1080/10428194.2019.1682571	results	1	NA	ss_adjusted_total_ipd	NA
10.1080/10428194.2019.1682571	results	1	NA	ss_total_nonipd	NA
10.1080/10428194.2019.1682571	results	1	NA	ss_anchor_nonipd	NA
10.1080/10428194.2019.1682571	results	1	NA	ss_anchor_ipd	NA
10.1080/10428194.2019.1682571	results	1	NA	ss_adjusted_anchor_ipd	NA
10.1080/10428194.2019.1682571	results	1	NA	effect_cutoff	1
10.1080/10428194.2019.1682571	results	1	NA	unadjusted_pval	0.51
10.1080/10428194.2019.1682571	results	1	NA	unadjusted_num_pval	0.51
10.1080/10428194.2019.1682571	results	1	NA	unadjusted_significant	FALSE
10.1080/10428194.2019.1682571	results	1	NA	adjusted_pval	0.086
10.1080/10428194.2019.1682571	results	1	NA	adjusted_num_pval	0.086
10.1080/10428194.2019.1682571	results	1	NA	adjusted_significant	FALSE
10.1080/10428194.2019.1682571	results	2	NA	contrast_effect_type	HR
10.1080/10428194.2019.1682571	results	2	NA	direction_benefit	inferior
10.1080/10428194.2019.1682571	results	2	NA	ss_ttt_nonipd	541
10.1080/10428194.2019.1682571	results	2	NA	ss_ttt_ipd	350
10.1080/10428194.2019.1682571	results	2	NA	ss_adjusted_ttt_ipd	246
10.1080/10428194.2019.1682571	results	2	NA	weights_yn	Not mentioned
10.1080/10428194.2019.1682571	results	2	NA	covariates_yn	Yes
10.1080/10428194.2019.1682571	results	2	NA	covariates_n	7
10.1080/10428194.2019.1682571	results	2	NA	covariates_names	Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Comorbidities and medical history (beside pathology/disease of interest in the comparison)
10.1080/10428194.2019.1682571	results	2	NA	contrast_effect_direction	Numerator if ratio, or left side if difference
10.1080/10428194.2019.1682571	results	2	NA	contrast_effect_unadjusted_value	0.78
10.1080/10428194.2019.1682571	results	2	NA	contrast_effect_unadjusted_pvalci	0.16
10.1080/10428194.2019.1682571	results	2	NA	contrast_effect_adjusted_value	0.6
10.1080/10428194.2019.1682571	results	2	NA	contrast_effect_adjusted_pvalci	0.02
10.1080/10428194.2019.1682571	results	2	NA	adjustment_geographical	NA
10.1080/10428194.2019.1682571	results	2	NA	ss_total_ipd	NA
10.1080/10428194.2019.1682571	results	2	NA	ss_adjusted_total_ipd	NA
10.1080/10428194.2019.1682571	results	2	NA	ss_total_nonipd	NA
10.1080/10428194.2019.1682571	results	2	NA	ss_anchor_nonipd	NA
10.1080/10428194.2019.1682571	results	2	NA	ss_anchor_ipd	NA
10.1080/10428194.2019.1682571	results	2	NA	ss_adjusted_anchor_ipd	NA
10.1080/10428194.2019.1682571	results	2	NA	effect_cutoff	1
10.1080/10428194.2019.1682571	results	2	NA	unadjusted_pval	0.16
10.1080/10428194.2019.1682571	results	2	NA	unadjusted_num_pval	0.16
10.1080/10428194.2019.1682571	results	2	NA	unadjusted_significant	FALSE
10.1080/10428194.2019.1682571	results	2	NA	adjusted_pval	0.02
10.1080/10428194.2019.1682571	results	2	NA	adjusted_num_pval	0.02
10.1080/10428194.2019.1682571	results	2	NA	adjusted_significant	TRUE
10.1080/10428194.2019.1682571	results	3	NA	contrast_effect_type	HR
10.1080/10428194.2019.1682571	results	3	NA	direction_benefit	inferior
10.1080/10428194.2019.1682571	results	3	NA	ss_ttt_nonipd	547
10.1080/10428194.2019.1682571	results	3	NA	ss_ttt_ipd	350
10.1080/10428194.2019.1682571	results	3	NA	ss_adjusted_ttt_ipd	248
10.1080/10428194.2019.1682571	results	3	NA	weights_yn	Not mentioned
10.1080/10428194.2019.1682571	results	3	NA	covariates_yn	Yes
10.1080/10428194.2019.1682571	results	3	NA	covariates_n	7
10.1080/10428194.2019.1682571	results	3	NA	covariates_names	Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Comorbidities and medical history (beside pathology/disease of interest in the comparison)
10.1080/10428194.2019.1682571	results	3	NA	contrast_effect_direction	Numerator if ratio, or left side if difference
10.1080/10428194.2019.1682571	results	3	NA	contrast_effect_unadjusted_value	0.68
10.1080/10428194.2019.1682571	results	3	NA	contrast_effect_unadjusted_pvalci	0.024
10.1080/10428194.2019.1682571	results	3	NA	contrast_effect_adjusted_value	0.53
10.1080/10428194.2019.1682571	results	3	NA	contrast_effect_adjusted_pvalci	0.003
10.1080/10428194.2019.1682571	results	3	NA	adjustment_geographical	NA
10.1080/10428194.2019.1682571	results	3	NA	ss_total_ipd	NA
10.1080/10428194.2019.1682571	results	3	NA	ss_adjusted_total_ipd	NA
10.1080/10428194.2019.1682571	results	3	NA	ss_total_nonipd	NA
10.1080/10428194.2019.1682571	results	3	NA	ss_anchor_nonipd	NA
10.1080/10428194.2019.1682571	results	3	NA	ss_anchor_ipd	NA
10.1080/10428194.2019.1682571	results	3	NA	ss_adjusted_anchor_ipd	NA
10.1080/10428194.2019.1682571	results	3	NA	effect_cutoff	1
10.1080/10428194.2019.1682571	results	3	NA	unadjusted_pval	0.024
10.1080/10428194.2019.1682571	results	3	NA	unadjusted_num_pval	0.024
10.1080/10428194.2019.1682571	results	3	NA	unadjusted_significant	TRUE
10.1080/10428194.2019.1682571	results	3	NA	adjusted_pval	0.003
10.1080/10428194.2019.1682571	results	3	NA	adjusted_num_pval	0.003
10.1080/10428194.2019.1682571	results	3	NA	adjusted_significant	TRUE
10.1080/10428194.2019.1682571	study_information	NA	1	ipd_yn	Yes
10.1080/10428194.2019.1682571	study_information	NA	1	ct_yn	Yes
10.1080/10428194.2019.1682571	study_information	NA	1	nct	NCT02195479
10.1080/10428194.2019.1682571	study_information	NA	1	country_study	international
10.1080/10428194.2019.1682571	study_information	NA	1	ct_phase	3
10.1080/10428194.2019.1682571	study_information	NA	1	ct_arms	2 or more
10.1080/10428194.2019.1682571	study_information	NA	2	ipd_yn	No
10.1080/10428194.2019.1682571	study_information	NA	2	ct_yn	Yes
10.1080/10428194.2019.1682571	study_information	NA	2	nct	NCT00689936
10.1080/10428194.2019.1682571	study_information	NA	2	country_study	international
10.1080/10428194.2019.1682571	study_information	NA	2	ct_phase	3
10.1080/10428194.2019.1682571	study_information	NA	2	ct_arms	2 or more
10.1080/10428194.2021.1913143	general_information	NA	NA	condition_name	relapsed and refractory multiple myeloma
10.1080/10428194.2021.1913143	general_information	NA	NA	country_first_author	spain
10.1080/10428194.2021.1913143	general_information	NA	NA	country_last_author	switzerland
10.1080/10428194.2021.1913143	general_information	NA	NA	positions	Academic, Pharmaceutical Industry, Private Data Analysis Company
10.1080/10428194.2021.1913143	general_information	NA	NA	methodologist_yn	Yes
10.1080/10428194.2021.1913143	general_information	NA	NA	funding_source	Pharmaceutical Industry
10.1080/10428194.2021.1913143	general_information	NA	NA	pharmaceutical_ties_yn	Yes
10.1080/10428194.2021.1913143	general_information	NA	NA	systematic_review_yn	Yes
10.1080/10428194.2021.1913143	methodology	1	NA	outcome_name	overall response rate
10.1080/10428194.2021.1913143	methodology	1	NA	outcome_short_name	Overall Response Rate
10.1080/10428194.2021.1913143	methodology	1	NA	outcome_variable_type	Binary (eg rates)
10.1080/10428194.2021.1913143	methodology	1	NA	treatment_name_ipd	idecabtagene vicleucel
10.1080/10428194.2021.1913143	methodology	1	NA	studies_number_ipd	1
10.1080/10428194.2021.1913143	methodology	1	NA	treatment_name_nonipd	selinexor + dexamethasone
10.1080/10428194.2021.1913143	methodology	1	NA	studies_number_nonipd	2
10.1080/10428194.2021.1913143	methodology	1	NA	paic_type	MAIC
10.1080/10428194.2021.1913143	methodology	1	NA	anchored_yn	No
10.1080/10428194.2021.1913143	methodology	1	NA	paic_form	Simple (ie treatments effects extracted from two studies)
10.1080/10428194.2021.1913143	methodology	1	NA	primary_outcome_yn	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.1080/10428194.2021.1913143	methodology	1	NA	variables_selection_justification	Statistical imbalanced between treatment groups (independently of the status of prognostic/effect modifier), A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion), Literature based (clinically or methodologically relevant to adjust on these variables based on the literature search conducted for this specific purpose)
10.1080/10428194.2021.1913143	methodology	1	NA	pf_yn	Yes
10.1080/10428194.2021.1913143	methodology	1	NA	tem_yn	No discussion (in the main text) of the status of treatment-effect modifiers of the variables
10.1080/10428194.2021.1913143	methodology	1	NA	adjustment_model_details_yn	No
10.1080/10428194.2021.1913143	methodology	1	NA	scale_choice_yn	No
10.1080/10428194.2021.1913143	methodology	2	NA	outcome_name	overall response rate
10.1080/10428194.2021.1913143	methodology	2	NA	outcome_short_name	Overall Response Rate
10.1080/10428194.2021.1913143	methodology	2	NA	outcome_variable_type	Binary (eg rates)
10.1080/10428194.2021.1913143	methodology	2	NA	treatment_name_ipd	idecabtagene + vicleucel
10.1080/10428194.2021.1913143	methodology	2	NA	studies_number_ipd	1
10.1080/10428194.2021.1913143	methodology	2	NA	treatment_name_nonipd	belantamab mafodotin
10.1080/10428194.2021.1913143	methodology	2	NA	studies_number_nonipd	3
10.1080/10428194.2021.1913143	methodology	2	NA	paic_type	MAIC
10.1080/10428194.2021.1913143	methodology	2	NA	anchored_yn	No
10.1080/10428194.2021.1913143	methodology	2	NA	paic_form	Simple (ie treatments effects extracted from two studies)
10.1080/10428194.2021.1913143	methodology	2	NA	primary_outcome_yn	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.1080/10428194.2021.1913143	methodology	2	NA	variables_selection_justification	Statistical imbalanced between treatment groups (independently of the status of prognostic/effect modifier), A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion), Literature based (clinically or methodologically relevant to adjust on these variables based on the literature search conducted for this specific purpose)
10.1080/10428194.2021.1913143	methodology	2	NA	pf_yn	Yes
10.1080/10428194.2021.1913143	methodology	2	NA	tem_yn	No discussion (in the main text) of the status of treatment-effect modifiers of the variables
10.1080/10428194.2021.1913143	methodology	2	NA	adjustment_model_details_yn	No
10.1080/10428194.2021.1913143	methodology	2	NA	scale_choice_yn	No
10.1080/10428194.2021.1913143	results	1	NA	contrast_effect_type	OR
10.1080/10428194.2021.1913143	results	1	NA	direction_benefit	superior
10.1080/10428194.2021.1913143	results	1	NA	ss_ttt_nonipd	122
10.1080/10428194.2021.1913143	results	1	NA	ss_ttt_ipd	128
10.1080/10428194.2021.1913143	results	1	NA	ss_adjusted_ttt_ipd	56
10.1080/10428194.2021.1913143	results	1	NA	weights_yn	Not mentioned
10.1080/10428194.2021.1913143	results	1	NA	covariates_yn	Yes
10.1080/10428194.2021.1913143	results	1	NA	covariates_n	6
10.1080/10428194.2021.1913143	results	1	NA	covariates_names	Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Past treatments for the disease of interest
10.1080/10428194.2021.1913143	results	1	NA	contrast_effect_direction	Numerator if ratio, or left side if difference
10.1080/10428194.2021.1913143	results	1	NA	contrast_effect_unadjusted_value	7.78
10.1080/10428194.2021.1913143	results	1	NA	contrast_effect_unadjusted_pvalci	[4.43;13.65]
10.1080/10428194.2021.1913143	results	1	NA	contrast_effect_adjusted_value	7.74
10.1080/10428194.2021.1913143	results	1	NA	contrast_effect_adjusted_pvalci	[3.83;15.62]
10.1080/10428194.2021.1913143	results	1	NA	adjustment_geographical	NA
10.1080/10428194.2021.1913143	results	1	NA	ss_total_ipd	NA
10.1080/10428194.2021.1913143	results	1	NA	ss_adjusted_total_ipd	NA
10.1080/10428194.2021.1913143	results	1	NA	ss_total_nonipd	NA
10.1080/10428194.2021.1913143	results	1	NA	ss_anchor_nonipd	NA
10.1080/10428194.2021.1913143	results	1	NA	ss_anchor_ipd	NA
10.1080/10428194.2021.1913143	results	1	NA	ss_adjusted_anchor_ipd	NA
10.1080/10428194.2021.1913143	results	1	NA	effect_cutoff	1
10.1080/10428194.2021.1913143	results	1	NA	unadjusted_lb_ci	4.43
10.1080/10428194.2021.1913143	results	1	NA	unadjusted_ub_ci	13.65
10.1080/10428194.2021.1913143	results	1	NA	unadjusted_significant	TRUE
10.1080/10428194.2021.1913143	results	1	NA	adjusted_lb_ci	3.83
10.1080/10428194.2021.1913143	results	1	NA	adjusted_ub_ci	15.62
10.1080/10428194.2021.1913143	results	1	NA	adjusted_significant	TRUE
10.1080/10428194.2021.1913143	results	2	NA	contrast_effect_type	OR
10.1080/10428194.2021.1913143	results	2	NA	direction_benefit	superior
10.1080/10428194.2021.1913143	results	2	NA	ss_ttt_nonipd	97
10.1080/10428194.2021.1913143	results	2	NA	ss_ttt_ipd	128
10.1080/10428194.2021.1913143	results	2	NA	ss_adjusted_ttt_ipd	45
10.1080/10428194.2021.1913143	results	2	NA	weights_yn	Not mentioned
10.1080/10428194.2021.1913143	results	2	NA	covariates_yn	Yes
10.1080/10428194.2021.1913143	results	2	NA	covariates_n	6
10.1080/10428194.2021.1913143	results	2	NA	covariates_names	Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Past treatments for the disease of interest
10.1080/10428194.2021.1913143	results	2	NA	contrast_effect_direction	Numerator if ratio, or left side if difference
10.1080/10428194.2021.1913143	results	2	NA	contrast_effect_unadjusted_value	6.17
10.1080/10428194.2021.1913143	results	2	NA	contrast_effect_unadjusted_pvalci	[3.45;11.05]
10.1080/10428194.2021.1913143	results	2	NA	contrast_effect_adjusted_value	5.12
10.1080/10428194.2021.1913143	results	2	NA	contrast_effect_adjusted_pvalci	[2.35;11.13]
10.1080/10428194.2021.1913143	results	2	NA	adjustment_geographical	NA
10.1080/10428194.2021.1913143	results	2	NA	ss_total_ipd	NA
10.1080/10428194.2021.1913143	results	2	NA	ss_adjusted_total_ipd	NA
10.1080/10428194.2021.1913143	results	2	NA	ss_total_nonipd	NA
10.1080/10428194.2021.1913143	results	2	NA	ss_anchor_nonipd	NA
10.1080/10428194.2021.1913143	results	2	NA	ss_anchor_ipd	NA
10.1080/10428194.2021.1913143	results	2	NA	ss_adjusted_anchor_ipd	NA
10.1080/10428194.2021.1913143	results	2	NA	effect_cutoff	1
10.1080/10428194.2021.1913143	results	2	NA	unadjusted_lb_ci	3.45
10.1080/10428194.2021.1913143	results	2	NA	unadjusted_ub_ci	11.05
10.1080/10428194.2021.1913143	results	2	NA	unadjusted_significant	TRUE
10.1080/10428194.2021.1913143	results	2	NA	adjusted_lb_ci	2.35
10.1080/10428194.2021.1913143	results	2	NA	adjusted_ub_ci	11.13
10.1080/10428194.2021.1913143	results	2	NA	adjusted_significant	TRUE
10.1080/10428194.2021.1913143	study_information	NA	1	ipd_yn	Yes
10.1080/10428194.2021.1913143	study_information	NA	1	ct_yn	Yes
10.1080/10428194.2021.1913143	study_information	NA	1	nct	NCT03361748
10.1080/10428194.2021.1913143	study_information	NA	1	country_study	international
10.1080/10428194.2021.1913143	study_information	NA	1	ct_phase	2
10.1080/10428194.2021.1913143	study_information	NA	1	ct_arms	1
10.1080/10428194.2021.1913143	study_information	NA	2	ipd_yn	No
10.1080/10428194.2021.1913143	study_information	NA	2	ct_yn	Yes
10.1080/10428194.2021.1913143	study_information	NA	2	nct	NCT02336815
10.1080/10428194.2021.1913143	study_information	NA	2	country_study	international
10.1080/10428194.2021.1913143	study_information	NA	2	ct_phase	2
10.1080/10428194.2021.1913143	study_information	NA	2	ct_arms	1
10.1080/10428194.2021.1913143	study_information	NA	3	ipd_yn	No
10.1080/10428194.2021.1913143	study_information	NA	3	ct_yn	Yes
10.1080/10428194.2021.1913143	study_information	NA	3	nct	NCT03525678
10.1080/10428194.2021.1913143	study_information	NA	3	country_study	international
10.1080/10428194.2021.1913143	study_information	NA	3	ct_phase	2
10.1080/10428194.2021.1913143	study_information	NA	3	ct_arms	1
10.1080/10428194.2021.1913144	general_information	NA	NA	condition_name	chronic lymphocytic leukemia
10.1080/10428194.2021.1913144	general_information	NA	NA	country_first_author	usa
10.1080/10428194.2021.1913144	general_information	NA	NA	country_last_author	uk
10.1080/10428194.2021.1913144	general_information	NA	NA	positions	Academic, Pharmaceutical Industry
10.1080/10428194.2021.1913144	general_information	NA	NA	methodologist_yn	Not mentioned
10.1080/10428194.2021.1913144	general_information	NA	NA	funding_source	Pharmaceutical Industry
10.1080/10428194.2021.1913144	general_information	NA	NA	pharmaceutical_ties_yn	Yes
10.1080/10428194.2021.1913144	general_information	NA	NA	systematic_review_yn	Yes
10.1080/10428194.2021.1913144	methodology	1	NA	outcome_name	progression-free survival
10.1080/10428194.2021.1913144	methodology	1	NA	outcome_short_name	Progression-free Survival
10.1080/10428194.2021.1913144	methodology	1	NA	outcome_variable_type	Time-to-event
10.1080/10428194.2021.1913144	methodology	1	NA	treatment_name_ipd	acalabrutinib + obinutuzumab
10.1080/10428194.2021.1913144	methodology	1	NA	studies_number_ipd	1
10.1080/10428194.2021.1913144	methodology	1	NA	treatment_name_nonipd	ibrutinib
10.1080/10428194.2021.1913144	methodology	1	NA	studies_number_nonipd	2
10.1080/10428194.2021.1913144	methodology	1	NA	paic_type	MAIC
10.1080/10428194.2021.1913144	methodology	1	NA	anchored_yn	No
10.1080/10428194.2021.1913144	methodology	1	NA	paic_form	Simple (ie treatments effects extracted from two studies)
10.1080/10428194.2021.1913144	methodology	1	NA	primary_outcome_yn	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.1080/10428194.2021.1913144	methodology	1	NA	variables_selection_justification	Statistical imbalanced between treatment groups (independently of the status of prognostic/effect modifier), A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion)
10.1080/10428194.2021.1913144	methodology	1	NA	pf_yn	No discussion (in the main text) of the status of prognostic factors of the variables
10.1080/10428194.2021.1913144	methodology	1	NA	tem_yn	No discussion (in the main text) of the status of treatment-effect modifiers of the variables
10.1080/10428194.2021.1913144	methodology	1	NA	adjustment_model_details_yn	No
10.1080/10428194.2021.1913144	methodology	1	NA	scale_choice_yn	No
10.1080/10428194.2021.1913144	methodology	2	NA	outcome_name	progression-free survival
10.1080/10428194.2021.1913144	methodology	2	NA	outcome_short_name	Progression-free Survival
10.1080/10428194.2021.1913144	methodology	2	NA	outcome_variable_type	Time-to-event
10.1080/10428194.2021.1913144	methodology	2	NA	treatment_name_ipd	acalabrutinib
10.1080/10428194.2021.1913144	methodology	2	NA	studies_number_ipd	1
10.1080/10428194.2021.1913144	methodology	2	NA	treatment_name_nonipd	ibrutinib
10.1080/10428194.2021.1913144	methodology	2	NA	studies_number_nonipd	2
10.1080/10428194.2021.1913144	methodology	2	NA	paic_type	MAIC
10.1080/10428194.2021.1913144	methodology	2	NA	anchored_yn	No
10.1080/10428194.2021.1913144	methodology	2	NA	paic_form	Simple (ie treatments effects extracted from two studies)
10.1080/10428194.2021.1913144	methodology	2	NA	primary_outcome_yn	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.1080/10428194.2021.1913144	methodology	2	NA	variables_selection_justification	Statistical imbalanced between treatment groups (independently of the status of prognostic/effect modifier), A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion)
10.1080/10428194.2021.1913144	methodology	2	NA	pf_yn	No discussion (in the main text) of the status of prognostic factors of the variables
10.1080/10428194.2021.1913144	methodology	2	NA	tem_yn	No discussion (in the main text) of the status of treatment-effect modifiers of the variables
10.1080/10428194.2021.1913144	methodology	2	NA	adjustment_model_details_yn	No
10.1080/10428194.2021.1913144	methodology	2	NA	scale_choice_yn	No
10.1080/10428194.2021.1913144	methodology	3	NA	outcome_name	progression-free survival
10.1080/10428194.2021.1913144	methodology	3	NA	outcome_short_name	Progression-free Survival
10.1080/10428194.2021.1913144	methodology	3	NA	outcome_variable_type	Time-to-event
10.1080/10428194.2021.1913144	methodology	3	NA	treatment_name_ipd	acalabrutinib + obinutuzumab
10.1080/10428194.2021.1913144	methodology	3	NA	studies_number_ipd	1
10.1080/10428194.2021.1913144	methodology	3	NA	treatment_name_nonipd	ibrutinib + obinutuzumab
10.1080/10428194.2021.1913144	methodology	3	NA	studies_number_nonipd	3
10.1080/10428194.2021.1913144	methodology	3	NA	paic_type	MAIC
10.1080/10428194.2021.1913144	methodology	3	NA	anchored_yn	No
10.1080/10428194.2021.1913144	methodology	3	NA	paic_form	Simple (ie treatments effects extracted from two studies)
10.1080/10428194.2021.1913144	methodology	3	NA	primary_outcome_yn	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.1080/10428194.2021.1913144	methodology	3	NA	variables_selection_justification	Statistical imbalanced between treatment groups (independently of the status of prognostic/effect modifier), A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion)
10.1080/10428194.2021.1913144	methodology	3	NA	pf_yn	No discussion (in the main text) of the status of prognostic factors of the variables
10.1080/10428194.2021.1913144	methodology	3	NA	tem_yn	No discussion (in the main text) of the status of treatment-effect modifiers of the variables
10.1080/10428194.2021.1913144	methodology	3	NA	adjustment_model_details_yn	No
10.1080/10428194.2021.1913144	methodology	3	NA	scale_choice_yn	No
10.1080/10428194.2021.1913144	methodology	4	NA	outcome_name	progression-free survival
10.1080/10428194.2021.1913144	methodology	4	NA	outcome_short_name	Progression-free Survival
10.1080/10428194.2021.1913144	methodology	4	NA	outcome_variable_type	Time-to-event
10.1080/10428194.2021.1913144	methodology	4	NA	treatment_name_ipd	acalabrutinib
10.1080/10428194.2021.1913144	methodology	4	NA	studies_number_ipd	1
10.1080/10428194.2021.1913144	methodology	4	NA	treatment_name_nonipd	ibrutinib + obinutuzumab
10.1080/10428194.2021.1913144	methodology	4	NA	studies_number_nonipd	3
10.1080/10428194.2021.1913144	methodology	4	NA	paic_type	MAIC
10.1080/10428194.2021.1913144	methodology	4	NA	anchored_yn	No
10.1080/10428194.2021.1913144	methodology	4	NA	paic_form	Simple (ie treatments effects extracted from two studies)
10.1080/10428194.2021.1913144	methodology	4	NA	primary_outcome_yn	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.1080/10428194.2021.1913144	methodology	4	NA	variables_selection_justification	Statistical imbalanced between treatment groups (independently of the status of prognostic/effect modifier), A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion)
10.1080/10428194.2021.1913144	methodology	4	NA	pf_yn	No discussion (in the main text) of the status of prognostic factors of the variables
10.1080/10428194.2021.1913144	methodology	4	NA	tem_yn	No discussion (in the main text) of the status of treatment-effect modifiers of the variables
10.1080/10428194.2021.1913144	methodology	4	NA	adjustment_model_details_yn	No
10.1080/10428194.2021.1913144	methodology	4	NA	scale_choice_yn	No
10.1080/10428194.2021.1913144	methodology	5	NA	outcome_name	progression-free survival
10.1080/10428194.2021.1913144	methodology	5	NA	outcome_short_name	Progression-free Survival
10.1080/10428194.2021.1913144	methodology	5	NA	outcome_variable_type	Time-to-event
10.1080/10428194.2021.1913144	methodology	5	NA	treatment_name_ipd	acalabrutinib + obinutuzumab
10.1080/10428194.2021.1913144	methodology	5	NA	studies_number_ipd	1
10.1080/10428194.2021.1913144	methodology	5	NA	treatment_name_nonipd	venetoclax + obinutuzumab
10.1080/10428194.2021.1913144	methodology	5	NA	studies_number_nonipd	4
10.1080/10428194.2021.1913144	methodology	5	NA	paic_type	MAIC
10.1080/10428194.2021.1913144	methodology	5	NA	anchored_yn	No
10.1080/10428194.2021.1913144	methodology	5	NA	paic_form	Simple (ie treatments effects extracted from two studies)
10.1080/10428194.2021.1913144	methodology	5	NA	primary_outcome_yn	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.1080/10428194.2021.1913144	methodology	5	NA	variables_selection_justification	Statistical imbalanced between treatment groups (independently of the status of prognostic/effect modifier), A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion)
10.1080/10428194.2021.1913144	methodology	5	NA	pf_yn	No discussion (in the main text) of the status of prognostic factors of the variables
10.1080/10428194.2021.1913144	methodology	5	NA	tem_yn	No discussion (in the main text) of the status of treatment-effect modifiers of the variables
10.1080/10428194.2021.1913144	methodology	5	NA	adjustment_model_details_yn	No
10.1080/10428194.2021.1913144	methodology	5	NA	scale_choice_yn	No
10.1080/10428194.2021.1913144	methodology	6	NA	outcome_name	progression-free survival
10.1080/10428194.2021.1913144	methodology	6	NA	outcome_short_name	Progression-free Survival
10.1080/10428194.2021.1913144	methodology	6	NA	outcome_variable_type	Time-to-event
10.1080/10428194.2021.1913144	methodology	6	NA	treatment_name_ipd	acalabrutinib
10.1080/10428194.2021.1913144	methodology	6	NA	studies_number_ipd	1
10.1080/10428194.2021.1913144	methodology	6	NA	treatment_name_nonipd	venetoclax + obinutuzumab
10.1080/10428194.2021.1913144	methodology	6	NA	studies_number_nonipd	4
10.1080/10428194.2021.1913144	methodology	6	NA	paic_type	MAIC
10.1080/10428194.2021.1913144	methodology	6	NA	anchored_yn	No
10.1080/10428194.2021.1913144	methodology	6	NA	paic_form	Simple (ie treatments effects extracted from two studies)
10.1080/10428194.2021.1913144	methodology	6	NA	primary_outcome_yn	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.1080/10428194.2021.1913144	methodology	6	NA	variables_selection_justification	Statistical imbalanced between treatment groups (independently of the status of prognostic/effect modifier), A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion)
10.1080/10428194.2021.1913144	methodology	6	NA	pf_yn	No discussion (in the main text) of the status of prognostic factors of the variables
10.1080/10428194.2021.1913144	methodology	6	NA	tem_yn	No discussion (in the main text) of the status of treatment-effect modifiers of the variables
10.1080/10428194.2021.1913144	methodology	6	NA	adjustment_model_details_yn	No
10.1080/10428194.2021.1913144	methodology	6	NA	scale_choice_yn	No
10.1080/10428194.2021.1913144	results	1	NA	contrast_effect_type	HR
10.1080/10428194.2021.1913144	results	1	NA	direction_benefit	inferior
10.1080/10428194.2021.1913144	results	1	NA	ss_ttt_nonipd	136
10.1080/10428194.2021.1913144	results	1	NA	ss_ttt_ipd	126
10.1080/10428194.2021.1913144	results	1	NA	ss_adjusted_ttt_ipd	59
10.1080/10428194.2021.1913144	results	1	NA	weights_yn	Yes, mentions that the weights distribution has been studied, but weights distribution not reported
10.1080/10428194.2021.1913144	results	1	NA	covariates_yn	Yes
10.1080/10428194.2021.1913144	results	1	NA	covariates_n	12
10.1080/10428194.2021.1913144	results	1	NA	covariates_names	Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Comorbidities and medical history (beside pathology/disease of interest in the comparison)
10.1080/10428194.2021.1913144	results	1	NA	contrast_effect_direction	Numerator if ratio, or left side if difference
10.1080/10428194.2021.1913144	results	1	NA	contrast_effect_unadjusted_value	NA
10.1080/10428194.2021.1913144	results	1	NA	contrast_effect_unadjusted_pvalci	NA
10.1080/10428194.2021.1913144	results	1	NA	contrast_effect_adjusted_value	0.61
10.1080/10428194.2021.1913144	results	1	NA	contrast_effect_adjusted_pvalci	0.3
10.1080/10428194.2021.1913144	results	1	NA	adjustment_geographical	No
10.1080/10428194.2021.1913144	results	1	NA	ss_total_ipd	NA
10.1080/10428194.2021.1913144	results	1	NA	ss_adjusted_total_ipd	NA
10.1080/10428194.2021.1913144	results	1	NA	ss_total_nonipd	NA
10.1080/10428194.2021.1913144	results	1	NA	ss_anchor_nonipd	NA
10.1080/10428194.2021.1913144	results	1	NA	ss_anchor_ipd	NA
10.1080/10428194.2021.1913144	results	1	NA	ss_adjusted_anchor_ipd	NA
10.1080/10428194.2021.1913144	results	1	NA	effect_cutoff	1
10.1080/10428194.2021.1913144	results	1	NA	adjusted_pval	0.3
10.1080/10428194.2021.1913144	results	1	NA	adjusted_num_pval	0.3
10.1080/10428194.2021.1913144	results	1	NA	adjusted_significant	FALSE
10.1080/10428194.2021.1913144	results	2	NA	contrast_effect_type	HR
10.1080/10428194.2021.1913144	results	2	NA	direction_benefit	inferior
10.1080/10428194.2021.1913144	results	2	NA	ss_ttt_nonipd	136
10.1080/10428194.2021.1913144	results	2	NA	ss_ttt_ipd	136
10.1080/10428194.2021.1913144	results	2	NA	ss_adjusted_ttt_ipd	79
10.1080/10428194.2021.1913144	results	2	NA	weights_yn	Yes, mentions that the weights distribution has been studied, but weights distribution not reported
10.1080/10428194.2021.1913144	results	2	NA	covariates_yn	Yes
10.1080/10428194.2021.1913144	results	2	NA	covariates_n	12
10.1080/10428194.2021.1913144	results	2	NA	covariates_names	Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Comorbidities and medical history (beside pathology/disease of interest in the comparison)
10.1080/10428194.2021.1913144	results	2	NA	contrast_effect_direction	Numerator if ratio, or left side if difference
10.1080/10428194.2021.1913144	results	2	NA	contrast_effect_unadjusted_value	NA
10.1080/10428194.2021.1913144	results	2	NA	contrast_effect_unadjusted_pvalci	NA
10.1080/10428194.2021.1913144	results	2	NA	contrast_effect_adjusted_value	0.92
10.1080/10428194.2021.1913144	results	2	NA	contrast_effect_adjusted_pvalci	0.83
10.1080/10428194.2021.1913144	results	2	NA	adjustment_geographical	No
10.1080/10428194.2021.1913144	results	2	NA	ss_total_ipd	NA
10.1080/10428194.2021.1913144	results	2	NA	ss_adjusted_total_ipd	NA
10.1080/10428194.2021.1913144	results	2	NA	ss_total_nonipd	NA
10.1080/10428194.2021.1913144	results	2	NA	ss_anchor_nonipd	NA
10.1080/10428194.2021.1913144	results	2	NA	ss_anchor_ipd	NA
10.1080/10428194.2021.1913144	results	2	NA	ss_adjusted_anchor_ipd	NA
10.1080/10428194.2021.1913144	results	2	NA	effect_cutoff	1
10.1080/10428194.2021.1913144	results	2	NA	adjusted_pval	0.83
10.1080/10428194.2021.1913144	results	2	NA	adjusted_num_pval	0.83
10.1080/10428194.2021.1913144	results	2	NA	adjusted_significant	FALSE
10.1080/10428194.2021.1913144	results	3	NA	contrast_effect_type	HR
10.1080/10428194.2021.1913144	results	3	NA	direction_benefit	inferior
10.1080/10428194.2021.1913144	results	3	NA	ss_ttt_nonipd	113
10.1080/10428194.2021.1913144	results	3	NA	ss_ttt_ipd	113
10.1080/10428194.2021.1913144	results	3	NA	ss_adjusted_ttt_ipd	97
10.1080/10428194.2021.1913144	results	3	NA	weights_yn	Yes, mentions that the weights distribution has been studied, but weights distribution not reported
10.1080/10428194.2021.1913144	results	3	NA	covariates_yn	Yes
10.1080/10428194.2021.1913144	results	3	NA	covariates_n	12
10.1080/10428194.2021.1913144	results	3	NA	covariates_names	Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Comorbidities and medical history (beside pathology/disease of interest in the comparison)
10.1080/10428194.2021.1913144	results	3	NA	contrast_effect_direction	Numerator if ratio, or left side if difference
10.1080/10428194.2021.1913144	results	3	NA	contrast_effect_unadjusted_value	NA
10.1080/10428194.2021.1913144	results	3	NA	contrast_effect_unadjusted_pvalci	NA
10.1080/10428194.2021.1913144	results	3	NA	contrast_effect_adjusted_value	0.55
10.1080/10428194.2021.1913144	results	3	NA	contrast_effect_adjusted_pvalci	0.11
10.1080/10428194.2021.1913144	results	3	NA	adjustment_geographical	No
10.1080/10428194.2021.1913144	results	3	NA	ss_total_ipd	NA
10.1080/10428194.2021.1913144	results	3	NA	ss_adjusted_total_ipd	NA
10.1080/10428194.2021.1913144	results	3	NA	ss_total_nonipd	NA
10.1080/10428194.2021.1913144	results	3	NA	ss_anchor_nonipd	NA
10.1080/10428194.2021.1913144	results	3	NA	ss_anchor_ipd	NA
10.1080/10428194.2021.1913144	results	3	NA	ss_adjusted_anchor_ipd	NA
10.1080/10428194.2021.1913144	results	3	NA	effect_cutoff	1
10.1080/10428194.2021.1913144	results	3	NA	adjusted_pval	0.11
10.1080/10428194.2021.1913144	results	3	NA	adjusted_num_pval	0.11
10.1080/10428194.2021.1913144	results	3	NA	adjusted_significant	FALSE
10.1080/10428194.2021.1913144	results	4	NA	contrast_effect_type	HR
10.1080/10428194.2021.1913144	results	4	NA	direction_benefit	inferior
10.1080/10428194.2021.1913144	results	4	NA	ss_ttt_nonipd	113
10.1080/10428194.2021.1913144	results	4	NA	ss_ttt_ipd	114
10.1080/10428194.2021.1913144	results	4	NA	ss_adjusted_ttt_ipd	97
10.1080/10428194.2021.1913144	results	4	NA	weights_yn	Yes, mentions that the weights distribution has been studied, but weights distribution not reported
10.1080/10428194.2021.1913144	results	4	NA	covariates_yn	Yes
10.1080/10428194.2021.1913144	results	4	NA	covariates_n	12
10.1080/10428194.2021.1913144	results	4	NA	covariates_names	Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Comorbidities and medical history (beside pathology/disease of interest in the comparison)
10.1080/10428194.2021.1913144	results	4	NA	contrast_effect_direction	Numerator if ratio, or left side if difference
10.1080/10428194.2021.1913144	results	4	NA	contrast_effect_unadjusted_value	NA
10.1080/10428194.2021.1913144	results	4	NA	contrast_effect_unadjusted_pvalci	NA
10.1080/10428194.2021.1913144	results	4	NA	contrast_effect_adjusted_value	0.53
10.1080/10428194.2021.1913144	results	4	NA	contrast_effect_adjusted_pvalci	0.08
10.1080/10428194.2021.1913144	results	4	NA	adjustment_geographical	No
10.1080/10428194.2021.1913144	results	4	NA	ss_total_ipd	NA
10.1080/10428194.2021.1913144	results	4	NA	ss_adjusted_total_ipd	NA
10.1080/10428194.2021.1913144	results	4	NA	ss_total_nonipd	NA
10.1080/10428194.2021.1913144	results	4	NA	ss_anchor_nonipd	NA
10.1080/10428194.2021.1913144	results	4	NA	ss_anchor_ipd	NA
10.1080/10428194.2021.1913144	results	4	NA	ss_adjusted_anchor_ipd	NA
10.1080/10428194.2021.1913144	results	4	NA	effect_cutoff	1
10.1080/10428194.2021.1913144	results	4	NA	adjusted_pval	0.08
10.1080/10428194.2021.1913144	results	4	NA	adjusted_num_pval	0.08
10.1080/10428194.2021.1913144	results	4	NA	adjusted_significant	FALSE
10.1080/10428194.2021.1913144	results	5	NA	contrast_effect_type	HR
10.1080/10428194.2021.1913144	results	5	NA	direction_benefit	inferior
10.1080/10428194.2021.1913144	results	5	NA	ss_ttt_nonipd	216
10.1080/10428194.2021.1913144	results	5	NA	ss_ttt_ipd	83
10.1080/10428194.2021.1913144	results	5	NA	ss_adjusted_ttt_ipd	43
10.1080/10428194.2021.1913144	results	5	NA	weights_yn	Yes, mentions that the weights distribution has been studied, but weights distribution not reported
10.1080/10428194.2021.1913144	results	5	NA	covariates_yn	Yes
10.1080/10428194.2021.1913144	results	5	NA	covariates_n	12
10.1080/10428194.2021.1913144	results	5	NA	covariates_names	Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Comorbidities and medical history (beside pathology/disease of interest in the comparison)
10.1080/10428194.2021.1913144	results	5	NA	contrast_effect_direction	Numerator if ratio, or left side if difference
10.1080/10428194.2021.1913144	results	5	NA	contrast_effect_unadjusted_value	NA
10.1080/10428194.2021.1913144	results	5	NA	contrast_effect_unadjusted_pvalci	NA
10.1080/10428194.2021.1913144	results	5	NA	contrast_effect_adjusted_value	0.78
10.1080/10428194.2021.1913144	results	5	NA	contrast_effect_adjusted_pvalci	0.57
10.1080/10428194.2021.1913144	results	5	NA	adjustment_geographical	No
10.1080/10428194.2021.1913144	results	5	NA	ss_total_ipd	NA
10.1080/10428194.2021.1913144	results	5	NA	ss_adjusted_total_ipd	NA
10.1080/10428194.2021.1913144	results	5	NA	ss_total_nonipd	NA
10.1080/10428194.2021.1913144	results	5	NA	ss_anchor_nonipd	NA
10.1080/10428194.2021.1913144	results	5	NA	ss_anchor_ipd	NA
10.1080/10428194.2021.1913144	results	5	NA	ss_adjusted_anchor_ipd	NA
10.1080/10428194.2021.1913144	results	5	NA	effect_cutoff	1
10.1080/10428194.2021.1913144	results	5	NA	adjusted_pval	0.57
10.1080/10428194.2021.1913144	results	5	NA	adjusted_num_pval	0.57
10.1080/10428194.2021.1913144	results	5	NA	adjusted_significant	FALSE
10.1080/10428194.2021.1913144	results	6	NA	contrast_effect_type	HR
10.1080/10428194.2021.1913144	results	6	NA	direction_benefit	inferior
10.1080/10428194.2021.1913144	results	6	NA	ss_ttt_nonipd	216
10.1080/10428194.2021.1913144	results	6	NA	ss_ttt_ipd	96
10.1080/10428194.2021.1913144	results	6	NA	ss_adjusted_ttt_ipd	51
10.1080/10428194.2021.1913144	results	6	NA	weights_yn	Yes, mentions that the weights distribution has been studied, but weights distribution not reported
10.1080/10428194.2021.1913144	results	6	NA	covariates_yn	Yes
10.1080/10428194.2021.1913144	results	6	NA	covariates_n	12
10.1080/10428194.2021.1913144	results	6	NA	covariates_names	Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Comorbidities and medical history (beside pathology/disease of interest in the comparison)
10.1080/10428194.2021.1913144	results	6	NA	contrast_effect_direction	Numerator if ratio, or left side if difference
10.1080/10428194.2021.1913144	results	6	NA	contrast_effect_unadjusted_value	NA
10.1080/10428194.2021.1913144	results	6	NA	contrast_effect_unadjusted_pvalci	NA
10.1080/10428194.2021.1913144	results	6	NA	contrast_effect_adjusted_value	1.24
10.1080/10428194.2021.1913144	results	6	NA	contrast_effect_adjusted_pvalci	0.59
10.1080/10428194.2021.1913144	results	6	NA	adjustment_geographical	No
10.1080/10428194.2021.1913144	results	6	NA	ss_total_ipd	NA
10.1080/10428194.2021.1913144	results	6	NA	ss_adjusted_total_ipd	NA
10.1080/10428194.2021.1913144	results	6	NA	ss_total_nonipd	NA
10.1080/10428194.2021.1913144	results	6	NA	ss_anchor_nonipd	NA
10.1080/10428194.2021.1913144	results	6	NA	ss_anchor_ipd	NA
10.1080/10428194.2021.1913144	results	6	NA	ss_adjusted_anchor_ipd	NA
10.1080/10428194.2021.1913144	results	6	NA	effect_cutoff	1
10.1080/10428194.2021.1913144	results	6	NA	adjusted_pval	0.59
10.1080/10428194.2021.1913144	results	6	NA	adjusted_num_pval	0.59
10.1080/10428194.2021.1913144	results	6	NA	adjusted_significant	FALSE
10.1080/10428194.2021.1913144	study_information	NA	1	ipd_yn	Yes
10.1080/10428194.2021.1913144	study_information	NA	1	ct_yn	Yes
10.1080/10428194.2021.1913144	study_information	NA	1	nct	NCT02475681
10.1080/10428194.2021.1913144	study_information	NA	1	country_study	international
10.1080/10428194.2021.1913144	study_information	NA	1	ct_phase	3
10.1080/10428194.2021.1913144	study_information	NA	1	ct_arms	2 or more
10.1080/10428194.2021.1913144	study_information	NA	2	ipd_yn	No
10.1080/10428194.2021.1913144	study_information	NA	2	ct_yn	Yes
10.1080/10428194.2021.1913144	study_information	NA	2	nct	NCT01722487
10.1080/10428194.2021.1913144	study_information	NA	2	country_study	international
10.1080/10428194.2021.1913144	study_information	NA	2	ct_phase	3
10.1080/10428194.2021.1913144	study_information	NA	2	ct_arms	2 or more
10.1080/10428194.2021.1913144	study_information	NA	3	ipd_yn	No
10.1080/10428194.2021.1913144	study_information	NA	3	ct_yn	Yes
10.1080/10428194.2021.1913144	study_information	NA	3	nct	NCT02264574
10.1080/10428194.2021.1913144	study_information	NA	3	country_study	international
10.1080/10428194.2021.1913144	study_information	NA	3	ct_phase	3
10.1080/10428194.2021.1913144	study_information	NA	3	ct_arms	2 or more
10.1080/10428194.2021.1913144	study_information	NA	4	ipd_yn	No
10.1080/10428194.2021.1913144	study_information	NA	4	ct_yn	Yes
10.1080/10428194.2021.1913144	study_information	NA	4	nct	NCT02242942
10.1080/10428194.2021.1913144	study_information	NA	4	country_study	international
10.1080/10428194.2021.1913144	study_information	NA	4	ct_phase	3
10.1080/10428194.2021.1913144	study_information	NA	4	ct_arms	2 or more
10.1080/10428194.2021.2010069	general_information	NA	NA	condition_name	relapsed or refractory large b-cell lymphomas
10.1080/10428194.2021.2010069	general_information	NA	NA	country_first_author	usa
10.1080/10428194.2021.2010069	general_information	NA	NA	country_last_author	netherlands
10.1080/10428194.2021.2010069	general_information	NA	NA	positions	Academic, Pharmaceutical Industry, Private Data Analysis Company
10.1080/10428194.2021.2010069	general_information	NA	NA	methodologist_yn	Yes
10.1080/10428194.2021.2010069	general_information	NA	NA	funding_source	Pharmaceutical Industry
10.1080/10428194.2021.2010069	general_information	NA	NA	pharmaceutical_ties_yn	Yes
10.1080/10428194.2021.2010069	general_information	NA	NA	systematic_review_yn	No
10.1080/10428194.2021.2010069	methodology	1	NA	outcome_name	overall response rate
10.1080/10428194.2021.2010069	methodology	1	NA	outcome_short_name	Overall Response Rate
10.1080/10428194.2021.2010069	methodology	1	NA	outcome_variable_type	Binary (eg rates)
10.1080/10428194.2021.2010069	methodology	1	NA	treatment_name_ipd	tisagenlecleucel
10.1080/10428194.2021.2010069	methodology	1	NA	studies_number_ipd	1
10.1080/10428194.2021.2010069	methodology	1	NA	treatment_name_nonipd	lisocabtagene
10.1080/10428194.2021.2010069	methodology	1	NA	studies_number_nonipd	2
10.1080/10428194.2021.2010069	methodology	1	NA	paic_type	MAIC
10.1080/10428194.2021.2010069	methodology	1	NA	anchored_yn	No
10.1080/10428194.2021.2010069	methodology	1	NA	paic_form	Simple (ie treatments effects extracted from two studies)
10.1080/10428194.2021.2010069	methodology	1	NA	primary_outcome_yn	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.1080/10428194.2021.2010069	methodology	1	NA	variables_selection_justification	A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion), Literature based (clinically or methodologically relevant to adjust on these variables based on the literature search conducted for this specific purpose)
10.1080/10428194.2021.2010069	methodology	1	NA	pf_yn	Yes
10.1080/10428194.2021.2010069	methodology	1	NA	tem_yn	No discussion (in the main text) of the status of treatment-effect modifiers of the variables
10.1080/10428194.2021.2010069	methodology	1	NA	adjustment_model_details_yn	No
10.1080/10428194.2021.2010069	methodology	1	NA	scale_choice_yn	No
10.1080/10428194.2021.2010069	results	1	NA	contrast_effect_type	Rate difference
10.1080/10428194.2021.2010069	results	1	NA	direction_benefit	superior
10.1080/10428194.2021.2010069	results	1	NA	ss_ttt_nonipd	256
10.1080/10428194.2021.2010069	results	1	NA	ss_ttt_ipd	106
10.1080/10428194.2021.2010069	results	1	NA	ss_adjusted_ttt_ipd	29
10.1080/10428194.2021.2010069	results	1	NA	weights_yn	Not mentioned
10.1080/10428194.2021.2010069	results	1	NA	covariates_yn	Yes
10.1080/10428194.2021.2010069	results	1	NA	covariates_n	12
10.1080/10428194.2021.2010069	results	1	NA	covariates_names	Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Past treatments for the disease of interest, Comorbidities and medical history (beside pathology/disease of interest in the comparison)
10.1080/10428194.2021.2010069	results	1	NA	contrast_effect_direction	Numerator if ratio, or left side if difference
10.1080/10428194.2021.2010069	results	1	NA	contrast_effect_unadjusted_value	-15.50
10.1080/10428194.2021.2010069	results	1	NA	contrast_effect_unadjusted_pvalci	<0.01
10.1080/10428194.2021.2010069	results	1	NA	contrast_effect_adjusted_value	-9.70
10.1080/10428194.2021.2010069	results	1	NA	contrast_effect_adjusted_pvalci	0.07
10.1080/10428194.2021.2010069	results	1	NA	adjustment_geographical	NA
10.1080/10428194.2021.2010069	results	1	NA	ss_total_ipd	NA
10.1080/10428194.2021.2010069	results	1	NA	ss_adjusted_total_ipd	NA
10.1080/10428194.2021.2010069	results	1	NA	ss_total_nonipd	NA
10.1080/10428194.2021.2010069	results	1	NA	ss_anchor_nonipd	NA
10.1080/10428194.2021.2010069	results	1	NA	ss_anchor_ipd	NA
10.1080/10428194.2021.2010069	results	1	NA	ss_adjusted_anchor_ipd	NA
10.1080/10428194.2021.2010069	results	1	NA	effect_cutoff	0
10.1080/10428194.2021.2010069	results	1	NA	unadjusted_pval	<0.01
10.1080/10428194.2021.2010069	results	1	NA	unadjusted_significant	TRUE
10.1080/10428194.2021.2010069	results	1	NA	adjusted_pval	0.07
10.1080/10428194.2021.2010069	results	1	NA	adjusted_num_pval	0.07
10.1080/10428194.2021.2010069	results	1	NA	adjusted_significant	FALSE
10.1080/10428194.2021.2010069	study_information	NA	1	ipd_yn	Yes
10.1080/10428194.2021.2010069	study_information	NA	1	ct_yn	Yes
10.1080/10428194.2021.2010069	study_information	NA	1	nct	NCT02445248
10.1080/10428194.2021.2010069	study_information	NA	1	country_study	international
10.1080/10428194.2021.2010069	study_information	NA	1	ct_phase	2
10.1080/10428194.2021.2010069	study_information	NA	1	ct_arms	1
10.1080/10428194.2021.2010069	study_information	NA	2	ipd_yn	No
10.1080/10428194.2021.2010069	study_information	NA	2	ct_yn	Yes
10.1080/10428194.2021.2010069	study_information	NA	2	nct	NCT02631044
10.1080/10428194.2021.2010069	study_information	NA	2	country_study	usa
10.1080/10428194.2021.2010069	study_information	NA	2	ct_phase	1
10.1080/10428194.2021.2010069	study_information	NA	2	ct_arms	1
10.1080/10428194.2022.2047962	general_information	NA	NA	condition_name	multiple myeloma
10.1080/10428194.2022.2047962	general_information	NA	NA	country_first_author	germany
10.1080/10428194.2022.2047962	general_information	NA	NA	country_last_author	usa
10.1080/10428194.2022.2047962	general_information	NA	NA	positions	Academic, Pharmaceutical Industry
10.1080/10428194.2022.2047962	general_information	NA	NA	methodologist_yn	Yes
10.1080/10428194.2022.2047962	general_information	NA	NA	funding_source	Pharmaceutical Industry
10.1080/10428194.2022.2047962	general_information	NA	NA	pharmaceutical_ties_yn	Yes
10.1080/10428194.2022.2047962	general_information	NA	NA	systematic_review_yn	Yes
10.1080/10428194.2022.2047962	methodology	1	NA	outcome_name	progression-free survival
10.1080/10428194.2022.2047962	methodology	1	NA	outcome_short_name	Progression-free Survival
10.1080/10428194.2022.2047962	methodology	1	NA	outcome_variable_type	Time-to-event
10.1080/10428194.2022.2047962	methodology	1	NA	treatment_name_ipd	carfizomib + dexamethasone+daratumumab
10.1080/10428194.2022.2047962	methodology	1	NA	studies_number_ipd	1
10.1080/10428194.2022.2047962	methodology	1	NA	treatment_name_nonipd	daratumumab + velcade+dexamethasone
10.1080/10428194.2022.2047962	methodology	1	NA	studies_number_nonipd	2
10.1080/10428194.2022.2047962	methodology	1	NA	paic_type	MAIC
10.1080/10428194.2022.2047962	methodology	1	NA	anchored_yn	No
10.1080/10428194.2022.2047962	methodology	1	NA	paic_form	Simple (ie treatments effects extracted from two studies)
10.1080/10428194.2022.2047962	methodology	1	NA	primary_outcome_yn	Yes
10.1080/10428194.2022.2047962	methodology	1	NA	variables_selection_justification	A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion)
10.1080/10428194.2022.2047962	methodology	1	NA	pf_yn	Yes
10.1080/10428194.2022.2047962	methodology	1	NA	tem_yn	No discussion (in the main text) of the status of treatment-effect modifiers of the variables
10.1080/10428194.2022.2047962	methodology	1	NA	adjustment_model_details_yn	No
10.1080/10428194.2022.2047962	methodology	1	NA	scale_choice_yn	No
10.1080/10428194.2022.2047962	results	1	NA	contrast_effect_type	HR
10.1080/10428194.2022.2047962	results	1	NA	direction_benefit	inferior
10.1080/10428194.2022.2047962	results	1	NA	ss_ttt_nonipd	251
10.1080/10428194.2022.2047962	results	1	NA	ss_ttt_ipd	198
10.1080/10428194.2022.2047962	results	1	NA	ss_adjusted_ttt_ipd	82
10.1080/10428194.2022.2047962	results	1	NA	weights_yn	Not mentioned
10.1080/10428194.2022.2047962	results	1	NA	covariates_yn	Yes
10.1080/10428194.2022.2047962	results	1	NA	covariates_n	10
10.1080/10428194.2022.2047962	results	1	NA	covariates_names	Age, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Past treatments for the disease of interest, Comorbidities and medical history (beside pathology/disease of interest in the comparison), Other(s)
10.1080/10428194.2022.2047962	results	1	NA	contrast_effect_direction	Numerator if ratio, or left side if difference
10.1080/10428194.2022.2047962	results	1	NA	contrast_effect_unadjusted_value	0.54
10.1080/10428194.2022.2047962	results	1	NA	contrast_effect_unadjusted_pvalci	[0.41;0.70]
10.1080/10428194.2022.2047962	results	1	NA	contrast_effect_adjusted_value	0.64
10.1080/10428194.2022.2047962	results	1	NA	contrast_effect_adjusted_pvalci	[0.46;0.90]
10.1080/10428194.2022.2047962	results	1	NA	adjustment_geographical	No
10.1080/10428194.2022.2047962	results	1	NA	ss_total_ipd	NA
10.1080/10428194.2022.2047962	results	1	NA	ss_adjusted_total_ipd	NA
10.1080/10428194.2022.2047962	results	1	NA	ss_total_nonipd	NA
10.1080/10428194.2022.2047962	results	1	NA	ss_anchor_nonipd	NA
10.1080/10428194.2022.2047962	results	1	NA	ss_anchor_ipd	NA
10.1080/10428194.2022.2047962	results	1	NA	ss_adjusted_anchor_ipd	NA
10.1080/10428194.2022.2047962	results	1	NA	effect_cutoff	1
10.1080/10428194.2022.2047962	results	1	NA	unadjusted_lb_ci	0.41
10.1080/10428194.2022.2047962	results	1	NA	unadjusted_ub_ci	0.7
10.1080/10428194.2022.2047962	results	1	NA	unadjusted_significant	TRUE
10.1080/10428194.2022.2047962	results	1	NA	adjusted_lb_ci	0.46
10.1080/10428194.2022.2047962	results	1	NA	adjusted_ub_ci	0.9
10.1080/10428194.2022.2047962	results	1	NA	adjusted_significant	TRUE
10.1080/10428194.2022.2047962	study_information	NA	1	ipd_yn	Yes
10.1080/10428194.2022.2047962	study_information	NA	1	ct_yn	Yes
10.1080/10428194.2022.2047962	study_information	NA	1	nct	NCT03158688
10.1080/10428194.2022.2047962	study_information	NA	1	country_study	international
10.1080/10428194.2022.2047962	study_information	NA	1	ct_phase	3
10.1080/10428194.2022.2047962	study_information	NA	1	ct_arms	2 or more
10.1080/10428194.2022.2047962	study_information	NA	2	ipd_yn	No
10.1080/10428194.2022.2047962	study_information	NA	2	ct_yn	Yes
10.1080/10428194.2022.2047962	study_information	NA	2	nct	NCT02136134
10.1080/10428194.2022.2047962	study_information	NA	2	country_study	international
10.1080/10428194.2022.2047962	study_information	NA	2	ct_phase	3
10.1080/10428194.2022.2047962	study_information	NA	2	ct_arms	2 or more
10.1080/13696998.2018.1443111	general_information	NA	NA	condition_name	(ALK)-positive metastatic non-small cell lung cancer
10.1080/13696998.2018.1443111	general_information	NA	NA	country_first_author	usa
10.1080/13696998.2018.1443111	general_information	NA	NA	country_last_author	usa
10.1080/13696998.2018.1443111	general_information	NA	NA	positions	Pharmaceutical Industry, Private Data Analysis Company
10.1080/13696998.2018.1443111	general_information	NA	NA	methodologist_yn	Yes
10.1080/13696998.2018.1443111	general_information	NA	NA	funding_source	Pharmaceutical Industry
10.1080/13696998.2018.1443111	general_information	NA	NA	pharmaceutical_ties_yn	Yes
10.1080/13696998.2018.1443111	general_information	NA	NA	systematic_review_yn	No
10.1080/13696998.2018.1443111	methodology	1	NA	outcome_name	progression-free survival
10.1080/13696998.2018.1443111	methodology	1	NA	outcome_short_name	Progression-free Survival
10.1080/13696998.2018.1443111	methodology	1	NA	outcome_variable_type	Time-to-event
10.1080/13696998.2018.1443111	methodology	1	NA	treatment_name_ipd	ceritinib
10.1080/13696998.2018.1443111	methodology	1	NA	studies_number_ipd	1
10.1080/13696998.2018.1443111	methodology	1	NA	treatment_name_nonipd	crizotinib
10.1080/13696998.2018.1443111	methodology	1	NA	studies_number_nonipd	2
10.1080/13696998.2018.1443111	methodology	1	NA	paic_type	MAIC
10.1080/13696998.2018.1443111	methodology	1	NA	anchored_yn	No
10.1080/13696998.2018.1443111	methodology	1	NA	paic_form	Simple (ie treatments effects extracted from two studies)
10.1080/13696998.2018.1443111	methodology	1	NA	primary_outcome_yn	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.1080/13696998.2018.1443111	methodology	1	NA	variables_selection_justification	Nothing mentioned, not reported
10.1080/13696998.2018.1443111	methodology	1	NA	pf_yn	No discussion (in the main text) of the status of prognostic factors of the variables
10.1080/13696998.2018.1443111	methodology	1	NA	tem_yn	No discussion (in the main text) of the status of treatment-effect modifiers of the variables
10.1080/13696998.2018.1443111	methodology	1	NA	adjustment_model_details_yn	No
10.1080/13696998.2018.1443111	methodology	1	NA	scale_choice_yn	No
10.1080/13696998.2018.1443111	results	1	NA	contrast_effect_type	HR
10.1080/13696998.2018.1443111	results	1	NA	direction_benefit	inferior
10.1080/13696998.2018.1443111	results	1	NA	ss_ttt_nonipd	NA
10.1080/13696998.2018.1443111	results	1	NA	ss_ttt_ipd	NA
10.1080/13696998.2018.1443111	results	1	NA	ss_adjusted_ttt_ipd	NA
10.1080/13696998.2018.1443111	results	1	NA	weights_yn	Not mentioned
10.1080/13696998.2018.1443111	results	1	NA	covariates_yn	No
10.1080/13696998.2018.1443111	results	1	NA	covariates_n	NA
10.1080/13696998.2018.1443111	results	1	NA	covariates_names	NA
10.1080/13696998.2018.1443111	results	1	NA	contrast_effect_direction	Numerator if ratio, or left side if difference
10.1080/13696998.2018.1443111	results	1	NA	contrast_effect_unadjusted_value	NA
10.1080/13696998.2018.1443111	results	1	NA	contrast_effect_unadjusted_pvalci	NA
10.1080/13696998.2018.1443111	results	1	NA	contrast_effect_adjusted_value	0.64
10.1080/13696998.2018.1443111	results	1	NA	contrast_effect_adjusted_pvalci	[0.47;0.87]
10.1080/13696998.2018.1443111	results	1	NA	adjustment_geographical	NA
10.1080/13696998.2018.1443111	results	1	NA	ss_total_ipd	NA
10.1080/13696998.2018.1443111	results	1	NA	ss_adjusted_total_ipd	NA
10.1080/13696998.2018.1443111	results	1	NA	ss_total_nonipd	NA
10.1080/13696998.2018.1443111	results	1	NA	ss_anchor_nonipd	NA
10.1080/13696998.2018.1443111	results	1	NA	ss_anchor_ipd	NA
10.1080/13696998.2018.1443111	results	1	NA	ss_adjusted_anchor_ipd	NA
10.1080/13696998.2018.1443111	results	1	NA	effect_cutoff	1
10.1080/13696998.2018.1443111	results	1	NA	adjusted_lb_ci	0.47
10.1080/13696998.2018.1443111	results	1	NA	adjusted_ub_ci	0.87
10.1080/13696998.2018.1443111	results	1	NA	adjusted_significant	TRUE
10.1080/13696998.2018.1443111	study_information	NA	1	ipd_yn	Yes
10.1080/13696998.2018.1443111	study_information	NA	1	ct_yn	Yes
10.1080/13696998.2018.1443111	study_information	NA	1	nct	NCT01828099
10.1080/13696998.2018.1443111	study_information	NA	1	country_study	international
10.1080/13696998.2018.1443111	study_information	NA	1	ct_phase	3
10.1080/13696998.2018.1443111	study_information	NA	1	ct_arms	2 or more
10.1080/13696998.2018.1443111	study_information	NA	2	ipd_yn	No
10.1080/13696998.2018.1443111	study_information	NA	2	ct_yn	Yes
10.1080/13696998.2018.1443111	study_information	NA	2	nct	NCT01154140
10.1080/13696998.2018.1443111	study_information	NA	2	country_study	international
10.1080/13696998.2018.1443111	study_information	NA	2	ct_phase	3
10.1080/13696998.2018.1443111	study_information	NA	2	ct_arms	2 or more
10.1080/13696998.2020.1722139	general_information	NA	NA	condition_name	plaque psoriasis
10.1080/13696998.2020.1722139	general_information	NA	NA	country_first_author	usa
10.1080/13696998.2020.1722139	general_information	NA	NA	country_last_author	usa
10.1080/13696998.2020.1722139	general_information	NA	NA	positions	Academic, Pharmaceutical Industry
10.1080/13696998.2020.1722139	general_information	NA	NA	methodologist_yn	Not mentioned
10.1080/13696998.2020.1722139	general_information	NA	NA	funding_source	Pharmaceutical Industry
10.1080/13696998.2020.1722139	general_information	NA	NA	pharmaceutical_ties_yn	Yes
10.1080/13696998.2020.1722139	general_information	NA	NA	systematic_review_yn	Yes
10.1080/13696998.2020.1722139	methodology	1	NA	outcome_name	physician's global assessment treatment success
10.1080/13696998.2020.1722139	methodology	1	NA	outcome_short_name	PGA responders Rate
10.1080/13696998.2020.1722139	methodology	1	NA	outcome_variable_type	Binary (eg rates)
10.1080/13696998.2020.1722139	methodology	1	NA	treatment_name_ipd	calcipotriene 0.005/betamethasone dipropionate 0.064% foam
10.1080/13696998.2020.1722139	methodology	1	NA	studies_number_ipd	1;2;3
10.1080/13696998.2020.1722139	methodology	1	NA	treatment_name_nonipd	halobetasol 0.01/tazarotene 0.045%
10.1080/13696998.2020.1722139	methodology	1	NA	studies_number_nonipd	4;5
10.1080/13696998.2020.1722139	methodology	1	NA	paic_type	MAIC
10.1080/13696998.2020.1722139	methodology	1	NA	anchored_yn	Yes
10.1080/13696998.2020.1722139	methodology	1	NA	paic_form	Aggregation of multiple studies to estimate individual treatment effects (e.g. meta-analysis in a first step to estimate treatment A effect, then population adjusted indirect comparison using treatment A effect estimate)
10.1080/13696998.2020.1722139	methodology	1	NA	primary_outcome_yn	Yes
10.1080/13696998.2020.1722139	methodology	1	NA	variables_selection_justification	Status of prognostic factor/treatment effect modified assessed in the IPD dataset, A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion)
10.1080/13696998.2020.1722139	methodology	1	NA	pf_yn	No
10.1080/13696998.2020.1722139	methodology	1	NA	tem_yn	Yes
10.1080/13696998.2020.1722139	methodology	1	NA	adjustment_model_details_yn	No
10.1080/13696998.2020.1722139	methodology	1	NA	scale_choice_yn	No
10.1080/13696998.2020.1722139	results	1	NA	contrast_effect_type	Rate difference
10.1080/13696998.2020.1722139	results	1	NA	direction_benefit	superior
10.1080/13696998.2020.1722139	results	1	NA	ss_ttt_nonipd	276
10.1080/13696998.2020.1722139	results	1	NA	ss_ttt_ipd	649
10.1080/13696998.2020.1722139	results	1	NA	ss_adjusted_ttt_ipd	NA
10.1080/13696998.2020.1722139	results	1	NA	weights_yn	Yes, mentions that the weights distribution has been studied, but weights distribution not reported
10.1080/13696998.2020.1722139	results	1	NA	covariates_yn	Yes
10.1080/13696998.2020.1722139	results	1	NA	covariates_n	4
10.1080/13696998.2020.1722139	results	1	NA	covariates_names	Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Race/ethnicity
10.1080/13696998.2020.1722139	results	1	NA	contrast_effect_direction	Numerator if ratio, or left side if difference
10.1080/13696998.2020.1722139	results	1	NA	contrast_effect_unadjusted_value	NA
10.1080/13696998.2020.1722139	results	1	NA	contrast_effect_unadjusted_pvalci	NA
10.1080/13696998.2020.1722139	results	1	NA	contrast_effect_adjusted_value	20.7
10.1080/13696998.2020.1722139	results	1	NA	contrast_effect_adjusted_pvalci	<0.001
10.1080/13696998.2020.1722139	results	1	NA	adjustment_geographical	NA
10.1080/13696998.2020.1722139	results	1	NA	ss_total_ipd	848
10.1080/13696998.2020.1722139	results	1	NA	ss_adjusted_total_ipd	586
10.1080/13696998.2020.1722139	results	1	NA	ss_total_nonipd	418
10.1080/13696998.2020.1722139	results	1	NA	ss_anchor_nonipd	142
10.1080/13696998.2020.1722139	results	1	NA	ss_anchor_ipd	199
10.1080/13696998.2020.1722139	results	1	NA	ss_adjusted_anchor_ipd	NA
10.1080/13696998.2020.1722139	results	1	NA	effect_cutoff	0
10.1080/13696998.2020.1722139	results	1	NA	adjusted_pval	<0.001
10.1080/13696998.2020.1722139	results	1	NA	adjusted_significant	TRUE
10.1080/13696998.2020.1722139	study_information	NA	1	ipd_yn	Yes
10.1080/13696998.2020.1722139	study_information	NA	1	ct_yn	Yes
10.1080/13696998.2020.1722139	study_information	NA	1	nct	NCT01866163
10.1080/13696998.2020.1722139	study_information	NA	1	country_study	usa
10.1080/13696998.2020.1722139	study_information	NA	1	ct_phase	3
10.1080/13696998.2020.1722139	study_information	NA	1	ct_arms	2 or more
10.1080/13696998.2020.1722139	study_information	NA	2	ipd_yn	Yes
10.1080/13696998.2020.1722139	study_information	NA	2	ct_yn	Yes
10.1080/13696998.2020.1722139	study_information	NA	2	nct	NCT02132936
10.1080/13696998.2020.1722139	study_information	NA	2	country_study	france
10.1080/13696998.2020.1722139	study_information	NA	2	ct_phase	3
10.1080/13696998.2020.1722139	study_information	NA	2	ct_arms	2 or more
10.1080/13696998.2020.1722139	study_information	NA	3	ipd_yn	Yes
10.1080/13696998.2020.1722139	study_information	NA	3	ct_yn	Yes
10.1080/13696998.2020.1722139	study_information	NA	3	nct	NCT01536886
10.1080/13696998.2020.1722139	study_information	NA	3	country_study	usa
10.1080/13696998.2020.1722139	study_information	NA	3	ct_phase	2
10.1080/13696998.2020.1722139	study_information	NA	3	ct_arms	2 or more
10.1080/13696998.2020.1722139	study_information	NA	4	ipd_yn	No
10.1080/13696998.2020.1722139	study_information	NA	4	ct_yn	Yes
10.1080/13696998.2020.1722139	study_information	NA	4	nct	NCT02462070
10.1080/13696998.2020.1722139	study_information	NA	4	country_study	usa
10.1080/13696998.2020.1722139	study_information	NA	4	ct_phase	3
10.1080/13696998.2020.1722139	study_information	NA	4	ct_arms	2 or more
10.1080/13696998.2020.1722139	study_information	NA	5	ipd_yn	No
10.1080/13696998.2020.1722139	study_information	NA	5	ct_yn	Yes
10.1080/13696998.2020.1722139	study_information	NA	5	nct	NCT02462122
10.1080/13696998.2020.1722139	study_information	NA	5	country_study	usa
10.1080/13696998.2020.1722139	study_information	NA	5	ct_phase	3
10.1080/13696998.2020.1722139	study_information	NA	5	ct_arms	2 or more
10.1080/14656566.2020.1811850	general_information	NA	NA	condition_name	amyloidosis with polyneuropathy
10.1080/14656566.2020.1811850	general_information	NA	NA	country_first_author	usa
10.1080/14656566.2020.1811850	general_information	NA	NA	country_last_author	usa
10.1080/14656566.2020.1811850	general_information	NA	NA	positions	Academic, Pharmaceutical Industry, Private Data Analysis Company
10.1080/14656566.2020.1811850	general_information	NA	NA	methodologist_yn	Yes
10.1080/14656566.2020.1811850	general_information	NA	NA	funding_source	Pharmaceutical Industry
10.1080/14656566.2020.1811850	general_information	NA	NA	pharmaceutical_ties_yn	Yes
10.1080/14656566.2020.1811850	general_information	NA	NA	systematic_review_yn	Yes
10.1080/14656566.2020.1811850	methodology	1	NA	outcome_name	15-month changes from baseline in mnis+7ionis (modified neuropathy impairment score +7)
10.1080/14656566.2020.1811850	methodology	1	NA	outcome_short_name	Modified neuropathy impairment score
10.1080/14656566.2020.1811850	methodology	1	NA	outcome_variable_type	Continuous (count, mean, ...)
10.1080/14656566.2020.1811850	methodology	1	NA	treatment_name_ipd	patisiran
10.1080/14656566.2020.1811850	methodology	1	NA	studies_number_ipd	1
10.1080/14656566.2020.1811850	methodology	1	NA	treatment_name_nonipd	inotersen
10.1080/14656566.2020.1811850	methodology	1	NA	studies_number_nonipd	2
10.1080/14656566.2020.1811850	methodology	1	NA	paic_type	MAIC
10.1080/14656566.2020.1811850	methodology	1	NA	anchored_yn	Yes
10.1080/14656566.2020.1811850	methodology	1	NA	paic_form	Simple (ie treatments effects extracted from two studies)
10.1080/14656566.2020.1811850	methodology	1	NA	primary_outcome_yn	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.1080/14656566.2020.1811850	methodology	1	NA	variables_selection_justification	Nothing mentioned, not reported
10.1080/14656566.2020.1811850	methodology	1	NA	pf_yn	No discussion (in the main text) of the status of prognostic factors of the variables
10.1080/14656566.2020.1811850	methodology	1	NA	tem_yn	No discussion (in the main text) of the status of treatment-effect modifiers of the variables
10.1080/14656566.2020.1811850	methodology	1	NA	adjustment_model_details_yn	No
10.1080/14656566.2020.1811850	methodology	1	NA	scale_choice_yn	No
10.1080/14656566.2020.1811850	results	1	NA	contrast_effect_type	Means difference
10.1080/14656566.2020.1811850	results	1	NA	direction_benefit	inferior
10.1080/14656566.2020.1811850	results	1	NA	ss_ttt_nonipd	112
10.1080/14656566.2020.1811850	results	1	NA	ss_ttt_ipd	148
10.1080/14656566.2020.1811850	results	1	NA	ss_adjusted_ttt_ipd	90
10.1080/14656566.2020.1811850	results	1	NA	weights_yn	Yes, mentions that the weights distribution has been studied, but weights distribution not reported
10.1080/14656566.2020.1811850	results	1	NA	covariates_yn	Yes
10.1080/14656566.2020.1811850	results	1	NA	covariates_n	9
10.1080/14656566.2020.1811850	results	1	NA	covariates_names	Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Race/ethnicity, Past treatments for the disease of interest, Other(s)
10.1080/14656566.2020.1811850	results	1	NA	contrast_effect_direction	Numerator if ratio, or left side if difference
10.1080/14656566.2020.1811850	results	1	NA	contrast_effect_unadjusted_value	-16.2
10.1080/14656566.2020.1811850	results	1	NA	contrast_effect_unadjusted_pvalci	0.001
10.1080/14656566.2020.1811850	results	1	NA	contrast_effect_adjusted_value	-12.3
10.1080/14656566.2020.1811850	results	1	NA	contrast_effect_adjusted_pvalci	0.007
10.1080/14656566.2020.1811850	results	1	NA	adjustment_geographical	No
10.1080/14656566.2020.1811850	results	1	NA	ss_total_ipd	NA
10.1080/14656566.2020.1811850	results	1	NA	ss_adjusted_total_ipd	NA
10.1080/14656566.2020.1811850	results	1	NA	ss_total_nonipd	NA
10.1080/14656566.2020.1811850	results	1	NA	ss_anchor_nonipd	60
10.1080/14656566.2020.1811850	results	1	NA	ss_anchor_ipd	77
10.1080/14656566.2020.1811850	results	1	NA	ss_adjusted_anchor_ipd	47
10.1080/14656566.2020.1811850	results	1	NA	effect_cutoff	0
10.1080/14656566.2020.1811850	results	1	NA	unadjusted_pval	0.001
10.1080/14656566.2020.1811850	results	1	NA	unadjusted_num_pval	0.001
10.1080/14656566.2020.1811850	results	1	NA	unadjusted_significant	TRUE
10.1080/14656566.2020.1811850	results	1	NA	adjusted_pval	0.007
10.1080/14656566.2020.1811850	results	1	NA	adjusted_num_pval	0.007
10.1080/14656566.2020.1811850	results	1	NA	adjusted_significant	TRUE
10.1080/14656566.2020.1811850	study_information	NA	1	ipd_yn	Yes
10.1080/14656566.2020.1811850	study_information	NA	1	ct_yn	Yes
10.1080/14656566.2020.1811850	study_information	NA	1	nct	NCT01960348
10.1080/14656566.2020.1811850	study_information	NA	1	country_study	international
10.1080/14656566.2020.1811850	study_information	NA	1	ct_phase	3
10.1080/14656566.2020.1811850	study_information	NA	1	ct_arms	2 or more
10.1080/14656566.2020.1811850	study_information	NA	2	ipd_yn	No
10.1080/14656566.2020.1811850	study_information	NA	2	ct_yn	Yes
10.1080/14656566.2020.1811850	study_information	NA	2	nct	NCT01737398
10.1080/14656566.2020.1811850	study_information	NA	2	country_study	international
10.1080/14656566.2020.1811850	study_information	NA	2	ct_phase	2, 3
10.1080/14656566.2020.1811850	study_information	NA	2	ct_arms	2 or more
10.1080/14760584.2021.1994858	general_information	NA	NA	condition_name	pneumococcal disease
10.1080/14760584.2021.1994858	general_information	NA	NA	country_first_author	switzerland
10.1080/14760584.2021.1994858	general_information	NA	NA	country_last_author	usa
10.1080/14760584.2021.1994858	general_information	NA	NA	positions	Pharmaceutical Industry
10.1080/14760584.2021.1994858	general_information	NA	NA	methodologist_yn	Yes
10.1080/14760584.2021.1994858	general_information	NA	NA	funding_source	Pharmaceutical Industry
10.1080/14760584.2021.1994858	general_information	NA	NA	pharmaceutical_ties_yn	Yes
10.1080/14760584.2021.1994858	general_information	NA	NA	systematic_review_yn	No
10.1080/14760584.2021.1994858	methodology	1	NA	outcome_name	30 days post-vaccination serotype-specific opa (opsonophagocytic activity)
10.1080/14760584.2021.1994858	methodology	1	NA	outcome_short_name	Serotype-specific opsonophagocytic activity
10.1080/14760584.2021.1994858	methodology	1	NA	outcome_variable_type	Continuous (count, mean, ...)
10.1080/14760584.2021.1994858	methodology	1	NA	treatment_name_ipd	15-valent pneumococcal conjugate vaccine
10.1080/14760584.2021.1994858	methodology	1	NA	studies_number_ipd	1;2;3
10.1080/14760584.2021.1994858	methodology	1	NA	treatment_name_nonipd	20-valent pneumococcal conjugate vaccine
10.1080/14760584.2021.1994858	methodology	1	NA	studies_number_nonipd	4
10.1080/14760584.2021.1994858	methodology	1	NA	paic_type	MAIC
10.1080/14760584.2021.1994858	methodology	1	NA	anchored_yn	Yes
10.1080/14760584.2021.1994858	methodology	1	NA	paic_form	Aggregation of multiple studies to estimate individual treatment effects (e.g. meta-analysis in a first step to estimate treatment A effect, then population adjusted indirect comparison using treatment A effect estimate)
10.1080/14760584.2021.1994858	methodology	1	NA	primary_outcome_yn	Yes
10.1080/14760584.2021.1994858	methodology	1	NA	variables_selection_justification	Literature based (clinically or methodologically relevant to adjust on these variables based on the literature search conducted for this specific purpose)
10.1080/14760584.2021.1994858	methodology	1	NA	pf_yn	Yes
10.1080/14760584.2021.1994858	methodology	1	NA	tem_yn	Yes
10.1080/14760584.2021.1994858	methodology	1	NA	adjustment_model_details_yn	Yes
10.1080/14760584.2021.1994858	methodology	1	NA	scale_choice_yn	Yes
10.1080/14760584.2021.1994858	results	1	NA	contrast_effect_type	Means Ratio
10.1080/14760584.2021.1994858	results	1	NA	direction_benefit	superior
10.1080/14760584.2021.1994858	results	1	NA	ss_ttt_nonipd	1507
10.1080/14760584.2021.1994858	results	1	NA	ss_ttt_ipd	2196
10.1080/14760584.2021.1994858	results	1	NA	ss_adjusted_ttt_ipd	NA
10.1080/14760584.2021.1994858	results	1	NA	weights_yn	Not mentioned
10.1080/14760584.2021.1994858	results	1	NA	covariates_yn	Yes
10.1080/14760584.2021.1994858	results	1	NA	covariates_n	2
10.1080/14760584.2021.1994858	results	1	NA	covariates_names	Age, Sex
10.1080/14760584.2021.1994858	results	1	NA	contrast_effect_direction	Numerator if ratio, or left side if difference
10.1080/14760584.2021.1994858	results	1	NA	contrast_effect_unadjusted_value	0.89
10.1080/14760584.2021.1994858	results	1	NA	contrast_effect_unadjusted_pvalci	[0.74;1.07]
10.1080/14760584.2021.1994858	results	1	NA	contrast_effect_adjusted_value	0.91
10.1080/14760584.2021.1994858	results	1	NA	contrast_effect_adjusted_pvalci	[0.76;1.10]
10.1080/14760584.2021.1994858	results	1	NA	adjustment_geographical	NA
10.1080/14760584.2021.1994858	results	1	NA	ss_total_ipd	3033
10.1080/14760584.2021.1994858	results	1	NA	ss_adjusted_total_ipd	1710
10.1080/14760584.2021.1994858	results	1	NA	ss_total_nonipd	2997
10.1080/14760584.2021.1994858	results	1	NA	ss_anchor_nonipd	1490
10.1080/14760584.2021.1994858	results	1	NA	ss_anchor_ipd	843
10.1080/14760584.2021.1994858	results	1	NA	ss_adjusted_anchor_ipd	NA
10.1080/14760584.2021.1994858	results	1	NA	effect_cutoff	1
10.1080/14760584.2021.1994858	results	1	NA	unadjusted_lb_ci	0.74
10.1080/14760584.2021.1994858	results	1	NA	unadjusted_ub_ci	1.07
10.1080/14760584.2021.1994858	results	1	NA	unadjusted_significant	FALSE
10.1080/14760584.2021.1994858	results	1	NA	adjusted_lb_ci	0.76
10.1080/14760584.2021.1994858	results	1	NA	adjusted_ub_ci	1.1
10.1080/14760584.2021.1994858	results	1	NA	adjusted_significant	FALSE
10.1080/14760584.2021.1994858	study_information	NA	1	ipd_yn	Yes
10.1080/14760584.2021.1994858	study_information	NA	1	ct_yn	Yes
10.1080/14760584.2021.1994858	study_information	NA	1	nct	NCT03950622
10.1080/14760584.2021.1994858	study_information	NA	1	country_study	international
10.1080/14760584.2021.1994858	study_information	NA	1	ct_phase	3
10.1080/14760584.2021.1994858	study_information	NA	1	ct_arms	2 or more
10.1080/14760584.2021.1994858	study_information	NA	2	ipd_yn	Yes
10.1080/14760584.2021.1994858	study_information	NA	2	ct_yn	Yes
10.1080/14760584.2021.1994858	study_information	NA	2	nct	NCT03480763
10.1080/14760584.2021.1994858	study_information	NA	2	country_study	international
10.1080/14760584.2021.1994858	study_information	NA	2	ct_phase	3
10.1080/14760584.2021.1994858	study_information	NA	2	ct_arms	2 or more
10.1080/14760584.2021.1994858	study_information	NA	3	ipd_yn	Yes
10.1080/14760584.2021.1994858	study_information	NA	3	ct_yn	Yes
10.1080/14760584.2021.1994858	study_information	NA	3	nct	NCT03950856
10.1080/14760584.2021.1994858	study_information	NA	3	country_study	international
10.1080/14760584.2021.1994858	study_information	NA	3	ct_phase	3
10.1080/14760584.2021.1994858	study_information	NA	3	ct_arms	2 or more
10.1080/14760584.2021.1994858	study_information	NA	4	ipd_yn	No
10.1080/14760584.2021.1994858	study_information	NA	4	ct_yn	Yes
10.1080/14760584.2021.1994858	study_information	NA	4	nct	NCT03760146
10.1080/14760584.2021.1994858	study_information	NA	4	country_study	international
10.1080/14760584.2021.1994858	study_information	NA	4	ct_phase	3
10.1080/14760584.2021.1994858	study_information	NA	4	ct_arms	2 or more
10.1080/17474086.2018.1475226	general_information	NA	NA	condition_name	relapsed and refractory classical hodgkins lymphoma
10.1080/17474086.2018.1475226	general_information	NA	NA	country_first_author	canada
10.1080/17474086.2018.1475226	general_information	NA	NA	country_last_author	usa
10.1080/17474086.2018.1475226	general_information	NA	NA	positions	Pharmaceutical Industry, Private Data Analysis Company
10.1080/17474086.2018.1475226	general_information	NA	NA	methodologist_yn	Yes
10.1080/17474086.2018.1475226	general_information	NA	NA	funding_source	Pharmaceutical Industry
10.1080/17474086.2018.1475226	general_information	NA	NA	pharmaceutical_ties_yn	Yes
10.1080/17474086.2018.1475226	general_information	NA	NA	systematic_review_yn	Yes
10.1080/17474086.2018.1475226	methodology	1	NA	outcome_name	progression-free survival
10.1080/17474086.2018.1475226	methodology	1	NA	outcome_short_name	Progression-free Survival
10.1080/17474086.2018.1475226	methodology	1	NA	outcome_variable_type	Time-to-event
10.1080/17474086.2018.1475226	methodology	1	NA	treatment_name_ipd	pembrolizumab
10.1080/17474086.2018.1475226	methodology	1	NA	studies_number_ipd	1
10.1080/17474086.2018.1475226	methodology	1	NA	treatment_name_nonipd	st + ard of care
10.1080/17474086.2018.1475226	methodology	1	NA	studies_number_nonipd	2
10.1080/17474086.2018.1475226	methodology	1	NA	paic_type	STC
10.1080/17474086.2018.1475226	methodology	1	NA	anchored_yn	No
10.1080/17474086.2018.1475226	methodology	1	NA	paic_form	Simple (ie treatments effects extracted from two studies)
10.1080/17474086.2018.1475226	methodology	1	NA	primary_outcome_yn	Yes
10.1080/17474086.2018.1475226	methodology	1	NA	variables_selection_justification	A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion)
10.1080/17474086.2018.1475226	methodology	1	NA	pf_yn	Yes
10.1080/17474086.2018.1475226	methodology	1	NA	tem_yn	No discussion (in the main text) of the status of treatment-effect modifiers of the variables
10.1080/17474086.2018.1475226	methodology	1	NA	adjustment_model_details_yn	Yes
10.1080/17474086.2018.1475226	methodology	1	NA	scale_choice_yn	No
10.1080/17474086.2018.1475226	results	1	NA	contrast_effect_type	HR
10.1080/17474086.2018.1475226	results	1	NA	direction_benefit	inferior
10.1080/17474086.2018.1475226	results	1	NA	ss_ttt_nonipd	83
10.1080/17474086.2018.1475226	results	1	NA	ss_ttt_ipd	175
10.1080/17474086.2018.1475226	results	1	NA	ss_adjusted_ttt_ipd	175
10.1080/17474086.2018.1475226	results	1	NA	weights_yn	Not mentioned
10.1080/17474086.2018.1475226	results	1	NA	covariates_yn	Yes
10.1080/17474086.2018.1475226	results	1	NA	covariates_n	7
10.1080/17474086.2018.1475226	results	1	NA	covariates_names	Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...)
10.1080/17474086.2018.1475226	results	1	NA	contrast_effect_direction	Denominator if ratio, or rightside if difference
10.1080/17474086.2018.1475226	results	1	NA	contrast_effect_unadjusted_value	5
10.1080/17474086.2018.1475226	results	1	NA	contrast_effect_unadjusted_pvalci	[3.56;7.01]
10.1080/17474086.2018.1475226	results	1	NA	contrast_effect_adjusted_value	6.35
10.1080/17474086.2018.1475226	results	1	NA	contrast_effect_adjusted_pvalci	[4.04;9.98]
10.1080/17474086.2018.1475226	results	1	NA	adjustment_geographical	NA
10.1080/17474086.2018.1475226	results	1	NA	ss_total_ipd	NA
10.1080/17474086.2018.1475226	results	1	NA	ss_adjusted_total_ipd	NA
10.1080/17474086.2018.1475226	results	1	NA	ss_total_nonipd	NA
10.1080/17474086.2018.1475226	results	1	NA	ss_anchor_nonipd	NA
10.1080/17474086.2018.1475226	results	1	NA	ss_anchor_ipd	NA
10.1080/17474086.2018.1475226	results	1	NA	ss_adjusted_anchor_ipd	NA
10.1080/17474086.2018.1475226	results	1	NA	effect_cutoff	1
10.1080/17474086.2018.1475226	results	1	NA	unadjusted_lb_ci	3.56
10.1080/17474086.2018.1475226	results	1	NA	unadjusted_ub_ci	7.01
10.1080/17474086.2018.1475226	results	1	NA	unadjusted_significant	TRUE
10.1080/17474086.2018.1475226	results	1	NA	adjusted_lb_ci	4.04
10.1080/17474086.2018.1475226	results	1	NA	adjusted_ub_ci	9.98
10.1080/17474086.2018.1475226	results	1	NA	adjusted_significant	TRUE
10.1080/17474086.2018.1475226	study_information	NA	1	ipd_yn	Yes
10.1080/17474086.2018.1475226	study_information	NA	1	ct_yn	Yes
10.1080/17474086.2018.1475226	study_information	NA	1	nct	NCT02453594
10.1080/17474086.2018.1475226	study_information	NA	1	ct_phase	2
10.1080/17474086.2018.1475226	study_information	NA	1	ct_arms	1
10.1080/17474086.2018.1475226	study_information	NA	1	country_study	unknown
10.1080/17474086.2018.1475226	study_information	NA	2	ipd_yn	No
10.1080/17474086.2018.1475226	study_information	NA	2	ct_yn	No
10.1080/17474086.2018.1475226	study_information	NA	2	data_source_name	cheah et al., 2016
10.1080/17474086.2018.1475226	study_information	NA	2	country_study	usa
10.1093/europace/euy160	general_information	NA	NA	condition_name	non-valvular atrial fibrillation
10.1093/europace/euy160	general_information	NA	NA	country_first_author	uk
10.1093/europace/euy160	general_information	NA	NA	country_last_author	canada
10.1093/europace/euy160	general_information	NA	NA	positions	Academic, Pharmaceutical Industry, Private Data Analysis Company
10.1093/europace/euy160	general_information	NA	NA	methodologist_yn	Yes
10.1093/europace/euy160	general_information	NA	NA	funding_source	Pharmaceutical Industry
10.1093/europace/euy160	general_information	NA	NA	pharmaceutical_ties_yn	Yes
10.1093/europace/euy160	general_information	NA	NA	systematic_review_yn	No
10.1093/europace/euy160	methodology	1	NA	outcome_name	treatment-emergent adjudicated major bleeding
10.1093/europace/euy160	methodology	1	NA	outcome_short_name	Major Bleeding
10.1093/europace/euy160	methodology	1	NA	outcome_variable_type	Binary (eg rates)
10.1093/europace/euy160	methodology	1	NA	treatment_name_ipd	rivaroxaban
10.1093/europace/euy160	methodology	1	NA	studies_number_ipd	1
10.1093/europace/euy160	methodology	1	NA	treatment_name_nonipd	rivaroxaban
10.1093/europace/euy160	methodology	1	NA	studies_number_nonipd	2
10.1093/europace/euy160	methodology	1	NA	paic_type	MAIC
10.1093/europace/euy160	methodology	1	NA	anchored_yn	No
10.1093/europace/euy160	methodology	1	NA	paic_form	Simple (ie treatments effects extracted from two studies)
10.1093/europace/euy160	methodology	1	NA	primary_outcome_yn	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.1093/europace/euy160	methodology	1	NA	variables_selection_justification	Nothing mentioned, not reported
10.1093/europace/euy160	methodology	1	NA	pf_yn	No discussion (in the main text) of the status of prognostic factors of the variables
10.1093/europace/euy160	methodology	1	NA	tem_yn	No discussion (in the main text) of the status of treatment-effect modifiers of the variables
10.1093/europace/euy160	methodology	1	NA	adjustment_model_details_yn	No
10.1093/europace/euy160	methodology	1	NA	scale_choice_yn	No
10.1093/europace/euy160	results	1	NA	contrast_effect_type	RR
10.1093/europace/euy160	results	1	NA	direction_benefit	inferior
10.1093/europace/euy160	results	1	NA	ss_ttt_nonipd	7061
10.1093/europace/euy160	results	1	NA	ss_ttt_ipd	4020
10.1093/europace/euy160	results	1	NA	ss_adjusted_ttt_ipd	2492
10.1093/europace/euy160	results	1	NA	weights_yn	Not mentioned
10.1093/europace/euy160	results	1	NA	covariates_yn	Yes
10.1093/europace/euy160	results	1	NA	covariates_n	2
10.1093/europace/euy160	results	1	NA	covariates_names	Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease)
10.1093/europace/euy160	results	1	NA	contrast_effect_direction	Numerator if ratio, or left side if difference
10.1093/europace/euy160	results	1	NA	contrast_effect_unadjusted_value	NA
10.1093/europace/euy160	results	1	NA	contrast_effect_unadjusted_pvalci	NA
10.1093/europace/euy160	results	1	NA	contrast_effect_adjusted_value	0.86
10.1093/europace/euy160	results	1	NA	contrast_effect_adjusted_pvalci	[0.67;1.12]
10.1093/europace/euy160	results	1	NA	adjustment_geographical	NA
10.1093/europace/euy160	results	1	NA	ss_total_ipd	NA
10.1093/europace/euy160	results	1	NA	ss_adjusted_total_ipd	NA
10.1093/europace/euy160	results	1	NA	ss_total_nonipd	NA
10.1093/europace/euy160	results	1	NA	ss_anchor_nonipd	NA
10.1093/europace/euy160	results	1	NA	ss_anchor_ipd	NA
10.1093/europace/euy160	results	1	NA	ss_adjusted_anchor_ipd	NA
10.1093/europace/euy160	results	1	NA	effect_cutoff	1
10.1093/europace/euy160	results	1	NA	adjusted_lb_ci	0.67
10.1093/europace/euy160	results	1	NA	adjusted_ub_ci	1.12
10.1093/europace/euy160	results	1	NA	adjusted_significant	FALSE
10.1093/europace/euy160	study_information	NA	1	ipd_yn	Yes
10.1093/europace/euy160	study_information	NA	1	ct_yn	No
10.1093/europace/euy160	study_information	NA	1	nct	NCT01606995
10.1093/europace/euy160	study_information	NA	1	country_study	international
10.1093/europace/euy160	study_information	NA	2	ipd_yn	No
10.1093/europace/euy160	study_information	NA	2	ct_yn	Yes
10.1093/europace/euy160	study_information	NA	2	nct	NCT00403767
10.1093/europace/euy160	study_information	NA	2	country_study	international
10.1093/europace/euy160	study_information	NA	2	ct_phase	3
10.1093/europace/euy160	study_information	NA	2	ct_arms	2 or more
10.1093/jnci/djab071	general_information	NA	NA	condition_name	nonmetastatic castration-resistant prostate cancer
10.1093/jnci/djab071	general_information	NA	NA	country_first_author	usa
10.1093/jnci/djab071	general_information	NA	NA	country_last_author	usa
10.1093/jnci/djab071	general_information	NA	NA	positions	Academic
10.1093/jnci/djab071	general_information	NA	NA	methodologist_yn	Yes
10.1093/jnci/djab071	general_information	NA	NA	funding_source	Public grants, Pharmaceutical Industry
10.1093/jnci/djab071	general_information	NA	NA	pharmaceutical_ties_yn	Yes
10.1093/jnci/djab071	general_information	NA	NA	systematic_review_yn	Yes
10.1093/jnci/djab071	methodology	1	NA	outcome_name	metastasis-free survival
10.1093/jnci/djab071	methodology	1	NA	outcome_short_name	Metastasis-free Survival
10.1093/jnci/djab071	methodology	1	NA	outcome_variable_type	Time-to-event
10.1093/jnci/djab071	methodology	1	NA	treatment_name_ipd	abiraterone acetate
10.1093/jnci/djab071	methodology	1	NA	studies_number_ipd	1
10.1093/jnci/djab071	methodology	1	NA	treatment_name_nonipd	placebo
10.1093/jnci/djab071	methodology	1	NA	studies_number_nonipd	2
10.1093/jnci/djab071	methodology	1	NA	paic_type	MAIC
10.1093/jnci/djab071	methodology	1	NA	anchored_yn	No
10.1093/jnci/djab071	methodology	1	NA	paic_form	Simple (ie treatments effects extracted from two studies)
10.1093/jnci/djab071	methodology	1	NA	primary_outcome_yn	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.1093/jnci/djab071	methodology	1	NA	variables_selection_justification	Nothing mentioned, not reported
10.1093/jnci/djab071	methodology	1	NA	pf_yn	No discussion (in the main text) of the status of prognostic factors of the variables
10.1093/jnci/djab071	methodology	1	NA	tem_yn	No discussion (in the main text) of the status of treatment-effect modifiers of the variables
10.1093/jnci/djab071	methodology	1	NA	adjustment_model_details_yn	No
10.1093/jnci/djab071	methodology	1	NA	scale_choice_yn	No
10.1093/jnci/djab071	results	1	NA	contrast_effect_type	HR
10.1093/jnci/djab071	results	1	NA	direction_benefit	inferior
10.1093/jnci/djab071	results	1	NA	ss_ttt_nonipd	1207
10.1093/jnci/djab071	results	1	NA	ss_ttt_ipd	131
10.1093/jnci/djab071	results	1	NA	ss_adjusted_ttt_ipd	81
10.1093/jnci/djab071	results	1	NA	weights_yn	Yes, mentions that the weights distribution has been studied, and weights distribution reported in main article or supplemental materials
10.1093/jnci/djab071	results	1	NA	covariates_yn	Yes
10.1093/jnci/djab071	results	1	NA	covariates_n	4
10.1093/jnci/djab071	results	1	NA	covariates_names	Age, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Past treatments for the disease of interest
10.1093/jnci/djab071	results	1	NA	contrast_effect_direction	Numerator if ratio, or left side if difference
10.1093/jnci/djab071	results	1	NA	contrast_effect_unadjusted_value	NA
10.1093/jnci/djab071	results	1	NA	contrast_effect_unadjusted_pvalci	NA
10.1093/jnci/djab071	results	1	NA	contrast_effect_adjusted_value	0.22
10.1093/jnci/djab071	results	1	NA	contrast_effect_adjusted_pvalci	[0.12;0.41]
10.1093/jnci/djab071	results	1	NA	adjustment_geographical	NA
10.1093/jnci/djab071	results	1	NA	ss_total_ipd	NA
10.1093/jnci/djab071	results	1	NA	ss_adjusted_total_ipd	NA
10.1093/jnci/djab071	results	1	NA	ss_total_nonipd	NA
10.1093/jnci/djab071	results	1	NA	ss_anchor_nonipd	NA
10.1093/jnci/djab071	results	1	NA	ss_anchor_ipd	NA
10.1093/jnci/djab071	results	1	NA	ss_adjusted_anchor_ipd	NA
10.1093/jnci/djab071	results	1	NA	effect_cutoff	1
10.1093/jnci/djab071	results	1	NA	adjusted_lb_ci	0.12
10.1093/jnci/djab071	results	1	NA	adjusted_ub_ci	0.41
10.1093/jnci/djab071	results	1	NA	adjusted_significant	TRUE
10.1093/jnci/djab071	study_information	NA	1	ipd_yn	Yes
10.1093/jnci/djab071	study_information	NA	1	ct_yn	Yes
10.1093/jnci/djab071	study_information	NA	1	nct	NCT01314118
10.1093/jnci/djab071	study_information	NA	1	country_study	usa
10.1093/jnci/djab071	study_information	NA	1	ct_phase	2
10.1093/jnci/djab071	study_information	NA	1	ct_arms	1
10.1093/jnci/djab071	study_information	NA	2	ipd_yn	No
10.1093/jnci/djab071	study_information	NA	2	ct_yn	Yes
10.1093/jnci/djab071	study_information	NA	2	nct	NCT01946204
10.1093/jnci/djab071	study_information	NA	2	country_study	international
10.1093/jnci/djab071	study_information	NA	2	ct_phase	3
10.1093/jnci/djab071	study_information	NA	2	ct_arms	2 or more
10.1097/brs.0000000000002647	general_information	NA	NA	condition_name	lumbar disc degeneration
10.1097/brs.0000000000002647	general_information	NA	NA	country_first_author	usa
10.1097/brs.0000000000002647	general_information	NA	NA	country_last_author	canada
10.1097/brs.0000000000002647	general_information	NA	NA	positions	Academic, Private Data Analysis Company
10.1097/brs.0000000000002647	general_information	NA	NA	methodologist_yn	Yes
10.1097/brs.0000000000002647	general_information	NA	NA	funding_source	Pharmaceutical Industry
10.1097/brs.0000000000002647	general_information	NA	NA	pharmaceutical_ties_yn	Yes
10.1097/brs.0000000000002647	general_information	NA	NA	systematic_review_yn	No
10.1097/brs.0000000000002647	methodology	1	NA	outcome_name	5-year change in radiographic adjacent-level degeneration
10.1097/brs.0000000000002647	methodology	1	NA	outcome_short_name	Radiographic degeneration
10.1097/brs.0000000000002647	methodology	1	NA	outcome_variable_type	Binary (eg rates)
10.1097/brs.0000000000002647	methodology	1	NA	treatment_name_ipd	total disc replacement
10.1097/brs.0000000000002647	methodology	1	NA	studies_number_ipd	1
10.1097/brs.0000000000002647	methodology	1	NA	treatment_name_nonipd	fusion
10.1097/brs.0000000000002647	methodology	1	NA	studies_number_nonipd	2
10.1097/brs.0000000000002647	methodology	1	NA	paic_type	MAIC
10.1097/brs.0000000000002647	methodology	1	NA	anchored_yn	No
10.1097/brs.0000000000002647	methodology	1	NA	paic_form	Simple (ie treatments effects extracted from two studies)
10.1097/brs.0000000000002647	methodology	1	NA	primary_outcome_yn	Yes
10.1097/brs.0000000000002647	methodology	1	NA	variables_selection_justification	Nothing mentioned, not reported
10.1097/brs.0000000000002647	methodology	1	NA	pf_yn	No discussion (in the main text) of the status of prognostic factors of the variables
10.1097/brs.0000000000002647	methodology	1	NA	tem_yn	No discussion (in the main text) of the status of treatment-effect modifiers of the variables
10.1097/brs.0000000000002647	methodology	1	NA	adjustment_model_details_yn	No
10.1097/brs.0000000000002647	methodology	1	NA	scale_choice_yn	No
10.1097/brs.0000000000002647	results	1	NA	contrast_effect_type	OR
10.1097/brs.0000000000002647	results	1	NA	direction_benefit	inferior
10.1097/brs.0000000000002647	results	1	NA	ss_ttt_nonipd	43
10.1097/brs.0000000000002647	results	1	NA	ss_ttt_ipd	175
10.1097/brs.0000000000002647	results	1	NA	ss_adjusted_ttt_ipd	139
10.1097/brs.0000000000002647	results	1	NA	weights_yn	Not mentioned
10.1097/brs.0000000000002647	results	1	NA	covariates_yn	Yes
10.1097/brs.0000000000002647	results	1	NA	covariates_n	7
10.1097/brs.0000000000002647	results	1	NA	covariates_names	Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Other(s)
10.1097/brs.0000000000002647	results	1	NA	contrast_effect_direction	Numerator if ratio, or left side if difference
10.1097/brs.0000000000002647	results	1	NA	contrast_effect_unadjusted_value	0.28
10.1097/brs.0000000000002647	results	1	NA	contrast_effect_unadjusted_pvalci	[0.12;0.63]
10.1097/brs.0000000000002647	results	1	NA	contrast_effect_adjusted_value	0.32
10.1097/brs.0000000000002647	results	1	NA	contrast_effect_adjusted_pvalci	[0.13;0.76]
10.1097/brs.0000000000002647	results	1	NA	adjustment_geographical	No
10.1097/brs.0000000000002647	results	1	NA	ss_total_ipd	NA
10.1097/brs.0000000000002647	results	1	NA	ss_adjusted_total_ipd	NA
10.1097/brs.0000000000002647	results	1	NA	ss_total_nonipd	NA
10.1097/brs.0000000000002647	results	1	NA	ss_anchor_nonipd	NA
10.1097/brs.0000000000002647	results	1	NA	ss_anchor_ipd	NA
10.1097/brs.0000000000002647	results	1	NA	ss_adjusted_anchor_ipd	NA
10.1097/brs.0000000000002647	results	1	NA	effect_cutoff	1
10.1097/brs.0000000000002647	results	1	NA	unadjusted_lb_ci	0.12
10.1097/brs.0000000000002647	results	1	NA	unadjusted_ub_ci	0.63
10.1097/brs.0000000000002647	results	1	NA	unadjusted_significant	TRUE
10.1097/brs.0000000000002647	results	1	NA	adjusted_lb_ci	0.13
10.1097/brs.0000000000002647	results	1	NA	adjusted_ub_ci	0.76
10.1097/brs.0000000000002647	results	1	NA	adjusted_significant	TRUE
10.1097/brs.0000000000002647	study_information	NA	1	ipd_yn	Yes
10.1097/brs.0000000000002647	study_information	NA	1	ct_yn	Yes
10.1097/brs.0000000000002647	study_information	NA	1	nct	NCT00589797
10.1097/brs.0000000000002647	study_information	NA	1	country_study	usa
10.1097/brs.0000000000002647	study_information	NA	1	ct_arms	2 or more
10.1097/brs.0000000000002647	study_information	NA	2	ipd_yn	No
10.1097/brs.0000000000002647	study_information	NA	2	ct_yn	Yes
10.1097/brs.0000000000002647	study_information	NA	2	nct	NCT00295009
10.1097/brs.0000000000002647	study_information	NA	2	country_study	usa
10.1097/brs.0000000000002647	study_information	NA	2	ct_arms	2 or more
10.1097/ju.0000000000001767	general_information	NA	NA	condition_name	nonmetastatic castration-resistant prostate cancer
10.1097/ju.0000000000001767	general_information	NA	NA	country_first_author	usa
10.1097/ju.0000000000001767	general_information	NA	NA	country_last_author	usa
10.1097/ju.0000000000001767	general_information	NA	NA	positions	Academic, Pharmaceutical Industry, Private Data Analysis Company
10.1097/ju.0000000000001767	general_information	NA	NA	methodologist_yn	Yes
10.1097/ju.0000000000001767	general_information	NA	NA	funding_source	Pharmaceutical Industry
10.1097/ju.0000000000001767	general_information	NA	NA	pharmaceutical_ties_yn	Yes
10.1097/ju.0000000000001767	general_information	NA	NA	systematic_review_yn	No
10.1097/ju.0000000000001767	methodology	1	NA	outcome_name	Risk of fall
10.1097/ju.0000000000001767	methodology	1	NA	outcome_short_name	Risk of fall
10.1097/ju.0000000000001767	methodology	1	NA	outcome_variable_type	Binary (eg rates)
10.1097/ju.0000000000001767	methodology	1	NA	treatment_name_ipd	darolutamide
10.1097/ju.0000000000001767	methodology	1	NA	studies_number_ipd	1
10.1097/ju.0000000000001767	methodology	1	NA	treatment_name_nonipd	apalutamide
10.1097/ju.0000000000001767	methodology	1	NA	studies_number_nonipd	2
10.1097/ju.0000000000001767	methodology	1	NA	paic_type	MAIC
10.1097/ju.0000000000001767	methodology	1	NA	anchored_yn	Yes
10.1097/ju.0000000000001767	methodology	1	NA	paic_form	Simple (ie treatments effects extracted from two studies)
10.1097/ju.0000000000001767	methodology	1	NA	primary_outcome_yn	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.1097/ju.0000000000001767	methodology	1	NA	variables_selection_justification	A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion)
10.1097/ju.0000000000001767	methodology	1	NA	pf_yn	No
10.1097/ju.0000000000001767	methodology	1	NA	tem_yn	Yes
10.1097/ju.0000000000001767	methodology	1	NA	adjustment_model_details_yn	No
10.1097/ju.0000000000001767	methodology	1	NA	scale_choice_yn	No
10.1097/ju.0000000000001767	methodology	2	NA	outcome_name	Risk of fall
10.1097/ju.0000000000001767	methodology	2	NA	outcome_short_name	Risk of fall
10.1097/ju.0000000000001767	methodology	2	NA	outcome_variable_type	Binary (eg rates)
10.1097/ju.0000000000001767	methodology	2	NA	treatment_name_ipd	darolutamide
10.1097/ju.0000000000001767	methodology	2	NA	studies_number_ipd	1
10.1097/ju.0000000000001767	methodology	2	NA	treatment_name_nonipd	enzalutamide
10.1097/ju.0000000000001767	methodology	2	NA	studies_number_nonipd	3
10.1097/ju.0000000000001767	methodology	2	NA	paic_type	MAIC
10.1097/ju.0000000000001767	methodology	2	NA	anchored_yn	Yes
10.1097/ju.0000000000001767	methodology	2	NA	paic_form	Simple (ie treatments effects extracted from two studies)
10.1097/ju.0000000000001767	methodology	2	NA	primary_outcome_yn	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.1097/ju.0000000000001767	methodology	2	NA	variables_selection_justification	Nothing mentioned, not reported
10.1097/ju.0000000000001767	methodology	2	NA	pf_yn	No discussion (in the main text) of the status of prognostic factors of the variables
10.1097/ju.0000000000001767	methodology	2	NA	tem_yn	No discussion (in the main text) of the status of treatment-effect modifiers of the variables
10.1097/ju.0000000000001767	methodology	2	NA	adjustment_model_details_yn	No
10.1097/ju.0000000000001767	methodology	2	NA	scale_choice_yn	No
10.1097/ju.0000000000001767	results	1	NA	contrast_effect_type	Risk difference
10.1097/ju.0000000000001767	results	1	NA	direction_benefit	inferior
10.1097/ju.0000000000001767	results	1	NA	ss_ttt_nonipd	806
10.1097/ju.0000000000001767	results	1	NA	ss_ttt_ipd	943
10.1097/ju.0000000000001767	results	1	NA	ss_adjusted_ttt_ipd	604
10.1097/ju.0000000000001767	results	1	NA	weights_yn	Not mentioned
10.1097/ju.0000000000001767	results	1	NA	covariates_yn	Yes
10.1097/ju.0000000000001767	results	1	NA	covariates_n	7
10.1097/ju.0000000000001767	results	1	NA	covariates_names	Age, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Past treatments for the disease of interest
10.1097/ju.0000000000001767	results	1	NA	contrast_effect_direction	Numerator if ratio, or left side if difference
10.1097/ju.0000000000001767	results	1	NA	contrast_effect_unadjusted_value	NA
10.1097/ju.0000000000001767	results	1	NA	contrast_effect_unadjusted_pvalci	NA
10.1097/ju.0000000000001767	results	1	NA	contrast_effect_adjusted_value	-6.3
10.1097/ju.0000000000001767	results	1	NA	contrast_effect_adjusted_pvalci	0.043
10.1097/ju.0000000000001767	results	1	NA	adjustment_geographical	NA
10.1097/ju.0000000000001767	results	1	NA	ss_total_ipd	NA
10.1097/ju.0000000000001767	results	1	NA	ss_adjusted_total_ipd	NA
10.1097/ju.0000000000001767	results	1	NA	ss_total_nonipd	NA
10.1097/ju.0000000000001767	results	1	NA	ss_anchor_nonipd	401
10.1097/ju.0000000000001767	results	1	NA	ss_anchor_ipd	553
10.1097/ju.0000000000001767	results	1	NA	ss_adjusted_anchor_ipd	391
10.1097/ju.0000000000001767	results	1	NA	effect_cutoff	0
10.1097/ju.0000000000001767	results	1	NA	adjusted_pval	0.043
10.1097/ju.0000000000001767	results	1	NA	adjusted_num_pval	0.043
10.1097/ju.0000000000001767	results	1	NA	adjusted_significant	TRUE
10.1097/ju.0000000000001767	results	2	NA	contrast_effect_type	Risk difference
10.1097/ju.0000000000001767	results	2	NA	direction_benefit	inferior
10.1097/ju.0000000000001767	results	2	NA	ss_ttt_nonipd	933
10.1097/ju.0000000000001767	results	2	NA	ss_ttt_ipd	943
10.1097/ju.0000000000001767	results	2	NA	ss_adjusted_ttt_ipd	580
10.1097/ju.0000000000001767	results	2	NA	weights_yn	Not mentioned
10.1097/ju.0000000000001767	results	2	NA	covariates_yn	Yes
10.1097/ju.0000000000001767	results	2	NA	covariates_n	8
10.1097/ju.0000000000001767	results	2	NA	covariates_names	Age, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Past treatments for the disease of interest, Other(s)
10.1097/ju.0000000000001767	results	2	NA	contrast_effect_direction	Numerator if ratio, or left side if difference
10.1097/ju.0000000000001767	results	2	NA	contrast_effect_unadjusted_value	NA
10.1097/ju.0000000000001767	results	2	NA	contrast_effect_unadjusted_pvalci	NA
10.1097/ju.0000000000001767	results	2	NA	contrast_effect_adjusted_value	-6.3
10.1097/ju.0000000000001767	results	2	NA	contrast_effect_adjusted_pvalci	0.004
10.1097/ju.0000000000001767	results	2	NA	adjustment_geographical	Yes
10.1097/ju.0000000000001767	results	2	NA	ss_total_ipd	NA
10.1097/ju.0000000000001767	results	2	NA	ss_adjusted_total_ipd	NA
10.1097/ju.0000000000001767	results	2	NA	ss_total_nonipd	NA
10.1097/ju.0000000000001767	results	2	NA	ss_anchor_nonipd	468
10.1097/ju.0000000000001767	results	2	NA	ss_anchor_ipd	553
10.1097/ju.0000000000001767	results	2	NA	ss_adjusted_anchor_ipd	395
10.1097/ju.0000000000001767	results	2	NA	effect_cutoff	0
10.1097/ju.0000000000001767	results	2	NA	adjusted_pval	0.004
10.1097/ju.0000000000001767	results	2	NA	adjusted_num_pval	0.004
10.1097/ju.0000000000001767	results	2	NA	adjusted_significant	TRUE
10.1097/ju.0000000000001767	study_information	NA	1	ipd_yn	Yes
10.1097/ju.0000000000001767	study_information	NA	1	ct_yn	Yes
10.1097/ju.0000000000001767	study_information	NA	1	nct	NCT02200614
10.1097/ju.0000000000001767	study_information	NA	1	country_study	international
10.1097/ju.0000000000001767	study_information	NA	1	ct_phase	3
10.1097/ju.0000000000001767	study_information	NA	1	ct_arms	2 or more
10.1097/ju.0000000000001767	study_information	NA	2	ipd_yn	No
10.1097/ju.0000000000001767	study_information	NA	2	ct_yn	Yes
10.1097/ju.0000000000001767	study_information	NA	2	nct	NCT01946204
10.1097/ju.0000000000001767	study_information	NA	2	country_study	international
10.1097/ju.0000000000001767	study_information	NA	2	ct_phase	3
10.1097/ju.0000000000001767	study_information	NA	2	ct_arms	2 or more
10.1097/ju.0000000000001767	study_information	NA	3	ipd_yn	No
10.1097/ju.0000000000001767	study_information	NA	3	ct_yn	Yes
10.1097/ju.0000000000001767	study_information	NA	3	nct	NCT02003924
10.1097/ju.0000000000001767	study_information	NA	3	country_study	international
10.1097/ju.0000000000001767	study_information	NA	3	ct_phase	3
10.1097/ju.0000000000001767	study_information	NA	3	ct_arms	2 or more
10.1111/bjd.16140	general_information	NA	NA	condition_name	moderate-to-severe plaque psoriasis
10.1111/bjd.16140	general_information	NA	NA	country_first_author	uk
10.1111/bjd.16140	general_information	NA	NA	country_last_author	germany
10.1111/bjd.16140	general_information	NA	NA	positions	Academic, Pharmaceutical Industry
10.1111/bjd.16140	general_information	NA	NA	methodologist_yn	Yes
10.1111/bjd.16140	general_information	NA	NA	funding_source	Pharmaceutical Industry
10.1111/bjd.16140	general_information	NA	NA	pharmaceutical_ties_yn	Yes
10.1111/bjd.16140	general_information	NA	NA	systematic_review_yn	Yes
10.1111/bjd.16140	methodology	3	NA	outcome_name	psoriasis area severity index 75 response rate at week 12
10.1111/bjd.16140	methodology	3	NA	outcome_short_name	PASI 75 Responders Rate
10.1111/bjd.16140	methodology	3	NA	outcome_variable_type	Binary (eg rates)
10.1111/bjd.16140	methodology	3	NA	treatment_name_ipd	ixekizumab
10.1111/bjd.16140	methodology	3	NA	studies_number_ipd	2;3
10.1111/bjd.16140	methodology	3	NA	treatment_name_nonipd	secukinumab
10.1111/bjd.16140	methodology	3	NA	studies_number_nonipd	5
10.1111/bjd.16140	methodology	3	NA	paic_type	MAIC
10.1111/bjd.16140	methodology	3	NA	anchored_yn	Yes
10.1111/bjd.16140	methodology	3	NA	paic_form	Aggregation of multiple studies to estimate individual treatment effects (e.g. meta-analysis in a first step to estimate treatment A effect, then population adjusted indirect comparison using treatment A effect estimate)
10.1111/bjd.16140	methodology	3	NA	primary_outcome_yn	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.1111/bjd.16140	methodology	3	NA	variables_selection_justification	Nothing mentioned, not reported
10.1111/bjd.16140	methodology	3	NA	pf_yn	No discussion (in the main text) of the status of prognostic factors of the variables
10.1111/bjd.16140	methodology	3	NA	tem_yn	No discussion (in the main text) of the status of treatment-effect modifiers of the variables
10.1111/bjd.16140	methodology	3	NA	adjustment_model_details_yn	No
10.1111/bjd.16140	methodology	3	NA	scale_choice_yn	No
10.1111/bjd.16140	methodology	5	NA	outcome_name	psoriasis area severity index 75 response rate at week 12
10.1111/bjd.16140	methodology	5	NA	outcome_short_name	PASI 75 Responders Rate
10.1111/bjd.16140	methodology	5	NA	outcome_variable_type	Binary (eg rates)
10.1111/bjd.16140	methodology	5	NA	treatment_name_ipd	ixekizumab
10.1111/bjd.16140	methodology	5	NA	studies_number_ipd	4
10.1111/bjd.16140	methodology	5	NA	treatment_name_nonipd	secukinumab
10.1111/bjd.16140	methodology	5	NA	studies_number_nonipd	9
10.1111/bjd.16140	methodology	5	NA	paic_type	MAIC
10.1111/bjd.16140	methodology	5	NA	anchored_yn	Yes
10.1111/bjd.16140	methodology	5	NA	paic_form	Simple (ie treatments effects extracted from two studies)
10.1111/bjd.16140	methodology	5	NA	primary_outcome_yn	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.1111/bjd.16140	methodology	5	NA	variables_selection_justification	Nothing mentioned, not reported
10.1111/bjd.16140	methodology	5	NA	pf_yn	No discussion (in the main text) of the status of prognostic factors of the variables
10.1111/bjd.16140	methodology	5	NA	tem_yn	No discussion (in the main text) of the status of treatment-effect modifiers of the variables
10.1111/bjd.16140	methodology	5	NA	adjustment_model_details_yn	No
10.1111/bjd.16140	methodology	5	NA	scale_choice_yn	No
10.1111/bjd.16140	results	3	NA	contrast_effect_type	Risk difference
10.1111/bjd.16140	results	3	NA	direction_benefit	superior
10.1111/bjd.16140	results	3	NA	ss_ttt_nonipd	653
10.1111/bjd.16140	results	3	NA	ss_ttt_ipd	1465
10.1111/bjd.16140	results	3	NA	ss_adjusted_ttt_ipd	989
10.1111/bjd.16140	results	3	NA	weights_yn	Not mentioned
10.1111/bjd.16140	results	3	NA	covariates_yn	Yes
10.1111/bjd.16140	results	3	NA	covariates_n	7
10.1111/bjd.16140	results	3	NA	covariates_names	Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Past treatments for the disease of interest, Other(s)
10.1111/bjd.16140	results	3	NA	contrast_effect_direction	Numerator if ratio, or left side if difference
10.1111/bjd.16140	results	3	NA	contrast_effect_unadjusted_value	NA
10.1111/bjd.16140	results	3	NA	contrast_effect_unadjusted_pvalci	0.1
10.1111/bjd.16140	results	3	NA	contrast_effect_adjusted_value	NA
10.1111/bjd.16140	results	3	NA	contrast_effect_adjusted_pvalci	0.7
10.1111/bjd.16140	results	3	NA	adjustment_geographical	No
10.1111/bjd.16140	results	3	NA	ss_total_ipd	1465
10.1111/bjd.16140	results	3	NA	ss_adjusted_total_ipd	989
10.1111/bjd.16140	results	3	NA	ss_total_nonipd	653
10.1111/bjd.16140	results	3	NA	ss_anchor_nonipd	NA
10.1111/bjd.16140	results	3	NA	ss_anchor_ipd	NA
10.1111/bjd.16140	results	3	NA	ss_adjusted_anchor_ipd	NA
10.1111/bjd.16140	results	3	NA	effect_cutoff	0
10.1111/bjd.16140	results	3	NA	unadjusted_pval	0.1
10.1111/bjd.16140	results	3	NA	unadjusted_num_pval	0.1
10.1111/bjd.16140	results	3	NA	unadjusted_significant	FALSE
10.1111/bjd.16140	results	3	NA	adjusted_pval	0.7
10.1111/bjd.16140	results	3	NA	adjusted_num_pval	0.7
10.1111/bjd.16140	results	3	NA	adjusted_significant	FALSE
10.1111/bjd.16140	results	5	NA	contrast_effect_type	Risk difference
10.1111/bjd.16140	results	5	NA	direction_benefit	superior
10.1111/bjd.16140	results	5	NA	ss_ttt_nonipd	676
10.1111/bjd.16140	results	5	NA	ss_ttt_ipd	259
10.1111/bjd.16140	results	5	NA	ss_adjusted_ttt_ipd	122
10.1111/bjd.16140	results	5	NA	weights_yn	Not mentioned
10.1111/bjd.16140	results	5	NA	covariates_yn	Yes
10.1111/bjd.16140	results	5	NA	covariates_n	8
10.1111/bjd.16140	results	5	NA	covariates_names	Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Past treatments for the disease of interest, Other(s)
10.1111/bjd.16140	results	5	NA	contrast_effect_direction	Numerator if ratio, or left side if difference
10.1111/bjd.16140	results	5	NA	contrast_effect_unadjusted_value	NA
10.1111/bjd.16140	results	5	NA	contrast_effect_unadjusted_pvalci	0.21
10.1111/bjd.16140	results	5	NA	contrast_effect_adjusted_value	NA
10.1111/bjd.16140	results	5	NA	contrast_effect_adjusted_pvalci	0.26
10.1111/bjd.16140	results	5	NA	adjustment_geographical	No
10.1111/bjd.16140	results	5	NA	ss_total_ipd	259
10.1111/bjd.16140	results	5	NA	ss_adjusted_total_ipd	122
10.1111/bjd.16140	results	5	NA	ss_total_nonipd	676
10.1111/bjd.16140	results	5	NA	ss_anchor_nonipd	NA
10.1111/bjd.16140	results	5	NA	ss_anchor_ipd	NA
10.1111/bjd.16140	results	5	NA	ss_adjusted_anchor_ipd	NA
10.1111/bjd.16140	results	5	NA	effect_cutoff	0
10.1111/bjd.16140	results	5	NA	unadjusted_pval	0.21
10.1111/bjd.16140	results	5	NA	unadjusted_num_pval	0.21
10.1111/bjd.16140	results	5	NA	unadjusted_significant	FALSE
10.1111/bjd.16140	results	5	NA	adjusted_pval	0.26
10.1111/bjd.16140	results	5	NA	adjusted_num_pval	0.26
10.1111/bjd.16140	results	5	NA	adjusted_significant	FALSE
10.1111/bjd.16140	study_information	NA	1	ipd_yn	Yes
10.1111/bjd.16140	study_information	NA	1	ct_yn	Yes
10.1111/bjd.16140	study_information	NA	1	nct	NCT01474512
10.1111/bjd.16140	study_information	NA	1	country_study	international
10.1111/bjd.16140	study_information	NA	1	ct_phase	3
10.1111/bjd.16140	study_information	NA	1	ct_arms	2 or more
10.1111/bjd.16140	study_information	NA	2	ipd_yn	Yes
10.1111/bjd.16140	study_information	NA	2	ct_yn	Yes
10.1111/bjd.16140	study_information	NA	2	nct	NCT01597245
10.1111/bjd.16140	study_information	NA	2	country_study	international
10.1111/bjd.16140	study_information	NA	2	ct_phase	3
10.1111/bjd.16140	study_information	NA	2	ct_arms	2 or more
10.1111/bjd.16140	study_information	NA	3	ipd_yn	Yes
10.1111/bjd.16140	study_information	NA	3	ct_yn	Yes
10.1111/bjd.16140	study_information	NA	3	nct	NCT01646177
10.1111/bjd.16140	study_information	NA	3	country_study	international
10.1111/bjd.16140	study_information	NA	3	ct_phase	3
10.1111/bjd.16140	study_information	NA	3	ct_arms	2 or more
10.1111/bjd.16140	study_information	NA	4	ipd_yn	Yes
10.1111/bjd.16140	study_information	NA	4	ct_yn	Yes
10.1111/bjd.16140	study_information	NA	4	nct	NCT02561806
10.1111/bjd.16140	study_information	NA	4	country_study	international
10.1111/bjd.16140	study_information	NA	4	ct_phase	3
10.1111/bjd.16140	study_information	NA	4	ct_arms	2 or more
10.1111/bjd.16140	study_information	NA	5	ipd_yn	No
10.1111/bjd.16140	study_information	NA	5	ct_yn	Yes
10.1111/bjd.16140	study_information	NA	5	nct	NCT01358578
10.1111/bjd.16140	study_information	NA	5	country_study	international
10.1111/bjd.16140	study_information	NA	5	ct_phase	3
10.1111/bjd.16140	study_information	NA	5	ct_arms	2 or more
10.1111/bjd.16140	study_information	NA	6	ipd_yn	No
10.1111/bjd.16140	study_information	NA	6	ct_yn	Yes
10.1111/bjd.16140	study_information	NA	6	nct	NCT01365455
10.1111/bjd.16140	study_information	NA	6	country_study	international
10.1111/bjd.16140	study_information	NA	6	ct_phase	3
10.1111/bjd.16140	study_information	NA	6	ct_arms	2 or more
10.1111/bjd.16140	study_information	NA	7	ipd_yn	No
10.1111/bjd.16140	study_information	NA	7	ct_yn	Yes
10.1111/bjd.16140	study_information	NA	7	nct	NCT01555125
10.1111/bjd.16140	study_information	NA	7	country_study	international
10.1111/bjd.16140	study_information	NA	7	ct_phase	3
10.1111/bjd.16140	study_information	NA	7	ct_arms	2 or more
10.1111/bjd.16140	study_information	NA	8	ipd_yn	No
10.1111/bjd.16140	study_information	NA	8	ct_yn	Yes
10.1111/bjd.16140	study_information	NA	8	nct	NCT01636687
10.1111/bjd.16140	study_information	NA	8	country_study	international
10.1111/bjd.16140	study_information	NA	8	ct_phase	3
10.1111/bjd.16140	study_information	NA	8	ct_arms	2 or more
10.1111/bjd.16140	study_information	NA	9	ipd_yn	No
10.1111/bjd.16140	study_information	NA	9	ct_yn	Yes
10.1111/bjd.16140	study_information	NA	9	nct	NCT02074982
10.1111/bjd.16140	study_information	NA	9	country_study	international
10.1111/bjd.16140	study_information	NA	9	ct_phase	3
10.1111/bjd.16140	study_information	NA	9	ct_arms	2 or more
10.1111/cea.13561	general_information	NA	NA	condition_name	asthma
10.1111/cea.13561	general_information	NA	NA	country_first_author	france
10.1111/cea.13561	general_information	NA	NA	country_last_author	usa
10.1111/cea.13561	general_information	NA	NA	positions	Academic, Pharmaceutical Industry, Private Data Analysis Company
10.1111/cea.13561	general_information	NA	NA	methodologist_yn	Yes
10.1111/cea.13561	general_information	NA	NA	funding_source	Pharmaceutical Industry
10.1111/cea.13561	general_information	NA	NA	pharmaceutical_ties_yn	Yes
10.1111/cea.13561	general_information	NA	NA	systematic_review_yn	Yes
10.1111/cea.13561	methodology	1	NA	outcome_name	ocs (oral corticosteroids) dosage reduction from baseline to week 24
10.1111/cea.13561	methodology	1	NA	outcome_short_name	Oral corticosteriods dosage reduction
10.1111/cea.13561	methodology	1	NA	outcome_variable_type	Continuous (count, mean, ...)
10.1111/cea.13561	methodology	1	NA	treatment_name_ipd	benralizumab
10.1111/cea.13561	methodology	1	NA	studies_number_ipd	1
10.1111/cea.13561	methodology	1	NA	treatment_name_nonipd	mepolizumab
10.1111/cea.13561	methodology	1	NA	studies_number_nonipd	2
10.1111/cea.13561	methodology	1	NA	paic_type	MAIC
10.1111/cea.13561	methodology	1	NA	anchored_yn	Yes
10.1111/cea.13561	methodology	1	NA	paic_form	Simple (ie treatments effects extracted from two studies)
10.1111/cea.13561	methodology	1	NA	primary_outcome_yn	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.1111/cea.13561	methodology	1	NA	variables_selection_justification	Statistical imbalanced between treatment groups (independently of the status of prognostic/effect modifier), Status of prognostic factor/treatment effect modified assessed in the IPD dataset, A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion)
10.1111/cea.13561	methodology	1	NA	pf_yn	No
10.1111/cea.13561	methodology	1	NA	tem_yn	Yes
10.1111/cea.13561	methodology	1	NA	adjustment_model_details_yn	No
10.1111/cea.13561	methodology	1	NA	scale_choice_yn	No
10.1111/cea.13561	methodology	2	NA	outcome_name	ocs (oral corticosteroids) dosage reduction from baseline to week 24
10.1111/cea.13561	methodology	2	NA	outcome_short_name	Oral corticosteriods dosage reduction
10.1111/cea.13561	methodology	2	NA	outcome_variable_type	Continuous (count, mean, ...)
10.1111/cea.13561	methodology	2	NA	treatment_name_ipd	benralizumab
10.1111/cea.13561	methodology	2	NA	studies_number_ipd	1
10.1111/cea.13561	methodology	2	NA	treatment_name_nonipd	dupilumab
10.1111/cea.13561	methodology	2	NA	studies_number_nonipd	3
10.1111/cea.13561	methodology	2	NA	paic_type	MAIC
10.1111/cea.13561	methodology	2	NA	anchored_yn	Yes
10.1111/cea.13561	methodology	2	NA	paic_form	Simple (ie treatments effects extracted from two studies)
10.1111/cea.13561	methodology	2	NA	primary_outcome_yn	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.1111/cea.13561	methodology	2	NA	variables_selection_justification	Statistical imbalanced between treatment groups (independently of the status of prognostic/effect modifier), Status of prognostic factor/treatment effect modified assessed in the IPD dataset, A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion)
10.1111/cea.13561	methodology	2	NA	pf_yn	No
10.1111/cea.13561	methodology	2	NA	tem_yn	Yes
10.1111/cea.13561	methodology	2	NA	adjustment_model_details_yn	No
10.1111/cea.13561	methodology	2	NA	scale_choice_yn	No
10.1111/cea.13561	results	1	NA	contrast_effect_type	Means difference
10.1111/cea.13561	results	1	NA	direction_benefit	superior
10.1111/cea.13561	results	1	NA	ss_ttt_nonipd	NA
10.1111/cea.13561	results	1	NA	ss_ttt_ipd	NA
10.1111/cea.13561	results	1	NA	ss_adjusted_ttt_ipd	NA
10.1111/cea.13561	results	1	NA	weights_yn	Not mentioned
10.1111/cea.13561	results	1	NA	covariates_yn	Yes
10.1111/cea.13561	results	1	NA	covariates_n	5
10.1111/cea.13561	results	1	NA	covariates_names	Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Past treatments for the disease of interest, Comorbidities and medical history (beside pathology/disease of interest in the comparison)
10.1111/cea.13561	results	1	NA	contrast_effect_direction	Numerator if ratio, or left side if difference
10.1111/cea.13561	results	1	NA	contrast_effect_unadjusted_value	20.1
10.1111/cea.13561	results	1	NA	contrast_effect_unadjusted_pvalci	0.1584
10.1111/cea.13561	results	1	NA	contrast_effect_adjusted_value	6.08
10.1111/cea.13561	results	1	NA	contrast_effect_adjusted_pvalci	0.67
10.1111/cea.13561	results	1	NA	adjustment_geographical	No
10.1111/cea.13561	results	1	NA	ss_total_ipd	148
10.1111/cea.13561	results	1	NA	ss_adjusted_total_ipd	72
10.1111/cea.13561	results	1	NA	ss_total_nonipd	135
10.1111/cea.13561	results	1	NA	ss_anchor_nonipd	NA
10.1111/cea.13561	results	1	NA	ss_anchor_ipd	NA
10.1111/cea.13561	results	1	NA	ss_adjusted_anchor_ipd	NA
10.1111/cea.13561	results	1	NA	effect_cutoff	0
10.1111/cea.13561	results	1	NA	unadjusted_pval	0.1584
10.1111/cea.13561	results	1	NA	unadjusted_num_pval	0.1584
10.1111/cea.13561	results	1	NA	unadjusted_significant	FALSE
10.1111/cea.13561	results	1	NA	adjusted_pval	0.67
10.1111/cea.13561	results	1	NA	adjusted_num_pval	0.67
10.1111/cea.13561	results	1	NA	adjusted_significant	FALSE
10.1111/cea.13561	results	2	NA	contrast_effect_type	Means difference
10.1111/cea.13561	results	2	NA	direction_benefit	superior
10.1111/cea.13561	results	2	NA	ss_ttt_nonipd	NA
10.1111/cea.13561	results	2	NA	ss_ttt_ipd	NA
10.1111/cea.13561	results	2	NA	ss_adjusted_ttt_ipd	NA
10.1111/cea.13561	results	2	NA	weights_yn	Not mentioned
10.1111/cea.13561	results	2	NA	covariates_yn	Yes
10.1111/cea.13561	results	2	NA	covariates_n	5
10.1111/cea.13561	results	2	NA	covariates_names	Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Past treatments for the disease of interest, Comorbidities and medical history (beside pathology/disease of interest in the comparison)
10.1111/cea.13561	results	2	NA	contrast_effect_direction	Numerator if ratio, or left side if difference
10.1111/cea.13561	results	2	NA	contrast_effect_unadjusted_value	8.1
10.1111/cea.13561	results	2	NA	contrast_effect_unadjusted_pvalci	0.46
10.1111/cea.13561	results	2	NA	contrast_effect_adjusted_value	-0.71
10.1111/cea.13561	results	2	NA	contrast_effect_adjusted_pvalci	0.94
10.1111/cea.13561	results	2	NA	adjustment_geographical	No
10.1111/cea.13561	results	2	NA	ss_total_ipd	148
10.1111/cea.13561	results	2	NA	ss_adjusted_total_ipd	36
10.1111/cea.13561	results	2	NA	ss_total_nonipd	210
10.1111/cea.13561	results	2	NA	ss_anchor_nonipd	NA
10.1111/cea.13561	results	2	NA	ss_anchor_ipd	NA
10.1111/cea.13561	results	2	NA	ss_adjusted_anchor_ipd	NA
10.1111/cea.13561	results	2	NA	effect_cutoff	0
10.1111/cea.13561	results	2	NA	unadjusted_pval	0.46
10.1111/cea.13561	results	2	NA	unadjusted_num_pval	0.46
10.1111/cea.13561	results	2	NA	unadjusted_significant	FALSE
10.1111/cea.13561	results	2	NA	adjusted_pval	0.94
10.1111/cea.13561	results	2	NA	adjusted_num_pval	0.94
10.1111/cea.13561	results	2	NA	adjusted_significant	FALSE
10.1111/cea.13561	study_information	NA	1	ipd_yn	Yes
10.1111/cea.13561	study_information	NA	1	ct_yn	Yes
10.1111/cea.13561	study_information	NA	1	nct	NCT02075255
10.1111/cea.13561	study_information	NA	1	country_study	international
10.1111/cea.13561	study_information	NA	1	ct_phase	3
10.1111/cea.13561	study_information	NA	1	ct_arms	2 or more
10.1111/cea.13561	study_information	NA	2	ipd_yn	No
10.1111/cea.13561	study_information	NA	2	ct_yn	Yes
10.1111/cea.13561	study_information	NA	2	nct	NCT01691508
10.1111/cea.13561	study_information	NA	2	country_study	international
10.1111/cea.13561	study_information	NA	2	ct_phase	3
10.1111/cea.13561	study_information	NA	2	ct_arms	2 or more
10.1111/cea.13561	study_information	NA	3	ipd_yn	No
10.1111/cea.13561	study_information	NA	3	ct_yn	Yes
10.1111/cea.13561	study_information	NA	3	nct	NCT02528214
10.1111/cea.13561	study_information	NA	3	country_study	international
10.1111/cea.13561	study_information	NA	3	ct_phase	3
10.1111/cea.13561	study_information	NA	3	ct_arms	2 or more
10.1111/dom.14497	general_information	NA	NA	condition_name	type 2 diabetes
10.1111/dom.14497	general_information	NA	NA	country_first_author	usa
10.1111/dom.14497	general_information	NA	NA	country_last_author	denmark
10.1111/dom.14497	general_information	NA	NA	positions	Academic, Pharmaceutical Industry, Private Data Analysis Company
10.1111/dom.14497	general_information	NA	NA	methodologist_yn	Yes
10.1111/dom.14497	general_information	NA	NA	funding_source	Pharmaceutical Industry
10.1111/dom.14497	general_information	NA	NA	pharmaceutical_ties_yn	Yes
10.1111/dom.14497	general_information	NA	NA	systematic_review_yn	No
10.1111/dom.14497	methodology	1	NA	outcome_name	change from baseline in hba1c
10.1111/dom.14497	methodology	1	NA	outcome_short_name	HbA1C
10.1111/dom.14497	methodology	1	NA	outcome_variable_type	Continuous (count, mean, ...)
10.1111/dom.14497	methodology	1	NA	treatment_name_ipd	semaglutide 1.0mg
10.1111/dom.14497	methodology	1	NA	studies_number_ipd	1
10.1111/dom.14497	methodology	1	NA	treatment_name_nonipd	dulaglutide 3.0mg
10.1111/dom.14497	methodology	1	NA	studies_number_nonipd	2
10.1111/dom.14497	methodology	1	NA	paic_type	MAIC
10.1111/dom.14497	methodology	1	NA	anchored_yn	Yes
10.1111/dom.14497	methodology	1	NA	paic_form	Simple (ie treatments effects extracted from two studies)
10.1111/dom.14497	methodology	1	NA	primary_outcome_yn	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.1111/dom.14497	methodology	1	NA	variables_selection_justification	Nothing mentioned, not reported
10.1111/dom.14497	methodology	1	NA	pf_yn	No
10.1111/dom.14497	methodology	1	NA	tem_yn	Yes
10.1111/dom.14497	methodology	1	NA	adjustment_model_details_yn	Yes
10.1111/dom.14497	methodology	1	NA	scale_choice_yn	No
10.1111/dom.14497	methodology	2	NA	outcome_name	change from baseline in hba1c
10.1111/dom.14497	methodology	2	NA	outcome_short_name	HbA1C
10.1111/dom.14497	methodology	2	NA	outcome_variable_type	Continuous (count, mean, ...)
10.1111/dom.14497	methodology	2	NA	treatment_name_ipd	semaglutide 1.0mg
10.1111/dom.14497	methodology	2	NA	studies_number_ipd	1
10.1111/dom.14497	methodology	2	NA	treatment_name_nonipd	dulaglutide 4.5mg
10.1111/dom.14497	methodology	2	NA	studies_number_nonipd	2
10.1111/dom.14497	methodology	2	NA	paic_type	MAIC
10.1111/dom.14497	methodology	2	NA	anchored_yn	Yes
10.1111/dom.14497	methodology	2	NA	paic_form	Simple (ie treatments effects extracted from two studies)
10.1111/dom.14497	methodology	2	NA	primary_outcome_yn	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.1111/dom.14497	methodology	2	NA	variables_selection_justification	Nothing mentioned, not reported
10.1111/dom.14497	methodology	2	NA	pf_yn	No
10.1111/dom.14497	methodology	2	NA	tem_yn	Yes
10.1111/dom.14497	methodology	2	NA	adjustment_model_details_yn	Yes
10.1111/dom.14497	methodology	2	NA	scale_choice_yn	No
10.1111/dom.14497	results	1	NA	contrast_effect_type	Means difference
10.1111/dom.14497	results	1	NA	direction_benefit	inferior
10.1111/dom.14497	results	1	NA	ss_ttt_nonipd	616
10.1111/dom.14497	results	1	NA	ss_ttt_ipd	300
10.1111/dom.14497	results	1	NA	ss_adjusted_ttt_ipd	NA
10.1111/dom.14497	results	1	NA	weights_yn	Not mentioned
10.1111/dom.14497	results	1	NA	covariates_yn	Yes
10.1111/dom.14497	results	1	NA	covariates_n	3
10.1111/dom.14497	results	1	NA	covariates_names	Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Comorbidities and medical history (beside pathology/disease of interest in the comparison), Other(s)
10.1111/dom.14497	results	1	NA	contrast_effect_direction	Numerator if ratio, or left side if difference
10.1111/dom.14497	results	1	NA	contrast_effect_unadjusted_value	-0.24
10.1111/dom.14497	results	1	NA	contrast_effect_unadjusted_pvalci	0.016
10.1111/dom.14497	results	1	NA	contrast_effect_adjusted_value	-0.25
10.1111/dom.14497	results	1	NA	contrast_effect_adjusted_pvalci	0.037
10.1111/dom.14497	results	1	NA	adjustment_geographical	No
10.1111/dom.14497	results	1	NA	ss_total_ipd	NA
10.1111/dom.14497	results	1	NA	ss_adjusted_total_ipd	NA
10.1111/dom.14497	results	1	NA	ss_total_nonipd	NA
10.1111/dom.14497	results	1	NA	ss_anchor_nonipd	612
10.1111/dom.14497	results	1	NA	ss_anchor_ipd	299
10.1111/dom.14497	results	1	NA	ss_adjusted_anchor_ipd	NA
10.1111/dom.14497	results	1	NA	effect_cutoff	0
10.1111/dom.14497	results	1	NA	unadjusted_pval	0.016
10.1111/dom.14497	results	1	NA	unadjusted_num_pval	0.016
10.1111/dom.14497	results	1	NA	unadjusted_significant	TRUE
10.1111/dom.14497	results	1	NA	adjusted_pval	0.037
10.1111/dom.14497	results	1	NA	adjusted_num_pval	0.037
10.1111/dom.14497	results	1	NA	adjusted_significant	TRUE
10.1111/dom.14497	results	2	NA	contrast_effect_type	Means difference
10.1111/dom.14497	results	2	NA	direction_benefit	inferior
10.1111/dom.14497	results	2	NA	ss_ttt_nonipd	614
10.1111/dom.14497	results	2	NA	ss_ttt_ipd	300
10.1111/dom.14497	results	2	NA	ss_adjusted_ttt_ipd	NA
10.1111/dom.14497	results	2	NA	weights_yn	Not mentioned
10.1111/dom.14497	results	2	NA	covariates_yn	Yes
10.1111/dom.14497	results	2	NA	covariates_n	3
10.1111/dom.14497	results	2	NA	covariates_names	Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Other(s)
10.1111/dom.14497	results	2	NA	contrast_effect_direction	Numerator if ratio, or left side if difference
10.1111/dom.14497	results	2	NA	contrast_effect_unadjusted_value	-0.07
10.1111/dom.14497	results	2	NA	contrast_effect_unadjusted_pvalci	0.484
10.1111/dom.14497	results	2	NA	contrast_effect_adjusted_value	-0.08
10.1111/dom.14497	results	2	NA	contrast_effect_adjusted_pvalci	0.523
10.1111/dom.14497	results	2	NA	adjustment_geographical	No
10.1111/dom.14497	results	2	NA	ss_total_ipd	NA
10.1111/dom.14497	results	2	NA	ss_adjusted_total_ipd	NA
10.1111/dom.14497	results	2	NA	ss_total_nonipd	NA
10.1111/dom.14497	results	2	NA	ss_anchor_nonipd	612
10.1111/dom.14497	results	2	NA	ss_anchor_ipd	299
10.1111/dom.14497	results	2	NA	ss_adjusted_anchor_ipd	NA
10.1111/dom.14497	results	2	NA	effect_cutoff	0
10.1111/dom.14497	results	2	NA	unadjusted_pval	0.484
10.1111/dom.14497	results	2	NA	unadjusted_num_pval	0.484
10.1111/dom.14497	results	2	NA	unadjusted_significant	FALSE
10.1111/dom.14497	results	2	NA	adjusted_pval	0.523
10.1111/dom.14497	results	2	NA	adjusted_num_pval	0.523
10.1111/dom.14497	results	2	NA	adjusted_significant	FALSE
10.1111/dom.14497	study_information	NA	1	ipd_yn	Yes
10.1111/dom.14497	study_information	NA	1	ct_yn	Yes
10.1111/dom.14497	study_information	NA	1	nct	NCT02648204
10.1111/dom.14497	study_information	NA	1	country_study	international
10.1111/dom.14497	study_information	NA	1	ct_phase	3
10.1111/dom.14497	study_information	NA	1	ct_arms	2 or more
10.1111/dom.14497	study_information	NA	2	ipd_yn	No
10.1111/dom.14497	study_information	NA	2	ct_yn	Yes
10.1111/dom.14497	study_information	NA	2	nct	NCT03495102
10.1111/dom.14497	study_information	NA	2	country_study	international
10.1111/dom.14497	study_information	NA	2	ct_phase	3
10.1111/dom.14497	study_information	NA	2	ct_arms	2 or more
10.1111/dom.14497	study_information	NA	3	ipd_yn	xx
10.1111/dom.14497	study_information	NA	3	ct_yn	xx
10.1111/dom.14497	study_information	NA	3	nct	xx
10.1111/dom.14497	study_information	NA	3	country_study	xx
10.1111/dom.14497	study_information	NA	3	ct_phase	xx
10.1111/dom.14497	study_information	NA	3	ct_arms	xx
10.1111/head.14128	general_information	NA	NA	condition_name	migraine
10.1111/head.14128	general_information	NA	NA	country_first_author	canada
10.1111/head.14128	general_information	NA	NA	country_last_author	usa
10.1111/head.14128	general_information	NA	NA	positions	Academic, Pharmaceutical Industry, Private Data Analysis Company
10.1111/head.14128	general_information	NA	NA	methodologist_yn	Yes
10.1111/head.14128	general_information	NA	NA	funding_source	Pharmaceutical Industry
10.1111/head.14128	general_information	NA	NA	pharmaceutical_ties_yn	Yes
10.1111/head.14128	general_information	NA	NA	systematic_review_yn	No
10.1111/head.14128	methodology	1	NA	outcome_name	change in midas (migraine disability assessment) from baseline to 12 weeks
10.1111/head.14128	methodology	1	NA	outcome_short_name	Migraine disability assessment Test
10.1111/head.14128	methodology	1	NA	outcome_variable_type	Continuous (count, mean, ...)
10.1111/head.14128	methodology	1	NA	treatment_name_ipd	rimegepant
10.1111/head.14128	methodology	1	NA	studies_number_ipd	1
10.1111/head.14128	methodology	1	NA	treatment_name_nonipd	placebo
10.1111/head.14128	methodology	1	NA	studies_number_nonipd	2;3
10.1111/head.14128	methodology	1	NA	paic_type	MAIC
10.1111/head.14128	methodology	1	NA	anchored_yn	No
10.1111/head.14128	methodology	1	NA	paic_form	Aggregation of multiple studies to estimate individual treatment effects (e.g. meta-analysis in a first step to estimate treatment A effect, then population adjusted indirect comparison using treatment A effect estimate)
10.1111/head.14128	methodology	1	NA	primary_outcome_yn	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.1111/head.14128	methodology	1	NA	variables_selection_justification	Nothing mentioned, not reported
10.1111/head.14128	methodology	1	NA	pf_yn	No discussion (in the main text) of the status of prognostic factors of the variables
10.1111/head.14128	methodology	1	NA	tem_yn	No discussion (in the main text) of the status of treatment-effect modifiers of the variables
10.1111/head.14128	methodology	1	NA	adjustment_model_details_yn	Yes
10.1111/head.14128	methodology	1	NA	scale_choice_yn	No
10.1111/head.14128	methodology	2	NA	outcome_name	change in midas (migraine disability assessment) from baseline to 12 weeks
10.1111/head.14128	methodology	2	NA	outcome_short_name	Migraine disability assessment Test
10.1111/head.14128	methodology	2	NA	outcome_variable_type	Continuous (count, mean, ...)
10.1111/head.14128	methodology	2	NA	treatment_name_ipd	rimegepant
10.1111/head.14128	methodology	2	NA	studies_number_ipd	1
10.1111/head.14128	methodology	2	NA	treatment_name_nonipd	galcanezumab
10.1111/head.14128	methodology	2	NA	studies_number_nonipd	2;3
10.1111/head.14128	methodology	2	NA	paic_type	MAIC
10.1111/head.14128	methodology	2	NA	anchored_yn	No
10.1111/head.14128	methodology	2	NA	paic_form	Aggregation of multiple studies to estimate individual treatment effects (e.g. meta-analysis in a first step to estimate treatment A effect, then population adjusted indirect comparison using treatment A effect estimate)
10.1111/head.14128	methodology	2	NA	primary_outcome_yn	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.1111/head.14128	methodology	2	NA	variables_selection_justification	Nothing mentioned, not reported
10.1111/head.14128	methodology	2	NA	pf_yn	No discussion (in the main text) of the status of prognostic factors of the variables
10.1111/head.14128	methodology	2	NA	tem_yn	No discussion (in the main text) of the status of treatment-effect modifiers of the variables
10.1111/head.14128	methodology	2	NA	adjustment_model_details_yn	Yes
10.1111/head.14128	methodology	2	NA	scale_choice_yn	No
10.1111/head.14128	methodology	3	NA	outcome_name	change in midas (migraine disability assessment) from baseline to 12 weeks
10.1111/head.14128	methodology	3	NA	outcome_short_name	Migraine disability assessment Test
10.1111/head.14128	methodology	3	NA	outcome_variable_type	Continuous (count, mean, ...)
10.1111/head.14128	methodology	3	NA	treatment_name_ipd	rimegepant
10.1111/head.14128	methodology	3	NA	studies_number_ipd	1
10.1111/head.14128	methodology	3	NA	treatment_name_nonipd	placebo
10.1111/head.14128	methodology	3	NA	studies_number_nonipd	4
10.1111/head.14128	methodology	3	NA	paic_type	MAIC
10.1111/head.14128	methodology	3	NA	anchored_yn	No
10.1111/head.14128	methodology	3	NA	paic_form	Simple (ie treatments effects extracted from two studies)
10.1111/head.14128	methodology	3	NA	primary_outcome_yn	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.1111/head.14128	methodology	3	NA	variables_selection_justification	Nothing mentioned, not reported
10.1111/head.14128	methodology	3	NA	pf_yn	No discussion (in the main text) of the status of prognostic factors of the variables
10.1111/head.14128	methodology	3	NA	tem_yn	No discussion (in the main text) of the status of treatment-effect modifiers of the variables
10.1111/head.14128	methodology	3	NA	adjustment_model_details_yn	Yes
10.1111/head.14128	methodology	3	NA	scale_choice_yn	No
10.1111/head.14128	methodology	4	NA	outcome_name	change in midas (migraine disability assessment) from baseline to 12 weeks
10.1111/head.14128	methodology	4	NA	outcome_short_name	Migraine disability assessment Test
10.1111/head.14128	methodology	4	NA	outcome_variable_type	Continuous (count, mean, ...)
10.1111/head.14128	methodology	4	NA	treatment_name_ipd	rimegepant
10.1111/head.14128	methodology	4	NA	studies_number_ipd	1
10.1111/head.14128	methodology	4	NA	treatment_name_nonipd	erenumab
10.1111/head.14128	methodology	4	NA	studies_number_nonipd	4
10.1111/head.14128	methodology	4	NA	paic_type	MAIC
10.1111/head.14128	methodology	4	NA	anchored_yn	No
10.1111/head.14128	methodology	4	NA	paic_form	Simple (ie treatments effects extracted from two studies)
10.1111/head.14128	methodology	4	NA	primary_outcome_yn	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.1111/head.14128	methodology	4	NA	variables_selection_justification	Nothing mentioned, not reported
10.1111/head.14128	methodology	4	NA	pf_yn	No discussion (in the main text) of the status of prognostic factors of the variables
10.1111/head.14128	methodology	4	NA	tem_yn	No discussion (in the main text) of the status of treatment-effect modifiers of the variables
10.1111/head.14128	methodology	4	NA	adjustment_model_details_yn	Yes
10.1111/head.14128	methodology	4	NA	scale_choice_yn	No
10.1111/head.14128	results	1	NA	contrast_effect_type	Means difference
10.1111/head.14128	results	1	NA	direction_benefit	inferior
10.1111/head.14128	results	1	NA	ss_ttt_nonipd	1773
10.1111/head.14128	results	1	NA	ss_ttt_ipd	257
10.1111/head.14128	results	1	NA	ss_adjusted_ttt_ipd	169
10.1111/head.14128	results	1	NA	weights_yn	Yes, mentions that the weights distribution has been studied, and weights distribution reported in main article or supplemental materials
10.1111/head.14128	results	1	NA	covariates_yn	Yes
10.1111/head.14128	results	1	NA	covariates_n	6
10.1111/head.14128	results	1	NA	covariates_names	Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Race/ethnicity
10.1111/head.14128	results	1	NA	contrast_effect_direction	Numerator if ratio, or left side if difference
10.1111/head.14128	results	1	NA	contrast_effect_unadjusted_value	-5.54
10.1111/head.14128	results	1	NA	contrast_effect_unadjusted_pvalci	0.026
10.1111/head.14128	results	1	NA	contrast_effect_adjusted_value	-7.37
10.1111/head.14128	results	1	NA	contrast_effect_adjusted_pvalci	0.009
10.1111/head.14128	results	1	NA	adjustment_geographical	NA
10.1111/head.14128	results	1	NA	ss_total_ipd	NA
10.1111/head.14128	results	1	NA	ss_adjusted_total_ipd	NA
10.1111/head.14128	results	1	NA	ss_total_nonipd	NA
10.1111/head.14128	results	1	NA	ss_anchor_nonipd	NA
10.1111/head.14128	results	1	NA	ss_anchor_ipd	NA
10.1111/head.14128	results	1	NA	ss_adjusted_anchor_ipd	NA
10.1111/head.14128	results	1	NA	effect_cutoff	0
10.1111/head.14128	results	1	NA	unadjusted_pval	0.026
10.1111/head.14128	results	1	NA	unadjusted_num_pval	0.026
10.1111/head.14128	results	1	NA	unadjusted_significant	TRUE
10.1111/head.14128	results	1	NA	adjusted_pval	0.009
10.1111/head.14128	results	1	NA	adjusted_num_pval	0.009
10.1111/head.14128	results	1	NA	adjusted_significant	TRUE
10.1111/head.14128	results	2	NA	contrast_effect_type	Means difference
10.1111/head.14128	results	2	NA	direction_benefit	inferior
10.1111/head.14128	results	2	NA	ss_ttt_nonipd	NA
10.1111/head.14128	results	2	NA	ss_ttt_ipd	257
10.1111/head.14128	results	2	NA	ss_adjusted_ttt_ipd	169
10.1111/head.14128	results	2	NA	weights_yn	Yes, mentions that the weights distribution has been studied, and weights distribution reported in main article or supplemental materials
10.1111/head.14128	results	2	NA	covariates_yn	Yes
10.1111/head.14128	results	2	NA	covariates_n	6
10.1111/head.14128	results	2	NA	covariates_names	Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Race/ethnicity
10.1111/head.14128	results	2	NA	contrast_effect_direction	Numerator if ratio, or left side if difference
10.1111/head.14128	results	2	NA	contrast_effect_unadjusted_value	1.75
10.1111/head.14128	results	2	NA	contrast_effect_unadjusted_pvalci	0.528
10.1111/head.14128	results	2	NA	contrast_effect_adjusted_value	-0.09
10.1111/head.14128	results	2	NA	contrast_effect_adjusted_pvalci	0.979
10.1111/head.14128	results	2	NA	adjustment_geographical	NA
10.1111/head.14128	results	2	NA	ss_total_ipd	NA
10.1111/head.14128	results	2	NA	ss_adjusted_total_ipd	NA
10.1111/head.14128	results	2	NA	ss_total_nonipd	NA
10.1111/head.14128	results	2	NA	ss_anchor_nonipd	NA
10.1111/head.14128	results	2	NA	ss_anchor_ipd	NA
10.1111/head.14128	results	2	NA	ss_adjusted_anchor_ipd	NA
10.1111/head.14128	results	2	NA	effect_cutoff	0
10.1111/head.14128	results	2	NA	unadjusted_pval	0.528
10.1111/head.14128	results	2	NA	unadjusted_num_pval	0.528
10.1111/head.14128	results	2	NA	unadjusted_significant	FALSE
10.1111/head.14128	results	2	NA	adjusted_pval	0.979
10.1111/head.14128	results	2	NA	adjusted_num_pval	0.979
10.1111/head.14128	results	2	NA	adjusted_significant	FALSE
10.1111/head.14128	results	3	NA	contrast_effect_type	Means difference
10.1111/head.14128	results	3	NA	direction_benefit	inferior
10.1111/head.14128	results	3	NA	ss_ttt_nonipd	NA
10.1111/head.14128	results	3	NA	ss_ttt_ipd	257
10.1111/head.14128	results	3	NA	ss_adjusted_ttt_ipd	214
10.1111/head.14128	results	3	NA	weights_yn	Yes, mentions that the weights distribution has been studied, and weights distribution reported in main article or supplemental materials
10.1111/head.14128	results	3	NA	covariates_yn	Yes
10.1111/head.14128	results	3	NA	covariates_n	4
10.1111/head.14128	results	3	NA	covariates_names	Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Race/ethnicity
10.1111/head.14128	results	3	NA	contrast_effect_direction	Numerator if ratio, or left side if difference
10.1111/head.14128	results	3	NA	contrast_effect_unadjusted_value	-3.94
10.1111/head.14128	results	3	NA	contrast_effect_unadjusted_pvalci	0.121
10.1111/head.14128	results	3	NA	contrast_effect_adjusted_value	-5.67
10.1111/head.14128	results	3	NA	contrast_effect_adjusted_pvalci	0.025
10.1111/head.14128	results	3	NA	adjustment_geographical	NA
10.1111/head.14128	results	3	NA	ss_total_ipd	NA
10.1111/head.14128	results	3	NA	ss_adjusted_total_ipd	NA
10.1111/head.14128	results	3	NA	ss_total_nonipd	NA
10.1111/head.14128	results	3	NA	ss_anchor_nonipd	NA
10.1111/head.14128	results	3	NA	ss_anchor_ipd	NA
10.1111/head.14128	results	3	NA	ss_adjusted_anchor_ipd	NA
10.1111/head.14128	results	3	NA	effect_cutoff	0
10.1111/head.14128	results	3	NA	unadjusted_pval	0.121
10.1111/head.14128	results	3	NA	unadjusted_num_pval	0.121
10.1111/head.14128	results	3	NA	unadjusted_significant	FALSE
10.1111/head.14128	results	3	NA	adjusted_pval	0.025
10.1111/head.14128	results	3	NA	adjusted_num_pval	0.025
10.1111/head.14128	results	3	NA	adjusted_significant	TRUE
10.1111/head.14128	results	4	NA	contrast_effect_type	Means difference
10.1111/head.14128	results	4	NA	direction_benefit	inferior
10.1111/head.14128	results	4	NA	ss_ttt_nonipd	NA
10.1111/head.14128	results	4	NA	ss_ttt_ipd	257
10.1111/head.14128	results	4	NA	ss_adjusted_ttt_ipd	214
10.1111/head.14128	results	4	NA	weights_yn	Yes, mentions that the weights distribution has been studied, and weights distribution reported in main article or supplemental materials
10.1111/head.14128	results	4	NA	covariates_yn	Yes
10.1111/head.14128	results	4	NA	covariates_n	4
10.1111/head.14128	results	4	NA	covariates_names	Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Race/ethnicity
10.1111/head.14128	results	4	NA	contrast_effect_direction	Numerator if ratio, or left side if difference
10.1111/head.14128	results	4	NA	contrast_effect_unadjusted_value	3.48
10.1111/head.14128	results	4	NA	contrast_effect_unadjusted_pvalci	0.172
10.1111/head.14128	results	4	NA	contrast_effect_adjusted_value	1.75
10.1111/head.14128	results	4	NA	contrast_effect_adjusted_pvalci	0.501
10.1111/head.14128	results	4	NA	adjustment_geographical	NA
10.1111/head.14128	results	4	NA	ss_total_ipd	NA
10.1111/head.14128	results	4	NA	ss_adjusted_total_ipd	NA
10.1111/head.14128	results	4	NA	ss_total_nonipd	NA
10.1111/head.14128	results	4	NA	ss_anchor_nonipd	NA
10.1111/head.14128	results	4	NA	ss_anchor_ipd	NA
10.1111/head.14128	results	4	NA	ss_adjusted_anchor_ipd	NA
10.1111/head.14128	results	4	NA	effect_cutoff	0
10.1111/head.14128	results	4	NA	unadjusted_pval	0.172
10.1111/head.14128	results	4	NA	unadjusted_num_pval	0.172
10.1111/head.14128	results	4	NA	unadjusted_significant	FALSE
10.1111/head.14128	results	4	NA	adjusted_pval	0.501
10.1111/head.14128	results	4	NA	adjusted_num_pval	0.501
10.1111/head.14128	results	4	NA	adjusted_significant	FALSE
10.1111/head.14128	study_information	NA	1	ipd_yn	Yes
10.1111/head.14128	study_information	NA	1	ct_yn	Yes
10.1111/head.14128	study_information	NA	1	nct	NCT03266588
10.1111/head.14128	study_information	NA	1	country_study	usa
10.1111/head.14128	study_information	NA	1	ct_phase	2, 3
10.1111/head.14128	study_information	NA	1	ct_arms	1
10.1111/head.14128	study_information	NA	2	ipd_yn	No
10.1111/head.14128	study_information	NA	2	ct_yn	Yes
10.1111/head.14128	study_information	NA	2	nct	NCT02614183
10.1111/head.14128	study_information	NA	2	country_study	international
10.1111/head.14128	study_information	NA	2	ct_phase	3
10.1111/head.14128	study_information	NA	2	ct_arms	2 or more
10.1111/head.14128	study_information	NA	3	ipd_yn	No
10.1111/head.14128	study_information	NA	3	ct_yn	Yes
10.1111/head.14128	study_information	NA	3	nct	NCT02614196
10.1111/head.14128	study_information	NA	3	country_study	international
10.1111/head.14128	study_information	NA	3	ct_phase	3
10.1111/head.14128	study_information	NA	3	ct_arms	2 or more
10.1111/head.14128	study_information	NA	4	ipd_yn	No
10.1111/head.14128	study_information	NA	4	ct_yn	Yes
10.1111/head.14128	study_information	NA	4	nct	NCT02456740
10.1111/head.14128	study_information	NA	4	country_study	international
10.1111/head.14128	study_information	NA	4	ct_phase	3
10.1111/head.14128	study_information	NA	4	ct_arms	2 or more
10.1111/jdv.15369	general_information	NA	NA	condition_name	plaque psoriasis
10.1111/jdv.15369	general_information	NA	NA	country_first_author	uk
10.1111/jdv.15369	general_information	NA	NA	country_last_author	usa
10.1111/jdv.15369	general_information	NA	NA	positions	Academic, Pharmaceutical Industry, Private Data Analysis Company
10.1111/jdv.15369	general_information	NA	NA	methodologist_yn	Yes
10.1111/jdv.15369	general_information	NA	NA	funding_source	Pharmaceutical Industry
10.1111/jdv.15369	general_information	NA	NA	pharmaceutical_ties_yn	Yes
10.1111/jdv.15369	general_information	NA	NA	systematic_review_yn	Yes
10.1111/jdv.15369	methodology	1	NA	outcome_name	physician global assessment (pga) 0/1 responders rate
10.1111/jdv.15369	methodology	1	NA	outcome_short_name	PGA responders Rate
10.1111/jdv.15369	methodology	1	NA	outcome_variable_type	Binary (eg rates)
10.1111/jdv.15369	methodology	1	NA	treatment_name_ipd	calcipotriol + betamethasone dipropionate aerosol foam
10.1111/jdv.15369	methodology	1	NA	studies_number_ipd	1;2;3;4
10.1111/jdv.15369	methodology	1	NA	treatment_name_nonipd	apremilast
10.1111/jdv.15369	methodology	1	NA	studies_number_nonipd	5
10.1111/jdv.15369	methodology	1	NA	paic_type	MAIC
10.1111/jdv.15369	methodology	1	NA	anchored_yn	No
10.1111/jdv.15369	methodology	1	NA	paic_form	Aggregation of multiple studies to estimate individual treatment effects (e.g. meta-analysis in a first step to estimate treatment A effect, then population adjusted indirect comparison using treatment A effect estimate)
10.1111/jdv.15369	methodology	1	NA	primary_outcome_yn	Yes
10.1111/jdv.15369	methodology	1	NA	variables_selection_justification	Status of prognostic factor/treatment effect modified assessed in the IPD dataset, A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion)
10.1111/jdv.15369	methodology	1	NA	pf_yn	No discussion (in the main text) of the status of prognostic factors of the variables
10.1111/jdv.15369	methodology	1	NA	tem_yn	No discussion (in the main text) of the status of treatment-effect modifiers of the variables
10.1111/jdv.15369	methodology	1	NA	adjustment_model_details_yn	No
10.1111/jdv.15369	methodology	1	NA	scale_choice_yn	No
10.1111/jdv.15369	methodology	2	NA	outcome_name	psoriasis area severity index (pasi) 75 responders rate
10.1111/jdv.15369	methodology	2	NA	outcome_short_name	PASI 75 Responders Rate
10.1111/jdv.15369	methodology	2	NA	outcome_variable_type	Binary (eg rates)
10.1111/jdv.15369	methodology	2	NA	treatment_name_ipd	calcipotriol + betamethasone dipropionate aerosol foam
10.1111/jdv.15369	methodology	2	NA	studies_number_ipd	1;2;3;4
10.1111/jdv.15369	methodology	2	NA	treatment_name_nonipd	methotrexate
10.1111/jdv.15369	methodology	2	NA	studies_number_nonipd	6
10.1111/jdv.15369	methodology	2	NA	paic_type	MAIC
10.1111/jdv.15369	methodology	2	NA	anchored_yn	No
10.1111/jdv.15369	methodology	2	NA	paic_form	Aggregation of multiple studies to estimate individual treatment effects (e.g. meta-analysis in a first step to estimate treatment A effect, then population adjusted indirect comparison using treatment A effect estimate)
10.1111/jdv.15369	methodology	2	NA	primary_outcome_yn	Yes
10.1111/jdv.15369	methodology	2	NA	variables_selection_justification	Status of prognostic factor/treatment effect modified assessed in the IPD dataset, A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion)
10.1111/jdv.15369	methodology	2	NA	pf_yn	No discussion (in the main text) of the status of prognostic factors of the variables
10.1111/jdv.15369	methodology	2	NA	tem_yn	No discussion (in the main text) of the status of treatment-effect modifiers of the variables
10.1111/jdv.15369	methodology	2	NA	adjustment_model_details_yn	No
10.1111/jdv.15369	methodology	2	NA	scale_choice_yn	No
10.1111/jdv.15369	methodology	3	NA	outcome_name	psoriasis area severity index (pasi) 75 responders rate
10.1111/jdv.15369	methodology	3	NA	outcome_short_name	PASI 75 Responders Rate
10.1111/jdv.15369	methodology	3	NA	outcome_variable_type	Binary (eg rates)
10.1111/jdv.15369	methodology	3	NA	treatment_name_ipd	calcipotriol + betamethasone dipropionate aerosol foam
10.1111/jdv.15369	methodology	3	NA	studies_number_ipd	1;2;3;4
10.1111/jdv.15369	methodology	3	NA	treatment_name_nonipd	acitretin
10.1111/jdv.15369	methodology	3	NA	studies_number_nonipd	7
10.1111/jdv.15369	methodology	3	NA	paic_type	MAIC
10.1111/jdv.15369	methodology	3	NA	anchored_yn	No
10.1111/jdv.15369	methodology	3	NA	paic_form	Aggregation of multiple studies to estimate individual treatment effects (e.g. meta-analysis in a first step to estimate treatment A effect, then population adjusted indirect comparison using treatment A effect estimate)
10.1111/jdv.15369	methodology	3	NA	primary_outcome_yn	Yes
10.1111/jdv.15369	methodology	3	NA	variables_selection_justification	Status of prognostic factor/treatment effect modified assessed in the IPD dataset, A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion)
10.1111/jdv.15369	methodology	3	NA	pf_yn	No discussion (in the main text) of the status of prognostic factors of the variables
10.1111/jdv.15369	methodology	3	NA	tem_yn	No discussion (in the main text) of the status of treatment-effect modifiers of the variables
10.1111/jdv.15369	methodology	3	NA	adjustment_model_details_yn	No
10.1111/jdv.15369	methodology	3	NA	scale_choice_yn	No
10.1111/jdv.15369	methodology	4	NA	outcome_name	psoriasis area severity index (pasi) 75 responders rate
10.1111/jdv.15369	methodology	4	NA	outcome_short_name	PASI 75 Responders Rate
10.1111/jdv.15369	methodology	4	NA	outcome_variable_type	Binary (eg rates)
10.1111/jdv.15369	methodology	4	NA	treatment_name_ipd	calcipotriol + betamethasone dipropionate aerosol foam
10.1111/jdv.15369	methodology	4	NA	studies_number_ipd	1;2;3;4
10.1111/jdv.15369	methodology	4	NA	treatment_name_nonipd	fumaric acid esters
10.1111/jdv.15369	methodology	4	NA	studies_number_nonipd	8
10.1111/jdv.15369	methodology	4	NA	paic_type	MAIC
10.1111/jdv.15369	methodology	4	NA	anchored_yn	No
10.1111/jdv.15369	methodology	4	NA	paic_form	Aggregation of multiple studies to estimate individual treatment effects (e.g. meta-analysis in a first step to estimate treatment A effect, then population adjusted indirect comparison using treatment A effect estimate)
10.1111/jdv.15369	methodology	4	NA	primary_outcome_yn	Yes
10.1111/jdv.15369	methodology	4	NA	variables_selection_justification	Status of prognostic factor/treatment effect modified assessed in the IPD dataset, A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion)
10.1111/jdv.15369	methodology	4	NA	pf_yn	No discussion (in the main text) of the status of prognostic factors of the variables
10.1111/jdv.15369	methodology	4	NA	tem_yn	No discussion (in the main text) of the status of treatment-effect modifiers of the variables
10.1111/jdv.15369	methodology	4	NA	adjustment_model_details_yn	No
10.1111/jdv.15369	methodology	4	NA	scale_choice_yn	No
10.1111/jdv.15369	results	1	NA	contrast_effect_type	Proportions difference
10.1111/jdv.15369	results	1	NA	direction_benefit	superior
10.1111/jdv.15369	results	1	NA	ss_ttt_nonipd	148
10.1111/jdv.15369	results	1	NA	ss_ttt_ipd	748
10.1111/jdv.15369	results	1	NA	ss_adjusted_ttt_ipd	640
10.1111/jdv.15369	results	1	NA	weights_yn	Yes, mentions that the weights distribution has been studied, but weights distribution not reported
10.1111/jdv.15369	results	1	NA	covariates_yn	Yes
10.1111/jdv.15369	results	1	NA	covariates_n	3
10.1111/jdv.15369	results	1	NA	covariates_names	Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Past treatments for the disease of interest, Other(s)
10.1111/jdv.15369	results	1	NA	contrast_effect_direction	Numerator if ratio, or left side if difference
10.1111/jdv.15369	results	1	NA	contrast_effect_unadjusted_value	NA
10.1111/jdv.15369	results	1	NA	contrast_effect_unadjusted_pvalci	NA
10.1111/jdv.15369	results	1	NA	contrast_effect_adjusted_value	0.223
10.1111/jdv.15369	results	1	NA	contrast_effect_adjusted_pvalci	<0.001
10.1111/jdv.15369	results	1	NA	adjustment_geographical	No
10.1111/jdv.15369	results	1	NA	ss_total_ipd	NA
10.1111/jdv.15369	results	1	NA	ss_adjusted_total_ipd	NA
10.1111/jdv.15369	results	1	NA	ss_total_nonipd	NA
10.1111/jdv.15369	results	1	NA	ss_anchor_nonipd	NA
10.1111/jdv.15369	results	1	NA	ss_anchor_ipd	NA
10.1111/jdv.15369	results	1	NA	ss_adjusted_anchor_ipd	NA
10.1111/jdv.15369	results	1	NA	effect_cutoff	0
10.1111/jdv.15369	results	1	NA	adjusted_pval	<0.001
10.1111/jdv.15369	results	1	NA	adjusted_significant	TRUE
10.1111/jdv.15369	results	2	NA	contrast_effect_type	Proportions difference
10.1111/jdv.15369	results	2	NA	direction_benefit	superior
10.1111/jdv.15369	results	2	NA	ss_ttt_nonipd	218
10.1111/jdv.15369	results	2	NA	ss_ttt_ipd	749
10.1111/jdv.15369	results	2	NA	ss_adjusted_ttt_ipd	633
10.1111/jdv.15369	results	2	NA	weights_yn	Yes, mentions that the weights distribution has been studied, but weights distribution not reported
10.1111/jdv.15369	results	2	NA	covariates_yn	Yes
10.1111/jdv.15369	results	2	NA	covariates_n	2
10.1111/jdv.15369	results	2	NA	covariates_names	Age, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease)
10.1111/jdv.15369	results	2	NA	contrast_effect_direction	Numerator if ratio, or left side if difference
10.1111/jdv.15369	results	2	NA	contrast_effect_unadjusted_value	NA
10.1111/jdv.15369	results	2	NA	contrast_effect_unadjusted_pvalci	NA
10.1111/jdv.15369	results	2	NA	contrast_effect_adjusted_value	0.173
10.1111/jdv.15369	results	2	NA	contrast_effect_adjusted_pvalci	<0.001
10.1111/jdv.15369	results	2	NA	adjustment_geographical	NA
10.1111/jdv.15369	results	2	NA	ss_total_ipd	NA
10.1111/jdv.15369	results	2	NA	ss_adjusted_total_ipd	NA
10.1111/jdv.15369	results	2	NA	ss_total_nonipd	NA
10.1111/jdv.15369	results	2	NA	ss_anchor_nonipd	NA
10.1111/jdv.15369	results	2	NA	ss_anchor_ipd	NA
10.1111/jdv.15369	results	2	NA	ss_adjusted_anchor_ipd	NA
10.1111/jdv.15369	results	2	NA	effect_cutoff	0
10.1111/jdv.15369	results	2	NA	adjusted_pval	<0.001
10.1111/jdv.15369	results	2	NA	adjusted_significant	TRUE
10.1111/jdv.15369	results	3	NA	contrast_effect_type	Proportions difference
10.1111/jdv.15369	results	3	NA	direction_benefit	superior
10.1111/jdv.15369	results	3	NA	ss_ttt_nonipd	41
10.1111/jdv.15369	results	3	NA	ss_ttt_ipd	748
10.1111/jdv.15369	results	3	NA	ss_adjusted_ttt_ipd	102
10.1111/jdv.15369	results	3	NA	weights_yn	Yes, mentions that the weights distribution has been studied, but weights distribution not reported
10.1111/jdv.15369	results	3	NA	covariates_yn	Yes
10.1111/jdv.15369	results	3	NA	covariates_n	4
10.1111/jdv.15369	results	3	NA	covariates_names	Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Other(s)
10.1111/jdv.15369	results	3	NA	contrast_effect_direction	Numerator if ratio, or left side if difference
10.1111/jdv.15369	results	3	NA	contrast_effect_unadjusted_value	NA
10.1111/jdv.15369	results	3	NA	contrast_effect_unadjusted_pvalci	NA
10.1111/jdv.15369	results	3	NA	contrast_effect_adjusted_value	0.192
10.1111/jdv.15369	results	3	NA	contrast_effect_adjusted_pvalci	0.009
10.1111/jdv.15369	results	3	NA	adjustment_geographical	No
10.1111/jdv.15369	results	3	NA	ss_total_ipd	NA
10.1111/jdv.15369	results	3	NA	ss_adjusted_total_ipd	NA
10.1111/jdv.15369	results	3	NA	ss_total_nonipd	NA
10.1111/jdv.15369	results	3	NA	ss_anchor_nonipd	NA
10.1111/jdv.15369	results	3	NA	ss_anchor_ipd	NA
10.1111/jdv.15369	results	3	NA	ss_adjusted_anchor_ipd	NA
10.1111/jdv.15369	results	3	NA	effect_cutoff	0
10.1111/jdv.15369	results	3	NA	adjusted_pval	0.009
10.1111/jdv.15369	results	3	NA	adjusted_num_pval	0.009
10.1111/jdv.15369	results	3	NA	adjusted_significant	TRUE
10.1111/jdv.15369	results	4	NA	contrast_effect_type	Proportions difference
10.1111/jdv.15369	results	4	NA	direction_benefit	superior
10.1111/jdv.15369	results	4	NA	ss_ttt_nonipd	115
10.1111/jdv.15369	results	4	NA	ss_ttt_ipd	749
10.1111/jdv.15369	results	4	NA	ss_adjusted_ttt_ipd	224
10.1111/jdv.15369	results	4	NA	weights_yn	Yes, mentions that the weights distribution has been studied, but weights distribution not reported
10.1111/jdv.15369	results	4	NA	covariates_yn	Yes
10.1111/jdv.15369	results	4	NA	covariates_n	2
10.1111/jdv.15369	results	4	NA	covariates_names	Age, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease)
10.1111/jdv.15369	results	4	NA	contrast_effect_direction	Numerator if ratio, or left side if difference
10.1111/jdv.15369	results	4	NA	contrast_effect_unadjusted_value	NA
10.1111/jdv.15369	results	4	NA	contrast_effect_unadjusted_pvalci	NA
10.1111/jdv.15369	results	4	NA	contrast_effect_adjusted_value	-0.044
10.1111/jdv.15369	results	4	NA	contrast_effect_adjusted_pvalci	0.451
10.1111/jdv.15369	results	4	NA	adjustment_geographical	NA
10.1111/jdv.15369	results	4	NA	ss_total_ipd	NA
10.1111/jdv.15369	results	4	NA	ss_adjusted_total_ipd	NA
10.1111/jdv.15369	results	4	NA	ss_total_nonipd	NA
10.1111/jdv.15369	results	4	NA	ss_anchor_nonipd	NA
10.1111/jdv.15369	results	4	NA	ss_anchor_ipd	NA
10.1111/jdv.15369	results	4	NA	ss_adjusted_anchor_ipd	NA
10.1111/jdv.15369	results	4	NA	effect_cutoff	0
10.1111/jdv.15369	results	4	NA	adjusted_pval	0.451
10.1111/jdv.15369	results	4	NA	adjusted_num_pval	0.451
10.1111/jdv.15369	results	4	NA	adjusted_significant	FALSE
10.1111/jdv.15369	study_information	NA	1	ipd_yn	Yes
10.1111/jdv.15369	study_information	NA	1	ct_yn	Yes
10.1111/jdv.15369	study_information	NA	1	nct	NCT02132936
10.1111/jdv.15369	study_information	NA	1	country_study	france
10.1111/jdv.15369	study_information	NA	1	ct_phase	3
10.1111/jdv.15369	study_information	NA	1	ct_arms	2 or more
10.1111/jdv.15369	study_information	NA	2	ipd_yn	Yes
10.1111/jdv.15369	study_information	NA	2	ct_yn	Yes
10.1111/jdv.15369	study_information	NA	2	nct	NCT01866163
10.1111/jdv.15369	study_information	NA	2	country_study	usa
10.1111/jdv.15369	study_information	NA	2	ct_phase	3
10.1111/jdv.15369	study_information	NA	2	ct_arms	2 or more
10.1111/jdv.15369	study_information	NA	3	ipd_yn	Yes
10.1111/jdv.15369	study_information	NA	3	ct_yn	Yes
10.1111/jdv.15369	study_information	NA	3	nct	NCT01536886
10.1111/jdv.15369	study_information	NA	3	country_study	usa
10.1111/jdv.15369	study_information	NA	3	ct_phase	2
10.1111/jdv.15369	study_information	NA	3	ct_arms	2 or more
10.1111/jdv.15369	study_information	NA	4	ipd_yn	Yes
10.1111/jdv.15369	study_information	NA	4	ct_yn	Yes
10.1111/jdv.15369	study_information	NA	4	nct	NCT01536938
10.1111/jdv.15369	study_information	NA	4	country_study	usa
10.1111/jdv.15369	study_information	NA	4	ct_phase	2
10.1111/jdv.15369	study_information	NA	4	ct_arms	2 or more
10.1111/jdv.15369	study_information	NA	5	ipd_yn	No
10.1111/jdv.15369	study_information	NA	5	ct_yn	Yes
10.1111/jdv.15369	study_information	NA	5	nct	NCT02425826
10.1111/jdv.15369	study_information	NA	5	country_study	usa
10.1111/jdv.15369	study_information	NA	5	ct_phase	4
10.1111/jdv.15369	study_information	NA	5	ct_arms	2 or more
10.1111/jdv.15369	study_information	NA	6	ipd_yn	No
10.1111/jdv.15369	study_information	NA	6	ct_yn	No
10.1111/jdv.15369	study_information	NA	6	data_source_name	zurita et al., (2017)
10.1111/jdv.15369	study_information	NA	6	country_study	spain
10.1111/jdv.15369	study_information	NA	7	ipd_yn	No
10.1111/jdv.15369	study_information	NA	7	ct_yn	No
10.1111/jdv.15369	study_information	NA	7	data_source_name	chiricozzi et al. (2016)
10.1111/jdv.15369	study_information	NA	7	country_study	italy
10.1111/jdv.15369	study_information	NA	8	ipd_yn	No
10.1111/jdv.15369	study_information	NA	8	ct_yn	No
10.1111/jdv.15369	study_information	NA	8	data_source_name	inzinger et al. (2013)
10.1111/jdv.15369	study_information	NA	8	country_study	austria
10.1136/rmdopen-2019-001131	general_information	NA	NA	condition_name	rheumatoid arthritis
10.1136/rmdopen-2019-001131	general_information	NA	NA	country_first_author	france
10.1136/rmdopen-2019-001131	general_information	NA	NA	country_last_author	usa
10.1136/rmdopen-2019-001131	general_information	NA	NA	positions	Academic, Pharmaceutical Industry
10.1136/rmdopen-2019-001131	general_information	NA	NA	methodologist_yn	Yes
10.1136/rmdopen-2019-001131	general_information	NA	NA	funding_source	Pharmaceutical Industry
10.1136/rmdopen-2019-001131	general_information	NA	NA	pharmaceutical_ties_yn	Yes
10.1136/rmdopen-2019-001131	general_information	NA	NA	systematic_review_yn	Yes
10.1136/rmdopen-2019-001131	methodology	1	NA	outcome_name	change in pain (vas scale) from baseline to 6 months
10.1136/rmdopen-2019-001131	methodology	1	NA	outcome_short_name	Visual Analogic Pain Scale
10.1136/rmdopen-2019-001131	methodology	1	NA	outcome_variable_type	Continuous (count, mean, ...)
10.1136/rmdopen-2019-001131	methodology	1	NA	treatment_name_ipd	baricitinib
10.1136/rmdopen-2019-001131	methodology	1	NA	studies_number_ipd	1
10.1136/rmdopen-2019-001131	methodology	1	NA	treatment_name_nonipd	adalimumab
10.1136/rmdopen-2019-001131	methodology	1	NA	studies_number_nonipd	5
10.1136/rmdopen-2019-001131	methodology	1	NA	paic_type	MAIC
10.1136/rmdopen-2019-001131	methodology	1	NA	anchored_yn	Yes
10.1136/rmdopen-2019-001131	methodology	1	NA	paic_form	Simple (ie treatments effects extracted from two studies)
10.1136/rmdopen-2019-001131	methodology	1	NA	primary_outcome_yn	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.1136/rmdopen-2019-001131	methodology	1	NA	variables_selection_justification	Nothing mentioned, not reported
10.1136/rmdopen-2019-001131	methodology	1	NA	pf_yn	No
10.1136/rmdopen-2019-001131	methodology	1	NA	tem_yn	Yes
10.1136/rmdopen-2019-001131	methodology	1	NA	adjustment_model_details_yn	No
10.1136/rmdopen-2019-001131	methodology	1	NA	scale_choice_yn	No
10.1136/rmdopen-2019-001131	methodology	2	NA	outcome_name	change in pain (vas scale) from baseline to 6 months
10.1136/rmdopen-2019-001131	methodology	2	NA	outcome_short_name	Visual Analogic Pain Scale
10.1136/rmdopen-2019-001131	methodology	2	NA	outcome_variable_type	Continuous (count, mean, ...)
10.1136/rmdopen-2019-001131	methodology	2	NA	treatment_name_ipd	baricitinib
10.1136/rmdopen-2019-001131	methodology	2	NA	studies_number_ipd	1
10.1136/rmdopen-2019-001131	methodology	2	NA	treatment_name_nonipd	tocilizumab
10.1136/rmdopen-2019-001131	methodology	2	NA	studies_number_nonipd	3
10.1136/rmdopen-2019-001131	methodology	2	NA	paic_type	MAIC
10.1136/rmdopen-2019-001131	methodology	2	NA	anchored_yn	Yes
10.1136/rmdopen-2019-001131	methodology	2	NA	paic_form	Simple (ie treatments effects extracted from two studies)
10.1136/rmdopen-2019-001131	methodology	2	NA	primary_outcome_yn	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.1136/rmdopen-2019-001131	methodology	2	NA	variables_selection_justification	Nothing mentioned, not reported
10.1136/rmdopen-2019-001131	methodology	2	NA	pf_yn	No
10.1136/rmdopen-2019-001131	methodology	2	NA	tem_yn	Yes
10.1136/rmdopen-2019-001131	methodology	2	NA	adjustment_model_details_yn	No
10.1136/rmdopen-2019-001131	methodology	2	NA	scale_choice_yn	No
10.1136/rmdopen-2019-001131	methodology	3	NA	outcome_name	change in pain (vas scale) from baseline to 6 months
10.1136/rmdopen-2019-001131	methodology	3	NA	outcome_short_name	Visual Analogic Pain Scale
10.1136/rmdopen-2019-001131	methodology	3	NA	outcome_variable_type	Continuous (count, mean, ...)
10.1136/rmdopen-2019-001131	methodology	3	NA	treatment_name_ipd	baricitinib
10.1136/rmdopen-2019-001131	methodology	3	NA	studies_number_ipd	1
10.1136/rmdopen-2019-001131	methodology	3	NA	treatment_name_nonipd	tofacitinib
10.1136/rmdopen-2019-001131	methodology	3	NA	studies_number_nonipd	4
10.1136/rmdopen-2019-001131	methodology	3	NA	paic_type	MAIC
10.1136/rmdopen-2019-001131	methodology	3	NA	anchored_yn	Yes
10.1136/rmdopen-2019-001131	methodology	3	NA	paic_form	Simple (ie treatments effects extracted from two studies)
10.1136/rmdopen-2019-001131	methodology	3	NA	primary_outcome_yn	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.1136/rmdopen-2019-001131	methodology	3	NA	variables_selection_justification	Nothing mentioned, not reported
10.1136/rmdopen-2019-001131	methodology	3	NA	pf_yn	No
10.1136/rmdopen-2019-001131	methodology	3	NA	tem_yn	Yes
10.1136/rmdopen-2019-001131	methodology	3	NA	adjustment_model_details_yn	No
10.1136/rmdopen-2019-001131	methodology	3	NA	scale_choice_yn	No
10.1136/rmdopen-2019-001131	results	1	NA	contrast_effect_type	Means difference
10.1136/rmdopen-2019-001131	results	1	NA	direction_benefit	inferior
10.1136/rmdopen-2019-001131	results	1	NA	ss_ttt_nonipd	274
10.1136/rmdopen-2019-001131	results	1	NA	ss_ttt_ipd	159
10.1136/rmdopen-2019-001131	results	1	NA	ss_adjusted_ttt_ipd	151.5
10.1136/rmdopen-2019-001131	results	1	NA	weights_yn	Not mentioned
10.1136/rmdopen-2019-001131	results	1	NA	covariates_yn	Yes
10.1136/rmdopen-2019-001131	results	1	NA	covariates_n	5
10.1136/rmdopen-2019-001131	results	1	NA	covariates_names	Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease)
10.1136/rmdopen-2019-001131	results	1	NA	contrast_effect_direction	Numerator if ratio, or left side if difference
10.1136/rmdopen-2019-001131	results	1	NA	contrast_effect_unadjusted_value	-12.1
10.1136/rmdopen-2019-001131	results	1	NA	contrast_effect_unadjusted_pvalci	<0.001
10.1136/rmdopen-2019-001131	results	1	NA	contrast_effect_adjusted_value	-12.3
10.1136/rmdopen-2019-001131	results	1	NA	contrast_effect_adjusted_pvalci	<0.001
10.1136/rmdopen-2019-001131	results	1	NA	adjustment_geographical	No
10.1136/rmdopen-2019-001131	results	1	NA	ss_total_ipd	NA
10.1136/rmdopen-2019-001131	results	1	NA	ss_adjusted_total_ipd	NA
10.1136/rmdopen-2019-001131	results	1	NA	ss_total_nonipd	NA
10.1136/rmdopen-2019-001131	results	1	NA	ss_anchor_nonipd	257
10.1136/rmdopen-2019-001131	results	1	NA	ss_anchor_ipd	210
10.1136/rmdopen-2019-001131	results	1	NA	ss_adjusted_anchor_ipd	181.4
10.1136/rmdopen-2019-001131	results	1	NA	effect_cutoff	0
10.1136/rmdopen-2019-001131	results	1	NA	unadjusted_pval	<0.001
10.1136/rmdopen-2019-001131	results	1	NA	unadjusted_significant	TRUE
10.1136/rmdopen-2019-001131	results	1	NA	adjusted_pval	<0.001
10.1136/rmdopen-2019-001131	results	1	NA	adjusted_significant	TRUE
10.1136/rmdopen-2019-001131	results	2	NA	contrast_effect_type	Means difference
10.1136/rmdopen-2019-001131	results	2	NA	direction_benefit	inferior
10.1136/rmdopen-2019-001131	results	2	NA	ss_ttt_nonipd	292
10.1136/rmdopen-2019-001131	results	2	NA	ss_ttt_ipd	159
10.1136/rmdopen-2019-001131	results	2	NA	ss_adjusted_ttt_ipd	NA
10.1136/rmdopen-2019-001131	results	2	NA	weights_yn	Not mentioned
10.1136/rmdopen-2019-001131	results	2	NA	covariates_yn	Yes
10.1136/rmdopen-2019-001131	results	2	NA	covariates_n	5
10.1136/rmdopen-2019-001131	results	2	NA	covariates_names	Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease)
10.1136/rmdopen-2019-001131	results	2	NA	contrast_effect_direction	Numerator if ratio, or left side if difference
10.1136/rmdopen-2019-001131	results	2	NA	contrast_effect_unadjusted_value	-8.7
10.1136/rmdopen-2019-001131	results	2	NA	contrast_effect_unadjusted_pvalci	<=0.05
10.1136/rmdopen-2019-001131	results	2	NA	contrast_effect_adjusted_value	-7.3
10.1136/rmdopen-2019-001131	results	2	NA	contrast_effect_adjusted_pvalci	<=0.05
10.1136/rmdopen-2019-001131	results	2	NA	adjustment_geographical	No
10.1136/rmdopen-2019-001131	results	2	NA	ss_total_ipd	369
10.1136/rmdopen-2019-001131	results	2	NA	ss_adjusted_total_ipd	331
10.1136/rmdopen-2019-001131	results	2	NA	ss_total_nonipd	NA
10.1136/rmdopen-2019-001131	results	2	NA	ss_anchor_nonipd	287
10.1136/rmdopen-2019-001131	results	2	NA	ss_anchor_ipd	210
10.1136/rmdopen-2019-001131	results	2	NA	ss_adjusted_anchor_ipd	NA
10.1136/rmdopen-2019-001131	results	2	NA	effect_cutoff	0
10.1136/rmdopen-2019-001131	results	2	NA	unadjusted_pval	<=0.05
10.1136/rmdopen-2019-001131	results	2	NA	unadjusted_significant	TRUE
10.1136/rmdopen-2019-001131	results	2	NA	adjusted_pval	<=0.05
10.1136/rmdopen-2019-001131	results	2	NA	adjusted_significant	TRUE
10.1136/rmdopen-2019-001131	results	3	NA	contrast_effect_type	Means difference
10.1136/rmdopen-2019-001131	results	3	NA	direction_benefit	inferior
10.1136/rmdopen-2019-001131	results	3	NA	ss_ttt_nonipd	373
10.1136/rmdopen-2019-001131	results	3	NA	ss_ttt_ipd	159
10.1136/rmdopen-2019-001131	results	3	NA	ss_adjusted_ttt_ipd	146.5
10.1136/rmdopen-2019-001131	results	3	NA	weights_yn	Not mentioned
10.1136/rmdopen-2019-001131	results	3	NA	covariates_yn	Yes
10.1136/rmdopen-2019-001131	results	3	NA	covariates_n	5
10.1136/rmdopen-2019-001131	results	3	NA	covariates_names	Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease)
10.1136/rmdopen-2019-001131	results	3	NA	contrast_effect_direction	Numerator if ratio, or left side if difference
10.1136/rmdopen-2019-001131	results	3	NA	contrast_effect_unadjusted_value	-7.1
10.1136/rmdopen-2019-001131	results	3	NA	contrast_effect_unadjusted_pvalci	<=0.05
10.1136/rmdopen-2019-001131	results	3	NA	contrast_effect_adjusted_value	-5.4
10.1136/rmdopen-2019-001131	results	3	NA	contrast_effect_adjusted_pvalci	>0.05
10.1136/rmdopen-2019-001131	results	3	NA	adjustment_geographical	No
10.1136/rmdopen-2019-001131	results	3	NA	ss_total_ipd	NA
10.1136/rmdopen-2019-001131	results	3	NA	ss_adjusted_total_ipd	NA
10.1136/rmdopen-2019-001131	results	3	NA	ss_total_nonipd	NA
10.1136/rmdopen-2019-001131	results	3	NA	ss_anchor_nonipd	186
10.1136/rmdopen-2019-001131	results	3	NA	ss_anchor_ipd	210
10.1136/rmdopen-2019-001131	results	3	NA	ss_adjusted_anchor_ipd	177.8
10.1136/rmdopen-2019-001131	results	3	NA	effect_cutoff	0
10.1136/rmdopen-2019-001131	results	3	NA	unadjusted_pval	<=0.05
10.1136/rmdopen-2019-001131	results	3	NA	unadjusted_significant	TRUE
10.1136/rmdopen-2019-001131	results	3	NA	adjusted_pval	>0.05
10.1136/rmdopen-2019-001131	study_information	NA	1	ipd_yn	Yes
10.1136/rmdopen-2019-001131	study_information	NA	1	ct_yn	Yes
10.1136/rmdopen-2019-001131	study_information	NA	1	nct	NCT01711359
10.1136/rmdopen-2019-001131	study_information	NA	1	country_study	international
10.1136/rmdopen-2019-001131	study_information	NA	1	ct_phase	3
10.1136/rmdopen-2019-001131	study_information	NA	1	ct_arms	2 or more
10.1136/rmdopen-2019-001131	study_information	NA	2	ipd_yn	No
10.1136/rmdopen-2019-001131	study_information	NA	2	ct_yn	Yes
10.1136/rmdopen-2019-001131	study_information	NA	2	nct	NCT00109408
10.1136/rmdopen-2019-001131	study_information	NA	2	country_study	international
10.1136/rmdopen-2019-001131	study_information	NA	2	ct_phase	3
10.1136/rmdopen-2019-001131	study_information	NA	2	ct_arms	2 or more
10.1136/rmdopen-2019-001131	study_information	NA	3	ipd_yn	No
10.1136/rmdopen-2019-001131	study_information	NA	3	ct_yn	Yes
10.1136/rmdopen-2019-001131	study_information	NA	3	nct	NCT01007435
10.1136/rmdopen-2019-001131	study_information	NA	3	country_study	international
10.1136/rmdopen-2019-001131	study_information	NA	3	ct_phase	3
10.1136/rmdopen-2019-001131	study_information	NA	3	ct_arms	2 or more
10.1136/rmdopen-2019-001131	study_information	NA	4	ipd_yn	No
10.1136/rmdopen-2019-001131	study_information	NA	4	ct_yn	Yes
10.1136/rmdopen-2019-001131	study_information	NA	4	nct	NCT01039688
10.1136/rmdopen-2019-001131	study_information	NA	4	country_study	international
10.1136/rmdopen-2019-001131	study_information	NA	4	ct_phase	3
10.1136/rmdopen-2019-001131	study_information	NA	4	ct_arms	2 or more
10.1136/rmdopen-2019-001131	study_information	NA	5	ipd_yn	No
10.1136/rmdopen-2019-001131	study_information	NA	5	ct_yn	Yes
10.1136/rmdopen-2019-001131	study_information	NA	5	nct	NCT00195663
10.1136/rmdopen-2019-001131	study_information	NA	5	country_study	international
10.1136/rmdopen-2019-001131	study_information	NA	5	ct_phase	3
10.1136/rmdopen-2019-001131	study_information	NA	5	ct_arms	2 or more
10.1155/2017/6121760	general_information	NA	NA	condition_name	basal cell carcinoma
10.1155/2017/6121760	general_information	NA	NA	country_first_author	usa
10.1155/2017/6121760	general_information	NA	NA	country_last_author	usa
10.1155/2017/6121760	general_information	NA	NA	positions	Pharmaceutical Industry, Private Data Analysis Company
10.1155/2017/6121760	general_information	NA	NA	methodologist_yn	Yes
10.1155/2017/6121760	general_information	NA	NA	funding_source	Pharmaceutical Industry
10.1155/2017/6121760	general_information	NA	NA	pharmaceutical_ties_yn	Yes
10.1155/2017/6121760	general_information	NA	NA	systematic_review_yn	No
10.1155/2017/6121760	methodology	1	NA	outcome_name	objective response rate
10.1155/2017/6121760	methodology	1	NA	outcome_short_name	Objective Response Rate
10.1155/2017/6121760	methodology	1	NA	outcome_variable_type	Binary (eg rates)
10.1155/2017/6121760	methodology	1	NA	treatment_name_ipd	sonidegib
10.1155/2017/6121760	methodology	1	NA	studies_number_ipd	1
10.1155/2017/6121760	methodology	1	NA	treatment_name_nonipd	vismodegib
10.1155/2017/6121760	methodology	1	NA	studies_number_nonipd	2
10.1155/2017/6121760	methodology	1	NA	paic_type	MAIC
10.1155/2017/6121760	methodology	1	NA	anchored_yn	No
10.1155/2017/6121760	methodology	1	NA	paic_form	Simple (ie treatments effects extracted from two studies)
10.1155/2017/6121760	methodology	1	NA	primary_outcome_yn	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.1155/2017/6121760	methodology	1	NA	variables_selection_justification	Statistical imbalanced between treatment groups (independently of the status of prognostic/effect modifier), A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion), Literature based (clinically or methodologically relevant to adjust on these variables based on the literature search conducted for this specific purpose)
10.1155/2017/6121760	methodology	1	NA	pf_yn	Yes
10.1155/2017/6121760	methodology	1	NA	tem_yn	No discussion (in the main text) of the status of treatment-effect modifiers of the variables
10.1155/2017/6121760	methodology	1	NA	adjustment_model_details_yn	No
10.1155/2017/6121760	methodology	1	NA	scale_choice_yn	No
10.1155/2017/6121760	results	1	NA	contrast_effect_type	NA
10.1155/2017/6121760	results	1	NA	direction_benefit	superior
10.1155/2017/6121760	results	1	NA	ss_ttt_nonipd	63
10.1155/2017/6121760	results	1	NA	ss_ttt_ipd	66
10.1155/2017/6121760	results	1	NA	ss_adjusted_ttt_ipd	NA
10.1155/2017/6121760	results	1	NA	weights_yn	Yes, mentions that the weights distribution has been studied, but weights distribution not reported
10.1155/2017/6121760	results	1	NA	covariates_yn	Yes
10.1155/2017/6121760	results	1	NA	covariates_n	2
10.1155/2017/6121760	results	1	NA	covariates_names	Past treatments for the disease of interest
10.1155/2017/6121760	results	1	NA	contrast_effect_direction	NA
10.1155/2017/6121760	results	1	NA	contrast_effect_unadjusted_value	NA
10.1155/2017/6121760	results	1	NA	contrast_effect_unadjusted_pvalci	NA
10.1155/2017/6121760	results	1	NA	contrast_effect_adjusted_value	NA
10.1155/2017/6121760	results	1	NA	contrast_effect_adjusted_pvalci	NA
10.1155/2017/6121760	results	1	NA	adjustment_geographical	NA
10.1155/2017/6121760	results	1	NA	ss_total_ipd	NA
10.1155/2017/6121760	results	1	NA	ss_adjusted_total_ipd	NA
10.1155/2017/6121760	results	1	NA	ss_total_nonipd	NA
10.1155/2017/6121760	results	1	NA	ss_anchor_nonipd	NA
10.1155/2017/6121760	results	1	NA	ss_anchor_ipd	NA
10.1155/2017/6121760	results	1	NA	ss_adjusted_anchor_ipd	NA
10.1155/2017/6121760	results	1	NA	effect_cutoff	NA
10.1155/2017/6121760	study_information	NA	1	ipd_yn	Yes
10.1155/2017/6121760	study_information	NA	1	ct_yn	Yes
10.1155/2017/6121760	study_information	NA	1	nct	NCT01327053
10.1155/2017/6121760	study_information	NA	1	country_study	international
10.1155/2017/6121760	study_information	NA	1	ct_phase	2
10.1155/2017/6121760	study_information	NA	1	ct_arms	1
10.1155/2017/6121760	study_information	NA	2	ipd_yn	No
10.1155/2017/6121760	study_information	NA	2	ct_yn	Yes
10.1155/2017/6121760	study_information	NA	2	nct	NCT00833417
10.1155/2017/6121760	study_information	NA	2	country_study	international
10.1155/2017/6121760	study_information	NA	2	ct_phase	2
10.1155/2017/6121760	study_information	NA	2	ct_arms	1
10.1177/1756286420975916	general_information	NA	NA	condition_name	relapsing multiple sclerosis
10.1177/1756286420975916	general_information	NA	NA	country_first_author	usa
10.1177/1756286420975916	general_information	NA	NA	country_last_author	usa
10.1177/1756286420975916	general_information	NA	NA	positions	Academic, Pharmaceutical Industry
10.1177/1756286420975916	general_information	NA	NA	methodologist_yn	Not mentioned
10.1177/1756286420975916	general_information	NA	NA	funding_source	Pharmaceutical Industry
10.1177/1756286420975916	general_information	NA	NA	pharmaceutical_ties_yn	Yes
10.1177/1756286420975916	general_information	NA	NA	systematic_review_yn	No
10.1177/1756286420975916	methodology	1	NA	outcome_name	annualized relapse rate (arr) at 1 year
10.1177/1756286420975916	methodology	1	NA	outcome_short_name	Annualized Relapse Rate
10.1177/1756286420975916	methodology	1	NA	outcome_variable_type	Binary (eg rates)
10.1177/1756286420975916	methodology	1	NA	treatment_name_ipd	peginterferon beta-1a
10.1177/1756286420975916	methodology	1	NA	studies_number_ipd	1
10.1177/1756286420975916	methodology	1	NA	treatment_name_nonipd	glatiramer acetate
10.1177/1756286420975916	methodology	1	NA	studies_number_nonipd	2
10.1177/1756286420975916	methodology	1	NA	paic_type	MAIC
10.1177/1756286420975916	methodology	1	NA	anchored_yn	No
10.1177/1756286420975916	methodology	1	NA	paic_form	Simple (ie treatments effects extracted from two studies)
10.1177/1756286420975916	methodology	1	NA	primary_outcome_yn	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.1177/1756286420975916	methodology	1	NA	variables_selection_justification	Nothing mentioned, not reported
10.1177/1756286420975916	methodology	1	NA	pf_yn	No discussion (in the main text) of the status of prognostic factors of the variables
10.1177/1756286420975916	methodology	1	NA	tem_yn	No discussion (in the main text) of the status of treatment-effect modifiers of the variables
10.1177/1756286420975916	methodology	1	NA	adjustment_model_details_yn	No
10.1177/1756286420975916	methodology	1	NA	scale_choice_yn	No
10.1177/1756286420975916	results	1	NA	contrast_effect_type	Rate difference
10.1177/1756286420975916	results	1	NA	direction_benefit	inferior
10.1177/1756286420975916	results	1	NA	ss_ttt_nonipd	834
10.1177/1756286420975916	results	1	NA	ss_ttt_ipd	407
10.1177/1756286420975916	results	1	NA	ss_adjusted_ttt_ipd	276
10.1177/1756286420975916	results	1	NA	weights_yn	Not mentioned
10.1177/1756286420975916	results	1	NA	covariates_yn	Yes
10.1177/1756286420975916	results	1	NA	covariates_n	5
10.1177/1756286420975916	results	1	NA	covariates_names	Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Other(s)
10.1177/1756286420975916	results	1	NA	contrast_effect_direction	Numerator if ratio, or left side if difference
10.1177/1756286420975916	results	1	NA	contrast_effect_unadjusted_value	NA
10.1177/1756286420975916	results	1	NA	contrast_effect_unadjusted_pvalci	NA
10.1177/1756286420975916	results	1	NA	contrast_effect_adjusted_value	-0.04
10.1177/1756286420975916	results	1	NA	contrast_effect_adjusted_pvalci	0.375
10.1177/1756286420975916	results	1	NA	adjustment_geographical	Yes
10.1177/1756286420975916	results	1	NA	ss_total_ipd	NA
10.1177/1756286420975916	results	1	NA	ss_adjusted_total_ipd	NA
10.1177/1756286420975916	results	1	NA	ss_total_nonipd	NA
10.1177/1756286420975916	results	1	NA	ss_anchor_nonipd	NA
10.1177/1756286420975916	results	1	NA	ss_anchor_ipd	NA
10.1177/1756286420975916	results	1	NA	ss_adjusted_anchor_ipd	NA
10.1177/1756286420975916	results	1	NA	effect_cutoff	0
10.1177/1756286420975916	results	1	NA	adjusted_pval	0.375
10.1177/1756286420975916	results	1	NA	adjusted_num_pval	0.375
10.1177/1756286420975916	results	1	NA	adjusted_significant	FALSE
10.1177/1756286420975916	study_information	NA	1	ipd_yn	Yes
10.1177/1756286420975916	study_information	NA	1	ct_yn	Yes
10.1177/1756286420975916	study_information	NA	1	nct	NCT00906399
10.1177/1756286420975916	study_information	NA	1	country_study	international
10.1177/1756286420975916	study_information	NA	1	ct_phase	3
10.1177/1756286420975916	study_information	NA	1	ct_arms	2 or more
10.1177/1756286420975916	study_information	NA	2	ipd_yn	No
10.1177/1756286420975916	study_information	NA	2	ct_yn	Yes
10.1177/1756286420975916	study_information	NA	2	nct	NCT01067521
10.1177/1756286420975916	study_information	NA	2	country_study	international
10.1177/1756286420975916	study_information	NA	2	ct_phase	3
10.1177/1756286420975916	study_information	NA	2	ct_arms	2 or more
10.1177/17588359211049639	general_information	NA	NA	condition_name	advanced ovarian cancer
10.1177/17588359211049639	general_information	NA	NA	country_first_author	uk
10.1177/17588359211049639	general_information	NA	NA	country_last_author	uk
10.1177/17588359211049639	general_information	NA	NA	positions	Academic, Pharmaceutical Industry
10.1177/17588359211049639	general_information	NA	NA	methodologist_yn	Yes
10.1177/17588359211049639	general_information	NA	NA	funding_source	Pharmaceutical Industry
10.1177/17588359211049639	general_information	NA	NA	pharmaceutical_ties_yn	Yes
10.1177/17588359211049639	general_information	NA	NA	systematic_review_yn	No
10.1177/17588359211049639	methodology	1	NA	outcome_name	progression-free survival
10.1177/17588359211049639	methodology	1	NA	outcome_short_name	Progression-free Survival
10.1177/17588359211049639	methodology	1	NA	outcome_variable_type	Time-to-event
10.1177/17588359211049639	methodology	1	NA	treatment_name_ipd	olaparib + bevacizumab
10.1177/17588359211049639	methodology	1	NA	studies_number_ipd	1
10.1177/17588359211049639	methodology	1	NA	treatment_name_nonipd	niraparib
10.1177/17588359211049639	methodology	1	NA	studies_number_nonipd	2
10.1177/17588359211049639	methodology	1	NA	paic_type	MAIC
10.1177/17588359211049639	methodology	1	NA	anchored_yn	No
10.1177/17588359211049639	methodology	1	NA	paic_form	Simple (ie treatments effects extracted from two studies)
10.1177/17588359211049639	methodology	1	NA	primary_outcome_yn	Yes
10.1177/17588359211049639	methodology	1	NA	variables_selection_justification	Status of prognostic factor/treatment effect modified assessed in the IPD dataset
10.1177/17588359211049639	methodology	1	NA	pf_yn	Yes
10.1177/17588359211049639	methodology	1	NA	tem_yn	Yes
10.1177/17588359211049639	methodology	1	NA	adjustment_model_details_yn	No
10.1177/17588359211049639	methodology	1	NA	scale_choice_yn	No
10.1177/17588359211049639	methodology	2	NA	outcome_name	progression-free survival
10.1177/17588359211049639	methodology	2	NA	outcome_short_name	Progression-free Survival
10.1177/17588359211049639	methodology	2	NA	outcome_variable_type	Time-to-event
10.1177/17588359211049639	methodology	2	NA	treatment_name_ipd	bevacizumab + placebo
10.1177/17588359211049639	methodology	2	NA	studies_number_ipd	1
10.1177/17588359211049639	methodology	2	NA	treatment_name_nonipd	niraparib
10.1177/17588359211049639	methodology	2	NA	studies_number_nonipd	2
10.1177/17588359211049639	methodology	2	NA	paic_type	MAIC
10.1177/17588359211049639	methodology	2	NA	anchored_yn	No
10.1177/17588359211049639	methodology	2	NA	paic_form	Simple (ie treatments effects extracted from two studies)
10.1177/17588359211049639	methodology	2	NA	primary_outcome_yn	Yes
10.1177/17588359211049639	methodology	2	NA	variables_selection_justification	Status of prognostic factor/treatment effect modified assessed in the IPD dataset
10.1177/17588359211049639	methodology	2	NA	pf_yn	Yes
10.1177/17588359211049639	methodology	2	NA	tem_yn	Yes
10.1177/17588359211049639	methodology	2	NA	adjustment_model_details_yn	No
10.1177/17588359211049639	methodology	2	NA	scale_choice_yn	No
10.1177/17588359211049639	methodology	3	NA	outcome_name	progression-free survival
10.1177/17588359211049639	methodology	3	NA	outcome_short_name	Progression-free Survival
10.1177/17588359211049639	methodology	3	NA	outcome_variable_type	Time-to-event
10.1177/17588359211049639	methodology	3	NA	treatment_name_ipd	olaparib + bevacizumab
10.1177/17588359211049639	methodology	3	NA	studies_number_ipd	1
10.1177/17588359211049639	methodology	3	NA	treatment_name_nonipd	placebo
10.1177/17588359211049639	methodology	3	NA	studies_number_nonipd	2
10.1177/17588359211049639	methodology	3	NA	paic_type	MAIC
10.1177/17588359211049639	methodology	3	NA	anchored_yn	No
10.1177/17588359211049639	methodology	3	NA	paic_form	Simple (ie treatments effects extracted from two studies)
10.1177/17588359211049639	methodology	3	NA	primary_outcome_yn	Yes
10.1177/17588359211049639	methodology	3	NA	variables_selection_justification	Status of prognostic factor/treatment effect modified assessed in the IPD dataset
10.1177/17588359211049639	methodology	3	NA	pf_yn	Yes
10.1177/17588359211049639	methodology	3	NA	tem_yn	Yes
10.1177/17588359211049639	methodology	3	NA	adjustment_model_details_yn	No
10.1177/17588359211049639	methodology	3	NA	scale_choice_yn	No
10.1177/17588359211049639	methodology	4	NA	outcome_name	progression-free survival
10.1177/17588359211049639	methodology	4	NA	outcome_short_name	Progression-free Survival
10.1177/17588359211049639	methodology	4	NA	outcome_variable_type	Time-to-event
10.1177/17588359211049639	methodology	4	NA	treatment_name_ipd	placebo + bevacizumab
10.1177/17588359211049639	methodology	4	NA	studies_number_ipd	1
10.1177/17588359211049639	methodology	4	NA	treatment_name_nonipd	placebo
10.1177/17588359211049639	methodology	4	NA	studies_number_nonipd	2
10.1177/17588359211049639	methodology	4	NA	paic_type	MAIC
10.1177/17588359211049639	methodology	4	NA	anchored_yn	No
10.1177/17588359211049639	methodology	4	NA	paic_form	Simple (ie treatments effects extracted from two studies)
10.1177/17588359211049639	methodology	4	NA	primary_outcome_yn	Yes
10.1177/17588359211049639	methodology	4	NA	variables_selection_justification	Status of prognostic factor/treatment effect modified assessed in the IPD dataset
10.1177/17588359211049639	methodology	4	NA	pf_yn	Yes
10.1177/17588359211049639	methodology	4	NA	tem_yn	Yes
10.1177/17588359211049639	methodology	4	NA	adjustment_model_details_yn	No
10.1177/17588359211049639	methodology	4	NA	scale_choice_yn	No
10.1177/17588359211049639	results	1	NA	contrast_effect_type	HR
10.1177/17588359211049639	results	1	NA	direction_benefit	inferior
10.1177/17588359211049639	results	1	NA	ss_ttt_nonipd	487
10.1177/17588359211049639	results	1	NA	ss_ttt_ipd	399
10.1177/17588359211049639	results	1	NA	ss_adjusted_ttt_ipd	358
10.1177/17588359211049639	results	1	NA	weights_yn	Yes, mentions that the weights distribution has been studied, and weights distribution reported in main article or supplemental materials
10.1177/17588359211049639	results	1	NA	covariates_yn	Yes
10.1177/17588359211049639	results	1	NA	covariates_n	8
10.1177/17588359211049639	results	1	NA	covariates_names	Age, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Past treatments for the disease of interest
10.1177/17588359211049639	results	1	NA	contrast_effect_direction	Numerator if ratio, or left side if difference
10.1177/17588359211049639	results	1	NA	contrast_effect_unadjusted_value	NA
10.1177/17588359211049639	results	1	NA	contrast_effect_unadjusted_pvalci	NA
10.1177/17588359211049639	results	1	NA	contrast_effect_adjusted_value	0.57
10.1177/17588359211049639	results	1	NA	contrast_effect_adjusted_pvalci	[0.47;0.69]
10.1177/17588359211049639	results	1	NA	adjustment_geographical	NA
10.1177/17588359211049639	results	1	NA	ss_total_ipd	NA
10.1177/17588359211049639	results	1	NA	ss_adjusted_total_ipd	NA
10.1177/17588359211049639	results	1	NA	ss_total_nonipd	NA
10.1177/17588359211049639	results	1	NA	ss_anchor_nonipd	NA
10.1177/17588359211049639	results	1	NA	ss_anchor_ipd	NA
10.1177/17588359211049639	results	1	NA	ss_adjusted_anchor_ipd	NA
10.1177/17588359211049639	results	1	NA	effect_cutoff	1
10.1177/17588359211049639	results	1	NA	adjusted_lb_ci	0.47
10.1177/17588359211049639	results	1	NA	adjusted_ub_ci	0.69
10.1177/17588359211049639	results	1	NA	adjusted_significant	TRUE
10.1177/17588359211049639	results	2	NA	contrast_effect_type	HR
10.1177/17588359211049639	results	2	NA	direction_benefit	inferior
10.1177/17588359211049639	results	2	NA	ss_ttt_nonipd	487
10.1177/17588359211049639	results	2	NA	ss_ttt_ipd	196
10.1177/17588359211049639	results	2	NA	ss_adjusted_ttt_ipd	174
10.1177/17588359211049639	results	2	NA	weights_yn	Yes, mentions that the weights distribution has been studied, and weights distribution reported in main article or supplemental materials
10.1177/17588359211049639	results	2	NA	covariates_yn	Yes
10.1177/17588359211049639	results	2	NA	covariates_n	8
10.1177/17588359211049639	results	2	NA	covariates_names	Age, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Past treatments for the disease of interest
10.1177/17588359211049639	results	2	NA	contrast_effect_direction	Denominator if ratio, or rightside if difference
10.1177/17588359211049639	results	2	NA	contrast_effect_unadjusted_value	NA
10.1177/17588359211049639	results	2	NA	contrast_effect_unadjusted_pvalci	NA
10.1177/17588359211049639	results	2	NA	contrast_effect_adjusted_value	1.07
10.1177/17588359211049639	results	2	NA	contrast_effect_adjusted_pvalci	[0.87;1.32]
10.1177/17588359211049639	results	2	NA	adjustment_geographical	NA
10.1177/17588359211049639	results	2	NA	ss_total_ipd	NA
10.1177/17588359211049639	results	2	NA	ss_adjusted_total_ipd	NA
10.1177/17588359211049639	results	2	NA	ss_total_nonipd	NA
10.1177/17588359211049639	results	2	NA	ss_anchor_nonipd	NA
10.1177/17588359211049639	results	2	NA	ss_anchor_ipd	NA
10.1177/17588359211049639	results	2	NA	ss_adjusted_anchor_ipd	NA
10.1177/17588359211049639	results	2	NA	effect_cutoff	1
10.1177/17588359211049639	results	2	NA	adjusted_lb_ci	0.87
10.1177/17588359211049639	results	2	NA	adjusted_ub_ci	1.32
10.1177/17588359211049639	results	2	NA	adjusted_significant	FALSE
10.1177/17588359211049639	results	3	NA	contrast_effect_type	HR
10.1177/17588359211049639	results	3	NA	direction_benefit	inferior
10.1177/17588359211049639	results	3	NA	ss_ttt_nonipd	246
10.1177/17588359211049639	results	3	NA	ss_ttt_ipd	399
10.1177/17588359211049639	results	3	NA	ss_adjusted_ttt_ipd	358
10.1177/17588359211049639	results	3	NA	weights_yn	Yes, mentions that the weights distribution has been studied, and weights distribution reported in main article or supplemental materials
10.1177/17588359211049639	results	3	NA	covariates_yn	Yes
10.1177/17588359211049639	results	3	NA	covariates_n	8
10.1177/17588359211049639	results	3	NA	covariates_names	Age, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Past treatments for the disease of interest
10.1177/17588359211049639	results	3	NA	contrast_effect_direction	Numerator if ratio, or left side if difference
10.1177/17588359211049639	results	3	NA	contrast_effect_unadjusted_value	NA
10.1177/17588359211049639	results	3	NA	contrast_effect_unadjusted_pvalci	NA
10.1177/17588359211049639	results	3	NA	contrast_effect_adjusted_value	0.33
10.1177/17588359211049639	results	3	NA	contrast_effect_adjusted_pvalci	[0.26;0.42]
10.1177/17588359211049639	results	3	NA	adjustment_geographical	NA
10.1177/17588359211049639	results	3	NA	ss_total_ipd	NA
10.1177/17588359211049639	results	3	NA	ss_adjusted_total_ipd	NA
10.1177/17588359211049639	results	3	NA	ss_total_nonipd	NA
10.1177/17588359211049639	results	3	NA	ss_anchor_nonipd	NA
10.1177/17588359211049639	results	3	NA	ss_anchor_ipd	NA
10.1177/17588359211049639	results	3	NA	ss_adjusted_anchor_ipd	NA
10.1177/17588359211049639	results	3	NA	effect_cutoff	1
10.1177/17588359211049639	results	3	NA	adjusted_lb_ci	0.26
10.1177/17588359211049639	results	3	NA	adjusted_ub_ci	0.42
10.1177/17588359211049639	results	3	NA	adjusted_significant	TRUE
10.1177/17588359211049639	results	4	NA	contrast_effect_type	HR
10.1177/17588359211049639	results	4	NA	direction_benefit	inferior
10.1177/17588359211049639	results	4	NA	ss_ttt_nonipd	246
10.1177/17588359211049639	results	4	NA	ss_ttt_ipd	196
10.1177/17588359211049639	results	4	NA	ss_adjusted_ttt_ipd	174
10.1177/17588359211049639	results	4	NA	weights_yn	Yes, mentions that the weights distribution has been studied, and weights distribution reported in main article or supplemental materials
10.1177/17588359211049639	results	4	NA	covariates_yn	Yes
10.1177/17588359211049639	results	4	NA	covariates_n	8
10.1177/17588359211049639	results	4	NA	covariates_names	Age, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Past treatments for the disease of interest
10.1177/17588359211049639	results	4	NA	contrast_effect_direction	Numerator if ratio, or left side if difference
10.1177/17588359211049639	results	4	NA	contrast_effect_unadjusted_value	NA
10.1177/17588359211049639	results	4	NA	contrast_effect_unadjusted_pvalci	NA
10.1177/17588359211049639	results	4	NA	contrast_effect_adjusted_value	0.55
10.1177/17588359211049639	results	4	NA	contrast_effect_adjusted_pvalci	[0.43;0.70]
10.1177/17588359211049639	results	4	NA	adjustment_geographical	NA
10.1177/17588359211049639	results	4	NA	ss_total_ipd	NA
10.1177/17588359211049639	results	4	NA	ss_adjusted_total_ipd	NA
10.1177/17588359211049639	results	4	NA	ss_total_nonipd	NA
10.1177/17588359211049639	results	4	NA	ss_anchor_nonipd	NA
10.1177/17588359211049639	results	4	NA	ss_anchor_ipd	NA
10.1177/17588359211049639	results	4	NA	ss_adjusted_anchor_ipd	NA
10.1177/17588359211049639	results	4	NA	effect_cutoff	1
10.1177/17588359211049639	results	4	NA	adjusted_lb_ci	0.43
10.1177/17588359211049639	results	4	NA	adjusted_ub_ci	0.7
10.1177/17588359211049639	results	4	NA	adjusted_significant	TRUE
10.1177/17588359211049639	study_information	NA	1	ipd_yn	Yes
10.1177/17588359211049639	study_information	NA	1	ct_yn	Yes
10.1177/17588359211049639	study_information	NA	1	nct	NCT02477644
10.1177/17588359211049639	study_information	NA	1	country_study	international
10.1177/17588359211049639	study_information	NA	1	ct_phase	3
10.1177/17588359211049639	study_information	NA	1	ct_arms	2 or more
10.1177/17588359211049639	study_information	NA	2	ipd_yn	No
10.1177/17588359211049639	study_information	NA	2	ct_yn	Yes
10.1177/17588359211049639	study_information	NA	2	nct	NCT02655016
10.1177/17588359211049639	study_information	NA	2	country_study	international
10.1177/17588359211049639	study_information	NA	2	ct_phase	3
10.1177/17588359211049639	study_information	NA	2	ct_arms	2 or more
10.1183/13993003.01393-2018	general_information	NA	NA	condition_name	severe uncontrolled asthma
10.1183/13993003.01393-2018	general_information	NA	NA	country_first_author	france
10.1183/13993003.01393-2018	general_information	NA	NA	country_last_author	usa
10.1183/13993003.01393-2018	general_information	NA	NA	positions	Academic, Pharmaceutical Industry, Private Data Analysis Company
10.1183/13993003.01393-2018	general_information	NA	NA	methodologist_yn	Yes
10.1183/13993003.01393-2018	general_information	NA	NA	funding_source	Pharmaceutical Industry
10.1183/13993003.01393-2018	general_information	NA	NA	pharmaceutical_ties_yn	Yes
10.1183/13993003.01393-2018	general_information	NA	NA	systematic_review_yn	Yes
10.1183/13993003.01393-2018	methodology	1	NA	outcome_name	annual rate of clinically significant exacerbations
10.1183/13993003.01393-2018	methodology	1	NA	outcome_short_name	Exacerbations annual Rate
10.1183/13993003.01393-2018	methodology	1	NA	outcome_variable_type	Binary (eg rates)
10.1183/13993003.01393-2018	methodology	1	NA	treatment_name_ipd	benralizumab
10.1183/13993003.01393-2018	methodology	1	NA	studies_number_ipd	1;2
10.1183/13993003.01393-2018	methodology	1	NA	treatment_name_nonipd	mepolizumab
10.1183/13993003.01393-2018	methodology	1	NA	studies_number_nonipd	3;4
10.1183/13993003.01393-2018	methodology	1	NA	paic_type	MAIC
10.1183/13993003.01393-2018	methodology	1	NA	anchored_yn	Yes
10.1183/13993003.01393-2018	methodology	1	NA	paic_form	Aggregation of multiple studies to estimate individual treatment effects (e.g. meta-analysis in a first step to estimate treatment A effect, then population adjusted indirect comparison using treatment A effect estimate)
10.1183/13993003.01393-2018	methodology	1	NA	primary_outcome_yn	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.1183/13993003.01393-2018	methodology	1	NA	variables_selection_justification	Status of prognostic factor/treatment effect modified assessed in the IPD dataset, A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion), Literature based (clinically or methodologically relevant to adjust on these variables based on the literature search conducted for this specific purpose)
10.1183/13993003.01393-2018	methodology	1	NA	pf_yn	No
10.1183/13993003.01393-2018	methodology	1	NA	tem_yn	Yes
10.1183/13993003.01393-2018	methodology	1	NA	adjustment_model_details_yn	No
10.1183/13993003.01393-2018	methodology	1	NA	scale_choice_yn	No
10.1183/13993003.01393-2018	results	1	NA	contrast_effect_type	RR
10.1183/13993003.01393-2018	results	1	NA	direction_benefit	inferior
10.1183/13993003.01393-2018	results	1	NA	ss_ttt_nonipd	538
10.1183/13993003.01393-2018	results	1	NA	ss_ttt_ipd	NA
10.1183/13993003.01393-2018	results	1	NA	ss_adjusted_ttt_ipd	NA
10.1183/13993003.01393-2018	results	1	NA	weights_yn	Not mentioned
10.1183/13993003.01393-2018	results	1	NA	covariates_yn	Yes
10.1183/13993003.01393-2018	results	1	NA	covariates_n	7
10.1183/13993003.01393-2018	results	1	NA	covariates_names	Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Past treatments for the disease of interest, Other(s)
10.1183/13993003.01393-2018	results	1	NA	contrast_effect_direction	Numerator if ratio, or left side if difference
10.1183/13993003.01393-2018	results	1	NA	contrast_effect_unadjusted_value	1.06
10.1183/13993003.01393-2018	results	1	NA	contrast_effect_unadjusted_pvalci	0.5553
10.1183/13993003.01393-2018	results	1	NA	contrast_effect_adjusted_value	0.94
10.1183/13993003.01393-2018	results	1	NA	contrast_effect_adjusted_pvalci	0.5207
10.1183/13993003.01393-2018	results	1	NA	adjustment_geographical	No
10.1183/13993003.01393-2018	results	1	NA	ss_total_ipd	959
10.1183/13993003.01393-2018	results	1	NA	ss_adjusted_total_ipd	639
10.1183/13993003.01393-2018	results	1	NA	ss_total_nonipd	884
10.1183/13993003.01393-2018	results	1	NA	ss_anchor_nonipd	346
10.1183/13993003.01393-2018	results	1	NA	ss_anchor_ipd	NA
10.1183/13993003.01393-2018	results	1	NA	ss_adjusted_anchor_ipd	NA
10.1183/13993003.01393-2018	results	1	NA	effect_cutoff	1
10.1183/13993003.01393-2018	results	1	NA	unadjusted_pval	0.5553
10.1183/13993003.01393-2018	results	1	NA	unadjusted_num_pval	0.5553
10.1183/13993003.01393-2018	results	1	NA	unadjusted_significant	FALSE
10.1183/13993003.01393-2018	results	1	NA	adjusted_pval	0.5207
10.1183/13993003.01393-2018	results	1	NA	adjusted_num_pval	0.5207
10.1183/13993003.01393-2018	results	1	NA	adjusted_significant	FALSE
10.1183/13993003.01393-2018	study_information	NA	1	ipd_yn	Yes
10.1183/13993003.01393-2018	study_information	NA	1	ct_yn	Yes
10.1183/13993003.01393-2018	study_information	NA	1	nct	NCT01928771
10.1183/13993003.01393-2018	study_information	NA	1	country_study	international
10.1183/13993003.01393-2018	study_information	NA	1	ct_phase	3
10.1183/13993003.01393-2018	study_information	NA	1	ct_arms	2 or more
10.1183/13993003.01393-2018	study_information	NA	2	ipd_yn	Yes
10.1183/13993003.01393-2018	study_information	NA	2	ct_yn	Yes
10.1183/13993003.01393-2018	study_information	NA	2	nct	NCT01914757
10.1183/13993003.01393-2018	study_information	NA	2	country_study	international
10.1183/13993003.01393-2018	study_information	NA	2	ct_phase	3
10.1183/13993003.01393-2018	study_information	NA	2	ct_arms	2 or more
10.1183/13993003.01393-2018	study_information	NA	3	ipd_yn	No
10.1183/13993003.01393-2018	study_information	NA	3	ct_yn	Yes
10.1183/13993003.01393-2018	study_information	NA	3	nct	NCT01691521
10.1183/13993003.01393-2018	study_information	NA	3	country_study	international
10.1183/13993003.01393-2018	study_information	NA	3	ct_phase	3
10.1183/13993003.01393-2018	study_information	NA	3	ct_arms	2 or more
10.1183/13993003.01393-2018	study_information	NA	4	ipd_yn	No
10.1183/13993003.01393-2018	study_information	NA	4	ct_yn	Yes
10.1183/13993003.01393-2018	study_information	NA	4	nct	NCT01000506
10.1183/13993003.01393-2018	study_information	NA	4	country_study	international
10.1183/13993003.01393-2018	study_information	NA	4	ct_phase	2
10.1183/13993003.01393-2018	study_information	NA	4	ct_arms	2 or more
10.1185/03007995.2011.576238	general_information	NA	NA	condition_name	chronic myeloid leukemia
10.1185/03007995.2011.576238	general_information	NA	NA	country_first_author	usa
10.1185/03007995.2011.576238	general_information	NA	NA	country_last_author	usa
10.1185/03007995.2011.576238	general_information	NA	NA	positions	Academic, Pharmaceutical Industry, Private Data Analysis Company
10.1185/03007995.2011.576238	general_information	NA	NA	methodologist_yn	Yes
10.1185/03007995.2011.576238	general_information	NA	NA	funding_source	Pharmaceutical Industry
10.1185/03007995.2011.576238	general_information	NA	NA	pharmaceutical_ties_yn	Yes
10.1185/03007995.2011.576238	general_information	NA	NA	systematic_review_yn	No
10.1185/03007995.2011.576238	methodology	1	NA	outcome_name	major molecular response by 12 months
10.1185/03007995.2011.576238	methodology	1	NA	outcome_short_name	Major Molecular Response
10.1185/03007995.2011.576238	methodology	1	NA	outcome_variable_type	Binary (eg rates)
10.1185/03007995.2011.576238	methodology	1	NA	treatment_name_ipd	nilotinib
10.1185/03007995.2011.576238	methodology	1	NA	studies_number_ipd	1
10.1185/03007995.2011.576238	methodology	1	NA	treatment_name_nonipd	dasatinib
10.1185/03007995.2011.576238	methodology	1	NA	studies_number_nonipd	2
10.1185/03007995.2011.576238	methodology	1	NA	paic_type	MAIC
10.1185/03007995.2011.576238	methodology	1	NA	anchored_yn	No
10.1185/03007995.2011.576238	methodology	1	NA	paic_form	Simple (ie treatments effects extracted from two studies)
10.1185/03007995.2011.576238	methodology	1	NA	primary_outcome_yn	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.1185/03007995.2011.576238	methodology	1	NA	variables_selection_justification	Nothing mentioned, not reported
10.1185/03007995.2011.576238	methodology	1	NA	pf_yn	No discussion (in the main text) of the status of prognostic factors of the variables
10.1185/03007995.2011.576238	methodology	1	NA	tem_yn	No discussion (in the main text) of the status of treatment-effect modifiers of the variables
10.1185/03007995.2011.576238	methodology	1	NA	adjustment_model_details_yn	No
10.1185/03007995.2011.576238	methodology	1	NA	scale_choice_yn	No
10.1185/03007995.2011.576238	results	1	NA	contrast_effect_type	Rate difference
10.1185/03007995.2011.576238	results	1	NA	direction_benefit	superior
10.1185/03007995.2011.576238	results	1	NA	ss_ttt_nonipd	259
10.1185/03007995.2011.576238	results	1	NA	ss_ttt_ipd	273
10.1185/03007995.2011.576238	results	1	NA	ss_adjusted_ttt_ipd	NA
10.1185/03007995.2011.576238	results	1	NA	weights_yn	Not mentioned
10.1185/03007995.2011.576238	results	1	NA	covariates_yn	Yes
10.1185/03007995.2011.576238	results	1	NA	covariates_n	6
10.1185/03007995.2011.576238	results	1	NA	covariates_names	Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...)
10.1185/03007995.2011.576238	results	1	NA	contrast_effect_direction	Numerator if ratio, or left side if difference
10.1185/03007995.2011.576238	results	1	NA	contrast_effect_unadjusted_value	9.4
10.1185/03007995.2011.576238	results	1	NA	contrast_effect_unadjusted_pvalci	0.03
10.1185/03007995.2011.576238	results	1	NA	contrast_effect_adjusted_value	10.8
10.1185/03007995.2011.576238	results	1	NA	contrast_effect_adjusted_pvalci	0.014
10.1185/03007995.2011.576238	results	1	NA	adjustment_geographical	NA
10.1185/03007995.2011.576238	results	1	NA	ss_total_ipd	NA
10.1185/03007995.2011.576238	results	1	NA	ss_adjusted_total_ipd	NA
10.1185/03007995.2011.576238	results	1	NA	ss_total_nonipd	NA
10.1185/03007995.2011.576238	results	1	NA	ss_anchor_nonipd	NA
10.1185/03007995.2011.576238	results	1	NA	ss_anchor_ipd	NA
10.1185/03007995.2011.576238	results	1	NA	ss_adjusted_anchor_ipd	NA
10.1185/03007995.2011.576238	results	1	NA	effect_cutoff	0
10.1185/03007995.2011.576238	results	1	NA	unadjusted_pval	0.03
10.1185/03007995.2011.576238	results	1	NA	unadjusted_num_pval	0.03
10.1185/03007995.2011.576238	results	1	NA	unadjusted_significant	TRUE
10.1185/03007995.2011.576238	results	1	NA	adjusted_pval	0.014
10.1185/03007995.2011.576238	results	1	NA	adjusted_num_pval	0.014
10.1185/03007995.2011.576238	results	1	NA	adjusted_significant	TRUE
10.1185/03007995.2011.576238	study_information	NA	1	ipd_yn	Yes
10.1185/03007995.2011.576238	study_information	NA	1	ct_yn	Yes
10.1185/03007995.2011.576238	study_information	NA	1	nct	NCT00471497
10.1185/03007995.2011.576238	study_information	NA	1	country_study	international
10.1185/03007995.2011.576238	study_information	NA	1	ct_phase	3
10.1185/03007995.2011.576238	study_information	NA	1	ct_arms	2 or more
10.1185/03007995.2011.576238	study_information	NA	2	ipd_yn	No
10.1185/03007995.2011.576238	study_information	NA	2	ct_yn	Yes
10.1185/03007995.2011.576238	study_information	NA	2	nct	NCT00481247
10.1185/03007995.2011.576238	study_information	NA	2	country_study	international
10.1185/03007995.2011.576238	study_information	NA	2	ct_phase	3
10.1185/03007995.2011.576238	study_information	NA	2	ct_arms	2 or more
10.1185/03007995.2014.977992	general_information	NA	NA	condition_name	chronic myeloid leukemia in chronic phase
10.1185/03007995.2014.977992	general_information	NA	NA	country_first_author	usa
10.1185/03007995.2014.977992	general_information	NA	NA	country_last_author	usa
10.1185/03007995.2014.977992	general_information	NA	NA	positions	Academic, Pharmaceutical Industry, Private Data Analysis Company
10.1185/03007995.2014.977992	general_information	NA	NA	methodologist_yn	Yes
10.1185/03007995.2014.977992	general_information	NA	NA	funding_source	Pharmaceutical Industry
10.1185/03007995.2014.977992	general_information	NA	NA	pharmaceutical_ties_yn	Yes
10.1185/03007995.2014.977992	general_information	NA	NA	systematic_review_yn	No
10.1185/03007995.2014.977992	methodology	1	NA	outcome_name	major molecular response by 12 months
10.1185/03007995.2014.977992	methodology	1	NA	outcome_short_name	Major Molecular Response
10.1185/03007995.2014.977992	methodology	1	NA	outcome_variable_type	Binary (eg rates)
10.1185/03007995.2014.977992	methodology	1	NA	treatment_name_ipd	nilotinib
10.1185/03007995.2014.977992	methodology	1	NA	studies_number_ipd	1
10.1185/03007995.2014.977992	methodology	1	NA	treatment_name_nonipd	dasatinib
10.1185/03007995.2014.977992	methodology	1	NA	studies_number_nonipd	2
10.1185/03007995.2014.977992	methodology	1	NA	paic_type	MAIC
10.1185/03007995.2014.977992	methodology	1	NA	anchored_yn	Yes
10.1185/03007995.2014.977992	methodology	1	NA	paic_form	Simple (ie treatments effects extracted from two studies)
10.1185/03007995.2014.977992	methodology	1	NA	primary_outcome_yn	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.1185/03007995.2014.977992	methodology	1	NA	variables_selection_justification	Nothing mentioned, not reported
10.1185/03007995.2014.977992	methodology	1	NA	pf_yn	No discussion (in the main text) of the status of prognostic factors of the variables
10.1185/03007995.2014.977992	methodology	1	NA	tem_yn	No discussion (in the main text) of the status of treatment-effect modifiers of the variables
10.1185/03007995.2014.977992	methodology	1	NA	adjustment_model_details_yn	No
10.1185/03007995.2014.977992	methodology	1	NA	scale_choice_yn	No
10.1185/03007995.2014.977992	results	1	NA	contrast_effect_type	Rate difference
10.1185/03007995.2014.977992	results	1	NA	direction_benefit	superior
10.1185/03007995.2014.977992	results	1	NA	ss_ttt_nonipd	259
10.1185/03007995.2014.977992	results	1	NA	ss_ttt_ipd	278
10.1185/03007995.2014.977992	results	1	NA	ss_adjusted_ttt_ipd	NA
10.1185/03007995.2014.977992	results	1	NA	weights_yn	Not mentioned
10.1185/03007995.2014.977992	results	1	NA	covariates_yn	Yes
10.1185/03007995.2014.977992	results	1	NA	covariates_n	5
10.1185/03007995.2014.977992	results	1	NA	covariates_names	Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Race/ethnicity, Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...)
10.1185/03007995.2014.977992	results	1	NA	contrast_effect_direction	Numerator if ratio, or left side if difference
10.1185/03007995.2014.977992	results	1	NA	contrast_effect_unadjusted_value	NA
10.1185/03007995.2014.977992	results	1	NA	contrast_effect_unadjusted_pvalci	NA
10.1185/03007995.2014.977992	results	1	NA	contrast_effect_adjusted_value	11.70
10.1185/03007995.2014.977992	results	1	NA	contrast_effect_adjusted_pvalci	0.045
10.1185/03007995.2014.977992	results	1	NA	adjustment_geographical	NA
10.1185/03007995.2014.977992	results	1	NA	ss_total_ipd	NA
10.1185/03007995.2014.977992	results	1	NA	ss_adjusted_total_ipd	NA
10.1185/03007995.2014.977992	results	1	NA	ss_total_nonipd	NA
10.1185/03007995.2014.977992	results	1	NA	ss_anchor_nonipd	260
10.1185/03007995.2014.977992	results	1	NA	ss_anchor_ipd	282
10.1185/03007995.2014.977992	results	1	NA	ss_adjusted_anchor_ipd	NA
10.1185/03007995.2014.977992	results	1	NA	effect_cutoff	0
10.1185/03007995.2014.977992	results	1	NA	adjusted_pval	0.045
10.1185/03007995.2014.977992	results	1	NA	adjusted_num_pval	0.045
10.1185/03007995.2014.977992	results	1	NA	adjusted_significant	TRUE
10.1185/03007995.2014.977992	study_information	NA	1	ipd_yn	Yes
10.1185/03007995.2014.977992	study_information	NA	1	ct_yn	Yes
10.1185/03007995.2014.977992	study_information	NA	1	nct	NCT00471497
10.1185/03007995.2014.977992	study_information	NA	1	country_study	international
10.1185/03007995.2014.977992	study_information	NA	1	ct_phase	3
10.1185/03007995.2014.977992	study_information	NA	1	ct_arms	2 or more
10.1185/03007995.2014.977992	study_information	NA	2	ipd_yn	No
10.1185/03007995.2014.977992	study_information	NA	2	ct_yn	Yes
10.1185/03007995.2014.977992	study_information	NA	2	nct	NCT00481247
10.1185/03007995.2014.977992	study_information	NA	2	country_study	international
10.1185/03007995.2014.977992	study_information	NA	2	ct_phase	3
10.1185/03007995.2014.977992	study_information	NA	2	ct_arms	2 or more
10.1185/03007995.2015.1106934	general_information	NA	NA	condition_name	genotype 4 hepatitis c virus (hcv) infection
10.1185/03007995.2015.1106934	general_information	NA	NA	country_first_author	belgium
10.1185/03007995.2015.1106934	general_information	NA	NA	country_last_author	uk
10.1185/03007995.2015.1106934	general_information	NA	NA	positions	Pharmaceutical Industry, Private Data Analysis Company
10.1185/03007995.2015.1106934	general_information	NA	NA	methodologist_yn	Yes
10.1185/03007995.2015.1106934	general_information	NA	NA	funding_source	Pharmaceutical Industry
10.1185/03007995.2015.1106934	general_information	NA	NA	pharmaceutical_ties_yn	Yes
10.1185/03007995.2015.1106934	general_information	NA	NA	systematic_review_yn	Yes
10.1185/03007995.2015.1106934	methodology	1	NA	outcome_name	sustained viral response
10.1185/03007995.2015.1106934	methodology	1	NA	outcome_short_name	SVR rate
10.1185/03007995.2015.1106934	methodology	1	NA	outcome_variable_type	Binary (eg rates)
10.1185/03007995.2015.1106934	methodology	1	NA	treatment_name_ipd	simeprevir + peginterferon alfa-2a + ribavirin
10.1185/03007995.2015.1106934	methodology	1	NA	studies_number_ipd	1
10.1185/03007995.2015.1106934	methodology	1	NA	treatment_name_nonipd	peginterferon alfa-2a + ribavirin
10.1185/03007995.2015.1106934	methodology	1	NA	studies_number_nonipd	2
10.1185/03007995.2015.1106934	methodology	1	NA	paic_type	MAIC
10.1185/03007995.2015.1106934	methodology	1	NA	anchored_yn	No
10.1185/03007995.2015.1106934	methodology	1	NA	paic_form	Simple (ie treatments effects extracted from two studies)
10.1185/03007995.2015.1106934	methodology	1	NA	primary_outcome_yn	Yes
10.1185/03007995.2015.1106934	methodology	1	NA	variables_selection_justification	A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion)
10.1185/03007995.2015.1106934	methodology	1	NA	pf_yn	No
10.1185/03007995.2015.1106934	methodology	1	NA	tem_yn	Yes
10.1185/03007995.2015.1106934	methodology	1	NA	adjustment_model_details_yn	No
10.1185/03007995.2015.1106934	methodology	1	NA	scale_choice_yn	No
10.1185/03007995.2015.1106934	methodology	2	NA	outcome_name	sustained viral response
10.1185/03007995.2015.1106934	methodology	2	NA	outcome_short_name	SVR rate
10.1185/03007995.2015.1106934	methodology	2	NA	outcome_variable_type	Binary (eg rates)
10.1185/03007995.2015.1106934	methodology	2	NA	treatment_name_ipd	simeprevir + peginterferon alfa-2a + ribavirin
10.1185/03007995.2015.1106934	methodology	2	NA	studies_number_ipd	1
10.1185/03007995.2015.1106934	methodology	2	NA	treatment_name_nonipd	peginterferon alfa-2a + ribavirin
10.1185/03007995.2015.1106934	methodology	2	NA	studies_number_nonipd	3
10.1185/03007995.2015.1106934	methodology	2	NA	paic_type	MAIC
10.1185/03007995.2015.1106934	methodology	2	NA	anchored_yn	No
10.1185/03007995.2015.1106934	methodology	2	NA	paic_form	Simple (ie treatments effects extracted from two studies)
10.1185/03007995.2015.1106934	methodology	2	NA	primary_outcome_yn	Yes
10.1185/03007995.2015.1106934	methodology	2	NA	variables_selection_justification	A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion)
10.1185/03007995.2015.1106934	methodology	2	NA	pf_yn	No
10.1185/03007995.2015.1106934	methodology	2	NA	tem_yn	Yes
10.1185/03007995.2015.1106934	methodology	2	NA	adjustment_model_details_yn	No
10.1185/03007995.2015.1106934	methodology	2	NA	scale_choice_yn	No
10.1185/03007995.2015.1106934	methodology	3	NA	outcome_name	sustained viral response
10.1185/03007995.2015.1106934	methodology	3	NA	outcome_short_name	SVR rate
10.1185/03007995.2015.1106934	methodology	3	NA	outcome_variable_type	Binary (eg rates)
10.1185/03007995.2015.1106934	methodology	3	NA	treatment_name_ipd	simeprevir + peginterferon alfa-2a + ribavirin
10.1185/03007995.2015.1106934	methodology	3	NA	studies_number_ipd	1
10.1185/03007995.2015.1106934	methodology	3	NA	treatment_name_nonipd	peginterferon alfa-2a + ribavirin
10.1185/03007995.2015.1106934	methodology	3	NA	studies_number_nonipd	4
10.1185/03007995.2015.1106934	methodology	3	NA	paic_type	MAIC
10.1185/03007995.2015.1106934	methodology	3	NA	anchored_yn	No
10.1185/03007995.2015.1106934	methodology	3	NA	paic_form	Simple (ie treatments effects extracted from two studies)
10.1185/03007995.2015.1106934	methodology	3	NA	primary_outcome_yn	Yes
10.1185/03007995.2015.1106934	methodology	3	NA	variables_selection_justification	A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion)
10.1185/03007995.2015.1106934	methodology	3	NA	pf_yn	No
10.1185/03007995.2015.1106934	methodology	3	NA	tem_yn	Yes
10.1185/03007995.2015.1106934	methodology	3	NA	adjustment_model_details_yn	No
10.1185/03007995.2015.1106934	methodology	3	NA	scale_choice_yn	No
10.1185/03007995.2015.1106934	methodology	4	NA	outcome_name	sustained viral response
10.1185/03007995.2015.1106934	methodology	4	NA	outcome_short_name	SVR rate
10.1185/03007995.2015.1106934	methodology	4	NA	outcome_variable_type	Binary (eg rates)
10.1185/03007995.2015.1106934	methodology	4	NA	treatment_name_ipd	simeprevir + peginterferon alfa-2a + ribavirin
10.1185/03007995.2015.1106934	methodology	4	NA	studies_number_ipd	1
10.1185/03007995.2015.1106934	methodology	4	NA	treatment_name_nonipd	peginterferon alfa-2a + ribavirin
10.1185/03007995.2015.1106934	methodology	4	NA	studies_number_nonipd	5
10.1185/03007995.2015.1106934	methodology	4	NA	paic_type	MAIC
10.1185/03007995.2015.1106934	methodology	4	NA	anchored_yn	No
10.1185/03007995.2015.1106934	methodology	4	NA	paic_form	Simple (ie treatments effects extracted from two studies)
10.1185/03007995.2015.1106934	methodology	4	NA	primary_outcome_yn	Yes
10.1185/03007995.2015.1106934	methodology	4	NA	variables_selection_justification	A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion)
10.1185/03007995.2015.1106934	methodology	4	NA	pf_yn	No
10.1185/03007995.2015.1106934	methodology	4	NA	tem_yn	Yes
10.1185/03007995.2015.1106934	methodology	4	NA	adjustment_model_details_yn	No
10.1185/03007995.2015.1106934	methodology	4	NA	scale_choice_yn	No
10.1185/03007995.2015.1106934	methodology	5	NA	outcome_name	sustained viral response
10.1185/03007995.2015.1106934	methodology	5	NA	outcome_short_name	SVR rate
10.1185/03007995.2015.1106934	methodology	5	NA	outcome_variable_type	Binary (eg rates)
10.1185/03007995.2015.1106934	methodology	5	NA	treatment_name_ipd	simeprevir + peginterferon alfa-2a + ribavirin
10.1185/03007995.2015.1106934	methodology	5	NA	studies_number_ipd	1
10.1185/03007995.2015.1106934	methodology	5	NA	treatment_name_nonipd	peginterferon alfa-2a + ribavirin
10.1185/03007995.2015.1106934	methodology	5	NA	studies_number_nonipd	6
10.1185/03007995.2015.1106934	methodology	5	NA	paic_type	MAIC
10.1185/03007995.2015.1106934	methodology	5	NA	anchored_yn	No
10.1185/03007995.2015.1106934	methodology	5	NA	paic_form	Simple (ie treatments effects extracted from two studies)
10.1185/03007995.2015.1106934	methodology	5	NA	primary_outcome_yn	Yes
10.1185/03007995.2015.1106934	methodology	5	NA	variables_selection_justification	A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion)
10.1185/03007995.2015.1106934	methodology	5	NA	pf_yn	No
10.1185/03007995.2015.1106934	methodology	5	NA	tem_yn	Yes
10.1185/03007995.2015.1106934	methodology	5	NA	adjustment_model_details_yn	No
10.1185/03007995.2015.1106934	methodology	5	NA	scale_choice_yn	No
10.1185/03007995.2015.1106934	results	1	NA	contrast_effect_type	OR
10.1185/03007995.2015.1106934	results	1	NA	direction_benefit	superior
10.1185/03007995.2015.1106934	results	1	NA	ss_ttt_nonipd	30
10.1185/03007995.2015.1106934	results	1	NA	ss_ttt_ipd	35
10.1185/03007995.2015.1106934	results	1	NA	ss_adjusted_ttt_ipd	29
10.1185/03007995.2015.1106934	results	1	NA	weights_yn	Not mentioned
10.1185/03007995.2015.1106934	results	1	NA	covariates_yn	Yes
10.1185/03007995.2015.1106934	results	1	NA	covariates_n	5
10.1185/03007995.2015.1106934	results	1	NA	covariates_names	Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Other(s)
10.1185/03007995.2015.1106934	results	1	NA	contrast_effect_direction	Numerator if ratio, or left side if difference
10.1185/03007995.2015.1106934	results	1	NA	contrast_effect_unadjusted_value	NA
10.1185/03007995.2015.1106934	results	1	NA	contrast_effect_unadjusted_pvalci	NA
10.1185/03007995.2015.1106934	results	1	NA	contrast_effect_adjusted_value	3.28
10.1185/03007995.2015.1106934	results	1	NA	contrast_effect_adjusted_pvalci	NA
10.1185/03007995.2015.1106934	results	1	NA	adjustment_geographical	No
10.1185/03007995.2015.1106934	results	1	NA	ss_total_ipd	NA
10.1185/03007995.2015.1106934	results	1	NA	ss_adjusted_total_ipd	NA
10.1185/03007995.2015.1106934	results	1	NA	ss_total_nonipd	NA
10.1185/03007995.2015.1106934	results	1	NA	ss_anchor_nonipd	NA
10.1185/03007995.2015.1106934	results	1	NA	ss_anchor_ipd	NA
10.1185/03007995.2015.1106934	results	1	NA	ss_adjusted_anchor_ipd	NA
10.1185/03007995.2015.1106934	results	1	NA	effect_cutoff	1
10.1185/03007995.2015.1106934	results	2	NA	contrast_effect_type	OR
10.1185/03007995.2015.1106934	results	2	NA	direction_benefit	superior
10.1185/03007995.2015.1106934	results	2	NA	ss_ttt_nonipd	18
10.1185/03007995.2015.1106934	results	2	NA	ss_ttt_ipd	35
10.1185/03007995.2015.1106934	results	2	NA	ss_adjusted_ttt_ipd	15
10.1185/03007995.2015.1106934	results	2	NA	weights_yn	Not mentioned
10.1185/03007995.2015.1106934	results	2	NA	covariates_yn	Yes
10.1185/03007995.2015.1106934	results	2	NA	covariates_n	5
10.1185/03007995.2015.1106934	results	2	NA	covariates_names	Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Other(s)
10.1185/03007995.2015.1106934	results	2	NA	contrast_effect_direction	Numerator if ratio, or left side if difference
10.1185/03007995.2015.1106934	results	2	NA	contrast_effect_unadjusted_value	NA
10.1185/03007995.2015.1106934	results	2	NA	contrast_effect_unadjusted_pvalci	NA
10.1185/03007995.2015.1106934	results	2	NA	contrast_effect_adjusted_value	4.26
10.1185/03007995.2015.1106934	results	2	NA	contrast_effect_adjusted_pvalci	NA
10.1185/03007995.2015.1106934	results	2	NA	adjustment_geographical	No
10.1185/03007995.2015.1106934	results	2	NA	ss_total_ipd	NA
10.1185/03007995.2015.1106934	results	2	NA	ss_adjusted_total_ipd	NA
10.1185/03007995.2015.1106934	results	2	NA	ss_total_nonipd	NA
10.1185/03007995.2015.1106934	results	2	NA	ss_anchor_nonipd	NA
10.1185/03007995.2015.1106934	results	2	NA	ss_anchor_ipd	NA
10.1185/03007995.2015.1106934	results	2	NA	ss_adjusted_anchor_ipd	NA
10.1185/03007995.2015.1106934	results	2	NA	effect_cutoff	1
10.1185/03007995.2015.1106934	results	3	NA	contrast_effect_type	OR
10.1185/03007995.2015.1106934	results	3	NA	direction_benefit	superior
10.1185/03007995.2015.1106934	results	3	NA	ss_ttt_nonipd	95
10.1185/03007995.2015.1106934	results	3	NA	ss_ttt_ipd	30
10.1185/03007995.2015.1106934	results	3	NA	ss_adjusted_ttt_ipd	14
10.1185/03007995.2015.1106934	results	3	NA	weights_yn	Not mentioned
10.1185/03007995.2015.1106934	results	3	NA	covariates_yn	Yes
10.1185/03007995.2015.1106934	results	3	NA	covariates_n	2
10.1185/03007995.2015.1106934	results	3	NA	covariates_names	Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease)
10.1185/03007995.2015.1106934	results	3	NA	contrast_effect_direction	Numerator if ratio, or left side if difference
10.1185/03007995.2015.1106934	results	3	NA	contrast_effect_unadjusted_value	NA
10.1185/03007995.2015.1106934	results	3	NA	contrast_effect_unadjusted_pvalci	NA
10.1185/03007995.2015.1106934	results	3	NA	contrast_effect_adjusted_value	10.02
10.1185/03007995.2015.1106934	results	3	NA	contrast_effect_adjusted_pvalci	NA
10.1185/03007995.2015.1106934	results	3	NA	adjustment_geographical	NA
10.1185/03007995.2015.1106934	results	3	NA	ss_total_ipd	NA
10.1185/03007995.2015.1106934	results	3	NA	ss_adjusted_total_ipd	NA
10.1185/03007995.2015.1106934	results	3	NA	ss_total_nonipd	NA
10.1185/03007995.2015.1106934	results	3	NA	ss_anchor_nonipd	NA
10.1185/03007995.2015.1106934	results	3	NA	ss_anchor_ipd	NA
10.1185/03007995.2015.1106934	results	3	NA	ss_adjusted_anchor_ipd	NA
10.1185/03007995.2015.1106934	results	3	NA	effect_cutoff	1
10.1185/03007995.2015.1106934	results	4	NA	contrast_effect_type	OR
10.1185/03007995.2015.1106934	results	4	NA	direction_benefit	superior
10.1185/03007995.2015.1106934	results	4	NA	ss_ttt_nonipd	40
10.1185/03007995.2015.1106934	results	4	NA	ss_ttt_ipd	35
10.1185/03007995.2015.1106934	results	4	NA	ss_adjusted_ttt_ipd	26
10.1185/03007995.2015.1106934	results	4	NA	weights_yn	Not mentioned
10.1185/03007995.2015.1106934	results	4	NA	covariates_yn	Yes
10.1185/03007995.2015.1106934	results	4	NA	covariates_n	2
10.1185/03007995.2015.1106934	results	4	NA	covariates_names	Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease)
10.1185/03007995.2015.1106934	results	4	NA	contrast_effect_direction	Numerator if ratio, or left side if difference
10.1185/03007995.2015.1106934	results	4	NA	contrast_effect_unadjusted_value	NA
10.1185/03007995.2015.1106934	results	4	NA	contrast_effect_unadjusted_pvalci	NA
10.1185/03007995.2015.1106934	results	4	NA	contrast_effect_adjusted_value	6.69
10.1185/03007995.2015.1106934	results	4	NA	contrast_effect_adjusted_pvalci	NA
10.1185/03007995.2015.1106934	results	4	NA	adjustment_geographical	NA
10.1185/03007995.2015.1106934	results	4	NA	ss_total_ipd	NA
10.1185/03007995.2015.1106934	results	4	NA	ss_adjusted_total_ipd	NA
10.1185/03007995.2015.1106934	results	4	NA	ss_total_nonipd	NA
10.1185/03007995.2015.1106934	results	4	NA	ss_anchor_nonipd	NA
10.1185/03007995.2015.1106934	results	4	NA	ss_anchor_ipd	NA
10.1185/03007995.2015.1106934	results	4	NA	ss_adjusted_anchor_ipd	NA
10.1185/03007995.2015.1106934	results	4	NA	effect_cutoff	1
10.1185/03007995.2015.1106934	results	5	NA	contrast_effect_type	OR
10.1185/03007995.2015.1106934	results	5	NA	direction_benefit	superior
10.1185/03007995.2015.1106934	results	5	NA	ss_ttt_nonipd	109
10.1185/03007995.2015.1106934	results	5	NA	ss_ttt_ipd	19
10.1185/03007995.2015.1106934	results	5	NA	ss_adjusted_ttt_ipd	17
10.1185/03007995.2015.1106934	results	5	NA	weights_yn	Not mentioned
10.1185/03007995.2015.1106934	results	5	NA	covariates_yn	Yes
10.1185/03007995.2015.1106934	results	5	NA	covariates_n	2
10.1185/03007995.2015.1106934	results	5	NA	covariates_names	Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease)
10.1185/03007995.2015.1106934	results	5	NA	contrast_effect_direction	Numerator if ratio, or left side if difference
10.1185/03007995.2015.1106934	results	5	NA	contrast_effect_unadjusted_value	NA
10.1185/03007995.2015.1106934	results	5	NA	contrast_effect_unadjusted_pvalci	NA
10.1185/03007995.2015.1106934	results	5	NA	contrast_effect_adjusted_value	5.43
10.1185/03007995.2015.1106934	results	5	NA	contrast_effect_adjusted_pvalci	NA
10.1185/03007995.2015.1106934	results	5	NA	adjustment_geographical	NA
10.1185/03007995.2015.1106934	results	5	NA	ss_total_ipd	NA
10.1185/03007995.2015.1106934	results	5	NA	ss_adjusted_total_ipd	NA
10.1185/03007995.2015.1106934	results	5	NA	ss_total_nonipd	NA
10.1185/03007995.2015.1106934	results	5	NA	ss_anchor_nonipd	NA
10.1185/03007995.2015.1106934	results	5	NA	ss_anchor_ipd	NA
10.1185/03007995.2015.1106934	results	5	NA	ss_adjusted_anchor_ipd	NA
10.1185/03007995.2015.1106934	results	5	NA	effect_cutoff	1
10.1185/03007995.2015.1106934	study_information	NA	1	ipd_yn	Yes
10.1185/03007995.2015.1106934	study_information	NA	1	ct_yn	Yes
10.1185/03007995.2015.1106934	study_information	NA	1	nct	NCT01567735
10.1185/03007995.2015.1106934	study_information	NA	1	country_study	international
10.1185/03007995.2015.1106934	study_information	NA	1	ct_phase	3
10.1185/03007995.2015.1106934	study_information	NA	1	ct_arms	1
10.1185/03007995.2015.1106934	study_information	NA	2	ipd_yn	No
10.1185/03007995.2015.1106934	study_information	NA	2	ct_yn	Yes
10.1185/03007995.2015.1106934	study_information	NA	2	data_source_name	varghese et al. (2009)
10.1185/03007995.2015.1106934	study_information	NA	2	country_study	kuwait
10.1185/03007995.2015.1106934	study_information	NA	2	ct_arms	1
10.1185/03007995.2015.1106934	study_information	NA	3	ipd_yn	No
10.1185/03007995.2015.1106934	study_information	NA	3	ct_yn	Yes
10.1185/03007995.2015.1106934	study_information	NA	3	data_source_name	rumi et al. (2010)
10.1185/03007995.2015.1106934	study_information	NA	3	country_study	italy
10.1185/03007995.2015.1106934	study_information	NA	3	ct_arms	2 or more
10.1185/03007995.2015.1106934	study_information	NA	4	ipd_yn	No
10.1185/03007995.2015.1106934	study_information	NA	4	ct_yn	Yes
10.1185/03007995.2015.1106934	study_information	NA	4	data_source_name	el makhzangy et al. (2009)
10.1185/03007995.2015.1106934	study_information	NA	4	country_study	egypt
10.1185/03007995.2015.1106934	study_information	NA	4	ct_arms	1
10.1185/03007995.2015.1106934	study_information	NA	5	ipd_yn	No
10.1185/03007995.2015.1106934	study_information	NA	5	ct_yn	Yes
10.1185/03007995.2015.1106934	study_information	NA	5	nct	NCT00421434
10.1185/03007995.2015.1106934	study_information	NA	5	country_study	egypt
10.1185/03007995.2015.1106934	study_information	NA	5	ct_phase	2, 3
10.1185/03007995.2015.1106934	study_information	NA	5	ct_arms	2 or more
10.1185/03007995.2015.1106934	study_information	NA	6	ipd_yn	No
10.1185/03007995.2015.1106934	study_information	NA	6	ct_yn	Yes
10.1185/03007995.2015.1106934	study_information	NA	6	nct	NCT00502099
10.1185/03007995.2015.1106934	study_information	NA	6	country_study	egypt
10.1185/03007995.2015.1106934	study_information	NA	6	ct_phase	4
10.1185/03007995.2015.1106934	study_information	NA	6	ct_arms	2 or more
10.1186/2162-3619-2-32	general_information	NA	NA	condition_name	advanced pancreatic neuroendocrine tumor
10.1186/2162-3619-2-32	general_information	NA	NA	country_first_author	usa
10.1186/2162-3619-2-32	general_information	NA	NA	country_last_author	canada
10.1186/2162-3619-2-32	general_information	NA	NA	positions	Academic, Pharmaceutical Industry, Private Data Analysis Company
10.1186/2162-3619-2-32	general_information	NA	NA	methodologist_yn	Yes
10.1186/2162-3619-2-32	general_information	NA	NA	funding_source	Pharmaceutical Industry
10.1186/2162-3619-2-32	general_information	NA	NA	pharmaceutical_ties_yn	Yes
10.1186/2162-3619-2-32	general_information	NA	NA	systematic_review_yn	No
10.1186/2162-3619-2-32	methodology	1	NA	outcome_name	overall survival
10.1186/2162-3619-2-32	methodology	1	NA	outcome_short_name	Overall Survival
10.1186/2162-3619-2-32	methodology	1	NA	outcome_variable_type	Time-to-event
10.1186/2162-3619-2-32	methodology	1	NA	treatment_name_ipd	everolimus
10.1186/2162-3619-2-32	methodology	1	NA	studies_number_ipd	1
10.1186/2162-3619-2-32	methodology	1	NA	treatment_name_nonipd	sunitinib
10.1186/2162-3619-2-32	methodology	1	NA	studies_number_nonipd	2
10.1186/2162-3619-2-32	methodology	1	NA	paic_type	MAIC
10.1186/2162-3619-2-32	methodology	1	NA	anchored_yn	No
10.1186/2162-3619-2-32	methodology	1	NA	paic_form	Simple (ie treatments effects extracted from two studies)
10.1186/2162-3619-2-32	methodology	1	NA	primary_outcome_yn	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.1186/2162-3619-2-32	methodology	1	NA	variables_selection_justification	Nothing mentioned, not reported
10.1186/2162-3619-2-32	methodology	1	NA	pf_yn	No discussion (in the main text) of the status of prognostic factors of the variables
10.1186/2162-3619-2-32	methodology	1	NA	tem_yn	No discussion (in the main text) of the status of treatment-effect modifiers of the variables
10.1186/2162-3619-2-32	methodology	1	NA	adjustment_model_details_yn	No
10.1186/2162-3619-2-32	methodology	1	NA	scale_choice_yn	No
10.1186/2162-3619-2-32	methodology	2	NA	outcome_name	overall survival
10.1186/2162-3619-2-32	methodology	2	NA	outcome_short_name	Overall Survival
10.1186/2162-3619-2-32	methodology	2	NA	outcome_variable_type	Time-to-event
10.1186/2162-3619-2-32	methodology	2	NA	treatment_name_ipd	everolimus
10.1186/2162-3619-2-32	methodology	2	NA	studies_number_ipd	1
10.1186/2162-3619-2-32	methodology	2	NA	treatment_name_nonipd	placebo
10.1186/2162-3619-2-32	methodology	2	NA	studies_number_nonipd	2
10.1186/2162-3619-2-32	methodology	2	NA	paic_type	MAIC
10.1186/2162-3619-2-32	methodology	2	NA	anchored_yn	No
10.1186/2162-3619-2-32	methodology	2	NA	paic_form	Simple (ie treatments effects extracted from two studies)
10.1186/2162-3619-2-32	methodology	2	NA	primary_outcome_yn	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.1186/2162-3619-2-32	methodology	2	NA	variables_selection_justification	Nothing mentioned, not reported
10.1186/2162-3619-2-32	methodology	2	NA	pf_yn	No discussion (in the main text) of the status of prognostic factors of the variables
10.1186/2162-3619-2-32	methodology	2	NA	tem_yn	No discussion (in the main text) of the status of treatment-effect modifiers of the variables
10.1186/2162-3619-2-32	methodology	2	NA	adjustment_model_details_yn	No
10.1186/2162-3619-2-32	methodology	2	NA	scale_choice_yn	No
10.1186/2162-3619-2-32	methodology	3	NA	outcome_name	progression-free survival
10.1186/2162-3619-2-32	methodology	3	NA	outcome_short_name	Progression-free Survival
10.1186/2162-3619-2-32	methodology	3	NA	outcome_variable_type	Time-to-event
10.1186/2162-3619-2-32	methodology	3	NA	treatment_name_ipd	everolimus
10.1186/2162-3619-2-32	methodology	3	NA	studies_number_ipd	1
10.1186/2162-3619-2-32	methodology	3	NA	treatment_name_nonipd	sunitinib
10.1186/2162-3619-2-32	methodology	3	NA	studies_number_nonipd	2
10.1186/2162-3619-2-32	methodology	3	NA	paic_type	MAIC
10.1186/2162-3619-2-32	methodology	3	NA	anchored_yn	Yes
10.1186/2162-3619-2-32	methodology	3	NA	paic_form	Simple (ie treatments effects extracted from two studies)
10.1186/2162-3619-2-32	methodology	3	NA	primary_outcome_yn	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.1186/2162-3619-2-32	methodology	3	NA	variables_selection_justification	Nothing mentioned, not reported
10.1186/2162-3619-2-32	methodology	3	NA	pf_yn	No discussion (in the main text) of the status of prognostic factors of the variables
10.1186/2162-3619-2-32	methodology	3	NA	tem_yn	No discussion (in the main text) of the status of treatment-effect modifiers of the variables
10.1186/2162-3619-2-32	methodology	3	NA	adjustment_model_details_yn	No
10.1186/2162-3619-2-32	methodology	3	NA	scale_choice_yn	No
10.1186/2162-3619-2-32	results	1	NA	contrast_effect_type	HR
10.1186/2162-3619-2-32	results	1	NA	direction_benefit	inferior
10.1186/2162-3619-2-32	results	1	NA	ss_ttt_nonipd	86
10.1186/2162-3619-2-32	results	1	NA	ss_ttt_ipd	207
10.1186/2162-3619-2-32	results	1	NA	ss_adjusted_ttt_ipd	NA
10.1186/2162-3619-2-32	results	1	NA	weights_yn	Not mentioned
10.1186/2162-3619-2-32	results	1	NA	covariates_yn	Yes
10.1186/2162-3619-2-32	results	1	NA	covariates_n	8
10.1186/2162-3619-2-32	results	1	NA	covariates_names	Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Past treatments for the disease of interest
10.1186/2162-3619-2-32	results	1	NA	contrast_effect_direction	Numerator if ratio, or left side if difference
10.1186/2162-3619-2-32	results	1	NA	contrast_effect_unadjusted_value	0.69
10.1186/2162-3619-2-32	results	1	NA	contrast_effect_unadjusted_pvalci	0.087
10.1186/2162-3619-2-32	results	1	NA	contrast_effect_adjusted_value	0.81
10.1186/2162-3619-2-32	results	1	NA	contrast_effect_adjusted_pvalci	0.383
10.1186/2162-3619-2-32	results	1	NA	adjustment_geographical	NA
10.1186/2162-3619-2-32	results	1	NA	ss_total_ipd	NA
10.1186/2162-3619-2-32	results	1	NA	ss_adjusted_total_ipd	NA
10.1186/2162-3619-2-32	results	1	NA	ss_total_nonipd	NA
10.1186/2162-3619-2-32	results	1	NA	ss_anchor_nonipd	NA
10.1186/2162-3619-2-32	results	1	NA	ss_anchor_ipd	NA
10.1186/2162-3619-2-32	results	1	NA	ss_adjusted_anchor_ipd	NA
10.1186/2162-3619-2-32	results	1	NA	effect_cutoff	1
10.1186/2162-3619-2-32	results	1	NA	unadjusted_pval	0.087
10.1186/2162-3619-2-32	results	1	NA	unadjusted_num_pval	0.087
10.1186/2162-3619-2-32	results	1	NA	unadjusted_significant	FALSE
10.1186/2162-3619-2-32	results	1	NA	adjusted_pval	0.383
10.1186/2162-3619-2-32	results	1	NA	adjusted_num_pval	0.383
10.1186/2162-3619-2-32	results	1	NA	adjusted_significant	FALSE
10.1186/2162-3619-2-32	results	2	NA	contrast_effect_type	HR
10.1186/2162-3619-2-32	results	2	NA	direction_benefit	inferior
10.1186/2162-3619-2-32	results	2	NA	ss_ttt_nonipd	85
10.1186/2162-3619-2-32	results	2	NA	ss_ttt_ipd	207
10.1186/2162-3619-2-32	results	2	NA	ss_adjusted_ttt_ipd	NA
10.1186/2162-3619-2-32	results	2	NA	weights_yn	Not mentioned
10.1186/2162-3619-2-32	results	2	NA	covariates_yn	Yes
10.1186/2162-3619-2-32	results	2	NA	covariates_n	8
10.1186/2162-3619-2-32	results	2	NA	covariates_names	Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Past treatments for the disease of interest
10.1186/2162-3619-2-32	results	2	NA	contrast_effect_direction	Numerator if ratio, or left side if difference
10.1186/2162-3619-2-32	results	2	NA	contrast_effect_unadjusted_value	0.53
10.1186/2162-3619-2-32	results	2	NA	contrast_effect_unadjusted_pvalci	0.002
10.1186/2162-3619-2-32	results	2	NA	contrast_effect_adjusted_value	0.61
10.1186/2162-3619-2-32	results	2	NA	contrast_effect_adjusted_pvalci	0.042
10.1186/2162-3619-2-32	results	2	NA	adjustment_geographical	NA
10.1186/2162-3619-2-32	results	2	NA	ss_total_ipd	NA
10.1186/2162-3619-2-32	results	2	NA	ss_adjusted_total_ipd	NA
10.1186/2162-3619-2-32	results	2	NA	ss_total_nonipd	NA
10.1186/2162-3619-2-32	results	2	NA	ss_anchor_nonipd	NA
10.1186/2162-3619-2-32	results	2	NA	ss_anchor_ipd	NA
10.1186/2162-3619-2-32	results	2	NA	ss_adjusted_anchor_ipd	NA
10.1186/2162-3619-2-32	results	2	NA	effect_cutoff	1
10.1186/2162-3619-2-32	results	2	NA	unadjusted_pval	0.002
10.1186/2162-3619-2-32	results	2	NA	unadjusted_num_pval	0.002
10.1186/2162-3619-2-32	results	2	NA	unadjusted_significant	TRUE
10.1186/2162-3619-2-32	results	2	NA	adjusted_pval	0.042
10.1186/2162-3619-2-32	results	2	NA	adjusted_num_pval	0.042
10.1186/2162-3619-2-32	results	2	NA	adjusted_significant	TRUE
10.1186/2162-3619-2-32	results	3	NA	contrast_effect_type	HR
10.1186/2162-3619-2-32	results	3	NA	direction_benefit	inferior
10.1186/2162-3619-2-32	results	3	NA	ss_ttt_nonipd	86
10.1186/2162-3619-2-32	results	3	NA	ss_ttt_ipd	207
10.1186/2162-3619-2-32	results	3	NA	ss_adjusted_ttt_ipd	NA
10.1186/2162-3619-2-32	results	3	NA	weights_yn	Not mentioned
10.1186/2162-3619-2-32	results	3	NA	covariates_yn	Yes
10.1186/2162-3619-2-32	results	3	NA	covariates_n	8
10.1186/2162-3619-2-32	results	3	NA	covariates_names	Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Past treatments for the disease of interest
10.1186/2162-3619-2-32	results	3	NA	contrast_effect_direction	Numerator if ratio, or left side if difference
10.1186/2162-3619-2-32	results	3	NA	contrast_effect_unadjusted_value	0.9
10.1186/2162-3619-2-32	results	3	NA	contrast_effect_unadjusted_pvalci	0.695
10.1186/2162-3619-2-32	results	3	NA	contrast_effect_adjusted_value	0.84
10.1186/2162-3619-2-32	results	3	NA	contrast_effect_adjusted_pvalci	0.578
10.1186/2162-3619-2-32	results	3	NA	adjustment_geographical	NA
10.1186/2162-3619-2-32	results	3	NA	ss_total_ipd	394
10.1186/2162-3619-2-32	results	3	NA	ss_adjusted_total_ipd	NA
10.1186/2162-3619-2-32	results	3	NA	ss_total_nonipd	NA
10.1186/2162-3619-2-32	results	3	NA	ss_anchor_nonipd	85
10.1186/2162-3619-2-32	results	3	NA	ss_anchor_ipd	203
10.1186/2162-3619-2-32	results	3	NA	ss_adjusted_anchor_ipd	NA
10.1186/2162-3619-2-32	results	3	NA	effect_cutoff	1
10.1186/2162-3619-2-32	results	3	NA	unadjusted_pval	0.695
10.1186/2162-3619-2-32	results	3	NA	unadjusted_num_pval	0.695
10.1186/2162-3619-2-32	results	3	NA	unadjusted_significant	FALSE
10.1186/2162-3619-2-32	results	3	NA	adjusted_pval	0.578
10.1186/2162-3619-2-32	results	3	NA	adjusted_num_pval	0.578
10.1186/2162-3619-2-32	results	3	NA	adjusted_significant	FALSE
10.1186/2162-3619-2-32	study_information	NA	1	ipd_yn	Yes
10.1186/2162-3619-2-32	study_information	NA	1	ct_yn	Yes
10.1186/2162-3619-2-32	study_information	NA	1	nct	NCT00510068
10.1186/2162-3619-2-32	study_information	NA	1	country_study	international
10.1186/2162-3619-2-32	study_information	NA	1	ct_phase	3
10.1186/2162-3619-2-32	study_information	NA	1	ct_arms	2 or more
10.1186/2162-3619-2-32	study_information	NA	2	ipd_yn	No
10.1186/2162-3619-2-32	study_information	NA	2	ct_yn	Yes
10.1186/2162-3619-2-32	study_information	NA	2	nct	NCT00428597
10.1186/2162-3619-2-32	study_information	NA	2	country_study	international
10.1186/2162-3619-2-32	study_information	NA	2	ct_phase	3
10.1186/2162-3619-2-32	study_information	NA	2	ct_arms	2 or more
10.1186/s12885-018-5157-0	general_information	NA	NA	condition_name	metastatic renal cell carcinoma
10.1186/s12885-018-5157-0	general_information	NA	NA	country_first_author	canada
10.1186/s12885-018-5157-0	general_information	NA	NA	country_last_author	uk
10.1186/s12885-018-5157-0	general_information	NA	NA	positions	Academic, Pharmaceutical Industry, Private Data Analysis Company
10.1186/s12885-018-5157-0	general_information	NA	NA	methodologist_yn	Yes
10.1186/s12885-018-5157-0	general_information	NA	NA	funding_source	Pharmaceutical Industry
10.1186/s12885-018-5157-0	general_information	NA	NA	pharmaceutical_ties_yn	Yes
10.1186/s12885-018-5157-0	general_information	NA	NA	systematic_review_yn	No
10.1186/s12885-018-5157-0	methodology	1	NA	outcome_name	progression-free survival
10.1186/s12885-018-5157-0	methodology	1	NA	outcome_short_name	Progression-free Survival
10.1186/s12885-018-5157-0	methodology	1	NA	outcome_variable_type	Time-to-event
10.1186/s12885-018-5157-0	methodology	1	NA	treatment_name_ipd	axitinib
10.1186/s12885-018-5157-0	methodology	1	NA	studies_number_ipd	1
10.1186/s12885-018-5157-0	methodology	1	NA	treatment_name_nonipd	cabozantinib
10.1186/s12885-018-5157-0	methodology	1	NA	studies_number_nonipd	2
10.1186/s12885-018-5157-0	methodology	1	NA	paic_type	MAIC
10.1186/s12885-018-5157-0	methodology	1	NA	anchored_yn	No
10.1186/s12885-018-5157-0	methodology	1	NA	paic_form	Simple (ie treatments effects extracted from two studies)
10.1186/s12885-018-5157-0	methodology	1	NA	primary_outcome_yn	Yes
10.1186/s12885-018-5157-0	methodology	1	NA	variables_selection_justification	Nothing mentioned, not reported
10.1186/s12885-018-5157-0	methodology	1	NA	pf_yn	Yes
10.1186/s12885-018-5157-0	methodology	1	NA	tem_yn	No discussion (in the main text) of the status of treatment-effect modifiers of the variables
10.1186/s12885-018-5157-0	methodology	1	NA	adjustment_model_details_yn	No
10.1186/s12885-018-5157-0	methodology	1	NA	scale_choice_yn	No
10.1186/s12885-018-5157-0	methodology	2	NA	outcome_name	progression-free survival
10.1186/s12885-018-5157-0	methodology	2	NA	outcome_short_name	Progression-free Survival
10.1186/s12885-018-5157-0	methodology	2	NA	outcome_variable_type	Time-to-event
10.1186/s12885-018-5157-0	methodology	2	NA	treatment_name_ipd	axitinib
10.1186/s12885-018-5157-0	methodology	2	NA	studies_number_ipd	1
10.1186/s12885-018-5157-0	methodology	2	NA	treatment_name_nonipd	everolimus
10.1186/s12885-018-5157-0	methodology	2	NA	studies_number_nonipd	2
10.1186/s12885-018-5157-0	methodology	2	NA	paic_type	MAIC
10.1186/s12885-018-5157-0	methodology	2	NA	anchored_yn	No
10.1186/s12885-018-5157-0	methodology	2	NA	paic_form	Simple (ie treatments effects extracted from two studies)
10.1186/s12885-018-5157-0	methodology	2	NA	primary_outcome_yn	Yes
10.1186/s12885-018-5157-0	methodology	2	NA	variables_selection_justification	Nothing mentioned, not reported
10.1186/s12885-018-5157-0	methodology	2	NA	pf_yn	Yes
10.1186/s12885-018-5157-0	methodology	2	NA	tem_yn	No discussion (in the main text) of the status of treatment-effect modifiers of the variables
10.1186/s12885-018-5157-0	methodology	2	NA	adjustment_model_details_yn	No
10.1186/s12885-018-5157-0	methodology	2	NA	scale_choice_yn	No
10.1186/s12885-018-5157-0	results	1	NA	contrast_effect_type	HR
10.1186/s12885-018-5157-0	results	1	NA	direction_benefit	inferior
10.1186/s12885-018-5157-0	results	1	NA	ss_ttt_nonipd	135
10.1186/s12885-018-5157-0	results	1	NA	ss_ttt_ipd	194
10.1186/s12885-018-5157-0	results	1	NA	ss_adjusted_ttt_ipd	104
10.1186/s12885-018-5157-0	results	1	NA	weights_yn	Not mentioned
10.1186/s12885-018-5157-0	results	1	NA	covariates_yn	Yes
10.1186/s12885-018-5157-0	results	1	NA	covariates_n	9
10.1186/s12885-018-5157-0	results	1	NA	covariates_names	Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Past treatments for the disease of interest, Other(s)
10.1186/s12885-018-5157-0	results	1	NA	contrast_effect_direction	Numerator if ratio, or left side if difference
10.1186/s12885-018-5157-0	results	1	NA	contrast_effect_unadjusted_value	NA
10.1186/s12885-018-5157-0	results	1	NA	contrast_effect_unadjusted_pvalci	NA
10.1186/s12885-018-5157-0	results	1	NA	contrast_effect_adjusted_value	1.15
10.1186/s12885-018-5157-0	results	1	NA	contrast_effect_adjusted_pvalci	0.423
10.1186/s12885-018-5157-0	results	1	NA	adjustment_geographical	Yes
10.1186/s12885-018-5157-0	results	1	NA	ss_total_ipd	NA
10.1186/s12885-018-5157-0	results	1	NA	ss_adjusted_total_ipd	NA
10.1186/s12885-018-5157-0	results	1	NA	ss_total_nonipd	NA
10.1186/s12885-018-5157-0	results	1	NA	ss_anchor_nonipd	NA
10.1186/s12885-018-5157-0	results	1	NA	ss_anchor_ipd	NA
10.1186/s12885-018-5157-0	results	1	NA	ss_adjusted_anchor_ipd	NA
10.1186/s12885-018-5157-0	results	1	NA	effect_cutoff	1
10.1186/s12885-018-5157-0	results	1	NA	adjusted_pval	0.423
10.1186/s12885-018-5157-0	results	1	NA	adjusted_num_pval	0.423
10.1186/s12885-018-5157-0	results	1	NA	adjusted_significant	FALSE
10.1186/s12885-018-5157-0	results	2	NA	contrast_effect_type	HR
10.1186/s12885-018-5157-0	results	2	NA	direction_benefit	inferior
10.1186/s12885-018-5157-0	results	2	NA	ss_ttt_nonipd	132
10.1186/s12885-018-5157-0	results	2	NA	ss_ttt_ipd	194
10.1186/s12885-018-5157-0	results	2	NA	ss_adjusted_ttt_ipd	61
10.1186/s12885-018-5157-0	results	2	NA	weights_yn	Not mentioned
10.1186/s12885-018-5157-0	results	2	NA	covariates_yn	Yes
10.1186/s12885-018-5157-0	results	2	NA	covariates_n	9
10.1186/s12885-018-5157-0	results	2	NA	covariates_names	Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Past treatments for the disease of interest, Other(s)
10.1186/s12885-018-5157-0	results	2	NA	contrast_effect_direction	Numerator if ratio, or left side if difference
10.1186/s12885-018-5157-0	results	2	NA	contrast_effect_unadjusted_value	NA
10.1186/s12885-018-5157-0	results	2	NA	contrast_effect_unadjusted_pvalci	NA
10.1186/s12885-018-5157-0	results	2	NA	contrast_effect_adjusted_value	0.53
10.1186/s12885-018-5157-0	results	2	NA	contrast_effect_adjusted_pvalci	0.002
10.1186/s12885-018-5157-0	results	2	NA	adjustment_geographical	Yes
10.1186/s12885-018-5157-0	results	2	NA	ss_total_ipd	NA
10.1186/s12885-018-5157-0	results	2	NA	ss_adjusted_total_ipd	NA
10.1186/s12885-018-5157-0	results	2	NA	ss_total_nonipd	NA
10.1186/s12885-018-5157-0	results	2	NA	ss_anchor_nonipd	NA
10.1186/s12885-018-5157-0	results	2	NA	ss_anchor_ipd	NA
10.1186/s12885-018-5157-0	results	2	NA	ss_adjusted_anchor_ipd	NA
10.1186/s12885-018-5157-0	results	2	NA	effect_cutoff	1
10.1186/s12885-018-5157-0	results	2	NA	adjusted_pval	0.002
10.1186/s12885-018-5157-0	results	2	NA	adjusted_num_pval	0.002
10.1186/s12885-018-5157-0	results	2	NA	adjusted_significant	TRUE
10.1186/s12885-018-5157-0	study_information	NA	1	ipd_yn	Yes
10.1186/s12885-018-5157-0	study_information	NA	1	ct_yn	Yes
10.1186/s12885-018-5157-0	study_information	NA	1	nct	NCT00678392
10.1186/s12885-018-5157-0	study_information	NA	1	country_study	international
10.1186/s12885-018-5157-0	study_information	NA	1	ct_phase	3
10.1186/s12885-018-5157-0	study_information	NA	1	ct_arms	2 or more
10.1186/s12885-018-5157-0	study_information	NA	2	ipd_yn	No
10.1186/s12885-018-5157-0	study_information	NA	2	ct_yn	Yes
10.1186/s12885-018-5157-0	study_information	NA	2	nct	NCT01865747
10.1186/s12885-018-5157-0	study_information	NA	2	country_study	international
10.1186/s12885-018-5157-0	study_information	NA	2	ct_phase	3
10.1186/s12885-018-5157-0	study_information	NA	2	ct_arms	2 or more
10.1186/s13045-021-01144-9	general_information	NA	NA	condition_name	relapsed or refractory large b cell lymphoma
10.1186/s13045-021-01144-9	general_information	NA	NA	country_first_author	usa
10.1186/s13045-021-01144-9	general_information	NA	NA	country_last_author	france
10.1186/s13045-021-01144-9	general_information	NA	NA	positions	Academic, Pharmaceutical Industry, Private Data Analysis Company
10.1186/s13045-021-01144-9	general_information	NA	NA	methodologist_yn	Yes
10.1186/s13045-021-01144-9	general_information	NA	NA	funding_source	Pharmaceutical Industry
10.1186/s13045-021-01144-9	general_information	NA	NA	pharmaceutical_ties_yn	Yes
10.1186/s13045-021-01144-9	general_information	NA	NA	systematic_review_yn	Yes
10.1186/s13045-021-01144-9	methodology	1	NA	outcome_name	objective response rate (orr)
10.1186/s13045-021-01144-9	methodology	1	NA	outcome_short_name	Objective Response Rate
10.1186/s13045-021-01144-9	methodology	1	NA	outcome_variable_type	Binary (eg rates)
10.1186/s13045-021-01144-9	methodology	1	NA	treatment_name_ipd	lisocabtagene maraleucel
10.1186/s13045-021-01144-9	methodology	1	NA	studies_number_ipd	1
10.1186/s13045-021-01144-9	methodology	1	NA	treatment_name_nonipd	axicabtagene ciloleucel
10.1186/s13045-021-01144-9	methodology	1	NA	studies_number_nonipd	2
10.1186/s13045-021-01144-9	methodology	1	NA	paic_type	MAIC
10.1186/s13045-021-01144-9	methodology	1	NA	anchored_yn	No
10.1186/s13045-021-01144-9	methodology	1	NA	paic_form	Simple (ie treatments effects extracted from two studies)
10.1186/s13045-021-01144-9	methodology	1	NA	primary_outcome_yn	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.1186/s13045-021-01144-9	methodology	1	NA	variables_selection_justification	Status of prognostic factor/treatment effect modified assessed in the IPD dataset, A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion), Literature based (clinically or methodologically relevant to adjust on these variables based on the literature search conducted for this specific purpose)
10.1186/s13045-021-01144-9	methodology	1	NA	pf_yn	Yes
10.1186/s13045-021-01144-9	methodology	1	NA	tem_yn	Yes
10.1186/s13045-021-01144-9	methodology	1	NA	adjustment_model_details_yn	No
10.1186/s13045-021-01144-9	methodology	1	NA	scale_choice_yn	No
10.1186/s13045-021-01144-9	results	1	NA	contrast_effect_type	OR
10.1186/s13045-021-01144-9	results	1	NA	direction_benefit	superior
10.1186/s13045-021-01144-9	results	1	NA	ss_ttt_nonipd	101
10.1186/s13045-021-01144-9	results	1	NA	ss_ttt_ipd	110
10.1186/s13045-021-01144-9	results	1	NA	ss_adjusted_ttt_ipd	42.1
10.1186/s13045-021-01144-9	results	1	NA	weights_yn	Yes, mentions that the weights distribution has been studied, but weights distribution not reported
10.1186/s13045-021-01144-9	results	1	NA	covariates_yn	Yes
10.1186/s13045-021-01144-9	results	1	NA	covariates_n	10
10.1186/s13045-021-01144-9	results	1	NA	covariates_names	Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Past treatments for the disease of interest, Comorbidities and medical history (beside pathology/disease of interest in the comparison)
10.1186/s13045-021-01144-9	results	1	NA	contrast_effect_direction	Numerator if ratio, or left side if difference
10.1186/s13045-021-01144-9	results	1	NA	contrast_effect_unadjusted_value	0.92
10.1186/s13045-021-01144-9	results	1	NA	contrast_effect_unadjusted_pvalci	0.753
10.1186/s13045-021-01144-9	results	1	NA	contrast_effect_adjusted_value	1.4
10.1186/s13045-021-01144-9	results	1	NA	contrast_effect_adjusted_pvalci	0.476
10.1186/s13045-021-01144-9	results	1	NA	adjustment_geographical	No
10.1186/s13045-021-01144-9	results	1	NA	ss_total_ipd	NA
10.1186/s13045-021-01144-9	results	1	NA	ss_adjusted_total_ipd	NA
10.1186/s13045-021-01144-9	results	1	NA	ss_total_nonipd	NA
10.1186/s13045-021-01144-9	results	1	NA	ss_anchor_nonipd	NA
10.1186/s13045-021-01144-9	results	1	NA	ss_anchor_ipd	NA
10.1186/s13045-021-01144-9	results	1	NA	ss_adjusted_anchor_ipd	NA
10.1186/s13045-021-01144-9	results	1	NA	effect_cutoff	1
10.1186/s13045-021-01144-9	results	1	NA	unadjusted_pval	0.753
10.1186/s13045-021-01144-9	results	1	NA	unadjusted_num_pval	0.753
10.1186/s13045-021-01144-9	results	1	NA	unadjusted_significant	FALSE
10.1186/s13045-021-01144-9	results	1	NA	adjusted_pval	0.476
10.1186/s13045-021-01144-9	results	1	NA	adjusted_num_pval	0.476
10.1186/s13045-021-01144-9	results	1	NA	adjusted_significant	FALSE
10.1186/s13045-021-01144-9	study_information	NA	1	ipd_yn	Yes
10.1186/s13045-021-01144-9	study_information	NA	1	ct_yn	Yes
10.1186/s13045-021-01144-9	study_information	NA	1	nct	NCT02631044
10.1186/s13045-021-01144-9	study_information	NA	1	country_study	usa
10.1186/s13045-021-01144-9	study_information	NA	1	ct_phase	1
10.1186/s13045-021-01144-9	study_information	NA	1	ct_arms	1
10.1186/s13045-021-01144-9	study_information	NA	2	ipd_yn	No
10.1186/s13045-021-01144-9	study_information	NA	2	ct_yn	Yes
10.1186/s13045-021-01144-9	study_information	NA	2	nct	NCT02348216
10.1186/s13045-021-01144-9	study_information	NA	2	country_study	international
10.1186/s13045-021-01144-9	study_information	NA	2	ct_phase	1, 2
10.1186/s13045-021-01144-9	study_information	NA	2	ct_arms	1
10.1186/s40164-022-00268-z	general_information	NA	NA	condition_name	relapsed or refractory aggressive large b-cell lymphomas
10.1186/s40164-022-00268-z	general_information	NA	NA	country_first_author	france
10.1186/s40164-022-00268-z	general_information	NA	NA	country_last_author	canada
10.1186/s40164-022-00268-z	general_information	NA	NA	positions	Academic, Private Data Analysis Company, Pharmaceutical Industry
10.1186/s40164-022-00268-z	general_information	NA	NA	methodologist_yn	Yes
10.1186/s40164-022-00268-z	general_information	NA	NA	funding_source	Pharmaceutical Industry
10.1186/s40164-022-00268-z	general_information	NA	NA	pharmaceutical_ties_yn	Yes
10.1186/s40164-022-00268-z	general_information	NA	NA	systematic_review_yn	No
10.1186/s40164-022-00268-z	methodology	1	NA	outcome_name	objective response rate
10.1186/s40164-022-00268-z	methodology	1	NA	outcome_short_name	Objective Response Rate
10.1186/s40164-022-00268-z	methodology	1	NA	outcome_variable_type	Binary (eg rates)
10.1186/s40164-022-00268-z	methodology	1	NA	treatment_name_ipd	lisocabtagene maraleucel
10.1186/s40164-022-00268-z	methodology	1	NA	studies_number_ipd	1
10.1186/s40164-022-00268-z	methodology	1	NA	treatment_name_nonipd	tisagenlecleucel
10.1186/s40164-022-00268-z	methodology	1	NA	studies_number_nonipd	2
10.1186/s40164-022-00268-z	methodology	1	NA	paic_type	MAIC
10.1186/s40164-022-00268-z	methodology	1	NA	anchored_yn	No
10.1186/s40164-022-00268-z	methodology	1	NA	paic_form	Simple (ie treatments effects extracted from two studies)
10.1186/s40164-022-00268-z	methodology	1	NA	primary_outcome_yn	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.1186/s40164-022-00268-z	methodology	1	NA	variables_selection_justification	Status of prognostic factor/treatment effect modified assessed in the IPD dataset, A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion), Literature based (clinically or methodologically relevant to adjust on these variables based on the literature search conducted for this specific purpose)
10.1186/s40164-022-00268-z	methodology	1	NA	pf_yn	Yes
10.1186/s40164-022-00268-z	methodology	1	NA	tem_yn	Yes
10.1186/s40164-022-00268-z	methodology	1	NA	adjustment_model_details_yn	No
10.1186/s40164-022-00268-z	methodology	1	NA	scale_choice_yn	No
10.1186/s40164-022-00268-z	results	1	NA	contrast_effect_type	OR
10.1186/s40164-022-00268-z	results	1	NA	direction_benefit	superior
10.1186/s40164-022-00268-z	results	1	NA	ss_ttt_nonipd	111
10.1186/s40164-022-00268-z	results	1	NA	ss_ttt_ipd	256
10.1186/s40164-022-00268-z	results	1	NA	ss_adjusted_ttt_ipd	164
10.1186/s40164-022-00268-z	results	1	NA	weights_yn	Yes, mentions that the weights distribution has been studied, but weights distribution not reported
10.1186/s40164-022-00268-z	results	1	NA	covariates_yn	Yes
10.1186/s40164-022-00268-z	results	1	NA	covariates_n	6
10.1186/s40164-022-00268-z	results	1	NA	covariates_names	Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Past treatments for the disease of interest, Comorbidities and medical history (beside pathology/disease of interest in the comparison)
10.1186/s40164-022-00268-z	results	1	NA	contrast_effect_direction	Numerator if ratio, or left side if difference
10.1186/s40164-022-00268-z	results	1	NA	contrast_effect_unadjusted_value	2.49
10.1186/s40164-022-00268-z	results	1	NA	contrast_effect_unadjusted_pvalci	[1.52;4.07]
10.1186/s40164-022-00268-z	results	1	NA	contrast_effect_adjusted_value	2.78
10.1186/s40164-022-00268-z	results	1	NA	contrast_effect_adjusted_pvalci	[1.63;4.74]
10.1186/s40164-022-00268-z	results	1	NA	adjustment_geographical	NA
10.1186/s40164-022-00268-z	results	1	NA	ss_total_ipd	NA
10.1186/s40164-022-00268-z	results	1	NA	ss_adjusted_total_ipd	NA
10.1186/s40164-022-00268-z	results	1	NA	ss_total_nonipd	NA
10.1186/s40164-022-00268-z	results	1	NA	ss_anchor_nonipd	NA
10.1186/s40164-022-00268-z	results	1	NA	ss_anchor_ipd	NA
10.1186/s40164-022-00268-z	results	1	NA	ss_adjusted_anchor_ipd	NA
10.1186/s40164-022-00268-z	results	1	NA	effect_cutoff	1
10.1186/s40164-022-00268-z	results	1	NA	unadjusted_lb_ci	1.52
10.1186/s40164-022-00268-z	results	1	NA	unadjusted_ub_ci	4.07
10.1186/s40164-022-00268-z	results	1	NA	unadjusted_significant	TRUE
10.1186/s40164-022-00268-z	results	1	NA	adjusted_lb_ci	1.63
10.1186/s40164-022-00268-z	results	1	NA	adjusted_ub_ci	4.74
10.1186/s40164-022-00268-z	results	1	NA	adjusted_significant	TRUE
10.1186/s40164-022-00268-z	study_information	NA	1	ipd_yn	Yes
10.1186/s40164-022-00268-z	study_information	NA	1	ct_yn	Yes
10.1186/s40164-022-00268-z	study_information	NA	1	nct	NCT02631044
10.1186/s40164-022-00268-z	study_information	NA	1	ct_phase	1
10.1186/s40164-022-00268-z	study_information	NA	1	ct_arms	1
10.1186/s40164-022-00268-z	study_information	NA	1	country_study	usa
10.1186/s40164-022-00268-z	study_information	NA	2	ipd_yn	No
10.1186/s40164-022-00268-z	study_information	NA	2	ct_yn	Yes
10.1186/s40164-022-00268-z	study_information	NA	2	nct	NCT02445248
10.1186/s40164-022-00268-z	study_information	NA	2	ct_phase	2
10.1186/s40164-022-00268-z	study_information	NA	2	ct_arms	1
10.1186/s40164-022-00268-z	study_information	NA	2	country_study	international
10.1186/s40734-017-0051-5	general_information	NA	NA	condition_name	huntington disease
10.1186/s40734-017-0051-5	general_information	NA	NA	country_first_author	usa
10.1186/s40734-017-0051-5	general_information	NA	NA	country_last_author	usa
10.1186/s40734-017-0051-5	general_information	NA	NA	positions	Academic, Pharmaceutical Industry, Private Data Analysis Company
10.1186/s40734-017-0051-5	general_information	NA	NA	methodologist_yn	Yes
10.1186/s40734-017-0051-5	general_information	NA	NA	funding_source	Pharmaceutical Industry
10.1186/s40734-017-0051-5	general_information	NA	NA	pharmaceutical_ties_yn	Yes
10.1186/s40734-017-0051-5	general_information	NA	NA	systematic_review_yn	No
10.1186/s40734-017-0051-5	methodology	1	NA	outcome_name	overall adverse events
10.1186/s40734-017-0051-5	methodology	1	NA	outcome_short_name	Adverse Event
10.1186/s40734-017-0051-5	methodology	1	NA	outcome_variable_type	Binary (eg rates)
10.1186/s40734-017-0051-5	methodology	1	NA	treatment_name_ipd	deutetrabenazine
10.1186/s40734-017-0051-5	methodology	1	NA	studies_number_ipd	1
10.1186/s40734-017-0051-5	methodology	1	NA	treatment_name_nonipd	tetrabenazine
10.1186/s40734-017-0051-5	methodology	1	NA	studies_number_nonipd	2
10.1186/s40734-017-0051-5	methodology	1	NA	paic_type	MAIC
10.1186/s40734-017-0051-5	methodology	1	NA	anchored_yn	Yes
10.1186/s40734-017-0051-5	methodology	1	NA	paic_form	Simple (ie treatments effects extracted from two studies)
10.1186/s40734-017-0051-5	methodology	1	NA	primary_outcome_yn	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.1186/s40734-017-0051-5	methodology	1	NA	variables_selection_justification	Statistical imbalanced between treatment groups (independently of the status of prognostic/effect modifier), A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion)
10.1186/s40734-017-0051-5	methodology	1	NA	pf_yn	No discussion (in the main text) of the status of prognostic factors of the variables
10.1186/s40734-017-0051-5	methodology	1	NA	tem_yn	No discussion (in the main text) of the status of treatment-effect modifiers of the variables
10.1186/s40734-017-0051-5	methodology	1	NA	adjustment_model_details_yn	No
10.1186/s40734-017-0051-5	methodology	1	NA	scale_choice_yn	No
10.1186/s40734-017-0051-5	results	1	NA	contrast_effect_type	Risk difference
10.1186/s40734-017-0051-5	results	1	NA	direction_benefit	inferior
10.1186/s40734-017-0051-5	results	1	NA	ss_ttt_nonipd	54
10.1186/s40734-017-0051-5	results	1	NA	ss_ttt_ipd	45
10.1186/s40734-017-0051-5	results	1	NA	ss_adjusted_ttt_ipd	NA
10.1186/s40734-017-0051-5	results	1	NA	weights_yn	Not mentioned
10.1186/s40734-017-0051-5	results	1	NA	covariates_yn	Yes
10.1186/s40734-017-0051-5	results	1	NA	covariates_n	3
10.1186/s40734-017-0051-5	results	1	NA	covariates_names	Age, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease)
10.1186/s40734-017-0051-5	results	1	NA	contrast_effect_direction	Numerator if ratio, or left side if difference
10.1186/s40734-017-0051-5	results	1	NA	contrast_effect_unadjusted_value	-20.70
10.1186/s40734-017-0051-5	results	1	NA	contrast_effect_unadjusted_pvalci	0.135
10.1186/s40734-017-0051-5	results	1	NA	contrast_effect_adjusted_value	-35.30
10.1186/s40734-017-0051-5	results	1	NA	contrast_effect_adjusted_pvalci	0.063
10.1186/s40734-017-0051-5	results	1	NA	adjustment_geographical	NA
10.1186/s40734-017-0051-5	results	1	NA	ss_total_ipd	NA
10.1186/s40734-017-0051-5	results	1	NA	ss_adjusted_total_ipd	NA
10.1186/s40734-017-0051-5	results	1	NA	ss_total_nonipd	NA
10.1186/s40734-017-0051-5	results	1	NA	ss_anchor_nonipd	30
10.1186/s40734-017-0051-5	results	1	NA	ss_anchor_ipd	45
10.1186/s40734-017-0051-5	results	1	NA	ss_adjusted_anchor_ipd	NA
10.1186/s40734-017-0051-5	results	1	NA	effect_cutoff	0
10.1186/s40734-017-0051-5	results	1	NA	unadjusted_pval	0.135
10.1186/s40734-017-0051-5	results	1	NA	unadjusted_num_pval	0.135
10.1186/s40734-017-0051-5	results	1	NA	unadjusted_significant	FALSE
10.1186/s40734-017-0051-5	results	1	NA	adjusted_pval	0.063
10.1186/s40734-017-0051-5	results	1	NA	adjusted_num_pval	0.063
10.1186/s40734-017-0051-5	results	1	NA	adjusted_significant	FALSE
10.1186/s40734-017-0051-5	study_information	NA	1	ipd_yn	Yes
10.1186/s40734-017-0051-5	study_information	NA	1	ct_yn	Yes
10.1186/s40734-017-0051-5	study_information	NA	1	nct	NCT01795859
10.1186/s40734-017-0051-5	study_information	NA	1	country_study	international
10.1186/s40734-017-0051-5	study_information	NA	1	ct_phase	3
10.1186/s40734-017-0051-5	study_information	NA	1	ct_arms	2 or more
10.1186/s40734-017-0051-5	study_information	NA	2	ipd_yn	No
10.1186/s40734-017-0051-5	study_information	NA	2	ct_yn	Yes
10.1186/s40734-017-0051-5	study_information	NA	2	nct	NCT00219804
10.1186/s40734-017-0051-5	study_information	NA	2	ct_phase	3
10.1186/s40734-017-0051-5	study_information	NA	2	ct_arms	2 or more
10.1186/s40734-017-0051-5	study_information	NA	2	country_study	unknown
10.1210/clinem/dgab905	general_information	NA	NA	condition_name	type 2 diabetes
10.1210/clinem/dgab905	general_information	NA	NA	country_first_author	usa
10.1210/clinem/dgab905	general_information	NA	NA	country_last_author	usa
10.1210/clinem/dgab905	general_information	NA	NA	positions	Academic, Pharmaceutical Industry, Private Data Analysis Company
10.1210/clinem/dgab905	general_information	NA	NA	methodologist_yn	Yes
10.1210/clinem/dgab905	general_information	NA	NA	funding_source	Pharmaceutical Industry
10.1210/clinem/dgab905	general_information	NA	NA	pharmaceutical_ties_yn	Yes
10.1210/clinem/dgab905	general_information	NA	NA	systematic_review_yn	No
10.1210/clinem/dgab905	methodology	1	NA	outcome_name	change from baseline in hba1c
10.1210/clinem/dgab905	methodology	1	NA	outcome_short_name	HbA1C
10.1210/clinem/dgab905	methodology	1	NA	outcome_variable_type	Continuous (count, mean, ...)
10.1210/clinem/dgab905	methodology	1	NA	treatment_name_ipd	semaglutide 2.0 mg
10.1210/clinem/dgab905	methodology	1	NA	studies_number_ipd	1
10.1210/clinem/dgab905	methodology	1	NA	treatment_name_nonipd	dulaglutide 3.0 mg
10.1210/clinem/dgab905	methodology	1	NA	studies_number_nonipd	3
10.1210/clinem/dgab905	methodology	1	NA	paic_type	Multilevel network meta-regression
10.1210/clinem/dgab905	methodology	1	NA	anchored_yn	Yes
10.1210/clinem/dgab905	methodology	1	NA	paic_form	Larger network (ie involving more than 2 studies)
10.1210/clinem/dgab905	methodology	1	NA	primary_outcome_yn	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.1210/clinem/dgab905	methodology	1	NA	variables_selection_justification	Literature based (clinically or methodologically relevant to adjust on these variables based on the literature search conducted for this specific purpose)
10.1210/clinem/dgab905	methodology	1	NA	pf_yn	No
10.1210/clinem/dgab905	methodology	1	NA	tem_yn	Yes
10.1210/clinem/dgab905	methodology	1	NA	adjustment_model_details_yn	No
10.1210/clinem/dgab905	methodology	1	NA	scale_choice_yn	No
10.1210/clinem/dgab905	methodology	2	NA	outcome_name	change from baseline in hba1c
10.1210/clinem/dgab905	methodology	2	NA	outcome_short_name	HbA1C
10.1210/clinem/dgab905	methodology	2	NA	outcome_variable_type	Continuous (count, mean, ...)
10.1210/clinem/dgab905	methodology	2	NA	treatment_name_ipd	semaglutide 2.0 mg
10.1210/clinem/dgab905	methodology	2	NA	studies_number_ipd	1
10.1210/clinem/dgab905	methodology	2	NA	treatment_name_nonipd	dulaglutide 4.5 mg
10.1210/clinem/dgab905	methodology	2	NA	studies_number_nonipd	3
10.1210/clinem/dgab905	methodology	2	NA	paic_type	Multilevel network meta-regression
10.1210/clinem/dgab905	methodology	2	NA	anchored_yn	Yes
10.1210/clinem/dgab905	methodology	2	NA	paic_form	Larger network (ie involving more than 2 studies)
10.1210/clinem/dgab905	methodology	2	NA	primary_outcome_yn	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.1210/clinem/dgab905	methodology	2	NA	variables_selection_justification	Literature based (clinically or methodologically relevant to adjust on these variables based on the literature search conducted for this specific purpose)
10.1210/clinem/dgab905	methodology	2	NA	pf_yn	No
10.1210/clinem/dgab905	methodology	2	NA	tem_yn	Yes
10.1210/clinem/dgab905	methodology	2	NA	adjustment_model_details_yn	No
10.1210/clinem/dgab905	methodology	2	NA	scale_choice_yn	No
10.1210/clinem/dgab905	results	1	NA	contrast_effect_type	Means difference
10.1210/clinem/dgab905	results	1	NA	direction_benefit	inferior
10.1210/clinem/dgab905	results	1	NA	ss_ttt_nonipd	616
10.1210/clinem/dgab905	results	1	NA	ss_ttt_ipd	480
10.1210/clinem/dgab905	results	1	NA	ss_adjusted_ttt_ipd	480
10.1210/clinem/dgab905	results	1	NA	weights_yn	NA
10.1210/clinem/dgab905	results	1	NA	covariates_yn	Yes
10.1210/clinem/dgab905	results	1	NA	covariates_n	3
10.1210/clinem/dgab905	results	1	NA	covariates_names	Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Comorbidities and medical history (beside pathology/disease of interest in the comparison)
10.1210/clinem/dgab905	results	1	NA	contrast_effect_direction	Numerator if ratio, or left side if difference
10.1210/clinem/dgab905	results	1	NA	contrast_effect_unadjusted_value	-0.47
10.1210/clinem/dgab905	results	1	NA	contrast_effect_unadjusted_pvalci	[-0.69;-0.23]
10.1210/clinem/dgab905	results	1	NA	contrast_effect_adjusted_value	-0.44
10.1210/clinem/dgab905	results	1	NA	contrast_effect_adjusted_pvalci	[-0.68;-0.19]
10.1210/clinem/dgab905	results	1	NA	adjustment_geographical	No
10.1210/clinem/dgab905	results	1	NA	ss_total_ipd	NA
10.1210/clinem/dgab905	results	1	NA	ss_adjusted_total_ipd	NA
10.1210/clinem/dgab905	results	1	NA	ss_total_nonipd	NA
10.1210/clinem/dgab905	results	1	NA	ss_anchor_nonipd	612
10.1210/clinem/dgab905	results	1	NA	ss_anchor_ipd	481
10.1210/clinem/dgab905	results	1	NA	ss_adjusted_anchor_ipd	481
10.1210/clinem/dgab905	results	1	NA	effect_cutoff	0
10.1210/clinem/dgab905	results	1	NA	unadjusted_lb_ci	-0.69
10.1210/clinem/dgab905	results	1	NA	unadjusted_ub_ci	-0.23
10.1210/clinem/dgab905	results	1	NA	unadjusted_significant	TRUE
10.1210/clinem/dgab905	results	1	NA	adjusted_lb_ci	-0.68
10.1210/clinem/dgab905	results	1	NA	adjusted_ub_ci	-0.19
10.1210/clinem/dgab905	results	1	NA	adjusted_significant	TRUE
10.1210/clinem/dgab905	results	2	NA	contrast_effect_type	Means difference
10.1210/clinem/dgab905	results	2	NA	direction_benefit	inferior
10.1210/clinem/dgab905	results	2	NA	ss_ttt_nonipd	614
10.1210/clinem/dgab905	results	2	NA	ss_ttt_ipd	480
10.1210/clinem/dgab905	results	2	NA	ss_adjusted_ttt_ipd	480
10.1210/clinem/dgab905	results	2	NA	weights_yn	NA
10.1210/clinem/dgab905	results	2	NA	covariates_yn	Yes
10.1210/clinem/dgab905	results	2	NA	covariates_n	3
10.1210/clinem/dgab905	results	2	NA	covariates_names	Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Comorbidities and medical history (beside pathology/disease of interest in the comparison)
10.1210/clinem/dgab905	results	2	NA	contrast_effect_direction	Numerator if ratio, or left side if difference
10.1210/clinem/dgab905	results	2	NA	contrast_effect_unadjusted_value	-0.31
10.1210/clinem/dgab905	results	2	NA	contrast_effect_unadjusted_pvalci	[-0.53;-0.08]
10.1210/clinem/dgab905	results	2	NA	contrast_effect_adjusted_value	-0.28
10.1210/clinem/dgab905	results	2	NA	contrast_effect_adjusted_pvalci	[-0.52;-0.03]
10.1210/clinem/dgab905	results	2	NA	adjustment_geographical	No
10.1210/clinem/dgab905	results	2	NA	ss_total_ipd	NA
10.1210/clinem/dgab905	results	2	NA	ss_adjusted_total_ipd	NA
10.1210/clinem/dgab905	results	2	NA	ss_total_nonipd	NA
10.1210/clinem/dgab905	results	2	NA	ss_anchor_nonipd	612
10.1210/clinem/dgab905	results	2	NA	ss_anchor_ipd	481
10.1210/clinem/dgab905	results	2	NA	ss_adjusted_anchor_ipd	481
10.1210/clinem/dgab905	results	2	NA	effect_cutoff	0
10.1210/clinem/dgab905	results	2	NA	unadjusted_lb_ci	-0.53
10.1210/clinem/dgab905	results	2	NA	unadjusted_ub_ci	-0.08
10.1210/clinem/dgab905	results	2	NA	unadjusted_significant	TRUE
10.1210/clinem/dgab905	results	2	NA	adjusted_lb_ci	-0.52
10.1210/clinem/dgab905	results	2	NA	adjusted_ub_ci	-0.03
10.1210/clinem/dgab905	results	2	NA	adjusted_significant	TRUE
10.1210/clinem/dgab905	study_information	NA	1	ipd_yn	Yes
10.1210/clinem/dgab905	study_information	NA	1	ct_yn	Yes
10.1210/clinem/dgab905	study_information	NA	1	nct	NCT03989232
10.1210/clinem/dgab905	study_information	NA	1	country_study	international
10.1210/clinem/dgab905	study_information	NA	1	ct_phase	3
10.1210/clinem/dgab905	study_information	NA	1	ct_arms	2 or more
10.1210/clinem/dgab905	study_information	NA	3	ipd_yn	No
10.1210/clinem/dgab905	study_information	NA	3	ct_yn	Yes
10.1210/clinem/dgab905	study_information	NA	3	nct	NCT03495102
10.1210/clinem/dgab905	study_information	NA	3	country_study	international
10.1210/clinem/dgab905	study_information	NA	3	ct_phase	3
10.1210/clinem/dgab905	study_information	NA	3	ct_arms	2 or more
10.1634/theoncologist.2017-0103	general_information	NA	NA	condition_name	relapsed/refractory multiple myeloma
10.1634/theoncologist.2017-0103	general_information	NA	NA	country_first_author	belgium
10.1634/theoncologist.2017-0103	general_information	NA	NA	country_last_author	spain
10.1634/theoncologist.2017-0103	general_information	NA	NA	positions	Academic, Pharmaceutical Industry
10.1634/theoncologist.2017-0103	general_information	NA	NA	methodologist_yn	Yes
10.1634/theoncologist.2017-0103	general_information	NA	NA	funding_source	Pharmaceutical Industry
10.1634/theoncologist.2017-0103	general_information	NA	NA	pharmaceutical_ties_yn	Yes
10.1634/theoncologist.2017-0103	general_information	NA	NA	systematic_review_yn	No
10.1634/theoncologist.2017-0103	methodology	1	NA	outcome_name	overall survival
10.1634/theoncologist.2017-0103	methodology	1	NA	outcome_short_name	Overall Survival
10.1634/theoncologist.2017-0103	methodology	1	NA	outcome_variable_type	Time-to-event
10.1634/theoncologist.2017-0103	methodology	1	NA	treatment_name_ipd	daratumumab
10.1634/theoncologist.2017-0103	methodology	1	NA	studies_number_ipd	1;2
10.1634/theoncologist.2017-0103	methodology	1	NA	treatment_name_nonipd	pomalidomide + low-dose dexamethasone
10.1634/theoncologist.2017-0103	methodology	1	NA	studies_number_nonipd	3
10.1634/theoncologist.2017-0103	methodology	1	NA	paic_type	MAIC
10.1634/theoncologist.2017-0103	methodology	1	NA	anchored_yn	No
10.1634/theoncologist.2017-0103	methodology	1	NA	paic_form	Aggregation of multiple studies to estimate individual treatment effects (e.g. meta-analysis in a first step to estimate treatment A effect, then population adjusted indirect comparison using treatment A effect estimate)
10.1634/theoncologist.2017-0103	methodology	1	NA	primary_outcome_yn	Yes
10.1634/theoncologist.2017-0103	methodology	1	NA	variables_selection_justification	Literature based (clinically or methodologically relevant to adjust on these variables based on the literature search conducted for this specific purpose)
10.1634/theoncologist.2017-0103	methodology	1	NA	pf_yn	Yes
10.1634/theoncologist.2017-0103	methodology	1	NA	tem_yn	No discussion (in the main text) of the status of treatment-effect modifiers of the variables
10.1634/theoncologist.2017-0103	methodology	1	NA	adjustment_model_details_yn	No
10.1634/theoncologist.2017-0103	methodology	1	NA	scale_choice_yn	No
10.1634/theoncologist.2017-0103	methodology	2	NA	outcome_name	overall survival
10.1634/theoncologist.2017-0103	methodology	2	NA	outcome_short_name	Overall Survival
10.1634/theoncologist.2017-0103	methodology	2	NA	outcome_variable_type	Time-to-event
10.1634/theoncologist.2017-0103	methodology	2	NA	treatment_name_ipd	daratumumab
10.1634/theoncologist.2017-0103	methodology	2	NA	studies_number_ipd	1;2
10.1634/theoncologist.2017-0103	methodology	2	NA	treatment_name_nonipd	pomalidomide + low-dose dexamethasone
10.1634/theoncologist.2017-0103	methodology	2	NA	studies_number_nonipd	4
10.1634/theoncologist.2017-0103	methodology	2	NA	paic_type	MAIC
10.1634/theoncologist.2017-0103	methodology	2	NA	anchored_yn	No
10.1634/theoncologist.2017-0103	methodology	2	NA	paic_form	Aggregation of multiple studies to estimate individual treatment effects (e.g. meta-analysis in a first step to estimate treatment A effect, then population adjusted indirect comparison using treatment A effect estimate)
10.1634/theoncologist.2017-0103	methodology	2	NA	primary_outcome_yn	Yes
10.1634/theoncologist.2017-0103	methodology	2	NA	variables_selection_justification	Literature based (clinically or methodologically relevant to adjust on these variables based on the literature search conducted for this specific purpose)
10.1634/theoncologist.2017-0103	methodology	2	NA	pf_yn	Yes
10.1634/theoncologist.2017-0103	methodology	2	NA	tem_yn	No discussion (in the main text) of the status of treatment-effect modifiers of the variables
10.1634/theoncologist.2017-0103	methodology	2	NA	adjustment_model_details_yn	No
10.1634/theoncologist.2017-0103	methodology	2	NA	scale_choice_yn	No
10.1634/theoncologist.2017-0103	results	1	NA	contrast_effect_type	HR
10.1634/theoncologist.2017-0103	results	1	NA	direction_benefit	inferior
10.1634/theoncologist.2017-0103	results	1	NA	ss_ttt_nonipd	302
10.1634/theoncologist.2017-0103	results	1	NA	ss_ttt_ipd	136
10.1634/theoncologist.2017-0103	results	1	NA	ss_adjusted_ttt_ipd	55
10.1634/theoncologist.2017-0103	results	1	NA	weights_yn	Not mentioned
10.1634/theoncologist.2017-0103	results	1	NA	covariates_yn	Yes
10.1634/theoncologist.2017-0103	results	1	NA	covariates_n	10
10.1634/theoncologist.2017-0103	results	1	NA	covariates_names	Age, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Race/ethnicity, Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Past treatments for the disease of interest, Comorbidities and medical history (beside pathology/disease of interest in the comparison)
10.1634/theoncologist.2017-0103	results	1	NA	contrast_effect_direction	Numerator if ratio, or left side if difference
10.1634/theoncologist.2017-0103	results	1	NA	contrast_effect_unadjusted_value	0.61
10.1634/theoncologist.2017-0103	results	1	NA	contrast_effect_unadjusted_pvalci	0.0005
10.1634/theoncologist.2017-0103	results	1	NA	contrast_effect_adjusted_value	0.56
10.1634/theoncologist.2017-0103	results	1	NA	contrast_effect_adjusted_pvalci	0.0041
10.1634/theoncologist.2017-0103	results	1	NA	adjustment_geographical	NA
10.1634/theoncologist.2017-0103	results	1	NA	ss_total_ipd	NA
10.1634/theoncologist.2017-0103	results	1	NA	ss_adjusted_total_ipd	NA
10.1634/theoncologist.2017-0103	results	1	NA	ss_total_nonipd	NA
10.1634/theoncologist.2017-0103	results	1	NA	ss_anchor_nonipd	NA
10.1634/theoncologist.2017-0103	results	1	NA	ss_anchor_ipd	NA
10.1634/theoncologist.2017-0103	results	1	NA	ss_adjusted_anchor_ipd	NA
10.1634/theoncologist.2017-0103	results	1	NA	effect_cutoff	1
10.1634/theoncologist.2017-0103	results	1	NA	unadjusted_pval	0.0005
10.1634/theoncologist.2017-0103	results	1	NA	unadjusted_num_pval	5e-04
10.1634/theoncologist.2017-0103	results	1	NA	unadjusted_significant	TRUE
10.1634/theoncologist.2017-0103	results	1	NA	adjusted_pval	0.0041
10.1634/theoncologist.2017-0103	results	1	NA	adjusted_num_pval	0.0041
10.1634/theoncologist.2017-0103	results	1	NA	adjusted_significant	TRUE
10.1634/theoncologist.2017-0103	results	2	NA	contrast_effect_type	HR
10.1634/theoncologist.2017-0103	results	2	NA	direction_benefit	inferior
10.1634/theoncologist.2017-0103	results	2	NA	ss_ttt_nonipd	682
10.1634/theoncologist.2017-0103	results	2	NA	ss_ttt_ipd	148
10.1634/theoncologist.2017-0103	results	2	NA	ss_adjusted_ttt_ipd	95
10.1634/theoncologist.2017-0103	results	2	NA	weights_yn	Not mentioned
10.1634/theoncologist.2017-0103	results	2	NA	covariates_yn	Yes
10.1634/theoncologist.2017-0103	results	2	NA	covariates_n	7
10.1634/theoncologist.2017-0103	results	2	NA	covariates_names	Age, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Past treatments for the disease of interest, Comorbidities and medical history (beside pathology/disease of interest in the comparison)
10.1634/theoncologist.2017-0103	results	2	NA	contrast_effect_direction	Numerator if ratio, or left side if difference
10.1634/theoncologist.2017-0103	results	2	NA	contrast_effect_unadjusted_value	0.55
10.1634/theoncologist.2017-0103	results	2	NA	contrast_effect_unadjusted_pvalci	<0.0001
10.1634/theoncologist.2017-0103	results	2	NA	contrast_effect_adjusted_value	0.51
10.1634/theoncologist.2017-0103	results	2	NA	contrast_effect_adjusted_pvalci	<0.0001
10.1634/theoncologist.2017-0103	results	2	NA	adjustment_geographical	NA
10.1634/theoncologist.2017-0103	results	2	NA	ss_total_ipd	NA
10.1634/theoncologist.2017-0103	results	2	NA	ss_adjusted_total_ipd	NA
10.1634/theoncologist.2017-0103	results	2	NA	ss_total_nonipd	NA
10.1634/theoncologist.2017-0103	results	2	NA	ss_anchor_nonipd	NA
10.1634/theoncologist.2017-0103	results	2	NA	ss_anchor_ipd	NA
10.1634/theoncologist.2017-0103	results	2	NA	ss_adjusted_anchor_ipd	NA
10.1634/theoncologist.2017-0103	results	2	NA	effect_cutoff	1
10.1634/theoncologist.2017-0103	results	2	NA	unadjusted_pval	<0.0001
10.1634/theoncologist.2017-0103	results	2	NA	unadjusted_significant	TRUE
10.1634/theoncologist.2017-0103	results	2	NA	adjusted_pval	<0.0001
10.1634/theoncologist.2017-0103	results	2	NA	adjusted_significant	TRUE
10.1634/theoncologist.2017-0103	study_information	NA	1	ipd_yn	Yes
10.1634/theoncologist.2017-0103	study_information	NA	1	ct_yn	Yes
10.1634/theoncologist.2017-0103	study_information	NA	1	nct	NCT00574288
10.1634/theoncologist.2017-0103	study_information	NA	1	country_study	international
10.1634/theoncologist.2017-0103	study_information	NA	1	ct_phase	2
10.1634/theoncologist.2017-0103	study_information	NA	1	ct_arms	1
10.1634/theoncologist.2017-0103	study_information	NA	2	ipd_yn	Yes
10.1634/theoncologist.2017-0103	study_information	NA	2	ct_yn	Yes
10.1634/theoncologist.2017-0103	study_information	NA	2	nct	NCT01985126
10.1634/theoncologist.2017-0103	study_information	NA	2	country_study	international
10.1634/theoncologist.2017-0103	study_information	NA	2	ct_phase	2
10.1634/theoncologist.2017-0103	study_information	NA	2	ct_arms	2 or more
10.1634/theoncologist.2017-0103	study_information	NA	3	ipd_yn	No
10.1634/theoncologist.2017-0103	study_information	NA	3	ct_yn	Yes
10.1634/theoncologist.2017-0103	study_information	NA	3	nct	NCT01311687
10.1634/theoncologist.2017-0103	study_information	NA	3	country_study	international
10.1634/theoncologist.2017-0103	study_information	NA	3	ct_phase	3
10.1634/theoncologist.2017-0103	study_information	NA	3	ct_arms	2 or more
10.1634/theoncologist.2017-0103	study_information	NA	4	ipd_yn	No
10.1634/theoncologist.2017-0103	study_information	NA	4	ct_yn	Yes
10.1634/theoncologist.2017-0103	study_information	NA	4	nct	NCT01712789
10.1634/theoncologist.2017-0103	study_information	NA	4	country_study	international
10.1634/theoncologist.2017-0103	study_information	NA	4	ct_phase	3
10.1634/theoncologist.2017-0103	study_information	NA	4	ct_arms	1
10.2147/ceor.s203482	general_information	NA	NA	condition_name	acute myeloid leukemia
10.2147/ceor.s203482	general_information	NA	NA	country_first_author	usa
10.2147/ceor.s203482	general_information	NA	NA	country_last_author	uk
10.2147/ceor.s203482	general_information	NA	NA	positions	Academic, Pharmaceutical Industry, Private Data Analysis Company
10.2147/ceor.s203482	general_information	NA	NA	methodologist_yn	Yes
10.2147/ceor.s203482	general_information	NA	NA	funding_source	Pharmaceutical Industry
10.2147/ceor.s203482	general_information	NA	NA	pharmaceutical_ties_yn	Yes
10.2147/ceor.s203482	general_information	NA	NA	systematic_review_yn	Yes
10.2147/ceor.s203482	methodology	1	NA	outcome_name	overall survival
10.2147/ceor.s203482	methodology	1	NA	outcome_short_name	Overall Survival
10.2147/ceor.s203482	methodology	1	NA	outcome_variable_type	Time-to-event
10.2147/ceor.s203482	methodology	1	NA	treatment_name_ipd	glasdegib + low-dose cytarabine
10.2147/ceor.s203482	methodology	1	NA	studies_number_ipd	1
10.2147/ceor.s203482	methodology	1	NA	treatment_name_nonipd	azacitidine
10.2147/ceor.s203482	methodology	1	NA	studies_number_nonipd	2
10.2147/ceor.s203482	methodology	1	NA	paic_type	STC
10.2147/ceor.s203482	methodology	1	NA	anchored_yn	Yes
10.2147/ceor.s203482	methodology	1	NA	paic_form	Simple (ie treatments effects extracted from two studies)
10.2147/ceor.s203482	methodology	1	NA	primary_outcome_yn	Yes
10.2147/ceor.s203482	methodology	1	NA	variables_selection_justification	Statistical imbalanced between treatment groups (independently of the status of prognostic/effect modifier), Status of prognostic factor/treatment effect modified assessed in the IPD dataset, Literature based (clinically or methodologically relevant to adjust on these variables based on the literature search conducted for this specific purpose)
10.2147/ceor.s203482	methodology	1	NA	pf_yn	Yes
10.2147/ceor.s203482	methodology	1	NA	tem_yn	Yes
10.2147/ceor.s203482	methodology	1	NA	adjustment_model_details_yn	No
10.2147/ceor.s203482	methodology	1	NA	scale_choice_yn	No
10.2147/ceor.s203482	methodology	2	NA	outcome_name	overall survival
10.2147/ceor.s203482	methodology	2	NA	outcome_short_name	Overall Survival
10.2147/ceor.s203482	methodology	2	NA	outcome_variable_type	Time-to-event
10.2147/ceor.s203482	methodology	2	NA	treatment_name_ipd	glasdegib + low-dose cytarabine
10.2147/ceor.s203482	methodology	2	NA	studies_number_ipd	1
10.2147/ceor.s203482	methodology	2	NA	treatment_name_nonipd	decitabine
10.2147/ceor.s203482	methodology	2	NA	studies_number_nonipd	3
10.2147/ceor.s203482	methodology	2	NA	paic_type	STC
10.2147/ceor.s203482	methodology	2	NA	anchored_yn	Yes
10.2147/ceor.s203482	methodology	2	NA	paic_form	Simple (ie treatments effects extracted from two studies)
10.2147/ceor.s203482	methodology	2	NA	primary_outcome_yn	Yes
10.2147/ceor.s203482	methodology	2	NA	variables_selection_justification	Statistical imbalanced between treatment groups (independently of the status of prognostic/effect modifier), Status of prognostic factor/treatment effect modified assessed in the IPD dataset, Literature based (clinically or methodologically relevant to adjust on these variables based on the literature search conducted for this specific purpose)
10.2147/ceor.s203482	methodology	2	NA	pf_yn	Yes
10.2147/ceor.s203482	methodology	2	NA	tem_yn	Yes
10.2147/ceor.s203482	methodology	2	NA	adjustment_model_details_yn	No
10.2147/ceor.s203482	methodology	2	NA	scale_choice_yn	No
10.2147/ceor.s203482	results	1	NA	contrast_effect_type	HR
10.2147/ceor.s203482	results	1	NA	direction_benefit	inferior
10.2147/ceor.s203482	results	1	NA	ss_ttt_nonipd	241
10.2147/ceor.s203482	results	1	NA	ss_ttt_ipd	78
10.2147/ceor.s203482	results	1	NA	ss_adjusted_ttt_ipd	78
10.2147/ceor.s203482	results	1	NA	weights_yn	NA
10.2147/ceor.s203482	results	1	NA	covariates_yn	Yes
10.2147/ceor.s203482	results	1	NA	covariates_n	3
10.2147/ceor.s203482	results	1	NA	covariates_names	Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease)
10.2147/ceor.s203482	results	1	NA	contrast_effect_direction	Numerator if ratio, or left side if difference
10.2147/ceor.s203482	results	1	NA	contrast_effect_unadjusted_value	0.514
10.2147/ceor.s203482	results	1	NA	contrast_effect_unadjusted_pvalci	[0.310;0.852]
10.2147/ceor.s203482	results	1	NA	contrast_effect_adjusted_value	0.424
10.2147/ceor.s203482	results	1	NA	contrast_effect_adjusted_pvalci	[0.228;0.789]
10.2147/ceor.s203482	results	1	NA	adjustment_geographical	NA
10.2147/ceor.s203482	results	1	NA	ss_total_ipd	NA
10.2147/ceor.s203482	results	1	NA	ss_adjusted_total_ipd	NA
10.2147/ceor.s203482	results	1	NA	ss_total_nonipd	NA
10.2147/ceor.s203482	results	1	NA	ss_anchor_nonipd	158
10.2147/ceor.s203482	results	1	NA	ss_anchor_ipd	38
10.2147/ceor.s203482	results	1	NA	ss_adjusted_anchor_ipd	38
10.2147/ceor.s203482	results	1	NA	effect_cutoff	1
10.2147/ceor.s203482	results	1	NA	unadjusted_lb_ci	0.31
10.2147/ceor.s203482	results	1	NA	unadjusted_ub_ci	0.852
10.2147/ceor.s203482	results	1	NA	unadjusted_significant	TRUE
10.2147/ceor.s203482	results	1	NA	adjusted_lb_ci	0.228
10.2147/ceor.s203482	results	1	NA	adjusted_ub_ci	0.789
10.2147/ceor.s203482	results	1	NA	adjusted_significant	TRUE
10.2147/ceor.s203482	results	2	NA	contrast_effect_type	HR
10.2147/ceor.s203482	results	2	NA	direction_benefit	inferior
10.2147/ceor.s203482	results	2	NA	ss_ttt_nonipd	242
10.2147/ceor.s203482	results	2	NA	ss_ttt_ipd	78
10.2147/ceor.s203482	results	2	NA	ss_adjusted_ttt_ipd	78
10.2147/ceor.s203482	results	2	NA	weights_yn	NA
10.2147/ceor.s203482	results	2	NA	covariates_yn	Yes
10.2147/ceor.s203482	results	2	NA	covariates_n	5
10.2147/ceor.s203482	results	2	NA	covariates_names	Age, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...)
10.2147/ceor.s203482	results	2	NA	contrast_effect_direction	Numerator if ratio, or left side if difference
10.2147/ceor.s203482	results	2	NA	contrast_effect_unadjusted_value	0.565
10.2147/ceor.s203482	results	2	NA	contrast_effect_unadjusted_pvalci	[0.351;0.909]
10.2147/ceor.s203482	results	2	NA	contrast_effect_adjusted_value	0.505
10.2147/ceor.s203482	results	2	NA	contrast_effect_adjusted_pvalci	[0.269;0.949]
10.2147/ceor.s203482	results	2	NA	adjustment_geographical	NA
10.2147/ceor.s203482	results	2	NA	ss_total_ipd	NA
10.2147/ceor.s203482	results	2	NA	ss_adjusted_total_ipd	NA
10.2147/ceor.s203482	results	2	NA	ss_total_nonipd	NA
10.2147/ceor.s203482	results	2	NA	ss_anchor_nonipd	215
10.2147/ceor.s203482	results	2	NA	ss_anchor_ipd	38
10.2147/ceor.s203482	results	2	NA	ss_adjusted_anchor_ipd	38
10.2147/ceor.s203482	results	2	NA	effect_cutoff	1
10.2147/ceor.s203482	results	2	NA	unadjusted_lb_ci	0.351
10.2147/ceor.s203482	results	2	NA	unadjusted_ub_ci	0.909
10.2147/ceor.s203482	results	2	NA	unadjusted_significant	TRUE
10.2147/ceor.s203482	results	2	NA	adjusted_lb_ci	0.269
10.2147/ceor.s203482	results	2	NA	adjusted_ub_ci	0.949
10.2147/ceor.s203482	results	2	NA	adjusted_significant	TRUE
10.2147/ceor.s203482	study_information	NA	1	ipd_yn	Yes
10.2147/ceor.s203482	study_information	NA	1	ct_yn	Yes
10.2147/ceor.s203482	study_information	NA	1	nct	NCT01546038
10.2147/ceor.s203482	study_information	NA	1	country_study	international
10.2147/ceor.s203482	study_information	NA	1	ct_phase	2
10.2147/ceor.s203482	study_information	NA	1	ct_arms	2 or more
10.2147/ceor.s203482	study_information	NA	2	ipd_yn	No
10.2147/ceor.s203482	study_information	NA	2	ct_yn	Yes
10.2147/ceor.s203482	study_information	NA	2	nct	NCT01074047
10.2147/ceor.s203482	study_information	NA	2	country_study	international
10.2147/ceor.s203482	study_information	NA	2	ct_phase	3
10.2147/ceor.s203482	study_information	NA	2	ct_arms	2 or more
10.2147/ceor.s203482	study_information	NA	3	ipd_yn	No
10.2147/ceor.s203482	study_information	NA	3	ct_yn	Yes
10.2147/ceor.s203482	study_information	NA	3	nct	NCT00260832
10.2147/ceor.s203482	study_information	NA	3	country_study	international
10.2147/ceor.s203482	study_information	NA	3	ct_phase	3
10.2147/ceor.s203482	study_information	NA	3	ct_arms	2 or more
10.2147/cmar.s163478	general_information	NA	NA	condition_name	hr+, her2- advanced breast cancer
10.2147/cmar.s163478	general_information	NA	NA	country_first_author	usa
10.2147/cmar.s163478	general_information	NA	NA	country_last_author	usa
10.2147/cmar.s163478	general_information	NA	NA	positions	Pharmaceutical Industry, Private Data Analysis Company
10.2147/cmar.s163478	general_information	NA	NA	methodologist_yn	Yes
10.2147/cmar.s163478	general_information	NA	NA	funding_source	Pharmaceutical Industry
10.2147/cmar.s163478	general_information	NA	NA	pharmaceutical_ties_yn	Yes
10.2147/cmar.s163478	general_information	NA	NA	systematic_review_yn	Yes
10.2147/cmar.s163478	methodology	1	NA	outcome_name	progression-free survival
10.2147/cmar.s163478	methodology	1	NA	outcome_short_name	Progression-free Survival
10.2147/cmar.s163478	methodology	1	NA	outcome_variable_type	Time-to-event
10.2147/cmar.s163478	methodology	1	NA	treatment_name_ipd	ribociclib
10.2147/cmar.s163478	methodology	1	NA	studies_number_ipd	1
10.2147/cmar.s163478	methodology	1	NA	treatment_name_nonipd	palbociclib
10.2147/cmar.s163478	methodology	1	NA	studies_number_nonipd	2
10.2147/cmar.s163478	methodology	1	NA	paic_type	MAIC
10.2147/cmar.s163478	methodology	1	NA	anchored_yn	Yes
10.2147/cmar.s163478	methodology	1	NA	paic_form	Simple (ie treatments effects extracted from two studies)
10.2147/cmar.s163478	methodology	1	NA	primary_outcome_yn	Yes
10.2147/cmar.s163478	methodology	1	NA	variables_selection_justification	Nothing mentioned, not reported
10.2147/cmar.s163478	methodology	1	NA	pf_yn	Yes
10.2147/cmar.s163478	methodology	1	NA	tem_yn	No discussion (in the main text) of the status of treatment-effect modifiers of the variables
10.2147/cmar.s163478	methodology	1	NA	adjustment_model_details_yn	No
10.2147/cmar.s163478	methodology	1	NA	scale_choice_yn	No
10.2147/cmar.s163478	results	1	NA	contrast_effect_type	HR
10.2147/cmar.s163478	results	1	NA	direction_benefit	inferior
10.2147/cmar.s163478	results	1	NA	ss_ttt_nonipd	444
10.2147/cmar.s163478	results	1	NA	ss_ttt_ipd	227
10.2147/cmar.s163478	results	1	NA	ss_adjusted_ttt_ipd	220
10.2147/cmar.s163478	results	1	NA	weights_yn	Not mentioned
10.2147/cmar.s163478	results	1	NA	covariates_yn	Yes
10.2147/cmar.s163478	results	1	NA	covariates_n	9
10.2147/cmar.s163478	results	1	NA	covariates_names	Age, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Race/ethnicity, Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Past treatments for the disease of interest, Other(s)
10.2147/cmar.s163478	results	1	NA	contrast_effect_direction	Numerator if ratio, or left side if difference
10.2147/cmar.s163478	results	1	NA	contrast_effect_unadjusted_value	0.959
10.2147/cmar.s163478	results	1	NA	contrast_effect_unadjusted_pvalci	[0.681;1.350]
10.2147/cmar.s163478	results	1	NA	contrast_effect_adjusted_value	0.904
10.2147/cmar.s163478	results	1	NA	contrast_effect_adjusted_pvalci	[0.644;1.268]
10.2147/cmar.s163478	results	1	NA	adjustment_geographical	Yes
10.2147/cmar.s163478	results	1	NA	ss_total_ipd	NA
10.2147/cmar.s163478	results	1	NA	ss_adjusted_total_ipd	NA
10.2147/cmar.s163478	results	1	NA	ss_total_nonipd	NA
10.2147/cmar.s163478	results	1	NA	ss_anchor_nonipd	222
10.2147/cmar.s163478	results	1	NA	ss_anchor_ipd	244
10.2147/cmar.s163478	results	1	NA	ss_adjusted_anchor_ipd	237
10.2147/cmar.s163478	results	1	NA	effect_cutoff	1
10.2147/cmar.s163478	results	1	NA	unadjusted_lb_ci	0.681
10.2147/cmar.s163478	results	1	NA	unadjusted_ub_ci	1.35
10.2147/cmar.s163478	results	1	NA	unadjusted_significant	FALSE
10.2147/cmar.s163478	results	1	NA	adjusted_lb_ci	0.644
10.2147/cmar.s163478	results	1	NA	adjusted_ub_ci	1.268
10.2147/cmar.s163478	results	1	NA	adjusted_significant	FALSE
10.2147/cmar.s163478	study_information	NA	1	ipd_yn	Yes
10.2147/cmar.s163478	study_information	NA	1	ct_yn	Yes
10.2147/cmar.s163478	study_information	NA	1	nct	NCT01958021
10.2147/cmar.s163478	study_information	NA	1	country_study	international
10.2147/cmar.s163478	study_information	NA	1	ct_phase	3
10.2147/cmar.s163478	study_information	NA	1	ct_arms	2 or more
10.2147/cmar.s163478	study_information	NA	2	ipd_yn	No
10.2147/cmar.s163478	study_information	NA	2	ct_yn	Yes
10.2147/cmar.s163478	study_information	NA	2	nct	NCT01740427
10.2147/cmar.s163478	study_information	NA	2	country_study	international
10.2147/cmar.s163478	study_information	NA	2	ct_phase	3
10.2147/cmar.s163478	study_information	NA	2	ct_arms	2 or more
10.2147/cmar.s325043	general_information	NA	NA	condition_name	hr+/her2? advanced breast cancer
10.2147/cmar.s325043	general_information	NA	NA	country_first_author	germany
10.2147/cmar.s325043	general_information	NA	NA	country_last_author	usa
10.2147/cmar.s325043	general_information	NA	NA	positions	Academic, Pharmaceutical Industry, Private Data Analysis Company
10.2147/cmar.s325043	general_information	NA	NA	methodologist_yn	Yes
10.2147/cmar.s325043	general_information	NA	NA	funding_source	Pharmaceutical Industry
10.2147/cmar.s325043	general_information	NA	NA	pharmaceutical_ties_yn	Yes
10.2147/cmar.s325043	general_information	NA	NA	systematic_review_yn	No
10.2147/cmar.s325043	methodology	1	NA	outcome_name	progression-free survival
10.2147/cmar.s325043	methodology	1	NA	outcome_short_name	Progression-free Survival
10.2147/cmar.s325043	methodology	1	NA	outcome_variable_type	Time-to-event
10.2147/cmar.s325043	methodology	1	NA	treatment_name_ipd	ribociclib + fulvestrant
10.2147/cmar.s325043	methodology	1	NA	studies_number_ipd	1
10.2147/cmar.s325043	methodology	1	NA	treatment_name_nonipd	palbociclib + letrozole
10.2147/cmar.s325043	methodology	1	NA	studies_number_nonipd	2
10.2147/cmar.s325043	methodology	1	NA	paic_type	MAIC
10.2147/cmar.s325043	methodology	1	NA	anchored_yn	No
10.2147/cmar.s325043	methodology	1	NA	paic_form	Simple (ie treatments effects extracted from two studies)
10.2147/cmar.s325043	methodology	1	NA	primary_outcome_yn	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.2147/cmar.s325043	methodology	1	NA	variables_selection_justification	Nothing mentioned, not reported
10.2147/cmar.s325043	methodology	1	NA	pf_yn	No discussion (in the main text) of the status of prognostic factors of the variables
10.2147/cmar.s325043	methodology	1	NA	tem_yn	No discussion (in the main text) of the status of treatment-effect modifiers of the variables
10.2147/cmar.s325043	methodology	1	NA	adjustment_model_details_yn	No
10.2147/cmar.s325043	methodology	1	NA	scale_choice_yn	No
10.2147/cmar.s325043	methodology	2	NA	outcome_name	progression-free survival
10.2147/cmar.s325043	methodology	2	NA	outcome_short_name	Progression-free Survival
10.2147/cmar.s325043	methodology	2	NA	outcome_variable_type	Time-to-event
10.2147/cmar.s325043	methodology	2	NA	treatment_name_ipd	placebo + fulvestrant
10.2147/cmar.s325043	methodology	2	NA	studies_number_ipd	1
10.2147/cmar.s325043	methodology	2	NA	treatment_name_nonipd	letrozole
10.2147/cmar.s325043	methodology	2	NA	studies_number_nonipd	2
10.2147/cmar.s325043	methodology	2	NA	paic_type	MAIC
10.2147/cmar.s325043	methodology	2	NA	anchored_yn	No
10.2147/cmar.s325043	methodology	2	NA	paic_form	Simple (ie treatments effects extracted from two studies)
10.2147/cmar.s325043	methodology	2	NA	primary_outcome_yn	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.2147/cmar.s325043	methodology	2	NA	variables_selection_justification	Nothing mentioned, not reported
10.2147/cmar.s325043	methodology	2	NA	pf_yn	No discussion (in the main text) of the status of prognostic factors of the variables
10.2147/cmar.s325043	methodology	2	NA	tem_yn	No discussion (in the main text) of the status of treatment-effect modifiers of the variables
10.2147/cmar.s325043	methodology	2	NA	adjustment_model_details_yn	No
10.2147/cmar.s325043	methodology	2	NA	scale_choice_yn	No
10.2147/cmar.s325043	results	1	NA	contrast_effect_type	HR
10.2147/cmar.s325043	results	1	NA	direction_benefit	inferior
10.2147/cmar.s325043	results	1	NA	ss_ttt_nonipd	84
10.2147/cmar.s325043	results	1	NA	ss_ttt_ipd	329
10.2147/cmar.s325043	results	1	NA	ss_adjusted_ttt_ipd	221
10.2147/cmar.s325043	results	1	NA	weights_yn	Yes, mentions that the weights distribution has been studied, and weights distribution reported in main article or supplemental materials
10.2147/cmar.s325043	results	1	NA	covariates_yn	Yes
10.2147/cmar.s325043	results	1	NA	covariates_n	7
10.2147/cmar.s325043	results	1	NA	covariates_names	Age, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Past treatments for the disease of interest
10.2147/cmar.s325043	results	1	NA	contrast_effect_direction	Numerator if ratio, or left side if difference
10.2147/cmar.s325043	results	1	NA	contrast_effect_unadjusted_value	0.83
10.2147/cmar.s325043	results	1	NA	contrast_effect_unadjusted_pvalci	0.2838
10.2147/cmar.s325043	results	1	NA	contrast_effect_adjusted_value	0.77
10.2147/cmar.s325043	results	1	NA	contrast_effect_adjusted_pvalci	0.1553
10.2147/cmar.s325043	results	1	NA	adjustment_geographical	NA
10.2147/cmar.s325043	results	1	NA	ss_total_ipd	NA
10.2147/cmar.s325043	results	1	NA	ss_adjusted_total_ipd	NA
10.2147/cmar.s325043	results	1	NA	ss_total_nonipd	NA
10.2147/cmar.s325043	results	1	NA	ss_anchor_nonipd	NA
10.2147/cmar.s325043	results	1	NA	ss_anchor_ipd	NA
10.2147/cmar.s325043	results	1	NA	ss_adjusted_anchor_ipd	NA
10.2147/cmar.s325043	results	1	NA	effect_cutoff	1
10.2147/cmar.s325043	results	1	NA	unadjusted_pval	0.2838
10.2147/cmar.s325043	results	1	NA	unadjusted_num_pval	0.2838
10.2147/cmar.s325043	results	1	NA	unadjusted_significant	FALSE
10.2147/cmar.s325043	results	1	NA	adjusted_pval	0.1553
10.2147/cmar.s325043	results	1	NA	adjusted_num_pval	0.1553
10.2147/cmar.s325043	results	1	NA	adjusted_significant	FALSE
10.2147/cmar.s325043	results	2	NA	contrast_effect_type	HR
10.2147/cmar.s325043	results	2	NA	direction_benefit	inferior
10.2147/cmar.s325043	results	2	NA	ss_ttt_nonipd	81
10.2147/cmar.s325043	results	2	NA	ss_ttt_ipd	178
10.2147/cmar.s325043	results	2	NA	ss_adjusted_ttt_ipd	117
10.2147/cmar.s325043	results	2	NA	weights_yn	Yes, mentions that the weights distribution has been studied, and weights distribution reported in main article or supplemental materials
10.2147/cmar.s325043	results	2	NA	covariates_yn	Yes
10.2147/cmar.s325043	results	2	NA	covariates_n	7
10.2147/cmar.s325043	results	2	NA	covariates_names	Age, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Past treatments for the disease of interest
10.2147/cmar.s325043	results	2	NA	contrast_effect_direction	Numerator if ratio, or left side if difference
10.2147/cmar.s325043	results	2	NA	contrast_effect_unadjusted_value	0.66
10.2147/cmar.s325043	results	2	NA	contrast_effect_unadjusted_pvalci	0.0094
10.2147/cmar.s325043	results	2	NA	contrast_effect_adjusted_value	0.58
10.2147/cmar.s325043	results	2	NA	contrast_effect_adjusted_pvalci	0.0019
10.2147/cmar.s325043	results	2	NA	adjustment_geographical	NA
10.2147/cmar.s325043	results	2	NA	ss_total_ipd	NA
10.2147/cmar.s325043	results	2	NA	ss_adjusted_total_ipd	NA
10.2147/cmar.s325043	results	2	NA	ss_total_nonipd	NA
10.2147/cmar.s325043	results	2	NA	ss_anchor_nonipd	NA
10.2147/cmar.s325043	results	2	NA	ss_anchor_ipd	NA
10.2147/cmar.s325043	results	2	NA	ss_adjusted_anchor_ipd	NA
10.2147/cmar.s325043	results	2	NA	effect_cutoff	1
10.2147/cmar.s325043	results	2	NA	unadjusted_pval	0.0094
10.2147/cmar.s325043	results	2	NA	unadjusted_num_pval	0.0094
10.2147/cmar.s325043	results	2	NA	unadjusted_significant	TRUE
10.2147/cmar.s325043	results	2	NA	adjusted_pval	0.0019
10.2147/cmar.s325043	results	2	NA	adjusted_num_pval	0.0019
10.2147/cmar.s325043	results	2	NA	adjusted_significant	TRUE
10.2147/cmar.s325043	study_information	NA	1	ipd_yn	Yes
10.2147/cmar.s325043	study_information	NA	1	ct_yn	Yes
10.2147/cmar.s325043	study_information	NA	1	nct	NCT02422615
10.2147/cmar.s325043	study_information	NA	1	country_study	international
10.2147/cmar.s325043	study_information	NA	1	ct_phase	3
10.2147/cmar.s325043	study_information	NA	1	ct_arms	2 or more
10.2147/cmar.s325043	study_information	NA	2	ipd_yn	No
10.2147/cmar.s325043	study_information	NA	2	ct_yn	Yes
10.2147/cmar.s325043	study_information	NA	2	nct	NCT00721409
10.2147/cmar.s325043	study_information	NA	2	country_study	international
10.2147/cmar.s325043	study_information	NA	2	ct_phase	2
10.2147/cmar.s325043	study_information	NA	2	ct_arms	2 or more
10.2147/jbm.s104074	general_information	NA	NA	condition_name	severe hemophilia a
10.2147/jbm.s104074	general_information	NA	NA	country_first_author	usa
10.2147/jbm.s104074	general_information	NA	NA	country_last_author	usa
10.2147/jbm.s104074	general_information	NA	NA	positions	Pharmaceutical Industry, Private Data Analysis Company
10.2147/jbm.s104074	general_information	NA	NA	methodologist_yn	Yes
10.2147/jbm.s104074	general_information	NA	NA	funding_source	Pharmaceutical Industry
10.2147/jbm.s104074	general_information	NA	NA	pharmaceutical_ties_yn	Yes
10.2147/jbm.s104074	general_information	NA	NA	systematic_review_yn	Yes
10.2147/jbm.s104074	methodology	1	NA	outcome_name	square root transformed abr : annualized bleed rates at 1 year (all bleed)
10.2147/jbm.s104074	methodology	1	NA	outcome_short_name	Annualized bleeding Rate
10.2147/jbm.s104074	methodology	1	NA	outcome_variable_type	Continuous (count, mean, ...)
10.2147/jbm.s104074	methodology	1	NA	treatment_name_ipd	bay 81-8973 (recombinant factor viii)
10.2147/jbm.s104074	methodology	1	NA	studies_number_ipd	1;2
10.2147/jbm.s104074	methodology	1	NA	treatment_name_nonipd	rahf-pfm
10.2147/jbm.s104074	methodology	1	NA	studies_number_nonipd	4
10.2147/jbm.s104074	methodology	1	NA	paic_type	MAIC
10.2147/jbm.s104074	methodology	1	NA	anchored_yn	No
10.2147/jbm.s104074	methodology	1	NA	paic_form	Aggregation of multiple studies to estimate individual treatment effects (e.g. meta-analysis in a first step to estimate treatment A effect, then population adjusted indirect comparison using treatment A effect estimate)
10.2147/jbm.s104074	methodology	1	NA	primary_outcome_yn	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.2147/jbm.s104074	methodology	1	NA	variables_selection_justification	Nothing mentioned, not reported
10.2147/jbm.s104074	methodology	1	NA	pf_yn	No discussion (in the main text) of the status of prognostic factors of the variables
10.2147/jbm.s104074	methodology	1	NA	tem_yn	No discussion (in the main text) of the status of treatment-effect modifiers of the variables
10.2147/jbm.s104074	methodology	1	NA	adjustment_model_details_yn	No
10.2147/jbm.s104074	methodology	1	NA	scale_choice_yn	No
10.2147/jbm.s104074	methodology	2	NA	outcome_name	annualized bleed rates for all bleeds (1-year)
10.2147/jbm.s104074	methodology	2	NA	outcome_short_name	Annualized bleeding Rate
10.2147/jbm.s104074	methodology	2	NA	outcome_variable_type	Continuous (count, mean, ...)
10.2147/jbm.s104074	methodology	2	NA	treatment_name_ipd	bay 81-8973 (recombinant factor viii)
10.2147/jbm.s104074	methodology	2	NA	studies_number_ipd	1;2
10.2147/jbm.s104074	methodology	2	NA	treatment_name_nonipd	rahf-pfm
10.2147/jbm.s104074	methodology	2	NA	studies_number_nonipd	3
10.2147/jbm.s104074	methodology	2	NA	paic_type	MAIC
10.2147/jbm.s104074	methodology	2	NA	anchored_yn	No
10.2147/jbm.s104074	methodology	2	NA	paic_form	Aggregation of multiple studies to estimate individual treatment effects (e.g. meta-analysis in a first step to estimate treatment A effect, then population adjusted indirect comparison using treatment A effect estimate)
10.2147/jbm.s104074	methodology	2	NA	primary_outcome_yn	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.2147/jbm.s104074	methodology	2	NA	variables_selection_justification	Nothing mentioned, not reported
10.2147/jbm.s104074	methodology	2	NA	pf_yn	No discussion (in the main text) of the status of prognostic factors of the variables
10.2147/jbm.s104074	methodology	2	NA	tem_yn	No discussion (in the main text) of the status of treatment-effect modifiers of the variables
10.2147/jbm.s104074	methodology	2	NA	adjustment_model_details_yn	No
10.2147/jbm.s104074	methodology	2	NA	scale_choice_yn	No
10.2147/jbm.s104074	methodology	3	NA	outcome_name	annualized bleed rates for all bleeds (1-year)
10.2147/jbm.s104074	methodology	3	NA	outcome_short_name	Annualized bleeding Rate
10.2147/jbm.s104074	methodology	3	NA	outcome_variable_type	Continuous (count, mean, ...)
10.2147/jbm.s104074	methodology	3	NA	treatment_name_ipd	bay 81-8973 (recombinant factor viii)
10.2147/jbm.s104074	methodology	3	NA	studies_number_ipd	1;2
10.2147/jbm.s104074	methodology	3	NA	treatment_name_nonipd	turoctocog alfa
10.2147/jbm.s104074	methodology	3	NA	studies_number_nonipd	5
10.2147/jbm.s104074	methodology	3	NA	paic_type	MAIC
10.2147/jbm.s104074	methodology	3	NA	anchored_yn	No
10.2147/jbm.s104074	methodology	3	NA	paic_form	Aggregation of multiple studies to estimate individual treatment effects (e.g. meta-analysis in a first step to estimate treatment A effect, then population adjusted indirect comparison using treatment A effect estimate)
10.2147/jbm.s104074	methodology	3	NA	primary_outcome_yn	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.2147/jbm.s104074	methodology	3	NA	variables_selection_justification	Nothing mentioned, not reported
10.2147/jbm.s104074	methodology	3	NA	pf_yn	No discussion (in the main text) of the status of prognostic factors of the variables
10.2147/jbm.s104074	methodology	3	NA	tem_yn	No discussion (in the main text) of the status of treatment-effect modifiers of the variables
10.2147/jbm.s104074	methodology	3	NA	adjustment_model_details_yn	No
10.2147/jbm.s104074	methodology	3	NA	scale_choice_yn	No
10.2147/jbm.s104074	results	1	NA	contrast_effect_type	Means difference
10.2147/jbm.s104074	results	1	NA	direction_benefit	inferior
10.2147/jbm.s104074	results	1	NA	ss_ttt_nonipd	66
10.2147/jbm.s104074	results	1	NA	ss_ttt_ipd	121
10.2147/jbm.s104074	results	1	NA	ss_adjusted_ttt_ipd	NA
10.2147/jbm.s104074	results	1	NA	weights_yn	Not mentioned
10.2147/jbm.s104074	results	1	NA	covariates_yn	Yes
10.2147/jbm.s104074	results	1	NA	covariates_n	2
10.2147/jbm.s104074	results	1	NA	covariates_names	Age, Race/ethnicity
10.2147/jbm.s104074	results	1	NA	contrast_effect_direction	Numerator if ratio, or left side if difference
10.2147/jbm.s104074	results	1	NA	contrast_effect_unadjusted_value	0.1
10.2147/jbm.s104074	results	1	NA	contrast_effect_unadjusted_pvalci	[-0.3;0.4]
10.2147/jbm.s104074	results	1	NA	contrast_effect_adjusted_value	0.1
10.2147/jbm.s104074	results	1	NA	contrast_effect_adjusted_pvalci	[-0.3;0.4]
10.2147/jbm.s104074	results	1	NA	adjustment_geographical	NA
10.2147/jbm.s104074	results	1	NA	ss_total_ipd	NA
10.2147/jbm.s104074	results	1	NA	ss_adjusted_total_ipd	NA
10.2147/jbm.s104074	results	1	NA	ss_total_nonipd	NA
10.2147/jbm.s104074	results	1	NA	ss_anchor_nonipd	NA
10.2147/jbm.s104074	results	1	NA	ss_anchor_ipd	NA
10.2147/jbm.s104074	results	1	NA	ss_adjusted_anchor_ipd	NA
10.2147/jbm.s104074	results	1	NA	effect_cutoff	0
10.2147/jbm.s104074	results	1	NA	unadjusted_lb_ci	-0.3
10.2147/jbm.s104074	results	1	NA	unadjusted_ub_ci	0.4
10.2147/jbm.s104074	results	1	NA	unadjusted_significant	FALSE
10.2147/jbm.s104074	results	1	NA	adjusted_lb_ci	-0.3
10.2147/jbm.s104074	results	1	NA	adjusted_ub_ci	0.4
10.2147/jbm.s104074	results	1	NA	adjusted_significant	FALSE
10.2147/jbm.s104074	results	2	NA	contrast_effect_type	Means difference
10.2147/jbm.s104074	results	2	NA	direction_benefit	inferior
10.2147/jbm.s104074	results	2	NA	ss_ttt_nonipd	107
10.2147/jbm.s104074	results	2	NA	ss_ttt_ipd	121
10.2147/jbm.s104074	results	2	NA	ss_adjusted_ttt_ipd	NA
10.2147/jbm.s104074	results	2	NA	weights_yn	Not mentioned
10.2147/jbm.s104074	results	2	NA	covariates_yn	Yes
10.2147/jbm.s104074	results	2	NA	covariates_n	2
10.2147/jbm.s104074	results	2	NA	covariates_names	Age, Race/ethnicity
10.2147/jbm.s104074	results	2	NA	contrast_effect_direction	Numerator if ratio, or left side if difference
10.2147/jbm.s104074	results	2	NA	contrast_effect_unadjusted_value	-1.9
10.2147/jbm.s104074	results	2	NA	contrast_effect_unadjusted_pvalci	[-3.5;-0.4] p<0.05
10.2147/jbm.s104074	results	2	NA	contrast_effect_adjusted_value	-1.5
10.2147/jbm.s104074	results	2	NA	contrast_effect_adjusted_pvalci	[-3.7;-0.7] p=0.18
10.2147/jbm.s104074	results	2	NA	adjustment_geographical	NA
10.2147/jbm.s104074	results	2	NA	ss_total_ipd	NA
10.2147/jbm.s104074	results	2	NA	ss_adjusted_total_ipd	NA
10.2147/jbm.s104074	results	2	NA	ss_total_nonipd	NA
10.2147/jbm.s104074	results	2	NA	ss_anchor_nonipd	NA
10.2147/jbm.s104074	results	2	NA	ss_anchor_ipd	NA
10.2147/jbm.s104074	results	2	NA	ss_adjusted_anchor_ipd	NA
10.2147/jbm.s104074	results	2	NA	effect_cutoff	0
10.2147/jbm.s104074	results	2	NA	unadjusted_lb_ci	-3.5
10.2147/jbm.s104074	results	2	NA	unadjusted_ub_ci	-0.4
10.2147/jbm.s104074	results	2	NA	unadjusted_pval	<0.05
10.2147/jbm.s104074	results	2	NA	unadjusted_significant	TRUE
10.2147/jbm.s104074	results	2	NA	adjusted_lb_ci	-3.7
10.2147/jbm.s104074	results	2	NA	adjusted_ub_ci	-0.7
10.2147/jbm.s104074	results	2	NA	adjusted_pval	=0.18
10.2147/jbm.s104074	results	2	NA	adjusted_significant	TRUE
10.2147/jbm.s104074	results	3	NA	contrast_effect_type	Means difference
10.2147/jbm.s104074	results	3	NA	direction_benefit	inferior
10.2147/jbm.s104074	results	3	NA	ss_ttt_nonipd	150
10.2147/jbm.s104074	results	3	NA	ss_ttt_ipd	121
10.2147/jbm.s104074	results	3	NA	ss_adjusted_ttt_ipd	NA
10.2147/jbm.s104074	results	3	NA	weights_yn	Not mentioned
10.2147/jbm.s104074	results	3	NA	covariates_yn	Yes
10.2147/jbm.s104074	results	3	NA	covariates_n	3
10.2147/jbm.s104074	results	3	NA	covariates_names	Age, Race/ethnicity, Other(s)
10.2147/jbm.s104074	results	3	NA	contrast_effect_direction	Numerator if ratio, or left side if difference
10.2147/jbm.s104074	results	3	NA	contrast_effect_unadjusted_value	-2.1
10.2147/jbm.s104074	results	3	NA	contrast_effect_unadjusted_pvalci	[-3.3;-1.0] p<0.01
10.2147/jbm.s104074	results	3	NA	contrast_effect_adjusted_value	-2.2
10.2147/jbm.s104074	results	3	NA	contrast_effect_adjusted_pvalci	[-3.4;-1.0] p<0.05
10.2147/jbm.s104074	results	3	NA	adjustment_geographical	No
10.2147/jbm.s104074	results	3	NA	ss_total_ipd	NA
10.2147/jbm.s104074	results	3	NA	ss_adjusted_total_ipd	NA
10.2147/jbm.s104074	results	3	NA	ss_total_nonipd	NA
10.2147/jbm.s104074	results	3	NA	ss_anchor_nonipd	NA
10.2147/jbm.s104074	results	3	NA	ss_anchor_ipd	NA
10.2147/jbm.s104074	results	3	NA	ss_adjusted_anchor_ipd	NA
10.2147/jbm.s104074	results	3	NA	effect_cutoff	0
10.2147/jbm.s104074	results	3	NA	unadjusted_lb_ci	-3.3
10.2147/jbm.s104074	results	3	NA	unadjusted_ub_ci	-1
10.2147/jbm.s104074	results	3	NA	unadjusted_pval	<0.01
10.2147/jbm.s104074	results	3	NA	unadjusted_significant	TRUE
10.2147/jbm.s104074	results	3	NA	adjusted_lb_ci	-3.4
10.2147/jbm.s104074	results	3	NA	adjusted_ub_ci	-1
10.2147/jbm.s104074	results	3	NA	adjusted_pval	<0.05
10.2147/jbm.s104074	results	3	NA	adjusted_significant	TRUE
10.2147/jbm.s104074	study_information	NA	1	ipd_yn	Yes
10.2147/jbm.s104074	study_information	NA	1	ct_yn	Yes
10.2147/jbm.s104074	study_information	NA	1	nct	NCT01029340
10.2147/jbm.s104074	study_information	NA	1	country_study	international
10.2147/jbm.s104074	study_information	NA	1	ct_phase	3
10.2147/jbm.s104074	study_information	NA	1	ct_arms	2 or more
10.2147/jbm.s104074	study_information	NA	2	ipd_yn	Yes
10.2147/jbm.s104074	study_information	NA	2	ct_yn	Yes
10.2147/jbm.s104074	study_information	NA	2	nct	NCT01233258
10.2147/jbm.s104074	study_information	NA	2	country_study	international
10.2147/jbm.s104074	study_information	NA	2	ct_phase	3
10.2147/jbm.s104074	study_information	NA	2	ct_arms	2 or more
10.2147/jbm.s104074	study_information	NA	3	ipd_yn	No
10.2147/jbm.s104074	study_information	NA	3	ct_yn	Yes
10.2147/jbm.s104074	study_information	NA	3	data_source_name	tarantino et al. (2004)
10.2147/jbm.s104074	study_information	NA	3	country_study	international
10.2147/jbm.s104074	study_information	NA	4	ipd_yn	No
10.2147/jbm.s104074	study_information	NA	4	ct_yn	Yes
10.2147/jbm.s104074	study_information	NA	4	nct	NCT00243386
10.2147/jbm.s104074	study_information	NA	4	country_study	international
10.2147/jbm.s104074	study_information	NA	4	ct_phase	4
10.2147/jbm.s104074	study_information	NA	4	ct_arms	1
10.2147/jbm.s104074	study_information	NA	5	ipd_yn	No
10.2147/jbm.s104074	study_information	NA	5	ct_yn	Yes
10.2147/jbm.s104074	study_information	NA	5	nct	NCT00840086
10.2147/jbm.s104074	study_information	NA	5	country_study	international
10.2147/jbm.s104074	study_information	NA	5	ct_phase	3
10.2147/jbm.s104074	study_information	NA	5	ct_arms	1
10.2147/jbm.s206806	general_information	NA	NA	condition_name	severe hemophilia a
10.2147/jbm.s206806	general_information	NA	NA	country_first_author	usa
10.2147/jbm.s206806	general_information	NA	NA	country_last_author	germany
10.2147/jbm.s206806	general_information	NA	NA	positions	Academic, Pharmaceutical Industry, Private Data Analysis Company
10.2147/jbm.s206806	general_information	NA	NA	methodologist_yn	Yes
10.2147/jbm.s206806	general_information	NA	NA	funding_source	Pharmaceutical Industry
10.2147/jbm.s206806	general_information	NA	NA	pharmaceutical_ties_yn	Yes
10.2147/jbm.s206806	general_information	NA	NA	systematic_review_yn	Yes
10.2147/jbm.s206806	methodology	1	NA	outcome_name	annualized bleeding rate
10.2147/jbm.s206806	methodology	1	NA	outcome_short_name	Mean Annualized Bleeding Rate
10.2147/jbm.s206806	methodology	1	NA	outcome_variable_type	Continuous (count, mean, ...)
10.2147/jbm.s206806	methodology	1	NA	treatment_name_ipd	bay 94-9027
10.2147/jbm.s206806	methodology	1	NA	studies_number_ipd	1
10.2147/jbm.s206806	methodology	1	NA	treatment_name_nonipd	rfviiifc
10.2147/jbm.s206806	methodology	1	NA	studies_number_nonipd	2
10.2147/jbm.s206806	methodology	1	NA	paic_type	MAIC
10.2147/jbm.s206806	methodology	1	NA	anchored_yn	No
10.2147/jbm.s206806	methodology	1	NA	paic_form	Simple (ie treatments effects extracted from two studies)
10.2147/jbm.s206806	methodology	1	NA	primary_outcome_yn	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.2147/jbm.s206806	methodology	1	NA	variables_selection_justification	Nothing mentioned, not reported
10.2147/jbm.s206806	methodology	1	NA	pf_yn	No discussion (in the main text) of the status of prognostic factors of the variables
10.2147/jbm.s206806	methodology	1	NA	tem_yn	No discussion (in the main text) of the status of treatment-effect modifiers of the variables
10.2147/jbm.s206806	methodology	1	NA	adjustment_model_details_yn	No
10.2147/jbm.s206806	methodology	1	NA	scale_choice_yn	No
10.2147/jbm.s206806	methodology	2	NA	outcome_name	annualized bleeding rate
10.2147/jbm.s206806	methodology	2	NA	outcome_short_name	Mean Annualized Bleeding Rate
10.2147/jbm.s206806	methodology	2	NA	outcome_variable_type	Continuous (count, mean, ...)
10.2147/jbm.s206806	methodology	2	NA	treatment_name_ipd	bay 94-9027
10.2147/jbm.s206806	methodology	2	NA	studies_number_ipd	1
10.2147/jbm.s206806	methodology	2	NA	treatment_name_nonipd	bax 855
10.2147/jbm.s206806	methodology	2	NA	studies_number_nonipd	3
10.2147/jbm.s206806	methodology	2	NA	paic_type	MAIC
10.2147/jbm.s206806	methodology	2	NA	anchored_yn	No
10.2147/jbm.s206806	methodology	2	NA	paic_form	Simple (ie treatments effects extracted from two studies)
10.2147/jbm.s206806	methodology	2	NA	primary_outcome_yn	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.2147/jbm.s206806	methodology	2	NA	variables_selection_justification	Nothing mentioned, not reported
10.2147/jbm.s206806	methodology	2	NA	pf_yn	No discussion (in the main text) of the status of prognostic factors of the variables
10.2147/jbm.s206806	methodology	2	NA	tem_yn	No discussion (in the main text) of the status of treatment-effect modifiers of the variables
10.2147/jbm.s206806	methodology	2	NA	adjustment_model_details_yn	No
10.2147/jbm.s206806	methodology	2	NA	scale_choice_yn	No
10.2147/jbm.s206806	methodology	3	NA	outcome_name	annualized bleeding rate
10.2147/jbm.s206806	methodology	3	NA	outcome_short_name	Mean Annualized Bleeding Rate
10.2147/jbm.s206806	methodology	3	NA	outcome_variable_type	Continuous (count, mean, ...)
10.2147/jbm.s206806	methodology	3	NA	treatment_name_ipd	bay 94-9027
10.2147/jbm.s206806	methodology	3	NA	studies_number_ipd	1
10.2147/jbm.s206806	methodology	3	NA	treatment_name_nonipd	rahf-pfm 2004
10.2147/jbm.s206806	methodology	3	NA	studies_number_nonipd	4
10.2147/jbm.s206806	methodology	3	NA	paic_type	MAIC
10.2147/jbm.s206806	methodology	3	NA	anchored_yn	No
10.2147/jbm.s206806	methodology	3	NA	paic_form	Simple (ie treatments effects extracted from two studies)
10.2147/jbm.s206806	methodology	3	NA	primary_outcome_yn	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.2147/jbm.s206806	methodology	3	NA	variables_selection_justification	Nothing mentioned, not reported
10.2147/jbm.s206806	methodology	3	NA	pf_yn	No discussion (in the main text) of the status of prognostic factors of the variables
10.2147/jbm.s206806	methodology	3	NA	tem_yn	No discussion (in the main text) of the status of treatment-effect modifiers of the variables
10.2147/jbm.s206806	methodology	3	NA	adjustment_model_details_yn	No
10.2147/jbm.s206806	methodology	3	NA	scale_choice_yn	No
10.2147/jbm.s206806	methodology	4	NA	outcome_name	annualized bleeding rate
10.2147/jbm.s206806	methodology	4	NA	outcome_short_name	Mean Annualized Bleeding Rate
10.2147/jbm.s206806	methodology	4	NA	outcome_variable_type	Continuous (count, mean, ...)
10.2147/jbm.s206806	methodology	4	NA	treatment_name_ipd	bay 94-9027
10.2147/jbm.s206806	methodology	4	NA	studies_number_ipd	1
10.2147/jbm.s206806	methodology	4	NA	treatment_name_nonipd	rahf-pfm 2012
10.2147/jbm.s206806	methodology	4	NA	studies_number_nonipd	5
10.2147/jbm.s206806	methodology	4	NA	paic_type	MAIC
10.2147/jbm.s206806	methodology	4	NA	anchored_yn	No
10.2147/jbm.s206806	methodology	4	NA	paic_form	Simple (ie treatments effects extracted from two studies)
10.2147/jbm.s206806	methodology	4	NA	primary_outcome_yn	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.2147/jbm.s206806	methodology	4	NA	variables_selection_justification	Nothing mentioned, not reported
10.2147/jbm.s206806	methodology	4	NA	pf_yn	No discussion (in the main text) of the status of prognostic factors of the variables
10.2147/jbm.s206806	methodology	4	NA	tem_yn	No discussion (in the main text) of the status of treatment-effect modifiers of the variables
10.2147/jbm.s206806	methodology	4	NA	adjustment_model_details_yn	No
10.2147/jbm.s206806	methodology	4	NA	scale_choice_yn	No
10.2147/jbm.s206806	results	1	NA	contrast_effect_type	Means difference
10.2147/jbm.s206806	results	1	NA	direction_benefit	inferior
10.2147/jbm.s206806	results	1	NA	ss_ttt_nonipd	140
10.2147/jbm.s206806	results	1	NA	ss_ttt_ipd	103
10.2147/jbm.s206806	results	1	NA	ss_adjusted_ttt_ipd	44.6
10.2147/jbm.s206806	results	1	NA	weights_yn	Not mentioned
10.2147/jbm.s206806	results	1	NA	covariates_yn	Yes
10.2147/jbm.s206806	results	1	NA	covariates_n	7
10.2147/jbm.s206806	results	1	NA	covariates_names	Age, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Race/ethnicity, Past treatments for the disease of interest, Other(s)
10.2147/jbm.s206806	results	1	NA	contrast_effect_direction	Numerator if ratio, or left side if difference
10.2147/jbm.s206806	results	1	NA	contrast_effect_unadjusted_value	0.17
10.2147/jbm.s206806	results	1	NA	contrast_effect_unadjusted_pvalci	[-1.35;1.70]
10.2147/jbm.s206806	results	1	NA	contrast_effect_adjusted_value	-0.12
10.2147/jbm.s206806	results	1	NA	contrast_effect_adjusted_pvalci	[-1.62;1.37]
10.2147/jbm.s206806	results	1	NA	adjustment_geographical	Yes
10.2147/jbm.s206806	results	1	NA	ss_total_ipd	NA
10.2147/jbm.s206806	results	1	NA	ss_adjusted_total_ipd	NA
10.2147/jbm.s206806	results	1	NA	ss_total_nonipd	NA
10.2147/jbm.s206806	results	1	NA	ss_anchor_nonipd	NA
10.2147/jbm.s206806	results	1	NA	ss_anchor_ipd	NA
10.2147/jbm.s206806	results	1	NA	ss_adjusted_anchor_ipd	NA
10.2147/jbm.s206806	results	1	NA	effect_cutoff	0
10.2147/jbm.s206806	results	1	NA	unadjusted_lb_ci	-1.35
10.2147/jbm.s206806	results	1	NA	unadjusted_ub_ci	1.7
10.2147/jbm.s206806	results	1	NA	unadjusted_significant	FALSE
10.2147/jbm.s206806	results	1	NA	adjusted_lb_ci	-1.62
10.2147/jbm.s206806	results	1	NA	adjusted_ub_ci	1.37
10.2147/jbm.s206806	results	1	NA	adjusted_significant	FALSE
10.2147/jbm.s206806	results	2	NA	contrast_effect_type	Means difference
10.2147/jbm.s206806	results	2	NA	direction_benefit	inferior
10.2147/jbm.s206806	results	2	NA	ss_ttt_nonipd	101
10.2147/jbm.s206806	results	2	NA	ss_ttt_ipd	104
10.2147/jbm.s206806	results	2	NA	ss_adjusted_ttt_ipd	78.3
10.2147/jbm.s206806	results	2	NA	weights_yn	Not mentioned
10.2147/jbm.s206806	results	2	NA	covariates_yn	Yes
10.2147/jbm.s206806	results	2	NA	covariates_n	5
10.2147/jbm.s206806	results	2	NA	covariates_names	Age, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Race/ethnicity, Past treatments for the disease of interest, Other(s)
10.2147/jbm.s206806	results	2	NA	contrast_effect_direction	Numerator if ratio, or left side if difference
10.2147/jbm.s206806	results	2	NA	contrast_effect_unadjusted_value	0.35
10.2147/jbm.s206806	results	2	NA	contrast_effect_unadjusted_pvalci	[-1.00;1.70]
10.2147/jbm.s206806	results	2	NA	contrast_effect_adjusted_value	0.25
10.2147/jbm.s206806	results	2	NA	contrast_effect_adjusted_pvalci	[-1.19;1.70]
10.2147/jbm.s206806	results	2	NA	adjustment_geographical	Yes
10.2147/jbm.s206806	results	2	NA	ss_total_ipd	NA
10.2147/jbm.s206806	results	2	NA	ss_adjusted_total_ipd	NA
10.2147/jbm.s206806	results	2	NA	ss_total_nonipd	NA
10.2147/jbm.s206806	results	2	NA	ss_anchor_nonipd	NA
10.2147/jbm.s206806	results	2	NA	ss_anchor_ipd	NA
10.2147/jbm.s206806	results	2	NA	ss_adjusted_anchor_ipd	NA
10.2147/jbm.s206806	results	2	NA	effect_cutoff	0
10.2147/jbm.s206806	results	2	NA	unadjusted_lb_ci	-1
10.2147/jbm.s206806	results	2	NA	unadjusted_ub_ci	1.7
10.2147/jbm.s206806	results	2	NA	unadjusted_significant	FALSE
10.2147/jbm.s206806	results	2	NA	adjusted_lb_ci	-1.19
10.2147/jbm.s206806	results	2	NA	adjusted_ub_ci	1.7
10.2147/jbm.s206806	results	2	NA	adjusted_significant	FALSE
10.2147/jbm.s206806	results	3	NA	contrast_effect_type	Means difference
10.2147/jbm.s206806	results	3	NA	direction_benefit	inferior
10.2147/jbm.s206806	results	3	NA	ss_ttt_nonipd	66
10.2147/jbm.s206806	results	3	NA	ss_ttt_ipd	104
10.2147/jbm.s206806	results	3	NA	ss_adjusted_ttt_ipd	25.32
10.2147/jbm.s206806	results	3	NA	weights_yn	Not mentioned
10.2147/jbm.s206806	results	3	NA	covariates_yn	Yes
10.2147/jbm.s206806	results	3	NA	covariates_n	3
10.2147/jbm.s206806	results	3	NA	covariates_names	Age, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Race/ethnicity
10.2147/jbm.s206806	results	3	NA	contrast_effect_direction	Numerator if ratio, or left side if difference
10.2147/jbm.s206806	results	3	NA	contrast_effect_unadjusted_value	-2.25
10.2147/jbm.s206806	results	3	NA	contrast_effect_unadjusted_pvalci	[-3.64;-0.85]
10.2147/jbm.s206806	results	3	NA	contrast_effect_adjusted_value	-2.02
10.2147/jbm.s206806	results	3	NA	contrast_effect_adjusted_pvalci	[-4.35;0.30]
10.2147/jbm.s206806	results	3	NA	adjustment_geographical	NA
10.2147/jbm.s206806	results	3	NA	ss_total_ipd	NA
10.2147/jbm.s206806	results	3	NA	ss_adjusted_total_ipd	NA
10.2147/jbm.s206806	results	3	NA	ss_total_nonipd	NA
10.2147/jbm.s206806	results	3	NA	ss_anchor_nonipd	NA
10.2147/jbm.s206806	results	3	NA	ss_anchor_ipd	NA
10.2147/jbm.s206806	results	3	NA	ss_adjusted_anchor_ipd	NA
10.2147/jbm.s206806	results	3	NA	effect_cutoff	0
10.2147/jbm.s206806	results	3	NA	unadjusted_lb_ci	-3.64
10.2147/jbm.s206806	results	3	NA	unadjusted_ub_ci	-0.85
10.2147/jbm.s206806	results	3	NA	unadjusted_significant	TRUE
10.2147/jbm.s206806	results	3	NA	adjusted_lb_ci	-4.35
10.2147/jbm.s206806	results	3	NA	adjusted_ub_ci	0.3
10.2147/jbm.s206806	results	3	NA	adjusted_significant	FALSE
10.2147/jbm.s206806	results	4	NA	contrast_effect_type	Means difference
10.2147/jbm.s206806	results	4	NA	direction_benefit	inferior
10.2147/jbm.s206806	results	4	NA	ss_ttt_nonipd	107
10.2147/jbm.s206806	results	4	NA	ss_ttt_ipd	104
10.2147/jbm.s206806	results	4	NA	ss_adjusted_ttt_ipd	55.33
10.2147/jbm.s206806	results	4	NA	weights_yn	Not mentioned
10.2147/jbm.s206806	results	4	NA	covariates_yn	Yes
10.2147/jbm.s206806	results	4	NA	covariates_n	3
10.2147/jbm.s206806	results	4	NA	covariates_names	Age, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Race/ethnicity
10.2147/jbm.s206806	results	4	NA	contrast_effect_direction	Numerator if ratio, or left side if difference
10.2147/jbm.s206806	results	4	NA	contrast_effect_unadjusted_value	0.03
10.2147/jbm.s206806	results	4	NA	contrast_effect_unadjusted_pvalci	[-0.32;0.37]
10.2147/jbm.s206806	results	4	NA	contrast_effect_adjusted_value	0.07
10.2147/jbm.s206806	results	4	NA	contrast_effect_adjusted_pvalci	[-0.32;0.46]
10.2147/jbm.s206806	results	4	NA	adjustment_geographical	NA
10.2147/jbm.s206806	results	4	NA	ss_total_ipd	NA
10.2147/jbm.s206806	results	4	NA	ss_adjusted_total_ipd	NA
10.2147/jbm.s206806	results	4	NA	ss_total_nonipd	NA
10.2147/jbm.s206806	results	4	NA	ss_anchor_nonipd	NA
10.2147/jbm.s206806	results	4	NA	ss_anchor_ipd	NA
10.2147/jbm.s206806	results	4	NA	ss_adjusted_anchor_ipd	NA
10.2147/jbm.s206806	results	4	NA	effect_cutoff	0
10.2147/jbm.s206806	results	4	NA	unadjusted_lb_ci	-0.32
10.2147/jbm.s206806	results	4	NA	unadjusted_ub_ci	0.37
10.2147/jbm.s206806	results	4	NA	unadjusted_significant	FALSE
10.2147/jbm.s206806	results	4	NA	adjusted_lb_ci	-0.32
10.2147/jbm.s206806	results	4	NA	adjusted_ub_ci	0.46
10.2147/jbm.s206806	results	4	NA	adjusted_significant	FALSE
10.2147/jbm.s206806	study_information	NA	1	ipd_yn	Yes
10.2147/jbm.s206806	study_information	NA	1	ct_yn	Yes
10.2147/jbm.s206806	study_information	NA	1	nct	NCT01580293
10.2147/jbm.s206806	study_information	NA	1	country_study	international
10.2147/jbm.s206806	study_information	NA	1	ct_phase	2, 3
10.2147/jbm.s206806	study_information	NA	1	ct_arms	2 or more
10.2147/jbm.s206806	study_information	NA	2	ipd_yn	No
10.2147/jbm.s206806	study_information	NA	2	ct_yn	Yes
10.2147/jbm.s206806	study_information	NA	2	nct	NCT01181128
10.2147/jbm.s206806	study_information	NA	2	country_study	international
10.2147/jbm.s206806	study_information	NA	2	ct_phase	3
10.2147/jbm.s206806	study_information	NA	2	ct_arms	2 or more
10.2147/jbm.s206806	study_information	NA	3	ipd_yn	No
10.2147/jbm.s206806	study_information	NA	3	ct_yn	Yes
10.2147/jbm.s206806	study_information	NA	3	nct	NCT01736475
10.2147/jbm.s206806	study_information	NA	3	country_study	international
10.2147/jbm.s206806	study_information	NA	3	ct_phase	2, 3
10.2147/jbm.s206806	study_information	NA	3	ct_arms	2 or more
10.2147/jbm.s206806	study_information	NA	4	ipd_yn	No
10.2147/jbm.s206806	study_information	NA	4	ct_yn	Yes
10.2147/jbm.s206806	study_information	NA	4	data_source_name	tarantino et al. (2004)
10.2147/jbm.s206806	study_information	NA	4	ct_arms	2 or more
10.2147/jbm.s206806	study_information	NA	4	country_study	international
10.2147/jbm.s206806	study_information	NA	5	ipd_yn	No
10.2147/jbm.s206806	study_information	NA	5	ct_yn	Yes
10.2147/jbm.s206806	study_information	NA	5	nct	NCT00243386
10.2147/jbm.s206806	study_information	NA	5	country_study	international
10.2147/jbm.s206806	study_information	NA	5	ct_phase	4
10.2147/jbm.s206806	study_information	NA	5	ct_arms	2 or more
10.2147/jbm.s288283	general_information	NA	NA	condition_name	hemophilia a without inhibitors
10.2147/jbm.s288283	general_information	NA	NA	country_first_author	germany
10.2147/jbm.s288283	general_information	NA	NA	country_last_author	usa
10.2147/jbm.s288283	general_information	NA	NA	positions	Academic, Pharmaceutical Industry, Private Data Analysis Company
10.2147/jbm.s288283	general_information	NA	NA	methodologist_yn	Yes
10.2147/jbm.s288283	general_information	NA	NA	funding_source	Pharmaceutical Industry
10.2147/jbm.s288283	general_information	NA	NA	pharmaceutical_ties_yn	Yes
10.2147/jbm.s288283	general_information	NA	NA	systematic_review_yn	No
10.2147/jbm.s288283	methodology	1	NA	outcome_name	mean annualized bleeding rate
10.2147/jbm.s288283	methodology	1	NA	outcome_short_name	Mean Annualized Bleeding Rate
10.2147/jbm.s288283	methodology	1	NA	outcome_variable_type	Continuous (count, mean, ...)
10.2147/jbm.s288283	methodology	1	NA	treatment_name_ipd	rfviiifc
10.2147/jbm.s288283	methodology	1	NA	studies_number_ipd	1
10.2147/jbm.s288283	methodology	1	NA	treatment_name_nonipd	emicizumab every week
10.2147/jbm.s288283	methodology	1	NA	studies_number_nonipd	2
10.2147/jbm.s288283	methodology	1	NA	paic_type	MAIC
10.2147/jbm.s288283	methodology	1	NA	anchored_yn	No
10.2147/jbm.s288283	methodology	1	NA	paic_form	Simple (ie treatments effects extracted from two studies)
10.2147/jbm.s288283	methodology	1	NA	primary_outcome_yn	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.2147/jbm.s288283	methodology	1	NA	variables_selection_justification	Nothing mentioned, not reported
10.2147/jbm.s288283	methodology	1	NA	pf_yn	No discussion (in the main text) of the status of prognostic factors of the variables
10.2147/jbm.s288283	methodology	1	NA	tem_yn	No discussion (in the main text) of the status of treatment-effect modifiers of the variables
10.2147/jbm.s288283	methodology	1	NA	adjustment_model_details_yn	Yes
10.2147/jbm.s288283	methodology	1	NA	scale_choice_yn	No
10.2147/jbm.s288283	methodology	2	NA	outcome_name	mean annualized bleeding rate
10.2147/jbm.s288283	methodology	2	NA	outcome_short_name	Mean Annualized Bleeding Rate
10.2147/jbm.s288283	methodology	2	NA	outcome_variable_type	Continuous (count, mean, ...)
10.2147/jbm.s288283	methodology	2	NA	treatment_name_ipd	rfviiifc
10.2147/jbm.s288283	methodology	2	NA	studies_number_ipd	1
10.2147/jbm.s288283	methodology	2	NA	treatment_name_nonipd	emicizumab every 2 weeks
10.2147/jbm.s288283	methodology	2	NA	studies_number_nonipd	2
10.2147/jbm.s288283	methodology	2	NA	paic_type	MAIC
10.2147/jbm.s288283	methodology	2	NA	anchored_yn	No
10.2147/jbm.s288283	methodology	2	NA	paic_form	Simple (ie treatments effects extracted from two studies)
10.2147/jbm.s288283	methodology	2	NA	primary_outcome_yn	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.2147/jbm.s288283	methodology	2	NA	variables_selection_justification	Nothing mentioned, not reported
10.2147/jbm.s288283	methodology	2	NA	pf_yn	No discussion (in the main text) of the status of prognostic factors of the variables
10.2147/jbm.s288283	methodology	2	NA	tem_yn	No discussion (in the main text) of the status of treatment-effect modifiers of the variables
10.2147/jbm.s288283	methodology	2	NA	adjustment_model_details_yn	Yes
10.2147/jbm.s288283	methodology	2	NA	scale_choice_yn	No
10.2147/jbm.s288283	methodology	3	NA	outcome_name	mean annualized bleeding rate
10.2147/jbm.s288283	methodology	3	NA	outcome_short_name	Mean Annualized Bleeding Rate
10.2147/jbm.s288283	methodology	3	NA	outcome_variable_type	Continuous (count, mean, ...)
10.2147/jbm.s288283	methodology	3	NA	treatment_name_ipd	rfviiifc
10.2147/jbm.s288283	methodology	3	NA	studies_number_ipd	1
10.2147/jbm.s288283	methodology	3	NA	treatment_name_nonipd	emicizumab every 4 weeks
10.2147/jbm.s288283	methodology	3	NA	studies_number_nonipd	3
10.2147/jbm.s288283	methodology	3	NA	paic_type	MAIC
10.2147/jbm.s288283	methodology	3	NA	anchored_yn	No
10.2147/jbm.s288283	methodology	3	NA	paic_form	Simple (ie treatments effects extracted from two studies)
10.2147/jbm.s288283	methodology	3	NA	primary_outcome_yn	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.2147/jbm.s288283	methodology	3	NA	variables_selection_justification	Nothing mentioned, not reported
10.2147/jbm.s288283	methodology	3	NA	pf_yn	No discussion (in the main text) of the status of prognostic factors of the variables
10.2147/jbm.s288283	methodology	3	NA	tem_yn	No discussion (in the main text) of the status of treatment-effect modifiers of the variables
10.2147/jbm.s288283	methodology	3	NA	adjustment_model_details_yn	Yes
10.2147/jbm.s288283	methodology	3	NA	scale_choice_yn	No
10.2147/jbm.s288283	results	1	NA	contrast_effect_type	Incidence Rate Ratio
10.2147/jbm.s288283	results	1	NA	direction_benefit	inferior
10.2147/jbm.s288283	results	1	NA	ss_ttt_nonipd	99
10.2147/jbm.s288283	results	1	NA	ss_ttt_ipd	117
10.2147/jbm.s288283	results	1	NA	ss_adjusted_ttt_ipd	94
10.2147/jbm.s288283	results	1	NA	weights_yn	Not mentioned
10.2147/jbm.s288283	results	1	NA	covariates_yn	Yes
10.2147/jbm.s288283	results	1	NA	covariates_n	5
10.2147/jbm.s288283	results	1	NA	covariates_names	Age, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Race/ethnicity, Past treatments for the disease of interest
10.2147/jbm.s288283	results	1	NA	contrast_effect_direction	Numerator if ratio, or left side if difference
10.2147/jbm.s288283	results	1	NA	contrast_effect_unadjusted_value	NA
10.2147/jbm.s288283	results	1	NA	contrast_effect_unadjusted_pvalci	NA
10.2147/jbm.s288283	results	1	NA	contrast_effect_adjusted_value	0.93
10.2147/jbm.s288283	results	1	NA	contrast_effect_adjusted_pvalci	[0.63;1.39]
10.2147/jbm.s288283	results	1	NA	adjustment_geographical	NA
10.2147/jbm.s288283	results	1	NA	ss_total_ipd	NA
10.2147/jbm.s288283	results	1	NA	ss_adjusted_total_ipd	NA
10.2147/jbm.s288283	results	1	NA	ss_total_nonipd	NA
10.2147/jbm.s288283	results	1	NA	ss_anchor_nonipd	NA
10.2147/jbm.s288283	results	1	NA	ss_anchor_ipd	NA
10.2147/jbm.s288283	results	1	NA	ss_adjusted_anchor_ipd	NA
10.2147/jbm.s288283	results	1	NA	effect_cutoff	1
10.2147/jbm.s288283	results	1	NA	adjusted_lb_ci	0.63
10.2147/jbm.s288283	results	1	NA	adjusted_ub_ci	1.39
10.2147/jbm.s288283	results	1	NA	adjusted_significant	FALSE
10.2147/jbm.s288283	results	2	NA	contrast_effect_type	Incidence Rate Ratio
10.2147/jbm.s288283	results	2	NA	direction_benefit	inferior
10.2147/jbm.s288283	results	2	NA	ss_ttt_nonipd	35
10.2147/jbm.s288283	results	2	NA	ss_ttt_ipd	117
10.2147/jbm.s288283	results	2	NA	ss_adjusted_ttt_ipd	19
10.2147/jbm.s288283	results	2	NA	weights_yn	Not mentioned
10.2147/jbm.s288283	results	2	NA	covariates_yn	Yes
10.2147/jbm.s288283	results	2	NA	covariates_n	5
10.2147/jbm.s288283	results	2	NA	covariates_names	Age, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Race/ethnicity, Past treatments for the disease of interest
10.2147/jbm.s288283	results	2	NA	contrast_effect_direction	Numerator if ratio, or left side if difference
10.2147/jbm.s288283	results	2	NA	contrast_effect_unadjusted_value	NA
10.2147/jbm.s288283	results	2	NA	contrast_effect_unadjusted_pvalci	NA
10.2147/jbm.s288283	results	2	NA	contrast_effect_adjusted_value	0.57
10.2147/jbm.s288283	results	2	NA	contrast_effect_adjusted_pvalci	[0.28;1.17]
10.2147/jbm.s288283	results	2	NA	adjustment_geographical	NA
10.2147/jbm.s288283	results	2	NA	ss_total_ipd	NA
10.2147/jbm.s288283	results	2	NA	ss_adjusted_total_ipd	NA
10.2147/jbm.s288283	results	2	NA	ss_total_nonipd	NA
10.2147/jbm.s288283	results	2	NA	ss_anchor_nonipd	NA
10.2147/jbm.s288283	results	2	NA	ss_anchor_ipd	NA
10.2147/jbm.s288283	results	2	NA	ss_adjusted_anchor_ipd	NA
10.2147/jbm.s288283	results	2	NA	effect_cutoff	1
10.2147/jbm.s288283	results	2	NA	adjusted_lb_ci	0.28
10.2147/jbm.s288283	results	2	NA	adjusted_ub_ci	1.17
10.2147/jbm.s288283	results	2	NA	adjusted_significant	FALSE
10.2147/jbm.s288283	results	3	NA	contrast_effect_type	Incidence Rate Ratio
10.2147/jbm.s288283	results	3	NA	direction_benefit	inferior
10.2147/jbm.s288283	results	3	NA	ss_ttt_nonipd	41
10.2147/jbm.s288283	results	3	NA	ss_ttt_ipd	117
10.2147/jbm.s288283	results	3	NA	ss_adjusted_ttt_ipd	36
10.2147/jbm.s288283	results	3	NA	weights_yn	Not mentioned
10.2147/jbm.s288283	results	3	NA	covariates_yn	Yes
10.2147/jbm.s288283	results	3	NA	covariates_n	5
10.2147/jbm.s288283	results	3	NA	covariates_names	Age, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Race/ethnicity, Past treatments for the disease of interest
10.2147/jbm.s288283	results	3	NA	contrast_effect_direction	Numerator if ratio, or left side if difference
10.2147/jbm.s288283	results	3	NA	contrast_effect_unadjusted_value	NA
10.2147/jbm.s288283	results	3	NA	contrast_effect_unadjusted_pvalci	NA
10.2147/jbm.s288283	results	3	NA	contrast_effect_adjusted_value	0.61
10.2147/jbm.s288283	results	3	NA	contrast_effect_adjusted_pvalci	[0.37;1.02]
10.2147/jbm.s288283	results	3	NA	adjustment_geographical	NA
10.2147/jbm.s288283	results	3	NA	ss_total_ipd	NA
10.2147/jbm.s288283	results	3	NA	ss_adjusted_total_ipd	NA
10.2147/jbm.s288283	results	3	NA	ss_total_nonipd	NA
10.2147/jbm.s288283	results	3	NA	ss_anchor_nonipd	NA
10.2147/jbm.s288283	results	3	NA	ss_anchor_ipd	NA
10.2147/jbm.s288283	results	3	NA	ss_adjusted_anchor_ipd	NA
10.2147/jbm.s288283	results	3	NA	effect_cutoff	1
10.2147/jbm.s288283	results	3	NA	adjusted_lb_ci	0.37
10.2147/jbm.s288283	results	3	NA	adjusted_ub_ci	1.02
10.2147/jbm.s288283	results	3	NA	adjusted_significant	FALSE
10.2147/jbm.s288283	study_information	NA	1	ipd_yn	Yes
10.2147/jbm.s288283	study_information	NA	1	ct_yn	Yes
10.2147/jbm.s288283	study_information	NA	1	nct	NCT01181128
10.2147/jbm.s288283	study_information	NA	1	country_study	international
10.2147/jbm.s288283	study_information	NA	1	ct_phase	3
10.2147/jbm.s288283	study_information	NA	1	ct_arms	2 or more
10.2147/jbm.s288283	study_information	NA	2	ipd_yn	No
10.2147/jbm.s288283	study_information	NA	2	ct_yn	Yes
10.2147/jbm.s288283	study_information	NA	2	nct	NCT02847637
10.2147/jbm.s288283	study_information	NA	2	country_study	international
10.2147/jbm.s288283	study_information	NA	2	ct_phase	3
10.2147/jbm.s288283	study_information	NA	2	ct_arms	2 or more
10.2147/jbm.s288283	study_information	NA	3	ipd_yn	No
10.2147/jbm.s288283	study_information	NA	3	ct_yn	Yes
10.2147/jbm.s288283	study_information	NA	3	nct	NCT03020160
10.2147/jbm.s288283	study_information	NA	3	country_study	international
10.2147/jbm.s288283	study_information	NA	3	ct_phase	3
10.2147/jbm.s288283	study_information	NA	3	ct_arms	2 or more
10.2147/jbm.s312885	general_information	NA	NA	condition_name	hemophilia b
10.2147/jbm.s312885	general_information	NA	NA	country_first_author	sweden
10.2147/jbm.s312885	general_information	NA	NA	country_last_author	germany
10.2147/jbm.s312885	general_information	NA	NA	positions	Academic, Pharmaceutical Industry, Private Data Analysis Company
10.2147/jbm.s312885	general_information	NA	NA	methodologist_yn	Yes
10.2147/jbm.s312885	general_information	NA	NA	funding_source	Pharmaceutical Industry
10.2147/jbm.s312885	general_information	NA	NA	pharmaceutical_ties_yn	Yes
10.2147/jbm.s312885	general_information	NA	NA	systematic_review_yn	No
10.2147/jbm.s312885	methodology	1	NA	outcome_name	annualized bleeding rate (abr)
10.2147/jbm.s312885	methodology	1	NA	outcome_short_name	Mean Annualized Bleeding Rate
10.2147/jbm.s312885	methodology	1	NA	outcome_variable_type	Continuous (count, mean, ...)
10.2147/jbm.s312885	methodology	1	NA	treatment_name_ipd	prior prophylaxis rfixfc
10.2147/jbm.s312885	methodology	1	NA	studies_number_ipd	1
10.2147/jbm.s312885	methodology	1	NA	treatment_name_nonipd	prior prophylaxis rix-fp
10.2147/jbm.s312885	methodology	1	NA	studies_number_nonipd	2
10.2147/jbm.s312885	methodology	1	NA	paic_type	MAIC
10.2147/jbm.s312885	methodology	1	NA	anchored_yn	No
10.2147/jbm.s312885	methodology	1	NA	paic_form	Simple (ie treatments effects extracted from two studies)
10.2147/jbm.s312885	methodology	1	NA	primary_outcome_yn	Yes
10.2147/jbm.s312885	methodology	1	NA	variables_selection_justification	Nothing mentioned, not reported
10.2147/jbm.s312885	methodology	1	NA	pf_yn	No discussion (in the main text) of the status of prognostic factors of the variables
10.2147/jbm.s312885	methodology	1	NA	tem_yn	No discussion (in the main text) of the status of treatment-effect modifiers of the variables
10.2147/jbm.s312885	methodology	1	NA	adjustment_model_details_yn	No
10.2147/jbm.s312885	methodology	1	NA	scale_choice_yn	No
10.2147/jbm.s312885	methodology	2	NA	outcome_name	annualized bleeding rate (abr)
10.2147/jbm.s312885	methodology	2	NA	outcome_short_name	Mean Annualized Bleeding Rate
10.2147/jbm.s312885	methodology	2	NA	outcome_variable_type	Continuous (count, mean, ...)
10.2147/jbm.s312885	methodology	2	NA	treatment_name_ipd	prior episodic treatment rfixfc
10.2147/jbm.s312885	methodology	2	NA	studies_number_ipd	1
10.2147/jbm.s312885	methodology	2	NA	treatment_name_nonipd	prior episodic treatment rix-fp
10.2147/jbm.s312885	methodology	2	NA	studies_number_nonipd	2
10.2147/jbm.s312885	methodology	2	NA	paic_type	MAIC
10.2147/jbm.s312885	methodology	2	NA	anchored_yn	No
10.2147/jbm.s312885	methodology	2	NA	paic_form	Simple (ie treatments effects extracted from two studies)
10.2147/jbm.s312885	methodology	2	NA	primary_outcome_yn	Yes
10.2147/jbm.s312885	methodology	2	NA	variables_selection_justification	Nothing mentioned, not reported
10.2147/jbm.s312885	methodology	2	NA	pf_yn	No discussion (in the main text) of the status of prognostic factors of the variables
10.2147/jbm.s312885	methodology	2	NA	tem_yn	No discussion (in the main text) of the status of treatment-effect modifiers of the variables
10.2147/jbm.s312885	methodology	2	NA	adjustment_model_details_yn	Yes
10.2147/jbm.s312885	methodology	2	NA	scale_choice_yn	No
10.2147/jbm.s312885	results	1	NA	contrast_effect_type	Incidence Rate Ratio
10.2147/jbm.s312885	results	1	NA	direction_benefit	inferior
10.2147/jbm.s312885	results	1	NA	ss_ttt_nonipd	40
10.2147/jbm.s312885	results	1	NA	ss_ttt_ipd	45
10.2147/jbm.s312885	results	1	NA	ss_adjusted_ttt_ipd	26
10.2147/jbm.s312885	results	1	NA	weights_yn	Not mentioned
10.2147/jbm.s312885	results	1	NA	covariates_yn	Yes
10.2147/jbm.s312885	results	1	NA	covariates_n	4
10.2147/jbm.s312885	results	1	NA	covariates_names	Age, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Race/ethnicity, Other(s)
10.2147/jbm.s312885	results	1	NA	contrast_effect_direction	Numerator if ratio, or left side if difference
10.2147/jbm.s312885	results	1	NA	contrast_effect_unadjusted_value	NA
10.2147/jbm.s312885	results	1	NA	contrast_effect_unadjusted_pvalci	NA
10.2147/jbm.s312885	results	1	NA	contrast_effect_adjusted_value	1.18
10.2147/jbm.s312885	results	1	NA	contrast_effect_adjusted_pvalci	[0.67;2.10]
10.2147/jbm.s312885	results	1	NA	adjustment_geographical	No
10.2147/jbm.s312885	results	1	NA	ss_total_ipd	NA
10.2147/jbm.s312885	results	1	NA	ss_adjusted_total_ipd	NA
10.2147/jbm.s312885	results	1	NA	ss_total_nonipd	NA
10.2147/jbm.s312885	results	1	NA	ss_anchor_nonipd	NA
10.2147/jbm.s312885	results	1	NA	ss_anchor_ipd	NA
10.2147/jbm.s312885	results	1	NA	ss_adjusted_anchor_ipd	NA
10.2147/jbm.s312885	results	1	NA	effect_cutoff	1
10.2147/jbm.s312885	results	1	NA	adjusted_lb_ci	0.67
10.2147/jbm.s312885	results	1	NA	adjusted_ub_ci	2.1
10.2147/jbm.s312885	results	1	NA	adjusted_significant	FALSE
10.2147/jbm.s312885	results	2	NA	contrast_effect_type	Incidence Rate Ratio
10.2147/jbm.s312885	results	2	NA	direction_benefit	inferior
10.2147/jbm.s312885	results	2	NA	ss_ttt_nonipd	19
10.2147/jbm.s312885	results	2	NA	ss_ttt_ipd	42
10.2147/jbm.s312885	results	2	NA	ss_adjusted_ttt_ipd	10
10.2147/jbm.s312885	results	2	NA	weights_yn	Not mentioned
10.2147/jbm.s312885	results	2	NA	covariates_yn	Yes
10.2147/jbm.s312885	results	2	NA	covariates_n	4
10.2147/jbm.s312885	results	2	NA	covariates_names	Age, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Race/ethnicity, Other(s)
10.2147/jbm.s312885	results	2	NA	contrast_effect_direction	Numerator if ratio, or left side if difference
10.2147/jbm.s312885	results	2	NA	contrast_effect_unadjusted_value	NA
10.2147/jbm.s312885	results	2	NA	contrast_effect_unadjusted_pvalci	NA
10.2147/jbm.s312885	results	2	NA	contrast_effect_adjusted_value	1.01
10.2147/jbm.s312885	results	2	NA	contrast_effect_adjusted_pvalci	[0.40;2.57]
10.2147/jbm.s312885	results	2	NA	adjustment_geographical	No
10.2147/jbm.s312885	results	2	NA	ss_total_ipd	NA
10.2147/jbm.s312885	results	2	NA	ss_adjusted_total_ipd	NA
10.2147/jbm.s312885	results	2	NA	ss_total_nonipd	NA
10.2147/jbm.s312885	results	2	NA	ss_anchor_nonipd	NA
10.2147/jbm.s312885	results	2	NA	ss_anchor_ipd	NA
10.2147/jbm.s312885	results	2	NA	ss_adjusted_anchor_ipd	NA
10.2147/jbm.s312885	results	2	NA	effect_cutoff	1
10.2147/jbm.s312885	results	2	NA	adjusted_lb_ci	0.4
10.2147/jbm.s312885	results	2	NA	adjusted_ub_ci	2.57
10.2147/jbm.s312885	results	2	NA	adjusted_significant	FALSE
10.2147/jbm.s312885	study_information	NA	1	ipd_yn	Yes
10.2147/jbm.s312885	study_information	NA	1	ct_yn	Yes
10.2147/jbm.s312885	study_information	NA	1	nct	NCT01027364
10.2147/jbm.s312885	study_information	NA	1	country_study	international
10.2147/jbm.s312885	study_information	NA	1	ct_phase	3
10.2147/jbm.s312885	study_information	NA	1	ct_arms	1
10.2147/jbm.s312885	study_information	NA	2	ipd_yn	No
10.2147/jbm.s312885	study_information	NA	2	ct_yn	Yes
10.2147/jbm.s312885	study_information	NA	2	nct	NCT01496274
10.2147/jbm.s312885	study_information	NA	2	country_study	international
10.2147/jbm.s312885	study_information	NA	2	ct_phase	2, 3
10.2147/jbm.s312885	study_information	NA	2	ct_arms	1
10.2147/jbm.s321288	general_information	NA	NA	condition_name	hemophilia a
10.2147/jbm.s321288	general_information	NA	NA	country_first_author	usa
10.2147/jbm.s321288	general_information	NA	NA	country_last_author	italy
10.2147/jbm.s321288	general_information	NA	NA	positions	Academic, Pharmaceutical Industry, Private Data Analysis Company
10.2147/jbm.s321288	general_information	NA	NA	methodologist_yn	Yes
10.2147/jbm.s321288	general_information	NA	NA	funding_source	Pharmaceutical Industry
10.2147/jbm.s321288	general_information	NA	NA	pharmaceutical_ties_yn	Yes
10.2147/jbm.s321288	general_information	NA	NA	systematic_review_yn	Yes
10.2147/jbm.s321288	methodology	1	NA	outcome_name	mean annualized bleeding rate
10.2147/jbm.s321288	methodology	1	NA	outcome_short_name	Mean Annualized Bleeding Rate
10.2147/jbm.s321288	methodology	1	NA	outcome_variable_type	Continuous (count, mean, ...)
10.2147/jbm.s321288	methodology	1	NA	treatment_name_ipd	damoctocog alfa pegol (bay 94-9027)
10.2147/jbm.s321288	methodology	1	NA	studies_number_ipd	1
10.2147/jbm.s321288	methodology	1	NA	treatment_name_nonipd	turoctocog alfa pegol (n8-gp)
10.2147/jbm.s321288	methodology	1	NA	studies_number_nonipd	2
10.2147/jbm.s321288	methodology	1	NA	paic_type	MAIC
10.2147/jbm.s321288	methodology	1	NA	anchored_yn	No
10.2147/jbm.s321288	methodology	1	NA	paic_form	Simple (ie treatments effects extracted from two studies)
10.2147/jbm.s321288	methodology	1	NA	primary_outcome_yn	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.2147/jbm.s321288	methodology	1	NA	variables_selection_justification	Nothing mentioned, not reported
10.2147/jbm.s321288	methodology	1	NA	pf_yn	No discussion (in the main text) of the status of prognostic factors of the variables
10.2147/jbm.s321288	methodology	1	NA	tem_yn	No discussion (in the main text) of the status of treatment-effect modifiers of the variables
10.2147/jbm.s321288	methodology	1	NA	adjustment_model_details_yn	No
10.2147/jbm.s321288	methodology	1	NA	scale_choice_yn	No
10.2147/jbm.s321288	results	1	NA	contrast_effect_type	Incidence Rate Ratio
10.2147/jbm.s321288	results	1	NA	direction_benefit	inferior
10.2147/jbm.s321288	results	1	NA	ss_ttt_nonipd	175
10.2147/jbm.s321288	results	1	NA	ss_ttt_ipd	102
10.2147/jbm.s321288	results	1	NA	ss_adjusted_ttt_ipd	61.94
10.2147/jbm.s321288	results	1	NA	weights_yn	Not mentioned
10.2147/jbm.s321288	results	1	NA	covariates_yn	Yes
10.2147/jbm.s321288	results	1	NA	covariates_n	6
10.2147/jbm.s321288	results	1	NA	covariates_names	Age, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Race/ethnicity, Past treatments for the disease of interest, Other(s)
10.2147/jbm.s321288	results	1	NA	contrast_effect_direction	Numerator if ratio, or left side if difference
10.2147/jbm.s321288	results	1	NA	contrast_effect_unadjusted_value	1.1
10.2147/jbm.s321288	results	1	NA	contrast_effect_unadjusted_pvalci	0.4492
10.2147/jbm.s321288	results	1	NA	contrast_effect_adjusted_value	1.11
10.2147/jbm.s321288	results	1	NA	contrast_effect_adjusted_pvalci	0.449
10.2147/jbm.s321288	results	1	NA	adjustment_geographical	No
10.2147/jbm.s321288	results	1	NA	ss_total_ipd	NA
10.2147/jbm.s321288	results	1	NA	ss_adjusted_total_ipd	NA
10.2147/jbm.s321288	results	1	NA	ss_total_nonipd	NA
10.2147/jbm.s321288	results	1	NA	ss_anchor_nonipd	NA
10.2147/jbm.s321288	results	1	NA	ss_anchor_ipd	NA
10.2147/jbm.s321288	results	1	NA	ss_adjusted_anchor_ipd	NA
10.2147/jbm.s321288	results	1	NA	effect_cutoff	1
10.2147/jbm.s321288	results	1	NA	unadjusted_pval	0.4492
10.2147/jbm.s321288	results	1	NA	unadjusted_num_pval	0.4492
10.2147/jbm.s321288	results	1	NA	unadjusted_significant	FALSE
10.2147/jbm.s321288	results	1	NA	adjusted_pval	0.449
10.2147/jbm.s321288	results	1	NA	adjusted_num_pval	0.449
10.2147/jbm.s321288	results	1	NA	adjusted_significant	FALSE
10.2147/jbm.s321288	study_information	NA	1	ipd_yn	Yes
10.2147/jbm.s321288	study_information	NA	1	ct_yn	Yes
10.2147/jbm.s321288	study_information	NA	1	nct	NCT01580293
10.2147/jbm.s321288	study_information	NA	1	country_study	international
10.2147/jbm.s321288	study_information	NA	1	ct_phase	2, 3
10.2147/jbm.s321288	study_information	NA	1	ct_arms	2 or more
10.2147/jbm.s321288	study_information	NA	2	ipd_yn	No
10.2147/jbm.s321288	study_information	NA	2	ct_yn	Yes
10.2147/jbm.s321288	study_information	NA	2	nct	NCT01480180
10.2147/jbm.s321288	study_information	NA	2	country_study	international
10.2147/jbm.s321288	study_information	NA	2	ct_phase	3
10.2147/jbm.s321288	study_information	NA	2	ct_arms	1
10.2147/ptt.s326121	general_information	NA	NA	condition_name	moderate-to-severe plaque psoriasis
10.2147/ptt.s326121	general_information	NA	NA	country_first_author	uk
10.2147/ptt.s326121	general_information	NA	NA	country_last_author	germany
10.2147/ptt.s326121	general_information	NA	NA	positions	Academic, Pharmaceutical Industry
10.2147/ptt.s326121	general_information	NA	NA	methodologist_yn	Not mentioned
10.2147/ptt.s326121	general_information	NA	NA	funding_source	Pharmaceutical Industry
10.2147/ptt.s326121	general_information	NA	NA	pharmaceutical_ties_yn	Yes
10.2147/ptt.s326121	general_information	NA	NA	systematic_review_yn	No
10.2147/ptt.s326121	methodology	1	NA	outcome_name	proportions of patients who achieved pasi 90 (psoriasis area severity index) at weeks 12
10.2147/ptt.s326121	methodology	1	NA	outcome_short_name	PASI 90 Responders Rate
10.2147/ptt.s326121	methodology	1	NA	outcome_variable_type	Binary (eg rates)
10.2147/ptt.s326121	methodology	1	NA	treatment_name_ipd	brodalumab
10.2147/ptt.s326121	methodology	1	NA	studies_number_ipd	1;2
10.2147/ptt.s326121	methodology	1	NA	treatment_name_nonipd	guselkumab
10.2147/ptt.s326121	methodology	1	NA	studies_number_nonipd	3
10.2147/ptt.s326121	methodology	1	NA	paic_type	MAIC
10.2147/ptt.s326121	methodology	1	NA	anchored_yn	No
10.2147/ptt.s326121	methodology	1	NA	paic_form	Aggregation of multiple studies to estimate individual treatment effects (e.g. meta-analysis in a first step to estimate treatment A effect, then population adjusted indirect comparison using treatment A effect estimate)
10.2147/ptt.s326121	methodology	1	NA	primary_outcome_yn	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.2147/ptt.s326121	methodology	1	NA	variables_selection_justification	Nothing mentioned, not reported
10.2147/ptt.s326121	methodology	1	NA	pf_yn	No discussion (in the main text) of the status of prognostic factors of the variables
10.2147/ptt.s326121	methodology	1	NA	tem_yn	No discussion (in the main text) of the status of treatment-effect modifiers of the variables
10.2147/ptt.s326121	methodology	1	NA	adjustment_model_details_yn	No
10.2147/ptt.s326121	methodology	1	NA	scale_choice_yn	No
10.2147/ptt.s326121	results	1	NA	contrast_effect_type	Risk difference
10.2147/ptt.s326121	results	1	NA	direction_benefit	superior
10.2147/ptt.s326121	results	1	NA	ss_ttt_nonipd	135
10.2147/ptt.s326121	results	1	NA	ss_ttt_ipd	121
10.2147/ptt.s326121	results	1	NA	ss_adjusted_ttt_ipd	90
10.2147/ptt.s326121	results	1	NA	weights_yn	Yes, mentions that the weights distribution has been studied, but weights distribution not reported
10.2147/ptt.s326121	results	1	NA	covariates_yn	Yes
10.2147/ptt.s326121	results	1	NA	covariates_n	11
10.2147/ptt.s326121	results	1	NA	covariates_names	Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Past treatments for the disease of interest, Comorbidities and medical history (beside pathology/disease of interest in the comparison)
10.2147/ptt.s326121	results	1	NA	contrast_effect_direction	Numerator if ratio, or left side if difference
10.2147/ptt.s326121	results	1	NA	contrast_effect_unadjusted_value	NA
10.2147/ptt.s326121	results	1	NA	contrast_effect_unadjusted_pvalci	NA
10.2147/ptt.s326121	results	1	NA	contrast_effect_adjusted_value	14.6
10.2147/ptt.s326121	results	1	NA	contrast_effect_adjusted_pvalci	0.002
10.2147/ptt.s326121	results	1	NA	adjustment_geographical	No
10.2147/ptt.s326121	results	1	NA	ss_total_ipd	NA
10.2147/ptt.s326121	results	1	NA	ss_adjusted_total_ipd	NA
10.2147/ptt.s326121	results	1	NA	ss_total_nonipd	NA
10.2147/ptt.s326121	results	1	NA	ss_anchor_nonipd	NA
10.2147/ptt.s326121	results	1	NA	ss_anchor_ipd	NA
10.2147/ptt.s326121	results	1	NA	ss_adjusted_anchor_ipd	NA
10.2147/ptt.s326121	results	1	NA	effect_cutoff	0
10.2147/ptt.s326121	results	1	NA	adjusted_pval	0.002
10.2147/ptt.s326121	results	1	NA	adjusted_num_pval	0.002
10.2147/ptt.s326121	results	1	NA	adjusted_significant	TRUE
10.2147/ptt.s326121	study_information	NA	1	ipd_yn	Yes
10.2147/ptt.s326121	study_information	NA	1	ct_yn	Yes
10.2147/ptt.s326121	study_information	NA	1	nct	NCT01708603
10.2147/ptt.s326121	study_information	NA	1	country_study	international
10.2147/ptt.s326121	study_information	NA	1	ct_phase	3
10.2147/ptt.s326121	study_information	NA	1	ct_arms	2 or more
10.2147/ptt.s326121	study_information	NA	2	ipd_yn	Yes
10.2147/ptt.s326121	study_information	NA	2	ct_yn	Yes
10.2147/ptt.s326121	study_information	NA	2	nct	NCT01708629
10.2147/ptt.s326121	study_information	NA	2	country_study	international
10.2147/ptt.s326121	study_information	NA	2	ct_phase	3
10.2147/ptt.s326121	study_information	NA	2	ct_arms	2 or more
10.2147/ptt.s326121	study_information	NA	3	ipd_yn	No
10.2147/ptt.s326121	study_information	NA	3	ct_yn	Yes
10.2147/ptt.s326121	study_information	NA	3	nct	NCT02203032
10.2147/ptt.s326121	study_information	NA	3	country_study	international
10.2147/ptt.s326121	study_information	NA	3	ct_phase	3
10.2147/ptt.s326121	study_information	NA	3	ct_arms	2 or more
10.2165/11592490-000000000-00000	general_information	NA	NA	condition_name	type 2 diabetes mellitus
10.2165/11592490-000000000-00000	general_information	NA	NA	country_first_author	usa
10.2165/11592490-000000000-00000	general_information	NA	NA	country_last_author	switzerland
10.2165/11592490-000000000-00000	general_information	NA	NA	positions	Pharmaceutical Industry, Private Data Analysis Company
10.2165/11592490-000000000-00000	general_information	NA	NA	methodologist_yn	Yes
10.2165/11592490-000000000-00000	general_information	NA	NA	funding_source	Pharmaceutical Industry
10.2165/11592490-000000000-00000	general_information	NA	NA	pharmaceutical_ties_yn	Yes
10.2165/11592490-000000000-00000	general_information	NA	NA	systematic_review_yn	Yes
10.2165/11592490-000000000-00000	methodology	1	NA	outcome_name	hba1c change from baseline to week 12
10.2165/11592490-000000000-00000	methodology	1	NA	outcome_short_name	HbA1C
10.2165/11592490-000000000-00000	methodology	1	NA	outcome_variable_type	Continuous (count, mean, ...)
10.2165/11592490-000000000-00000	methodology	1	NA	treatment_name_ipd	vildagliptin 50 mg twice daily
10.2165/11592490-000000000-00000	methodology	1	NA	studies_number_ipd	1
10.2165/11592490-000000000-00000	methodology	1	NA	treatment_name_nonipd	sitagliptin 50 mg once daily
10.2165/11592490-000000000-00000	methodology	1	NA	studies_number_nonipd	3
10.2165/11592490-000000000-00000	methodology	1	NA	paic_type	MAIC
10.2165/11592490-000000000-00000	methodology	1	NA	anchored_yn	Yes
10.2165/11592490-000000000-00000	methodology	1	NA	paic_form	Simple (ie treatments effects extracted from two studies)
10.2165/11592490-000000000-00000	methodology	1	NA	primary_outcome_yn	Yes
10.2165/11592490-000000000-00000	methodology	1	NA	variables_selection_justification	Nothing mentioned, not reported
10.2165/11592490-000000000-00000	methodology	1	NA	pf_yn	No discussion (in the main text) of the status of prognostic factors of the variables
10.2165/11592490-000000000-00000	methodology	1	NA	tem_yn	No discussion (in the main text) of the status of treatment-effect modifiers of the variables
10.2165/11592490-000000000-00000	methodology	1	NA	adjustment_model_details_yn	No
10.2165/11592490-000000000-00000	methodology	1	NA	scale_choice_yn	No
10.2165/11592490-000000000-00000	methodology	2	NA	outcome_name	hba1c change from baseline to week 12
10.2165/11592490-000000000-00000	methodology	2	NA	outcome_short_name	HbA1C
10.2165/11592490-000000000-00000	methodology	2	NA	outcome_variable_type	Continuous (count, mean, ...)
10.2165/11592490-000000000-00000	methodology	2	NA	treatment_name_ipd	vildagliptin 50 mg twice daily
10.2165/11592490-000000000-00000	methodology	2	NA	studies_number_ipd	2
10.2165/11592490-000000000-00000	methodology	2	NA	treatment_name_nonipd	sitagliptin 50 mg once daily
10.2165/11592490-000000000-00000	methodology	2	NA	studies_number_nonipd	4
10.2165/11592490-000000000-00000	methodology	2	NA	paic_type	MAIC
10.2165/11592490-000000000-00000	methodology	2	NA	anchored_yn	Yes
10.2165/11592490-000000000-00000	methodology	2	NA	paic_form	Simple (ie treatments effects extracted from two studies)
10.2165/11592490-000000000-00000	methodology	2	NA	primary_outcome_yn	Yes
10.2165/11592490-000000000-00000	methodology	2	NA	variables_selection_justification	Nothing mentioned, not reported
10.2165/11592490-000000000-00000	methodology	2	NA	pf_yn	No discussion (in the main text) of the status of prognostic factors of the variables
10.2165/11592490-000000000-00000	methodology	2	NA	tem_yn	No discussion (in the main text) of the status of treatment-effect modifiers of the variables
10.2165/11592490-000000000-00000	methodology	2	NA	adjustment_model_details_yn	No
10.2165/11592490-000000000-00000	methodology	2	NA	scale_choice_yn	No
10.2165/11592490-000000000-00000	methodology	3	NA	outcome_name	hba1c change from baseline to week 12
10.2165/11592490-000000000-00000	methodology	3	NA	outcome_short_name	HbA1C
10.2165/11592490-000000000-00000	methodology	3	NA	outcome_variable_type	Continuous (count, mean, ...)
10.2165/11592490-000000000-00000	methodology	3	NA	treatment_name_ipd	vildagliptin 50 mg twice daily
10.2165/11592490-000000000-00000	methodology	3	NA	studies_number_ipd	2
10.2165/11592490-000000000-00000	methodology	3	NA	treatment_name_nonipd	sitagliptin 100 mg once daily
10.2165/11592490-000000000-00000	methodology	3	NA	studies_number_nonipd	4;5
10.2165/11592490-000000000-00000	methodology	3	NA	paic_type	MAIC
10.2165/11592490-000000000-00000	methodology	3	NA	anchored_yn	Yes
10.2165/11592490-000000000-00000	methodology	3	NA	paic_form	Aggregation of multiple studies to estimate individual treatment effects (e.g. meta-analysis in a first step to estimate treatment A effect, then population adjusted indirect comparison using treatment A effect estimate)
10.2165/11592490-000000000-00000	methodology	3	NA	primary_outcome_yn	Yes
10.2165/11592490-000000000-00000	methodology	3	NA	variables_selection_justification	Nothing mentioned, not reported
10.2165/11592490-000000000-00000	methodology	3	NA	pf_yn	No discussion (in the main text) of the status of prognostic factors of the variables
10.2165/11592490-000000000-00000	methodology	3	NA	tem_yn	No discussion (in the main text) of the status of treatment-effect modifiers of the variables
10.2165/11592490-000000000-00000	methodology	3	NA	adjustment_model_details_yn	No
10.2165/11592490-000000000-00000	methodology	3	NA	scale_choice_yn	No
10.2165/11592490-000000000-00000	results	1	NA	contrast_effect_type	Means difference
10.2165/11592490-000000000-00000	results	1	NA	direction_benefit	inferior
10.2165/11592490-000000000-00000	results	1	NA	ss_ttt_nonipd	163
10.2165/11592490-000000000-00000	results	1	NA	ss_ttt_ipd	188
10.2165/11592490-000000000-00000	results	1	NA	ss_adjusted_ttt_ipd	NA
10.2165/11592490-000000000-00000	results	1	NA	weights_yn	Not mentioned
10.2165/11592490-000000000-00000	results	1	NA	covariates_yn	Yes
10.2165/11592490-000000000-00000	results	1	NA	covariates_n	7
10.2165/11592490-000000000-00000	results	1	NA	covariates_names	Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Other(s)
10.2165/11592490-000000000-00000	results	1	NA	contrast_effect_direction	Numerator if ratio, or left side if difference
10.2165/11592490-000000000-00000	results	1	NA	contrast_effect_unadjusted_value	-0.17
10.2165/11592490-000000000-00000	results	1	NA	contrast_effect_unadjusted_pvalci	0.024
10.2165/11592490-000000000-00000	results	1	NA	contrast_effect_adjusted_value	-0.2
10.2165/11592490-000000000-00000	results	1	NA	contrast_effect_adjusted_pvalci	0.009
10.2165/11592490-000000000-00000	results	1	NA	adjustment_geographical	No
10.2165/11592490-000000000-00000	results	1	NA	ss_total_ipd	NA
10.2165/11592490-000000000-00000	results	1	NA	ss_adjusted_total_ipd	NA
10.2165/11592490-000000000-00000	results	1	NA	ss_total_nonipd	NA
10.2165/11592490-000000000-00000	results	1	NA	ss_anchor_nonipd	156
10.2165/11592490-000000000-00000	results	1	NA	ss_anchor_ipd	192
10.2165/11592490-000000000-00000	results	1	NA	ss_adjusted_anchor_ipd	NA
10.2165/11592490-000000000-00000	results	1	NA	effect_cutoff	0
10.2165/11592490-000000000-00000	results	1	NA	unadjusted_pval	0.024
10.2165/11592490-000000000-00000	results	1	NA	unadjusted_num_pval	0.024
10.2165/11592490-000000000-00000	results	1	NA	unadjusted_significant	TRUE
10.2165/11592490-000000000-00000	results	1	NA	adjusted_pval	0.009
10.2165/11592490-000000000-00000	results	1	NA	adjusted_num_pval	0.009
10.2165/11592490-000000000-00000	results	1	NA	adjusted_significant	TRUE
10.2165/11592490-000000000-00000	results	2	NA	contrast_effect_type	Means difference
10.2165/11592490-000000000-00000	results	2	NA	direction_benefit	inferior
10.2165/11592490-000000000-00000	results	2	NA	ss_ttt_nonipd	72
10.2165/11592490-000000000-00000	results	2	NA	ss_ttt_ipd	76
10.2165/11592490-000000000-00000	results	2	NA	ss_adjusted_ttt_ipd	NA
10.2165/11592490-000000000-00000	results	2	NA	weights_yn	Not mentioned
10.2165/11592490-000000000-00000	results	2	NA	covariates_yn	Yes
10.2165/11592490-000000000-00000	results	2	NA	covariates_n	6
10.2165/11592490-000000000-00000	results	2	NA	covariates_names	Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Other(s)
10.2165/11592490-000000000-00000	results	2	NA	contrast_effect_direction	Numerator if ratio, or left side if difference
10.2165/11592490-000000000-00000	results	2	NA	contrast_effect_unadjusted_value	-0.2
10.2165/11592490-000000000-00000	results	2	NA	contrast_effect_unadjusted_pvalci	0.133
10.2165/11592490-000000000-00000	results	2	NA	contrast_effect_adjusted_value	-0.56
10.2165/11592490-000000000-00000	results	2	NA	contrast_effect_adjusted_pvalci	<0.001
10.2165/11592490-000000000-00000	results	2	NA	adjustment_geographical	No
10.2165/11592490-000000000-00000	results	2	NA	ss_total_ipd	NA
10.2165/11592490-000000000-00000	results	2	NA	ss_adjusted_total_ipd	NA
10.2165/11592490-000000000-00000	results	2	NA	ss_total_nonipd	NA
10.2165/11592490-000000000-00000	results	2	NA	ss_anchor_nonipd	73
10.2165/11592490-000000000-00000	results	2	NA	ss_anchor_ipd	72
10.2165/11592490-000000000-00000	results	2	NA	ss_adjusted_anchor_ipd	NA
10.2165/11592490-000000000-00000	results	2	NA	effect_cutoff	0
10.2165/11592490-000000000-00000	results	2	NA	unadjusted_pval	0.133
10.2165/11592490-000000000-00000	results	2	NA	unadjusted_num_pval	0.133
10.2165/11592490-000000000-00000	results	2	NA	unadjusted_significant	FALSE
10.2165/11592490-000000000-00000	results	2	NA	adjusted_pval	<0.001
10.2165/11592490-000000000-00000	results	2	NA	adjusted_significant	TRUE
10.2165/11592490-000000000-00000	results	3	NA	contrast_effect_type	Means difference
10.2165/11592490-000000000-00000	results	3	NA	direction_benefit	inferior
10.2165/11592490-000000000-00000	results	3	NA	ss_ttt_nonipd	145
10.2165/11592490-000000000-00000	results	3	NA	ss_ttt_ipd	76
10.2165/11592490-000000000-00000	results	3	NA	ss_adjusted_ttt_ipd	NA
10.2165/11592490-000000000-00000	results	3	NA	weights_yn	Not mentioned
10.2165/11592490-000000000-00000	results	3	NA	covariates_yn	Yes
10.2165/11592490-000000000-00000	results	3	NA	covariates_n	6
10.2165/11592490-000000000-00000	results	3	NA	covariates_names	Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Other(s)
10.2165/11592490-000000000-00000	results	3	NA	contrast_effect_direction	Numerator if ratio, or left side if difference
10.2165/11592490-000000000-00000	results	3	NA	contrast_effect_unadjusted_value	-0.19
10.2165/11592490-000000000-00000	results	3	NA	contrast_effect_unadjusted_pvalci	0.113
10.2165/11592490-000000000-00000	results	3	NA	contrast_effect_adjusted_value	-0.35
10.2165/11592490-000000000-00000	results	3	NA	contrast_effect_adjusted_pvalci	0.013
10.2165/11592490-000000000-00000	results	3	NA	adjustment_geographical	No
10.2165/11592490-000000000-00000	results	3	NA	ss_total_ipd	NA
10.2165/11592490-000000000-00000	results	3	NA	ss_adjusted_total_ipd	NA
10.2165/11592490-000000000-00000	results	3	NA	ss_total_nonipd	NA
10.2165/11592490-000000000-00000	results	3	NA	ss_anchor_nonipd	149
10.2165/11592490-000000000-00000	results	3	NA	ss_anchor_ipd	72
10.2165/11592490-000000000-00000	results	3	NA	ss_adjusted_anchor_ipd	NA
10.2165/11592490-000000000-00000	results	3	NA	effect_cutoff	0
10.2165/11592490-000000000-00000	results	3	NA	unadjusted_pval	0.113
10.2165/11592490-000000000-00000	results	3	NA	unadjusted_num_pval	0.113
10.2165/11592490-000000000-00000	results	3	NA	unadjusted_significant	FALSE
10.2165/11592490-000000000-00000	results	3	NA	adjusted_pval	0.013
10.2165/11592490-000000000-00000	results	3	NA	adjusted_num_pval	0.013
10.2165/11592490-000000000-00000	results	3	NA	adjusted_significant	TRUE
10.2165/11592490-000000000-00000	study_information	NA	1	ipd_yn	Yes
10.2165/11592490-000000000-00000	study_information	NA	1	ct_yn	Yes
10.2165/11592490-000000000-00000	study_information	NA	1	nct	NCT00368134
10.2165/11592490-000000000-00000	study_information	NA	1	country_study	japan
10.2165/11592490-000000000-00000	study_information	NA	1	ct_phase	3
10.2165/11592490-000000000-00000	study_information	NA	1	ct_arms	2 or more
10.2165/11592490-000000000-00000	study_information	NA	2	ipd_yn	Yes
10.2165/11592490-000000000-00000	study_information	NA	2	ct_yn	Yes
10.2165/11592490-000000000-00000	study_information	NA	2	nct	NCT00351832
10.2165/11592490-000000000-00000	study_information	NA	2	country_study	japan
10.2165/11592490-000000000-00000	study_information	NA	2	ct_phase	3
10.2165/11592490-000000000-00000	study_information	NA	2	ct_arms	2 or more
10.2165/11592490-000000000-00000	study_information	NA	3	ipd_yn	No
10.2165/11592490-000000000-00000	study_information	NA	3	ct_yn	Yes
10.2165/11592490-000000000-00000	study_information	NA	3	nct	NCT00411554
10.2165/11592490-000000000-00000	study_information	NA	3	country_study	japan
10.2165/11592490-000000000-00000	study_information	NA	3	ct_phase	3
10.2165/11592490-000000000-00000	study_information	NA	3	ct_arms	2 or more
10.2165/11592490-000000000-00000	study_information	NA	4	ipd_yn	No
10.2165/11592490-000000000-00000	study_information	NA	4	ct_yn	Yes
10.2165/11592490-000000000-00000	study_information	NA	4	nct	NCT00127192
10.2165/11592490-000000000-00000	study_information	NA	4	country_study	japan
10.2165/11592490-000000000-00000	study_information	NA	4	ct_phase	2
10.2165/11592490-000000000-00000	study_information	NA	4	ct_arms	2 or more
10.2165/11592490-000000000-00000	study_information	NA	5	ipd_yn	No
10.2165/11592490-000000000-00000	study_information	NA	5	ct_yn	Yes
10.2165/11592490-000000000-00000	study_information	NA	5	country_study	japan
10.2165/11592490-000000000-00000	study_information	NA	5	ct_phase	2
10.2165/11592490-000000000-00000	study_information	NA	5	ct_arms	2 or more
10.2165/11592490-000000000-00000	study_information	NA	5	nct	NCT00371007
10.2217/cer-2016-0085	general_information	NA	NA	condition_name	relapsingremitting multiple sclerosis
10.2217/cer-2016-0085	general_information	NA	NA	country_first_author	switzerland
10.2217/cer-2016-0085	general_information	NA	NA	country_last_author	usa
10.2217/cer-2016-0085	general_information	NA	NA	positions	Academic, Pharmaceutical Industry
10.2217/cer-2016-0085	general_information	NA	NA	methodologist_yn	Yes
10.2217/cer-2016-0085	general_information	NA	NA	funding_source	Pharmaceutical Industry
10.2217/cer-2016-0085	general_information	NA	NA	pharmaceutical_ties_yn	Yes
10.2217/cer-2016-0085	general_information	NA	NA	systematic_review_yn	No
10.2217/cer-2016-0085	methodology	1	NA	outcome_name	annualized relapse rate at 2 years
10.2217/cer-2016-0085	methodology	1	NA	outcome_short_name	Annualized Relapse Rate
10.2217/cer-2016-0085	methodology	1	NA	outcome_variable_type	Continuous (count, mean, ...)
10.2217/cer-2016-0085	methodology	1	NA	treatment_name_ipd	delayed-release dimethyl fumarate
10.2217/cer-2016-0085	methodology	1	NA	studies_number_ipd	1;2
10.2217/cer-2016-0085	methodology	1	NA	treatment_name_nonipd	glatiramer acetate
10.2217/cer-2016-0085	methodology	1	NA	studies_number_nonipd	3
10.2217/cer-2016-0085	methodology	1	NA	paic_type	MAIC
10.2217/cer-2016-0085	methodology	1	NA	anchored_yn	Yes
10.2217/cer-2016-0085	methodology	1	NA	paic_form	Aggregation of multiple studies to estimate individual treatment effects (e.g. meta-analysis in a first step to estimate treatment A effect, then population adjusted indirect comparison using treatment A effect estimate)
10.2217/cer-2016-0085	methodology	1	NA	primary_outcome_yn	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.2217/cer-2016-0085	methodology	1	NA	variables_selection_justification	Nothing mentioned, not reported
10.2217/cer-2016-0085	methodology	1	NA	pf_yn	No discussion (in the main text) of the status of prognostic factors of the variables
10.2217/cer-2016-0085	methodology	1	NA	tem_yn	No discussion (in the main text) of the status of treatment-effect modifiers of the variables
10.2217/cer-2016-0085	methodology	1	NA	adjustment_model_details_yn	No
10.2217/cer-2016-0085	methodology	1	NA	scale_choice_yn	No
10.2217/cer-2016-0085	methodology	2	NA	outcome_name	annualized relapse rate at 2 years
10.2217/cer-2016-0085	methodology	2	NA	outcome_short_name	Annualized Relapse Rate
10.2217/cer-2016-0085	methodology	2	NA	outcome_variable_type	Continuous (count, mean, ...)
10.2217/cer-2016-0085	methodology	2	NA	treatment_name_ipd	delayed-release dimethyl fumarate
10.2217/cer-2016-0085	methodology	2	NA	studies_number_ipd	1;2
10.2217/cer-2016-0085	methodology	2	NA	treatment_name_nonipd	glatiramer acetate
10.2217/cer-2016-0085	methodology	2	NA	studies_number_nonipd	4
10.2217/cer-2016-0085	methodology	2	NA	paic_type	MAIC
10.2217/cer-2016-0085	methodology	2	NA	anchored_yn	Yes
10.2217/cer-2016-0085	methodology	2	NA	paic_form	Aggregation of multiple studies to estimate individual treatment effects (e.g. meta-analysis in a first step to estimate treatment A effect, then population adjusted indirect comparison using treatment A effect estimate)
10.2217/cer-2016-0085	methodology	2	NA	primary_outcome_yn	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.2217/cer-2016-0085	methodology	2	NA	variables_selection_justification	Nothing mentioned, not reported
10.2217/cer-2016-0085	methodology	2	NA	pf_yn	No discussion (in the main text) of the status of prognostic factors of the variables
10.2217/cer-2016-0085	methodology	2	NA	tem_yn	No discussion (in the main text) of the status of treatment-effect modifiers of the variables
10.2217/cer-2016-0085	methodology	2	NA	adjustment_model_details_yn	No
10.2217/cer-2016-0085	methodology	2	NA	scale_choice_yn	No
10.2217/cer-2016-0085	methodology	3	NA	outcome_name	12-week confirmed disability progression
10.2217/cer-2016-0085	methodology	3	NA	outcome_short_name	Confirmed disability progression
10.2217/cer-2016-0085	methodology	3	NA	outcome_variable_type	Binary (eg rates)
10.2217/cer-2016-0085	methodology	3	NA	treatment_name_ipd	delayed-release dimethyl fumarate
10.2217/cer-2016-0085	methodology	3	NA	studies_number_ipd	1;2
10.2217/cer-2016-0085	methodology	3	NA	treatment_name_nonipd	glatiramer acetate
10.2217/cer-2016-0085	methodology	3	NA	studies_number_nonipd	5
10.2217/cer-2016-0085	methodology	3	NA	paic_type	MAIC
10.2217/cer-2016-0085	methodology	3	NA	anchored_yn	No
10.2217/cer-2016-0085	methodology	3	NA	paic_form	Aggregation of multiple studies to estimate individual treatment effects (e.g. meta-analysis in a first step to estimate treatment A effect, then population adjusted indirect comparison using treatment A effect estimate)
10.2217/cer-2016-0085	methodology	3	NA	primary_outcome_yn	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.2217/cer-2016-0085	methodology	3	NA	variables_selection_justification	Nothing mentioned, not reported
10.2217/cer-2016-0085	methodology	3	NA	pf_yn	No discussion (in the main text) of the status of prognostic factors of the variables
10.2217/cer-2016-0085	methodology	3	NA	tem_yn	No discussion (in the main text) of the status of treatment-effect modifiers of the variables
10.2217/cer-2016-0085	methodology	3	NA	adjustment_model_details_yn	No
10.2217/cer-2016-0085	methodology	3	NA	scale_choice_yn	No
10.2217/cer-2016-0085	results	1	NA	contrast_effect_type	Rate ratio
10.2217/cer-2016-0085	results	1	NA	direction_benefit	inferior
10.2217/cer-2016-0085	results	1	NA	ss_ttt_nonipd	NA
10.2217/cer-2016-0085	results	1	NA	ss_ttt_ipd	NA
10.2217/cer-2016-0085	results	1	NA	ss_adjusted_ttt_ipd	NA
10.2217/cer-2016-0085	results	1	NA	weights_yn	Not mentioned
10.2217/cer-2016-0085	results	1	NA	covariates_yn	Yes
10.2217/cer-2016-0085	results	1	NA	covariates_n	7
10.2217/cer-2016-0085	results	1	NA	covariates_names	Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Race/ethnicity, Past treatments for the disease of interest
10.2217/cer-2016-0085	results	1	NA	contrast_effect_direction	Numerator if ratio, or left side if difference
10.2217/cer-2016-0085	results	1	NA	contrast_effect_unadjusted_value	NA
10.2217/cer-2016-0085	results	1	NA	contrast_effect_unadjusted_pvalci	NA
10.2217/cer-2016-0085	results	1	NA	contrast_effect_adjusted_value	NA
10.2217/cer-2016-0085	results	1	NA	contrast_effect_adjusted_pvalci	NA
10.2217/cer-2016-0085	results	1	NA	adjustment_geographical	NA
10.2217/cer-2016-0085	results	1	NA	ss_total_ipd	2651
10.2217/cer-2016-0085	results	1	NA	ss_adjusted_total_ipd	1032
10.2217/cer-2016-0085	results	1	NA	ss_total_nonipd	251
10.2217/cer-2016-0085	results	1	NA	ss_anchor_nonipd	NA
10.2217/cer-2016-0085	results	1	NA	ss_anchor_ipd	NA
10.2217/cer-2016-0085	results	1	NA	ss_adjusted_anchor_ipd	NA
10.2217/cer-2016-0085	results	1	NA	effect_cutoff	1
10.2217/cer-2016-0085	results	2	NA	contrast_effect_type	Rate ratio
10.2217/cer-2016-0085	results	2	NA	direction_benefit	inferior
10.2217/cer-2016-0085	results	2	NA	ss_ttt_nonipd	NA
10.2217/cer-2016-0085	results	2	NA	ss_ttt_ipd	NA
10.2217/cer-2016-0085	results	2	NA	ss_adjusted_ttt_ipd	NA
10.2217/cer-2016-0085	results	2	NA	weights_yn	Not mentioned
10.2217/cer-2016-0085	results	2	NA	covariates_yn	Yes
10.2217/cer-2016-0085	results	2	NA	covariates_n	5
10.2217/cer-2016-0085	results	2	NA	covariates_names	Age, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Past treatments for the disease of interest
10.2217/cer-2016-0085	results	2	NA	contrast_effect_direction	Numerator if ratio, or left side if difference
10.2217/cer-2016-0085	results	2	NA	contrast_effect_unadjusted_value	NA
10.2217/cer-2016-0085	results	2	NA	contrast_effect_unadjusted_pvalci	NA
10.2217/cer-2016-0085	results	2	NA	contrast_effect_adjusted_value	NA
10.2217/cer-2016-0085	results	2	NA	contrast_effect_adjusted_pvalci	NA
10.2217/cer-2016-0085	results	2	NA	adjustment_geographical	NA
10.2217/cer-2016-0085	results	2	NA	ss_total_ipd	2651
10.2217/cer-2016-0085	results	2	NA	ss_adjusted_total_ipd	1206
10.2217/cer-2016-0085	results	2	NA	ss_total_nonipd	239
10.2217/cer-2016-0085	results	2	NA	ss_anchor_nonipd	NA
10.2217/cer-2016-0085	results	2	NA	ss_anchor_ipd	NA
10.2217/cer-2016-0085	results	2	NA	ss_adjusted_anchor_ipd	NA
10.2217/cer-2016-0085	results	2	NA	effect_cutoff	1
10.2217/cer-2016-0085	results	3	NA	contrast_effect_type	RR
10.2217/cer-2016-0085	results	3	NA	direction_benefit	inferior
10.2217/cer-2016-0085	results	3	NA	ss_ttt_nonipd	NA
10.2217/cer-2016-0085	results	3	NA	ss_ttt_ipd	NA
10.2217/cer-2016-0085	results	3	NA	ss_adjusted_ttt_ipd	NA
10.2217/cer-2016-0085	results	3	NA	weights_yn	Not mentioned
10.2217/cer-2016-0085	results	3	NA	covariates_yn	Yes
10.2217/cer-2016-0085	results	3	NA	covariates_n	7
10.2217/cer-2016-0085	results	3	NA	covariates_names	Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Race/ethnicity, Past treatments for the disease of interest
10.2217/cer-2016-0085	results	3	NA	contrast_effect_direction	Numerator if ratio, or left side if difference
10.2217/cer-2016-0085	results	3	NA	contrast_effect_unadjusted_value	0.73
10.2217/cer-2016-0085	results	3	NA	contrast_effect_unadjusted_pvalci	0.015
10.2217/cer-2016-0085	results	3	NA	contrast_effect_adjusted_value	0.51
10.2217/cer-2016-0085	results	3	NA	contrast_effect_adjusted_pvalci	<0.001
10.2217/cer-2016-0085	results	3	NA	adjustment_geographical	NA
10.2217/cer-2016-0085	results	3	NA	ss_total_ipd	2651
10.2217/cer-2016-0085	results	3	NA	ss_adjusted_total_ipd	364
10.2217/cer-2016-0085	results	3	NA	ss_total_nonipd	448
10.2217/cer-2016-0085	results	3	NA	ss_anchor_nonipd	NA
10.2217/cer-2016-0085	results	3	NA	ss_anchor_ipd	NA
10.2217/cer-2016-0085	results	3	NA	ss_adjusted_anchor_ipd	NA
10.2217/cer-2016-0085	results	3	NA	effect_cutoff	1
10.2217/cer-2016-0085	results	3	NA	unadjusted_pval	0.015
10.2217/cer-2016-0085	results	3	NA	unadjusted_num_pval	0.015
10.2217/cer-2016-0085	results	3	NA	unadjusted_significant	TRUE
10.2217/cer-2016-0085	results	3	NA	adjusted_pval	<0.001
10.2217/cer-2016-0085	results	3	NA	adjusted_significant	TRUE
10.2217/cer-2016-0085	study_information	NA	1	ipd_yn	Yes
10.2217/cer-2016-0085	study_information	NA	1	ct_yn	Yes
10.2217/cer-2016-0085	study_information	NA	1	nct	NCT00420212
10.2217/cer-2016-0085	study_information	NA	1	country_study	international
10.2217/cer-2016-0085	study_information	NA	1	ct_phase	3
10.2217/cer-2016-0085	study_information	NA	1	ct_arms	2 or more
10.2217/cer-2016-0085	study_information	NA	2	ipd_yn	Yes
10.2217/cer-2016-0085	study_information	NA	2	ct_yn	Yes
10.2217/cer-2016-0085	study_information	NA	2	nct	NCT00451451
10.2217/cer-2016-0085	study_information	NA	2	country_study	international
10.2217/cer-2016-0085	study_information	NA	2	ct_phase	3
10.2217/cer-2016-0085	study_information	NA	2	ct_arms	2 or more
10.2217/cer-2016-0085	study_information	NA	3	ipd_yn	No
10.2217/cer-2016-0085	study_information	NA	3	ct_yn	Yes
10.2217/cer-2016-0085	study_information	NA	3	nct	NCT00004814
10.2217/cer-2016-0085	study_information	NA	3	country_study	usa
10.2217/cer-2016-0085	study_information	NA	3	ct_phase	3
10.2217/cer-2016-0085	study_information	NA	3	ct_arms	2 or more
10.2217/cer-2016-0085	study_information	NA	4	ipd_yn	No
10.2217/cer-2016-0085	study_information	NA	4	ct_yn	Yes
10.2217/cer-2016-0085	study_information	NA	4	data_source_name	eur/can study
10.2217/cer-2016-0085	study_information	NA	4	country_study	international
10.2217/cer-2016-0085	study_information	NA	4	ct_arms	2 or more
10.2217/cer-2016-0085	study_information	NA	4	ct_phase	3
10.2217/cer-2016-0085	study_information	NA	5	ipd_yn	No
10.2217/cer-2016-0085	study_information	NA	5	ct_yn	Yes
10.2217/cer-2016-0085	study_information	NA	5	nct	NCT00099502
10.2217/cer-2016-0085	study_information	NA	5	country_study	international
10.2217/cer-2016-0085	study_information	NA	5	ct_phase	3
10.2217/cer-2016-0085	study_information	NA	5	ct_arms	2 or more
10.2217/cer-2018-0020	general_information	NA	NA	condition_name	advanced pancreatic neuroendocrine tumors
10.2217/cer-2018-0020	general_information	NA	NA	country_first_author	canada
10.2217/cer-2018-0020	general_information	NA	NA	country_last_author	uk
10.2217/cer-2018-0020	general_information	NA	NA	positions	Academic, Pharmaceutical Industry, Private Data Analysis Company
10.2217/cer-2018-0020	general_information	NA	NA	methodologist_yn	Yes
10.2217/cer-2018-0020	general_information	NA	NA	funding_source	Pharmaceutical Industry
10.2217/cer-2018-0020	general_information	NA	NA	pharmaceutical_ties_yn	Yes
10.2217/cer-2018-0020	general_information	NA	NA	systematic_review_yn	No
10.2217/cer-2018-0020	methodology	1	NA	outcome_name	progression-free survival
10.2217/cer-2018-0020	methodology	1	NA	outcome_short_name	Progression-free Survival
10.2217/cer-2018-0020	methodology	1	NA	outcome_variable_type	Time-to-event
10.2217/cer-2018-0020	methodology	1	NA	treatment_name_ipd	sunitinib
10.2217/cer-2018-0020	methodology	1	NA	studies_number_ipd	1
10.2217/cer-2018-0020	methodology	1	NA	treatment_name_nonipd	everolimus
10.2217/cer-2018-0020	methodology	1	NA	studies_number_nonipd	2
10.2217/cer-2018-0020	methodology	1	NA	paic_type	MAIC
10.2217/cer-2018-0020	methodology	1	NA	anchored_yn	Yes
10.2217/cer-2018-0020	methodology	1	NA	paic_form	Simple (ie treatments effects extracted from two studies)
10.2217/cer-2018-0020	methodology	1	NA	primary_outcome_yn	Yes
10.2217/cer-2018-0020	methodology	1	NA	variables_selection_justification	Nothing mentioned, not reported
10.2217/cer-2018-0020	methodology	1	NA	pf_yn	No discussion (in the main text) of the status of prognostic factors of the variables
10.2217/cer-2018-0020	methodology	1	NA	tem_yn	No discussion (in the main text) of the status of treatment-effect modifiers of the variables
10.2217/cer-2018-0020	methodology	1	NA	adjustment_model_details_yn	No
10.2217/cer-2018-0020	methodology	1	NA	scale_choice_yn	No
10.2217/cer-2018-0020	methodology	2	NA	outcome_name	overall survival
10.2217/cer-2018-0020	methodology	2	NA	outcome_short_name	Overall Survival
10.2217/cer-2018-0020	methodology	2	NA	outcome_variable_type	Time-to-event
10.2217/cer-2018-0020	methodology	2	NA	treatment_name_ipd	sunitinib
10.2217/cer-2018-0020	methodology	2	NA	studies_number_ipd	1
10.2217/cer-2018-0020	methodology	2	NA	treatment_name_nonipd	everolimus
10.2217/cer-2018-0020	methodology	2	NA	studies_number_nonipd	2
10.2217/cer-2018-0020	methodology	2	NA	paic_type	MAIC
10.2217/cer-2018-0020	methodology	2	NA	anchored_yn	No
10.2217/cer-2018-0020	methodology	2	NA	paic_form	Simple (ie treatments effects extracted from two studies)
10.2217/cer-2018-0020	methodology	2	NA	primary_outcome_yn	Yes
10.2217/cer-2018-0020	methodology	2	NA	variables_selection_justification	Nothing mentioned, not reported
10.2217/cer-2018-0020	methodology	2	NA	pf_yn	No discussion (in the main text) of the status of prognostic factors of the variables
10.2217/cer-2018-0020	methodology	2	NA	tem_yn	No discussion (in the main text) of the status of treatment-effect modifiers of the variables
10.2217/cer-2018-0020	methodology	2	NA	adjustment_model_details_yn	No
10.2217/cer-2018-0020	methodology	2	NA	scale_choice_yn	No
10.2217/cer-2018-0020	results	1	NA	contrast_effect_type	HR
10.2217/cer-2018-0020	results	1	NA	direction_benefit	inferior
10.2217/cer-2018-0020	results	1	NA	ss_ttt_nonipd	207
10.2217/cer-2018-0020	results	1	NA	ss_ttt_ipd	86
10.2217/cer-2018-0020	results	1	NA	ss_adjusted_ttt_ipd	43
10.2217/cer-2018-0020	results	1	NA	weights_yn	Not mentioned
10.2217/cer-2018-0020	results	1	NA	covariates_yn	Yes
10.2217/cer-2018-0020	results	1	NA	covariates_n	11
10.2217/cer-2018-0020	results	1	NA	covariates_names	Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Race/ethnicity, Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Past treatments for the disease of interest
10.2217/cer-2018-0020	results	1	NA	contrast_effect_direction	Numerator if ratio, or left side if difference
10.2217/cer-2018-0020	results	1	NA	contrast_effect_unadjusted_value	1.2
10.2217/cer-2018-0020	results	1	NA	contrast_effect_unadjusted_pvalci	[0.72;2.01]
10.2217/cer-2018-0020	results	1	NA	contrast_effect_adjusted_value	0.85
10.2217/cer-2018-0020	results	1	NA	contrast_effect_adjusted_pvalci	[0.39;1.89]
10.2217/cer-2018-0020	results	1	NA	adjustment_geographical	No
10.2217/cer-2018-0020	results	1	NA	ss_total_ipd	NA
10.2217/cer-2018-0020	results	1	NA	ss_adjusted_total_ipd	NA
10.2217/cer-2018-0020	results	1	NA	ss_total_nonipd	NA
10.2217/cer-2018-0020	results	1	NA	ss_anchor_nonipd	203
10.2217/cer-2018-0020	results	1	NA	ss_anchor_ipd	85
10.2217/cer-2018-0020	results	1	NA	ss_adjusted_anchor_ipd	31
10.2217/cer-2018-0020	results	1	NA	effect_cutoff	1
10.2217/cer-2018-0020	results	1	NA	unadjusted_lb_ci	0.72
10.2217/cer-2018-0020	results	1	NA	unadjusted_ub_ci	2.01
10.2217/cer-2018-0020	results	1	NA	unadjusted_significant	FALSE
10.2217/cer-2018-0020	results	1	NA	adjusted_lb_ci	0.39
10.2217/cer-2018-0020	results	1	NA	adjusted_ub_ci	1.89
10.2217/cer-2018-0020	results	1	NA	adjusted_significant	FALSE
10.2217/cer-2018-0020	results	2	NA	contrast_effect_type	HR
10.2217/cer-2018-0020	results	2	NA	direction_benefit	inferior
10.2217/cer-2018-0020	results	2	NA	ss_ttt_nonipd	207
10.2217/cer-2018-0020	results	2	NA	ss_ttt_ipd	86
10.2217/cer-2018-0020	results	2	NA	ss_adjusted_ttt_ipd	43
10.2217/cer-2018-0020	results	2	NA	weights_yn	Not mentioned
10.2217/cer-2018-0020	results	2	NA	covariates_yn	Yes
10.2217/cer-2018-0020	results	2	NA	covariates_n	11
10.2217/cer-2018-0020	results	2	NA	covariates_names	Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Race/ethnicity, Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Past treatments for the disease of interest
10.2217/cer-2018-0020	results	2	NA	contrast_effect_direction	Numerator if ratio, or left side if difference
10.2217/cer-2018-0020	results	2	NA	contrast_effect_unadjusted_value	1.03
10.2217/cer-2018-0020	results	2	NA	contrast_effect_unadjusted_pvalci	[0.75;1.42]
10.2217/cer-2018-0020	results	2	NA	contrast_effect_adjusted_value	0.82
10.2217/cer-2018-0020	results	2	NA	contrast_effect_adjusted_pvalci	[0.53;1.27]
10.2217/cer-2018-0020	results	2	NA	adjustment_geographical	No
10.2217/cer-2018-0020	results	2	NA	ss_total_ipd	NA
10.2217/cer-2018-0020	results	2	NA	ss_adjusted_total_ipd	NA
10.2217/cer-2018-0020	results	2	NA	ss_total_nonipd	NA
10.2217/cer-2018-0020	results	2	NA	ss_anchor_nonipd	NA
10.2217/cer-2018-0020	results	2	NA	ss_anchor_ipd	NA
10.2217/cer-2018-0020	results	2	NA	ss_adjusted_anchor_ipd	NA
10.2217/cer-2018-0020	results	2	NA	effect_cutoff	1
10.2217/cer-2018-0020	results	2	NA	unadjusted_lb_ci	0.75
10.2217/cer-2018-0020	results	2	NA	unadjusted_ub_ci	1.42
10.2217/cer-2018-0020	results	2	NA	unadjusted_significant	FALSE
10.2217/cer-2018-0020	results	2	NA	adjusted_lb_ci	0.53
10.2217/cer-2018-0020	results	2	NA	adjusted_ub_ci	1.27
10.2217/cer-2018-0020	results	2	NA	adjusted_significant	FALSE
10.2217/cer-2018-0020	study_information	NA	1	ipd_yn	Yes
10.2217/cer-2018-0020	study_information	NA	1	ct_yn	Yes
10.2217/cer-2018-0020	study_information	NA	1	nct	NCT00428597
10.2217/cer-2018-0020	study_information	NA	1	country_study	international
10.2217/cer-2018-0020	study_information	NA	1	ct_phase	3
10.2217/cer-2018-0020	study_information	NA	1	ct_arms	2 or more
10.2217/cer-2018-0020	study_information	NA	2	ipd_yn	No
10.2217/cer-2018-0020	study_information	NA	2	ct_yn	Yes
10.2217/cer-2018-0020	study_information	NA	2	nct	NCT00510068
10.2217/cer-2018-0020	study_information	NA	2	country_study	international
10.2217/cer-2018-0020	study_information	NA	2	ct_phase	3
10.2217/cer-2018-0020	study_information	NA	2	ct_arms	2 or more
10.2217/cer-2018-0141	general_information	NA	NA	condition_name	psoriatic arthritis
10.2217/cer-2018-0141	general_information	NA	NA	country_first_author	usa
10.2217/cer-2018-0141	general_information	NA	NA	country_last_author	uk
10.2217/cer-2018-0141	general_information	NA	NA	positions	Academic, Pharmaceutical Industry, Private Data Analysis Company
10.2217/cer-2018-0141	general_information	NA	NA	methodologist_yn	Yes
10.2217/cer-2018-0141	general_information	NA	NA	funding_source	Pharmaceutical Industry
10.2217/cer-2018-0141	general_information	NA	NA	pharmaceutical_ties_yn	Yes
10.2217/cer-2018-0141	general_information	NA	NA	systematic_review_yn	Yes
10.2217/cer-2018-0141	methodology	1	NA	outcome_name	american college of rheumatology (acr) responses rate at week 24
10.2217/cer-2018-0141	methodology	1	NA	outcome_short_name	ACR Response Rate
10.2217/cer-2018-0141	methodology	1	NA	outcome_variable_type	Binary (eg rates)
10.2217/cer-2018-0141	methodology	1	NA	treatment_name_ipd	secukinumab 150mg
10.2217/cer-2018-0141	methodology	1	NA	studies_number_ipd	1;2
10.2217/cer-2018-0141	methodology	1	NA	treatment_name_nonipd	infliximab
10.2217/cer-2018-0141	methodology	1	NA	studies_number_nonipd	3
10.2217/cer-2018-0141	methodology	1	NA	paic_type	MAIC
10.2217/cer-2018-0141	methodology	1	NA	anchored_yn	No
10.2217/cer-2018-0141	methodology	1	NA	paic_form	Aggregation of multiple studies to estimate individual treatment effects (e.g. meta-analysis in a first step to estimate treatment A effect, then population adjusted indirect comparison using treatment A effect estimate)
10.2217/cer-2018-0141	methodology	1	NA	primary_outcome_yn	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.2217/cer-2018-0141	methodology	1	NA	variables_selection_justification	Status of prognostic factor/treatment effect modified assessed in the IPD dataset, A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion), Literature based (clinically or methodologically relevant to adjust on these variables based on the literature search conducted for this specific purpose)
10.2217/cer-2018-0141	methodology	1	NA	pf_yn	Yes
10.2217/cer-2018-0141	methodology	1	NA	tem_yn	Yes
10.2217/cer-2018-0141	methodology	1	NA	adjustment_model_details_yn	No
10.2217/cer-2018-0141	methodology	1	NA	scale_choice_yn	Yes
10.2217/cer-2018-0141	methodology	2	NA	outcome_name	american college of rheumatology (acr) responses at week 54
10.2217/cer-2018-0141	methodology	2	NA	outcome_short_name	ACR Response Rate
10.2217/cer-2018-0141	methodology	2	NA	outcome_variable_type	Binary (eg rates)
10.2217/cer-2018-0141	methodology	2	NA	treatment_name_ipd	secukinumab 300mg
10.2217/cer-2018-0141	methodology	2	NA	studies_number_ipd	1;2
10.2217/cer-2018-0141	methodology	2	NA	treatment_name_nonipd	infliximab
10.2217/cer-2018-0141	methodology	2	NA	studies_number_nonipd	3
10.2217/cer-2018-0141	methodology	2	NA	paic_type	MAIC
10.2217/cer-2018-0141	methodology	2	NA	anchored_yn	No
10.2217/cer-2018-0141	methodology	2	NA	paic_form	Aggregation of multiple studies to estimate individual treatment effects (e.g. meta-analysis in a first step to estimate treatment A effect, then population adjusted indirect comparison using treatment A effect estimate)
10.2217/cer-2018-0141	methodology	2	NA	primary_outcome_yn	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.2217/cer-2018-0141	methodology	2	NA	variables_selection_justification	Statistical imbalanced between treatment groups (independently of the status of prognostic/effect modifier), A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion), Literature based (clinically or methodologically relevant to adjust on these variables based on the literature search conducted for this specific purpose)
10.2217/cer-2018-0141	methodology	2	NA	pf_yn	Yes
10.2217/cer-2018-0141	methodology	2	NA	tem_yn	Yes
10.2217/cer-2018-0141	methodology	2	NA	adjustment_model_details_yn	No
10.2217/cer-2018-0141	methodology	2	NA	scale_choice_yn	Yes
10.2217/cer-2018-0141	results	1	NA	contrast_effect_type	OR
10.2217/cer-2018-0141	results	1	NA	direction_benefit	superior
10.2217/cer-2018-0141	results	1	NA	ss_ttt_nonipd	100
10.2217/cer-2018-0141	results	1	NA	ss_ttt_ipd	238
10.2217/cer-2018-0141	results	1	NA	ss_adjusted_ttt_ipd	84
10.2217/cer-2018-0141	results	1	NA	weights_yn	Not mentioned
10.2217/cer-2018-0141	results	1	NA	covariates_yn	Yes
10.2217/cer-2018-0141	results	1	NA	covariates_n	11
10.2217/cer-2018-0141	results	1	NA	covariates_names	Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Race/ethnicity, Past treatments for the disease of interest, Other(s)
10.2217/cer-2018-0141	results	1	NA	contrast_effect_direction	Numerator if ratio, or left side if difference
10.2217/cer-2018-0141	results	1	NA	contrast_effect_unadjusted_value	NA
10.2217/cer-2018-0141	results	1	NA	contrast_effect_unadjusted_pvalci	NA
10.2217/cer-2018-0141	results	1	NA	contrast_effect_adjusted_value	2.31
10.2217/cer-2018-0141	results	1	NA	contrast_effect_adjusted_pvalci	0.008
10.2217/cer-2018-0141	results	1	NA	adjustment_geographical	No
10.2217/cer-2018-0141	results	1	NA	ss_total_ipd	NA
10.2217/cer-2018-0141	results	1	NA	ss_adjusted_total_ipd	NA
10.2217/cer-2018-0141	results	1	NA	ss_total_nonipd	NA
10.2217/cer-2018-0141	results	1	NA	ss_anchor_nonipd	NA
10.2217/cer-2018-0141	results	1	NA	ss_anchor_ipd	NA
10.2217/cer-2018-0141	results	1	NA	ss_adjusted_anchor_ipd	NA
10.2217/cer-2018-0141	results	1	NA	effect_cutoff	1
10.2217/cer-2018-0141	results	1	NA	adjusted_pval	0.008
10.2217/cer-2018-0141	results	1	NA	adjusted_num_pval	0.008
10.2217/cer-2018-0141	results	1	NA	adjusted_significant	TRUE
10.2217/cer-2018-0141	results	2	NA	contrast_effect_type	OR
10.2217/cer-2018-0141	results	2	NA	direction_benefit	superior
10.2217/cer-2018-0141	results	2	NA	ss_ttt_nonipd	100
10.2217/cer-2018-0141	results	2	NA	ss_ttt_ipd	239
10.2217/cer-2018-0141	results	2	NA	ss_adjusted_ttt_ipd	70
10.2217/cer-2018-0141	results	2	NA	weights_yn	Not mentioned
10.2217/cer-2018-0141	results	2	NA	covariates_yn	Yes
10.2217/cer-2018-0141	results	2	NA	covariates_n	11
10.2217/cer-2018-0141	results	2	NA	covariates_names	Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Race/ethnicity, Past treatments for the disease of interest, Other(s)
10.2217/cer-2018-0141	results	2	NA	contrast_effect_direction	Numerator if ratio, or left side if difference
10.2217/cer-2018-0141	results	2	NA	contrast_effect_unadjusted_value	NA
10.2217/cer-2018-0141	results	2	NA	contrast_effect_unadjusted_pvalci	NA
10.2217/cer-2018-0141	results	2	NA	contrast_effect_adjusted_value	2.72
10.2217/cer-2018-0141	results	2	NA	contrast_effect_adjusted_pvalci	0.006
10.2217/cer-2018-0141	results	2	NA	adjustment_geographical	No
10.2217/cer-2018-0141	results	2	NA	ss_total_ipd	NA
10.2217/cer-2018-0141	results	2	NA	ss_adjusted_total_ipd	NA
10.2217/cer-2018-0141	results	2	NA	ss_total_nonipd	NA
10.2217/cer-2018-0141	results	2	NA	ss_anchor_nonipd	NA
10.2217/cer-2018-0141	results	2	NA	ss_anchor_ipd	NA
10.2217/cer-2018-0141	results	2	NA	ss_adjusted_anchor_ipd	NA
10.2217/cer-2018-0141	results	2	NA	effect_cutoff	1
10.2217/cer-2018-0141	results	2	NA	adjusted_pval	0.006
10.2217/cer-2018-0141	results	2	NA	adjusted_num_pval	0.006
10.2217/cer-2018-0141	results	2	NA	adjusted_significant	TRUE
10.2217/cer-2018-0141	study_information	NA	1	ipd_yn	Yes
10.2217/cer-2018-0141	study_information	NA	1	ct_yn	Yes
10.2217/cer-2018-0141	study_information	NA	1	nct	NCT01752634
10.2217/cer-2018-0141	study_information	NA	1	country_study	international
10.2217/cer-2018-0141	study_information	NA	1	ct_phase	3
10.2217/cer-2018-0141	study_information	NA	1	ct_arms	2 or more
10.2217/cer-2018-0141	study_information	NA	2	ipd_yn	Yes
10.2217/cer-2018-0141	study_information	NA	2	ct_yn	Yes
10.2217/cer-2018-0141	study_information	NA	2	nct	NCT01989468
10.2217/cer-2018-0141	study_information	NA	2	country_study	international
10.2217/cer-2018-0141	study_information	NA	2	ct_phase	3
10.2217/cer-2018-0141	study_information	NA	2	ct_arms	2 or more
10.2217/cer-2018-0141	study_information	NA	3	ipd_yn	No
10.2217/cer-2018-0141	study_information	NA	3	ct_yn	Yes
10.2217/cer-2018-0141	study_information	NA	3	nct	NCT00051623
10.2217/cer-2018-0141	study_information	NA	3	ct_phase	3
10.2217/cer-2018-0141	study_information	NA	3	ct_arms	2 or more
10.2217/cer-2018-0141	study_information	NA	3	country_study	unknown
10.2217/cer-2019-0145	general_information	NA	NA	condition_name	advanced gastric or gastroesophageal junction cancer
10.2217/cer-2019-0145	general_information	NA	NA	country_first_author	UK
10.2217/cer-2019-0145	general_information	NA	NA	country_last_author	USA
10.2217/cer-2019-0145	general_information	NA	NA	positions	Academic, Pharmaceutical Industry, Private Data Analysis Company
10.2217/cer-2019-0145	general_information	NA	NA	methodologist_yn	Yes
10.2217/cer-2019-0145	general_information	NA	NA	funding_source	Pharmaceutical Industry
10.2217/cer-2019-0145	general_information	NA	NA	pharmaceutical_ties_yn	Yes
10.2217/cer-2019-0145	general_information	NA	NA	systematic_review_yn	No
10.2217/cer-2019-0145	methodology	1	NA	outcome_name	overall survival
10.2217/cer-2019-0145	methodology	1	NA	outcome_short_name	Overall Survival
10.2217/cer-2019-0145	methodology	1	NA	outcome_variable_type	Time-to-event
10.2217/cer-2019-0145	methodology	1	NA	treatment_name_ipd	nivolumab
10.2217/cer-2019-0145	methodology	1	NA	studies_number_ipd	1
10.2217/cer-2019-0145	methodology	1	NA	treatment_name_nonipd	routine clinical practice
10.2217/cer-2019-0145	methodology	1	NA	studies_number_nonipd	2
10.2217/cer-2019-0145	methodology	1	NA	paic_type	STC
10.2217/cer-2019-0145	methodology	1	NA	anchored_yn	No
10.2217/cer-2019-0145	methodology	1	NA	paic_form	Simple (ie treatments effects extracted from two studies)
10.2217/cer-2019-0145	methodology	1	NA	primary_outcome_yn	Yes
10.2217/cer-2019-0145	methodology	1	NA	variables_selection_justification	Status of prognostic factor/treatment effect modified assessed in the IPD dataset, A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion), Literature based (clinically or methodologically relevant to adjust on these variables based on the literature search conducted for this specific purpose)
10.2217/cer-2019-0145	methodology	1	NA	pf_yn	Yes
10.2217/cer-2019-0145	methodology	1	NA	tem_yn	Yes
10.2217/cer-2019-0145	methodology	1	NA	adjustment_model_details_yn	Yes
10.2217/cer-2019-0145	methodology	1	NA	scale_choice_yn	No
10.2217/cer-2019-0145	results	1	NA	contrast_effect_type	HR
10.2217/cer-2019-0145	results	1	NA	direction_benefit	inferior
10.2217/cer-2019-0145	results	1	NA	ss_ttt_nonipd	34
10.2217/cer-2019-0145	results	1	NA	ss_ttt_ipd	42
10.2217/cer-2019-0145	results	1	NA	ss_adjusted_ttt_ipd	42
10.2217/cer-2019-0145	results	1	NA	weights_yn	NA
10.2217/cer-2019-0145	results	1	NA	covariates_yn	Yes
10.2217/cer-2019-0145	results	1	NA	covariates_n	6
10.2217/cer-2019-0145	results	1	NA	covariates_names	Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Past treatments for the disease of interest, Other(s)
10.2217/cer-2019-0145	results	1	NA	contrast_effect_direction	Numerator if ratio, or left side if difference
10.2217/cer-2019-0145	results	1	NA	contrast_effect_unadjusted_value	0.46
10.2217/cer-2019-0145	results	1	NA	contrast_effect_unadjusted_pvalci	[0.36;0.59]
10.2217/cer-2019-0145	results	1	NA	contrast_effect_adjusted_value	0.5
10.2217/cer-2019-0145	results	1	NA	contrast_effect_adjusted_pvalci	[0.36;0.68]
10.2217/cer-2019-0145	results	1	NA	adjustment_geographical	NA
10.2217/cer-2019-0145	results	1	NA	ss_total_ipd	NA
10.2217/cer-2019-0145	results	1	NA	ss_adjusted_total_ipd	NA
10.2217/cer-2019-0145	results	1	NA	ss_total_nonipd	NA
10.2217/cer-2019-0145	results	1	NA	ss_anchor_nonipd	NA
10.2217/cer-2019-0145	results	1	NA	ss_anchor_ipd	NA
10.2217/cer-2019-0145	results	1	NA	ss_adjusted_anchor_ipd	NA
10.2217/cer-2019-0145	results	1	NA	effect_cutoff	1
10.2217/cer-2019-0145	results	1	NA	adjusted_lb_ci	0.36
10.2217/cer-2019-0145	results	1	NA	adjusted_ub_ci	0.68
10.2217/cer-2019-0145	results	1	NA	adjusted_significant	TRUE
10.2217/cer-2019-0145	results	1	NA	unadjusted_lb_ci	0.36
10.2217/cer-2019-0145	results	1	NA	unadjusted_ub_ci	0.59
10.2217/cer-2019-0145	results	1	NA	unadjusted_significant	TRUE
10.2217/cer-2019-0145	study_information	NA	1	ipd_yn	Yes
10.2217/cer-2019-0145	study_information	NA	1	ct_yn	Yes
10.2217/cer-2019-0145	study_information	NA	1	nct	NCT01928394
10.2217/cer-2019-0145	study_information	NA	1	country_study	international
10.2217/cer-2019-0145	study_information	NA	1	ct_phase	1, 2
10.2217/cer-2019-0145	study_information	NA	1	ct_arms	2 or more
10.2217/cer-2019-0145	study_information	NA	2	ipd_yn	No
10.2217/cer-2019-0145	study_information	NA	2	ct_yn	No
10.2217/cer-2019-0145	study_information	NA	2	data_source_name	flatiron healths electronic health record database
10.2217/cer-2019-0145	study_information	NA	2	country_study	usa
10.2217/cer-2019-0169	general_information	NA	NA	condition_name	relapsing multiple sclerosis
10.2217/cer-2019-0169	general_information	NA	NA	country_first_author	usa
10.2217/cer-2019-0169	general_information	NA	NA	country_last_author	usa
10.2217/cer-2019-0169	general_information	NA	NA	positions	Pharmaceutical Industry, Private Data Analysis Company
10.2217/cer-2019-0169	general_information	NA	NA	methodologist_yn	Yes
10.2217/cer-2019-0169	general_information	NA	NA	funding_source	Pharmaceutical Industry
10.2217/cer-2019-0169	general_information	NA	NA	pharmaceutical_ties_yn	Yes
10.2217/cer-2019-0169	general_information	NA	NA	systematic_review_yn	No
10.2217/cer-2019-0169	methodology	1	NA	outcome_name	percentage of patients whose lowest hourly recorded heart rate was <45 bpm in the first 6 h after their first dose ( first-dose cardiac monitoring outcomes)
10.2217/cer-2019-0169	methodology	1	NA	outcome_short_name	Bradycardia proportion
10.2217/cer-2019-0169	methodology	1	NA	outcome_variable_type	Binary (eg rates)
10.2217/cer-2019-0169	methodology	1	NA	treatment_name_ipd	ozanimod
10.2217/cer-2019-0169	methodology	1	NA	studies_number_ipd	1;2
10.2217/cer-2019-0169	methodology	1	NA	treatment_name_nonipd	fingolimod
10.2217/cer-2019-0169	methodology	1	NA	studies_number_nonipd	3;4;5
10.2217/cer-2019-0169	methodology	1	NA	paic_type	MAIC
10.2217/cer-2019-0169	methodology	1	NA	anchored_yn	No
10.2217/cer-2019-0169	methodology	1	NA	paic_form	Aggregation of multiple studies to estimate individual treatment effects (e.g. meta-analysis in a first step to estimate treatment A effect, then population adjusted indirect comparison using treatment A effect estimate)
10.2217/cer-2019-0169	methodology	1	NA	primary_outcome_yn	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.2217/cer-2019-0169	methodology	1	NA	variables_selection_justification	A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion)
10.2217/cer-2019-0169	methodology	1	NA	pf_yn	No discussion (in the main text) of the status of prognostic factors of the variables
10.2217/cer-2019-0169	methodology	1	NA	tem_yn	No discussion (in the main text) of the status of treatment-effect modifiers of the variables
10.2217/cer-2019-0169	methodology	1	NA	adjustment_model_details_yn	Yes
10.2217/cer-2019-0169	methodology	1	NA	scale_choice_yn	No
10.2217/cer-2019-0169	methodology	2	NA	outcome_name	risk of any adverse events at year 1 (1-year outcomes)
10.2217/cer-2019-0169	methodology	2	NA	outcome_short_name	Adverse Event
10.2217/cer-2019-0169	methodology	2	NA	outcome_variable_type	Binary (eg rates)
10.2217/cer-2019-0169	methodology	2	NA	treatment_name_ipd	ozanimod
10.2217/cer-2019-0169	methodology	2	NA	studies_number_ipd	1;2
10.2217/cer-2019-0169	methodology	2	NA	treatment_name_nonipd	fingolimod
10.2217/cer-2019-0169	methodology	2	NA	studies_number_nonipd	3
10.2217/cer-2019-0169	methodology	2	NA	paic_type	MAIC
10.2217/cer-2019-0169	methodology	2	NA	anchored_yn	Yes
10.2217/cer-2019-0169	methodology	2	NA	paic_form	Aggregation of multiple studies to estimate individual treatment effects (e.g. meta-analysis in a first step to estimate treatment A effect, then population adjusted indirect comparison using treatment A effect estimate)
10.2217/cer-2019-0169	methodology	2	NA	primary_outcome_yn	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.2217/cer-2019-0169	methodology	2	NA	variables_selection_justification	A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion)
10.2217/cer-2019-0169	methodology	2	NA	pf_yn	No discussion (in the main text) of the status of prognostic factors of the variables
10.2217/cer-2019-0169	methodology	2	NA	tem_yn	No discussion (in the main text) of the status of treatment-effect modifiers of the variables
10.2217/cer-2019-0169	methodology	2	NA	adjustment_model_details_yn	Yes
10.2217/cer-2019-0169	methodology	2	NA	scale_choice_yn	No
10.2217/cer-2019-0169	methodology	3	NA	outcome_name	risk of any adverse effect at 2 years
10.2217/cer-2019-0169	methodology	3	NA	outcome_short_name	Adverse Event
10.2217/cer-2019-0169	methodology	3	NA	outcome_variable_type	Binary (eg rates)
10.2217/cer-2019-0169	methodology	3	NA	treatment_name_ipd	ozanimod
10.2217/cer-2019-0169	methodology	3	NA	studies_number_ipd	1
10.2217/cer-2019-0169	methodology	3	NA	treatment_name_nonipd	fingolimod
10.2217/cer-2019-0169	methodology	3	NA	studies_number_nonipd	4;5
10.2217/cer-2019-0169	methodology	3	NA	paic_type	MAIC
10.2217/cer-2019-0169	methodology	3	NA	anchored_yn	No
10.2217/cer-2019-0169	methodology	3	NA	paic_form	Aggregation of multiple studies to estimate individual treatment effects (e.g. meta-analysis in a first step to estimate treatment A effect, then population adjusted indirect comparison using treatment A effect estimate)
10.2217/cer-2019-0169	methodology	3	NA	primary_outcome_yn	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.2217/cer-2019-0169	methodology	3	NA	variables_selection_justification	A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion)
10.2217/cer-2019-0169	methodology	3	NA	pf_yn	No discussion (in the main text) of the status of prognostic factors of the variables
10.2217/cer-2019-0169	methodology	3	NA	tem_yn	No discussion (in the main text) of the status of treatment-effect modifiers of the variables
10.2217/cer-2019-0169	methodology	3	NA	adjustment_model_details_yn	Yes
10.2217/cer-2019-0169	methodology	3	NA	scale_choice_yn	No
10.2217/cer-2019-0169	results	1	NA	contrast_effect_type	Risk difference
10.2217/cer-2019-0169	results	1	NA	direction_benefit	inferior
10.2217/cer-2019-0169	results	1	NA	ss_ttt_nonipd	1212
10.2217/cer-2019-0169	results	1	NA	ss_ttt_ipd	1773
10.2217/cer-2019-0169	results	1	NA	ss_adjusted_ttt_ipd	597
10.2217/cer-2019-0169	results	1	NA	weights_yn	Not mentioned
10.2217/cer-2019-0169	results	1	NA	covariates_yn	Yes
10.2217/cer-2019-0169	results	1	NA	covariates_n	11
10.2217/cer-2019-0169	results	1	NA	covariates_names	Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Past treatments for the disease of interest, Comorbidities and medical history (beside pathology/disease of interest in the comparison), Other(s)
10.2217/cer-2019-0169	results	1	NA	contrast_effect_direction	Numerator if ratio, or left side if difference
10.2217/cer-2019-0169	results	1	NA	contrast_effect_unadjusted_value	NA
10.2217/cer-2019-0169	results	1	NA	contrast_effect_unadjusted_pvalci	NA
10.2217/cer-2019-0169	results	1	NA	contrast_effect_adjusted_value	-1.4
10.2217/cer-2019-0169	results	1	NA	contrast_effect_adjusted_pvalci	<0.001
10.2217/cer-2019-0169	results	1	NA	adjustment_geographical	No
10.2217/cer-2019-0169	results	1	NA	ss_total_ipd	NA
10.2217/cer-2019-0169	results	1	NA	ss_adjusted_total_ipd	NA
10.2217/cer-2019-0169	results	1	NA	ss_total_nonipd	NA
10.2217/cer-2019-0169	results	1	NA	ss_anchor_nonipd	NA
10.2217/cer-2019-0169	results	1	NA	ss_anchor_ipd	NA
10.2217/cer-2019-0169	results	1	NA	ss_adjusted_anchor_ipd	NA
10.2217/cer-2019-0169	results	1	NA	effect_cutoff	0
10.2217/cer-2019-0169	results	1	NA	adjusted_pval	<0.001
10.2217/cer-2019-0169	results	1	NA	adjusted_significant	TRUE
10.2217/cer-2019-0169	results	2	NA	contrast_effect_type	Risk difference
10.2217/cer-2019-0169	results	2	NA	direction_benefit	inferior
10.2217/cer-2019-0169	results	2	NA	ss_ttt_nonipd	429
10.2217/cer-2019-0169	results	2	NA	ss_ttt_ipd	882
10.2217/cer-2019-0169	results	2	NA	ss_adjusted_ttt_ipd	276
10.2217/cer-2019-0169	results	2	NA	weights_yn	Not mentioned
10.2217/cer-2019-0169	results	2	NA	covariates_yn	Yes
10.2217/cer-2019-0169	results	2	NA	covariates_n	9
10.2217/cer-2019-0169	results	2	NA	covariates_names	Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Past treatments for the disease of interest, Other(s)
10.2217/cer-2019-0169	results	2	NA	contrast_effect_direction	Numerator if ratio, or left side if difference
10.2217/cer-2019-0169	results	2	NA	contrast_effect_unadjusted_value	NA
10.2217/cer-2019-0169	results	2	NA	contrast_effect_unadjusted_pvalci	NA
10.2217/cer-2019-0169	results	2	NA	contrast_effect_adjusted_value	-9.9
10.2217/cer-2019-0169	results	2	NA	contrast_effect_adjusted_pvalci	<0.05
10.2217/cer-2019-0169	results	2	NA	adjustment_geographical	No
10.2217/cer-2019-0169	results	2	NA	ss_total_ipd	NA
10.2217/cer-2019-0169	results	2	NA	ss_adjusted_total_ipd	NA
10.2217/cer-2019-0169	results	2	NA	ss_total_nonipd	NA
10.2217/cer-2019-0169	results	2	NA	ss_anchor_nonipd	431
10.2217/cer-2019-0169	results	2	NA	ss_anchor_ipd	885
10.2217/cer-2019-0169	results	2	NA	ss_adjusted_anchor_ipd	317
10.2217/cer-2019-0169	results	2	NA	effect_cutoff	0
10.2217/cer-2019-0169	results	2	NA	adjusted_pval	<0.05
10.2217/cer-2019-0169	results	2	NA	adjusted_significant	TRUE
10.2217/cer-2019-0169	results	3	NA	contrast_effect_type	Risk difference
10.2217/cer-2019-0169	results	3	NA	direction_benefit	inferior
10.2217/cer-2019-0169	results	3	NA	ss_ttt_nonipd	783
10.2217/cer-2019-0169	results	3	NA	ss_ttt_ipd	434
10.2217/cer-2019-0169	results	3	NA	ss_adjusted_ttt_ipd	158
10.2217/cer-2019-0169	results	3	NA	weights_yn	Not mentioned
10.2217/cer-2019-0169	results	3	NA	covariates_yn	Yes
10.2217/cer-2019-0169	results	3	NA	covariates_n	8
10.2217/cer-2019-0169	results	3	NA	covariates_names	Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Past treatments for the disease of interest
10.2217/cer-2019-0169	results	3	NA	contrast_effect_direction	Numerator if ratio, or left side if difference
10.2217/cer-2019-0169	results	3	NA	contrast_effect_unadjusted_value	NA
10.2217/cer-2019-0169	results	3	NA	contrast_effect_unadjusted_pvalci	NA
10.2217/cer-2019-0169	results	3	NA	contrast_effect_adjusted_value	-22.7
10.2217/cer-2019-0169	results	3	NA	contrast_effect_adjusted_pvalci	<0.001
10.2217/cer-2019-0169	results	3	NA	adjustment_geographical	NA
10.2217/cer-2019-0169	results	3	NA	ss_total_ipd	NA
10.2217/cer-2019-0169	results	3	NA	ss_adjusted_total_ipd	NA
10.2217/cer-2019-0169	results	3	NA	ss_total_nonipd	NA
10.2217/cer-2019-0169	results	3	NA	ss_anchor_nonipd	NA
10.2217/cer-2019-0169	results	3	NA	ss_anchor_ipd	NA
10.2217/cer-2019-0169	results	3	NA	ss_adjusted_anchor_ipd	NA
10.2217/cer-2019-0169	results	3	NA	effect_cutoff	0
10.2217/cer-2019-0169	results	3	NA	adjusted_pval	<0.001
10.2217/cer-2019-0169	results	3	NA	adjusted_significant	TRUE
10.2217/cer-2019-0169	study_information	NA	1	ipd_yn	Yes
10.2217/cer-2019-0169	study_information	NA	1	ct_yn	Yes
10.2217/cer-2019-0169	study_information	NA	1	nct	NCT02047734
10.2217/cer-2019-0169	study_information	NA	1	country_study	international
10.2217/cer-2019-0169	study_information	NA	1	ct_phase	3
10.2217/cer-2019-0169	study_information	NA	1	ct_arms	2 or more
10.2217/cer-2019-0169	study_information	NA	2	ipd_yn	Yes
10.2217/cer-2019-0169	study_information	NA	2	ct_yn	Yes
10.2217/cer-2019-0169	study_information	NA	2	nct	NCT02294058
10.2217/cer-2019-0169	study_information	NA	2	country_study	international
10.2217/cer-2019-0169	study_information	NA	2	ct_phase	3
10.2217/cer-2019-0169	study_information	NA	2	ct_arms	2 or more
10.2217/cer-2019-0169	study_information	NA	3	ipd_yn	No
10.2217/cer-2019-0169	study_information	NA	3	ct_yn	Yes
10.2217/cer-2019-0169	study_information	NA	3	nct	NCT00340834
10.2217/cer-2019-0169	study_information	NA	3	country_study	international
10.2217/cer-2019-0169	study_information	NA	3	ct_phase	3
10.2217/cer-2019-0169	study_information	NA	3	ct_arms	2 or more
10.2217/cer-2019-0169	study_information	NA	4	ipd_yn	No
10.2217/cer-2019-0169	study_information	NA	4	ct_yn	Yes
10.2217/cer-2019-0169	study_information	NA	4	nct	NCT00289978
10.2217/cer-2019-0169	study_information	NA	4	country_study	international
10.2217/cer-2019-0169	study_information	NA	4	ct_phase	3
10.2217/cer-2019-0169	study_information	NA	4	ct_arms	2 or more
10.2217/cer-2019-0169	study_information	NA	5	ipd_yn	No
10.2217/cer-2019-0169	study_information	NA	5	ct_yn	Yes
10.2217/cer-2019-0169	study_information	NA	5	nct	NCT00355134
10.2217/cer-2019-0169	study_information	NA	5	country_study	international
10.2217/cer-2019-0169	study_information	NA	5	ct_phase	3
10.2217/cer-2019-0169	study_information	NA	5	ct_arms	2 or more
10.2217/cer-2020-0063	general_information	NA	NA	condition_name	non-small cell lung cancer
10.2217/cer-2020-0063	general_information	NA	NA	country_first_author	switzerland
10.2217/cer-2020-0063	general_information	NA	NA	country_last_author	switzerland
10.2217/cer-2020-0063	general_information	NA	NA	positions	Pharmaceutical Industry, Private Data Analysis Company
10.2217/cer-2020-0063	general_information	NA	NA	methodologist_yn	Yes
10.2217/cer-2020-0063	general_information	NA	NA	funding_source	Pharmaceutical Industry
10.2217/cer-2020-0063	general_information	NA	NA	pharmaceutical_ties_yn	Yes
10.2217/cer-2020-0063	general_information	NA	NA	systematic_review_yn	Yes
10.2217/cer-2020-0063	methodology	1	NA	outcome_name	overall survival
10.2217/cer-2020-0063	methodology	1	NA	outcome_short_name	Overall Survival
10.2217/cer-2020-0063	methodology	1	NA	outcome_variable_type	Time-to-event
10.2217/cer-2020-0063	methodology	1	NA	treatment_name_ipd	entrectinib
10.2217/cer-2020-0063	methodology	1	NA	studies_number_ipd	1;2;3
10.2217/cer-2020-0063	methodology	1	NA	treatment_name_nonipd	crizotinib
10.2217/cer-2020-0063	methodology	1	NA	studies_number_nonipd	4
10.2217/cer-2020-0063	methodology	1	NA	paic_type	MAIC
10.2217/cer-2020-0063	methodology	1	NA	anchored_yn	No
10.2217/cer-2020-0063	methodology	1	NA	paic_form	Aggregation of multiple studies to estimate individual treatment effects (e.g. meta-analysis in a first step to estimate treatment A effect, then population adjusted indirect comparison using treatment A effect estimate)
10.2217/cer-2020-0063	methodology	1	NA	primary_outcome_yn	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.2217/cer-2020-0063	methodology	1	NA	variables_selection_justification	Nothing mentioned, not reported
10.2217/cer-2020-0063	methodology	1	NA	pf_yn	Yes
10.2217/cer-2020-0063	methodology	1	NA	tem_yn	Yes
10.2217/cer-2020-0063	methodology	1	NA	adjustment_model_details_yn	No
10.2217/cer-2020-0063	methodology	1	NA	scale_choice_yn	No
10.2217/cer-2020-0063	methodology	2	NA	outcome_name	overall survival
10.2217/cer-2020-0063	methodology	2	NA	outcome_short_name	Overall Survival
10.2217/cer-2020-0063	methodology	2	NA	outcome_variable_type	Time-to-event
10.2217/cer-2020-0063	methodology	2	NA	treatment_name_ipd	entrectinib
10.2217/cer-2020-0063	methodology	2	NA	studies_number_ipd	1;2;3
10.2217/cer-2020-0063	methodology	2	NA	treatment_name_nonipd	pemetrexed + platinum followed by pemetrexed maintenance
10.2217/cer-2020-0063	methodology	2	NA	studies_number_nonipd	5
10.2217/cer-2020-0063	methodology	2	NA	paic_type	MAIC
10.2217/cer-2020-0063	methodology	2	NA	anchored_yn	No
10.2217/cer-2020-0063	methodology	2	NA	paic_form	Aggregation of multiple studies to estimate individual treatment effects (e.g. meta-analysis in a first step to estimate treatment A effect, then population adjusted indirect comparison using treatment A effect estimate)
10.2217/cer-2020-0063	methodology	2	NA	primary_outcome_yn	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.2217/cer-2020-0063	methodology	2	NA	variables_selection_justification	Nothing mentioned, not reported
10.2217/cer-2020-0063	methodology	2	NA	pf_yn	Yes
10.2217/cer-2020-0063	methodology	2	NA	tem_yn	Yes
10.2217/cer-2020-0063	methodology	2	NA	adjustment_model_details_yn	No
10.2217/cer-2020-0063	methodology	2	NA	scale_choice_yn	No
10.2217/cer-2020-0063	methodology	3	NA	outcome_name	overall survival
10.2217/cer-2020-0063	methodology	3	NA	outcome_short_name	Overall Survival
10.2217/cer-2020-0063	methodology	3	NA	outcome_variable_type	Time-to-event
10.2217/cer-2020-0063	methodology	3	NA	treatment_name_ipd	entrectinib
10.2217/cer-2020-0063	methodology	3	NA	studies_number_ipd	1;2;3
10.2217/cer-2020-0063	methodology	3	NA	treatment_name_nonipd	pemetrexed/docetaxel
10.2217/cer-2020-0063	methodology	3	NA	studies_number_nonipd	6
10.2217/cer-2020-0063	methodology	3	NA	paic_type	MAIC
10.2217/cer-2020-0063	methodology	3	NA	anchored_yn	No
10.2217/cer-2020-0063	methodology	3	NA	paic_form	Aggregation of multiple studies to estimate individual treatment effects (e.g. meta-analysis in a first step to estimate treatment A effect, then population adjusted indirect comparison using treatment A effect estimate)
10.2217/cer-2020-0063	methodology	3	NA	primary_outcome_yn	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.2217/cer-2020-0063	methodology	3	NA	variables_selection_justification	Nothing mentioned, not reported
10.2217/cer-2020-0063	methodology	3	NA	pf_yn	Yes
10.2217/cer-2020-0063	methodology	3	NA	tem_yn	Yes
10.2217/cer-2020-0063	methodology	3	NA	adjustment_model_details_yn	No
10.2217/cer-2020-0063	methodology	3	NA	scale_choice_yn	No
10.2217/cer-2020-0063	results	1	NA	contrast_effect_type	HR
10.2217/cer-2020-0063	results	1	NA	direction_benefit	inferior
10.2217/cer-2020-0063	results	1	NA	ss_ttt_nonipd	53
10.2217/cer-2020-0063	results	1	NA	ss_ttt_ipd	53
10.2217/cer-2020-0063	results	1	NA	ss_adjusted_ttt_ipd	34.18
10.2217/cer-2020-0063	results	1	NA	weights_yn	Not mentioned
10.2217/cer-2020-0063	results	1	NA	covariates_yn	Yes
10.2217/cer-2020-0063	results	1	NA	covariates_n	6
10.2217/cer-2020-0063	results	1	NA	covariates_names	Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Past treatments for the disease of interest, Comorbidities and medical history (beside pathology/disease of interest in the comparison)
10.2217/cer-2020-0063	results	1	NA	contrast_effect_direction	Numerator if ratio, or left side if difference
10.2217/cer-2020-0063	results	1	NA	contrast_effect_unadjusted_value	NA
10.2217/cer-2020-0063	results	1	NA	contrast_effect_unadjusted_pvalci	NA
10.2217/cer-2020-0063	results	1	NA	contrast_effect_adjusted_value	0.471
10.2217/cer-2020-0063	results	1	NA	contrast_effect_adjusted_pvalci	[0.112;1.034]
10.2217/cer-2020-0063	results	1	NA	adjustment_geographical	NA
10.2217/cer-2020-0063	results	1	NA	ss_total_ipd	NA
10.2217/cer-2020-0063	results	1	NA	ss_adjusted_total_ipd	NA
10.2217/cer-2020-0063	results	1	NA	ss_total_nonipd	NA
10.2217/cer-2020-0063	results	1	NA	ss_anchor_nonipd	NA
10.2217/cer-2020-0063	results	1	NA	ss_anchor_ipd	NA
10.2217/cer-2020-0063	results	1	NA	ss_adjusted_anchor_ipd	NA
10.2217/cer-2020-0063	results	1	NA	effect_cutoff	1
10.2217/cer-2020-0063	results	1	NA	adjusted_lb_ci	0.112
10.2217/cer-2020-0063	results	1	NA	adjusted_ub_ci	1.034
10.2217/cer-2020-0063	results	1	NA	adjusted_significant	FALSE
10.2217/cer-2020-0063	results	2	NA	contrast_effect_type	HR
10.2217/cer-2020-0063	results	2	NA	direction_benefit	inferior
10.2217/cer-2020-0063	results	2	NA	ss_ttt_nonipd	187
10.2217/cer-2020-0063	results	2	NA	ss_ttt_ipd	53
10.2217/cer-2020-0063	results	2	NA	ss_adjusted_ttt_ipd	47.5
10.2217/cer-2020-0063	results	2	NA	weights_yn	Not mentioned
10.2217/cer-2020-0063	results	2	NA	covariates_yn	Yes
10.2217/cer-2020-0063	results	2	NA	covariates_n	5
10.2217/cer-2020-0063	results	2	NA	covariates_names	Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Comorbidities and medical history (beside pathology/disease of interest in the comparison)
10.2217/cer-2020-0063	results	2	NA	contrast_effect_direction	Numerator if ratio, or left side if difference
10.2217/cer-2020-0063	results	2	NA	contrast_effect_unadjusted_value	NA
10.2217/cer-2020-0063	results	2	NA	contrast_effect_unadjusted_pvalci	NA
10.2217/cer-2020-0063	results	2	NA	contrast_effect_adjusted_value	0.478
10.2217/cer-2020-0063	results	2	NA	contrast_effect_adjusted_pvalci	[0.167;0.918]
10.2217/cer-2020-0063	results	2	NA	adjustment_geographical	NA
10.2217/cer-2020-0063	results	2	NA	ss_total_ipd	NA
10.2217/cer-2020-0063	results	2	NA	ss_adjusted_total_ipd	NA
10.2217/cer-2020-0063	results	2	NA	ss_total_nonipd	NA
10.2217/cer-2020-0063	results	2	NA	ss_anchor_nonipd	NA
10.2217/cer-2020-0063	results	2	NA	ss_anchor_ipd	NA
10.2217/cer-2020-0063	results	2	NA	ss_adjusted_anchor_ipd	NA
10.2217/cer-2020-0063	results	2	NA	effect_cutoff	1
10.2217/cer-2020-0063	results	2	NA	adjusted_lb_ci	0.167
10.2217/cer-2020-0063	results	2	NA	adjusted_ub_ci	0.918
10.2217/cer-2020-0063	results	2	NA	adjusted_significant	TRUE
10.2217/cer-2020-0063	results	3	NA	contrast_effect_type	HR
10.2217/cer-2020-0063	results	3	NA	direction_benefit	inferior
10.2217/cer-2020-0063	results	3	NA	ss_ttt_nonipd	174
10.2217/cer-2020-0063	results	3	NA	ss_ttt_ipd	53
10.2217/cer-2020-0063	results	3	NA	ss_adjusted_ttt_ipd	36.09
10.2217/cer-2020-0063	results	3	NA	weights_yn	Not mentioned
10.2217/cer-2020-0063	results	3	NA	covariates_yn	Yes
10.2217/cer-2020-0063	results	3	NA	covariates_n	5
10.2217/cer-2020-0063	results	3	NA	covariates_names	Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Comorbidities and medical history (beside pathology/disease of interest in the comparison)
10.2217/cer-2020-0063	results	3	NA	contrast_effect_direction	Numerator if ratio, or left side if difference
10.2217/cer-2020-0063	results	3	NA	contrast_effect_unadjusted_value	NA
10.2217/cer-2020-0063	results	3	NA	contrast_effect_unadjusted_pvalci	NA
10.2217/cer-2020-0063	results	3	NA	contrast_effect_adjusted_value	0.434
10.2217/cer-2020-0063	results	3	NA	contrast_effect_adjusted_pvalci	[0.157;0.755]
10.2217/cer-2020-0063	results	3	NA	adjustment_geographical	NA
10.2217/cer-2020-0063	results	3	NA	ss_total_ipd	NA
10.2217/cer-2020-0063	results	3	NA	ss_adjusted_total_ipd	NA
10.2217/cer-2020-0063	results	3	NA	ss_total_nonipd	NA
10.2217/cer-2020-0063	results	3	NA	ss_anchor_nonipd	NA
10.2217/cer-2020-0063	results	3	NA	ss_anchor_ipd	NA
10.2217/cer-2020-0063	results	3	NA	ss_adjusted_anchor_ipd	NA
10.2217/cer-2020-0063	results	3	NA	effect_cutoff	1
10.2217/cer-2020-0063	results	3	NA	adjusted_lb_ci	0.157
10.2217/cer-2020-0063	results	3	NA	adjusted_ub_ci	0.755
10.2217/cer-2020-0063	results	3	NA	adjusted_significant	TRUE
10.2217/cer-2020-0063	study_information	NA	1	ipd_yn	Yes
10.2217/cer-2020-0063	study_information	NA	1	ct_yn	Yes
10.2217/cer-2020-0063	study_information	NA	1	eudract	2012-000148-88
10.2217/cer-2020-0063	study_information	NA	1	country_study	italy
10.2217/cer-2020-0063	study_information	NA	1	ct_phase	1
10.2217/cer-2020-0063	study_information	NA	1	ct_arms	1
10.2217/cer-2020-0063	study_information	NA	2	ipd_yn	Yes
10.2217/cer-2020-0063	study_information	NA	2	ct_yn	Yes
10.2217/cer-2020-0063	study_information	NA	2	nct	NCT02097810
10.2217/cer-2020-0063	study_information	NA	2	country_study	international
10.2217/cer-2020-0063	study_information	NA	2	ct_phase	1
10.2217/cer-2020-0063	study_information	NA	2	ct_arms	1
10.2217/cer-2020-0063	study_information	NA	3	ipd_yn	Yes
10.2217/cer-2020-0063	study_information	NA	3	ct_yn	Yes
10.2217/cer-2020-0063	study_information	NA	3	nct	NCT02568267
10.2217/cer-2020-0063	study_information	NA	3	country_study	international
10.2217/cer-2020-0063	study_information	NA	3	ct_phase	2
10.2217/cer-2020-0063	study_information	NA	3	ct_arms	1
10.2217/cer-2020-0063	study_information	NA	4	ipd_yn	No
10.2217/cer-2020-0063	study_information	NA	4	ct_yn	Yes
10.2217/cer-2020-0063	study_information	NA	4	nct	NCT00585195
10.2217/cer-2020-0063	study_information	NA	4	country_study	international
10.2217/cer-2020-0063	study_information	NA	4	ct_phase	1
10.2217/cer-2020-0063	study_information	NA	4	ct_arms	1
10.2217/cer-2020-0063	study_information	NA	5	ipd_yn	No
10.2217/cer-2020-0063	study_information	NA	5	ct_yn	Yes
10.2217/cer-2020-0063	study_information	NA	5	nct	NCT01828099
10.2217/cer-2020-0063	study_information	NA	5	country_study	international
10.2217/cer-2020-0063	study_information	NA	5	ct_phase	3
10.2217/cer-2020-0063	study_information	NA	5	ct_arms	2 or more
10.2217/cer-2020-0063	study_information	NA	6	ipd_yn	No
10.2217/cer-2020-0063	study_information	NA	6	ct_yn	Yes
10.2217/cer-2020-0063	study_information	NA	6	nct	NCT00932893
10.2217/cer-2020-0063	study_information	NA	6	country_study	international
10.2217/cer-2020-0063	study_information	NA	6	ct_phase	3
10.2217/cer-2020-0063	study_information	NA	6	ct_arms	2 or more
10.2217/cer-2020-0069	general_information	NA	NA	condition_name	pediatric relapsed/refractory acute lymphoblastic leukemia
10.2217/cer-2020-0069	general_information	NA	NA	country_first_author	usa
10.2217/cer-2020-0069	general_information	NA	NA	country_last_author	usa
10.2217/cer-2020-0069	general_information	NA	NA	positions	Pharmaceutical Industry, Private Data Analysis Company
10.2217/cer-2020-0069	general_information	NA	NA	methodologist_yn	Yes
10.2217/cer-2020-0069	general_information	NA	NA	funding_source	Pharmaceutical Industry
10.2217/cer-2020-0069	general_information	NA	NA	pharmaceutical_ties_yn	Yes
10.2217/cer-2020-0069	general_information	NA	NA	systematic_review_yn	Yes
10.2217/cer-2020-0069	methodology	1	NA	outcome_name	overall survival
10.2217/cer-2020-0069	methodology	1	NA	outcome_short_name	Overall Survival
10.2217/cer-2020-0069	methodology	1	NA	outcome_variable_type	Time-to-event
10.2217/cer-2020-0069	methodology	1	NA	treatment_name_ipd	tisagenlecleucel
10.2217/cer-2020-0069	methodology	1	NA	studies_number_ipd	1
10.2217/cer-2020-0069	methodology	1	NA	treatment_name_nonipd	blinatumomab
10.2217/cer-2020-0069	methodology	1	NA	studies_number_nonipd	2
10.2217/cer-2020-0069	methodology	1	NA	paic_type	MAIC
10.2217/cer-2020-0069	methodology	1	NA	anchored_yn	No
10.2217/cer-2020-0069	methodology	1	NA	paic_form	Simple (ie treatments effects extracted from two studies)
10.2217/cer-2020-0069	methodology	1	NA	primary_outcome_yn	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.2217/cer-2020-0069	methodology	1	NA	variables_selection_justification	A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion), Literature based (clinically or methodologically relevant to adjust on these variables based on the literature search conducted for this specific purpose)
10.2217/cer-2020-0069	methodology	1	NA	pf_yn	No discussion (in the main text) of the status of prognostic factors of the variables
10.2217/cer-2020-0069	methodology	1	NA	tem_yn	No discussion (in the main text) of the status of treatment-effect modifiers of the variables
10.2217/cer-2020-0069	methodology	1	NA	adjustment_model_details_yn	No
10.2217/cer-2020-0069	methodology	1	NA	scale_choice_yn	No
10.2217/cer-2020-0069	methodology	2	NA	outcome_name	overall survival
10.2217/cer-2020-0069	methodology	2	NA	outcome_short_name	Overall Survival
10.2217/cer-2020-0069	methodology	2	NA	outcome_variable_type	Time-to-event
10.2217/cer-2020-0069	methodology	2	NA	treatment_name_ipd	tisagenlecleucel
10.2217/cer-2020-0069	methodology	2	NA	studies_number_ipd	1
10.2217/cer-2020-0069	methodology	2	NA	treatment_name_nonipd	clofarabine
10.2217/cer-2020-0069	methodology	2	NA	studies_number_nonipd	3
10.2217/cer-2020-0069	methodology	2	NA	paic_type	MAIC
10.2217/cer-2020-0069	methodology	2	NA	anchored_yn	No
10.2217/cer-2020-0069	methodology	2	NA	paic_form	Simple (ie treatments effects extracted from two studies)
10.2217/cer-2020-0069	methodology	2	NA	primary_outcome_yn	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.2217/cer-2020-0069	methodology	2	NA	variables_selection_justification	A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion), Literature based (clinically or methodologically relevant to adjust on these variables based on the literature search conducted for this specific purpose)
10.2217/cer-2020-0069	methodology	2	NA	pf_yn	No discussion (in the main text) of the status of prognostic factors of the variables
10.2217/cer-2020-0069	methodology	2	NA	tem_yn	No discussion (in the main text) of the status of treatment-effect modifiers of the variables
10.2217/cer-2020-0069	methodology	2	NA	adjustment_model_details_yn	No
10.2217/cer-2020-0069	methodology	2	NA	scale_choice_yn	No
10.2217/cer-2020-0069	methodology	3	NA	outcome_name	overall survival
10.2217/cer-2020-0069	methodology	3	NA	outcome_short_name	Overall Survival
10.2217/cer-2020-0069	methodology	3	NA	outcome_variable_type	Time-to-event
10.2217/cer-2020-0069	methodology	3	NA	treatment_name_ipd	tisagenlecleucel
10.2217/cer-2020-0069	methodology	3	NA	studies_number_ipd	1
10.2217/cer-2020-0069	methodology	3	NA	treatment_name_nonipd	clofarabine + etoposide plus cyclophosphamide
10.2217/cer-2020-0069	methodology	3	NA	studies_number_nonipd	4;5;6
10.2217/cer-2020-0069	methodology	3	NA	paic_type	MAIC
10.2217/cer-2020-0069	methodology	3	NA	anchored_yn	No
10.2217/cer-2020-0069	methodology	3	NA	paic_form	Aggregation of multiple studies to estimate individual treatment effects (e.g. meta-analysis in a first step to estimate treatment A effect, then population adjusted indirect comparison using treatment A effect estimate)
10.2217/cer-2020-0069	methodology	3	NA	primary_outcome_yn	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.2217/cer-2020-0069	methodology	3	NA	variables_selection_justification	A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion), Literature based (clinically or methodologically relevant to adjust on these variables based on the literature search conducted for this specific purpose)
10.2217/cer-2020-0069	methodology	3	NA	pf_yn	No discussion (in the main text) of the status of prognostic factors of the variables
10.2217/cer-2020-0069	methodology	3	NA	tem_yn	No discussion (in the main text) of the status of treatment-effect modifiers of the variables
10.2217/cer-2020-0069	methodology	3	NA	adjustment_model_details_yn	No
10.2217/cer-2020-0069	methodology	3	NA	scale_choice_yn	No
10.2217/cer-2020-0069	methodology	4	NA	outcome_name	overall survival
10.2217/cer-2020-0069	methodology	4	NA	outcome_short_name	Overall Survival
10.2217/cer-2020-0069	methodology	4	NA	outcome_variable_type	Time-to-event
10.2217/cer-2020-0069	methodology	4	NA	treatment_name_ipd	tisagenlecleucel
10.2217/cer-2020-0069	methodology	4	NA	studies_number_ipd	1
10.2217/cer-2020-0069	methodology	4	NA	treatment_name_nonipd	polychemotherapy/high-dose single-agent regimens/stem-cell transplantation (salvage-1)
10.2217/cer-2020-0069	methodology	4	NA	studies_number_nonipd	7
10.2217/cer-2020-0069	methodology	4	NA	paic_type	MAIC
10.2217/cer-2020-0069	methodology	4	NA	anchored_yn	No
10.2217/cer-2020-0069	methodology	4	NA	paic_form	Simple (ie treatments effects extracted from two studies)
10.2217/cer-2020-0069	methodology	4	NA	primary_outcome_yn	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.2217/cer-2020-0069	methodology	4	NA	variables_selection_justification	A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion), Literature based (clinically or methodologically relevant to adjust on these variables based on the literature search conducted for this specific purpose)
10.2217/cer-2020-0069	methodology	4	NA	pf_yn	No discussion (in the main text) of the status of prognostic factors of the variables
10.2217/cer-2020-0069	methodology	4	NA	tem_yn	No discussion (in the main text) of the status of treatment-effect modifiers of the variables
10.2217/cer-2020-0069	methodology	4	NA	adjustment_model_details_yn	No
10.2217/cer-2020-0069	methodology	4	NA	scale_choice_yn	No
10.2217/cer-2020-0069	methodology	5	NA	outcome_name	overall survival
10.2217/cer-2020-0069	methodology	5	NA	outcome_short_name	Overall Survival
10.2217/cer-2020-0069	methodology	5	NA	outcome_variable_type	Time-to-event
10.2217/cer-2020-0069	methodology	5	NA	treatment_name_ipd	tisagenlecleucel
10.2217/cer-2020-0069	methodology	5	NA	studies_number_ipd	1
10.2217/cer-2020-0069	methodology	5	NA	treatment_name_nonipd	palliative therapy/salvage therapy  second stem-cell transplantation (salvage-2)
10.2217/cer-2020-0069	methodology	5	NA	studies_number_nonipd	8
10.2217/cer-2020-0069	methodology	5	NA	paic_type	MAIC
10.2217/cer-2020-0069	methodology	5	NA	anchored_yn	No
10.2217/cer-2020-0069	methodology	5	NA	paic_form	Simple (ie treatments effects extracted from two studies)
10.2217/cer-2020-0069	methodology	5	NA	primary_outcome_yn	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.2217/cer-2020-0069	methodology	5	NA	variables_selection_justification	A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion), Literature based (clinically or methodologically relevant to adjust on these variables based on the literature search conducted for this specific purpose)
10.2217/cer-2020-0069	methodology	5	NA	pf_yn	No discussion (in the main text) of the status of prognostic factors of the variables
10.2217/cer-2020-0069	methodology	5	NA	tem_yn	No discussion (in the main text) of the status of treatment-effect modifiers of the variables
10.2217/cer-2020-0069	methodology	5	NA	adjustment_model_details_yn	No
10.2217/cer-2020-0069	methodology	5	NA	scale_choice_yn	No
10.2217/cer-2020-0069	results	1	NA	contrast_effect_type	HR
10.2217/cer-2020-0069	results	1	NA	direction_benefit	inferior
10.2217/cer-2020-0069	results	1	NA	ss_ttt_nonipd	70
10.2217/cer-2020-0069	results	1	NA	ss_ttt_ipd	79
10.2217/cer-2020-0069	results	1	NA	ss_adjusted_ttt_ipd	28.7
10.2217/cer-2020-0069	results	1	NA	weights_yn	Not mentioned
10.2217/cer-2020-0069	results	1	NA	covariates_yn	Yes
10.2217/cer-2020-0069	results	1	NA	covariates_n	9
10.2217/cer-2020-0069	results	1	NA	covariates_names	Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Past treatments for the disease of interest, Other(s)
10.2217/cer-2020-0069	results	1	NA	contrast_effect_direction	Numerator if ratio, or left side if difference
10.2217/cer-2020-0069	results	1	NA	contrast_effect_unadjusted_value	0.28
10.2217/cer-2020-0069	results	1	NA	contrast_effect_unadjusted_pvalci	<0.0001
10.2217/cer-2020-0069	results	1	NA	contrast_effect_adjusted_value	0.32
10.2217/cer-2020-0069	results	1	NA	contrast_effect_adjusted_pvalci	0.0015
10.2217/cer-2020-0069	results	1	NA	adjustment_geographical	Yes
10.2217/cer-2020-0069	results	1	NA	ss_total_ipd	NA
10.2217/cer-2020-0069	results	1	NA	ss_adjusted_total_ipd	NA
10.2217/cer-2020-0069	results	1	NA	ss_total_nonipd	NA
10.2217/cer-2020-0069	results	1	NA	ss_anchor_nonipd	NA
10.2217/cer-2020-0069	results	1	NA	ss_anchor_ipd	NA
10.2217/cer-2020-0069	results	1	NA	ss_adjusted_anchor_ipd	NA
10.2217/cer-2020-0069	results	1	NA	effect_cutoff	1
10.2217/cer-2020-0069	results	1	NA	unadjusted_pval	<0.0001
10.2217/cer-2020-0069	results	1	NA	unadjusted_significant	TRUE
10.2217/cer-2020-0069	results	1	NA	adjusted_pval	0.0015
10.2217/cer-2020-0069	results	1	NA	adjusted_num_pval	0.0015
10.2217/cer-2020-0069	results	1	NA	adjusted_significant	TRUE
10.2217/cer-2020-0069	results	2	NA	contrast_effect_type	HR
10.2217/cer-2020-0069	results	2	NA	direction_benefit	inferior
10.2217/cer-2020-0069	results	2	NA	ss_ttt_nonipd	61
10.2217/cer-2020-0069	results	2	NA	ss_ttt_ipd	79
10.2217/cer-2020-0069	results	2	NA	ss_adjusted_ttt_ipd	43
10.2217/cer-2020-0069	results	2	NA	weights_yn	Not mentioned
10.2217/cer-2020-0069	results	2	NA	covariates_yn	Yes
10.2217/cer-2020-0069	results	2	NA	covariates_n	5
10.2217/cer-2020-0069	results	2	NA	covariates_names	Age, Sex, Race/ethnicity, Past treatments for the disease of interest
10.2217/cer-2020-0069	results	2	NA	contrast_effect_direction	Numerator if ratio, or left side if difference
10.2217/cer-2020-0069	results	2	NA	contrast_effect_unadjusted_value	0.17
10.2217/cer-2020-0069	results	2	NA	contrast_effect_unadjusted_pvalci	<0.0001
10.2217/cer-2020-0069	results	2	NA	contrast_effect_adjusted_value	0.24
10.2217/cer-2020-0069	results	2	NA	contrast_effect_adjusted_pvalci	<0.0001
10.2217/cer-2020-0069	results	2	NA	adjustment_geographical	NA
10.2217/cer-2020-0069	results	2	NA	ss_total_ipd	NA
10.2217/cer-2020-0069	results	2	NA	ss_adjusted_total_ipd	NA
10.2217/cer-2020-0069	results	2	NA	ss_total_nonipd	NA
10.2217/cer-2020-0069	results	2	NA	ss_anchor_nonipd	NA
10.2217/cer-2020-0069	results	2	NA	ss_anchor_ipd	NA
10.2217/cer-2020-0069	results	2	NA	ss_adjusted_anchor_ipd	NA
10.2217/cer-2020-0069	results	2	NA	effect_cutoff	1
10.2217/cer-2020-0069	results	2	NA	unadjusted_pval	<0.0001
10.2217/cer-2020-0069	results	2	NA	unadjusted_significant	TRUE
10.2217/cer-2020-0069	results	2	NA	adjusted_pval	<0.0001
10.2217/cer-2020-0069	results	2	NA	adjusted_significant	TRUE
10.2217/cer-2020-0069	results	3	NA	contrast_effect_type	HR
10.2217/cer-2020-0069	results	3	NA	direction_benefit	inferior
10.2217/cer-2020-0069	results	3	NA	ss_ttt_nonipd	74
10.2217/cer-2020-0069	results	3	NA	ss_ttt_ipd	79
10.2217/cer-2020-0069	results	3	NA	ss_adjusted_ttt_ipd	53.5
10.2217/cer-2020-0069	results	3	NA	weights_yn	Not mentioned
10.2217/cer-2020-0069	results	3	NA	covariates_yn	Yes
10.2217/cer-2020-0069	results	3	NA	covariates_n	2
10.2217/cer-2020-0069	results	3	NA	covariates_names	Sex, Past treatments for the disease of interest
10.2217/cer-2020-0069	results	3	NA	contrast_effect_direction	Numerator if ratio, or left side if difference
10.2217/cer-2020-0069	results	3	NA	contrast_effect_unadjusted_value	0.22
10.2217/cer-2020-0069	results	3	NA	contrast_effect_unadjusted_pvalci	<0.0001
10.2217/cer-2020-0069	results	3	NA	contrast_effect_adjusted_value	0.26
10.2217/cer-2020-0069	results	3	NA	contrast_effect_adjusted_pvalci	<0.0001
10.2217/cer-2020-0069	results	3	NA	adjustment_geographical	NA
10.2217/cer-2020-0069	results	3	NA	ss_total_ipd	NA
10.2217/cer-2020-0069	results	3	NA	ss_adjusted_total_ipd	NA
10.2217/cer-2020-0069	results	3	NA	ss_total_nonipd	NA
10.2217/cer-2020-0069	results	3	NA	ss_anchor_nonipd	NA
10.2217/cer-2020-0069	results	3	NA	ss_anchor_ipd	NA
10.2217/cer-2020-0069	results	3	NA	ss_adjusted_anchor_ipd	NA
10.2217/cer-2020-0069	results	3	NA	effect_cutoff	1
10.2217/cer-2020-0069	results	3	NA	unadjusted_pval	<0.0001
10.2217/cer-2020-0069	results	3	NA	unadjusted_significant	TRUE
10.2217/cer-2020-0069	results	3	NA	adjusted_pval	<0.0001
10.2217/cer-2020-0069	results	3	NA	adjusted_significant	TRUE
10.2217/cer-2020-0069	results	4	NA	contrast_effect_type	HR
10.2217/cer-2020-0069	results	4	NA	direction_benefit	inferior
10.2217/cer-2020-0069	results	4	NA	ss_ttt_nonipd	51
10.2217/cer-2020-0069	results	4	NA	ss_ttt_ipd	79
10.2217/cer-2020-0069	results	4	NA	ss_adjusted_ttt_ipd	75
10.2217/cer-2020-0069	results	4	NA	weights_yn	Not mentioned
10.2217/cer-2020-0069	results	4	NA	covariates_yn	Yes
10.2217/cer-2020-0069	results	4	NA	covariates_n	3
10.2217/cer-2020-0069	results	4	NA	covariates_names	Age, Sex, Past treatments for the disease of interest
10.2217/cer-2020-0069	results	4	NA	contrast_effect_direction	Numerator if ratio, or left side if difference
10.2217/cer-2020-0069	results	4	NA	contrast_effect_unadjusted_value	0.14
10.2217/cer-2020-0069	results	4	NA	contrast_effect_unadjusted_pvalci	<0.0001
10.2217/cer-2020-0069	results	4	NA	contrast_effect_adjusted_value	0.15
10.2217/cer-2020-0069	results	4	NA	contrast_effect_adjusted_pvalci	<0.0001
10.2217/cer-2020-0069	results	4	NA	adjustment_geographical	NA
10.2217/cer-2020-0069	results	4	NA	ss_total_ipd	NA
10.2217/cer-2020-0069	results	4	NA	ss_adjusted_total_ipd	NA
10.2217/cer-2020-0069	results	4	NA	ss_total_nonipd	NA
10.2217/cer-2020-0069	results	4	NA	ss_anchor_nonipd	NA
10.2217/cer-2020-0069	results	4	NA	ss_anchor_ipd	NA
10.2217/cer-2020-0069	results	4	NA	ss_adjusted_anchor_ipd	NA
10.2217/cer-2020-0069	results	4	NA	effect_cutoff	1
10.2217/cer-2020-0069	results	4	NA	unadjusted_pval	<0.0001
10.2217/cer-2020-0069	results	4	NA	unadjusted_significant	TRUE
10.2217/cer-2020-0069	results	4	NA	adjusted_pval	<0.0001
10.2217/cer-2020-0069	results	4	NA	adjusted_significant	TRUE
10.2217/cer-2020-0069	results	5	NA	contrast_effect_type	HR
10.2217/cer-2020-0069	results	5	NA	direction_benefit	inferior
10.2217/cer-2020-0069	results	5	NA	ss_ttt_nonipd	242
10.2217/cer-2020-0069	results	5	NA	ss_ttt_ipd	79
10.2217/cer-2020-0069	results	5	NA	ss_adjusted_ttt_ipd	36.2
10.2217/cer-2020-0069	results	5	NA	weights_yn	Not mentioned
10.2217/cer-2020-0069	results	5	NA	covariates_yn	Yes
10.2217/cer-2020-0069	results	5	NA	covariates_n	3
10.2217/cer-2020-0069	results	5	NA	covariates_names	Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease)
10.2217/cer-2020-0069	results	5	NA	contrast_effect_direction	Numerator if ratio, or left side if difference
10.2217/cer-2020-0069	results	5	NA	contrast_effect_unadjusted_value	0.28
10.2217/cer-2020-0069	results	5	NA	contrast_effect_unadjusted_pvalci	<0.0001
10.2217/cer-2020-0069	results	5	NA	contrast_effect_adjusted_value	0.27
10.2217/cer-2020-0069	results	5	NA	contrast_effect_adjusted_pvalci	<0.0001
10.2217/cer-2020-0069	results	5	NA	adjustment_geographical	NA
10.2217/cer-2020-0069	results	5	NA	ss_total_ipd	NA
10.2217/cer-2020-0069	results	5	NA	ss_adjusted_total_ipd	NA
10.2217/cer-2020-0069	results	5	NA	ss_total_nonipd	NA
10.2217/cer-2020-0069	results	5	NA	ss_anchor_nonipd	NA
10.2217/cer-2020-0069	results	5	NA	ss_anchor_ipd	NA
10.2217/cer-2020-0069	results	5	NA	ss_adjusted_anchor_ipd	NA
10.2217/cer-2020-0069	results	5	NA	effect_cutoff	1
10.2217/cer-2020-0069	results	5	NA	unadjusted_pval	<0.0001
10.2217/cer-2020-0069	results	5	NA	unadjusted_significant	TRUE
10.2217/cer-2020-0069	results	5	NA	adjusted_pval	<0.0001
10.2217/cer-2020-0069	results	5	NA	adjusted_significant	TRUE
10.2217/cer-2020-0069	study_information	NA	1	ipd_yn	Yes
10.2217/cer-2020-0069	study_information	NA	1	ct_yn	Yes
10.2217/cer-2020-0069	study_information	NA	1	nct	NCT02435849
10.2217/cer-2020-0069	study_information	NA	1	country_study	international
10.2217/cer-2020-0069	study_information	NA	1	ct_phase	2
10.2217/cer-2020-0069	study_information	NA	1	ct_arms	1
10.2217/cer-2020-0069	study_information	NA	2	ipd_yn	No
10.2217/cer-2020-0069	study_information	NA	2	ct_yn	Yes
10.2217/cer-2020-0069	study_information	NA	2	nct	NCT01471782
10.2217/cer-2020-0069	study_information	NA	2	country_study	international
10.2217/cer-2020-0069	study_information	NA	2	ct_phase	1, 2
10.2217/cer-2020-0069	study_information	NA	2	ct_arms	1
10.2217/cer-2020-0069	study_information	NA	3	ipd_yn	No
10.2217/cer-2020-0069	study_information	NA	3	ct_yn	Yes
10.2217/cer-2020-0069	study_information	NA	3	data_source_name	jeha et al. (2006)
10.2217/cer-2020-0069	study_information	NA	3	ct_phase	2
10.2217/cer-2020-0069	study_information	NA	3	ct_arms	1
10.2217/cer-2020-0069	study_information	NA	3	country_study	usa
10.2217/cer-2020-0069	study_information	NA	4	ipd_yn	No
10.2217/cer-2020-0069	study_information	NA	4	ct_yn	Yes
10.2217/cer-2020-0069	study_information	NA	4	nct	NCT00315705
10.2217/cer-2020-0069	study_information	NA	4	country_study	usa
10.2217/cer-2020-0069	study_information	NA	4	ct_phase	1, 2
10.2217/cer-2020-0069	study_information	NA	4	ct_arms	1
10.2217/cer-2020-0069	study_information	NA	5	ipd_yn	No
10.2217/cer-2020-0069	study_information	NA	5	ct_yn	Yes
10.2217/cer-2020-0069	study_information	NA	5	data_source_name	locatelli et al. (2017)
10.2217/cer-2020-0069	study_information	NA	5	ct_phase	2
10.2217/cer-2020-0069	study_information	NA	5	ct_arms	1
10.2217/cer-2020-0069	study_information	NA	5	country_study	italy
10.2217/cer-2020-0069	study_information	NA	6	ipd_yn	No
10.2217/cer-2020-0069	study_information	NA	6	ct_yn	No
10.2217/cer-2020-0069	study_information	NA	6	data_source_name	miano et al. (2012)
10.2217/cer-2020-0069	study_information	NA	6	country_study	italy
10.2217/cer-2020-0069	study_information	NA	6	ct_arms	1
10.2217/cer-2020-0069	study_information	NA	7	ipd_yn	No
10.2217/cer-2020-0069	study_information	NA	7	ct_yn	No
10.2217/cer-2020-0069	study_information	NA	7	data_source_name	von stackelbeg et al. (2010)
10.2217/cer-2020-0069	study_information	NA	7	country_study	germany
10.2217/cer-2020-0069	study_information	NA	8	ipd_yn	No
10.2217/cer-2020-0069	study_information	NA	8	ct_yn	No
10.2217/cer-2020-0069	study_information	NA	8	data_source_name	all-sct-bfm 2003 & all-sct-bfm
10.2217/cer-2020-0069	study_information	NA	8	country_study	international
10.2217/cer-2020-0236	general_information	NA	NA	condition_name	advanced hepatocellular carcinoma
10.2217/cer-2020-0236	general_information	NA	NA	country_first_author	usa
10.2217/cer-2020-0236	general_information	NA	NA	country_last_author	usa
10.2217/cer-2020-0236	general_information	NA	NA	positions	Academic, Pharmaceutical Industry, Private Data Analysis Company
10.2217/cer-2020-0236	general_information	NA	NA	methodologist_yn	Yes
10.2217/cer-2020-0236	general_information	NA	NA	funding_source	Pharmaceutical Industry
10.2217/cer-2020-0236	general_information	NA	NA	pharmaceutical_ties_yn	Yes
10.2217/cer-2020-0236	general_information	NA	NA	systematic_review_yn	Yes
10.2217/cer-2020-0236	methodology	1	NA	outcome_name	overall survival
10.2217/cer-2020-0236	methodology	1	NA	outcome_short_name	Overall Survival
10.2217/cer-2020-0236	methodology	1	NA	outcome_variable_type	Time-to-event
10.2217/cer-2020-0236	methodology	1	NA	treatment_name_ipd	nivolumab + ipilimumab
10.2217/cer-2020-0236	methodology	1	NA	studies_number_ipd	1
10.2217/cer-2020-0236	methodology	1	NA	treatment_name_nonipd	placebo
10.2217/cer-2020-0236	methodology	1	NA	studies_number_nonipd	2
10.2217/cer-2020-0236	methodology	1	NA	paic_type	MAIC
10.2217/cer-2020-0236	methodology	1	NA	anchored_yn	No
10.2217/cer-2020-0236	methodology	1	NA	paic_form	Simple (ie treatments effects extracted from two studies)
10.2217/cer-2020-0236	methodology	1	NA	primary_outcome_yn	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.2217/cer-2020-0236	methodology	1	NA	variables_selection_justification	Statistical imbalanced between treatment groups (independently of the status of prognostic/effect modifier), Status of prognostic factor/treatment effect modified assessed in the IPD dataset
10.2217/cer-2020-0236	methodology	1	NA	pf_yn	Yes
10.2217/cer-2020-0236	methodology	1	NA	tem_yn	No discussion (in the main text) of the status of treatment-effect modifiers of the variables
10.2217/cer-2020-0236	methodology	1	NA	adjustment_model_details_yn	No
10.2217/cer-2020-0236	methodology	1	NA	scale_choice_yn	No
10.2217/cer-2020-0236	results	1	NA	contrast_effect_type	HR
10.2217/cer-2020-0236	results	1	NA	direction_benefit	inferior
10.2217/cer-2020-0236	results	1	NA	ss_ttt_nonipd	237
10.2217/cer-2020-0236	results	1	NA	ss_ttt_ipd	50
10.2217/cer-2020-0236	results	1	NA	ss_adjusted_ttt_ipd	NA
10.2217/cer-2020-0236	results	1	NA	weights_yn	Not mentioned
10.2217/cer-2020-0236	results	1	NA	covariates_yn	Yes
10.2217/cer-2020-0236	results	1	NA	covariates_n	6
10.2217/cer-2020-0236	results	1	NA	covariates_names	Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Past treatments for the disease of interest
10.2217/cer-2020-0236	results	1	NA	contrast_effect_direction	Numerator if ratio, or left side if difference
10.2217/cer-2020-0236	results	1	NA	contrast_effect_unadjusted_value	NA
10.2217/cer-2020-0236	results	1	NA	contrast_effect_unadjusted_pvalci	NA
10.2217/cer-2020-0236	results	1	NA	contrast_effect_adjusted_value	0.35
10.2217/cer-2020-0236	results	1	NA	contrast_effect_adjusted_pvalci	[0.21;0.58]
10.2217/cer-2020-0236	results	1	NA	adjustment_geographical	NA
10.2217/cer-2020-0236	results	1	NA	ss_total_ipd	NA
10.2217/cer-2020-0236	results	1	NA	ss_adjusted_total_ipd	NA
10.2217/cer-2020-0236	results	1	NA	ss_total_nonipd	NA
10.2217/cer-2020-0236	results	1	NA	ss_anchor_nonipd	NA
10.2217/cer-2020-0236	results	1	NA	ss_anchor_ipd	NA
10.2217/cer-2020-0236	results	1	NA	ss_adjusted_anchor_ipd	NA
10.2217/cer-2020-0236	results	1	NA	effect_cutoff	1
10.2217/cer-2020-0236	results	1	NA	adjusted_lb_ci	0.21
10.2217/cer-2020-0236	results	1	NA	adjusted_ub_ci	0.58
10.2217/cer-2020-0236	results	1	NA	adjusted_significant	TRUE
10.2217/cer-2020-0236	study_information	NA	1	ipd_yn	Yes
10.2217/cer-2020-0236	study_information	NA	1	ct_yn	Yes
10.2217/cer-2020-0236	study_information	NA	1	nct	NCT01658878
10.2217/cer-2020-0236	study_information	NA	1	country_study	international
10.2217/cer-2020-0236	study_information	NA	1	ct_phase	1, 2
10.2217/cer-2020-0236	study_information	NA	1	ct_arms	2 or more
10.2217/cer-2020-0236	study_information	NA	2	ipd_yn	No
10.2217/cer-2020-0236	study_information	NA	2	ct_yn	Yes
10.2217/cer-2020-0236	study_information	NA	2	nct	NCT01908426
10.2217/cer-2020-0236	study_information	NA	2	country_study	international
10.2217/cer-2020-0236	study_information	NA	2	ct_phase	3
10.2217/cer-2020-0236	study_information	NA	2	ct_arms	2 or more
10.2217/cer-2020-0272	general_information	NA	NA	condition_name	hr+/her2- advanced breast cancer
10.2217/cer-2020-0272	general_information	NA	NA	country_first_author	usa
10.2217/cer-2020-0272	general_information	NA	NA	country_last_author	canada
10.2217/cer-2020-0272	general_information	NA	NA	positions	Academic, Pharmaceutical Industry, Private Data Analysis Company
10.2217/cer-2020-0272	general_information	NA	NA	methodologist_yn	Yes
10.2217/cer-2020-0272	general_information	NA	NA	funding_source	Pharmaceutical Industry
10.2217/cer-2020-0272	general_information	NA	NA	pharmaceutical_ties_yn	Yes
10.2217/cer-2020-0272	general_information	NA	NA	systematic_review_yn	No
10.2217/cer-2020-0272	methodology	1	NA	outcome_name	overall survival
10.2217/cer-2020-0272	methodology	1	NA	outcome_short_name	Overall Survival
10.2217/cer-2020-0272	methodology	1	NA	outcome_variable_type	Time-to-event
10.2217/cer-2020-0272	methodology	1	NA	treatment_name_ipd	palbociclib + fulvestrant
10.2217/cer-2020-0272	methodology	1	NA	studies_number_ipd	1
10.2217/cer-2020-0272	methodology	1	NA	treatment_name_nonipd	abemaciclib + fulvestrant
10.2217/cer-2020-0272	methodology	1	NA	studies_number_nonipd	2
10.2217/cer-2020-0272	methodology	1	NA	paic_type	MAIC
10.2217/cer-2020-0272	methodology	1	NA	anchored_yn	Yes
10.2217/cer-2020-0272	methodology	1	NA	paic_form	Simple (ie treatments effects extracted from two studies)
10.2217/cer-2020-0272	methodology	1	NA	primary_outcome_yn	Yes
10.2217/cer-2020-0272	methodology	1	NA	variables_selection_justification	Statistical imbalanced between treatment groups (independently of the status of prognostic/effect modifier), Status of prognostic factor/treatment effect modified assessed in the IPD dataset, A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion), Literature based (clinically or methodologically relevant to adjust on these variables based on the literature search conducted for this specific purpose)
10.2217/cer-2020-0272	methodology	1	NA	pf_yn	No
10.2217/cer-2020-0272	methodology	1	NA	tem_yn	Yes
10.2217/cer-2020-0272	methodology	1	NA	adjustment_model_details_yn	No
10.2217/cer-2020-0272	methodology	1	NA	scale_choice_yn	No
10.2217/cer-2020-0272	methodology	2	NA	outcome_name	overall survival
10.2217/cer-2020-0272	methodology	2	NA	outcome_short_name	Overall Survival
10.2217/cer-2020-0272	methodology	2	NA	outcome_variable_type	Time-to-event
10.2217/cer-2020-0272	methodology	2	NA	treatment_name_ipd	palbociclib + fulvestrant
10.2217/cer-2020-0272	methodology	2	NA	studies_number_ipd	1
10.2217/cer-2020-0272	methodology	2	NA	treatment_name_nonipd	ribociclib + fulvestrant
10.2217/cer-2020-0272	methodology	2	NA	studies_number_nonipd	3
10.2217/cer-2020-0272	methodology	2	NA	paic_type	MAIC
10.2217/cer-2020-0272	methodology	2	NA	anchored_yn	Yes
10.2217/cer-2020-0272	methodology	2	NA	paic_form	Simple (ie treatments effects extracted from two studies)
10.2217/cer-2020-0272	methodology	2	NA	primary_outcome_yn	Yes
10.2217/cer-2020-0272	methodology	2	NA	variables_selection_justification	Statistical imbalanced between treatment groups (independently of the status of prognostic/effect modifier), Status of prognostic factor/treatment effect modified assessed in the IPD dataset, A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion), Literature based (clinically or methodologically relevant to adjust on these variables based on the literature search conducted for this specific purpose)
10.2217/cer-2020-0272	methodology	2	NA	pf_yn	No
10.2217/cer-2020-0272	methodology	2	NA	tem_yn	Yes
10.2217/cer-2020-0272	methodology	2	NA	adjustment_model_details_yn	No
10.2217/cer-2020-0272	methodology	2	NA	scale_choice_yn	No
10.2217/cer-2020-0272	results	1	NA	contrast_effect_type	HR
10.2217/cer-2020-0272	results	1	NA	direction_benefit	inferior
10.2217/cer-2020-0272	results	1	NA	ss_ttt_nonipd	NA
10.2217/cer-2020-0272	results	1	NA	ss_ttt_ipd	183
10.2217/cer-2020-0272	results	1	NA	ss_adjusted_ttt_ipd	NA
10.2217/cer-2020-0272	results	1	NA	weights_yn	Not mentioned
10.2217/cer-2020-0272	results	1	NA	covariates_yn	Yes
10.2217/cer-2020-0272	results	1	NA	covariates_n	12
10.2217/cer-2020-0272	results	1	NA	covariates_names	Age, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Race/ethnicity, Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Past treatments for the disease of interest, Other(s)
10.2217/cer-2020-0272	results	1	NA	contrast_effect_direction	Numerator if ratio, or left side if difference
10.2217/cer-2020-0272	results	1	NA	contrast_effect_unadjusted_value	1.02
10.2217/cer-2020-0272	results	1	NA	contrast_effect_unadjusted_pvalci	[0.69;1.52]
10.2217/cer-2020-0272	results	1	NA	contrast_effect_adjusted_value	0.87
10.2217/cer-2020-0272	results	1	NA	contrast_effect_adjusted_pvalci	[0.54;1.40]
10.2217/cer-2020-0272	results	1	NA	adjustment_geographical	Yes
10.2217/cer-2020-0272	results	1	NA	ss_total_ipd	280
10.2217/cer-2020-0272	results	1	NA	ss_adjusted_total_ipd	135
10.2217/cer-2020-0272	results	1	NA	ss_total_nonipd	669
10.2217/cer-2020-0272	results	1	NA	ss_anchor_nonipd	NA
10.2217/cer-2020-0272	results	1	NA	ss_anchor_ipd	97
10.2217/cer-2020-0272	results	1	NA	ss_adjusted_anchor_ipd	NA
10.2217/cer-2020-0272	results	1	NA	effect_cutoff	1
10.2217/cer-2020-0272	results	1	NA	unadjusted_lb_ci	0.69
10.2217/cer-2020-0272	results	1	NA	unadjusted_ub_ci	1.52
10.2217/cer-2020-0272	results	1	NA	unadjusted_significant	FALSE
10.2217/cer-2020-0272	results	1	NA	adjusted_lb_ci	0.54
10.2217/cer-2020-0272	results	1	NA	adjusted_ub_ci	1.4
10.2217/cer-2020-0272	results	1	NA	adjusted_significant	FALSE
10.2217/cer-2020-0272	results	2	NA	contrast_effect_type	HR
10.2217/cer-2020-0272	results	2	NA	direction_benefit	inferior
10.2217/cer-2020-0272	results	2	NA	ss_ttt_nonipd	NA
10.2217/cer-2020-0272	results	2	NA	ss_ttt_ipd	142
10.2217/cer-2020-0272	results	2	NA	ss_adjusted_ttt_ipd	NA
10.2217/cer-2020-0272	results	2	NA	weights_yn	Not mentioned
10.2217/cer-2020-0272	results	2	NA	covariates_yn	Yes
10.2217/cer-2020-0272	results	2	NA	covariates_n	8
10.2217/cer-2020-0272	results	2	NA	covariates_names	Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Race/ethnicity, Past treatments for the disease of interest, Other(s)
10.2217/cer-2020-0272	results	2	NA	contrast_effect_direction	Numerator if ratio, or left side if difference
10.2217/cer-2020-0272	results	2	NA	contrast_effect_unadjusted_value	1.09
10.2217/cer-2020-0272	results	2	NA	contrast_effect_unadjusted_pvalci	[0.70;1.69]
10.2217/cer-2020-0272	results	2	NA	contrast_effect_adjusted_value	0.89
10.2217/cer-2020-0272	results	2	NA	contrast_effect_adjusted_pvalci	[0.48;1.63]
10.2217/cer-2020-0272	results	2	NA	adjustment_geographical	Yes
10.2217/cer-2020-0272	results	2	NA	ss_total_ipd	217
10.2217/cer-2020-0272	results	2	NA	ss_adjusted_total_ipd	64
10.2217/cer-2020-0272	results	2	NA	ss_total_nonipd	726
10.2217/cer-2020-0272	results	2	NA	ss_anchor_nonipd	NA
10.2217/cer-2020-0272	results	2	NA	ss_anchor_ipd	75
10.2217/cer-2020-0272	results	2	NA	ss_adjusted_anchor_ipd	NA
10.2217/cer-2020-0272	results	2	NA	effect_cutoff	1
10.2217/cer-2020-0272	results	2	NA	unadjusted_lb_ci	0.7
10.2217/cer-2020-0272	results	2	NA	unadjusted_ub_ci	1.69
10.2217/cer-2020-0272	results	2	NA	unadjusted_significant	FALSE
10.2217/cer-2020-0272	results	2	NA	adjusted_lb_ci	0.48
10.2217/cer-2020-0272	results	2	NA	adjusted_ub_ci	1.63
10.2217/cer-2020-0272	results	2	NA	adjusted_significant	FALSE
10.2217/cer-2020-0272	study_information	NA	1	ipd_yn	Yes
10.2217/cer-2020-0272	study_information	NA	1	ct_yn	Yes
10.2217/cer-2020-0272	study_information	NA	1	nct	NCT01942135
10.2217/cer-2020-0272	study_information	NA	1	country_study	international
10.2217/cer-2020-0272	study_information	NA	1	ct_phase	3
10.2217/cer-2020-0272	study_information	NA	1	ct_arms	2 or more
10.2217/cer-2020-0272	study_information	NA	2	ipd_yn	No
10.2217/cer-2020-0272	study_information	NA	2	ct_yn	Yes
10.2217/cer-2020-0272	study_information	NA	2	nct	NCT02107703
10.2217/cer-2020-0272	study_information	NA	2	country_study	international
10.2217/cer-2020-0272	study_information	NA	2	ct_phase	3
10.2217/cer-2020-0272	study_information	NA	2	ct_arms	2 or more
10.2217/cer-2020-0272	study_information	NA	3	ipd_yn	No
10.2217/cer-2020-0272	study_information	NA	3	ct_yn	Yes
10.2217/cer-2020-0272	study_information	NA	3	nct	NCT02422615
10.2217/cer-2020-0272	study_information	NA	3	country_study	international
10.2217/cer-2020-0272	study_information	NA	3	ct_phase	3
10.2217/cer-2020-0272	study_information	NA	3	ct_arms	2 or more
10.2217/cer-2020-0280	general_information	NA	NA	condition_name	acute myeloid leukemia
10.2217/cer-2020-0280	general_information	NA	NA	country_first_author	canada
10.2217/cer-2020-0280	general_information	NA	NA	country_last_author	usa
10.2217/cer-2020-0280	general_information	NA	NA	positions	Pharmaceutical Industry, Private Data Analysis Company
10.2217/cer-2020-0280	general_information	NA	NA	methodologist_yn	Yes
10.2217/cer-2020-0280	general_information	NA	NA	funding_source	Pharmaceutical Industry
10.2217/cer-2020-0280	general_information	NA	NA	pharmaceutical_ties_yn	Yes
10.2217/cer-2020-0280	general_information	NA	NA	systematic_review_yn	No
10.2217/cer-2020-0280	methodology	1	NA	outcome_name	overall survival
10.2217/cer-2020-0280	methodology	1	NA	outcome_short_name	Overall Survival
10.2217/cer-2020-0280	methodology	1	NA	outcome_variable_type	Time-to-event
10.2217/cer-2020-0280	methodology	1	NA	treatment_name_ipd	glasdegib + low-dose cytarabine
10.2217/cer-2020-0280	methodology	1	NA	studies_number_ipd	1
10.2217/cer-2020-0280	methodology	1	NA	treatment_name_nonipd	venetoclax + low-dose cytarabine
10.2217/cer-2020-0280	methodology	1	NA	studies_number_nonipd	2
10.2217/cer-2020-0280	methodology	1	NA	paic_type	STC
10.2217/cer-2020-0280	methodology	1	NA	anchored_yn	Yes
10.2217/cer-2020-0280	methodology	1	NA	paic_form	Simple (ie treatments effects extracted from two studies)
10.2217/cer-2020-0280	methodology	1	NA	primary_outcome_yn	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.2217/cer-2020-0280	methodology	1	NA	variables_selection_justification	Statistical imbalanced between treatment groups (independently of the status of prognostic/effect modifier), Literature based (clinically or methodologically relevant to adjust on these variables based on the literature search conducted for this specific purpose)
10.2217/cer-2020-0280	methodology	1	NA	pf_yn	Yes
10.2217/cer-2020-0280	methodology	1	NA	tem_yn	Yes
10.2217/cer-2020-0280	methodology	1	NA	adjustment_model_details_yn	Yes
10.2217/cer-2020-0280	methodology	1	NA	scale_choice_yn	Yes
10.2217/cer-2020-0280	results	1	NA	contrast_effect_type	HR
10.2217/cer-2020-0280	results	1	NA	direction_benefit	inferior
10.2217/cer-2020-0280	results	1	NA	ss_ttt_nonipd	143
10.2217/cer-2020-0280	results	1	NA	ss_ttt_ipd	78
10.2217/cer-2020-0280	results	1	NA	ss_adjusted_ttt_ipd	78
10.2217/cer-2020-0280	results	1	NA	weights_yn	NA
10.2217/cer-2020-0280	results	1	NA	covariates_yn	Yes
10.2217/cer-2020-0280	results	1	NA	covariates_n	6
10.2217/cer-2020-0280	results	1	NA	covariates_names	Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...)
10.2217/cer-2020-0280	results	1	NA	contrast_effect_direction	Numerator if ratio, or left side if difference
10.2217/cer-2020-0280	results	1	NA	contrast_effect_unadjusted_value	0.66
10.2217/cer-2020-0280	results	1	NA	contrast_effect_unadjusted_pvalci	[0.38;1.15]
10.2217/cer-2020-0280	results	1	NA	contrast_effect_adjusted_value	0.56
10.2217/cer-2020-0280	results	1	NA	contrast_effect_adjusted_pvalci	[0.24;1.32]
10.2217/cer-2020-0280	results	1	NA	adjustment_geographical	NA
10.2217/cer-2020-0280	results	1	NA	ss_total_ipd	NA
10.2217/cer-2020-0280	results	1	NA	ss_adjusted_total_ipd	NA
10.2217/cer-2020-0280	results	1	NA	ss_total_nonipd	NA
10.2217/cer-2020-0280	results	1	NA	ss_anchor_nonipd	68
10.2217/cer-2020-0280	results	1	NA	ss_anchor_ipd	38
10.2217/cer-2020-0280	results	1	NA	ss_adjusted_anchor_ipd	38
10.2217/cer-2020-0280	results	1	NA	effect_cutoff	1
10.2217/cer-2020-0280	results	1	NA	unadjusted_lb_ci	0.38
10.2217/cer-2020-0280	results	1	NA	unadjusted_ub_ci	1.15
10.2217/cer-2020-0280	results	1	NA	unadjusted_significant	FALSE
10.2217/cer-2020-0280	results	1	NA	adjusted_lb_ci	0.24
10.2217/cer-2020-0280	results	1	NA	adjusted_ub_ci	1.32
10.2217/cer-2020-0280	results	1	NA	adjusted_significant	FALSE
10.2217/cer-2020-0280	study_information	NA	1	ipd_yn	Yes
10.2217/cer-2020-0280	study_information	NA	1	ct_yn	Yes
10.2217/cer-2020-0280	study_information	NA	1	nct	NCT01546038
10.2217/cer-2020-0280	study_information	NA	1	country_study	international
10.2217/cer-2020-0280	study_information	NA	1	ct_phase	2
10.2217/cer-2020-0280	study_information	NA	1	ct_arms	2 or more
10.2217/cer-2020-0280	study_information	NA	2	ipd_yn	No
10.2217/cer-2020-0280	study_information	NA	2	ct_yn	Yes
10.2217/cer-2020-0280	study_information	NA	2	nct	NCT03069352
10.2217/cer-2020-0280	study_information	NA	2	country_study	international
10.2217/cer-2020-0280	study_information	NA	2	ct_phase	3
10.2217/cer-2020-0280	study_information	NA	2	ct_arms	2 or more
10.2217/cer-2021-0178	general_information	NA	NA	condition_name	parkinson's disease
10.2217/cer-2021-0178	general_information	NA	NA	country_first_author	usa
10.2217/cer-2021-0178	general_information	NA	NA	country_last_author	usa
10.2217/cer-2021-0178	general_information	NA	NA	positions	Pharmaceutical Industry, Private Data Analysis Company
10.2217/cer-2021-0178	general_information	NA	NA	methodologist_yn	Yes
10.2217/cer-2021-0178	general_information	NA	NA	funding_source	Pharmaceutical Industry
10.2217/cer-2021-0178	general_information	NA	NA	pharmaceutical_ties_yn	Yes
10.2217/cer-2021-0178	general_information	NA	NA	systematic_review_yn	Yes
10.2217/cer-2021-0178	methodology	1	NA	outcome_name	the mean change in the updrs part iii score at week 12 from predose to the following timepoints postdose: 15 (apomorphine sublingual film) or 20 (levodopa),30 and 60 min.
10.2217/cer-2021-0178	methodology	1	NA	outcome_short_name	UPDRS part III score at week 12
10.2217/cer-2021-0178	methodology	1	NA	outcome_variable_type	Continuous (count, mean, ...)
10.2217/cer-2021-0178	methodology	1	NA	treatment_name_ipd	apomorphine sublingual film
10.2217/cer-2021-0178	methodology	1	NA	studies_number_ipd	1
10.2217/cer-2021-0178	methodology	1	NA	treatment_name_nonipd	levodopa inhalation powder
10.2217/cer-2021-0178	methodology	1	NA	studies_number_nonipd	2
10.2217/cer-2021-0178	methodology	1	NA	paic_type	MAIC
10.2217/cer-2021-0178	methodology	1	NA	anchored_yn	Yes
10.2217/cer-2021-0178	methodology	1	NA	paic_form	Simple (ie treatments effects extracted from two studies)
10.2217/cer-2021-0178	methodology	1	NA	primary_outcome_yn	Yes
10.2217/cer-2021-0178	methodology	1	NA	variables_selection_justification	Statistical imbalanced between treatment groups (independently of the status of prognostic/effect modifier), A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion)
10.2217/cer-2021-0178	methodology	1	NA	pf_yn	No discussion (in the main text) of the status of prognostic factors of the variables
10.2217/cer-2021-0178	methodology	1	NA	tem_yn	Yes
10.2217/cer-2021-0178	methodology	1	NA	adjustment_model_details_yn	No
10.2217/cer-2021-0178	methodology	1	NA	scale_choice_yn	No
10.2217/cer-2021-0178	results	1	NA	contrast_effect_type	Means difference
10.2217/cer-2021-0178	results	1	NA	direction_benefit	inferior
10.2217/cer-2021-0178	results	1	NA	ss_ttt_nonipd	114
10.2217/cer-2021-0178	results	1	NA	ss_ttt_ipd	44
10.2217/cer-2021-0178	results	1	NA	ss_adjusted_ttt_ipd	NA
10.2217/cer-2021-0178	results	1	NA	weights_yn	Not mentioned
10.2217/cer-2021-0178	results	1	NA	covariates_yn	Yes
10.2217/cer-2021-0178	results	1	NA	covariates_n	4
10.2217/cer-2021-0178	results	1	NA	covariates_names	Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease)
10.2217/cer-2021-0178	results	1	NA	contrast_effect_direction	Numerator if ratio, or left side if difference
10.2217/cer-2021-0178	results	1	NA	contrast_effect_unadjusted_value	0.57
10.2217/cer-2021-0178	results	1	NA	contrast_effect_unadjusted_pvalci	0.818
10.2217/cer-2021-0178	results	1	NA	contrast_effect_adjusted_value	0.15
10.2217/cer-2021-0178	results	1	NA	contrast_effect_adjusted_pvalci	0.953
10.2217/cer-2021-0178	results	1	NA	adjustment_geographical	NA
10.2217/cer-2021-0178	results	1	NA	ss_total_ipd	NA
10.2217/cer-2021-0178	results	1	NA	ss_adjusted_total_ipd	NA
10.2217/cer-2021-0178	results	1	NA	ss_total_nonipd	NA
10.2217/cer-2021-0178	results	1	NA	ss_anchor_nonipd	112
10.2217/cer-2021-0178	results	1	NA	ss_anchor_ipd	37
10.2217/cer-2021-0178	results	1	NA	ss_adjusted_anchor_ipd	NA
10.2217/cer-2021-0178	results	1	NA	effect_cutoff	0
10.2217/cer-2021-0178	results	1	NA	unadjusted_pval	0.818
10.2217/cer-2021-0178	results	1	NA	unadjusted_num_pval	0.818
10.2217/cer-2021-0178	results	1	NA	unadjusted_significant	FALSE
10.2217/cer-2021-0178	results	1	NA	adjusted_pval	0.953
10.2217/cer-2021-0178	results	1	NA	adjusted_num_pval	0.953
10.2217/cer-2021-0178	results	1	NA	adjusted_significant	FALSE
10.2217/cer-2021-0178	study_information	NA	1	ipd_yn	Yes
10.2217/cer-2021-0178	study_information	NA	1	ct_yn	Yes
10.2217/cer-2021-0178	study_information	NA	1	nct	NCT02469090
10.2217/cer-2021-0178	study_information	NA	1	country_study	international
10.2217/cer-2021-0178	study_information	NA	1	ct_phase	3
10.2217/cer-2021-0178	study_information	NA	1	ct_arms	2 or more
10.2217/cer-2021-0178	study_information	NA	2	ipd_yn	No
10.2217/cer-2021-0178	study_information	NA	2	ct_yn	Yes
10.2217/cer-2021-0178	study_information	NA	2	country_study	international
10.2217/cer-2021-0178	study_information	NA	2	ct_phase	3
10.2217/cer-2021-0178	study_information	NA	2	ct_arms	2 or more
10.2217/cer-2021-0178	study_information	NA	2	nct	NCT02240030
10.2217/cer-2021-0216	general_information	NA	NA	condition_name	spinal muscular atrophy
10.2217/cer-2021-0216	general_information	NA	NA	country_first_author	switzerland
10.2217/cer-2021-0216	general_information	NA	NA	country_last_author	uk
10.2217/cer-2021-0216	general_information	NA	NA	positions	Pharmaceutical Industry, Private Data Analysis Company
10.2217/cer-2021-0216	general_information	NA	NA	methodologist_yn	Yes
10.2217/cer-2021-0216	general_information	NA	NA	funding_source	Pharmaceutical Industry
10.2217/cer-2021-0216	general_information	NA	NA	pharmaceutical_ties_yn	Yes
10.2217/cer-2021-0216	general_information	NA	NA	systematic_review_yn	Yes
10.2217/cer-2021-0216	methodology	1	NA	outcome_name	event-free survival
10.2217/cer-2021-0216	methodology	1	NA	outcome_short_name	Event-free Survival
10.2217/cer-2021-0216	methodology	1	NA	outcome_variable_type	Time-to-event
10.2217/cer-2021-0216	methodology	1	NA	treatment_name_ipd	risdiplam
10.2217/cer-2021-0216	methodology	1	NA	studies_number_ipd	1
10.2217/cer-2021-0216	methodology	1	NA	treatment_name_nonipd	nusinersen
10.2217/cer-2021-0216	methodology	1	NA	studies_number_nonipd	3
10.2217/cer-2021-0216	methodology	1	NA	paic_type	MAIC
10.2217/cer-2021-0216	methodology	1	NA	anchored_yn	No
10.2217/cer-2021-0216	methodology	1	NA	paic_form	Simple (ie treatments effects extracted from two studies)
10.2217/cer-2021-0216	methodology	1	NA	primary_outcome_yn	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.2217/cer-2021-0216	methodology	1	NA	variables_selection_justification	A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion), Literature based (clinically or methodologically relevant to adjust on these variables based on the literature search conducted for this specific purpose)
10.2217/cer-2021-0216	methodology	1	NA	pf_yn	Yes
10.2217/cer-2021-0216	methodology	1	NA	tem_yn	Yes
10.2217/cer-2021-0216	methodology	1	NA	adjustment_model_details_yn	Yes
10.2217/cer-2021-0216	methodology	1	NA	scale_choice_yn	No
10.2217/cer-2021-0216	methodology	2	NA	outcome_name	event-free survival
10.2217/cer-2021-0216	methodology	2	NA	outcome_short_name	Event-free Survival
10.2217/cer-2021-0216	methodology	2	NA	outcome_variable_type	Time-to-event
10.2217/cer-2021-0216	methodology	2	NA	treatment_name_ipd	risdiplam
10.2217/cer-2021-0216	methodology	2	NA	studies_number_ipd	1
10.2217/cer-2021-0216	methodology	2	NA	treatment_name_nonipd	onasemnogene abeparvovec
10.2217/cer-2021-0216	methodology	2	NA	studies_number_nonipd	5
10.2217/cer-2021-0216	methodology	2	NA	paic_type	STC
10.2217/cer-2021-0216	methodology	2	NA	anchored_yn	No
10.2217/cer-2021-0216	methodology	2	NA	paic_form	Simple (ie treatments effects extracted from two studies)
10.2217/cer-2021-0216	methodology	2	NA	primary_outcome_yn	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.2217/cer-2021-0216	methodology	2	NA	variables_selection_justification	A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion), Literature based (clinically or methodologically relevant to adjust on these variables based on the literature search conducted for this specific purpose)
10.2217/cer-2021-0216	methodology	2	NA	pf_yn	Yes
10.2217/cer-2021-0216	methodology	2	NA	tem_yn	Yes
10.2217/cer-2021-0216	methodology	2	NA	adjustment_model_details_yn	No
10.2217/cer-2021-0216	methodology	2	NA	scale_choice_yn	No
10.2217/cer-2021-0216	methodology	3	NA	outcome_name	the 12-month rulm (revised upper limb module) score change from baseline
10.2217/cer-2021-0216	methodology	3	NA	outcome_short_name	Revised Upper Limb Module
10.2217/cer-2021-0216	methodology	3	NA	outcome_variable_type	Continuous (count, mean, ...)
10.2217/cer-2021-0216	methodology	3	NA	treatment_name_ipd	risdiplam
10.2217/cer-2021-0216	methodology	3	NA	studies_number_ipd	2
10.2217/cer-2021-0216	methodology	3	NA	treatment_name_nonipd	nusinersen
10.2217/cer-2021-0216	methodology	3	NA	studies_number_nonipd	4
10.2217/cer-2021-0216	methodology	3	NA	paic_type	MAIC
10.2217/cer-2021-0216	methodology	3	NA	anchored_yn	Yes
10.2217/cer-2021-0216	methodology	3	NA	paic_form	Simple (ie treatments effects extracted from two studies)
10.2217/cer-2021-0216	methodology	3	NA	primary_outcome_yn	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.2217/cer-2021-0216	methodology	3	NA	variables_selection_justification	A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion), Literature based (clinically or methodologically relevant to adjust on these variables based on the literature search conducted for this specific purpose)
10.2217/cer-2021-0216	methodology	3	NA	pf_yn	Yes
10.2217/cer-2021-0216	methodology	3	NA	tem_yn	Yes
10.2217/cer-2021-0216	methodology	3	NA	adjustment_model_details_yn	Yes
10.2217/cer-2021-0216	methodology	3	NA	scale_choice_yn	No
10.2217/cer-2021-0216	results	1	NA	contrast_effect_type	HR
10.2217/cer-2021-0216	results	1	NA	direction_benefit	inferior
10.2217/cer-2021-0216	results	1	NA	ss_ttt_nonipd	121
10.2217/cer-2021-0216	results	1	NA	ss_ttt_ipd	58
10.2217/cer-2021-0216	results	1	NA	ss_adjusted_ttt_ipd	36.5
10.2217/cer-2021-0216	results	1	NA	weights_yn	Yes, mentions that the weights distribution has been studied, and weights distribution reported in main article or supplemental materials
10.2217/cer-2021-0216	results	1	NA	covariates_yn	Yes
10.2217/cer-2021-0216	results	1	NA	covariates_n	3
10.2217/cer-2021-0216	results	1	NA	covariates_names	Age, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease)
10.2217/cer-2021-0216	results	1	NA	contrast_effect_direction	Numerator if ratio, or left side if difference
10.2217/cer-2021-0216	results	1	NA	contrast_effect_unadjusted_value	0.24
10.2217/cer-2021-0216	results	1	NA	contrast_effect_unadjusted_pvalci	[0.09;0.46]
10.2217/cer-2021-0216	results	1	NA	contrast_effect_adjusted_value	0.2
10.2217/cer-2021-0216	results	1	NA	contrast_effect_adjusted_pvalci	[0.06;0.42]
10.2217/cer-2021-0216	results	1	NA	adjustment_geographical	NA
10.2217/cer-2021-0216	results	1	NA	ss_total_ipd	NA
10.2217/cer-2021-0216	results	1	NA	ss_adjusted_total_ipd	NA
10.2217/cer-2021-0216	results	1	NA	ss_total_nonipd	NA
10.2217/cer-2021-0216	results	1	NA	ss_anchor_nonipd	NA
10.2217/cer-2021-0216	results	1	NA	ss_anchor_ipd	NA
10.2217/cer-2021-0216	results	1	NA	ss_adjusted_anchor_ipd	NA
10.2217/cer-2021-0216	results	1	NA	effect_cutoff	1
10.2217/cer-2021-0216	results	1	NA	unadjusted_lb_ci	0.09
10.2217/cer-2021-0216	results	1	NA	unadjusted_ub_ci	0.46
10.2217/cer-2021-0216	results	1	NA	unadjusted_significant	TRUE
10.2217/cer-2021-0216	results	1	NA	adjusted_lb_ci	0.06
10.2217/cer-2021-0216	results	1	NA	adjusted_ub_ci	0.42
10.2217/cer-2021-0216	results	1	NA	adjusted_significant	TRUE
10.2217/cer-2021-0216	results	2	NA	contrast_effect_type	HR
10.2217/cer-2021-0216	results	2	NA	direction_benefit	inferior
10.2217/cer-2021-0216	results	2	NA	ss_ttt_nonipd	22
10.2217/cer-2021-0216	results	2	NA	ss_ttt_ipd	58
10.2217/cer-2021-0216	results	2	NA	ss_adjusted_ttt_ipd	58
10.2217/cer-2021-0216	results	2	NA	weights_yn	NA
10.2217/cer-2021-0216	results	2	NA	covariates_yn	Yes
10.2217/cer-2021-0216	results	2	NA	covariates_n	2
10.2217/cer-2021-0216	results	2	NA	covariates_names	Age, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease)
10.2217/cer-2021-0216	results	2	NA	contrast_effect_direction	Numerator if ratio, or left side if difference
10.2217/cer-2021-0216	results	2	NA	contrast_effect_unadjusted_value	1.532
10.2217/cer-2021-0216	results	2	NA	contrast_effect_unadjusted_pvalci	[0.721;2.665]
10.2217/cer-2021-0216	results	2	NA	contrast_effect_adjusted_value	0.936
10.2217/cer-2021-0216	results	2	NA	contrast_effect_adjusted_pvalci	[0.033;4.064]
10.2217/cer-2021-0216	results	2	NA	adjustment_geographical	NA
10.2217/cer-2021-0216	results	2	NA	ss_total_ipd	NA
10.2217/cer-2021-0216	results	2	NA	ss_adjusted_total_ipd	NA
10.2217/cer-2021-0216	results	2	NA	ss_total_nonipd	NA
10.2217/cer-2021-0216	results	2	NA	ss_anchor_nonipd	NA
10.2217/cer-2021-0216	results	2	NA	ss_anchor_ipd	NA
10.2217/cer-2021-0216	results	2	NA	ss_adjusted_anchor_ipd	NA
10.2217/cer-2021-0216	results	2	NA	effect_cutoff	1
10.2217/cer-2021-0216	results	2	NA	unadjusted_lb_ci	0.721
10.2217/cer-2021-0216	results	2	NA	unadjusted_ub_ci	2.665
10.2217/cer-2021-0216	results	2	NA	unadjusted_significant	FALSE
10.2217/cer-2021-0216	results	2	NA	adjusted_lb_ci	0.033
10.2217/cer-2021-0216	results	2	NA	adjusted_ub_ci	4.064
10.2217/cer-2021-0216	results	2	NA	adjusted_significant	FALSE
10.2217/cer-2021-0216	results	3	NA	contrast_effect_type	Means difference
10.2217/cer-2021-0216	results	3	NA	direction_benefit	superior
10.2217/cer-2021-0216	results	3	NA	ss_ttt_nonipd	126
10.2217/cer-2021-0216	results	3	NA	ss_ttt_ipd	43
10.2217/cer-2021-0216	results	3	NA	ss_adjusted_ttt_ipd	28.3
10.2217/cer-2021-0216	results	3	NA	weights_yn	Yes, mentions that the weights distribution has been studied, and weights distribution reported in main article or supplemental materials
10.2217/cer-2021-0216	results	3	NA	covariates_yn	Yes
10.2217/cer-2021-0216	results	3	NA	covariates_n	3
10.2217/cer-2021-0216	results	3	NA	covariates_names	Age, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease)
10.2217/cer-2021-0216	results	3	NA	contrast_effect_direction	Numerator if ratio, or left side if difference
10.2217/cer-2021-0216	results	3	NA	contrast_effect_unadjusted_value	-0.6
10.2217/cer-2021-0216	results	3	NA	contrast_effect_unadjusted_pvalci	[-2.24;1.22]
10.2217/cer-2021-0216	results	3	NA	contrast_effect_adjusted_value	-0.49
10.2217/cer-2021-0216	results	3	NA	contrast_effect_adjusted_pvalci	[-3.33;2.53]
10.2217/cer-2021-0216	results	3	NA	adjustment_geographical	NA
10.2217/cer-2021-0216	results	3	NA	ss_total_ipd	NA
10.2217/cer-2021-0216	results	3	NA	ss_adjusted_total_ipd	NA
10.2217/cer-2021-0216	results	3	NA	ss_total_nonipd	NA
10.2217/cer-2021-0216	results	3	NA	ss_anchor_nonipd	126
10.2217/cer-2021-0216	results	3	NA	ss_anchor_ipd	25
10.2217/cer-2021-0216	results	3	NA	ss_adjusted_anchor_ipd	8.8
10.2217/cer-2021-0216	results	3	NA	effect_cutoff	0
10.2217/cer-2021-0216	results	3	NA	unadjusted_lb_ci	-2.24
10.2217/cer-2021-0216	results	3	NA	unadjusted_ub_ci	1.22
10.2217/cer-2021-0216	results	3	NA	unadjusted_significant	FALSE
10.2217/cer-2021-0216	results	3	NA	adjusted_lb_ci	-3.33
10.2217/cer-2021-0216	results	3	NA	adjusted_ub_ci	2.53
10.2217/cer-2021-0216	results	3	NA	adjusted_significant	FALSE
10.2217/cer-2021-0216	study_information	NA	1	ipd_yn	Yes
10.2217/cer-2021-0216	study_information	NA	1	ct_yn	Yes
10.2217/cer-2021-0216	study_information	NA	1	nct	NCT02913482
10.2217/cer-2021-0216	study_information	NA	1	country_study	international
10.2217/cer-2021-0216	study_information	NA	1	ct_phase	2, 3
10.2217/cer-2021-0216	study_information	NA	1	ct_arms	1
10.2217/cer-2021-0216	study_information	NA	2	ipd_yn	Yes
10.2217/cer-2021-0216	study_information	NA	2	ct_yn	Yes
10.2217/cer-2021-0216	study_information	NA	2	nct	NCT02908685
10.2217/cer-2021-0216	study_information	NA	2	country_study	international
10.2217/cer-2021-0216	study_information	NA	2	ct_phase	2, 3
10.2217/cer-2021-0216	study_information	NA	2	ct_arms	2 or more
10.2217/cer-2021-0216	study_information	NA	3	ipd_yn	No
10.2217/cer-2021-0216	study_information	NA	3	ct_yn	Yes
10.2217/cer-2021-0216	study_information	NA	3	nct	NCT02193074
10.2217/cer-2021-0216	study_information	NA	3	country_study	international
10.2217/cer-2021-0216	study_information	NA	3	ct_phase	3
10.2217/cer-2021-0216	study_information	NA	3	ct_arms	2 or more
10.2217/cer-2021-0216	study_information	NA	4	ipd_yn	No
10.2217/cer-2021-0216	study_information	NA	4	ct_yn	Yes
10.2217/cer-2021-0216	study_information	NA	4	nct	NCT02292537
10.2217/cer-2021-0216	study_information	NA	4	country_study	international
10.2217/cer-2021-0216	study_information	NA	4	ct_phase	3
10.2217/cer-2021-0216	study_information	NA	4	ct_arms	2 or more
10.2217/cer-2021-0216	study_information	NA	5	ipd_yn	No
10.2217/cer-2021-0216	study_information	NA	5	ct_yn	Yes
10.2217/cer-2021-0216	study_information	NA	5	nct	NCT03306277
10.2217/cer-2021-0216	study_information	NA	5	country_study	usa
10.2217/cer-2021-0216	study_information	NA	5	ct_phase	3
10.2217/cer-2021-0216	study_information	NA	5	ct_arms	1
10.2217/cer-2021-0221	general_information	NA	NA	condition_name	hr+/her2- advanced breast cancer
10.2217/cer-2021-0221	general_information	NA	NA	country_first_author	usa
10.2217/cer-2021-0221	general_information	NA	NA	country_last_author	canada
10.2217/cer-2021-0221	general_information	NA	NA	positions	Pharmaceutical Industry, Private Data Analysis Company
10.2217/cer-2021-0221	general_information	NA	NA	methodologist_yn	Yes
10.2217/cer-2021-0221	general_information	NA	NA	funding_source	Pharmaceutical Industry
10.2217/cer-2021-0221	general_information	NA	NA	pharmaceutical_ties_yn	Yes
10.2217/cer-2021-0221	general_information	NA	NA	systematic_review_yn	No
10.2217/cer-2021-0221	methodology	1	NA	outcome_name	global quality of life (european organisation for research and treatment of cancerquality of life questionnaire core 30 items) change from baseline
10.2217/cer-2021-0221	methodology	1	NA	outcome_short_name	Global Quality of Life
10.2217/cer-2021-0221	methodology	1	NA	outcome_variable_type	Continuous (count, mean, ...)
10.2217/cer-2021-0221	methodology	1	NA	treatment_name_ipd	palbociclib + fulvestrant
10.2217/cer-2021-0221	methodology	1	NA	studies_number_ipd	1
10.2217/cer-2021-0221	methodology	1	NA	treatment_name_nonipd	abemaciclib + fulvestrant
10.2217/cer-2021-0221	methodology	1	NA	studies_number_nonipd	2
10.2217/cer-2021-0221	methodology	1	NA	paic_type	MAIC
10.2217/cer-2021-0221	methodology	1	NA	anchored_yn	Yes
10.2217/cer-2021-0221	methodology	1	NA	paic_form	Simple (ie treatments effects extracted from two studies)
10.2217/cer-2021-0221	methodology	1	NA	primary_outcome_yn	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.2217/cer-2021-0221	methodology	1	NA	variables_selection_justification	Statistical imbalanced between treatment groups (independently of the status of prognostic/effect modifier), Status of prognostic factor/treatment effect modified assessed in the IPD dataset, A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion), Literature based (clinically or methodologically relevant to adjust on these variables based on the literature search conducted for this specific purpose)
10.2217/cer-2021-0221	methodology	1	NA	pf_yn	No
10.2217/cer-2021-0221	methodology	1	NA	tem_yn	Yes
10.2217/cer-2021-0221	methodology	1	NA	adjustment_model_details_yn	No
10.2217/cer-2021-0221	methodology	1	NA	scale_choice_yn	No
10.2217/cer-2021-0221	results	1	NA	contrast_effect_type	Means difference
10.2217/cer-2021-0221	results	1	NA	direction_benefit	superior
10.2217/cer-2021-0221	results	1	NA	ss_ttt_nonipd	NA
10.2217/cer-2021-0221	results	1	NA	ss_ttt_ipd	180
10.2217/cer-2021-0221	results	1	NA	ss_adjusted_ttt_ipd	NA
10.2217/cer-2021-0221	results	1	NA	weights_yn	Yes, mentions that the weights distribution has been studied, and weights distribution reported in main article or supplemental materials
10.2217/cer-2021-0221	results	1	NA	covariates_yn	Yes
10.2217/cer-2021-0221	results	1	NA	covariates_n	11
10.2217/cer-2021-0221	results	1	NA	covariates_names	Age, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Race/ethnicity, Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Past treatments for the disease of interest, Other(s)
10.2217/cer-2021-0221	results	1	NA	contrast_effect_direction	Numerator if ratio, or left side if difference
10.2217/cer-2021-0221	results	1	NA	contrast_effect_unadjusted_value	4.6
10.2217/cer-2021-0221	results	1	NA	contrast_effect_unadjusted_pvalci	0.016
10.2217/cer-2021-0221	results	1	NA	contrast_effect_adjusted_value	6.95
10.2217/cer-2021-0221	results	1	NA	contrast_effect_adjusted_pvalci	0.004
10.2217/cer-2021-0221	results	1	NA	adjustment_geographical	Yes
10.2217/cer-2021-0221	results	1	NA	ss_total_ipd	270
10.2217/cer-2021-0221	results	1	NA	ss_adjusted_total_ipd	NA
10.2217/cer-2021-0221	results	1	NA	ss_total_nonipd	669
10.2217/cer-2021-0221	results	1	NA	ss_anchor_nonipd	NA
10.2217/cer-2021-0221	results	1	NA	ss_anchor_ipd	90
10.2217/cer-2021-0221	results	1	NA	ss_adjusted_anchor_ipd	NA
10.2217/cer-2021-0221	results	1	NA	effect_cutoff	0
10.2217/cer-2021-0221	results	1	NA	unadjusted_pval	0.016
10.2217/cer-2021-0221	results	1	NA	unadjusted_num_pval	0.016
10.2217/cer-2021-0221	results	1	NA	unadjusted_significant	TRUE
10.2217/cer-2021-0221	results	1	NA	adjusted_pval	0.004
10.2217/cer-2021-0221	results	1	NA	adjusted_num_pval	0.004
10.2217/cer-2021-0221	results	1	NA	adjusted_significant	TRUE
10.2217/cer-2021-0221	study_information	NA	1	ipd_yn	Yes
10.2217/cer-2021-0221	study_information	NA	1	ct_yn	Yes
10.2217/cer-2021-0221	study_information	NA	1	nct	NCT01942135
10.2217/cer-2021-0221	study_information	NA	1	country_study	international
10.2217/cer-2021-0221	study_information	NA	1	ct_phase	3
10.2217/cer-2021-0221	study_information	NA	1	ct_arms	2 or more
10.2217/cer-2021-0221	study_information	NA	2	ipd_yn	No
10.2217/cer-2021-0221	study_information	NA	2	ct_yn	Yes
10.2217/cer-2021-0221	study_information	NA	2	nct	NCT02107703
10.2217/cer-2021-0221	study_information	NA	2	country_study	international
10.2217/cer-2021-0221	study_information	NA	2	ct_phase	3
10.2217/cer-2021-0221	study_information	NA	2	ct_arms	2 or more
10.2217/cer.15.33	general_information	NA	NA	condition_name	chronic genotype 1b hepatitis c
10.2217/cer.15.33	general_information	NA	NA	country_first_author	usa
10.2217/cer.15.33	general_information	NA	NA	country_last_author	usa
10.2217/cer.15.33	general_information	NA	NA	positions	Pharmaceutical Industry, Private Data Analysis Company
10.2217/cer.15.33	general_information	NA	NA	methodologist_yn	Yes
10.2217/cer.15.33	general_information	NA	NA	funding_source	Pharmaceutical Industry
10.2217/cer.15.33	general_information	NA	NA	pharmaceutical_ties_yn	Yes
10.2217/cer.15.33	general_information	NA	NA	systematic_review_yn	Yes
10.2217/cer.15.33	methodology	1	NA	outcome_name	sustained virologic response
10.2217/cer.15.33	methodology	1	NA	outcome_short_name	SVR rate
10.2217/cer.15.33	methodology	1	NA	outcome_variable_type	Binary (eg rates)
10.2217/cer.15.33	methodology	1	NA	treatment_name_ipd	daclatasvir + asunaprevir
10.2217/cer.15.33	methodology	1	NA	studies_number_ipd	2;3
10.2217/cer.15.33	methodology	1	NA	treatment_name_nonipd	telaprevir + peginterferon- + ribavirin
10.2217/cer.15.33	methodology	1	NA	studies_number_nonipd	4;5;6
10.2217/cer.15.33	methodology	1	NA	paic_type	MAIC
10.2217/cer.15.33	methodology	1	NA	anchored_yn	No
10.2217/cer.15.33	methodology	1	NA	paic_form	Aggregation of multiple studies to estimate individual treatment effects (e.g. meta-analysis in a first step to estimate treatment A effect, then population adjusted indirect comparison using treatment A effect estimate)
10.2217/cer.15.33	methodology	1	NA	primary_outcome_yn	Yes
10.2217/cer.15.33	methodology	1	NA	variables_selection_justification	Nothing mentioned, not reported
10.2217/cer.15.33	methodology	1	NA	pf_yn	No discussion (in the main text) of the status of prognostic factors of the variables
10.2217/cer.15.33	methodology	1	NA	tem_yn	No discussion (in the main text) of the status of treatment-effect modifiers of the variables
10.2217/cer.15.33	methodology	1	NA	adjustment_model_details_yn	No
10.2217/cer.15.33	methodology	1	NA	scale_choice_yn	No
10.2217/cer.15.33	methodology	2	NA	outcome_name	sustained virologic response
10.2217/cer.15.33	methodology	2	NA	outcome_short_name	SVR rate
10.2217/cer.15.33	methodology	2	NA	outcome_variable_type	Binary (eg rates)
10.2217/cer.15.33	methodology	2	NA	treatment_name_ipd	daclatasvir + asunaprevir
10.2217/cer.15.33	methodology	2	NA	studies_number_ipd	2;3
10.2217/cer.15.33	methodology	2	NA	treatment_name_nonipd	boceprevir + peginterferon- + ribavirin
10.2217/cer.15.33	methodology	2	NA	studies_number_nonipd	8
10.2217/cer.15.33	methodology	2	NA	paic_type	MAIC
10.2217/cer.15.33	methodology	2	NA	anchored_yn	No
10.2217/cer.15.33	methodology	2	NA	paic_form	Aggregation of multiple studies to estimate individual treatment effects (e.g. meta-analysis in a first step to estimate treatment A effect, then population adjusted indirect comparison using treatment A effect estimate)
10.2217/cer.15.33	methodology	2	NA	primary_outcome_yn	Yes
10.2217/cer.15.33	methodology	2	NA	variables_selection_justification	Nothing mentioned, not reported
10.2217/cer.15.33	methodology	2	NA	pf_yn	No discussion (in the main text) of the status of prognostic factors of the variables
10.2217/cer.15.33	methodology	2	NA	tem_yn	No discussion (in the main text) of the status of treatment-effect modifiers of the variables
10.2217/cer.15.33	methodology	2	NA	adjustment_model_details_yn	No
10.2217/cer.15.33	methodology	2	NA	scale_choice_yn	No
10.2217/cer.15.33	methodology	3	NA	outcome_name	sustained virologic response
10.2217/cer.15.33	methodology	3	NA	outcome_short_name	SVR rate
10.2217/cer.15.33	methodology	3	NA	outcome_variable_type	Binary (eg rates)
10.2217/cer.15.33	methodology	3	NA	treatment_name_ipd	daclatasvir + asunaprevir
10.2217/cer.15.33	methodology	3	NA	studies_number_ipd	2;3
10.2217/cer.15.33	methodology	3	NA	treatment_name_nonipd	simeprevir + peginterferon- + ribavirin
10.2217/cer.15.33	methodology	3	NA	studies_number_nonipd	10;11
10.2217/cer.15.33	methodology	3	NA	paic_type	MAIC
10.2217/cer.15.33	methodology	3	NA	anchored_yn	No
10.2217/cer.15.33	methodology	3	NA	paic_form	Aggregation of multiple studies to estimate individual treatment effects (e.g. meta-analysis in a first step to estimate treatment A effect, then population adjusted indirect comparison using treatment A effect estimate)
10.2217/cer.15.33	methodology	3	NA	primary_outcome_yn	Yes
10.2217/cer.15.33	methodology	3	NA	variables_selection_justification	Nothing mentioned, not reported
10.2217/cer.15.33	methodology	3	NA	pf_yn	No discussion (in the main text) of the status of prognostic factors of the variables
10.2217/cer.15.33	methodology	3	NA	tem_yn	No discussion (in the main text) of the status of treatment-effect modifiers of the variables
10.2217/cer.15.33	methodology	3	NA	adjustment_model_details_yn	No
10.2217/cer.15.33	methodology	3	NA	scale_choice_yn	No
10.2217/cer.15.33	methodology	4	NA	outcome_name	sustained virologic response
10.2217/cer.15.33	methodology	4	NA	outcome_short_name	SVR rate
10.2217/cer.15.33	methodology	4	NA	outcome_variable_type	Binary (eg rates)
10.2217/cer.15.33	methodology	4	NA	treatment_name_ipd	daclatasvir + asunaprevir
10.2217/cer.15.33	methodology	4	NA	studies_number_ipd	2;3
10.2217/cer.15.33	methodology	4	NA	treatment_name_nonipd	sofosbuvir + peginterferon- + ribavirin
10.2217/cer.15.33	methodology	4	NA	studies_number_nonipd	13
10.2217/cer.15.33	methodology	4	NA	paic_type	MAIC
10.2217/cer.15.33	methodology	4	NA	anchored_yn	No
10.2217/cer.15.33	methodology	4	NA	paic_form	Aggregation of multiple studies to estimate individual treatment effects (e.g. meta-analysis in a first step to estimate treatment A effect, then population adjusted indirect comparison using treatment A effect estimate)
10.2217/cer.15.33	methodology	4	NA	primary_outcome_yn	Yes
10.2217/cer.15.33	methodology	4	NA	variables_selection_justification	Nothing mentioned, not reported
10.2217/cer.15.33	methodology	4	NA	pf_yn	No discussion (in the main text) of the status of prognostic factors of the variables
10.2217/cer.15.33	methodology	4	NA	tem_yn	No discussion (in the main text) of the status of treatment-effect modifiers of the variables
10.2217/cer.15.33	methodology	4	NA	adjustment_model_details_yn	No
10.2217/cer.15.33	methodology	4	NA	scale_choice_yn	No
10.2217/cer.15.33	methodology	5	NA	outcome_name	sustained virologic response
10.2217/cer.15.33	methodology	5	NA	outcome_short_name	SVR rate
10.2217/cer.15.33	methodology	5	NA	outcome_variable_type	Binary (eg rates)
10.2217/cer.15.33	methodology	5	NA	treatment_name_ipd	daclatasvir + asunaprevir
10.2217/cer.15.33	methodology	5	NA	studies_number_ipd	2;3
10.2217/cer.15.33	methodology	5	NA	treatment_name_nonipd	peginterferon- + ribavirin
10.2217/cer.15.33	methodology	5	NA	studies_number_nonipd	4;8;10;11
10.2217/cer.15.33	methodology	5	NA	paic_type	MAIC
10.2217/cer.15.33	methodology	5	NA	anchored_yn	No
10.2217/cer.15.33	methodology	5	NA	paic_form	Aggregation of multiple studies to estimate individual treatment effects (e.g. meta-analysis in a first step to estimate treatment A effect, then population adjusted indirect comparison using treatment A effect estimate)
10.2217/cer.15.33	methodology	5	NA	primary_outcome_yn	Yes
10.2217/cer.15.33	methodology	5	NA	variables_selection_justification	Nothing mentioned, not reported
10.2217/cer.15.33	methodology	5	NA	pf_yn	No discussion (in the main text) of the status of prognostic factors of the variables
10.2217/cer.15.33	methodology	5	NA	tem_yn	No discussion (in the main text) of the status of treatment-effect modifiers of the variables
10.2217/cer.15.33	methodology	5	NA	adjustment_model_details_yn	No
10.2217/cer.15.33	methodology	5	NA	scale_choice_yn	No
10.2217/cer.15.33	methodology	6	NA	outcome_name	sustained virologic response
10.2217/cer.15.33	methodology	6	NA	outcome_short_name	SVR rate
10.2217/cer.15.33	methodology	6	NA	outcome_variable_type	Binary (eg rates)
10.2217/cer.15.33	methodology	6	NA	treatment_name_ipd	daclatasvir + asunaprevir
10.2217/cer.15.33	methodology	6	NA	studies_number_ipd	1;2;3
10.2217/cer.15.33	methodology	6	NA	treatment_name_nonipd	telaprevir + peginterferon- + ribavirin
10.2217/cer.15.33	methodology	6	NA	studies_number_nonipd	7
10.2217/cer.15.33	methodology	6	NA	paic_type	MAIC
10.2217/cer.15.33	methodology	6	NA	anchored_yn	No
10.2217/cer.15.33	methodology	6	NA	paic_form	Aggregation of multiple studies to estimate individual treatment effects (e.g. meta-analysis in a first step to estimate treatment A effect, then population adjusted indirect comparison using treatment A effect estimate)
10.2217/cer.15.33	methodology	6	NA	primary_outcome_yn	Yes
10.2217/cer.15.33	methodology	6	NA	variables_selection_justification	Nothing mentioned, not reported
10.2217/cer.15.33	methodology	6	NA	pf_yn	No discussion (in the main text) of the status of prognostic factors of the variables
10.2217/cer.15.33	methodology	6	NA	tem_yn	No discussion (in the main text) of the status of treatment-effect modifiers of the variables
10.2217/cer.15.33	methodology	6	NA	adjustment_model_details_yn	No
10.2217/cer.15.33	methodology	6	NA	scale_choice_yn	No
10.2217/cer.15.33	methodology	7	NA	outcome_name	sustained virologic response
10.2217/cer.15.33	methodology	7	NA	outcome_short_name	SVR rate
10.2217/cer.15.33	methodology	7	NA	outcome_variable_type	Binary (eg rates)
10.2217/cer.15.33	methodology	7	NA	treatment_name_ipd	daclatasvir + asunaprevir
10.2217/cer.15.33	methodology	7	NA	studies_number_ipd	1;2;3
10.2217/cer.15.33	methodology	7	NA	treatment_name_nonipd	boceprevir + peginterferon- + ribavirin
10.2217/cer.15.33	methodology	7	NA	studies_number_nonipd	9
10.2217/cer.15.33	methodology	7	NA	paic_type	MAIC
10.2217/cer.15.33	methodology	7	NA	anchored_yn	No
10.2217/cer.15.33	methodology	7	NA	paic_form	Aggregation of multiple studies to estimate individual treatment effects (e.g. meta-analysis in a first step to estimate treatment A effect, then population adjusted indirect comparison using treatment A effect estimate)
10.2217/cer.15.33	methodology	7	NA	primary_outcome_yn	Yes
10.2217/cer.15.33	methodology	7	NA	variables_selection_justification	Nothing mentioned, not reported
10.2217/cer.15.33	methodology	7	NA	pf_yn	No discussion (in the main text) of the status of prognostic factors of the variables
10.2217/cer.15.33	methodology	7	NA	tem_yn	No discussion (in the main text) of the status of treatment-effect modifiers of the variables
10.2217/cer.15.33	methodology	7	NA	adjustment_model_details_yn	No
10.2217/cer.15.33	methodology	7	NA	scale_choice_yn	No
10.2217/cer.15.33	methodology	8	NA	outcome_name	sustained virologic response
10.2217/cer.15.33	methodology	8	NA	outcome_short_name	SVR rate
10.2217/cer.15.33	methodology	8	NA	outcome_variable_type	Binary (eg rates)
10.2217/cer.15.33	methodology	8	NA	treatment_name_ipd	daclatasvir + asunaprevir
10.2217/cer.15.33	methodology	8	NA	studies_number_ipd	1;2;3
10.2217/cer.15.33	methodology	8	NA	treatment_name_nonipd	simeprevir + peginterferon- + ribavirin
10.2217/cer.15.33	methodology	8	NA	studies_number_nonipd	12
10.2217/cer.15.33	methodology	8	NA	paic_type	MAIC
10.2217/cer.15.33	methodology	8	NA	anchored_yn	No
10.2217/cer.15.33	methodology	8	NA	paic_form	Aggregation of multiple studies to estimate individual treatment effects (e.g. meta-analysis in a first step to estimate treatment A effect, then population adjusted indirect comparison using treatment A effect estimate)
10.2217/cer.15.33	methodology	8	NA	primary_outcome_yn	Yes
10.2217/cer.15.33	methodology	8	NA	variables_selection_justification	Nothing mentioned, not reported
10.2217/cer.15.33	methodology	8	NA	pf_yn	No discussion (in the main text) of the status of prognostic factors of the variables
10.2217/cer.15.33	methodology	8	NA	tem_yn	No discussion (in the main text) of the status of treatment-effect modifiers of the variables
10.2217/cer.15.33	methodology	8	NA	adjustment_model_details_yn	No
10.2217/cer.15.33	methodology	8	NA	scale_choice_yn	No
10.2217/cer.15.33	methodology	9	NA	outcome_name	sustained virologic response
10.2217/cer.15.33	methodology	9	NA	outcome_short_name	SVR rate
10.2217/cer.15.33	methodology	9	NA	outcome_variable_type	Binary (eg rates)
10.2217/cer.15.33	methodology	9	NA	treatment_name_ipd	daclatasvir + asunaprevir
10.2217/cer.15.33	methodology	9	NA	studies_number_ipd	1;2;3
10.2217/cer.15.33	methodology	9	NA	treatment_name_nonipd	peginterferon- + ribavirin
10.2217/cer.15.33	methodology	9	NA	studies_number_nonipd	9;12
10.2217/cer.15.33	methodology	9	NA	paic_type	MAIC
10.2217/cer.15.33	methodology	9	NA	anchored_yn	No
10.2217/cer.15.33	methodology	9	NA	paic_form	Aggregation of multiple studies to estimate individual treatment effects (e.g. meta-analysis in a first step to estimate treatment A effect, then population adjusted indirect comparison using treatment A effect estimate)
10.2217/cer.15.33	methodology	9	NA	primary_outcome_yn	Yes
10.2217/cer.15.33	methodology	9	NA	variables_selection_justification	Nothing mentioned, not reported
10.2217/cer.15.33	methodology	9	NA	pf_yn	No discussion (in the main text) of the status of prognostic factors of the variables
10.2217/cer.15.33	methodology	9	NA	tem_yn	No discussion (in the main text) of the status of treatment-effect modifiers of the variables
10.2217/cer.15.33	methodology	9	NA	adjustment_model_details_yn	No
10.2217/cer.15.33	methodology	9	NA	scale_choice_yn	No
10.2217/cer.15.33	results	1	NA	contrast_effect_type	Rate difference
10.2217/cer.15.33	results	1	NA	direction_benefit	superior
10.2217/cer.15.33	results	1	NA	ss_ttt_nonipd	1643
10.2217/cer.15.33	results	1	NA	ss_ttt_ipd	324
10.2217/cer.15.33	results	1	NA	ss_adjusted_ttt_ipd	NA
10.2217/cer.15.33	results	1	NA	weights_yn	Not mentioned
10.2217/cer.15.33	results	1	NA	covariates_yn	No
10.2217/cer.15.33	results	1	NA	covariates_n	NA
10.2217/cer.15.33	results	1	NA	covariates_names	NA
10.2217/cer.15.33	results	1	NA	contrast_effect_direction	Numerator if ratio, or left side if difference
10.2217/cer.15.33	results	1	NA	contrast_effect_unadjusted_value	NA
10.2217/cer.15.33	results	1	NA	contrast_effect_unadjusted_pvalci	NA
10.2217/cer.15.33	results	1	NA	contrast_effect_adjusted_value	8.7
10.2217/cer.15.33	results	1	NA	contrast_effect_adjusted_pvalci	[0.2;17.3]
10.2217/cer.15.33	results	1	NA	adjustment_geographical	NA
10.2217/cer.15.33	results	1	NA	ss_total_ipd	NA
10.2217/cer.15.33	results	1	NA	ss_adjusted_total_ipd	NA
10.2217/cer.15.33	results	1	NA	ss_total_nonipd	NA
10.2217/cer.15.33	results	1	NA	ss_anchor_nonipd	NA
10.2217/cer.15.33	results	1	NA	ss_anchor_ipd	NA
10.2217/cer.15.33	results	1	NA	ss_adjusted_anchor_ipd	NA
10.2217/cer.15.33	results	1	NA	effect_cutoff	0
10.2217/cer.15.33	results	1	NA	adjusted_lb_ci	0.2
10.2217/cer.15.33	results	1	NA	adjusted_ub_ci	17.3
10.2217/cer.15.33	results	1	NA	adjusted_significant	TRUE
10.2217/cer.15.33	results	2	NA	contrast_effect_type	Rate difference
10.2217/cer.15.33	results	2	NA	direction_benefit	superior
10.2217/cer.15.33	results	2	NA	ss_ttt_nonipd	368
10.2217/cer.15.33	results	2	NA	ss_ttt_ipd	324
10.2217/cer.15.33	results	2	NA	ss_adjusted_ttt_ipd	NA
10.2217/cer.15.33	results	2	NA	weights_yn	Not mentioned
10.2217/cer.15.33	results	2	NA	covariates_yn	No
10.2217/cer.15.33	results	2	NA	covariates_n	NA
10.2217/cer.15.33	results	2	NA	covariates_names	NA
10.2217/cer.15.33	results	2	NA	contrast_effect_direction	Numerator if ratio, or left side if difference
10.2217/cer.15.33	results	2	NA	contrast_effect_unadjusted_value	NA
10.2217/cer.15.33	results	2	NA	contrast_effect_unadjusted_pvalci	NA
10.2217/cer.15.33	results	2	NA	contrast_effect_adjusted_value	16.5
10.2217/cer.15.33	results	2	NA	contrast_effect_adjusted_pvalci	[2.5;30.5]
10.2217/cer.15.33	results	2	NA	adjustment_geographical	NA
10.2217/cer.15.33	results	2	NA	ss_total_ipd	NA
10.2217/cer.15.33	results	2	NA	ss_adjusted_total_ipd	NA
10.2217/cer.15.33	results	2	NA	ss_total_nonipd	NA
10.2217/cer.15.33	results	2	NA	ss_anchor_nonipd	NA
10.2217/cer.15.33	results	2	NA	ss_anchor_ipd	NA
10.2217/cer.15.33	results	2	NA	ss_adjusted_anchor_ipd	NA
10.2217/cer.15.33	results	2	NA	effect_cutoff	0
10.2217/cer.15.33	results	2	NA	adjusted_lb_ci	2.5
10.2217/cer.15.33	results	2	NA	adjusted_ub_ci	30.5
10.2217/cer.15.33	results	2	NA	adjusted_significant	TRUE
10.2217/cer.15.33	results	3	NA	contrast_effect_type	Rate difference
10.2217/cer.15.33	results	3	NA	direction_benefit	superior
10.2217/cer.15.33	results	3	NA	ss_ttt_nonipd	521
10.2217/cer.15.33	results	3	NA	ss_ttt_ipd	324
10.2217/cer.15.33	results	3	NA	ss_adjusted_ttt_ipd	NA
10.2217/cer.15.33	results	3	NA	weights_yn	Not mentioned
10.2217/cer.15.33	results	3	NA	covariates_yn	No
10.2217/cer.15.33	results	3	NA	covariates_n	NA
10.2217/cer.15.33	results	3	NA	covariates_names	NA
10.2217/cer.15.33	results	3	NA	contrast_effect_direction	Numerator if ratio, or left side if difference
10.2217/cer.15.33	results	3	NA	contrast_effect_unadjusted_value	NA
10.2217/cer.15.33	results	3	NA	contrast_effect_unadjusted_pvalci	NA
10.2217/cer.15.33	results	3	NA	contrast_effect_adjusted_value	0.4
10.2217/cer.15.33	results	3	NA	contrast_effect_adjusted_pvalci	[-8.9;9.7]
10.2217/cer.15.33	results	3	NA	adjustment_geographical	NA
10.2217/cer.15.33	results	3	NA	ss_total_ipd	NA
10.2217/cer.15.33	results	3	NA	ss_adjusted_total_ipd	NA
10.2217/cer.15.33	results	3	NA	ss_total_nonipd	NA
10.2217/cer.15.33	results	3	NA	ss_anchor_nonipd	NA
10.2217/cer.15.33	results	3	NA	ss_anchor_ipd	NA
10.2217/cer.15.33	results	3	NA	ss_adjusted_anchor_ipd	NA
10.2217/cer.15.33	results	3	NA	effect_cutoff	0
10.2217/cer.15.33	results	3	NA	adjusted_lb_ci	-8.9
10.2217/cer.15.33	results	3	NA	adjusted_ub_ci	9.7
10.2217/cer.15.33	results	3	NA	adjusted_significant	FALSE
10.2217/cer.15.33	results	4	NA	contrast_effect_type	Rate difference
10.2217/cer.15.33	results	4	NA	direction_benefit	superior
10.2217/cer.15.33	results	4	NA	ss_ttt_nonipd	327
10.2217/cer.15.33	results	4	NA	ss_ttt_ipd	324
10.2217/cer.15.33	results	4	NA	ss_adjusted_ttt_ipd	NA
10.2217/cer.15.33	results	4	NA	weights_yn	Not mentioned
10.2217/cer.15.33	results	4	NA	covariates_yn	No
10.2217/cer.15.33	results	4	NA	covariates_n	NA
10.2217/cer.15.33	results	4	NA	covariates_names	NA
10.2217/cer.15.33	results	4	NA	contrast_effect_direction	Numerator if ratio, or left side if difference
10.2217/cer.15.33	results	4	NA	contrast_effect_unadjusted_value	NA
10.2217/cer.15.33	results	4	NA	contrast_effect_unadjusted_pvalci	NA
10.2217/cer.15.33	results	4	NA	contrast_effect_adjusted_value	3
10.2217/cer.15.33	results	4	NA	contrast_effect_adjusted_pvalci	[-21.2;27.1]
10.2217/cer.15.33	results	4	NA	adjustment_geographical	NA
10.2217/cer.15.33	results	4	NA	ss_total_ipd	NA
10.2217/cer.15.33	results	4	NA	ss_adjusted_total_ipd	NA
10.2217/cer.15.33	results	4	NA	ss_total_nonipd	NA
10.2217/cer.15.33	results	4	NA	ss_anchor_nonipd	NA
10.2217/cer.15.33	results	4	NA	ss_anchor_ipd	NA
10.2217/cer.15.33	results	4	NA	ss_adjusted_anchor_ipd	NA
10.2217/cer.15.33	results	4	NA	effect_cutoff	0
10.2217/cer.15.33	results	4	NA	adjusted_lb_ci	-21.2
10.2217/cer.15.33	results	4	NA	adjusted_ub_ci	27.1
10.2217/cer.15.33	results	4	NA	adjusted_significant	FALSE
10.2217/cer.15.33	results	5	NA	contrast_effect_type	Rate difference
10.2217/cer.15.33	results	5	NA	direction_benefit	superior
10.2217/cer.15.33	results	5	NA	ss_ttt_nonipd	988
10.2217/cer.15.33	results	5	NA	ss_ttt_ipd	324
10.2217/cer.15.33	results	5	NA	ss_adjusted_ttt_ipd	NA
10.2217/cer.15.33	results	5	NA	weights_yn	Not mentioned
10.2217/cer.15.33	results	5	NA	covariates_yn	No
10.2217/cer.15.33	results	5	NA	covariates_n	NA
10.2217/cer.15.33	results	5	NA	covariates_names	NA
10.2217/cer.15.33	results	5	NA	contrast_effect_direction	Numerator if ratio, or left side if difference
10.2217/cer.15.33	results	5	NA	contrast_effect_unadjusted_value	NA
10.2217/cer.15.33	results	5	NA	contrast_effect_unadjusted_pvalci	NA
10.2217/cer.15.33	results	5	NA	contrast_effect_adjusted_value	39.6
10.2217/cer.15.33	results	5	NA	contrast_effect_adjusted_pvalci	[30.3;48.9]
10.2217/cer.15.33	results	5	NA	adjustment_geographical	NA
10.2217/cer.15.33	results	5	NA	ss_total_ipd	NA
10.2217/cer.15.33	results	5	NA	ss_adjusted_total_ipd	NA
10.2217/cer.15.33	results	5	NA	ss_total_nonipd	NA
10.2217/cer.15.33	results	5	NA	ss_anchor_nonipd	NA
10.2217/cer.15.33	results	5	NA	ss_anchor_ipd	NA
10.2217/cer.15.33	results	5	NA	ss_adjusted_anchor_ipd	NA
10.2217/cer.15.33	results	5	NA	effect_cutoff	0
10.2217/cer.15.33	results	5	NA	adjusted_lb_ci	30.3
10.2217/cer.15.33	results	5	NA	adjusted_ub_ci	48.9
10.2217/cer.15.33	results	5	NA	adjusted_significant	TRUE
10.2217/cer.15.33	results	6	NA	contrast_effect_type	Rate difference
10.2217/cer.15.33	results	6	NA	direction_benefit	superior
10.2217/cer.15.33	results	6	NA	ss_ttt_nonipd	266
10.2217/cer.15.33	results	6	NA	ss_ttt_ipd	314
10.2217/cer.15.33	results	6	NA	ss_adjusted_ttt_ipd	NA
10.2217/cer.15.33	results	6	NA	weights_yn	Not mentioned
10.2217/cer.15.33	results	6	NA	covariates_yn	No
10.2217/cer.15.33	results	6	NA	covariates_n	NA
10.2217/cer.15.33	results	6	NA	covariates_names	NA
10.2217/cer.15.33	results	6	NA	contrast_effect_direction	Numerator if ratio, or left side if difference
10.2217/cer.15.33	results	6	NA	contrast_effect_unadjusted_value	NA
10.2217/cer.15.33	results	6	NA	contrast_effect_unadjusted_pvalci	NA
10.2217/cer.15.33	results	6	NA	contrast_effect_adjusted_value	17
10.2217/cer.15.33	results	6	NA	contrast_effect_adjusted_pvalci	[5.3;28.7]
10.2217/cer.15.33	results	6	NA	adjustment_geographical	NA
10.2217/cer.15.33	results	6	NA	ss_total_ipd	NA
10.2217/cer.15.33	results	6	NA	ss_adjusted_total_ipd	NA
10.2217/cer.15.33	results	6	NA	ss_total_nonipd	NA
10.2217/cer.15.33	results	6	NA	ss_anchor_nonipd	NA
10.2217/cer.15.33	results	6	NA	ss_anchor_ipd	NA
10.2217/cer.15.33	results	6	NA	ss_adjusted_anchor_ipd	NA
10.2217/cer.15.33	results	6	NA	effect_cutoff	0
10.2217/cer.15.33	results	6	NA	adjusted_lb_ci	5.3
10.2217/cer.15.33	results	6	NA	adjusted_ub_ci	28.7
10.2217/cer.15.33	results	6	NA	adjusted_significant	TRUE
10.2217/cer.15.33	results	7	NA	contrast_effect_type	Rate difference
10.2217/cer.15.33	results	7	NA	direction_benefit	superior
10.2217/cer.15.33	results	7	NA	ss_ttt_nonipd	162
10.2217/cer.15.33	results	7	NA	ss_ttt_ipd	314
10.2217/cer.15.33	results	7	NA	ss_adjusted_ttt_ipd	NA
10.2217/cer.15.33	results	7	NA	weights_yn	Not mentioned
10.2217/cer.15.33	results	7	NA	covariates_yn	No
10.2217/cer.15.33	results	7	NA	covariates_n	NA
10.2217/cer.15.33	results	7	NA	covariates_names	NA
10.2217/cer.15.33	results	7	NA	contrast_effect_direction	Numerator if ratio, or left side if difference
10.2217/cer.15.33	results	7	NA	contrast_effect_unadjusted_value	NA
10.2217/cer.15.33	results	7	NA	contrast_effect_unadjusted_pvalci	NA
10.2217/cer.15.33	results	7	NA	contrast_effect_adjusted_value	22.8
10.2217/cer.15.33	results	7	NA	contrast_effect_adjusted_pvalci	[6.9;38.7]
10.2217/cer.15.33	results	7	NA	adjustment_geographical	NA
10.2217/cer.15.33	results	7	NA	ss_total_ipd	NA
10.2217/cer.15.33	results	7	NA	ss_adjusted_total_ipd	NA
10.2217/cer.15.33	results	7	NA	ss_total_nonipd	NA
10.2217/cer.15.33	results	7	NA	ss_anchor_nonipd	NA
10.2217/cer.15.33	results	7	NA	ss_anchor_ipd	NA
10.2217/cer.15.33	results	7	NA	ss_adjusted_anchor_ipd	NA
10.2217/cer.15.33	results	7	NA	effect_cutoff	0
10.2217/cer.15.33	results	7	NA	adjusted_lb_ci	6.9
10.2217/cer.15.33	results	7	NA	adjusted_ub_ci	38.7
10.2217/cer.15.33	results	7	NA	adjusted_significant	TRUE
10.2217/cer.15.33	results	8	NA	contrast_effect_type	Rate difference
10.2217/cer.15.33	results	8	NA	direction_benefit	superior
10.2217/cer.15.33	results	8	NA	ss_ttt_nonipd	260
10.2217/cer.15.33	results	8	NA	ss_ttt_ipd	314
10.2217/cer.15.33	results	8	NA	ss_adjusted_ttt_ipd	NA
10.2217/cer.15.33	results	8	NA	weights_yn	Not mentioned
10.2217/cer.15.33	results	8	NA	covariates_yn	No
10.2217/cer.15.33	results	8	NA	covariates_n	NA
10.2217/cer.15.33	results	8	NA	covariates_names	NA
10.2217/cer.15.33	results	8	NA	contrast_effect_direction	Numerator if ratio, or left side if difference
10.2217/cer.15.33	results	8	NA	contrast_effect_unadjusted_value	NA
10.2217/cer.15.33	results	8	NA	contrast_effect_unadjusted_pvalci	NA
10.2217/cer.15.33	results	8	NA	contrast_effect_adjusted_value	10.3
10.2217/cer.15.33	results	8	NA	contrast_effect_adjusted_pvalci	[1.1;19.5]
10.2217/cer.15.33	results	8	NA	adjustment_geographical	NA
10.2217/cer.15.33	results	8	NA	ss_total_ipd	NA
10.2217/cer.15.33	results	8	NA	ss_adjusted_total_ipd	NA
10.2217/cer.15.33	results	8	NA	ss_total_nonipd	NA
10.2217/cer.15.33	results	8	NA	ss_anchor_nonipd	NA
10.2217/cer.15.33	results	8	NA	ss_anchor_ipd	NA
10.2217/cer.15.33	results	8	NA	ss_adjusted_anchor_ipd	NA
10.2217/cer.15.33	results	8	NA	effect_cutoff	0
10.2217/cer.15.33	results	8	NA	adjusted_lb_ci	1.1
10.2217/cer.15.33	results	8	NA	adjusted_ub_ci	19.5
10.2217/cer.15.33	results	8	NA	adjusted_significant	TRUE
10.2217/cer.15.33	results	9	NA	contrast_effect_type	Rate difference
10.2217/cer.15.33	results	9	NA	direction_benefit	superior
10.2217/cer.15.33	results	9	NA	ss_ttt_nonipd	213
10.2217/cer.15.33	results	9	NA	ss_ttt_ipd	314
10.2217/cer.15.33	results	9	NA	ss_adjusted_ttt_ipd	NA
10.2217/cer.15.33	results	9	NA	weights_yn	Not mentioned
10.2217/cer.15.33	results	9	NA	covariates_yn	No
10.2217/cer.15.33	results	9	NA	covariates_n	NA
10.2217/cer.15.33	results	9	NA	covariates_names	NA
10.2217/cer.15.33	results	9	NA	contrast_effect_direction	Numerator if ratio, or left side if difference
10.2217/cer.15.33	results	9	NA	contrast_effect_unadjusted_value	NA
10.2217/cer.15.33	results	9	NA	contrast_effect_unadjusted_pvalci	NA
10.2217/cer.15.33	results	9	NA	contrast_effect_adjusted_value	57.7
10.2217/cer.15.33	results	9	NA	contrast_effect_adjusted_pvalci	[44.0;71.4]
10.2217/cer.15.33	results	9	NA	adjustment_geographical	NA
10.2217/cer.15.33	results	9	NA	ss_total_ipd	NA
10.2217/cer.15.33	results	9	NA	ss_adjusted_total_ipd	NA
10.2217/cer.15.33	results	9	NA	ss_total_nonipd	NA
10.2217/cer.15.33	results	9	NA	ss_anchor_nonipd	NA
10.2217/cer.15.33	results	9	NA	ss_anchor_ipd	NA
10.2217/cer.15.33	results	9	NA	ss_adjusted_anchor_ipd	NA
10.2217/cer.15.33	results	9	NA	effect_cutoff	0
10.2217/cer.15.33	results	9	NA	adjusted_lb_ci	44
10.2217/cer.15.33	results	9	NA	adjusted_ub_ci	71.4
10.2217/cer.15.33	results	9	NA	adjusted_significant	TRUE
10.2217/cer.15.33	study_information	NA	1	ipd_yn	Yes
10.2217/cer.15.33	study_information	NA	1	ct_yn	Yes
10.2217/cer.15.33	study_information	NA	1	nct	NCT01497834
10.2217/cer.15.33	study_information	NA	1	country_study	japan
10.2217/cer.15.33	study_information	NA	1	ct_phase	3
10.2217/cer.15.33	study_information	NA	1	ct_arms	1
10.2217/cer.15.33	study_information	NA	10	ipd_yn	No
10.2217/cer.15.33	study_information	NA	10	ct_yn	Yes
10.2217/cer.15.33	study_information	NA	10	nct	NCT01289782
10.2217/cer.15.33	study_information	NA	10	country_study	international
10.2217/cer.15.33	study_information	NA	10	ct_phase	3
10.2217/cer.15.33	study_information	NA	10	ct_arms	2 or more
10.2217/cer.15.33	study_information	NA	11	ipd_yn	No
10.2217/cer.15.33	study_information	NA	11	ct_yn	Yes
10.2217/cer.15.33	study_information	NA	11	nct	NCT01290679
10.2217/cer.15.33	study_information	NA	11	country_study	international
10.2217/cer.15.33	study_information	NA	11	ct_phase	3
10.2217/cer.15.33	study_information	NA	11	ct_arms	2 or more
10.2217/cer.15.33	study_information	NA	12	ipd_yn	No
10.2217/cer.15.33	study_information	NA	12	ct_yn	Yes
10.2217/cer.15.33	study_information	NA	12	nct	NCT01281839
10.2217/cer.15.33	study_information	NA	12	country_study	international
10.2217/cer.15.33	study_information	NA	12	ct_phase	3
10.2217/cer.15.33	study_information	NA	12	ct_arms	2 or more
10.2217/cer.15.33	study_information	NA	13	ipd_yn	No
10.2217/cer.15.33	study_information	NA	13	ct_yn	Yes
10.2217/cer.15.33	study_information	NA	13	nct	NCT01641640
10.2217/cer.15.33	study_information	NA	13	country_study	usa
10.2217/cer.15.33	study_information	NA	13	ct_phase	3
10.2217/cer.15.33	study_information	NA	13	ct_arms	1
10.2217/cer.15.33	study_information	NA	2	ipd_yn	Yes
10.2217/cer.15.33	study_information	NA	2	ct_yn	Yes
10.2217/cer.15.33	study_information	NA	2	nct	NCT01581203
10.2217/cer.15.33	study_information	NA	2	country_study	international
10.2217/cer.15.33	study_information	NA	2	ct_phase	3
10.2217/cer.15.33	study_information	NA	2	ct_arms	2 or more
10.2217/cer.15.33	study_information	NA	3	ipd_yn	Yes
10.2217/cer.15.33	study_information	NA	3	ct_yn	Yes
10.2217/cer.15.33	study_information	NA	3	nct	NCT01718145
10.2217/cer.15.33	study_information	NA	3	country_study	japan
10.2217/cer.15.33	study_information	NA	3	ct_phase	3
10.2217/cer.15.33	study_information	NA	3	ct_arms	2 or more
10.2217/cer.15.33	study_information	NA	4	ipd_yn	No
10.2217/cer.15.33	study_information	NA	4	ct_yn	Yes
10.2217/cer.15.33	study_information	NA	4	nct	NCT00627926
10.2217/cer.15.33	study_information	NA	4	country_study	international
10.2217/cer.15.33	study_information	NA	4	ct_phase	3
10.2217/cer.15.33	study_information	NA	4	ct_arms	2 or more
10.2217/cer.15.33	study_information	NA	5	ipd_yn	No
10.2217/cer.15.33	study_information	NA	5	ct_yn	Yes
10.2217/cer.15.33	study_information	NA	5	nct	NCT01241760
10.2217/cer.15.33	study_information	NA	5	country_study	international
10.2217/cer.15.33	study_information	NA	5	ct_phase	3
10.2217/cer.15.33	study_information	NA	5	ct_arms	2 or more
10.2217/cer.15.33	study_information	NA	6	ipd_yn	No
10.2217/cer.15.33	study_information	NA	6	ct_yn	Yes
10.2217/cer.15.33	study_information	NA	6	nct	NCT00758043
10.2217/cer.15.33	study_information	NA	6	country_study	international
10.2217/cer.15.33	study_information	NA	6	ct_phase	3
10.2217/cer.15.33	study_information	NA	6	ct_arms	2 or more
10.2217/cer.15.33	study_information	NA	7	ipd_yn	No
10.2217/cer.15.33	study_information	NA	7	ct_yn	Yes
10.2217/cer.15.33	study_information	NA	7	nct	NCT00703118
10.2217/cer.15.33	study_information	NA	7	country_study	international
10.2217/cer.15.33	study_information	NA	7	ct_phase	3
10.2217/cer.15.33	study_information	NA	7	ct_arms	2 or more
10.2217/cer.15.33	study_information	NA	8	ipd_yn	No
10.2217/cer.15.33	study_information	NA	8	ct_yn	Yes
10.2217/cer.15.33	study_information	NA	8	nct	NCT00705432
10.2217/cer.15.33	study_information	NA	8	ct_phase	3
10.2217/cer.15.33	study_information	NA	8	ct_arms	2 or more
10.2217/cer.15.33	study_information	NA	8	country_study	unknown
10.2217/cer.15.33	study_information	NA	9	ipd_yn	No
10.2217/cer.15.33	study_information	NA	9	ct_yn	Yes
10.2217/cer.15.33	study_information	NA	9	nct	NCT00708500
10.2217/cer.15.33	study_information	NA	9	ct_phase	3
10.2217/cer.15.33	study_information	NA	9	ct_arms	2 or more
10.2217/cer.15.33	study_information	NA	9	country_study	unknown
10.2217/cer.15.49	general_information	NA	NA	condition_name	hepatitis c genotype 3
10.2217/cer.15.49	general_information	NA	NA	country_first_author	usa
10.2217/cer.15.49	general_information	NA	NA	country_last_author	usa
10.2217/cer.15.49	general_information	NA	NA	positions	Pharmaceutical Industry, Private Data Analysis Company
10.2217/cer.15.49	general_information	NA	NA	methodologist_yn	Yes
10.2217/cer.15.49	general_information	NA	NA	funding_source	Pharmaceutical Industry
10.2217/cer.15.49	general_information	NA	NA	pharmaceutical_ties_yn	Yes
10.2217/cer.15.49	general_information	NA	NA	systematic_review_yn	Yes
10.2217/cer.15.49	methodology	1	NA	outcome_name	sustained virologic response at week 12 post-treatment (svr12)
10.2217/cer.15.49	methodology	1	NA	outcome_short_name	SVR rate
10.2217/cer.15.49	methodology	1	NA	outcome_variable_type	Binary (eg rates)
10.2217/cer.15.49	methodology	1	NA	treatment_name_ipd	daclatasvir + sofosbuvir
10.2217/cer.15.49	methodology	1	NA	studies_number_ipd	1
10.2217/cer.15.49	methodology	1	NA	treatment_name_nonipd	sofosbuvir + ribavirin
10.2217/cer.15.49	methodology	1	NA	studies_number_nonipd	2
10.2217/cer.15.49	methodology	1	NA	paic_type	MAIC
10.2217/cer.15.49	methodology	1	NA	anchored_yn	No
10.2217/cer.15.49	methodology	1	NA	paic_form	Simple (ie treatments effects extracted from two studies)
10.2217/cer.15.49	methodology	1	NA	primary_outcome_yn	Yes
10.2217/cer.15.49	methodology	1	NA	variables_selection_justification	Nothing mentioned, not reported
10.2217/cer.15.49	methodology	1	NA	pf_yn	No discussion (in the main text) of the status of prognostic factors of the variables
10.2217/cer.15.49	methodology	1	NA	tem_yn	No discussion (in the main text) of the status of treatment-effect modifiers of the variables
10.2217/cer.15.49	methodology	1	NA	adjustment_model_details_yn	No
10.2217/cer.15.49	methodology	1	NA	scale_choice_yn	No
10.2217/cer.15.49	methodology	2	NA	outcome_name	rate of svr12 in patients treated with dcv + sof (study 1). the rate of svr24 in patients treated with a/r (studies 3 and 4)
10.2217/cer.15.49	methodology	2	NA	outcome_short_name	SVR rate
10.2217/cer.15.49	methodology	2	NA	outcome_variable_type	Binary (eg rates)
10.2217/cer.15.49	methodology	2	NA	treatment_name_ipd	daclatasvir + sofosbuvir
10.2217/cer.15.49	methodology	2	NA	studies_number_ipd	1
10.2217/cer.15.49	methodology	2	NA	treatment_name_nonipd	peginterferon-alfa + ribavirin
10.2217/cer.15.49	methodology	2	NA	studies_number_nonipd	3;4
10.2217/cer.15.49	methodology	2	NA	paic_type	MAIC
10.2217/cer.15.49	methodology	2	NA	anchored_yn	No
10.2217/cer.15.49	methodology	2	NA	paic_form	Aggregation of multiple studies to estimate individual treatment effects (e.g. meta-analysis in a first step to estimate treatment A effect, then population adjusted indirect comparison using treatment A effect estimate)
10.2217/cer.15.49	methodology	2	NA	primary_outcome_yn	Yes
10.2217/cer.15.49	methodology	2	NA	variables_selection_justification	Nothing mentioned, not reported
10.2217/cer.15.49	methodology	2	NA	pf_yn	No discussion (in the main text) of the status of prognostic factors of the variables
10.2217/cer.15.49	methodology	2	NA	tem_yn	No discussion (in the main text) of the status of treatment-effect modifiers of the variables
10.2217/cer.15.49	methodology	2	NA	adjustment_model_details_yn	No
10.2217/cer.15.49	methodology	2	NA	scale_choice_yn	No
10.2217/cer.15.49	results	1	NA	contrast_effect_type	Rate difference
10.2217/cer.15.49	results	1	NA	direction_benefit	superior
10.2217/cer.15.49	results	1	NA	ss_ttt_nonipd	250
10.2217/cer.15.49	results	1	NA	ss_ttt_ipd	144
10.2217/cer.15.49	results	1	NA	ss_adjusted_ttt_ipd	NA
10.2217/cer.15.49	results	1	NA	weights_yn	Not mentioned
10.2217/cer.15.49	results	1	NA	covariates_yn	Yes
10.2217/cer.15.49	results	1	NA	covariates_n	11
10.2217/cer.15.49	results	1	NA	covariates_names	Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Race/ethnicity, Past treatments for the disease of interest, Other(s)
10.2217/cer.15.49	results	1	NA	contrast_effect_direction	Numerator if ratio, or left side if difference
10.2217/cer.15.49	results	1	NA	contrast_effect_unadjusted_value	4.40
10.2217/cer.15.49	results	1	NA	contrast_effect_unadjusted_pvalci	0.216
10.2217/cer.15.49	results	1	NA	contrast_effect_adjusted_value	3.60
10.2217/cer.15.49	results	1	NA	contrast_effect_adjusted_pvalci	0.537
10.2217/cer.15.49	results	1	NA	adjustment_geographical	No
10.2217/cer.15.49	results	1	NA	ss_total_ipd	NA
10.2217/cer.15.49	results	1	NA	ss_adjusted_total_ipd	NA
10.2217/cer.15.49	results	1	NA	ss_total_nonipd	NA
10.2217/cer.15.49	results	1	NA	ss_anchor_nonipd	NA
10.2217/cer.15.49	results	1	NA	ss_anchor_ipd	NA
10.2217/cer.15.49	results	1	NA	ss_adjusted_anchor_ipd	NA
10.2217/cer.15.49	results	1	NA	effect_cutoff	0
10.2217/cer.15.49	results	1	NA	unadjusted_pval	0.216
10.2217/cer.15.49	results	1	NA	unadjusted_num_pval	0.216
10.2217/cer.15.49	results	1	NA	unadjusted_significant	FALSE
10.2217/cer.15.49	results	1	NA	adjusted_pval	0.537
10.2217/cer.15.49	results	1	NA	adjusted_num_pval	0.537
10.2217/cer.15.49	results	1	NA	adjusted_significant	FALSE
10.2217/cer.15.49	results	2	NA	contrast_effect_type	Rate difference
10.2217/cer.15.49	results	2	NA	direction_benefit	superior
10.2217/cer.15.49	results	2	NA	ss_ttt_nonipd	492
10.2217/cer.15.49	results	2	NA	ss_ttt_ipd	74
10.2217/cer.15.49	results	2	NA	ss_adjusted_ttt_ipd	NA
10.2217/cer.15.49	results	2	NA	weights_yn	Not mentioned
10.2217/cer.15.49	results	2	NA	covariates_yn	Yes
10.2217/cer.15.49	results	2	NA	covariates_n	4
10.2217/cer.15.49	results	2	NA	covariates_names	Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Other(s)
10.2217/cer.15.49	results	2	NA	contrast_effect_direction	Numerator if ratio, or left side if difference
10.2217/cer.15.49	results	2	NA	contrast_effect_unadjusted_value	21.30
10.2217/cer.15.49	results	2	NA	contrast_effect_unadjusted_pvalci	<0.001
10.2217/cer.15.49	results	2	NA	contrast_effect_adjusted_value	18.90
10.2217/cer.15.49	results	2	NA	contrast_effect_adjusted_pvalci	<0.001
10.2217/cer.15.49	results	2	NA	adjustment_geographical	No
10.2217/cer.15.49	results	2	NA	ss_total_ipd	NA
10.2217/cer.15.49	results	2	NA	ss_adjusted_total_ipd	NA
10.2217/cer.15.49	results	2	NA	ss_total_nonipd	NA
10.2217/cer.15.49	results	2	NA	ss_anchor_nonipd	NA
10.2217/cer.15.49	results	2	NA	ss_anchor_ipd	NA
10.2217/cer.15.49	results	2	NA	ss_adjusted_anchor_ipd	NA
10.2217/cer.15.49	results	2	NA	effect_cutoff	0
10.2217/cer.15.49	results	2	NA	unadjusted_pval	<0.001
10.2217/cer.15.49	results	2	NA	unadjusted_significant	TRUE
10.2217/cer.15.49	results	2	NA	adjusted_pval	<0.001
10.2217/cer.15.49	results	2	NA	adjusted_significant	TRUE
10.2217/cer.15.49	study_information	NA	1	ipd_yn	Yes
10.2217/cer.15.49	study_information	NA	1	ct_yn	Yes
10.2217/cer.15.49	study_information	NA	1	nct	NCT02032901
10.2217/cer.15.49	study_information	NA	1	country_study	international
10.2217/cer.15.49	study_information	NA	1	ct_phase	3
10.2217/cer.15.49	study_information	NA	1	ct_arms	1
10.2217/cer.15.49	study_information	NA	2	ipd_yn	No
10.2217/cer.15.49	study_information	NA	2	ct_yn	Yes
10.2217/cer.15.49	study_information	NA	2	nct	NCT01682720
10.2217/cer.15.49	study_information	NA	2	country_study	international
10.2217/cer.15.49	study_information	NA	2	ct_phase	3
10.2217/cer.15.49	study_information	NA	2	ct_arms	2 or more
10.2217/cer.15.49	study_information	NA	3	ipd_yn	No
10.2217/cer.15.49	study_information	NA	3	ct_yn	Yes
10.2217/cer.15.49	study_information	NA	3	data_source_name	ferenci et al. (2008)
10.2217/cer.15.49	study_information	NA	3	country_study	unknown
10.2217/cer.15.49	study_information	NA	3	ct_arms	2 or more
10.2217/cer.15.49	study_information	NA	4	ipd_yn	No
10.2217/cer.15.49	study_information	NA	4	ct_yn	Yes
10.2217/cer.15.49	study_information	NA	4	nct	NCT00077636
10.2217/cer.15.49	study_information	NA	4	country_study	international
10.2217/cer.15.49	study_information	NA	4	ct_phase	4
10.2217/cer.15.49	study_information	NA	4	ct_arms	1
10.2217/cer.15.69	general_information	NA	NA	condition_name	hepatitis c virus genotype 1b
10.2217/cer.15.69	general_information	NA	NA	country_first_author	usa
10.2217/cer.15.69	general_information	NA	NA	country_last_author	usa
10.2217/cer.15.69	general_information	NA	NA	positions	Pharmaceutical Industry, Private Data Analysis Company
10.2217/cer.15.69	general_information	NA	NA	methodologist_yn	Yes
10.2217/cer.15.69	general_information	NA	NA	funding_source	Pharmaceutical Industry
10.2217/cer.15.69	general_information	NA	NA	pharmaceutical_ties_yn	Yes
10.2217/cer.15.69	general_information	NA	NA	systematic_review_yn	Yes
10.2217/cer.15.69	methodology	1	NA	outcome_name	sustained virologic response at week 12 post-treatment
10.2217/cer.15.69	methodology	1	NA	outcome_short_name	SVR rate
10.2217/cer.15.69	methodology	1	NA	outcome_variable_type	Binary (eg rates)
10.2217/cer.15.69	methodology	1	NA	treatment_name_ipd	daclatasvir + asunaprevir
10.2217/cer.15.69	methodology	1	NA	studies_number_ipd	1;2
10.2217/cer.15.69	methodology	1	NA	treatment_name_nonipd	sofosbuvir + ledipasvir
10.2217/cer.15.69	methodology	1	NA	studies_number_nonipd	3
10.2217/cer.15.69	methodology	1	NA	paic_type	MAIC
10.2217/cer.15.69	methodology	1	NA	anchored_yn	No
10.2217/cer.15.69	methodology	1	NA	paic_form	Simple (ie treatments effects extracted from two studies)
10.2217/cer.15.69	methodology	1	NA	primary_outcome_yn	Yes
10.2217/cer.15.69	methodology	1	NA	variables_selection_justification	Nothing mentioned, not reported
10.2217/cer.15.69	methodology	1	NA	pf_yn	No discussion (in the main text) of the status of prognostic factors of the variables
10.2217/cer.15.69	methodology	1	NA	tem_yn	No discussion (in the main text) of the status of treatment-effect modifiers of the variables
10.2217/cer.15.69	methodology	1	NA	adjustment_model_details_yn	No
10.2217/cer.15.69	methodology	1	NA	scale_choice_yn	No
10.2217/cer.15.69	results	1	NA	contrast_effect_type	Rate difference
10.2217/cer.15.69	results	1	NA	direction_benefit	superior
10.2217/cer.15.69	results	1	NA	ss_ttt_nonipd	171
10.2217/cer.15.69	results	1	NA	ss_ttt_ipd	252
10.2217/cer.15.69	results	1	NA	ss_adjusted_ttt_ipd	NA
10.2217/cer.15.69	results	1	NA	weights_yn	Not mentioned
10.2217/cer.15.69	results	1	NA	covariates_yn	Yes
10.2217/cer.15.69	results	1	NA	covariates_n	11
10.2217/cer.15.69	results	1	NA	covariates_names	Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Past treatments for the disease of interest, Other(s)
10.2217/cer.15.69	results	1	NA	contrast_effect_direction	Numerator if ratio, or left side if difference
10.2217/cer.15.69	results	1	NA	contrast_effect_unadjusted_value	NA
10.2217/cer.15.69	results	1	NA	contrast_effect_unadjusted_pvalci	0.004
10.2217/cer.15.69	results	1	NA	contrast_effect_adjusted_value	NA
10.2217/cer.15.69	results	1	NA	contrast_effect_adjusted_pvalci	0.398
10.2217/cer.15.69	results	1	NA	adjustment_geographical	No
10.2217/cer.15.69	results	1	NA	ss_total_ipd	NA
10.2217/cer.15.69	results	1	NA	ss_adjusted_total_ipd	NA
10.2217/cer.15.69	results	1	NA	ss_total_nonipd	NA
10.2217/cer.15.69	results	1	NA	ss_anchor_nonipd	NA
10.2217/cer.15.69	results	1	NA	ss_anchor_ipd	NA
10.2217/cer.15.69	results	1	NA	ss_adjusted_anchor_ipd	NA
10.2217/cer.15.69	results	1	NA	effect_cutoff	0
10.2217/cer.15.69	results	1	NA	unadjusted_pval	0.004
10.2217/cer.15.69	results	1	NA	unadjusted_num_pval	0.004
10.2217/cer.15.69	results	1	NA	unadjusted_significant	TRUE
10.2217/cer.15.69	results	1	NA	adjusted_pval	0.398
10.2217/cer.15.69	results	1	NA	adjusted_num_pval	0.398
10.2217/cer.15.69	results	1	NA	adjusted_significant	FALSE
10.2217/cer.15.69	study_information	NA	1	ipd_yn	Yes
10.2217/cer.15.69	study_information	NA	1	ct_yn	Yes
10.2217/cer.15.69	study_information	NA	1	nct	NCT01497834
10.2217/cer.15.69	study_information	NA	1	country_study	japan
10.2217/cer.15.69	study_information	NA	1	ct_phase	3
10.2217/cer.15.69	study_information	NA	1	ct_arms	1
10.2217/cer.15.69	study_information	NA	2	ipd_yn	Yes
10.2217/cer.15.69	study_information	NA	2	ct_yn	Yes
10.2217/cer.15.69	study_information	NA	2	nct	NCT01718145
10.2217/cer.15.69	study_information	NA	2	country_study	japan
10.2217/cer.15.69	study_information	NA	2	ct_phase	3
10.2217/cer.15.69	study_information	NA	2	ct_arms	2 or more
10.2217/cer.15.69	study_information	NA	3	ipd_yn	No
10.2217/cer.15.69	study_information	NA	3	ct_yn	Yes
10.2217/cer.15.69	study_information	NA	3	nct	NCT01975675
10.2217/cer.15.69	study_information	NA	3	country_study	japan
10.2217/cer.15.69	study_information	NA	3	ct_phase	3
10.2217/cer.15.69	study_information	NA	3	ct_arms	2 or more
10.2217/fon-2020-0823	general_information	NA	NA	condition_name	advanced cutaneous squamous cell carcinoma
10.2217/fon-2020-0823	general_information	NA	NA	country_first_author	canada
10.2217/fon-2020-0823	general_information	NA	NA	country_last_author	usa
10.2217/fon-2020-0823	general_information	NA	NA	positions	Academic, Pharmaceutical Industry, Private Data Analysis Company
10.2217/fon-2020-0823	general_information	NA	NA	methodologist_yn	Yes
10.2217/fon-2020-0823	general_information	NA	NA	funding_source	Pharmaceutical Industry
10.2217/fon-2020-0823	general_information	NA	NA	pharmaceutical_ties_yn	Yes
10.2217/fon-2020-0823	general_information	NA	NA	systematic_review_yn	Yes
10.2217/fon-2020-0823	methodology	1	NA	outcome_name	overall survival
10.2217/fon-2020-0823	methodology	1	NA	outcome_short_name	Overall Survival
10.2217/fon-2020-0823	methodology	1	NA	outcome_variable_type	Time-to-event
10.2217/fon-2020-0823	methodology	1	NA	treatment_name_ipd	cemiplimab
10.2217/fon-2020-0823	methodology	1	NA	studies_number_ipd	1
10.2217/fon-2020-0823	methodology	1	NA	treatment_name_nonipd	erlotinib
10.2217/fon-2020-0823	methodology	1	NA	studies_number_nonipd	2
10.2217/fon-2020-0823	methodology	1	NA	paic_type	MAIC
10.2217/fon-2020-0823	methodology	1	NA	anchored_yn	No
10.2217/fon-2020-0823	methodology	1	NA	paic_form	Simple (ie treatments effects extracted from two studies)
10.2217/fon-2020-0823	methodology	1	NA	primary_outcome_yn	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.2217/fon-2020-0823	methodology	1	NA	variables_selection_justification	Literature based (clinically or methodologically relevant to adjust on these variables based on the literature search conducted for this specific purpose)
10.2217/fon-2020-0823	methodology	1	NA	pf_yn	Yes
10.2217/fon-2020-0823	methodology	1	NA	tem_yn	No discussion (in the main text) of the status of treatment-effect modifiers of the variables
10.2217/fon-2020-0823	methodology	1	NA	adjustment_model_details_yn	No
10.2217/fon-2020-0823	methodology	1	NA	scale_choice_yn	No
10.2217/fon-2020-0823	methodology	10	NA	outcome_name	overall survival
10.2217/fon-2020-0823	methodology	10	NA	outcome_short_name	Overall Survival
10.2217/fon-2020-0823	methodology	10	NA	outcome_variable_type	Time-to-event
10.2217/fon-2020-0823	methodology	10	NA	treatment_name_ipd	cemiplimab
10.2217/fon-2020-0823	methodology	10	NA	studies_number_ipd	1
10.2217/fon-2020-0823	methodology	10	NA	treatment_name_nonipd	gefitinib
10.2217/fon-2020-0823	methodology	10	NA	studies_number_nonipd	6
10.2217/fon-2020-0823	methodology	10	NA	paic_type	STC
10.2217/fon-2020-0823	methodology	10	NA	anchored_yn	No
10.2217/fon-2020-0823	methodology	10	NA	paic_form	Simple (ie treatments effects extracted from two studies)
10.2217/fon-2020-0823	methodology	10	NA	primary_outcome_yn	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.2217/fon-2020-0823	methodology	10	NA	variables_selection_justification	Literature based (clinically or methodologically relevant to adjust on these variables based on the literature search conducted for this specific purpose)
10.2217/fon-2020-0823	methodology	10	NA	pf_yn	Yes
10.2217/fon-2020-0823	methodology	10	NA	tem_yn	No discussion (in the main text) of the status of treatment-effect modifiers of the variables
10.2217/fon-2020-0823	methodology	10	NA	adjustment_model_details_yn	No
10.2217/fon-2020-0823	methodology	10	NA	scale_choice_yn	No
10.2217/fon-2020-0823	methodology	11	NA	outcome_name	overall survival
10.2217/fon-2020-0823	methodology	11	NA	outcome_short_name	Overall Survival
10.2217/fon-2020-0823	methodology	11	NA	outcome_variable_type	Time-to-event
10.2217/fon-2020-0823	methodology	11	NA	treatment_name_ipd	cemiplimab
10.2217/fon-2020-0823	methodology	11	NA	studies_number_ipd	1
10.2217/fon-2020-0823	methodology	11	NA	treatment_name_nonipd	dacomitinib
10.2217/fon-2020-0823	methodology	11	NA	studies_number_nonipd	7
10.2217/fon-2020-0823	methodology	11	NA	paic_type	MAIC
10.2217/fon-2020-0823	methodology	11	NA	anchored_yn	No
10.2217/fon-2020-0823	methodology	11	NA	paic_form	Simple (ie treatments effects extracted from two studies)
10.2217/fon-2020-0823	methodology	11	NA	primary_outcome_yn	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.2217/fon-2020-0823	methodology	11	NA	variables_selection_justification	Literature based (clinically or methodologically relevant to adjust on these variables based on the literature search conducted for this specific purpose)
10.2217/fon-2020-0823	methodology	11	NA	pf_yn	Yes
10.2217/fon-2020-0823	methodology	11	NA	tem_yn	No discussion (in the main text) of the status of treatment-effect modifiers of the variables
10.2217/fon-2020-0823	methodology	11	NA	adjustment_model_details_yn	No
10.2217/fon-2020-0823	methodology	11	NA	scale_choice_yn	No
10.2217/fon-2020-0823	methodology	12	NA	outcome_name	overall survival
10.2217/fon-2020-0823	methodology	12	NA	outcome_short_name	Overall Survival
10.2217/fon-2020-0823	methodology	12	NA	outcome_variable_type	Time-to-event
10.2217/fon-2020-0823	methodology	12	NA	treatment_name_ipd	cemiplimab
10.2217/fon-2020-0823	methodology	12	NA	studies_number_ipd	1
10.2217/fon-2020-0823	methodology	12	NA	treatment_name_nonipd	dacomitinib
10.2217/fon-2020-0823	methodology	12	NA	studies_number_nonipd	7
10.2217/fon-2020-0823	methodology	12	NA	paic_type	STC
10.2217/fon-2020-0823	methodology	12	NA	anchored_yn	No
10.2217/fon-2020-0823	methodology	12	NA	paic_form	Simple (ie treatments effects extracted from two studies)
10.2217/fon-2020-0823	methodology	12	NA	primary_outcome_yn	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.2217/fon-2020-0823	methodology	12	NA	variables_selection_justification	Literature based (clinically or methodologically relevant to adjust on these variables based on the literature search conducted for this specific purpose)
10.2217/fon-2020-0823	methodology	12	NA	pf_yn	Yes
10.2217/fon-2020-0823	methodology	12	NA	tem_yn	No discussion (in the main text) of the status of treatment-effect modifiers of the variables
10.2217/fon-2020-0823	methodology	12	NA	adjustment_model_details_yn	No
10.2217/fon-2020-0823	methodology	12	NA	scale_choice_yn	No
10.2217/fon-2020-0823	methodology	13	NA	outcome_name	overall survival
10.2217/fon-2020-0823	methodology	13	NA	outcome_short_name	Overall Survival
10.2217/fon-2020-0823	methodology	13	NA	outcome_variable_type	Time-to-event
10.2217/fon-2020-0823	methodology	13	NA	treatment_name_ipd	cemiplimab
10.2217/fon-2020-0823	methodology	13	NA	studies_number_ipd	1
10.2217/fon-2020-0823	methodology	13	NA	treatment_name_nonipd	panitumumab
10.2217/fon-2020-0823	methodology	13	NA	studies_number_nonipd	8
10.2217/fon-2020-0823	methodology	13	NA	paic_type	MAIC
10.2217/fon-2020-0823	methodology	13	NA	anchored_yn	No
10.2217/fon-2020-0823	methodology	13	NA	paic_form	Simple (ie treatments effects extracted from two studies)
10.2217/fon-2020-0823	methodology	13	NA	primary_outcome_yn	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.2217/fon-2020-0823	methodology	13	NA	variables_selection_justification	Literature based (clinically or methodologically relevant to adjust on these variables based on the literature search conducted for this specific purpose)
10.2217/fon-2020-0823	methodology	13	NA	pf_yn	Yes
10.2217/fon-2020-0823	methodology	13	NA	tem_yn	No discussion (in the main text) of the status of treatment-effect modifiers of the variables
10.2217/fon-2020-0823	methodology	13	NA	adjustment_model_details_yn	No
10.2217/fon-2020-0823	methodology	13	NA	scale_choice_yn	No
10.2217/fon-2020-0823	methodology	14	NA	outcome_name	overall survival
10.2217/fon-2020-0823	methodology	14	NA	outcome_short_name	Overall Survival
10.2217/fon-2020-0823	methodology	14	NA	outcome_variable_type	Time-to-event
10.2217/fon-2020-0823	methodology	14	NA	treatment_name_ipd	cemiplimab
10.2217/fon-2020-0823	methodology	14	NA	studies_number_ipd	1
10.2217/fon-2020-0823	methodology	14	NA	treatment_name_nonipd	panitumumab
10.2217/fon-2020-0823	methodology	14	NA	studies_number_nonipd	8
10.2217/fon-2020-0823	methodology	14	NA	paic_type	STC
10.2217/fon-2020-0823	methodology	14	NA	anchored_yn	No
10.2217/fon-2020-0823	methodology	14	NA	paic_form	Simple (ie treatments effects extracted from two studies)
10.2217/fon-2020-0823	methodology	14	NA	primary_outcome_yn	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.2217/fon-2020-0823	methodology	14	NA	variables_selection_justification	Literature based (clinically or methodologically relevant to adjust on these variables based on the literature search conducted for this specific purpose)
10.2217/fon-2020-0823	methodology	14	NA	pf_yn	Yes
10.2217/fon-2020-0823	methodology	14	NA	tem_yn	No discussion (in the main text) of the status of treatment-effect modifiers of the variables
10.2217/fon-2020-0823	methodology	14	NA	adjustment_model_details_yn	No
10.2217/fon-2020-0823	methodology	14	NA	scale_choice_yn	No
10.2217/fon-2020-0823	methodology	15	NA	outcome_name	overall survival
10.2217/fon-2020-0823	methodology	15	NA	outcome_short_name	Overall Survival
10.2217/fon-2020-0823	methodology	15	NA	outcome_variable_type	Time-to-event
10.2217/fon-2020-0823	methodology	15	NA	treatment_name_ipd	cemiplimab
10.2217/fon-2020-0823	methodology	15	NA	studies_number_ipd	1
10.2217/fon-2020-0823	methodology	15	NA	treatment_name_nonipd	pembrolizumab
10.2217/fon-2020-0823	methodology	15	NA	studies_number_nonipd	9
10.2217/fon-2020-0823	methodology	15	NA	paic_type	MAIC
10.2217/fon-2020-0823	methodology	15	NA	anchored_yn	No
10.2217/fon-2020-0823	methodology	15	NA	paic_form	Simple (ie treatments effects extracted from two studies)
10.2217/fon-2020-0823	methodology	15	NA	primary_outcome_yn	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.2217/fon-2020-0823	methodology	15	NA	variables_selection_justification	Literature based (clinically or methodologically relevant to adjust on these variables based on the literature search conducted for this specific purpose)
10.2217/fon-2020-0823	methodology	15	NA	pf_yn	Yes
10.2217/fon-2020-0823	methodology	15	NA	tem_yn	No discussion (in the main text) of the status of treatment-effect modifiers of the variables
10.2217/fon-2020-0823	methodology	15	NA	adjustment_model_details_yn	No
10.2217/fon-2020-0823	methodology	15	NA	scale_choice_yn	No
10.2217/fon-2020-0823	methodology	16	NA	outcome_name	overall survival
10.2217/fon-2020-0823	methodology	16	NA	outcome_short_name	Overall Survival
10.2217/fon-2020-0823	methodology	16	NA	outcome_variable_type	Time-to-event
10.2217/fon-2020-0823	methodology	16	NA	treatment_name_ipd	cemiplimab
10.2217/fon-2020-0823	methodology	16	NA	studies_number_ipd	1
10.2217/fon-2020-0823	methodology	16	NA	treatment_name_nonipd	pembrolizumab
10.2217/fon-2020-0823	methodology	16	NA	studies_number_nonipd	9
10.2217/fon-2020-0823	methodology	16	NA	paic_type	STC
10.2217/fon-2020-0823	methodology	16	NA	anchored_yn	No
10.2217/fon-2020-0823	methodology	16	NA	paic_form	Simple (ie treatments effects extracted from two studies)
10.2217/fon-2020-0823	methodology	16	NA	primary_outcome_yn	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.2217/fon-2020-0823	methodology	16	NA	variables_selection_justification	Literature based (clinically or methodologically relevant to adjust on these variables based on the literature search conducted for this specific purpose)
10.2217/fon-2020-0823	methodology	16	NA	pf_yn	Yes
10.2217/fon-2020-0823	methodology	16	NA	tem_yn	No discussion (in the main text) of the status of treatment-effect modifiers of the variables
10.2217/fon-2020-0823	methodology	16	NA	adjustment_model_details_yn	No
10.2217/fon-2020-0823	methodology	16	NA	scale_choice_yn	No
10.2217/fon-2020-0823	methodology	17	NA	outcome_name	overall survival
10.2217/fon-2020-0823	methodology	17	NA	outcome_short_name	Overall Survival
10.2217/fon-2020-0823	methodology	17	NA	outcome_variable_type	Time-to-event
10.2217/fon-2020-0823	methodology	17	NA	treatment_name_ipd	cemiplimab
10.2217/fon-2020-0823	methodology	17	NA	studies_number_ipd	1
10.2217/fon-2020-0823	methodology	17	NA	treatment_name_nonipd	pembrolizumab
10.2217/fon-2020-0823	methodology	17	NA	studies_number_nonipd	10
10.2217/fon-2020-0823	methodology	17	NA	paic_type	MAIC
10.2217/fon-2020-0823	methodology	17	NA	anchored_yn	No
10.2217/fon-2020-0823	methodology	17	NA	paic_form	Simple (ie treatments effects extracted from two studies)
10.2217/fon-2020-0823	methodology	17	NA	primary_outcome_yn	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.2217/fon-2020-0823	methodology	17	NA	variables_selection_justification	Literature based (clinically or methodologically relevant to adjust on these variables based on the literature search conducted for this specific purpose)
10.2217/fon-2020-0823	methodology	17	NA	pf_yn	Yes
10.2217/fon-2020-0823	methodology	17	NA	tem_yn	No discussion (in the main text) of the status of treatment-effect modifiers of the variables
10.2217/fon-2020-0823	methodology	17	NA	adjustment_model_details_yn	No
10.2217/fon-2020-0823	methodology	17	NA	scale_choice_yn	No
10.2217/fon-2020-0823	methodology	18	NA	outcome_name	overall survival
10.2217/fon-2020-0823	methodology	18	NA	outcome_short_name	Overall Survival
10.2217/fon-2020-0823	methodology	18	NA	outcome_variable_type	Time-to-event
10.2217/fon-2020-0823	methodology	18	NA	treatment_name_ipd	cemiplimab
10.2217/fon-2020-0823	methodology	18	NA	studies_number_ipd	1
10.2217/fon-2020-0823	methodology	18	NA	treatment_name_nonipd	pembrolizumab
10.2217/fon-2020-0823	methodology	18	NA	studies_number_nonipd	10
10.2217/fon-2020-0823	methodology	18	NA	paic_type	STC
10.2217/fon-2020-0823	methodology	18	NA	anchored_yn	No
10.2217/fon-2020-0823	methodology	18	NA	paic_form	Simple (ie treatments effects extracted from two studies)
10.2217/fon-2020-0823	methodology	18	NA	primary_outcome_yn	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.2217/fon-2020-0823	methodology	18	NA	variables_selection_justification	Literature based (clinically or methodologically relevant to adjust on these variables based on the literature search conducted for this specific purpose)
10.2217/fon-2020-0823	methodology	18	NA	pf_yn	Yes
10.2217/fon-2020-0823	methodology	18	NA	tem_yn	No discussion (in the main text) of the status of treatment-effect modifiers of the variables
10.2217/fon-2020-0823	methodology	18	NA	adjustment_model_details_yn	No
10.2217/fon-2020-0823	methodology	18	NA	scale_choice_yn	No
10.2217/fon-2020-0823	methodology	19	NA	outcome_name	overall survival
10.2217/fon-2020-0823	methodology	19	NA	outcome_short_name	Overall Survival
10.2217/fon-2020-0823	methodology	19	NA	outcome_variable_type	Time-to-event
10.2217/fon-2020-0823	methodology	19	NA	treatment_name_ipd	cemiplimab
10.2217/fon-2020-0823	methodology	19	NA	studies_number_ipd	1
10.2217/fon-2020-0823	methodology	19	NA	treatment_name_nonipd	cetuximab
10.2217/fon-2020-0823	methodology	19	NA	studies_number_nonipd	11
10.2217/fon-2020-0823	methodology	19	NA	paic_type	MAIC
10.2217/fon-2020-0823	methodology	19	NA	anchored_yn	No
10.2217/fon-2020-0823	methodology	19	NA	paic_form	Simple (ie treatments effects extracted from two studies)
10.2217/fon-2020-0823	methodology	19	NA	primary_outcome_yn	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.2217/fon-2020-0823	methodology	19	NA	variables_selection_justification	Literature based (clinically or methodologically relevant to adjust on these variables based on the literature search conducted for this specific purpose)
10.2217/fon-2020-0823	methodology	19	NA	pf_yn	Yes
10.2217/fon-2020-0823	methodology	19	NA	tem_yn	No discussion (in the main text) of the status of treatment-effect modifiers of the variables
10.2217/fon-2020-0823	methodology	19	NA	adjustment_model_details_yn	No
10.2217/fon-2020-0823	methodology	19	NA	scale_choice_yn	No
10.2217/fon-2020-0823	methodology	2	NA	outcome_name	overall survival
10.2217/fon-2020-0823	methodology	2	NA	outcome_short_name	Overall Survival
10.2217/fon-2020-0823	methodology	2	NA	outcome_variable_type	Time-to-event
10.2217/fon-2020-0823	methodology	2	NA	treatment_name_ipd	cemiplimab
10.2217/fon-2020-0823	methodology	2	NA	studies_number_ipd	1
10.2217/fon-2020-0823	methodology	2	NA	treatment_name_nonipd	erlotinib
10.2217/fon-2020-0823	methodology	2	NA	studies_number_nonipd	2
10.2217/fon-2020-0823	methodology	2	NA	paic_type	STC
10.2217/fon-2020-0823	methodology	2	NA	anchored_yn	No
10.2217/fon-2020-0823	methodology	2	NA	paic_form	Simple (ie treatments effects extracted from two studies)
10.2217/fon-2020-0823	methodology	2	NA	primary_outcome_yn	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.2217/fon-2020-0823	methodology	2	NA	variables_selection_justification	Literature based (clinically or methodologically relevant to adjust on these variables based on the literature search conducted for this specific purpose)
10.2217/fon-2020-0823	methodology	2	NA	pf_yn	Yes
10.2217/fon-2020-0823	methodology	2	NA	tem_yn	No discussion (in the main text) of the status of treatment-effect modifiers of the variables
10.2217/fon-2020-0823	methodology	2	NA	adjustment_model_details_yn	No
10.2217/fon-2020-0823	methodology	2	NA	scale_choice_yn	No
10.2217/fon-2020-0823	methodology	20	NA	outcome_name	overall survival
10.2217/fon-2020-0823	methodology	20	NA	outcome_short_name	Overall Survival
10.2217/fon-2020-0823	methodology	20	NA	outcome_variable_type	Time-to-event
10.2217/fon-2020-0823	methodology	20	NA	treatment_name_ipd	cemiplimab
10.2217/fon-2020-0823	methodology	20	NA	studies_number_ipd	1
10.2217/fon-2020-0823	methodology	20	NA	treatment_name_nonipd	cetuximab
10.2217/fon-2020-0823	methodology	20	NA	studies_number_nonipd	11
10.2217/fon-2020-0823	methodology	20	NA	paic_type	STC
10.2217/fon-2020-0823	methodology	20	NA	anchored_yn	No
10.2217/fon-2020-0823	methodology	20	NA	paic_form	Simple (ie treatments effects extracted from two studies)
10.2217/fon-2020-0823	methodology	20	NA	primary_outcome_yn	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.2217/fon-2020-0823	methodology	20	NA	variables_selection_justification	Literature based (clinically or methodologically relevant to adjust on these variables based on the literature search conducted for this specific purpose)
10.2217/fon-2020-0823	methodology	20	NA	pf_yn	Yes
10.2217/fon-2020-0823	methodology	20	NA	tem_yn	No discussion (in the main text) of the status of treatment-effect modifiers of the variables
10.2217/fon-2020-0823	methodology	20	NA	adjustment_model_details_yn	No
10.2217/fon-2020-0823	methodology	20	NA	scale_choice_yn	No
10.2217/fon-2020-0823	methodology	3	NA	outcome_name	overall survival
10.2217/fon-2020-0823	methodology	3	NA	outcome_short_name	Overall Survival
10.2217/fon-2020-0823	methodology	3	NA	outcome_variable_type	Time-to-event
10.2217/fon-2020-0823	methodology	3	NA	treatment_name_ipd	cemiplimab
10.2217/fon-2020-0823	methodology	3	NA	studies_number_ipd	1
10.2217/fon-2020-0823	methodology	3	NA	treatment_name_nonipd	platinum-based chemotherapy
10.2217/fon-2020-0823	methodology	3	NA	studies_number_nonipd	3
10.2217/fon-2020-0823	methodology	3	NA	paic_type	MAIC
10.2217/fon-2020-0823	methodology	3	NA	anchored_yn	No
10.2217/fon-2020-0823	methodology	3	NA	paic_form	Simple (ie treatments effects extracted from two studies)
10.2217/fon-2020-0823	methodology	3	NA	primary_outcome_yn	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.2217/fon-2020-0823	methodology	3	NA	variables_selection_justification	Literature based (clinically or methodologically relevant to adjust on these variables based on the literature search conducted for this specific purpose)
10.2217/fon-2020-0823	methodology	3	NA	pf_yn	Yes
10.2217/fon-2020-0823	methodology	3	NA	tem_yn	No discussion (in the main text) of the status of treatment-effect modifiers of the variables
10.2217/fon-2020-0823	methodology	3	NA	adjustment_model_details_yn	No
10.2217/fon-2020-0823	methodology	3	NA	scale_choice_yn	No
10.2217/fon-2020-0823	methodology	4	NA	outcome_name	overall survival
10.2217/fon-2020-0823	methodology	4	NA	outcome_short_name	Overall Survival
10.2217/fon-2020-0823	methodology	4	NA	outcome_variable_type	Time-to-event
10.2217/fon-2020-0823	methodology	4	NA	treatment_name_ipd	cemiplimab
10.2217/fon-2020-0823	methodology	4	NA	studies_number_ipd	1
10.2217/fon-2020-0823	methodology	4	NA	treatment_name_nonipd	platinum-based chemotherapy
10.2217/fon-2020-0823	methodology	4	NA	studies_number_nonipd	3
10.2217/fon-2020-0823	methodology	4	NA	paic_type	STC
10.2217/fon-2020-0823	methodology	4	NA	anchored_yn	No
10.2217/fon-2020-0823	methodology	4	NA	paic_form	Simple (ie treatments effects extracted from two studies)
10.2217/fon-2020-0823	methodology	4	NA	primary_outcome_yn	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.2217/fon-2020-0823	methodology	4	NA	variables_selection_justification	Literature based (clinically or methodologically relevant to adjust on these variables based on the literature search conducted for this specific purpose)
10.2217/fon-2020-0823	methodology	4	NA	pf_yn	Yes
10.2217/fon-2020-0823	methodology	4	NA	tem_yn	No discussion (in the main text) of the status of treatment-effect modifiers of the variables
10.2217/fon-2020-0823	methodology	4	NA	adjustment_model_details_yn	No
10.2217/fon-2020-0823	methodology	4	NA	scale_choice_yn	No
10.2217/fon-2020-0823	methodology	5	NA	outcome_name	overall survival
10.2217/fon-2020-0823	methodology	5	NA	outcome_short_name	Overall Survival
10.2217/fon-2020-0823	methodology	5	NA	outcome_variable_type	Time-to-event
10.2217/fon-2020-0823	methodology	5	NA	treatment_name_ipd	cemiplimab
10.2217/fon-2020-0823	methodology	5	NA	studies_number_ipd	1
10.2217/fon-2020-0823	methodology	5	NA	treatment_name_nonipd	cetuximab
10.2217/fon-2020-0823	methodology	5	NA	studies_number_nonipd	4
10.2217/fon-2020-0823	methodology	5	NA	paic_type	MAIC
10.2217/fon-2020-0823	methodology	5	NA	anchored_yn	No
10.2217/fon-2020-0823	methodology	5	NA	paic_form	Simple (ie treatments effects extracted from two studies)
10.2217/fon-2020-0823	methodology	5	NA	primary_outcome_yn	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.2217/fon-2020-0823	methodology	5	NA	variables_selection_justification	Literature based (clinically or methodologically relevant to adjust on these variables based on the literature search conducted for this specific purpose)
10.2217/fon-2020-0823	methodology	5	NA	pf_yn	Yes
10.2217/fon-2020-0823	methodology	5	NA	tem_yn	No discussion (in the main text) of the status of treatment-effect modifiers of the variables
10.2217/fon-2020-0823	methodology	5	NA	adjustment_model_details_yn	No
10.2217/fon-2020-0823	methodology	5	NA	scale_choice_yn	No
10.2217/fon-2020-0823	methodology	6	NA	outcome_name	overall survival
10.2217/fon-2020-0823	methodology	6	NA	outcome_short_name	Overall Survival
10.2217/fon-2020-0823	methodology	6	NA	outcome_variable_type	Time-to-event
10.2217/fon-2020-0823	methodology	6	NA	treatment_name_ipd	cemiplimab
10.2217/fon-2020-0823	methodology	6	NA	studies_number_ipd	1
10.2217/fon-2020-0823	methodology	6	NA	treatment_name_nonipd	cetuximab
10.2217/fon-2020-0823	methodology	6	NA	studies_number_nonipd	4
10.2217/fon-2020-0823	methodology	6	NA	paic_type	STC
10.2217/fon-2020-0823	methodology	6	NA	anchored_yn	No
10.2217/fon-2020-0823	methodology	6	NA	paic_form	Simple (ie treatments effects extracted from two studies)
10.2217/fon-2020-0823	methodology	6	NA	primary_outcome_yn	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.2217/fon-2020-0823	methodology	6	NA	variables_selection_justification	Literature based (clinically or methodologically relevant to adjust on these variables based on the literature search conducted for this specific purpose)
10.2217/fon-2020-0823	methodology	6	NA	pf_yn	Yes
10.2217/fon-2020-0823	methodology	6	NA	tem_yn	No discussion (in the main text) of the status of treatment-effect modifiers of the variables
10.2217/fon-2020-0823	methodology	6	NA	adjustment_model_details_yn	No
10.2217/fon-2020-0823	methodology	6	NA	scale_choice_yn	No
10.2217/fon-2020-0823	methodology	7	NA	outcome_name	overall survival
10.2217/fon-2020-0823	methodology	7	NA	outcome_short_name	Overall Survival
10.2217/fon-2020-0823	methodology	7	NA	outcome_variable_type	Time-to-event
10.2217/fon-2020-0823	methodology	7	NA	treatment_name_ipd	cemiplimab
10.2217/fon-2020-0823	methodology	7	NA	studies_number_ipd	1
10.2217/fon-2020-0823	methodology	7	NA	treatment_name_nonipd	cetuximab
10.2217/fon-2020-0823	methodology	7	NA	studies_number_nonipd	5
10.2217/fon-2020-0823	methodology	7	NA	paic_type	MAIC
10.2217/fon-2020-0823	methodology	7	NA	anchored_yn	No
10.2217/fon-2020-0823	methodology	7	NA	paic_form	Simple (ie treatments effects extracted from two studies)
10.2217/fon-2020-0823	methodology	7	NA	primary_outcome_yn	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.2217/fon-2020-0823	methodology	7	NA	variables_selection_justification	Literature based (clinically or methodologically relevant to adjust on these variables based on the literature search conducted for this specific purpose)
10.2217/fon-2020-0823	methodology	7	NA	pf_yn	Yes
10.2217/fon-2020-0823	methodology	7	NA	tem_yn	No discussion (in the main text) of the status of treatment-effect modifiers of the variables
10.2217/fon-2020-0823	methodology	7	NA	adjustment_model_details_yn	No
10.2217/fon-2020-0823	methodology	7	NA	scale_choice_yn	No
10.2217/fon-2020-0823	methodology	8	NA	outcome_name	overall survival
10.2217/fon-2020-0823	methodology	8	NA	outcome_short_name	Overall Survival
10.2217/fon-2020-0823	methodology	8	NA	outcome_variable_type	Time-to-event
10.2217/fon-2020-0823	methodology	8	NA	treatment_name_ipd	cemiplimab
10.2217/fon-2020-0823	methodology	8	NA	studies_number_ipd	1
10.2217/fon-2020-0823	methodology	8	NA	treatment_name_nonipd	cetuximab
10.2217/fon-2020-0823	methodology	8	NA	studies_number_nonipd	5
10.2217/fon-2020-0823	methodology	8	NA	paic_type	STC
10.2217/fon-2020-0823	methodology	8	NA	anchored_yn	No
10.2217/fon-2020-0823	methodology	8	NA	paic_form	Simple (ie treatments effects extracted from two studies)
10.2217/fon-2020-0823	methodology	8	NA	primary_outcome_yn	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.2217/fon-2020-0823	methodology	8	NA	variables_selection_justification	Literature based (clinically or methodologically relevant to adjust on these variables based on the literature search conducted for this specific purpose)
10.2217/fon-2020-0823	methodology	8	NA	pf_yn	Yes
10.2217/fon-2020-0823	methodology	8	NA	tem_yn	No discussion (in the main text) of the status of treatment-effect modifiers of the variables
10.2217/fon-2020-0823	methodology	8	NA	adjustment_model_details_yn	No
10.2217/fon-2020-0823	methodology	8	NA	scale_choice_yn	No
10.2217/fon-2020-0823	methodology	9	NA	outcome_name	overall survival
10.2217/fon-2020-0823	methodology	9	NA	outcome_short_name	Overall Survival
10.2217/fon-2020-0823	methodology	9	NA	outcome_variable_type	Time-to-event
10.2217/fon-2020-0823	methodology	9	NA	treatment_name_ipd	cemiplimab
10.2217/fon-2020-0823	methodology	9	NA	studies_number_ipd	1
10.2217/fon-2020-0823	methodology	9	NA	treatment_name_nonipd	gefitinib
10.2217/fon-2020-0823	methodology	9	NA	studies_number_nonipd	6
10.2217/fon-2020-0823	methodology	9	NA	paic_type	MAIC
10.2217/fon-2020-0823	methodology	9	NA	anchored_yn	No
10.2217/fon-2020-0823	methodology	9	NA	paic_form	Simple (ie treatments effects extracted from two studies)
10.2217/fon-2020-0823	methodology	9	NA	primary_outcome_yn	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.2217/fon-2020-0823	methodology	9	NA	variables_selection_justification	Literature based (clinically or methodologically relevant to adjust on these variables based on the literature search conducted for this specific purpose)
10.2217/fon-2020-0823	methodology	9	NA	pf_yn	Yes
10.2217/fon-2020-0823	methodology	9	NA	tem_yn	No discussion (in the main text) of the status of treatment-effect modifiers of the variables
10.2217/fon-2020-0823	methodology	9	NA	adjustment_model_details_yn	No
10.2217/fon-2020-0823	methodology	9	NA	scale_choice_yn	No
10.2217/fon-2020-0823	results	1	NA	contrast_effect_type	HR
10.2217/fon-2020-0823	results	1	NA	direction_benefit	inferior
10.2217/fon-2020-0823	results	1	NA	ss_ttt_nonipd	39
10.2217/fon-2020-0823	results	1	NA	ss_ttt_ipd	193
10.2217/fon-2020-0823	results	1	NA	ss_adjusted_ttt_ipd	NA
10.2217/fon-2020-0823	results	1	NA	weights_yn	Yes, mentions that the weights distribution has been studied, but weights distribution not reported
10.2217/fon-2020-0823	results	1	NA	covariates_yn	Yes
10.2217/fon-2020-0823	results	1	NA	covariates_n	8
10.2217/fon-2020-0823	results	1	NA	covariates_names	Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Past treatments for the disease of interest
10.2217/fon-2020-0823	results	1	NA	contrast_effect_direction	Numerator if ratio, or left side if difference
10.2217/fon-2020-0823	results	1	NA	contrast_effect_unadjusted_value	0.28
10.2217/fon-2020-0823	results	1	NA	contrast_effect_unadjusted_pvalci	[0.16;0.50]
10.2217/fon-2020-0823	results	1	NA	contrast_effect_adjusted_value	0.41
10.2217/fon-2020-0823	results	1	NA	contrast_effect_adjusted_pvalci	[0.24;0.70]
10.2217/fon-2020-0823	results	1	NA	adjustment_geographical	NA
10.2217/fon-2020-0823	results	1	NA	ss_total_ipd	NA
10.2217/fon-2020-0823	results	1	NA	ss_adjusted_total_ipd	NA
10.2217/fon-2020-0823	results	1	NA	ss_total_nonipd	NA
10.2217/fon-2020-0823	results	1	NA	ss_anchor_nonipd	NA
10.2217/fon-2020-0823	results	1	NA	ss_anchor_ipd	NA
10.2217/fon-2020-0823	results	1	NA	ss_adjusted_anchor_ipd	NA
10.2217/fon-2020-0823	results	1	NA	effect_cutoff	1
10.2217/fon-2020-0823	results	1	NA	unadjusted_lb_ci	0.16
10.2217/fon-2020-0823	results	1	NA	unadjusted_ub_ci	0.5
10.2217/fon-2020-0823	results	1	NA	unadjusted_significant	TRUE
10.2217/fon-2020-0823	results	1	NA	adjusted_lb_ci	0.24
10.2217/fon-2020-0823	results	1	NA	adjusted_ub_ci	0.7
10.2217/fon-2020-0823	results	1	NA	adjusted_significant	TRUE
10.2217/fon-2020-0823	results	10	NA	contrast_effect_type	HR
10.2217/fon-2020-0823	results	10	NA	direction_benefit	inferior
10.2217/fon-2020-0823	results	10	NA	ss_ttt_nonipd	40
10.2217/fon-2020-0823	results	10	NA	ss_ttt_ipd	193
10.2217/fon-2020-0823	results	10	NA	ss_adjusted_ttt_ipd	193
10.2217/fon-2020-0823	results	10	NA	weights_yn	NA
10.2217/fon-2020-0823	results	10	NA	covariates_yn	Yes
10.2217/fon-2020-0823	results	10	NA	covariates_n	8
10.2217/fon-2020-0823	results	10	NA	covariates_names	Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Past treatments for the disease of interest
10.2217/fon-2020-0823	results	10	NA	contrast_effect_direction	Numerator if ratio, or left side if difference
10.2217/fon-2020-0823	results	10	NA	contrast_effect_unadjusted_value	0.27
10.2217/fon-2020-0823	results	10	NA	contrast_effect_unadjusted_pvalci	[0.16;0.44]
10.2217/fon-2020-0823	results	10	NA	contrast_effect_adjusted_value	0.29
10.2217/fon-2020-0823	results	10	NA	contrast_effect_adjusted_pvalci	[0.18;0.45]
10.2217/fon-2020-0823	results	10	NA	adjustment_geographical	NA
10.2217/fon-2020-0823	results	10	NA	ss_total_ipd	NA
10.2217/fon-2020-0823	results	10	NA	ss_adjusted_total_ipd	NA
10.2217/fon-2020-0823	results	10	NA	ss_total_nonipd	NA
10.2217/fon-2020-0823	results	10	NA	ss_anchor_nonipd	NA
10.2217/fon-2020-0823	results	10	NA	ss_anchor_ipd	NA
10.2217/fon-2020-0823	results	10	NA	ss_adjusted_anchor_ipd	NA
10.2217/fon-2020-0823	results	10	NA	effect_cutoff	1
10.2217/fon-2020-0823	results	10	NA	unadjusted_lb_ci	0.16
10.2217/fon-2020-0823	results	10	NA	unadjusted_ub_ci	0.44
10.2217/fon-2020-0823	results	10	NA	unadjusted_significant	TRUE
10.2217/fon-2020-0823	results	10	NA	adjusted_lb_ci	0.18
10.2217/fon-2020-0823	results	10	NA	adjusted_ub_ci	0.45
10.2217/fon-2020-0823	results	10	NA	adjusted_significant	TRUE
10.2217/fon-2020-0823	results	11	NA	contrast_effect_type	HR
10.2217/fon-2020-0823	results	11	NA	direction_benefit	inferior
10.2217/fon-2020-0823	results	11	NA	ss_ttt_nonipd	42
10.2217/fon-2020-0823	results	11	NA	ss_ttt_ipd	193
10.2217/fon-2020-0823	results	11	NA	ss_adjusted_ttt_ipd	NA
10.2217/fon-2020-0823	results	11	NA	weights_yn	Yes, mentions that the weights distribution has been studied, but weights distribution not reported
10.2217/fon-2020-0823	results	11	NA	covariates_yn	Yes
10.2217/fon-2020-0823	results	11	NA	covariates_n	8
10.2217/fon-2020-0823	results	11	NA	covariates_names	Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Past treatments for the disease of interest
10.2217/fon-2020-0823	results	11	NA	contrast_effect_direction	Numerator if ratio, or left side if difference
10.2217/fon-2020-0823	results	11	NA	contrast_effect_unadjusted_value	0.2
10.2217/fon-2020-0823	results	11	NA	contrast_effect_unadjusted_pvalci	[0.13;0.33]
10.2217/fon-2020-0823	results	11	NA	contrast_effect_adjusted_value	0.17
10.2217/fon-2020-0823	results	11	NA	contrast_effect_adjusted_pvalci	[0.10;0.28]
10.2217/fon-2020-0823	results	11	NA	adjustment_geographical	NA
10.2217/fon-2020-0823	results	11	NA	ss_total_ipd	NA
10.2217/fon-2020-0823	results	11	NA	ss_adjusted_total_ipd	NA
10.2217/fon-2020-0823	results	11	NA	ss_total_nonipd	NA
10.2217/fon-2020-0823	results	11	NA	ss_anchor_nonipd	NA
10.2217/fon-2020-0823	results	11	NA	ss_anchor_ipd	NA
10.2217/fon-2020-0823	results	11	NA	ss_adjusted_anchor_ipd	NA
10.2217/fon-2020-0823	results	11	NA	effect_cutoff	1
10.2217/fon-2020-0823	results	11	NA	unadjusted_lb_ci	0.13
10.2217/fon-2020-0823	results	11	NA	unadjusted_ub_ci	0.33
10.2217/fon-2020-0823	results	11	NA	unadjusted_significant	TRUE
10.2217/fon-2020-0823	results	11	NA	adjusted_lb_ci	0.1
10.2217/fon-2020-0823	results	11	NA	adjusted_ub_ci	0.28
10.2217/fon-2020-0823	results	11	NA	adjusted_significant	TRUE
10.2217/fon-2020-0823	results	12	NA	contrast_effect_type	HR
10.2217/fon-2020-0823	results	12	NA	direction_benefit	inferior
10.2217/fon-2020-0823	results	12	NA	ss_ttt_nonipd	42
10.2217/fon-2020-0823	results	12	NA	ss_ttt_ipd	193
10.2217/fon-2020-0823	results	12	NA	ss_adjusted_ttt_ipd	193
10.2217/fon-2020-0823	results	12	NA	weights_yn	NA
10.2217/fon-2020-0823	results	12	NA	covariates_yn	Yes
10.2217/fon-2020-0823	results	12	NA	covariates_n	8
10.2217/fon-2020-0823	results	12	NA	covariates_names	Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Past treatments for the disease of interest
10.2217/fon-2020-0823	results	12	NA	contrast_effect_direction	Numerator if ratio, or left side if difference
10.2217/fon-2020-0823	results	12	NA	contrast_effect_unadjusted_value	0.2
10.2217/fon-2020-0823	results	12	NA	contrast_effect_unadjusted_pvalci	[0.13;0.33]
10.2217/fon-2020-0823	results	12	NA	contrast_effect_adjusted_value	0.07
10.2217/fon-2020-0823	results	12	NA	contrast_effect_adjusted_pvalci	[0.04;0.13]
10.2217/fon-2020-0823	results	12	NA	adjustment_geographical	NA
10.2217/fon-2020-0823	results	12	NA	ss_total_ipd	NA
10.2217/fon-2020-0823	results	12	NA	ss_adjusted_total_ipd	NA
10.2217/fon-2020-0823	results	12	NA	ss_total_nonipd	NA
10.2217/fon-2020-0823	results	12	NA	ss_anchor_nonipd	NA
10.2217/fon-2020-0823	results	12	NA	ss_anchor_ipd	NA
10.2217/fon-2020-0823	results	12	NA	ss_adjusted_anchor_ipd	NA
10.2217/fon-2020-0823	results	12	NA	effect_cutoff	1
10.2217/fon-2020-0823	results	12	NA	unadjusted_lb_ci	0.13
10.2217/fon-2020-0823	results	12	NA	unadjusted_ub_ci	0.33
10.2217/fon-2020-0823	results	12	NA	unadjusted_significant	TRUE
10.2217/fon-2020-0823	results	12	NA	adjusted_lb_ci	0.04
10.2217/fon-2020-0823	results	12	NA	adjusted_ub_ci	0.13
10.2217/fon-2020-0823	results	12	NA	adjusted_significant	TRUE
10.2217/fon-2020-0823	results	13	NA	contrast_effect_type	HR
10.2217/fon-2020-0823	results	13	NA	direction_benefit	inferior
10.2217/fon-2020-0823	results	13	NA	ss_ttt_nonipd	16
10.2217/fon-2020-0823	results	13	NA	ss_ttt_ipd	193
10.2217/fon-2020-0823	results	13	NA	ss_adjusted_ttt_ipd	NA
10.2217/fon-2020-0823	results	13	NA	weights_yn	Yes, mentions that the weights distribution has been studied, but weights distribution not reported
10.2217/fon-2020-0823	results	13	NA	covariates_yn	Yes
10.2217/fon-2020-0823	results	13	NA	covariates_n	8
10.2217/fon-2020-0823	results	13	NA	covariates_names	Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Past treatments for the disease of interest
10.2217/fon-2020-0823	results	13	NA	contrast_effect_direction	Numerator if ratio, or left side if difference
10.2217/fon-2020-0823	results	13	NA	contrast_effect_unadjusted_value	0.27
10.2217/fon-2020-0823	results	13	NA	contrast_effect_unadjusted_pvalci	[0.13;0.54]
10.2217/fon-2020-0823	results	13	NA	contrast_effect_adjusted_value	0.52
10.2217/fon-2020-0823	results	13	NA	contrast_effect_adjusted_pvalci	[0.26;1.01]
10.2217/fon-2020-0823	results	13	NA	adjustment_geographical	NA
10.2217/fon-2020-0823	results	13	NA	ss_total_ipd	NA
10.2217/fon-2020-0823	results	13	NA	ss_adjusted_total_ipd	NA
10.2217/fon-2020-0823	results	13	NA	ss_total_nonipd	NA
10.2217/fon-2020-0823	results	13	NA	ss_anchor_nonipd	NA
10.2217/fon-2020-0823	results	13	NA	ss_anchor_ipd	NA
10.2217/fon-2020-0823	results	13	NA	ss_adjusted_anchor_ipd	NA
10.2217/fon-2020-0823	results	13	NA	effect_cutoff	1
10.2217/fon-2020-0823	results	13	NA	unadjusted_lb_ci	0.13
10.2217/fon-2020-0823	results	13	NA	unadjusted_ub_ci	0.54
10.2217/fon-2020-0823	results	13	NA	unadjusted_significant	TRUE
10.2217/fon-2020-0823	results	13	NA	adjusted_lb_ci	0.26
10.2217/fon-2020-0823	results	13	NA	adjusted_ub_ci	1.01
10.2217/fon-2020-0823	results	13	NA	adjusted_significant	FALSE
10.2217/fon-2020-0823	results	14	NA	contrast_effect_type	HR
10.2217/fon-2020-0823	results	14	NA	direction_benefit	inferior
10.2217/fon-2020-0823	results	14	NA	ss_ttt_nonipd	16
10.2217/fon-2020-0823	results	14	NA	ss_ttt_ipd	193
10.2217/fon-2020-0823	results	14	NA	ss_adjusted_ttt_ipd	193
10.2217/fon-2020-0823	results	14	NA	weights_yn	NA
10.2217/fon-2020-0823	results	14	NA	covariates_yn	Yes
10.2217/fon-2020-0823	results	14	NA	covariates_n	8
10.2217/fon-2020-0823	results	14	NA	covariates_names	Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Past treatments for the disease of interest
10.2217/fon-2020-0823	results	14	NA	contrast_effect_direction	Numerator if ratio, or left side if difference
10.2217/fon-2020-0823	results	14	NA	contrast_effect_unadjusted_value	0.27
10.2217/fon-2020-0823	results	14	NA	contrast_effect_unadjusted_pvalci	[0.13;0.54]
10.2217/fon-2020-0823	results	14	NA	contrast_effect_adjusted_value	0.36
10.2217/fon-2020-0823	results	14	NA	contrast_effect_adjusted_pvalci	[0.18;0.70]
10.2217/fon-2020-0823	results	14	NA	adjustment_geographical	NA
10.2217/fon-2020-0823	results	14	NA	ss_total_ipd	NA
10.2217/fon-2020-0823	results	14	NA	ss_adjusted_total_ipd	NA
10.2217/fon-2020-0823	results	14	NA	ss_total_nonipd	NA
10.2217/fon-2020-0823	results	14	NA	ss_anchor_nonipd	NA
10.2217/fon-2020-0823	results	14	NA	ss_anchor_ipd	NA
10.2217/fon-2020-0823	results	14	NA	ss_adjusted_anchor_ipd	NA
10.2217/fon-2020-0823	results	14	NA	effect_cutoff	1
10.2217/fon-2020-0823	results	14	NA	unadjusted_lb_ci	0.13
10.2217/fon-2020-0823	results	14	NA	unadjusted_ub_ci	0.54
10.2217/fon-2020-0823	results	14	NA	unadjusted_significant	TRUE
10.2217/fon-2020-0823	results	14	NA	adjusted_lb_ci	0.18
10.2217/fon-2020-0823	results	14	NA	adjusted_ub_ci	0.7
10.2217/fon-2020-0823	results	14	NA	adjusted_significant	TRUE
10.2217/fon-2020-0823	results	15	NA	contrast_effect_type	HR
10.2217/fon-2020-0823	results	15	NA	direction_benefit	inferior
10.2217/fon-2020-0823	results	15	NA	ss_ttt_nonipd	39
10.2217/fon-2020-0823	results	15	NA	ss_ttt_ipd	193
10.2217/fon-2020-0823	results	15	NA	ss_adjusted_ttt_ipd	NA
10.2217/fon-2020-0823	results	15	NA	weights_yn	Yes, mentions that the weights distribution has been studied, but weights distribution not reported
10.2217/fon-2020-0823	results	15	NA	covariates_yn	Yes
10.2217/fon-2020-0823	results	15	NA	covariates_n	8
10.2217/fon-2020-0823	results	15	NA	covariates_names	Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Past treatments for the disease of interest
10.2217/fon-2020-0823	results	15	NA	contrast_effect_direction	Numerator if ratio, or left side if difference
10.2217/fon-2020-0823	results	15	NA	contrast_effect_unadjusted_value	0.41
10.2217/fon-2020-0823	results	15	NA	contrast_effect_unadjusted_pvalci	[0.20;0.87]
10.2217/fon-2020-0823	results	15	NA	contrast_effect_adjusted_value	0.39
10.2217/fon-2020-0823	results	15	NA	contrast_effect_adjusted_pvalci	[0.17;0.86]
10.2217/fon-2020-0823	results	15	NA	adjustment_geographical	NA
10.2217/fon-2020-0823	results	15	NA	ss_total_ipd	NA
10.2217/fon-2020-0823	results	15	NA	ss_adjusted_total_ipd	NA
10.2217/fon-2020-0823	results	15	NA	ss_total_nonipd	NA
10.2217/fon-2020-0823	results	15	NA	ss_anchor_nonipd	NA
10.2217/fon-2020-0823	results	15	NA	ss_anchor_ipd	NA
10.2217/fon-2020-0823	results	15	NA	ss_adjusted_anchor_ipd	NA
10.2217/fon-2020-0823	results	15	NA	effect_cutoff	1
10.2217/fon-2020-0823	results	15	NA	unadjusted_lb_ci	0.2
10.2217/fon-2020-0823	results	15	NA	unadjusted_ub_ci	0.87
10.2217/fon-2020-0823	results	15	NA	unadjusted_significant	TRUE
10.2217/fon-2020-0823	results	15	NA	adjusted_lb_ci	0.17
10.2217/fon-2020-0823	results	15	NA	adjusted_ub_ci	0.86
10.2217/fon-2020-0823	results	15	NA	adjusted_significant	TRUE
10.2217/fon-2020-0823	results	16	NA	contrast_effect_type	HR
10.2217/fon-2020-0823	results	16	NA	direction_benefit	inferior
10.2217/fon-2020-0823	results	16	NA	ss_ttt_nonipd	39
10.2217/fon-2020-0823	results	16	NA	ss_ttt_ipd	193
10.2217/fon-2020-0823	results	16	NA	ss_adjusted_ttt_ipd	193
10.2217/fon-2020-0823	results	16	NA	weights_yn	NA
10.2217/fon-2020-0823	results	16	NA	covariates_yn	Yes
10.2217/fon-2020-0823	results	16	NA	covariates_n	8
10.2217/fon-2020-0823	results	16	NA	covariates_names	Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Past treatments for the disease of interest
10.2217/fon-2020-0823	results	16	NA	contrast_effect_direction	Numerator if ratio, or left side if difference
10.2217/fon-2020-0823	results	16	NA	contrast_effect_unadjusted_value	0.41
10.2217/fon-2020-0823	results	16	NA	contrast_effect_unadjusted_pvalci	[0.20;0.87]
10.2217/fon-2020-0823	results	16	NA	contrast_effect_adjusted_value	0.21
10.2217/fon-2020-0823	results	16	NA	contrast_effect_adjusted_pvalci	[0.09;0.48]
10.2217/fon-2020-0823	results	16	NA	adjustment_geographical	NA
10.2217/fon-2020-0823	results	16	NA	ss_total_ipd	NA
10.2217/fon-2020-0823	results	16	NA	ss_adjusted_total_ipd	NA
10.2217/fon-2020-0823	results	16	NA	ss_total_nonipd	NA
10.2217/fon-2020-0823	results	16	NA	ss_anchor_nonipd	NA
10.2217/fon-2020-0823	results	16	NA	ss_anchor_ipd	NA
10.2217/fon-2020-0823	results	16	NA	ss_adjusted_anchor_ipd	NA
10.2217/fon-2020-0823	results	16	NA	effect_cutoff	1
10.2217/fon-2020-0823	results	16	NA	unadjusted_lb_ci	0.2
10.2217/fon-2020-0823	results	16	NA	unadjusted_ub_ci	0.87
10.2217/fon-2020-0823	results	16	NA	unadjusted_significant	TRUE
10.2217/fon-2020-0823	results	16	NA	adjusted_lb_ci	0.09
10.2217/fon-2020-0823	results	16	NA	adjusted_ub_ci	0.48
10.2217/fon-2020-0823	results	16	NA	adjusted_significant	TRUE
10.2217/fon-2020-0823	results	17	NA	contrast_effect_type	HR
10.2217/fon-2020-0823	results	17	NA	direction_benefit	inferior
10.2217/fon-2020-0823	results	17	NA	ss_ttt_nonipd	105
10.2217/fon-2020-0823	results	17	NA	ss_ttt_ipd	193
10.2217/fon-2020-0823	results	17	NA	ss_adjusted_ttt_ipd	NA
10.2217/fon-2020-0823	results	17	NA	weights_yn	Yes, mentions that the weights distribution has been studied, but weights distribution not reported
10.2217/fon-2020-0823	results	17	NA	covariates_yn	Yes
10.2217/fon-2020-0823	results	17	NA	covariates_n	8
10.2217/fon-2020-0823	results	17	NA	covariates_names	Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Past treatments for the disease of interest
10.2217/fon-2020-0823	results	17	NA	contrast_effect_direction	Numerator if ratio, or left side if difference
10.2217/fon-2020-0823	results	17	NA	contrast_effect_unadjusted_value	0.4
10.2217/fon-2020-0823	results	17	NA	contrast_effect_unadjusted_pvalci	[0.25;0.63]
10.2217/fon-2020-0823	results	17	NA	contrast_effect_adjusted_value	0.52
10.2217/fon-2020-0823	results	17	NA	contrast_effect_adjusted_pvalci	[0.34;0.80]
10.2217/fon-2020-0823	results	17	NA	adjustment_geographical	NA
10.2217/fon-2020-0823	results	17	NA	ss_total_ipd	NA
10.2217/fon-2020-0823	results	17	NA	ss_adjusted_total_ipd	NA
10.2217/fon-2020-0823	results	17	NA	ss_total_nonipd	NA
10.2217/fon-2020-0823	results	17	NA	ss_anchor_nonipd	NA
10.2217/fon-2020-0823	results	17	NA	ss_anchor_ipd	NA
10.2217/fon-2020-0823	results	17	NA	ss_adjusted_anchor_ipd	NA
10.2217/fon-2020-0823	results	17	NA	effect_cutoff	1
10.2217/fon-2020-0823	results	17	NA	unadjusted_lb_ci	0.25
10.2217/fon-2020-0823	results	17	NA	unadjusted_ub_ci	0.63
10.2217/fon-2020-0823	results	17	NA	unadjusted_significant	TRUE
10.2217/fon-2020-0823	results	17	NA	adjusted_lb_ci	0.34
10.2217/fon-2020-0823	results	17	NA	adjusted_ub_ci	0.8
10.2217/fon-2020-0823	results	17	NA	adjusted_significant	TRUE
10.2217/fon-2020-0823	results	18	NA	contrast_effect_type	HR
10.2217/fon-2020-0823	results	18	NA	direction_benefit	inferior
10.2217/fon-2020-0823	results	18	NA	ss_ttt_nonipd	105
10.2217/fon-2020-0823	results	18	NA	ss_ttt_ipd	193
10.2217/fon-2020-0823	results	18	NA	ss_adjusted_ttt_ipd	193
10.2217/fon-2020-0823	results	18	NA	weights_yn	NA
10.2217/fon-2020-0823	results	18	NA	covariates_yn	Yes
10.2217/fon-2020-0823	results	18	NA	covariates_n	8
10.2217/fon-2020-0823	results	18	NA	covariates_names	Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Past treatments for the disease of interest
10.2217/fon-2020-0823	results	18	NA	contrast_effect_direction	Numerator if ratio, or left side if difference
10.2217/fon-2020-0823	results	18	NA	contrast_effect_unadjusted_value	0.4
10.2217/fon-2020-0823	results	18	NA	contrast_effect_unadjusted_pvalci	[0.25;0.63]
10.2217/fon-2020-0823	results	18	NA	contrast_effect_adjusted_value	0.26
10.2217/fon-2020-0823	results	18	NA	contrast_effect_adjusted_pvalci	[0.16;0.42]
10.2217/fon-2020-0823	results	18	NA	adjustment_geographical	NA
10.2217/fon-2020-0823	results	18	NA	ss_total_ipd	NA
10.2217/fon-2020-0823	results	18	NA	ss_adjusted_total_ipd	NA
10.2217/fon-2020-0823	results	18	NA	ss_total_nonipd	NA
10.2217/fon-2020-0823	results	18	NA	ss_anchor_nonipd	NA
10.2217/fon-2020-0823	results	18	NA	ss_anchor_ipd	NA
10.2217/fon-2020-0823	results	18	NA	ss_adjusted_anchor_ipd	NA
10.2217/fon-2020-0823	results	18	NA	effect_cutoff	1
10.2217/fon-2020-0823	results	18	NA	unadjusted_lb_ci	0.25
10.2217/fon-2020-0823	results	18	NA	unadjusted_ub_ci	0.63
10.2217/fon-2020-0823	results	18	NA	unadjusted_significant	TRUE
10.2217/fon-2020-0823	results	18	NA	adjusted_lb_ci	0.16
10.2217/fon-2020-0823	results	18	NA	adjusted_ub_ci	0.42
10.2217/fon-2020-0823	results	18	NA	adjusted_significant	TRUE
10.2217/fon-2020-0823	results	19	NA	contrast_effect_type	HR
10.2217/fon-2020-0823	results	19	NA	direction_benefit	inferior
10.2217/fon-2020-0823	results	19	NA	ss_ttt_nonipd	58
10.2217/fon-2020-0823	results	19	NA	ss_ttt_ipd	193
10.2217/fon-2020-0823	results	19	NA	ss_adjusted_ttt_ipd	NA
10.2217/fon-2020-0823	results	19	NA	weights_yn	Yes, mentions that the weights distribution has been studied, but weights distribution not reported
10.2217/fon-2020-0823	results	19	NA	covariates_yn	Yes
10.2217/fon-2020-0823	results	19	NA	covariates_n	8
10.2217/fon-2020-0823	results	19	NA	covariates_names	Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Past treatments for the disease of interest
10.2217/fon-2020-0823	results	19	NA	contrast_effect_direction	Numerator if ratio, or left side if difference
10.2217/fon-2020-0823	results	19	NA	contrast_effect_unadjusted_value	0.34
10.2217/fon-2020-0823	results	19	NA	contrast_effect_unadjusted_pvalci	[0.21;0.55]
10.2217/fon-2020-0823	results	19	NA	contrast_effect_adjusted_value	0.29
10.2217/fon-2020-0823	results	19	NA	contrast_effect_adjusted_pvalci	[0.16;0.54]
10.2217/fon-2020-0823	results	19	NA	adjustment_geographical	NA
10.2217/fon-2020-0823	results	19	NA	ss_total_ipd	NA
10.2217/fon-2020-0823	results	19	NA	ss_adjusted_total_ipd	NA
10.2217/fon-2020-0823	results	19	NA	ss_total_nonipd	NA
10.2217/fon-2020-0823	results	19	NA	ss_anchor_nonipd	NA
10.2217/fon-2020-0823	results	19	NA	ss_anchor_ipd	NA
10.2217/fon-2020-0823	results	19	NA	ss_adjusted_anchor_ipd	NA
10.2217/fon-2020-0823	results	19	NA	effect_cutoff	1
10.2217/fon-2020-0823	results	19	NA	unadjusted_lb_ci	0.21
10.2217/fon-2020-0823	results	19	NA	unadjusted_ub_ci	0.55
10.2217/fon-2020-0823	results	19	NA	unadjusted_significant	TRUE
10.2217/fon-2020-0823	results	19	NA	adjusted_lb_ci	0.16
10.2217/fon-2020-0823	results	19	NA	adjusted_ub_ci	0.54
10.2217/fon-2020-0823	results	19	NA	adjusted_significant	TRUE
10.2217/fon-2020-0823	results	2	NA	contrast_effect_type	HR
10.2217/fon-2020-0823	results	2	NA	direction_benefit	inferior
10.2217/fon-2020-0823	results	2	NA	ss_ttt_nonipd	39
10.2217/fon-2020-0823	results	2	NA	ss_ttt_ipd	193
10.2217/fon-2020-0823	results	2	NA	ss_adjusted_ttt_ipd	193
10.2217/fon-2020-0823	results	2	NA	weights_yn	NA
10.2217/fon-2020-0823	results	2	NA	covariates_yn	Yes
10.2217/fon-2020-0823	results	2	NA	covariates_n	8
10.2217/fon-2020-0823	results	2	NA	covariates_names	Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Past treatments for the disease of interest
10.2217/fon-2020-0823	results	2	NA	contrast_effect_direction	Numerator if ratio, or left side if difference
10.2217/fon-2020-0823	results	2	NA	contrast_effect_unadjusted_value	0.28
10.2217/fon-2020-0823	results	2	NA	contrast_effect_unadjusted_pvalci	[0.16;0.50]
10.2217/fon-2020-0823	results	2	NA	contrast_effect_adjusted_value	0.23
10.2217/fon-2020-0823	results	2	NA	contrast_effect_adjusted_pvalci	[0.14;0.39]
10.2217/fon-2020-0823	results	2	NA	adjustment_geographical	NA
10.2217/fon-2020-0823	results	2	NA	ss_total_ipd	NA
10.2217/fon-2020-0823	results	2	NA	ss_adjusted_total_ipd	NA
10.2217/fon-2020-0823	results	2	NA	ss_total_nonipd	NA
10.2217/fon-2020-0823	results	2	NA	ss_anchor_nonipd	NA
10.2217/fon-2020-0823	results	2	NA	ss_anchor_ipd	NA
10.2217/fon-2020-0823	results	2	NA	ss_adjusted_anchor_ipd	NA
10.2217/fon-2020-0823	results	2	NA	effect_cutoff	1
10.2217/fon-2020-0823	results	2	NA	unadjusted_lb_ci	0.16
10.2217/fon-2020-0823	results	2	NA	unadjusted_ub_ci	0.5
10.2217/fon-2020-0823	results	2	NA	unadjusted_significant	TRUE
10.2217/fon-2020-0823	results	2	NA	adjusted_lb_ci	0.14
10.2217/fon-2020-0823	results	2	NA	adjusted_ub_ci	0.39
10.2217/fon-2020-0823	results	2	NA	adjusted_significant	TRUE
10.2217/fon-2020-0823	results	20	NA	contrast_effect_type	HR
10.2217/fon-2020-0823	results	20	NA	direction_benefit	inferior
10.2217/fon-2020-0823	results	20	NA	ss_ttt_nonipd	58
10.2217/fon-2020-0823	results	20	NA	ss_ttt_ipd	193
10.2217/fon-2020-0823	results	20	NA	ss_adjusted_ttt_ipd	193
10.2217/fon-2020-0823	results	20	NA	weights_yn	NA
10.2217/fon-2020-0823	results	20	NA	covariates_yn	Yes
10.2217/fon-2020-0823	results	20	NA	covariates_n	8
10.2217/fon-2020-0823	results	20	NA	covariates_names	Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Past treatments for the disease of interest
10.2217/fon-2020-0823	results	20	NA	contrast_effect_direction	Numerator if ratio, or left side if difference
10.2217/fon-2020-0823	results	20	NA	contrast_effect_unadjusted_value	0.34
10.2217/fon-2020-0823	results	20	NA	contrast_effect_unadjusted_pvalci	[0.21;0.55]
10.2217/fon-2020-0823	results	20	NA	contrast_effect_adjusted_value	0.19
10.2217/fon-2020-0823	results	20	NA	contrast_effect_adjusted_pvalci	[0.11;0.31]
10.2217/fon-2020-0823	results	20	NA	adjustment_geographical	NA
10.2217/fon-2020-0823	results	20	NA	ss_total_ipd	NA
10.2217/fon-2020-0823	results	20	NA	ss_adjusted_total_ipd	NA
10.2217/fon-2020-0823	results	20	NA	ss_total_nonipd	NA
10.2217/fon-2020-0823	results	20	NA	ss_anchor_nonipd	NA
10.2217/fon-2020-0823	results	20	NA	ss_anchor_ipd	NA
10.2217/fon-2020-0823	results	20	NA	ss_adjusted_anchor_ipd	NA
10.2217/fon-2020-0823	results	20	NA	effect_cutoff	1
10.2217/fon-2020-0823	results	20	NA	unadjusted_lb_ci	0.21
10.2217/fon-2020-0823	results	20	NA	unadjusted_ub_ci	0.55
10.2217/fon-2020-0823	results	20	NA	unadjusted_significant	TRUE
10.2217/fon-2020-0823	results	20	NA	adjusted_lb_ci	0.11
10.2217/fon-2020-0823	results	20	NA	adjusted_ub_ci	0.31
10.2217/fon-2020-0823	results	20	NA	adjusted_significant	TRUE
10.2217/fon-2020-0823	results	3	NA	contrast_effect_type	HR
10.2217/fon-2020-0823	results	3	NA	direction_benefit	inferior
10.2217/fon-2020-0823	results	3	NA	ss_ttt_nonipd	18
10.2217/fon-2020-0823	results	3	NA	ss_ttt_ipd	193
10.2217/fon-2020-0823	results	3	NA	ss_adjusted_ttt_ipd	NA
10.2217/fon-2020-0823	results	3	NA	weights_yn	Yes, mentions that the weights distribution has been studied, but weights distribution not reported
10.2217/fon-2020-0823	results	3	NA	covariates_yn	Yes
10.2217/fon-2020-0823	results	3	NA	covariates_n	4
10.2217/fon-2020-0823	results	3	NA	covariates_names	Age, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease)
10.2217/fon-2020-0823	results	3	NA	contrast_effect_direction	Numerator if ratio, or left side if difference
10.2217/fon-2020-0823	results	3	NA	contrast_effect_unadjusted_value	0.3
10.2217/fon-2020-0823	results	3	NA	contrast_effect_unadjusted_pvalci	[0.16;0.58]
10.2217/fon-2020-0823	results	3	NA	contrast_effect_adjusted_value	0.19
10.2217/fon-2020-0823	results	3	NA	contrast_effect_adjusted_pvalci	[0.10;0.39]
10.2217/fon-2020-0823	results	3	NA	adjustment_geographical	NA
10.2217/fon-2020-0823	results	3	NA	ss_total_ipd	NA
10.2217/fon-2020-0823	results	3	NA	ss_adjusted_total_ipd	NA
10.2217/fon-2020-0823	results	3	NA	ss_total_nonipd	NA
10.2217/fon-2020-0823	results	3	NA	ss_anchor_nonipd	NA
10.2217/fon-2020-0823	results	3	NA	ss_anchor_ipd	NA
10.2217/fon-2020-0823	results	3	NA	ss_adjusted_anchor_ipd	NA
10.2217/fon-2020-0823	results	3	NA	effect_cutoff	1
10.2217/fon-2020-0823	results	3	NA	unadjusted_lb_ci	0.16
10.2217/fon-2020-0823	results	3	NA	unadjusted_ub_ci	0.58
10.2217/fon-2020-0823	results	3	NA	unadjusted_significant	TRUE
10.2217/fon-2020-0823	results	3	NA	adjusted_lb_ci	0.1
10.2217/fon-2020-0823	results	3	NA	adjusted_ub_ci	0.39
10.2217/fon-2020-0823	results	3	NA	adjusted_significant	TRUE
10.2217/fon-2020-0823	results	4	NA	contrast_effect_type	HR
10.2217/fon-2020-0823	results	4	NA	direction_benefit	inferior
10.2217/fon-2020-0823	results	4	NA	ss_ttt_nonipd	18
10.2217/fon-2020-0823	results	4	NA	ss_ttt_ipd	193
10.2217/fon-2020-0823	results	4	NA	ss_adjusted_ttt_ipd	193
10.2217/fon-2020-0823	results	4	NA	weights_yn	NA
10.2217/fon-2020-0823	results	4	NA	covariates_yn	Yes
10.2217/fon-2020-0823	results	4	NA	covariates_n	4
10.2217/fon-2020-0823	results	4	NA	covariates_names	Age, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease)
10.2217/fon-2020-0823	results	4	NA	contrast_effect_direction	Numerator if ratio, or left side if difference
10.2217/fon-2020-0823	results	4	NA	contrast_effect_unadjusted_value	0.3
10.2217/fon-2020-0823	results	4	NA	contrast_effect_unadjusted_pvalci	[0.16;0.58]
10.2217/fon-2020-0823	results	4	NA	contrast_effect_adjusted_value	0.17
10.2217/fon-2020-0823	results	4	NA	contrast_effect_adjusted_pvalci	[0.09;0.33]
10.2217/fon-2020-0823	results	4	NA	adjustment_geographical	NA
10.2217/fon-2020-0823	results	4	NA	ss_total_ipd	NA
10.2217/fon-2020-0823	results	4	NA	ss_adjusted_total_ipd	NA
10.2217/fon-2020-0823	results	4	NA	ss_total_nonipd	NA
10.2217/fon-2020-0823	results	4	NA	ss_anchor_nonipd	NA
10.2217/fon-2020-0823	results	4	NA	ss_anchor_ipd	NA
10.2217/fon-2020-0823	results	4	NA	ss_adjusted_anchor_ipd	NA
10.2217/fon-2020-0823	results	4	NA	effect_cutoff	1
10.2217/fon-2020-0823	results	4	NA	unadjusted_lb_ci	0.16
10.2217/fon-2020-0823	results	4	NA	unadjusted_ub_ci	0.58
10.2217/fon-2020-0823	results	4	NA	unadjusted_significant	TRUE
10.2217/fon-2020-0823	results	4	NA	adjusted_lb_ci	0.09
10.2217/fon-2020-0823	results	4	NA	adjusted_ub_ci	0.33
10.2217/fon-2020-0823	results	4	NA	adjusted_significant	TRUE
10.2217/fon-2020-0823	results	5	NA	contrast_effect_type	HR
10.2217/fon-2020-0823	results	5	NA	direction_benefit	inferior
10.2217/fon-2020-0823	results	5	NA	ss_ttt_nonipd	36
10.2217/fon-2020-0823	results	5	NA	ss_ttt_ipd	193
10.2217/fon-2020-0823	results	5	NA	ss_adjusted_ttt_ipd	NA
10.2217/fon-2020-0823	results	5	NA	weights_yn	Yes, mentions that the weights distribution has been studied, but weights distribution not reported
10.2217/fon-2020-0823	results	5	NA	covariates_yn	Yes
10.2217/fon-2020-0823	results	5	NA	covariates_n	8
10.2217/fon-2020-0823	results	5	NA	covariates_names	Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Past treatments for the disease of interest
10.2217/fon-2020-0823	results	5	NA	contrast_effect_direction	Numerator if ratio, or left side if difference
10.2217/fon-2020-0823	results	5	NA	contrast_effect_unadjusted_value	0.25
10.2217/fon-2020-0823	results	5	NA	contrast_effect_unadjusted_pvalci	[0.13;0.46]
10.2217/fon-2020-0823	results	5	NA	contrast_effect_adjusted_value	0.25
10.2217/fon-2020-0823	results	5	NA	contrast_effect_adjusted_pvalci	[0.13;0.49]
10.2217/fon-2020-0823	results	5	NA	adjustment_geographical	NA
10.2217/fon-2020-0823	results	5	NA	ss_total_ipd	NA
10.2217/fon-2020-0823	results	5	NA	ss_adjusted_total_ipd	NA
10.2217/fon-2020-0823	results	5	NA	ss_total_nonipd	NA
10.2217/fon-2020-0823	results	5	NA	ss_anchor_nonipd	NA
10.2217/fon-2020-0823	results	5	NA	ss_anchor_ipd	NA
10.2217/fon-2020-0823	results	5	NA	ss_adjusted_anchor_ipd	NA
10.2217/fon-2020-0823	results	5	NA	effect_cutoff	1
10.2217/fon-2020-0823	results	5	NA	unadjusted_lb_ci	0.13
10.2217/fon-2020-0823	results	5	NA	unadjusted_ub_ci	0.46
10.2217/fon-2020-0823	results	5	NA	unadjusted_significant	TRUE
10.2217/fon-2020-0823	results	5	NA	adjusted_lb_ci	0.13
10.2217/fon-2020-0823	results	5	NA	adjusted_ub_ci	0.49
10.2217/fon-2020-0823	results	5	NA	adjusted_significant	TRUE
10.2217/fon-2020-0823	results	6	NA	contrast_effect_type	HR
10.2217/fon-2020-0823	results	6	NA	direction_benefit	inferior
10.2217/fon-2020-0823	results	6	NA	ss_ttt_nonipd	36
10.2217/fon-2020-0823	results	6	NA	ss_ttt_ipd	193
10.2217/fon-2020-0823	results	6	NA	ss_adjusted_ttt_ipd	193
10.2217/fon-2020-0823	results	6	NA	weights_yn	NA
10.2217/fon-2020-0823	results	6	NA	covariates_yn	Yes
10.2217/fon-2020-0823	results	6	NA	covariates_n	8
10.2217/fon-2020-0823	results	6	NA	covariates_names	Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Past treatments for the disease of interest
10.2217/fon-2020-0823	results	6	NA	contrast_effect_direction	Numerator if ratio, or left side if difference
10.2217/fon-2020-0823	results	6	NA	contrast_effect_unadjusted_value	0.25
10.2217/fon-2020-0823	results	6	NA	contrast_effect_unadjusted_pvalci	[0.13;0.46]
10.2217/fon-2020-0823	results	6	NA	contrast_effect_adjusted_value	0.11
10.2217/fon-2020-0823	results	6	NA	contrast_effect_adjusted_pvalci	[0.05;0.22]
10.2217/fon-2020-0823	results	6	NA	adjustment_geographical	NA
10.2217/fon-2020-0823	results	6	NA	ss_total_ipd	NA
10.2217/fon-2020-0823	results	6	NA	ss_adjusted_total_ipd	NA
10.2217/fon-2020-0823	results	6	NA	ss_total_nonipd	NA
10.2217/fon-2020-0823	results	6	NA	ss_anchor_nonipd	NA
10.2217/fon-2020-0823	results	6	NA	ss_anchor_ipd	NA
10.2217/fon-2020-0823	results	6	NA	ss_adjusted_anchor_ipd	NA
10.2217/fon-2020-0823	results	6	NA	effect_cutoff	1
10.2217/fon-2020-0823	results	6	NA	unadjusted_lb_ci	0.13
10.2217/fon-2020-0823	results	6	NA	unadjusted_ub_ci	0.46
10.2217/fon-2020-0823	results	6	NA	unadjusted_significant	TRUE
10.2217/fon-2020-0823	results	6	NA	adjusted_lb_ci	0.05
10.2217/fon-2020-0823	results	6	NA	adjusted_ub_ci	0.22
10.2217/fon-2020-0823	results	6	NA	adjusted_significant	TRUE
10.2217/fon-2020-0823	results	7	NA	contrast_effect_type	HR
10.2217/fon-2020-0823	results	7	NA	direction_benefit	inferior
10.2217/fon-2020-0823	results	7	NA	ss_ttt_nonipd	31
10.2217/fon-2020-0823	results	7	NA	ss_ttt_ipd	193
10.2217/fon-2020-0823	results	7	NA	ss_adjusted_ttt_ipd	NA
10.2217/fon-2020-0823	results	7	NA	weights_yn	Yes, mentions that the weights distribution has been studied, but weights distribution not reported
10.2217/fon-2020-0823	results	7	NA	covariates_yn	Yes
10.2217/fon-2020-0823	results	7	NA	covariates_n	8
10.2217/fon-2020-0823	results	7	NA	covariates_names	Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Past treatments for the disease of interest
10.2217/fon-2020-0823	results	7	NA	contrast_effect_direction	Numerator if ratio, or left side if difference
10.2217/fon-2020-0823	results	7	NA	contrast_effect_unadjusted_value	0.28
10.2217/fon-2020-0823	results	7	NA	contrast_effect_unadjusted_pvalci	[0.16;0.50]
10.2217/fon-2020-0823	results	7	NA	contrast_effect_adjusted_value	0.37
10.2217/fon-2020-0823	results	7	NA	contrast_effect_adjusted_pvalci	[0.20;0.69]
10.2217/fon-2020-0823	results	7	NA	adjustment_geographical	NA
10.2217/fon-2020-0823	results	7	NA	ss_total_ipd	NA
10.2217/fon-2020-0823	results	7	NA	ss_adjusted_total_ipd	NA
10.2217/fon-2020-0823	results	7	NA	ss_total_nonipd	NA
10.2217/fon-2020-0823	results	7	NA	ss_anchor_nonipd	NA
10.2217/fon-2020-0823	results	7	NA	ss_anchor_ipd	NA
10.2217/fon-2020-0823	results	7	NA	ss_adjusted_anchor_ipd	NA
10.2217/fon-2020-0823	results	7	NA	effect_cutoff	1
10.2217/fon-2020-0823	results	7	NA	unadjusted_lb_ci	0.16
10.2217/fon-2020-0823	results	7	NA	unadjusted_ub_ci	0.5
10.2217/fon-2020-0823	results	7	NA	unadjusted_significant	TRUE
10.2217/fon-2020-0823	results	7	NA	adjusted_lb_ci	0.2
10.2217/fon-2020-0823	results	7	NA	adjusted_ub_ci	0.69
10.2217/fon-2020-0823	results	7	NA	adjusted_significant	TRUE
10.2217/fon-2020-0823	results	8	NA	contrast_effect_type	HR
10.2217/fon-2020-0823	results	8	NA	direction_benefit	inferior
10.2217/fon-2020-0823	results	8	NA	ss_ttt_nonipd	31
10.2217/fon-2020-0823	results	8	NA	ss_ttt_ipd	193
10.2217/fon-2020-0823	results	8	NA	ss_adjusted_ttt_ipd	193
10.2217/fon-2020-0823	results	8	NA	weights_yn	NA
10.2217/fon-2020-0823	results	8	NA	covariates_yn	Yes
10.2217/fon-2020-0823	results	8	NA	covariates_n	8
10.2217/fon-2020-0823	results	8	NA	covariates_names	Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Past treatments for the disease of interest
10.2217/fon-2020-0823	results	8	NA	contrast_effect_direction	Numerator if ratio, or left side if difference
10.2217/fon-2020-0823	results	8	NA	contrast_effect_unadjusted_value	0.28
10.2217/fon-2020-0823	results	8	NA	contrast_effect_unadjusted_pvalci	[0.16;0.50]
10.2217/fon-2020-0823	results	8	NA	contrast_effect_adjusted_value	0.25
10.2217/fon-2020-0823	results	8	NA	contrast_effect_adjusted_pvalci	[0.14;0.44]
10.2217/fon-2020-0823	results	8	NA	adjustment_geographical	NA
10.2217/fon-2020-0823	results	8	NA	ss_total_ipd	NA
10.2217/fon-2020-0823	results	8	NA	ss_adjusted_total_ipd	NA
10.2217/fon-2020-0823	results	8	NA	ss_total_nonipd	NA
10.2217/fon-2020-0823	results	8	NA	ss_anchor_nonipd	NA
10.2217/fon-2020-0823	results	8	NA	ss_anchor_ipd	NA
10.2217/fon-2020-0823	results	8	NA	ss_adjusted_anchor_ipd	NA
10.2217/fon-2020-0823	results	8	NA	effect_cutoff	1
10.2217/fon-2020-0823	results	8	NA	unadjusted_lb_ci	0.16
10.2217/fon-2020-0823	results	8	NA	unadjusted_ub_ci	0.5
10.2217/fon-2020-0823	results	8	NA	unadjusted_significant	TRUE
10.2217/fon-2020-0823	results	8	NA	adjusted_lb_ci	0.14
10.2217/fon-2020-0823	results	8	NA	adjusted_ub_ci	0.44
10.2217/fon-2020-0823	results	8	NA	adjusted_significant	TRUE
10.2217/fon-2020-0823	results	9	NA	contrast_effect_type	HR
10.2217/fon-2020-0823	results	9	NA	direction_benefit	inferior
10.2217/fon-2020-0823	results	9	NA	ss_ttt_nonipd	40
10.2217/fon-2020-0823	results	9	NA	ss_ttt_ipd	193
10.2217/fon-2020-0823	results	9	NA	ss_adjusted_ttt_ipd	NA
10.2217/fon-2020-0823	results	9	NA	weights_yn	Yes, mentions that the weights distribution has been studied, but weights distribution not reported
10.2217/fon-2020-0823	results	9	NA	covariates_yn	Yes
10.2217/fon-2020-0823	results	9	NA	covariates_n	8
10.2217/fon-2020-0823	results	9	NA	covariates_names	Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Past treatments for the disease of interest
10.2217/fon-2020-0823	results	9	NA	contrast_effect_direction	Numerator if ratio, or left side if difference
10.2217/fon-2020-0823	results	9	NA	contrast_effect_unadjusted_value	0.27
10.2217/fon-2020-0823	results	9	NA	contrast_effect_unadjusted_pvalci	[0.16;0.44]
10.2217/fon-2020-0823	results	9	NA	contrast_effect_adjusted_value	0.47
10.2217/fon-2020-0823	results	9	NA	contrast_effect_adjusted_pvalci	[0.29;0.75]
10.2217/fon-2020-0823	results	9	NA	adjustment_geographical	NA
10.2217/fon-2020-0823	results	9	NA	ss_total_ipd	NA
10.2217/fon-2020-0823	results	9	NA	ss_adjusted_total_ipd	NA
10.2217/fon-2020-0823	results	9	NA	ss_total_nonipd	NA
10.2217/fon-2020-0823	results	9	NA	ss_anchor_nonipd	NA
10.2217/fon-2020-0823	results	9	NA	ss_anchor_ipd	NA
10.2217/fon-2020-0823	results	9	NA	ss_adjusted_anchor_ipd	NA
10.2217/fon-2020-0823	results	9	NA	effect_cutoff	1
10.2217/fon-2020-0823	results	9	NA	unadjusted_lb_ci	0.16
10.2217/fon-2020-0823	results	9	NA	unadjusted_ub_ci	0.44
10.2217/fon-2020-0823	results	9	NA	unadjusted_significant	TRUE
10.2217/fon-2020-0823	results	9	NA	adjusted_lb_ci	0.29
10.2217/fon-2020-0823	results	9	NA	adjusted_ub_ci	0.75
10.2217/fon-2020-0823	results	9	NA	adjusted_significant	TRUE
10.2217/fon-2020-0823	study_information	NA	1	ipd_yn	Yes
10.2217/fon-2020-0823	study_information	NA	1	ct_yn	Yes
10.2217/fon-2020-0823	study_information	NA	1	nct	NCT02760498
10.2217/fon-2020-0823	study_information	NA	1	country_study	international
10.2217/fon-2020-0823	study_information	NA	1	ct_phase	2
10.2217/fon-2020-0823	study_information	NA	1	ct_arms	1
10.2217/fon-2020-0823	study_information	NA	10	ipd_yn	No
10.2217/fon-2020-0823	study_information	NA	10	ct_yn	Yes
10.2217/fon-2020-0823	study_information	NA	10	nct	NCT03284424
10.2217/fon-2020-0823	study_information	NA	10	country_study	international
10.2217/fon-2020-0823	study_information	NA	10	ct_phase	2
10.2217/fon-2020-0823	study_information	NA	10	ct_arms	1
10.2217/fon-2020-0823	study_information	NA	11	ipd_yn	No
10.2217/fon-2020-0823	study_information	NA	11	ct_yn	No
10.2217/fon-2020-0823	study_information	NA	11	data_source_name	peyrade et al. (2018)
10.2217/fon-2020-0823	study_information	NA	2	ipd_yn	No
10.2217/fon-2020-0823	study_information	NA	2	ct_yn	Yes
10.2217/fon-2020-0823	study_information	NA	2	nct	NCT01198028
10.2217/fon-2020-0823	study_information	NA	2	country_study	usa
10.2217/fon-2020-0823	study_information	NA	2	ct_phase	2
10.2217/fon-2020-0823	study_information	NA	2	ct_arms	1
10.2217/fon-2020-0823	study_information	NA	3	ipd_yn	No
10.2217/fon-2020-0823	study_information	NA	3	ct_yn	No
10.2217/fon-2020-0823	study_information	NA	3	data_source_name	jarkowski et al. (2016)
10.2217/fon-2020-0823	study_information	NA	4	ipd_yn	No
10.2217/fon-2020-0823	study_information	NA	4	ct_yn	Yes
10.2217/fon-2020-0823	study_information	NA	4	nct	NCT00240682
10.2217/fon-2020-0823	study_information	NA	4	country_study	france
10.2217/fon-2020-0823	study_information	NA	4	ct_phase	2
10.2217/fon-2020-0823	study_information	NA	4	ct_arms	1
10.2217/fon-2020-0823	study_information	NA	5	ipd_yn	No
10.2217/fon-2020-0823	study_information	NA	5	ct_yn	No
10.2217/fon-2020-0823	study_information	NA	5	data_source_name	picard et al. (2017)
10.2217/fon-2020-0823	study_information	NA	5	country_study	france
10.2217/fon-2020-0823	study_information	NA	6	ipd_yn	No
10.2217/fon-2020-0823	study_information	NA	6	ct_yn	Yes
10.2217/fon-2020-0823	study_information	NA	6	nct	NCT00054691
10.2217/fon-2020-0823	study_information	NA	6	country_study	usa
10.2217/fon-2020-0823	study_information	NA	6	ct_phase	2
10.2217/fon-2020-0823	study_information	NA	6	ct_arms	1
10.2217/fon-2020-0823	study_information	NA	7	ipd_yn	No
10.2217/fon-2020-0823	study_information	NA	7	ct_yn	Yes
10.2217/fon-2020-0823	study_information	NA	7	nct	NCT02268747
10.2217/fon-2020-0823	study_information	NA	7	country_study	italy
10.2217/fon-2020-0823	study_information	NA	7	ct_phase	2
10.2217/fon-2020-0823	study_information	NA	7	ct_arms	1
10.2217/fon-2020-0823	study_information	NA	8	ipd_yn	No
10.2217/fon-2020-0823	study_information	NA	8	ct_yn	Yes
10.2217/fon-2020-0823	study_information	NA	8	data_source_name	foote et al. (2014)
10.2217/fon-2020-0823	study_information	NA	8	country_study	australia
10.2217/fon-2020-0823	study_information	NA	8	ct_phase	2
10.2217/fon-2020-0823	study_information	NA	8	ct_arms	1
10.2217/fon-2020-0823	study_information	NA	9	ipd_yn	No
10.2217/fon-2020-0823	study_information	NA	9	ct_yn	Yes
10.2217/fon-2020-0823	study_information	NA	9	nct	NCT02883556
10.2217/fon-2020-0823	study_information	NA	9	country_study	france
10.2217/fon-2020-0823	study_information	NA	9	ct_phase	2
10.2217/fon-2020-0823	study_information	NA	9	ct_arms	1
10.2217/fon-2021-1102	general_information	NA	NA	condition_name	ros1-positive non-small-cell lung cancer
10.2217/fon-2021-1102	general_information	NA	NA	country_first_author	usa
10.2217/fon-2021-1102	general_information	NA	NA	country_last_author	usa
10.2217/fon-2021-1102	general_information	NA	NA	positions	Academic, Pharmaceutical Industry, Private Data Analysis Company
10.2217/fon-2021-1102	general_information	NA	NA	methodologist_yn	Yes
10.2217/fon-2021-1102	general_information	NA	NA	funding_source	Pharmaceutical Industry
10.2217/fon-2021-1102	general_information	NA	NA	pharmaceutical_ties_yn	Yes
10.2217/fon-2021-1102	general_information	NA	NA	systematic_review_yn	No
10.2217/fon-2021-1102	methodology	1	NA	outcome_name	objective response rate (orr)
10.2217/fon-2021-1102	methodology	1	NA	outcome_short_name	Objective Response Rate
10.2217/fon-2021-1102	methodology	1	NA	outcome_variable_type	Binary (eg rates)
10.2217/fon-2021-1102	methodology	1	NA	treatment_name_ipd	crizotinib
10.2217/fon-2021-1102	methodology	1	NA	studies_number_ipd	1
10.2217/fon-2021-1102	methodology	1	NA	treatment_name_nonipd	entrectinib
10.2217/fon-2021-1102	methodology	1	NA	studies_number_nonipd	2;3;4
10.2217/fon-2021-1102	methodology	1	NA	paic_type	STC
10.2217/fon-2021-1102	methodology	1	NA	anchored_yn	No
10.2217/fon-2021-1102	methodology	1	NA	paic_form	Aggregation of multiple studies to estimate individual treatment effects (e.g. meta-analysis in a first step to estimate treatment A effect, then population adjusted indirect comparison using treatment A effect estimate)
10.2217/fon-2021-1102	methodology	1	NA	primary_outcome_yn	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.2217/fon-2021-1102	methodology	1	NA	variables_selection_justification	Statistical imbalanced between treatment groups (independently of the status of prognostic/effect modifier), A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion)
10.2217/fon-2021-1102	methodology	1	NA	pf_yn	Yes
10.2217/fon-2021-1102	methodology	1	NA	tem_yn	Yes
10.2217/fon-2021-1102	methodology	1	NA	adjustment_model_details_yn	No
10.2217/fon-2021-1102	methodology	1	NA	scale_choice_yn	No
10.2217/fon-2021-1102	methodology	2	NA	outcome_name	progression-free survival
10.2217/fon-2021-1102	methodology	2	NA	outcome_short_name	Progression-free Survival
10.2217/fon-2021-1102	methodology	2	NA	outcome_variable_type	Time-to-event
10.2217/fon-2021-1102	methodology	2	NA	treatment_name_ipd	crizotinib
10.2217/fon-2021-1102	methodology	2	NA	studies_number_ipd	1
10.2217/fon-2021-1102	methodology	2	NA	treatment_name_nonipd	crizotinib
10.2217/fon-2021-1102	methodology	2	NA	studies_number_nonipd	5
10.2217/fon-2021-1102	methodology	2	NA	paic_type	STC
10.2217/fon-2021-1102	methodology	2	NA	anchored_yn	No
10.2217/fon-2021-1102	methodology	2	NA	paic_form	Simple (ie treatments effects extracted from two studies)
10.2217/fon-2021-1102	methodology	2	NA	primary_outcome_yn	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.2217/fon-2021-1102	methodology	2	NA	variables_selection_justification	Statistical imbalanced between treatment groups (independently of the status of prognostic/effect modifier), A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion)
10.2217/fon-2021-1102	methodology	2	NA	pf_yn	Yes
10.2217/fon-2021-1102	methodology	2	NA	tem_yn	Yes
10.2217/fon-2021-1102	methodology	2	NA	adjustment_model_details_yn	No
10.2217/fon-2021-1102	methodology	2	NA	scale_choice_yn	No
10.2217/fon-2021-1102	methodology	3	NA	outcome_name	overall survival
10.2217/fon-2021-1102	methodology	3	NA	outcome_short_name	Overall Survival
10.2217/fon-2021-1102	methodology	3	NA	outcome_variable_type	Time-to-event
10.2217/fon-2021-1102	methodology	3	NA	treatment_name_ipd	crizotinib
10.2217/fon-2021-1102	methodology	3	NA	studies_number_ipd	1
10.2217/fon-2021-1102	methodology	3	NA	treatment_name_nonipd	crizotinib
10.2217/fon-2021-1102	methodology	3	NA	studies_number_nonipd	6
10.2217/fon-2021-1102	methodology	3	NA	paic_type	STC
10.2217/fon-2021-1102	methodology	3	NA	anchored_yn	No
10.2217/fon-2021-1102	methodology	3	NA	paic_form	Simple (ie treatments effects extracted from two studies)
10.2217/fon-2021-1102	methodology	3	NA	primary_outcome_yn	Yes
10.2217/fon-2021-1102	methodology	3	NA	variables_selection_justification	Statistical imbalanced between treatment groups (independently of the status of prognostic/effect modifier), A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion)
10.2217/fon-2021-1102	methodology	3	NA	pf_yn	Yes
10.2217/fon-2021-1102	methodology	3	NA	tem_yn	Yes
10.2217/fon-2021-1102	methodology	3	NA	adjustment_model_details_yn	No
10.2217/fon-2021-1102	methodology	3	NA	scale_choice_yn	No
10.2217/fon-2021-1102	results	1	NA	contrast_effect_type	RR
10.2217/fon-2021-1102	results	1	NA	direction_benefit	superior
10.2217/fon-2021-1102	results	1	NA	ss_ttt_nonipd	161
10.2217/fon-2021-1102	results	1	NA	ss_ttt_ipd	53
10.2217/fon-2021-1102	results	1	NA	ss_adjusted_ttt_ipd	53
10.2217/fon-2021-1102	results	1	NA	weights_yn	NA
10.2217/fon-2021-1102	results	1	NA	covariates_yn	Yes
10.2217/fon-2021-1102	results	1	NA	covariates_n	4
10.2217/fon-2021-1102	results	1	NA	covariates_names	Age, Sex, Comorbidities and medical history (beside pathology/disease of interest in the comparison), Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...)
10.2217/fon-2021-1102	results	1	NA	contrast_effect_direction	Numerator if ratio, or left side if difference
10.2217/fon-2021-1102	results	1	NA	contrast_effect_unadjusted_value	1.07
10.2217/fon-2021-1102	results	1	NA	contrast_effect_unadjusted_pvalci	[0.88;1.31]
10.2217/fon-2021-1102	results	1	NA	contrast_effect_adjusted_value	1.04
10.2217/fon-2021-1102	results	1	NA	contrast_effect_adjusted_pvalci	[0.85;1.28]
10.2217/fon-2021-1102	results	1	NA	adjustment_geographical	NA
10.2217/fon-2021-1102	results	1	NA	ss_total_ipd	NA
10.2217/fon-2021-1102	results	1	NA	ss_adjusted_total_ipd	NA
10.2217/fon-2021-1102	results	1	NA	ss_total_nonipd	NA
10.2217/fon-2021-1102	results	1	NA	ss_anchor_nonipd	NA
10.2217/fon-2021-1102	results	1	NA	ss_anchor_ipd	NA
10.2217/fon-2021-1102	results	1	NA	ss_adjusted_anchor_ipd	NA
10.2217/fon-2021-1102	results	1	NA	effect_cutoff	1
10.2217/fon-2021-1102	results	1	NA	unadjusted_lb_ci	0.88
10.2217/fon-2021-1102	results	1	NA	unadjusted_ub_ci	1.31
10.2217/fon-2021-1102	results	1	NA	unadjusted_significant	FALSE
10.2217/fon-2021-1102	results	1	NA	adjusted_lb_ci	0.85
10.2217/fon-2021-1102	results	1	NA	adjusted_ub_ci	1.28
10.2217/fon-2021-1102	results	1	NA	adjusted_significant	FALSE
10.2217/fon-2021-1102	results	2	NA	contrast_effect_type	Median difference
10.2217/fon-2021-1102	results	2	NA	direction_benefit	superior
10.2217/fon-2021-1102	results	2	NA	ss_ttt_nonipd	69
10.2217/fon-2021-1102	results	2	NA	ss_ttt_ipd	53
10.2217/fon-2021-1102	results	2	NA	ss_adjusted_ttt_ipd	53
10.2217/fon-2021-1102	results	2	NA	weights_yn	NA
10.2217/fon-2021-1102	results	2	NA	covariates_yn	Yes
10.2217/fon-2021-1102	results	2	NA	covariates_n	2
10.2217/fon-2021-1102	results	2	NA	covariates_names	Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Other(s)
10.2217/fon-2021-1102	results	2	NA	contrast_effect_direction	Numerator if ratio, or left side if difference
10.2217/fon-2021-1102	results	2	NA	contrast_effect_unadjusted_value	10.8
10.2217/fon-2021-1102	results	2	NA	contrast_effect_unadjusted_pvalci	NA
10.2217/fon-2021-1102	results	2	NA	contrast_effect_adjusted_value	8.3
10.2217/fon-2021-1102	results	2	NA	contrast_effect_adjusted_pvalci	[0.26;16.94]
10.2217/fon-2021-1102	results	2	NA	adjustment_geographical	No
10.2217/fon-2021-1102	results	2	NA	ss_total_ipd	NA
10.2217/fon-2021-1102	results	2	NA	ss_adjusted_total_ipd	NA
10.2217/fon-2021-1102	results	2	NA	ss_total_nonipd	NA
10.2217/fon-2021-1102	results	2	NA	ss_anchor_nonipd	NA
10.2217/fon-2021-1102	results	2	NA	ss_anchor_ipd	NA
10.2217/fon-2021-1102	results	2	NA	ss_adjusted_anchor_ipd	NA
10.2217/fon-2021-1102	results	2	NA	effect_cutoff	0
10.2217/fon-2021-1102	results	2	NA	adjusted_lb_ci	0.26
10.2217/fon-2021-1102	results	2	NA	adjusted_ub_ci	16.94
10.2217/fon-2021-1102	results	2	NA	adjusted_significant	TRUE
10.2217/fon-2021-1102	results	3	NA	contrast_effect_type	Median difference
10.2217/fon-2021-1102	results	3	NA	direction_benefit	superior
10.2217/fon-2021-1102	results	3	NA	ss_ttt_nonipd	38
10.2217/fon-2021-1102	results	3	NA	ss_ttt_ipd	53
10.2217/fon-2021-1102	results	3	NA	ss_adjusted_ttt_ipd	53
10.2217/fon-2021-1102	results	3	NA	weights_yn	Not mentioned
10.2217/fon-2021-1102	results	3	NA	covariates_yn	Yes
10.2217/fon-2021-1102	results	3	NA	covariates_n	4
10.2217/fon-2021-1102	results	3	NA	covariates_names	Age, Sex, Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Comorbidities and medical history (beside pathology/disease of interest in the comparison)
10.2217/fon-2021-1102	results	3	NA	contrast_effect_direction	Numerator if ratio, or left side if difference
10.2217/fon-2021-1102	results	3	NA	contrast_effect_unadjusted_value	15.2
10.2217/fon-2021-1102	results	3	NA	contrast_effect_unadjusted_pvalci	NA
10.2217/fon-2021-1102	results	3	NA	contrast_effect_adjusted_value	-10.5
10.2217/fon-2021-1102	results	3	NA	contrast_effect_adjusted_pvalci	NA
10.2217/fon-2021-1102	results	3	NA	adjustment_geographical	No
10.2217/fon-2021-1102	results	3	NA	ss_total_ipd	NA
10.2217/fon-2021-1102	results	3	NA	ss_adjusted_total_ipd	NA
10.2217/fon-2021-1102	results	3	NA	ss_total_nonipd	NA
10.2217/fon-2021-1102	results	3	NA	ss_anchor_nonipd	NA
10.2217/fon-2021-1102	results	3	NA	ss_anchor_ipd	NA
10.2217/fon-2021-1102	results	3	NA	ss_adjusted_anchor_ipd	NA
10.2217/fon-2021-1102	results	3	NA	effect_cutoff	0
10.2217/fon-2021-1102	study_information	NA	1	ipd_yn	Yes
10.2217/fon-2021-1102	study_information	NA	1	ct_yn	Yes
10.2217/fon-2021-1102	study_information	NA	1	nct	NCT00585195
10.2217/fon-2021-1102	study_information	NA	1	country_study	international
10.2217/fon-2021-1102	study_information	NA	1	ct_phase	1
10.2217/fon-2021-1102	study_information	NA	1	ct_arms	1
10.2217/fon-2021-1102	study_information	NA	2	ipd_yn	No
10.2217/fon-2021-1102	study_information	NA	2	ct_yn	Yes
10.2217/fon-2021-1102	study_information	NA	2	eudract	2012-000148-88
10.2217/fon-2021-1102	study_information	NA	2	country_study	italy
10.2217/fon-2021-1102	study_information	NA	2	ct_phase	1
10.2217/fon-2021-1102	study_information	NA	2	ct_arms	1
10.2217/fon-2021-1102	study_information	NA	3	ipd_yn	No
10.2217/fon-2021-1102	study_information	NA	3	ct_yn	Yes
10.2217/fon-2021-1102	study_information	NA	3	nct	NCT02097810
10.2217/fon-2021-1102	study_information	NA	3	country_study	international
10.2217/fon-2021-1102	study_information	NA	3	ct_phase	1
10.2217/fon-2021-1102	study_information	NA	3	ct_arms	1
10.2217/fon-2021-1102	study_information	NA	4	ipd_yn	No
10.2217/fon-2021-1102	study_information	NA	4	ct_yn	Yes
10.2217/fon-2021-1102	study_information	NA	4	nct	NCT02568267
10.2217/fon-2021-1102	study_information	NA	4	country_study	international
10.2217/fon-2021-1102	study_information	NA	4	ct_phase	2
10.2217/fon-2021-1102	study_information	NA	4	ct_arms	1
10.2217/fon-2021-1102	study_information	NA	5	ipd_yn	No
10.2217/fon-2021-1102	study_information	NA	5	ct_yn	No
10.2217/fon-2021-1102	study_information	NA	5	data_source_name	flatiron health
10.2217/fon-2021-1102	study_information	NA	5	country_study	usa
10.2217/fon-2021-1102	study_information	NA	6	ipd_yn	No
10.2217/fon-2021-1102	study_information	NA	6	ct_yn	No
10.2217/fon-2021-1102	study_information	NA	6	data_source_name	ontada (oncology insights & technology)
10.2217/fon-2021-1102	study_information	NA	6	country_study	usa
10.2217/fon-2021-1509	general_information	NA	NA	condition_name	advanced systemic mastocytosis
10.2217/fon-2021-1509	general_information	NA	NA	country_first_author	uk
10.2217/fon-2021-1509	general_information	NA	NA	country_last_author	switzerland
10.2217/fon-2021-1509	general_information	NA	NA	positions	Pharmaceutical Industry, Private Data Analysis Company
10.2217/fon-2021-1509	general_information	NA	NA	methodologist_yn	Yes
10.2217/fon-2021-1509	general_information	NA	NA	funding_source	Pharmaceutical Industry
10.2217/fon-2021-1509	general_information	NA	NA	pharmaceutical_ties_yn	Yes
10.2217/fon-2021-1509	general_information	NA	NA	systematic_review_yn	Yes
10.2217/fon-2021-1509	methodology	1	NA	outcome_name	overall survival
10.2217/fon-2021-1509	methodology	1	NA	outcome_short_name	Overall Survival
10.2217/fon-2021-1509	methodology	1	NA	outcome_variable_type	Time-to-event
10.2217/fon-2021-1509	methodology	1	NA	treatment_name_ipd	avapritinib
10.2217/fon-2021-1509	methodology	1	NA	studies_number_ipd	1;2
10.2217/fon-2021-1509	methodology	1	NA	treatment_name_nonipd	midostaurin
10.2217/fon-2021-1509	methodology	1	NA	studies_number_nonipd	3;4
10.2217/fon-2021-1509	methodology	1	NA	paic_type	MAIC
10.2217/fon-2021-1509	methodology	1	NA	anchored_yn	No
10.2217/fon-2021-1509	methodology	1	NA	paic_form	Aggregation of multiple studies to estimate individual treatment effects (e.g. meta-analysis in a first step to estimate treatment A effect, then population adjusted indirect comparison using treatment A effect estimate)
10.2217/fon-2021-1509	methodology	1	NA	primary_outcome_yn	Yes
10.2217/fon-2021-1509	methodology	1	NA	variables_selection_justification	Status of prognostic factor/treatment effect modified assessed in the IPD dataset
10.2217/fon-2021-1509	methodology	1	NA	pf_yn	Yes
10.2217/fon-2021-1509	methodology	1	NA	tem_yn	No discussion (in the main text) of the status of treatment-effect modifiers of the variables
10.2217/fon-2021-1509	methodology	1	NA	adjustment_model_details_yn	No
10.2217/fon-2021-1509	methodology	1	NA	scale_choice_yn	No
10.2217/fon-2021-1509	results	1	NA	contrast_effect_type	HR
10.2217/fon-2021-1509	results	1	NA	direction_benefit	inferior
10.2217/fon-2021-1509	results	1	NA	ss_ttt_nonipd	115
10.2217/fon-2021-1509	results	1	NA	ss_ttt_ipd	85
10.2217/fon-2021-1509	results	1	NA	ss_adjusted_ttt_ipd	NA
10.2217/fon-2021-1509	results	1	NA	weights_yn	Not mentioned
10.2217/fon-2021-1509	results	1	NA	covariates_yn	Yes
10.2217/fon-2021-1509	results	1	NA	covariates_n	3
10.2217/fon-2021-1509	results	1	NA	covariates_names	Age, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Race/ethnicity
10.2217/fon-2021-1509	results	1	NA	contrast_effect_direction	Numerator if ratio, or left side if difference
10.2217/fon-2021-1509	results	1	NA	contrast_effect_unadjusted_value	0.54
10.2217/fon-2021-1509	results	1	NA	contrast_effect_unadjusted_pvalci	[0.32;0.92]
10.2217/fon-2021-1509	results	1	NA	contrast_effect_adjusted_value	0.44
10.2217/fon-2021-1509	results	1	NA	contrast_effect_adjusted_pvalci	[0.25;0.76]
10.2217/fon-2021-1509	results	1	NA	adjustment_geographical	NA
10.2217/fon-2021-1509	results	1	NA	ss_total_ipd	NA
10.2217/fon-2021-1509	results	1	NA	ss_adjusted_total_ipd	NA
10.2217/fon-2021-1509	results	1	NA	ss_total_nonipd	NA
10.2217/fon-2021-1509	results	1	NA	ss_anchor_nonipd	NA
10.2217/fon-2021-1509	results	1	NA	ss_anchor_ipd	NA
10.2217/fon-2021-1509	results	1	NA	ss_adjusted_anchor_ipd	NA
10.2217/fon-2021-1509	results	1	NA	effect_cutoff	1
10.2217/fon-2021-1509	results	1	NA	unadjusted_lb_ci	0.32
10.2217/fon-2021-1509	results	1	NA	unadjusted_ub_ci	0.92
10.2217/fon-2021-1509	results	1	NA	unadjusted_significant	TRUE
10.2217/fon-2021-1509	results	1	NA	adjusted_lb_ci	0.25
10.2217/fon-2021-1509	results	1	NA	adjusted_ub_ci	0.76
10.2217/fon-2021-1509	results	1	NA	adjusted_significant	TRUE
10.2217/fon-2021-1509	study_information	NA	1	ipd_yn	Yes
10.2217/fon-2021-1509	study_information	NA	1	ct_yn	Yes
10.2217/fon-2021-1509	study_information	NA	1	nct	NCT02561988
10.2217/fon-2021-1509	study_information	NA	1	country_study	international
10.2217/fon-2021-1509	study_information	NA	1	ct_phase	1
10.2217/fon-2021-1509	study_information	NA	1	ct_arms	1
10.2217/fon-2021-1509	study_information	NA	2	ipd_yn	Yes
10.2217/fon-2021-1509	study_information	NA	2	ct_yn	Yes
10.2217/fon-2021-1509	study_information	NA	2	nct	NCT03580655
10.2217/fon-2021-1509	study_information	NA	2	country_study	international
10.2217/fon-2021-1509	study_information	NA	2	ct_phase	2
10.2217/fon-2021-1509	study_information	NA	2	ct_arms	1
10.2217/fon-2021-1509	study_information	NA	3	ipd_yn	No
10.2217/fon-2021-1509	study_information	NA	3	ct_yn	Yes
10.2217/fon-2021-1509	study_information	NA	3	nct	NCT00782067
10.2217/fon-2021-1509	study_information	NA	3	country_study	international
10.2217/fon-2021-1509	study_information	NA	3	ct_phase	2
10.2217/fon-2021-1509	study_information	NA	3	ct_arms	1
10.2217/fon-2021-1509	study_information	NA	4	ipd_yn	No
10.2217/fon-2021-1509	study_information	NA	4	ct_yn	Yes
10.2217/fon-2021-1509	study_information	NA	4	nct	NCT00233454
10.2217/fon-2021-1509	study_information	NA	4	country_study	usa
10.2217/fon-2021-1509	study_information	NA	4	ct_phase	2
10.2217/fon-2021-1509	study_information	NA	4	ct_arms	1
10.2217/imt-2018-0208	general_information	NA	NA	condition_name	braf-mutant advanced melanoma
10.2217/imt-2018-0208	general_information	NA	NA	country_first_author	usa
10.2217/imt-2018-0208	general_information	NA	NA	country_last_author	usa
10.2217/imt-2018-0208	general_information	NA	NA	positions	Academic, Pharmaceutical Industry, Private Data Analysis Company
10.2217/imt-2018-0208	general_information	NA	NA	methodologist_yn	Yes
10.2217/imt-2018-0208	general_information	NA	NA	funding_source	Pharmaceutical Industry
10.2217/imt-2018-0208	general_information	NA	NA	pharmaceutical_ties_yn	Yes
10.2217/imt-2018-0208	general_information	NA	NA	systematic_review_yn	No
10.2217/imt-2018-0208	methodology	1	NA	outcome_name	overall survival
10.2217/imt-2018-0208	methodology	1	NA	outcome_short_name	Overall Survival
10.2217/imt-2018-0208	methodology	1	NA	outcome_variable_type	Time-to-event
10.2217/imt-2018-0208	methodology	1	NA	treatment_name_ipd	nivolumab + ipilimumab
10.2217/imt-2018-0208	methodology	1	NA	studies_number_ipd	1;2
10.2217/imt-2018-0208	methodology	1	NA	treatment_name_nonipd	dabrafenib + trametinib
10.2217/imt-2018-0208	methodology	1	NA	studies_number_nonipd	3;4
10.2217/imt-2018-0208	methodology	1	NA	paic_type	MAIC
10.2217/imt-2018-0208	methodology	1	NA	anchored_yn	No
10.2217/imt-2018-0208	methodology	1	NA	paic_form	Aggregation of multiple studies to estimate individual treatment effects (e.g. meta-analysis in a first step to estimate treatment A effect, then population adjusted indirect comparison using treatment A effect estimate)
10.2217/imt-2018-0208	methodology	1	NA	primary_outcome_yn	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.2217/imt-2018-0208	methodology	1	NA	variables_selection_justification	A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion)
10.2217/imt-2018-0208	methodology	1	NA	pf_yn	Yes
10.2217/imt-2018-0208	methodology	1	NA	tem_yn	Yes
10.2217/imt-2018-0208	methodology	1	NA	adjustment_model_details_yn	No
10.2217/imt-2018-0208	methodology	1	NA	scale_choice_yn	No
10.2217/imt-2018-0208	methodology	2	NA	outcome_name	overall survival
10.2217/imt-2018-0208	methodology	2	NA	outcome_short_name	Overall Survival
10.2217/imt-2018-0208	methodology	2	NA	outcome_variable_type	Time-to-event
10.2217/imt-2018-0208	methodology	2	NA	treatment_name_ipd	nivolumab + ipilimumab
10.2217/imt-2018-0208	methodology	2	NA	studies_number_ipd	1;2
10.2217/imt-2018-0208	methodology	2	NA	treatment_name_nonipd	vemurafenib + cobimetinib
10.2217/imt-2018-0208	methodology	2	NA	studies_number_nonipd	5
10.2217/imt-2018-0208	methodology	2	NA	paic_type	MAIC
10.2217/imt-2018-0208	methodology	2	NA	anchored_yn	No
10.2217/imt-2018-0208	methodology	2	NA	paic_form	Aggregation of multiple studies to estimate individual treatment effects (e.g. meta-analysis in a first step to estimate treatment A effect, then population adjusted indirect comparison using treatment A effect estimate)
10.2217/imt-2018-0208	methodology	2	NA	primary_outcome_yn	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.2217/imt-2018-0208	methodology	2	NA	variables_selection_justification	A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion)
10.2217/imt-2018-0208	methodology	2	NA	pf_yn	Yes
10.2217/imt-2018-0208	methodology	2	NA	tem_yn	Yes
10.2217/imt-2018-0208	methodology	2	NA	adjustment_model_details_yn	No
10.2217/imt-2018-0208	methodology	2	NA	scale_choice_yn	No
10.2217/imt-2018-0208	results	1	NA	contrast_effect_type	HR
10.2217/imt-2018-0208	results	1	NA	direction_benefit	inferior
10.2217/imt-2018-0208	results	1	NA	ss_ttt_nonipd	563
10.2217/imt-2018-0208	results	1	NA	ss_ttt_ipd	124
10.2217/imt-2018-0208	results	1	NA	ss_adjusted_ttt_ipd	106.3
10.2217/imt-2018-0208	results	1	NA	weights_yn	Not mentioned
10.2217/imt-2018-0208	results	1	NA	covariates_yn	Yes
10.2217/imt-2018-0208	results	1	NA	covariates_n	7
10.2217/imt-2018-0208	results	1	NA	covariates_names	Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Past treatments for the disease of interest
10.2217/imt-2018-0208	results	1	NA	contrast_effect_direction	Numerator if ratio, or left side if difference
10.2217/imt-2018-0208	results	1	NA	contrast_effect_unadjusted_value	0.58
10.2217/imt-2018-0208	results	1	NA	contrast_effect_unadjusted_pvalci	0.001
10.2217/imt-2018-0208	results	1	NA	contrast_effect_adjusted_value	0.64
10.2217/imt-2018-0208	results	1	NA	contrast_effect_adjusted_pvalci	0.009
10.2217/imt-2018-0208	results	1	NA	adjustment_geographical	NA
10.2217/imt-2018-0208	results	1	NA	ss_total_ipd	NA
10.2217/imt-2018-0208	results	1	NA	ss_adjusted_total_ipd	NA
10.2217/imt-2018-0208	results	1	NA	ss_total_nonipd	NA
10.2217/imt-2018-0208	results	1	NA	ss_anchor_nonipd	NA
10.2217/imt-2018-0208	results	1	NA	ss_anchor_ipd	NA
10.2217/imt-2018-0208	results	1	NA	ss_adjusted_anchor_ipd	NA
10.2217/imt-2018-0208	results	1	NA	effect_cutoff	1
10.2217/imt-2018-0208	results	1	NA	unadjusted_pval	0.001
10.2217/imt-2018-0208	results	1	NA	unadjusted_num_pval	0.001
10.2217/imt-2018-0208	results	1	NA	unadjusted_significant	TRUE
10.2217/imt-2018-0208	results	1	NA	adjusted_pval	0.009
10.2217/imt-2018-0208	results	1	NA	adjusted_num_pval	0.009
10.2217/imt-2018-0208	results	1	NA	adjusted_significant	TRUE
10.2217/imt-2018-0208	results	2	NA	contrast_effect_type	HR
10.2217/imt-2018-0208	results	2	NA	direction_benefit	inferior
10.2217/imt-2018-0208	results	2	NA	ss_ttt_nonipd	247
10.2217/imt-2018-0208	results	2	NA	ss_ttt_ipd	124
10.2217/imt-2018-0208	results	2	NA	ss_adjusted_ttt_ipd	59.2
10.2217/imt-2018-0208	results	2	NA	weights_yn	Not mentioned
10.2217/imt-2018-0208	results	2	NA	covariates_yn	Yes
10.2217/imt-2018-0208	results	2	NA	covariates_n	8
10.2217/imt-2018-0208	results	2	NA	covariates_names	Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Race/ethnicity, Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Other(s)
10.2217/imt-2018-0208	results	2	NA	contrast_effect_direction	Numerator if ratio, or left side if difference
10.2217/imt-2018-0208	results	2	NA	contrast_effect_unadjusted_value	0.53
10.2217/imt-2018-0208	results	2	NA	contrast_effect_unadjusted_pvalci	<0.001
10.2217/imt-2018-0208	results	2	NA	contrast_effect_adjusted_value	0.56
10.2217/imt-2018-0208	results	2	NA	contrast_effect_adjusted_pvalci	0.014
10.2217/imt-2018-0208	results	2	NA	adjustment_geographical	Yes
10.2217/imt-2018-0208	results	2	NA	ss_total_ipd	NA
10.2217/imt-2018-0208	results	2	NA	ss_adjusted_total_ipd	NA
10.2217/imt-2018-0208	results	2	NA	ss_total_nonipd	NA
10.2217/imt-2018-0208	results	2	NA	ss_anchor_nonipd	NA
10.2217/imt-2018-0208	results	2	NA	ss_anchor_ipd	NA
10.2217/imt-2018-0208	results	2	NA	ss_adjusted_anchor_ipd	NA
10.2217/imt-2018-0208	results	2	NA	effect_cutoff	1
10.2217/imt-2018-0208	results	2	NA	unadjusted_pval	<0.001
10.2217/imt-2018-0208	results	2	NA	unadjusted_significant	TRUE
10.2217/imt-2018-0208	results	2	NA	adjusted_pval	0.014
10.2217/imt-2018-0208	results	2	NA	adjusted_num_pval	0.014
10.2217/imt-2018-0208	results	2	NA	adjusted_significant	TRUE
10.2217/imt-2018-0208	study_information	NA	1	ipd_yn	Yes
10.2217/imt-2018-0208	study_information	NA	1	ct_yn	Yes
10.2217/imt-2018-0208	study_information	NA	1	nct	NCT01844505
10.2217/imt-2018-0208	study_information	NA	1	country_study	international
10.2217/imt-2018-0208	study_information	NA	1	ct_phase	3
10.2217/imt-2018-0208	study_information	NA	1	ct_arms	2 or more
10.2217/imt-2018-0208	study_information	NA	2	ipd_yn	Yes
10.2217/imt-2018-0208	study_information	NA	2	ct_yn	Yes
10.2217/imt-2018-0208	study_information	NA	2	nct	NCT01927419
10.2217/imt-2018-0208	study_information	NA	2	country_study	international
10.2217/imt-2018-0208	study_information	NA	2	ct_phase	2
10.2217/imt-2018-0208	study_information	NA	2	ct_arms	2 or more
10.2217/imt-2018-0208	study_information	NA	3	ipd_yn	No
10.2217/imt-2018-0208	study_information	NA	3	ct_yn	Yes
10.2217/imt-2018-0208	study_information	NA	3	nct	NCT01584648
10.2217/imt-2018-0208	study_information	NA	3	country_study	international
10.2217/imt-2018-0208	study_information	NA	3	ct_phase	3
10.2217/imt-2018-0208	study_information	NA	3	ct_arms	2 or more
10.2217/imt-2018-0208	study_information	NA	4	ipd_yn	No
10.2217/imt-2018-0208	study_information	NA	4	ct_yn	Yes
10.2217/imt-2018-0208	study_information	NA	4	nct	NCT01597908
10.2217/imt-2018-0208	study_information	NA	4	country_study	international
10.2217/imt-2018-0208	study_information	NA	4	ct_phase	3
10.2217/imt-2018-0208	study_information	NA	4	ct_arms	2 or more
10.2217/imt-2018-0208	study_information	NA	5	ipd_yn	No
10.2217/imt-2018-0208	study_information	NA	5	ct_yn	Yes
10.2217/imt-2018-0208	study_information	NA	5	nct	NCT01689519
10.2217/imt-2018-0208	study_information	NA	5	country_study	international
10.2217/imt-2018-0208	study_information	NA	5	ct_phase	3
10.2217/imt-2018-0208	study_information	NA	5	ct_arms	2 or more
10.2217/imt-2020-0266	general_information	NA	NA	condition_name	multiple myeloma
10.2217/imt-2020-0266	general_information	NA	NA	country_first_author	france
10.2217/imt-2020-0266	general_information	NA	NA	country_last_author	the netherlands
10.2217/imt-2020-0266	general_information	NA	NA	positions	Academic, Pharmaceutical Industry, Private Data Analysis Company
10.2217/imt-2020-0266	general_information	NA	NA	methodologist_yn	Yes
10.2217/imt-2020-0266	general_information	NA	NA	funding_source	Pharmaceutical Industry
10.2217/imt-2020-0266	general_information	NA	NA	pharmaceutical_ties_yn	Yes
10.2217/imt-2020-0266	general_information	NA	NA	systematic_review_yn	Yes
10.2217/imt-2020-0266	methodology	1	NA	outcome_name	progression-free survival
10.2217/imt-2020-0266	methodology	1	NA	outcome_short_name	Progression-free Survival
10.2217/imt-2020-0266	methodology	1	NA	outcome_variable_type	Time-to-event
10.2217/imt-2020-0266	methodology	1	NA	treatment_name_ipd	daratumumab + bortezomib + thalidomide + dexamethasone
10.2217/imt-2020-0266	methodology	1	NA	studies_number_ipd	1
10.2217/imt-2020-0266	methodology	1	NA	treatment_name_nonipd	bortezomib + lenalidomide + dexamethasone
10.2217/imt-2020-0266	methodology	1	NA	studies_number_nonipd	2
10.2217/imt-2020-0266	methodology	1	NA	paic_type	MAIC
10.2217/imt-2020-0266	methodology	1	NA	anchored_yn	No
10.2217/imt-2020-0266	methodology	1	NA	paic_form	Simple (ie treatments effects extracted from two studies)
10.2217/imt-2020-0266	methodology	1	NA	primary_outcome_yn	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.2217/imt-2020-0266	methodology	1	NA	variables_selection_justification	A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion)
10.2217/imt-2020-0266	methodology	1	NA	pf_yn	Yes
10.2217/imt-2020-0266	methodology	1	NA	tem_yn	Yes
10.2217/imt-2020-0266	methodology	1	NA	adjustment_model_details_yn	No
10.2217/imt-2020-0266	methodology	1	NA	scale_choice_yn	No
10.2217/imt-2020-0266	methodology	2	NA	outcome_name	progression-free survival
10.2217/imt-2020-0266	methodology	2	NA	outcome_short_name	Progression-free Survival
10.2217/imt-2020-0266	methodology	2	NA	outcome_variable_type	Time-to-event
10.2217/imt-2020-0266	methodology	2	NA	treatment_name_ipd	bortezomib + thalidomide + dexamethasone
10.2217/imt-2020-0266	methodology	2	NA	studies_number_ipd	1
10.2217/imt-2020-0266	methodology	2	NA	treatment_name_nonipd	bortezomib + lenalidomide + dexamethasone
10.2217/imt-2020-0266	methodology	2	NA	studies_number_nonipd	2
10.2217/imt-2020-0266	methodology	2	NA	paic_type	MAIC
10.2217/imt-2020-0266	methodology	2	NA	anchored_yn	No
10.2217/imt-2020-0266	methodology	2	NA	paic_form	Simple (ie treatments effects extracted from two studies)
10.2217/imt-2020-0266	methodology	2	NA	primary_outcome_yn	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.2217/imt-2020-0266	methodology	2	NA	variables_selection_justification	A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion)
10.2217/imt-2020-0266	methodology	2	NA	pf_yn	Yes
10.2217/imt-2020-0266	methodology	2	NA	tem_yn	Yes
10.2217/imt-2020-0266	methodology	2	NA	adjustment_model_details_yn	No
10.2217/imt-2020-0266	methodology	2	NA	scale_choice_yn	No
10.2217/imt-2020-0266	methodology	3	NA	outcome_name	progression-free survival
10.2217/imt-2020-0266	methodology	3	NA	outcome_short_name	Progression-free Survival
10.2217/imt-2020-0266	methodology	3	NA	outcome_variable_type	Time-to-event
10.2217/imt-2020-0266	methodology	3	NA	treatment_name_ipd	daratumumab + bortezomib + thalidomide + dexamethasone
10.2217/imt-2020-0266	methodology	3	NA	studies_number_ipd	1
10.2217/imt-2020-0266	methodology	3	NA	treatment_name_nonipd	bortezomib + cyclophosphamide + dexamethasone
10.2217/imt-2020-0266	methodology	3	NA	studies_number_nonipd	3
10.2217/imt-2020-0266	methodology	3	NA	paic_type	MAIC
10.2217/imt-2020-0266	methodology	3	NA	anchored_yn	No
10.2217/imt-2020-0266	methodology	3	NA	paic_form	Simple (ie treatments effects extracted from two studies)
10.2217/imt-2020-0266	methodology	3	NA	primary_outcome_yn	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.2217/imt-2020-0266	methodology	3	NA	variables_selection_justification	A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion)
10.2217/imt-2020-0266	methodology	3	NA	pf_yn	Yes
10.2217/imt-2020-0266	methodology	3	NA	tem_yn	Yes
10.2217/imt-2020-0266	methodology	3	NA	adjustment_model_details_yn	No
10.2217/imt-2020-0266	methodology	3	NA	scale_choice_yn	No
10.2217/imt-2020-0266	methodology	4	NA	outcome_name	progression-free survival
10.2217/imt-2020-0266	methodology	4	NA	outcome_short_name	Progression-free Survival
10.2217/imt-2020-0266	methodology	4	NA	outcome_variable_type	Time-to-event
10.2217/imt-2020-0266	methodology	4	NA	treatment_name_ipd	bortezomib + thalidomide + dexamethasone
10.2217/imt-2020-0266	methodology	4	NA	studies_number_ipd	1
10.2217/imt-2020-0266	methodology	4	NA	treatment_name_nonipd	bortezomib + cyclophosphamide + dexamethasone
10.2217/imt-2020-0266	methodology	4	NA	studies_number_nonipd	3
10.2217/imt-2020-0266	methodology	4	NA	paic_type	MAIC
10.2217/imt-2020-0266	methodology	4	NA	anchored_yn	No
10.2217/imt-2020-0266	methodology	4	NA	paic_form	Simple (ie treatments effects extracted from two studies)
10.2217/imt-2020-0266	methodology	4	NA	primary_outcome_yn	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.2217/imt-2020-0266	methodology	4	NA	variables_selection_justification	A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion)
10.2217/imt-2020-0266	methodology	4	NA	pf_yn	Yes
10.2217/imt-2020-0266	methodology	4	NA	tem_yn	Yes
10.2217/imt-2020-0266	methodology	4	NA	adjustment_model_details_yn	No
10.2217/imt-2020-0266	methodology	4	NA	scale_choice_yn	No
10.2217/imt-2020-0266	methodology	5	NA	outcome_name	progression-free survival
10.2217/imt-2020-0266	methodology	5	NA	outcome_short_name	Progression-free Survival
10.2217/imt-2020-0266	methodology	5	NA	outcome_variable_type	Time-to-event
10.2217/imt-2020-0266	methodology	5	NA	treatment_name_ipd	daratumumab + bortezomib + thalidomide + dexamethasone
10.2217/imt-2020-0266	methodology	5	NA	studies_number_ipd	1
10.2217/imt-2020-0266	methodology	5	NA	treatment_name_nonipd	bortezomib + dexamethasone
10.2217/imt-2020-0266	methodology	5	NA	studies_number_nonipd	4
10.2217/imt-2020-0266	methodology	5	NA	paic_type	MAIC
10.2217/imt-2020-0266	methodology	5	NA	anchored_yn	No
10.2217/imt-2020-0266	methodology	5	NA	paic_form	Simple (ie treatments effects extracted from two studies)
10.2217/imt-2020-0266	methodology	5	NA	primary_outcome_yn	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.2217/imt-2020-0266	methodology	5	NA	variables_selection_justification	A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion)
10.2217/imt-2020-0266	methodology	5	NA	pf_yn	Yes
10.2217/imt-2020-0266	methodology	5	NA	tem_yn	Yes
10.2217/imt-2020-0266	methodology	5	NA	adjustment_model_details_yn	No
10.2217/imt-2020-0266	methodology	5	NA	scale_choice_yn	No
10.2217/imt-2020-0266	methodology	6	NA	outcome_name	progression-free survival
10.2217/imt-2020-0266	methodology	6	NA	outcome_short_name	Progression-free Survival
10.2217/imt-2020-0266	methodology	6	NA	outcome_variable_type	Time-to-event
10.2217/imt-2020-0266	methodology	6	NA	treatment_name_ipd	bortezomib + thalidomide + dexamethasone
10.2217/imt-2020-0266	methodology	6	NA	studies_number_ipd	1
10.2217/imt-2020-0266	methodology	6	NA	treatment_name_nonipd	bortezomib + dexamethasone
10.2217/imt-2020-0266	methodology	6	NA	studies_number_nonipd	4
10.2217/imt-2020-0266	methodology	6	NA	paic_type	MAIC
10.2217/imt-2020-0266	methodology	6	NA	anchored_yn	No
10.2217/imt-2020-0266	methodology	6	NA	paic_form	Simple (ie treatments effects extracted from two studies)
10.2217/imt-2020-0266	methodology	6	NA	primary_outcome_yn	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.2217/imt-2020-0266	methodology	6	NA	variables_selection_justification	A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion)
10.2217/imt-2020-0266	methodology	6	NA	pf_yn	Yes
10.2217/imt-2020-0266	methodology	6	NA	tem_yn	Yes
10.2217/imt-2020-0266	methodology	6	NA	adjustment_model_details_yn	No
10.2217/imt-2020-0266	methodology	6	NA	scale_choice_yn	No
10.2217/imt-2020-0266	results	1	NA	contrast_effect_type	HR
10.2217/imt-2020-0266	results	1	NA	direction_benefit	inferior
10.2217/imt-2020-0266	results	1	NA	ss_ttt_nonipd	350
10.2217/imt-2020-0266	results	1	NA	ss_ttt_ipd	543
10.2217/imt-2020-0266	results	1	NA	ss_adjusted_ttt_ipd	529
10.2217/imt-2020-0266	results	1	NA	weights_yn	Not mentioned
10.2217/imt-2020-0266	results	1	NA	covariates_yn	Yes
10.2217/imt-2020-0266	results	1	NA	covariates_n	4
10.2217/imt-2020-0266	results	1	NA	covariates_names	Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease)
10.2217/imt-2020-0266	results	1	NA	contrast_effect_direction	Numerator if ratio, or left side if difference
10.2217/imt-2020-0266	results	1	NA	contrast_effect_unadjusted_value	0.48
10.2217/imt-2020-0266	results	1	NA	contrast_effect_unadjusted_pvalci	<0.001
10.2217/imt-2020-0266	results	1	NA	contrast_effect_adjusted_value	0.47
10.2217/imt-2020-0266	results	1	NA	contrast_effect_adjusted_pvalci	<0.001
10.2217/imt-2020-0266	results	1	NA	adjustment_geographical	NA
10.2217/imt-2020-0266	results	1	NA	ss_total_ipd	NA
10.2217/imt-2020-0266	results	1	NA	ss_adjusted_total_ipd	NA
10.2217/imt-2020-0266	results	1	NA	ss_total_nonipd	NA
10.2217/imt-2020-0266	results	1	NA	ss_anchor_nonipd	NA
10.2217/imt-2020-0266	results	1	NA	ss_anchor_ipd	NA
10.2217/imt-2020-0266	results	1	NA	ss_adjusted_anchor_ipd	NA
10.2217/imt-2020-0266	results	1	NA	effect_cutoff	1
10.2217/imt-2020-0266	results	1	NA	unadjusted_pval	<0.001
10.2217/imt-2020-0266	results	1	NA	unadjusted_significant	TRUE
10.2217/imt-2020-0266	results	1	NA	adjusted_pval	<0.001
10.2217/imt-2020-0266	results	1	NA	adjusted_significant	TRUE
10.2217/imt-2020-0266	results	2	NA	contrast_effect_type	HR
10.2217/imt-2020-0266	results	2	NA	direction_benefit	inferior
10.2217/imt-2020-0266	results	2	NA	ss_ttt_nonipd	350
10.2217/imt-2020-0266	results	2	NA	ss_ttt_ipd	542
10.2217/imt-2020-0266	results	2	NA	ss_adjusted_ttt_ipd	515
10.2217/imt-2020-0266	results	2	NA	weights_yn	Not mentioned
10.2217/imt-2020-0266	results	2	NA	covariates_yn	Yes
10.2217/imt-2020-0266	results	2	NA	covariates_n	4
10.2217/imt-2020-0266	results	2	NA	covariates_names	Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease)
10.2217/imt-2020-0266	results	2	NA	contrast_effect_direction	Numerator if ratio, or left side if difference
10.2217/imt-2020-0266	results	2	NA	contrast_effect_unadjusted_value	1.07
10.2217/imt-2020-0266	results	2	NA	contrast_effect_unadjusted_pvalci	0.655
10.2217/imt-2020-0266	results	2	NA	contrast_effect_adjusted_value	1.13
10.2217/imt-2020-0266	results	2	NA	contrast_effect_adjusted_pvalci	0.419
10.2217/imt-2020-0266	results	2	NA	adjustment_geographical	NA
10.2217/imt-2020-0266	results	2	NA	ss_total_ipd	NA
10.2217/imt-2020-0266	results	2	NA	ss_adjusted_total_ipd	NA
10.2217/imt-2020-0266	results	2	NA	ss_total_nonipd	NA
10.2217/imt-2020-0266	results	2	NA	ss_anchor_nonipd	NA
10.2217/imt-2020-0266	results	2	NA	ss_anchor_ipd	NA
10.2217/imt-2020-0266	results	2	NA	ss_adjusted_anchor_ipd	NA
10.2217/imt-2020-0266	results	2	NA	effect_cutoff	1
10.2217/imt-2020-0266	results	2	NA	unadjusted_pval	0.655
10.2217/imt-2020-0266	results	2	NA	unadjusted_num_pval	0.655
10.2217/imt-2020-0266	results	2	NA	unadjusted_significant	FALSE
10.2217/imt-2020-0266	results	2	NA	adjusted_pval	0.419
10.2217/imt-2020-0266	results	2	NA	adjusted_num_pval	0.419
10.2217/imt-2020-0266	results	2	NA	adjusted_significant	FALSE
10.2217/imt-2020-0266	results	3	NA	contrast_effect_type	HR
10.2217/imt-2020-0266	results	3	NA	direction_benefit	inferior
10.2217/imt-2020-0266	results	3	NA	ss_ttt_nonipd	125
10.2217/imt-2020-0266	results	3	NA	ss_ttt_ipd	543
10.2217/imt-2020-0266	results	3	NA	ss_adjusted_ttt_ipd	206
10.2217/imt-2020-0266	results	3	NA	weights_yn	Not mentioned
10.2217/imt-2020-0266	results	3	NA	covariates_yn	Yes
10.2217/imt-2020-0266	results	3	NA	covariates_n	12
10.2217/imt-2020-0266	results	3	NA	covariates_names	Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Other(s)
10.2217/imt-2020-0266	results	3	NA	contrast_effect_direction	Numerator if ratio, or left side if difference
10.2217/imt-2020-0266	results	3	NA	contrast_effect_unadjusted_value	0.4
10.2217/imt-2020-0266	results	3	NA	contrast_effect_unadjusted_pvalci	<0.001
10.2217/imt-2020-0266	results	3	NA	contrast_effect_adjusted_value	0.35
10.2217/imt-2020-0266	results	3	NA	contrast_effect_adjusted_pvalci	<0.001
10.2217/imt-2020-0266	results	3	NA	adjustment_geographical	No
10.2217/imt-2020-0266	results	3	NA	ss_total_ipd	NA
10.2217/imt-2020-0266	results	3	NA	ss_adjusted_total_ipd	NA
10.2217/imt-2020-0266	results	3	NA	ss_total_nonipd	NA
10.2217/imt-2020-0266	results	3	NA	ss_anchor_nonipd	NA
10.2217/imt-2020-0266	results	3	NA	ss_anchor_ipd	NA
10.2217/imt-2020-0266	results	3	NA	ss_adjusted_anchor_ipd	NA
10.2217/imt-2020-0266	results	3	NA	effect_cutoff	1
10.2217/imt-2020-0266	results	3	NA	unadjusted_pval	<0.001
10.2217/imt-2020-0266	results	3	NA	unadjusted_significant	TRUE
10.2217/imt-2020-0266	results	3	NA	adjusted_pval	<0.001
10.2217/imt-2020-0266	results	3	NA	adjusted_significant	TRUE
10.2217/imt-2020-0266	results	4	NA	contrast_effect_type	HR
10.2217/imt-2020-0266	results	4	NA	direction_benefit	inferior
10.2217/imt-2020-0266	results	4	NA	ss_ttt_nonipd	126
10.2217/imt-2020-0266	results	4	NA	ss_ttt_ipd	542
10.2217/imt-2020-0266	results	4	NA	ss_adjusted_ttt_ipd	211
10.2217/imt-2020-0266	results	4	NA	weights_yn	Not mentioned
10.2217/imt-2020-0266	results	4	NA	covariates_yn	Yes
10.2217/imt-2020-0266	results	4	NA	covariates_n	12
10.2217/imt-2020-0266	results	4	NA	covariates_names	Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Other(s)
10.2217/imt-2020-0266	results	4	NA	contrast_effect_direction	Numerator if ratio, or left side if difference
10.2217/imt-2020-0266	results	4	NA	contrast_effect_unadjusted_value	0.89
10.2217/imt-2020-0266	results	4	NA	contrast_effect_unadjusted_pvalci	0.549
10.2217/imt-2020-0266	results	4	NA	contrast_effect_adjusted_value	1
10.2217/imt-2020-0266	results	4	NA	contrast_effect_adjusted_pvalci	0.987
10.2217/imt-2020-0266	results	4	NA	adjustment_geographical	No
10.2217/imt-2020-0266	results	4	NA	ss_total_ipd	NA
10.2217/imt-2020-0266	results	4	NA	ss_adjusted_total_ipd	NA
10.2217/imt-2020-0266	results	4	NA	ss_total_nonipd	NA
10.2217/imt-2020-0266	results	4	NA	ss_anchor_nonipd	NA
10.2217/imt-2020-0266	results	4	NA	ss_anchor_ipd	NA
10.2217/imt-2020-0266	results	4	NA	ss_adjusted_anchor_ipd	NA
10.2217/imt-2020-0266	results	4	NA	effect_cutoff	1
10.2217/imt-2020-0266	results	4	NA	unadjusted_pval	0.549
10.2217/imt-2020-0266	results	4	NA	unadjusted_num_pval	0.549
10.2217/imt-2020-0266	results	4	NA	unadjusted_significant	FALSE
10.2217/imt-2020-0266	results	4	NA	adjusted_pval	0.987
10.2217/imt-2020-0266	results	4	NA	adjusted_num_pval	0.987
10.2217/imt-2020-0266	results	4	NA	adjusted_significant	FALSE
10.2217/imt-2020-0266	results	5	NA	contrast_effect_type	HR
10.2217/imt-2020-0266	results	5	NA	direction_benefit	inferior
10.2217/imt-2020-0266	results	5	NA	ss_ttt_nonipd	240
10.2217/imt-2020-0266	results	5	NA	ss_ttt_ipd	543
10.2217/imt-2020-0266	results	5	NA	ss_adjusted_ttt_ipd	416
10.2217/imt-2020-0266	results	5	NA	weights_yn	Not mentioned
10.2217/imt-2020-0266	results	5	NA	covariates_yn	Yes
10.2217/imt-2020-0266	results	5	NA	covariates_n	7
10.2217/imt-2020-0266	results	5	NA	covariates_names	Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Other(s)
10.2217/imt-2020-0266	results	5	NA	contrast_effect_direction	Numerator if ratio, or left side if difference
10.2217/imt-2020-0266	results	5	NA	contrast_effect_unadjusted_value	0.37
10.2217/imt-2020-0266	results	5	NA	contrast_effect_unadjusted_pvalci	<0.001
10.2217/imt-2020-0266	results	5	NA	contrast_effect_adjusted_value	0.42
10.2217/imt-2020-0266	results	5	NA	contrast_effect_adjusted_pvalci	<0.001
10.2217/imt-2020-0266	results	5	NA	adjustment_geographical	No
10.2217/imt-2020-0266	results	5	NA	ss_total_ipd	NA
10.2217/imt-2020-0266	results	5	NA	ss_adjusted_total_ipd	NA
10.2217/imt-2020-0266	results	5	NA	ss_total_nonipd	NA
10.2217/imt-2020-0266	results	5	NA	ss_anchor_nonipd	NA
10.2217/imt-2020-0266	results	5	NA	ss_anchor_ipd	NA
10.2217/imt-2020-0266	results	5	NA	ss_adjusted_anchor_ipd	NA
10.2217/imt-2020-0266	results	5	NA	effect_cutoff	1
10.2217/imt-2020-0266	results	5	NA	unadjusted_pval	<0.001
10.2217/imt-2020-0266	results	5	NA	unadjusted_significant	TRUE
10.2217/imt-2020-0266	results	5	NA	adjusted_pval	<0.001
10.2217/imt-2020-0266	results	5	NA	adjusted_significant	TRUE
10.2217/imt-2020-0266	results	6	NA	contrast_effect_type	HR
10.2217/imt-2020-0266	results	6	NA	direction_benefit	inferior
10.2217/imt-2020-0266	results	6	NA	ss_ttt_nonipd	240
10.2217/imt-2020-0266	results	6	NA	ss_ttt_ipd	542
10.2217/imt-2020-0266	results	6	NA	ss_adjusted_ttt_ipd	393
10.2217/imt-2020-0266	results	6	NA	weights_yn	Not mentioned
10.2217/imt-2020-0266	results	6	NA	covariates_yn	Yes
10.2217/imt-2020-0266	results	6	NA	covariates_n	7
10.2217/imt-2020-0266	results	6	NA	covariates_names	Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Other(s)
10.2217/imt-2020-0266	results	6	NA	contrast_effect_direction	Numerator if ratio, or left side if difference
10.2217/imt-2020-0266	results	6	NA	contrast_effect_unadjusted_value	0.82
10.2217/imt-2020-0266	results	6	NA	contrast_effect_unadjusted_pvalci	0.222
10.2217/imt-2020-0266	results	6	NA	contrast_effect_adjusted_value	0.94
10.2217/imt-2020-0266	results	6	NA	contrast_effect_adjusted_pvalci	0.738
10.2217/imt-2020-0266	results	6	NA	adjustment_geographical	No
10.2217/imt-2020-0266	results	6	NA	ss_total_ipd	NA
10.2217/imt-2020-0266	results	6	NA	ss_adjusted_total_ipd	NA
10.2217/imt-2020-0266	results	6	NA	ss_total_nonipd	NA
10.2217/imt-2020-0266	results	6	NA	ss_anchor_nonipd	NA
10.2217/imt-2020-0266	results	6	NA	ss_anchor_ipd	NA
10.2217/imt-2020-0266	results	6	NA	ss_adjusted_anchor_ipd	NA
10.2217/imt-2020-0266	results	6	NA	effect_cutoff	1
10.2217/imt-2020-0266	results	6	NA	unadjusted_pval	0.222
10.2217/imt-2020-0266	results	6	NA	unadjusted_num_pval	0.222
10.2217/imt-2020-0266	results	6	NA	unadjusted_significant	FALSE
10.2217/imt-2020-0266	results	6	NA	adjusted_pval	0.738
10.2217/imt-2020-0266	results	6	NA	adjusted_num_pval	0.738
10.2217/imt-2020-0266	results	6	NA	adjusted_significant	FALSE
10.2217/imt-2020-0266	study_information	NA	1	ipd_yn	Yes
10.2217/imt-2020-0266	study_information	NA	1	ct_yn	Yes
10.2217/imt-2020-0266	study_information	NA	1	nct	NCT02541383
10.2217/imt-2020-0266	study_information	NA	1	country_study	international
10.2217/imt-2020-0266	study_information	NA	1	ct_phase	3
10.2217/imt-2020-0266	study_information	NA	1	ct_arms	2 or more
10.2217/imt-2020-0266	study_information	NA	2	ipd_yn	No
10.2217/imt-2020-0266	study_information	NA	2	ct_yn	Yes
10.2217/imt-2020-0266	study_information	NA	2	nct	NCT01191060
10.2217/imt-2020-0266	study_information	NA	2	country_study	france
10.2217/imt-2020-0266	study_information	NA	2	ct_phase	3
10.2217/imt-2020-0266	study_information	NA	2	ct_arms	2 or more
10.2217/imt-2020-0266	study_information	NA	3	ipd_yn	No
10.2217/imt-2020-0266	study_information	NA	3	ct_yn	Yes
10.2217/imt-2020-0266	study_information	NA	3	eudract	2010-019173-16
10.2217/imt-2020-0266	study_information	NA	3	country_study	germany
10.2217/imt-2020-0266	study_information	NA	3	ct_phase	3
10.2217/imt-2020-0266	study_information	NA	3	ct_arms	2 or more
10.2217/imt-2020-0266	study_information	NA	4	ipd_yn	No
10.2217/imt-2020-0266	study_information	NA	4	ct_yn	Yes
10.2217/imt-2020-0266	study_information	NA	4	nct	NCT00200681
10.2217/imt-2020-0266	study_information	NA	4	country_study	france
10.2217/imt-2020-0266	study_information	NA	4	ct_phase	3
10.2217/imt-2020-0266	study_information	NA	4	ct_arms	2 or more
10.2217/imt-2021-0273	general_information	NA	NA	condition_name	metastatic non-small-cell lung cancer with pd-l1
10.2217/imt-2021-0273	general_information	NA	NA	country_first_author	usa
10.2217/imt-2021-0273	general_information	NA	NA	country_last_author	usa
10.2217/imt-2021-0273	general_information	NA	NA	positions	Academic, Pharmaceutical Industry, Private Data Analysis Company
10.2217/imt-2021-0273	general_information	NA	NA	methodologist_yn	Yes
10.2217/imt-2021-0273	general_information	NA	NA	funding_source	Pharmaceutical Industry
10.2217/imt-2021-0273	general_information	NA	NA	pharmaceutical_ties_yn	Yes
10.2217/imt-2021-0273	general_information	NA	NA	systematic_review_yn	Yes
10.2217/imt-2021-0273	methodology	1	NA	outcome_name	overall survival
10.2217/imt-2021-0273	methodology	1	NA	outcome_short_name	Overall Survival
10.2217/imt-2021-0273	methodology	1	NA	outcome_variable_type	Time-to-event
10.2217/imt-2021-0273	methodology	1	NA	treatment_name_ipd	pembrolizumab
10.2217/imt-2021-0273	methodology	1	NA	studies_number_ipd	1;2
10.2217/imt-2021-0273	methodology	1	NA	treatment_name_nonipd	nivolumab + ipilimumab
10.2217/imt-2021-0273	methodology	1	NA	studies_number_nonipd	3
10.2217/imt-2021-0273	methodology	1	NA	paic_type	MAIC
10.2217/imt-2021-0273	methodology	1	NA	anchored_yn	Yes
10.2217/imt-2021-0273	methodology	1	NA	paic_form	Aggregation of multiple studies to estimate individual treatment effects (e.g. meta-analysis in a first step to estimate treatment A effect, then population adjusted indirect comparison using treatment A effect estimate)
10.2217/imt-2021-0273	methodology	1	NA	primary_outcome_yn	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.2217/imt-2021-0273	methodology	1	NA	variables_selection_justification	Statistical imbalanced between treatment groups (independently of the status of prognostic/effect modifier), A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion), Literature based (clinically or methodologically relevant to adjust on these variables based on the literature search conducted for this specific purpose)
10.2217/imt-2021-0273	methodology	1	NA	pf_yn	No
10.2217/imt-2021-0273	methodology	1	NA	tem_yn	Yes
10.2217/imt-2021-0273	methodology	1	NA	adjustment_model_details_yn	No
10.2217/imt-2021-0273	methodology	1	NA	scale_choice_yn	No
10.2217/imt-2021-0273	results	1	NA	contrast_effect_type	HR
10.2217/imt-2021-0273	results	1	NA	direction_benefit	inferior
10.2217/imt-2021-0273	results	1	NA	ss_ttt_nonipd	793
10.2217/imt-2021-0273	results	1	NA	ss_ttt_ipd	1428
10.2217/imt-2021-0273	results	1	NA	ss_adjusted_ttt_ipd	993
10.2217/imt-2021-0273	results	1	NA	weights_yn	Not mentioned
10.2217/imt-2021-0273	results	1	NA	covariates_yn	Yes
10.2217/imt-2021-0273	results	1	NA	covariates_n	8
10.2217/imt-2021-0273	results	1	NA	covariates_names	Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Other(s), Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...)
10.2217/imt-2021-0273	results	1	NA	contrast_effect_direction	Numerator if ratio, or left side if difference
10.2217/imt-2021-0273	results	1	NA	contrast_effect_unadjusted_value	0.98
10.2217/imt-2021-0273	results	1	NA	contrast_effect_unadjusted_pvalci	NA
10.2217/imt-2021-0273	results	1	NA	contrast_effect_adjusted_value	1.07
10.2217/imt-2021-0273	results	1	NA	contrast_effect_adjusted_pvalci	[0.82;1.39]
10.2217/imt-2021-0273	results	1	NA	adjustment_geographical	Yes
10.2217/imt-2021-0273	results	1	NA	ss_total_ipd	1428
10.2217/imt-2021-0273	results	1	NA	ss_adjusted_total_ipd	993
10.2217/imt-2021-0273	results	1	NA	ss_total_nonipd	793
10.2217/imt-2021-0273	results	1	NA	ss_anchor_nonipd	NA
10.2217/imt-2021-0273	results	1	NA	ss_anchor_ipd	NA
10.2217/imt-2021-0273	results	1	NA	ss_adjusted_anchor_ipd	NA
10.2217/imt-2021-0273	results	1	NA	effect_cutoff	1
10.2217/imt-2021-0273	results	1	NA	adjusted_lb_ci	0.82
10.2217/imt-2021-0273	results	1	NA	adjusted_ub_ci	1.39
10.2217/imt-2021-0273	results	1	NA	adjusted_significant	FALSE
10.2217/imt-2021-0273	study_information	NA	1	ipd_yn	Yes
10.2217/imt-2021-0273	study_information	NA	1	ct_yn	Yes
10.2217/imt-2021-0273	study_information	NA	1	nct	NCT02142738
10.2217/imt-2021-0273	study_information	NA	1	country_study	international
10.2217/imt-2021-0273	study_information	NA	1	ct_phase	3
10.2217/imt-2021-0273	study_information	NA	1	ct_arms	2 or more
10.2217/imt-2021-0273	study_information	NA	2	ipd_yn	Yes
10.2217/imt-2021-0273	study_information	NA	2	ct_yn	Yes
10.2217/imt-2021-0273	study_information	NA	2	nct	NCT02220894
10.2217/imt-2021-0273	study_information	NA	2	country_study	international
10.2217/imt-2021-0273	study_information	NA	2	ct_phase	3
10.2217/imt-2021-0273	study_information	NA	2	ct_arms	2 or more
10.2217/imt-2021-0273	study_information	NA	3	ipd_yn	No
10.2217/imt-2021-0273	study_information	NA	3	ct_yn	Yes
10.2217/imt-2021-0273	study_information	NA	3	nct	NCT02477826
10.2217/imt-2021-0273	study_information	NA	3	country_study	international
10.2217/imt-2021-0273	study_information	NA	3	ct_phase	3
10.2217/imt-2021-0273	study_information	NA	3	ct_arms	2 or more
10.3111/13696998.2013.768530	general_information	NA	NA	condition_name	psoriatic arthritis
10.3111/13696998.2013.768530	general_information	NA	NA	country_first_author	usa
10.3111/13696998.2013.768530	general_information	NA	NA	country_last_author	usa
10.3111/13696998.2013.768530	general_information	NA	NA	positions	Pharmaceutical Industry, Private Data Analysis Company
10.3111/13696998.2013.768530	general_information	NA	NA	methodologist_yn	Yes
10.3111/13696998.2013.768530	general_information	NA	NA	funding_source	Pharmaceutical Industry
10.3111/13696998.2013.768530	general_information	NA	NA	pharmaceutical_ties_yn	Yes
10.3111/13696998.2013.768530	general_information	NA	NA	systematic_review_yn	Yes
10.3111/13696998.2013.768530	methodology	1	NA	outcome_name	proportion of patients who achieved acr70 at week 12
10.3111/13696998.2013.768530	methodology	1	NA	outcome_short_name	ACR Response Rate
10.3111/13696998.2013.768530	methodology	1	NA	outcome_variable_type	Binary (eg rates)
10.3111/13696998.2013.768530	methodology	1	NA	treatment_name_ipd	adalimumab
10.3111/13696998.2013.768530	methodology	1	NA	studies_number_ipd	1
10.3111/13696998.2013.768530	methodology	1	NA	treatment_name_nonipd	etanercept
10.3111/13696998.2013.768530	methodology	1	NA	studies_number_nonipd	2
10.3111/13696998.2013.768530	methodology	1	NA	paic_type	MAIC
10.3111/13696998.2013.768530	methodology	1	NA	anchored_yn	Yes
10.3111/13696998.2013.768530	methodology	1	NA	paic_form	Simple (ie treatments effects extracted from two studies)
10.3111/13696998.2013.768530	methodology	1	NA	primary_outcome_yn	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.3111/13696998.2013.768530	methodology	1	NA	variables_selection_justification	Nothing mentioned, not reported
10.3111/13696998.2013.768530	methodology	1	NA	pf_yn	No discussion (in the main text) of the status of prognostic factors of the variables
10.3111/13696998.2013.768530	methodology	1	NA	tem_yn	No discussion (in the main text) of the status of treatment-effect modifiers of the variables
10.3111/13696998.2013.768530	methodology	1	NA	adjustment_model_details_yn	No
10.3111/13696998.2013.768530	methodology	1	NA	scale_choice_yn	No
10.3111/13696998.2013.768530	methodology	2	NA	outcome_name	proportion of patients who achieved acr70 at week 14
10.3111/13696998.2013.768530	methodology	2	NA	outcome_short_name	ACR Response Rate
10.3111/13696998.2013.768530	methodology	2	NA	outcome_variable_type	Binary (eg rates)
10.3111/13696998.2013.768530	methodology	2	NA	treatment_name_ipd	adalimumab
10.3111/13696998.2013.768530	methodology	2	NA	studies_number_ipd	1
10.3111/13696998.2013.768530	methodology	2	NA	treatment_name_nonipd	infliximab
10.3111/13696998.2013.768530	methodology	2	NA	studies_number_nonipd	3
10.3111/13696998.2013.768530	methodology	2	NA	paic_type	MAIC
10.3111/13696998.2013.768530	methodology	2	NA	anchored_yn	Yes
10.3111/13696998.2013.768530	methodology	2	NA	paic_form	Simple (ie treatments effects extracted from two studies)
10.3111/13696998.2013.768530	methodology	2	NA	primary_outcome_yn	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.3111/13696998.2013.768530	methodology	2	NA	variables_selection_justification	Nothing mentioned, not reported
10.3111/13696998.2013.768530	methodology	2	NA	pf_yn	No discussion (in the main text) of the status of prognostic factors of the variables
10.3111/13696998.2013.768530	methodology	2	NA	tem_yn	No discussion (in the main text) of the status of treatment-effect modifiers of the variables
10.3111/13696998.2013.768530	methodology	2	NA	adjustment_model_details_yn	No
10.3111/13696998.2013.768530	methodology	2	NA	scale_choice_yn	No
10.3111/13696998.2013.768530	results	1	NA	contrast_effect_type	Proportion difference
10.3111/13696998.2013.768530	results	1	NA	direction_benefit	superior
10.3111/13696998.2013.768530	results	1	NA	ss_ttt_nonipd	101
10.3111/13696998.2013.768530	results	1	NA	ss_ttt_ipd	142
10.3111/13696998.2013.768530	results	1	NA	ss_adjusted_ttt_ipd	NA
10.3111/13696998.2013.768530	results	1	NA	weights_yn	Not mentioned
10.3111/13696998.2013.768530	results	1	NA	covariates_yn	Yes
10.3111/13696998.2013.768530	results	1	NA	covariates_n	12
10.3111/13696998.2013.768530	results	1	NA	covariates_names	Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Race/ethnicity, Past treatments for the disease of interest
10.3111/13696998.2013.768530	results	1	NA	contrast_effect_direction	Numerator if ratio, or left side if difference
10.3111/13696998.2013.768530	results	1	NA	contrast_effect_unadjusted_value	NA
10.3111/13696998.2013.768530	results	1	NA	contrast_effect_unadjusted_pvalci	NA
10.3111/13696998.2013.768530	results	1	NA	contrast_effect_adjusted_value	0.097
10.3111/13696998.2013.768530	results	1	NA	contrast_effect_adjusted_pvalci	0.055
10.3111/13696998.2013.768530	results	1	NA	adjustment_geographical	NA
10.3111/13696998.2013.768530	results	1	NA	ss_total_ipd	NA
10.3111/13696998.2013.768530	results	1	NA	ss_adjusted_total_ipd	NA
10.3111/13696998.2013.768530	results	1	NA	ss_total_nonipd	NA
10.3111/13696998.2013.768530	results	1	NA	ss_anchor_nonipd	104
10.3111/13696998.2013.768530	results	1	NA	ss_anchor_ipd	154
10.3111/13696998.2013.768530	results	1	NA	ss_adjusted_anchor_ipd	NA
10.3111/13696998.2013.768530	results	1	NA	effect_cutoff	0
10.3111/13696998.2013.768530	results	1	NA	adjusted_pval	0.055
10.3111/13696998.2013.768530	results	1	NA	adjusted_num_pval	0.055
10.3111/13696998.2013.768530	results	1	NA	adjusted_significant	FALSE
10.3111/13696998.2013.768530	results	2	NA	contrast_effect_type	Proportion difference
10.3111/13696998.2013.768530	results	2	NA	direction_benefit	superior
10.3111/13696998.2013.768530	results	2	NA	ss_ttt_nonipd	100
10.3111/13696998.2013.768530	results	2	NA	ss_ttt_ipd	108
10.3111/13696998.2013.768530	results	2	NA	ss_adjusted_ttt_ipd	NA
10.3111/13696998.2013.768530	results	2	NA	weights_yn	Not mentioned
10.3111/13696998.2013.768530	results	2	NA	covariates_yn	Yes
10.3111/13696998.2013.768530	results	2	NA	covariates_n	17
10.3111/13696998.2013.768530	results	2	NA	covariates_names	Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Past treatments for the disease of interest
10.3111/13696998.2013.768530	results	2	NA	contrast_effect_direction	Numerator if ratio, or left side if difference
10.3111/13696998.2013.768530	results	2	NA	contrast_effect_unadjusted_value	NA
10.3111/13696998.2013.768530	results	2	NA	contrast_effect_unadjusted_pvalci	NA
10.3111/13696998.2013.768530	results	2	NA	contrast_effect_adjusted_value	0.189
10.3111/13696998.2013.768530	results	2	NA	contrast_effect_adjusted_pvalci	0.034
10.3111/13696998.2013.768530	results	2	NA	adjustment_geographical	NA
10.3111/13696998.2013.768530	results	2	NA	ss_total_ipd	NA
10.3111/13696998.2013.768530	results	2	NA	ss_adjusted_total_ipd	NA
10.3111/13696998.2013.768530	results	2	NA	ss_total_nonipd	NA
10.3111/13696998.2013.768530	results	2	NA	ss_anchor_nonipd	100
10.3111/13696998.2013.768530	results	2	NA	ss_anchor_ipd	126
10.3111/13696998.2013.768530	results	2	NA	ss_adjusted_anchor_ipd	NA
10.3111/13696998.2013.768530	results	2	NA	effect_cutoff	0
10.3111/13696998.2013.768530	results	2	NA	adjusted_pval	0.034
10.3111/13696998.2013.768530	results	2	NA	adjusted_num_pval	0.034
10.3111/13696998.2013.768530	results	2	NA	adjusted_significant	TRUE
10.3111/13696998.2013.768530	study_information	NA	1	ipd_yn	Yes
10.3111/13696998.2013.768530	study_information	NA	1	ct_yn	Yes
10.3111/13696998.2013.768530	study_information	NA	1	nct	NCT00195689
10.3111/13696998.2013.768530	study_information	NA	1	country_study	usa
10.3111/13696998.2013.768530	study_information	NA	1	ct_phase	3
10.3111/13696998.2013.768530	study_information	NA	1	ct_arms	2 or more
10.3111/13696998.2013.768530	study_information	NA	2	ipd_yn	No
10.3111/13696998.2013.768530	study_information	NA	2	ct_yn	Yes
10.3111/13696998.2013.768530	study_information	NA	2	data_source_name	mease et al. (2004)
10.3111/13696998.2013.768530	study_information	NA	2	country_study	usa
10.3111/13696998.2013.768530	study_information	NA	2	ct_phase	3
10.3111/13696998.2013.768530	study_information	NA	2	ct_arms	2 or more
10.3111/13696998.2013.768530	study_information	NA	3	ipd_yn	No
10.3111/13696998.2013.768530	study_information	NA	3	ct_yn	Yes
10.3111/13696998.2013.768530	study_information	NA	3	country_study	international
10.3111/13696998.2013.768530	study_information	NA	3	ct_phase	3
10.3111/13696998.2013.768530	study_information	NA	3	ct_arms	2 or more
10.3111/13696998.2013.768530	study_information	NA	3	nct	NCT00051623
10.3390/biom11060780	general_information	NA	NA	condition_name	metastatic pancreatic cancer
10.3390/biom11060780	general_information	NA	NA	country_first_author	italy
10.3390/biom11060780	general_information	NA	NA	country_last_author	italy
10.3390/biom11060780	general_information	NA	NA	positions	Academic
10.3390/biom11060780	general_information	NA	NA	methodologist_yn	Not mentioned
10.3390/biom11060780	general_information	NA	NA	funding_source	No fundings
10.3390/biom11060780	general_information	NA	NA	pharmaceutical_ties_yn	None
10.3390/biom11060780	general_information	NA	NA	systematic_review_yn	No
10.3390/biom11060780	methodology	1	NA	outcome_name	overall survival (os)
10.3390/biom11060780	methodology	1	NA	outcome_short_name	Overall Survival
10.3390/biom11060780	methodology	1	NA	outcome_variable_type	Time-to-event
10.3390/biom11060780	methodology	1	NA	treatment_name_ipd	gemcitabine + nab-paclitaxel
10.3390/biom11060780	methodology	1	NA	studies_number_ipd	1
10.3390/biom11060780	methodology	1	NA	treatment_name_nonipd	folfirinox
10.3390/biom11060780	methodology	1	NA	studies_number_nonipd	2
10.3390/biom11060780	methodology	1	NA	paic_type	MAIC
10.3390/biom11060780	methodology	1	NA	anchored_yn	No
10.3390/biom11060780	methodology	1	NA	paic_form	Simple (ie treatments effects extracted from two studies)
10.3390/biom11060780	methodology	1	NA	primary_outcome_yn	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.3390/biom11060780	methodology	1	NA	variables_selection_justification	Nothing mentioned, not reported
10.3390/biom11060780	methodology	1	NA	pf_yn	No discussion (in the main text) of the status of prognostic factors of the variables
10.3390/biom11060780	methodology	1	NA	tem_yn	No discussion (in the main text) of the status of treatment-effect modifiers of the variables
10.3390/biom11060780	methodology	1	NA	adjustment_model_details_yn	No
10.3390/biom11060780	methodology	1	NA	scale_choice_yn	No
10.3390/biom11060780	results	1	NA	contrast_effect_type	HR
10.3390/biom11060780	results	1	NA	direction_benefit	inferior
10.3390/biom11060780	results	1	NA	ss_ttt_nonipd	171
10.3390/biom11060780	results	1	NA	ss_ttt_ipd	268
10.3390/biom11060780	results	1	NA	ss_adjusted_ttt_ipd	NA
10.3390/biom11060780	results	1	NA	weights_yn	Not mentioned
10.3390/biom11060780	results	1	NA	covariates_yn	Yes
10.3390/biom11060780	results	1	NA	covariates_n	NA
10.3390/biom11060780	results	1	NA	covariates_names	Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Past treatments for the disease of interest, Comorbidities and medical history (beside pathology/disease of interest in the comparison)
10.3390/biom11060780	results	1	NA	contrast_effect_direction	Denominator if ratio, or rightside if difference
10.3390/biom11060780	results	1	NA	contrast_effect_unadjusted_value	NA
10.3390/biom11060780	results	1	NA	contrast_effect_unadjusted_pvalci	NA
10.3390/biom11060780	results	1	NA	contrast_effect_adjusted_value	1.1
10.3390/biom11060780	results	1	NA	contrast_effect_adjusted_pvalci	0.527
10.3390/biom11060780	results	1	NA	adjustment_geographical	NA
10.3390/biom11060780	results	1	NA	ss_total_ipd	NA
10.3390/biom11060780	results	1	NA	ss_adjusted_total_ipd	NA
10.3390/biom11060780	results	1	NA	ss_total_nonipd	NA
10.3390/biom11060780	results	1	NA	ss_anchor_nonipd	NA
10.3390/biom11060780	results	1	NA	ss_anchor_ipd	NA
10.3390/biom11060780	results	1	NA	ss_adjusted_anchor_ipd	NA
10.3390/biom11060780	results	1	NA	effect_cutoff	1
10.3390/biom11060780	results	1	NA	adjusted_pval	0.527
10.3390/biom11060780	results	1	NA	adjusted_num_pval	0.527
10.3390/biom11060780	results	1	NA	adjusted_significant	FALSE
10.3390/biom11060780	study_information	NA	1	ipd_yn	Yes
10.3390/biom11060780	study_information	NA	1	ct_yn	No
10.3390/biom11060780	study_information	NA	1	data_source_name	local retrospective cohort from ehr
10.3390/biom11060780	study_information	NA	1	country_study	italy
10.3390/biom11060780	study_information	NA	2	ipd_yn	No
10.3390/biom11060780	study_information	NA	2	ct_yn	Yes
10.3390/biom11060780	study_information	NA	2	nct	NCT00112658
10.3390/biom11060780	study_information	NA	2	country_study	france
10.3390/biom11060780	study_information	NA	2	ct_phase	2, 3
10.3390/biom11060780	study_information	NA	2	ct_arms	2 or more
10.3390/cancers12123648	general_information	NA	NA	condition_name	metastatic non small cell lung cancer
10.3390/cancers12123648	general_information	NA	NA	country_first_author	usa
10.3390/cancers12123648	general_information	NA	NA	country_last_author	usa
10.3390/cancers12123648	general_information	NA	NA	positions	Academic, Pharmaceutical Industry, Private Data Analysis Company
10.3390/cancers12123648	general_information	NA	NA	methodologist_yn	Yes
10.3390/cancers12123648	general_information	NA	NA	funding_source	Pharmaceutical Industry
10.3390/cancers12123648	general_information	NA	NA	pharmaceutical_ties_yn	Yes
10.3390/cancers12123648	general_information	NA	NA	systematic_review_yn	Yes
10.3390/cancers12123648	methodology	1	NA	outcome_name	overall survival
10.3390/cancers12123648	methodology	1	NA	outcome_short_name	Overall Survival
10.3390/cancers12123648	methodology	1	NA	outcome_variable_type	Time-to-event
10.3390/cancers12123648	methodology	1	NA	treatment_name_ipd	pembrolizumab + chemotherapy
10.3390/cancers12123648	methodology	1	NA	studies_number_ipd	1;2;3
10.3390/cancers12123648	methodology	1	NA	treatment_name_nonipd	nivolumab + ipilimumab
10.3390/cancers12123648	methodology	1	NA	studies_number_nonipd	4
10.3390/cancers12123648	methodology	1	NA	paic_type	MAIC
10.3390/cancers12123648	methodology	1	NA	anchored_yn	Yes
10.3390/cancers12123648	methodology	1	NA	paic_form	Aggregation of multiple studies to estimate individual treatment effects (e.g. meta-analysis in a first step to estimate treatment A effect, then population adjusted indirect comparison using treatment A effect estimate)
10.3390/cancers12123648	methodology	1	NA	primary_outcome_yn	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.3390/cancers12123648	methodology	1	NA	variables_selection_justification	Statistical imbalanced between treatment groups (independently of the status of prognostic/effect modifier), A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion), Literature based (clinically or methodologically relevant to adjust on these variables based on the literature search conducted for this specific purpose)
10.3390/cancers12123648	methodology	1	NA	pf_yn	No
10.3390/cancers12123648	methodology	1	NA	tem_yn	Yes
10.3390/cancers12123648	methodology	1	NA	adjustment_model_details_yn	No
10.3390/cancers12123648	methodology	1	NA	scale_choice_yn	No
10.3390/cancers12123648	results	1	NA	contrast_effect_type	HR
10.3390/cancers12123648	results	1	NA	direction_benefit	inferior
10.3390/cancers12123648	results	1	NA	ss_ttt_nonipd	NA
10.3390/cancers12123648	results	1	NA	ss_ttt_ipd	NA
10.3390/cancers12123648	results	1	NA	ss_adjusted_ttt_ipd	NA
10.3390/cancers12123648	results	1	NA	weights_yn	Not mentioned
10.3390/cancers12123648	results	1	NA	covariates_yn	Yes
10.3390/cancers12123648	results	1	NA	covariates_n	8
10.3390/cancers12123648	results	1	NA	covariates_names	Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Performance score (ECOG PS, Karnofsky, Lansky, OMS, Ranson, ...), Other(s)
10.3390/cancers12123648	results	1	NA	contrast_effect_direction	Numerator if ratio, or left side if difference
10.3390/cancers12123648	results	1	NA	contrast_effect_unadjusted_value	0.84
10.3390/cancers12123648	results	1	NA	contrast_effect_unadjusted_pvalci	0.218
10.3390/cancers12123648	results	1	NA	contrast_effect_adjusted_value	0.8
10.3390/cancers12123648	results	1	NA	contrast_effect_adjusted_pvalci	0.152
10.3390/cancers12123648	results	1	NA	adjustment_geographical	Yes
10.3390/cancers12123648	results	1	NA	ss_total_ipd	816
10.3390/cancers12123648	results	1	NA	ss_adjusted_total_ipd	456
10.3390/cancers12123648	results	1	NA	ss_total_nonipd	793
10.3390/cancers12123648	results	1	NA	ss_anchor_nonipd	NA
10.3390/cancers12123648	results	1	NA	ss_anchor_ipd	NA
10.3390/cancers12123648	results	1	NA	ss_adjusted_anchor_ipd	NA
10.3390/cancers12123648	results	1	NA	effect_cutoff	1
10.3390/cancers12123648	results	1	NA	unadjusted_pval	0.218
10.3390/cancers12123648	results	1	NA	unadjusted_num_pval	0.218
10.3390/cancers12123648	results	1	NA	unadjusted_significant	FALSE
10.3390/cancers12123648	results	1	NA	adjusted_pval	0.152
10.3390/cancers12123648	results	1	NA	adjusted_num_pval	0.152
10.3390/cancers12123648	results	1	NA	adjusted_significant	FALSE
10.3390/cancers12123648	study_information	NA	1	ipd_yn	Yes
10.3390/cancers12123648	study_information	NA	1	ct_yn	Yes
10.3390/cancers12123648	study_information	NA	1	nct	NCT02039674
10.3390/cancers12123648	study_information	NA	1	country_study	unknown
10.3390/cancers12123648	study_information	NA	1	ct_phase	1, 2
10.3390/cancers12123648	study_information	NA	1	ct_arms	2 or more
10.3390/cancers12123648	study_information	NA	2	ipd_yn	Yes
10.3390/cancers12123648	study_information	NA	2	ct_yn	Yes
10.3390/cancers12123648	study_information	NA	2	nct	NCT02578680
10.3390/cancers12123648	study_information	NA	2	country_study	unknown
10.3390/cancers12123648	study_information	NA	2	ct_phase	3
10.3390/cancers12123648	study_information	NA	2	ct_arms	2 or more
10.3390/cancers12123648	study_information	NA	3	ipd_yn	Yes
10.3390/cancers12123648	study_information	NA	3	ct_yn	Yes
10.3390/cancers12123648	study_information	NA	3	nct	NCT02775435
10.3390/cancers12123648	study_information	NA	3	country_study	unknown
10.3390/cancers12123648	study_information	NA	3	ct_phase	3
10.3390/cancers12123648	study_information	NA	3	ct_arms	2 or more
10.3390/cancers12123648	study_information	NA	4	ipd_yn	No
10.3390/cancers12123648	study_information	NA	4	ct_yn	Yes
10.3390/cancers12123648	study_information	NA	4	nct	NCT02477826
10.3390/cancers12123648	study_information	NA	4	country_study	international
10.3390/cancers12123648	study_information	NA	4	ct_phase	3
10.3390/cancers12123648	study_information	NA	4	ct_arms	2 or more
10.3390/cancers13102406	general_information	NA	NA	condition_name	hepatocellular carcinoma
10.3390/cancers13102406	general_information	NA	NA	country_first_author	italy
10.3390/cancers13102406	general_information	NA	NA	country_last_author	italy
10.3390/cancers13102406	general_information	NA	NA	positions	Academic
10.3390/cancers13102406	general_information	NA	NA	methodologist_yn	Not mentioned
10.3390/cancers13102406	general_information	NA	NA	funding_source	No fundings
10.3390/cancers13102406	general_information	NA	NA	pharmaceutical_ties_yn	None
10.3390/cancers13102406	general_information	NA	NA	systematic_review_yn	No
10.3390/cancers13102406	methodology	1	NA	outcome_name	downstaging failures
10.3390/cancers13102406	methodology	1	NA	outcome_short_name	Downstaging failure
10.3390/cancers13102406	methodology	1	NA	outcome_variable_type	Binary (eg rates)
10.3390/cancers13102406	methodology	1	NA	treatment_name_ipd	padua surgical aggressive downstaging
10.3390/cancers13102406	methodology	1	NA	studies_number_ipd	1
10.3390/cancers13102406	methodology	1	NA	treatment_name_nonipd	xxl protocol downstaging
10.3390/cancers13102406	methodology	1	NA	studies_number_nonipd	2
10.3390/cancers13102406	methodology	1	NA	paic_type	MAIC
10.3390/cancers13102406	methodology	1	NA	anchored_yn	No
10.3390/cancers13102406	methodology	1	NA	paic_form	Simple (ie treatments effects extracted from two studies)
10.3390/cancers13102406	methodology	1	NA	primary_outcome_yn	Yes
10.3390/cancers13102406	methodology	1	NA	variables_selection_justification	Nothing mentioned, not reported
10.3390/cancers13102406	methodology	1	NA	pf_yn	No discussion (in the main text) of the status of prognostic factors of the variables
10.3390/cancers13102406	methodology	1	NA	tem_yn	No discussion (in the main text) of the status of treatment-effect modifiers of the variables
10.3390/cancers13102406	methodology	1	NA	adjustment_model_details_yn	No
10.3390/cancers13102406	methodology	1	NA	scale_choice_yn	No
10.3390/cancers13102406	results	1	NA	contrast_effect_type	NA
10.3390/cancers13102406	results	1	NA	direction_benefit	inferior
10.3390/cancers13102406	results	1	NA	ss_ttt_nonipd	74
10.3390/cancers13102406	results	1	NA	ss_ttt_ipd	191
10.3390/cancers13102406	results	1	NA	ss_adjusted_ttt_ipd	NA
10.3390/cancers13102406	results	1	NA	weights_yn	Not mentioned
10.3390/cancers13102406	results	1	NA	covariates_yn	No
10.3390/cancers13102406	results	1	NA	covariates_n	NA
10.3390/cancers13102406	results	1	NA	covariates_names	NA
10.3390/cancers13102406	results	1	NA	contrast_effect_direction	NA
10.3390/cancers13102406	results	1	NA	contrast_effect_unadjusted_value	NA
10.3390/cancers13102406	results	1	NA	contrast_effect_unadjusted_pvalci	NA
10.3390/cancers13102406	results	1	NA	contrast_effect_adjusted_value	NA
10.3390/cancers13102406	results	1	NA	contrast_effect_adjusted_pvalci	NA
10.3390/cancers13102406	results	1	NA	adjustment_geographical	NA
10.3390/cancers13102406	results	1	NA	ss_total_ipd	NA
10.3390/cancers13102406	results	1	NA	ss_adjusted_total_ipd	NA
10.3390/cancers13102406	results	1	NA	ss_total_nonipd	NA
10.3390/cancers13102406	results	1	NA	ss_anchor_nonipd	NA
10.3390/cancers13102406	results	1	NA	ss_anchor_ipd	NA
10.3390/cancers13102406	results	1	NA	ss_adjusted_anchor_ipd	NA
10.3390/cancers13102406	results	1	NA	effect_cutoff	NA
10.3390/cancers13102406	study_information	NA	1	ipd_yn	Yes
10.3390/cancers13102406	study_information	NA	1	ct_yn	No
10.3390/cancers13102406	study_information	NA	1	data_source_name	retrospective cohort of patients affected by hcc who underwent surgical at the hepatobiliary surgery and liver transplantation unit, university of padua.
10.3390/cancers13102406	study_information	NA	1	country_study	italy
10.3390/cancers13102406	study_information	NA	2	ipd_yn	No
10.3390/cancers13102406	study_information	NA	2	ct_yn	Yes
10.3390/cancers13102406	study_information	NA	2	nct	NCT01387503
10.3390/cancers13102406	study_information	NA	2	country_study	italy
10.3390/cancers13102406	study_information	NA	2	ct_phase	2, 3
10.3390/cancers13102406	study_information	NA	2	ct_arms	2 or more
10.36469/jheor.2021.19008	general_information	NA	NA	condition_name	steroid-refractory acute graft-versus-host disease
10.36469/jheor.2021.19008	general_information	NA	NA	country_first_author	usa
10.36469/jheor.2021.19008	general_information	NA	NA	country_last_author	usa
10.36469/jheor.2021.19008	general_information	NA	NA	positions	Pharmaceutical Industry, Private Data Analysis Company
10.36469/jheor.2021.19008	general_information	NA	NA	methodologist_yn	Yes
10.36469/jheor.2021.19008	general_information	NA	NA	funding_source	None mentioned
10.36469/jheor.2021.19008	general_information	NA	NA	pharmaceutical_ties_yn	No such section presenting competing interest/conflict of interest
10.36469/jheor.2021.19008	general_information	NA	NA	systematic_review_yn	No
10.36469/jheor.2021.19008	methodology	1	NA	outcome_name	day 28 overall response rate (orr)
10.36469/jheor.2021.19008	methodology	1	NA	outcome_short_name	Overall Response Rate
10.36469/jheor.2021.19008	methodology	1	NA	outcome_variable_type	Binary (eg rates)
10.36469/jheor.2021.19008	methodology	1	NA	treatment_name_ipd	remestemcel-l-rknd
10.36469/jheor.2021.19008	methodology	1	NA	studies_number_ipd	1
10.36469/jheor.2021.19008	methodology	1	NA	treatment_name_nonipd	ruxolitinib
10.36469/jheor.2021.19008	methodology	1	NA	studies_number_nonipd	2
10.36469/jheor.2021.19008	methodology	1	NA	paic_type	STC
10.36469/jheor.2021.19008	methodology	1	NA	anchored_yn	No
10.36469/jheor.2021.19008	methodology	1	NA	paic_form	Simple (ie treatments effects extracted from two studies)
10.36469/jheor.2021.19008	methodology	1	NA	primary_outcome_yn	Yes
10.36469/jheor.2021.19008	methodology	1	NA	variables_selection_justification	Status of prognostic factor/treatment effect modified assessed in the IPD dataset, A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion), Literature based (clinically or methodologically relevant to adjust on these variables based on the literature search conducted for this specific purpose)
10.36469/jheor.2021.19008	methodology	1	NA	pf_yn	Yes
10.36469/jheor.2021.19008	methodology	1	NA	tem_yn	Yes
10.36469/jheor.2021.19008	methodology	1	NA	adjustment_model_details_yn	No
10.36469/jheor.2021.19008	methodology	1	NA	scale_choice_yn	No
10.36469/jheor.2021.19008	results	1	NA	contrast_effect_type	RR
10.36469/jheor.2021.19008	results	1	NA	direction_benefit	superior
10.36469/jheor.2021.19008	results	1	NA	ss_ttt_nonipd	49
10.36469/jheor.2021.19008	results	1	NA	ss_ttt_ipd	55
10.36469/jheor.2021.19008	results	1	NA	ss_adjusted_ttt_ipd	55
10.36469/jheor.2021.19008	results	1	NA	weights_yn	NA
10.36469/jheor.2021.19008	results	1	NA	covariates_yn	Yes
10.36469/jheor.2021.19008	results	1	NA	covariates_n	3
10.36469/jheor.2021.19008	results	1	NA	covariates_names	Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Race/ethnicity
10.36469/jheor.2021.19008	results	1	NA	contrast_effect_direction	Numerator if ratio, or left side if difference
10.36469/jheor.2021.19008	results	1	NA	contrast_effect_unadjusted_value	1.21
10.36469/jheor.2021.19008	results	1	NA	contrast_effect_unadjusted_pvalci	0.21
10.36469/jheor.2021.19008	results	1	NA	contrast_effect_adjusted_value	1.13
10.36469/jheor.2021.19008	results	1	NA	contrast_effect_adjusted_pvalci	0.45
10.36469/jheor.2021.19008	results	1	NA	adjustment_geographical	NA
10.36469/jheor.2021.19008	results	1	NA	ss_total_ipd	NA
10.36469/jheor.2021.19008	results	1	NA	ss_adjusted_total_ipd	NA
10.36469/jheor.2021.19008	results	1	NA	ss_total_nonipd	NA
10.36469/jheor.2021.19008	results	1	NA	ss_anchor_nonipd	NA
10.36469/jheor.2021.19008	results	1	NA	ss_anchor_ipd	NA
10.36469/jheor.2021.19008	results	1	NA	ss_adjusted_anchor_ipd	NA
10.36469/jheor.2021.19008	results	1	NA	effect_cutoff	1
10.36469/jheor.2021.19008	results	1	NA	unadjusted_pval	0.21
10.36469/jheor.2021.19008	results	1	NA	unadjusted_num_pval	0.21
10.36469/jheor.2021.19008	results	1	NA	unadjusted_significant	FALSE
10.36469/jheor.2021.19008	results	1	NA	adjusted_pval	0.45
10.36469/jheor.2021.19008	results	1	NA	adjusted_num_pval	0.45
10.36469/jheor.2021.19008	results	1	NA	adjusted_significant	FALSE
10.36469/jheor.2021.19008	study_information	NA	1	ipd_yn	Yes
10.36469/jheor.2021.19008	study_information	NA	1	ct_yn	Yes
10.36469/jheor.2021.19008	study_information	NA	1	nct	NCT02336230
10.36469/jheor.2021.19008	study_information	NA	1	country_study	usa
10.36469/jheor.2021.19008	study_information	NA	1	ct_phase	3
10.36469/jheor.2021.19008	study_information	NA	1	ct_arms	1
10.36469/jheor.2021.19008	study_information	NA	2	ipd_yn	No
10.36469/jheor.2021.19008	study_information	NA	2	ct_yn	Yes
10.36469/jheor.2021.19008	study_information	NA	2	nct	NCT02953678
10.36469/jheor.2021.19008	study_information	NA	2	country_study	usa
10.36469/jheor.2021.19008	study_information	NA	2	ct_phase	2
10.36469/jheor.2021.19008	study_information	NA	2	ct_arms	1
10.5152/eurjrheum.2018.18162	general_information	NA	NA	condition_name	ankylosing spondylitis
10.5152/eurjrheum.2018.18162	general_information	NA	NA	country_first_author	canada
10.5152/eurjrheum.2018.18162	general_information	NA	NA	country_last_author	switzerland
10.5152/eurjrheum.2018.18162	general_information	NA	NA	positions	Academic, Pharmaceutical Industry, Private Data Analysis Company
10.5152/eurjrheum.2018.18162	general_information	NA	NA	methodologist_yn	Yes
10.5152/eurjrheum.2018.18162	general_information	NA	NA	funding_source	Pharmaceutical Industry
10.5152/eurjrheum.2018.18162	general_information	NA	NA	pharmaceutical_ties_yn	Yes
10.5152/eurjrheum.2018.18162	general_information	NA	NA	systematic_review_yn	Yes
10.5152/eurjrheum.2018.18162	methodology	1	NA	outcome_name	assessment of spondylarthritis international society (asas) 20 response rate at week 8
10.5152/eurjrheum.2018.18162	methodology	1	NA	outcome_short_name	ASAS 20 response rate
10.5152/eurjrheum.2018.18162	methodology	1	NA	outcome_variable_type	Binary (eg rates)
10.5152/eurjrheum.2018.18162	methodology	1	NA	treatment_name_ipd	secukinumab
10.5152/eurjrheum.2018.18162	methodology	1	NA	studies_number_ipd	1;2
10.5152/eurjrheum.2018.18162	methodology	1	NA	treatment_name_nonipd	adalimumab
10.5152/eurjrheum.2018.18162	methodology	1	NA	studies_number_nonipd	3
10.5152/eurjrheum.2018.18162	methodology	1	NA	paic_type	MAIC
10.5152/eurjrheum.2018.18162	methodology	1	NA	anchored_yn	Yes
10.5152/eurjrheum.2018.18162	methodology	1	NA	paic_form	Aggregation of multiple studies to estimate individual treatment effects (e.g. meta-analysis in a first step to estimate treatment A effect, then population adjusted indirect comparison using treatment A effect estimate)
10.5152/eurjrheum.2018.18162	methodology	1	NA	primary_outcome_yn	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.5152/eurjrheum.2018.18162	methodology	1	NA	variables_selection_justification	Status of prognostic factor/treatment effect modified assessed in the IPD dataset, A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion), Literature based (clinically or methodologically relevant to adjust on these variables based on the literature search conducted for this specific purpose)
10.5152/eurjrheum.2018.18162	methodology	1	NA	pf_yn	Yes
10.5152/eurjrheum.2018.18162	methodology	1	NA	tem_yn	Yes
10.5152/eurjrheum.2018.18162	methodology	1	NA	adjustment_model_details_yn	No
10.5152/eurjrheum.2018.18162	methodology	1	NA	scale_choice_yn	No
10.5152/eurjrheum.2018.18162	methodology	2	NA	outcome_name	assessment of spondylarthritis international society (asas) 20 response rate at week 16
10.5152/eurjrheum.2018.18162	methodology	2	NA	outcome_short_name	ASAS 20 response rate
10.5152/eurjrheum.2018.18162	methodology	2	NA	outcome_variable_type	Binary (eg rates)
10.5152/eurjrheum.2018.18162	methodology	2	NA	treatment_name_ipd	secukinumab
10.5152/eurjrheum.2018.18162	methodology	2	NA	studies_number_ipd	1;2
10.5152/eurjrheum.2018.18162	methodology	2	NA	treatment_name_nonipd	adalimumab
10.5152/eurjrheum.2018.18162	methodology	2	NA	studies_number_nonipd	3
10.5152/eurjrheum.2018.18162	methodology	2	NA	paic_type	MAIC
10.5152/eurjrheum.2018.18162	methodology	2	NA	anchored_yn	No
10.5152/eurjrheum.2018.18162	methodology	2	NA	paic_form	Aggregation of multiple studies to estimate individual treatment effects (e.g. meta-analysis in a first step to estimate treatment A effect, then population adjusted indirect comparison using treatment A effect estimate)
10.5152/eurjrheum.2018.18162	methodology	2	NA	primary_outcome_yn	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.5152/eurjrheum.2018.18162	methodology	2	NA	variables_selection_justification	Status of prognostic factor/treatment effect modified assessed in the IPD dataset, A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion), Literature based (clinically or methodologically relevant to adjust on these variables based on the literature search conducted for this specific purpose)
10.5152/eurjrheum.2018.18162	methodology	2	NA	pf_yn	Yes
10.5152/eurjrheum.2018.18162	methodology	2	NA	tem_yn	Yes
10.5152/eurjrheum.2018.18162	methodology	2	NA	adjustment_model_details_yn	No
10.5152/eurjrheum.2018.18162	methodology	2	NA	scale_choice_yn	No
10.5152/eurjrheum.2018.18162	results	1	NA	contrast_effect_type	OR
10.5152/eurjrheum.2018.18162	results	1	NA	direction_benefit	superior
10.5152/eurjrheum.2018.18162	results	1	NA	ss_ttt_nonipd	208
10.5152/eurjrheum.2018.18162	results	1	NA	ss_ttt_ipd	197
10.5152/eurjrheum.2018.18162	results	1	NA	ss_adjusted_ttt_ipd	120
10.5152/eurjrheum.2018.18162	results	1	NA	weights_yn	Not mentioned
10.5152/eurjrheum.2018.18162	results	1	NA	covariates_yn	Yes
10.5152/eurjrheum.2018.18162	results	1	NA	covariates_n	5
10.5152/eurjrheum.2018.18162	results	1	NA	covariates_names	Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Past treatments for the disease of interest
10.5152/eurjrheum.2018.18162	results	1	NA	contrast_effect_direction	Numerator if ratio, or left side if difference
10.5152/eurjrheum.2018.18162	results	1	NA	contrast_effect_unadjusted_value	NA
10.5152/eurjrheum.2018.18162	results	1	NA	contrast_effect_unadjusted_pvalci	NA
10.5152/eurjrheum.2018.18162	results	1	NA	contrast_effect_adjusted_value	0.91
10.5152/eurjrheum.2018.18162	results	1	NA	contrast_effect_adjusted_pvalci	0.795
10.5152/eurjrheum.2018.18162	results	1	NA	adjustment_geographical	NA
10.5152/eurjrheum.2018.18162	results	1	NA	ss_total_ipd	NA
10.5152/eurjrheum.2018.18162	results	1	NA	ss_adjusted_total_ipd	NA
10.5152/eurjrheum.2018.18162	results	1	NA	ss_total_nonipd	NA
10.5152/eurjrheum.2018.18162	results	1	NA	ss_anchor_nonipd	107
10.5152/eurjrheum.2018.18162	results	1	NA	ss_anchor_ipd	196
10.5152/eurjrheum.2018.18162	results	1	NA	ss_adjusted_anchor_ipd	120
10.5152/eurjrheum.2018.18162	results	1	NA	effect_cutoff	1
10.5152/eurjrheum.2018.18162	results	1	NA	adjusted_pval	0.795
10.5152/eurjrheum.2018.18162	results	1	NA	adjusted_num_pval	0.795
10.5152/eurjrheum.2018.18162	results	1	NA	adjusted_significant	FALSE
10.5152/eurjrheum.2018.18162	results	2	NA	contrast_effect_type	OR
10.5152/eurjrheum.2018.18162	results	2	NA	direction_benefit	superior
10.5152/eurjrheum.2018.18162	results	2	NA	ss_ttt_nonipd	208
10.5152/eurjrheum.2018.18162	results	2	NA	ss_ttt_ipd	197
10.5152/eurjrheum.2018.18162	results	2	NA	ss_adjusted_ttt_ipd	120
10.5152/eurjrheum.2018.18162	results	2	NA	weights_yn	Not mentioned
10.5152/eurjrheum.2018.18162	results	2	NA	covariates_yn	Yes
10.5152/eurjrheum.2018.18162	results	2	NA	covariates_n	5
10.5152/eurjrheum.2018.18162	results	2	NA	covariates_names	Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Past treatments for the disease of interest
10.5152/eurjrheum.2018.18162	results	2	NA	contrast_effect_direction	Numerator if ratio, or left side if difference
10.5152/eurjrheum.2018.18162	results	2	NA	contrast_effect_unadjusted_value	NA
10.5152/eurjrheum.2018.18162	results	2	NA	contrast_effect_unadjusted_pvalci	NA
10.5152/eurjrheum.2018.18162	results	2	NA	contrast_effect_adjusted_value	1.6
10.5152/eurjrheum.2018.18162	results	2	NA	contrast_effect_adjusted_pvalci	0.047
10.5152/eurjrheum.2018.18162	results	2	NA	adjustment_geographical	NA
10.5152/eurjrheum.2018.18162	results	2	NA	ss_total_ipd	NA
10.5152/eurjrheum.2018.18162	results	2	NA	ss_adjusted_total_ipd	NA
10.5152/eurjrheum.2018.18162	results	2	NA	ss_total_nonipd	NA
10.5152/eurjrheum.2018.18162	results	2	NA	ss_anchor_nonipd	NA
10.5152/eurjrheum.2018.18162	results	2	NA	ss_anchor_ipd	NA
10.5152/eurjrheum.2018.18162	results	2	NA	ss_adjusted_anchor_ipd	NA
10.5152/eurjrheum.2018.18162	results	2	NA	effect_cutoff	1
10.5152/eurjrheum.2018.18162	results	2	NA	adjusted_pval	0.047
10.5152/eurjrheum.2018.18162	results	2	NA	adjusted_num_pval	0.047
10.5152/eurjrheum.2018.18162	results	2	NA	adjusted_significant	TRUE
10.5152/eurjrheum.2018.18162	study_information	NA	1	ipd_yn	Yes
10.5152/eurjrheum.2018.18162	study_information	NA	1	ct_yn	Yes
10.5152/eurjrheum.2018.18162	study_information	NA	1	nct	NCT01358175
10.5152/eurjrheum.2018.18162	study_information	NA	1	country_study	international
10.5152/eurjrheum.2018.18162	study_information	NA	1	ct_phase	3
10.5152/eurjrheum.2018.18162	study_information	NA	1	ct_arms	2 or more
10.5152/eurjrheum.2018.18162	study_information	NA	2	ipd_yn	Yes
10.5152/eurjrheum.2018.18162	study_information	NA	2	ct_yn	Yes
10.5152/eurjrheum.2018.18162	study_information	NA	2	nct	NCT01649375
10.5152/eurjrheum.2018.18162	study_information	NA	2	country_study	international
10.5152/eurjrheum.2018.18162	study_information	NA	2	ct_phase	3
10.5152/eurjrheum.2018.18162	study_information	NA	2	ct_arms	2 or more
10.5152/eurjrheum.2018.18162	study_information	NA	3	ipd_yn	No
10.5152/eurjrheum.2018.18162	study_information	NA	3	ct_yn	Yes
10.5152/eurjrheum.2018.18162	study_information	NA	3	nct	NCT00085644
10.5152/eurjrheum.2018.18162	study_information	NA	3	country_study	usa
10.5152/eurjrheum.2018.18162	study_information	NA	3	ct_phase	3
10.5152/eurjrheum.2018.18162	study_information	NA	3	ct_arms	2 or more
10.5152/eurjrheum.2019.19057	general_information	NA	NA	condition_name	psoriatic arthritis
10.5152/eurjrheum.2019.19057	general_information	NA	NA	country_first_author	usa
10.5152/eurjrheum.2019.19057	general_information	NA	NA	country_last_author	uk
10.5152/eurjrheum.2019.19057	general_information	NA	NA	positions	Academic, Pharmaceutical Industry, Private Data Analysis Company
10.5152/eurjrheum.2019.19057	general_information	NA	NA	methodologist_yn	Yes
10.5152/eurjrheum.2019.19057	general_information	NA	NA	funding_source	Pharmaceutical Industry
10.5152/eurjrheum.2019.19057	general_information	NA	NA	pharmaceutical_ties_yn	Yes
10.5152/eurjrheum.2019.19057	general_information	NA	NA	systematic_review_yn	Yes
10.5152/eurjrheum.2019.19057	methodology	1	NA	outcome_name	acr 20 (american college of rheumatology ) response rates at week 12
10.5152/eurjrheum.2019.19057	methodology	1	NA	outcome_short_name	ACR Response Rate
10.5152/eurjrheum.2019.19057	methodology	1	NA	outcome_variable_type	Binary (eg rates)
10.5152/eurjrheum.2019.19057	methodology	1	NA	treatment_name_ipd	secukinumab 150 mg
10.5152/eurjrheum.2019.19057	methodology	1	NA	studies_number_ipd	1;2;3
10.5152/eurjrheum.2019.19057	methodology	1	NA	treatment_name_nonipd	etanercept
10.5152/eurjrheum.2019.19057	methodology	1	NA	studies_number_nonipd	4
10.5152/eurjrheum.2019.19057	methodology	1	NA	paic_type	MAIC
10.5152/eurjrheum.2019.19057	methodology	1	NA	anchored_yn	Yes
10.5152/eurjrheum.2019.19057	methodology	1	NA	paic_form	Aggregation of multiple studies to estimate individual treatment effects (e.g. meta-analysis in a first step to estimate treatment A effect, then population adjusted indirect comparison using treatment A effect estimate)
10.5152/eurjrheum.2019.19057	methodology	1	NA	primary_outcome_yn	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.5152/eurjrheum.2019.19057	methodology	1	NA	variables_selection_justification	Status of prognostic factor/treatment effect modified assessed in the IPD dataset, A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion), Literature based (clinically or methodologically relevant to adjust on these variables based on the literature search conducted for this specific purpose)
10.5152/eurjrheum.2019.19057	methodology	1	NA	pf_yn	Yes
10.5152/eurjrheum.2019.19057	methodology	1	NA	tem_yn	Yes
10.5152/eurjrheum.2019.19057	methodology	1	NA	adjustment_model_details_yn	No
10.5152/eurjrheum.2019.19057	methodology	1	NA	scale_choice_yn	No
10.5152/eurjrheum.2019.19057	methodology	2	NA	outcome_name	acr 20 (american college of rheumatology ) response rates at week 24
10.5152/eurjrheum.2019.19057	methodology	2	NA	outcome_short_name	ACR Response Rate
10.5152/eurjrheum.2019.19057	methodology	2	NA	outcome_variable_type	Binary (eg rates)
10.5152/eurjrheum.2019.19057	methodology	2	NA	treatment_name_ipd	secukinumab 150 mg
10.5152/eurjrheum.2019.19057	methodology	2	NA	studies_number_ipd	1;2;3
10.5152/eurjrheum.2019.19057	methodology	2	NA	treatment_name_nonipd	etanercept
10.5152/eurjrheum.2019.19057	methodology	2	NA	studies_number_nonipd	4
10.5152/eurjrheum.2019.19057	methodology	2	NA	paic_type	MAIC
10.5152/eurjrheum.2019.19057	methodology	2	NA	anchored_yn	No
10.5152/eurjrheum.2019.19057	methodology	2	NA	paic_form	Aggregation of multiple studies to estimate individual treatment effects (e.g. meta-analysis in a first step to estimate treatment A effect, then population adjusted indirect comparison using treatment A effect estimate)
10.5152/eurjrheum.2019.19057	methodology	2	NA	primary_outcome_yn	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.5152/eurjrheum.2019.19057	methodology	2	NA	variables_selection_justification	Status of prognostic factor/treatment effect modified assessed in the IPD dataset, A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion), Literature based (clinically or methodologically relevant to adjust on these variables based on the literature search conducted for this specific purpose)
10.5152/eurjrheum.2019.19057	methodology	2	NA	pf_yn	Yes
10.5152/eurjrheum.2019.19057	methodology	2	NA	tem_yn	Yes
10.5152/eurjrheum.2019.19057	methodology	2	NA	adjustment_model_details_yn	No
10.5152/eurjrheum.2019.19057	methodology	2	NA	scale_choice_yn	No
10.5152/eurjrheum.2019.19057	methodology	3	NA	outcome_name	acr 20 (american college of rheumatology ) response rates at week 12
10.5152/eurjrheum.2019.19057	methodology	3	NA	outcome_short_name	ACR Response Rate
10.5152/eurjrheum.2019.19057	methodology	3	NA	outcome_variable_type	Binary (eg rates)
10.5152/eurjrheum.2019.19057	methodology	3	NA	treatment_name_ipd	secukinumab 300mg
10.5152/eurjrheum.2019.19057	methodology	3	NA	studies_number_ipd	1;2;3
10.5152/eurjrheum.2019.19057	methodology	3	NA	treatment_name_nonipd	etanercept
10.5152/eurjrheum.2019.19057	methodology	3	NA	studies_number_nonipd	4
10.5152/eurjrheum.2019.19057	methodology	3	NA	paic_type	MAIC
10.5152/eurjrheum.2019.19057	methodology	3	NA	anchored_yn	Yes
10.5152/eurjrheum.2019.19057	methodology	3	NA	paic_form	Aggregation of multiple studies to estimate individual treatment effects (e.g. meta-analysis in a first step to estimate treatment A effect, then population adjusted indirect comparison using treatment A effect estimate)
10.5152/eurjrheum.2019.19057	methodology	3	NA	primary_outcome_yn	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.5152/eurjrheum.2019.19057	methodology	3	NA	variables_selection_justification	Status of prognostic factor/treatment effect modified assessed in the IPD dataset, A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion), Literature based (clinically or methodologically relevant to adjust on these variables based on the literature search conducted for this specific purpose)
10.5152/eurjrheum.2019.19057	methodology	3	NA	pf_yn	Yes
10.5152/eurjrheum.2019.19057	methodology	3	NA	tem_yn	Yes
10.5152/eurjrheum.2019.19057	methodology	3	NA	adjustment_model_details_yn	No
10.5152/eurjrheum.2019.19057	methodology	3	NA	scale_choice_yn	No
10.5152/eurjrheum.2019.19057	methodology	4	NA	outcome_name	acr 20 (american college of rheumatology ) response rates at week 24
10.5152/eurjrheum.2019.19057	methodology	4	NA	outcome_short_name	ACR Response Rate
10.5152/eurjrheum.2019.19057	methodology	4	NA	outcome_variable_type	Binary (eg rates)
10.5152/eurjrheum.2019.19057	methodology	4	NA	treatment_name_ipd	secukinumab 300mg
10.5152/eurjrheum.2019.19057	methodology	4	NA	studies_number_ipd	1;2;3
10.5152/eurjrheum.2019.19057	methodology	4	NA	treatment_name_nonipd	etanercept
10.5152/eurjrheum.2019.19057	methodology	4	NA	studies_number_nonipd	4
10.5152/eurjrheum.2019.19057	methodology	4	NA	paic_type	MAIC
10.5152/eurjrheum.2019.19057	methodology	4	NA	anchored_yn	No
10.5152/eurjrheum.2019.19057	methodology	4	NA	paic_form	Aggregation of multiple studies to estimate individual treatment effects (e.g. meta-analysis in a first step to estimate treatment A effect, then population adjusted indirect comparison using treatment A effect estimate)
10.5152/eurjrheum.2019.19057	methodology	4	NA	primary_outcome_yn	No primary outcome defined, or multiple primary outcomes without any clear distinction between them
10.5152/eurjrheum.2019.19057	methodology	4	NA	variables_selection_justification	Status of prognostic factor/treatment effect modified assessed in the IPD dataset, A priori expert-knowledge (clinically or methodologically relevant to adjust on these variables based on experts/clinicians opinion), Literature based (clinically or methodologically relevant to adjust on these variables based on the literature search conducted for this specific purpose)
10.5152/eurjrheum.2019.19057	methodology	4	NA	pf_yn	Yes
10.5152/eurjrheum.2019.19057	methodology	4	NA	tem_yn	Yes
10.5152/eurjrheum.2019.19057	methodology	4	NA	adjustment_model_details_yn	No
10.5152/eurjrheum.2019.19057	methodology	4	NA	scale_choice_yn	No
10.5152/eurjrheum.2019.19057	results	1	NA	contrast_effect_type	OR
10.5152/eurjrheum.2019.19057	results	1	NA	direction_benefit	superior
10.5152/eurjrheum.2019.19057	results	1	NA	ss_ttt_nonipd	101
10.5152/eurjrheum.2019.19057	results	1	NA	ss_ttt_ipd	458
10.5152/eurjrheum.2019.19057	results	1	NA	ss_adjusted_ttt_ipd	104
10.5152/eurjrheum.2019.19057	results	1	NA	weights_yn	Not mentioned
10.5152/eurjrheum.2019.19057	results	1	NA	covariates_yn	Yes
10.5152/eurjrheum.2019.19057	results	1	NA	covariates_n	11
10.5152/eurjrheum.2019.19057	results	1	NA	covariates_names	Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Race/ethnicity, Past treatments for the disease of interest, Other(s)
10.5152/eurjrheum.2019.19057	results	1	NA	contrast_effect_direction	Numerator if ratio, or left side if difference
10.5152/eurjrheum.2019.19057	results	1	NA	contrast_effect_unadjusted_value	NA
10.5152/eurjrheum.2019.19057	results	1	NA	contrast_effect_unadjusted_pvalci	NA
10.5152/eurjrheum.2019.19057	results	1	NA	contrast_effect_adjusted_value	0.57
10.5152/eurjrheum.2019.19057	results	1	NA	contrast_effect_adjusted_pvalci	0.186
10.5152/eurjrheum.2019.19057	results	1	NA	adjustment_geographical	Yes
10.5152/eurjrheum.2019.19057	results	1	NA	ss_total_ipd	NA
10.5152/eurjrheum.2019.19057	results	1	NA	ss_adjusted_total_ipd	NA
10.5152/eurjrheum.2019.19057	results	1	NA	ss_total_nonipd	NA
10.5152/eurjrheum.2019.19057	results	1	NA	ss_anchor_nonipd	104
10.5152/eurjrheum.2019.19057	results	1	NA	ss_anchor_ipd	567
10.5152/eurjrheum.2019.19057	results	1	NA	ss_adjusted_anchor_ipd	159
10.5152/eurjrheum.2019.19057	results	1	NA	effect_cutoff	1
10.5152/eurjrheum.2019.19057	results	1	NA	adjusted_pval	0.186
10.5152/eurjrheum.2019.19057	results	1	NA	adjusted_num_pval	0.186
10.5152/eurjrheum.2019.19057	results	1	NA	adjusted_significant	FALSE
10.5152/eurjrheum.2019.19057	results	2	NA	contrast_effect_type	OR
10.5152/eurjrheum.2019.19057	results	2	NA	direction_benefit	superior
10.5152/eurjrheum.2019.19057	results	2	NA	ss_ttt_nonipd	101
10.5152/eurjrheum.2019.19057	results	2	NA	ss_ttt_ipd	458
10.5152/eurjrheum.2019.19057	results	2	NA	ss_adjusted_ttt_ipd	104
10.5152/eurjrheum.2019.19057	results	2	NA	weights_yn	Not mentioned
10.5152/eurjrheum.2019.19057	results	2	NA	covariates_yn	Yes
10.5152/eurjrheum.2019.19057	results	2	NA	covariates_n	11
10.5152/eurjrheum.2019.19057	results	2	NA	covariates_names	Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Race/ethnicity, Past treatments for the disease of interest, Other(s)
10.5152/eurjrheum.2019.19057	results	2	NA	contrast_effect_direction	Numerator if ratio, or left side if difference
10.5152/eurjrheum.2019.19057	results	2	NA	contrast_effect_unadjusted_value	NA
10.5152/eurjrheum.2019.19057	results	2	NA	contrast_effect_unadjusted_pvalci	NA
10.5152/eurjrheum.2019.19057	results	2	NA	contrast_effect_adjusted_value	1.47
10.5152/eurjrheum.2019.19057	results	2	NA	contrast_effect_adjusted_pvalci	0.173
10.5152/eurjrheum.2019.19057	results	2	NA	adjustment_geographical	Yes
10.5152/eurjrheum.2019.19057	results	2	NA	ss_total_ipd	NA
10.5152/eurjrheum.2019.19057	results	2	NA	ss_adjusted_total_ipd	NA
10.5152/eurjrheum.2019.19057	results	2	NA	ss_total_nonipd	NA
10.5152/eurjrheum.2019.19057	results	2	NA	ss_anchor_nonipd	NA
10.5152/eurjrheum.2019.19057	results	2	NA	ss_anchor_ipd	NA
10.5152/eurjrheum.2019.19057	results	2	NA	ss_adjusted_anchor_ipd	NA
10.5152/eurjrheum.2019.19057	results	2	NA	effect_cutoff	1
10.5152/eurjrheum.2019.19057	results	2	NA	adjusted_pval	0.173
10.5152/eurjrheum.2019.19057	results	2	NA	adjusted_num_pval	0.173
10.5152/eurjrheum.2019.19057	results	2	NA	adjusted_significant	FALSE
10.5152/eurjrheum.2019.19057	results	3	NA	contrast_effect_type	OR
10.5152/eurjrheum.2019.19057	results	3	NA	direction_benefit	superior
10.5152/eurjrheum.2019.19057	results	3	NA	ss_ttt_nonipd	101
10.5152/eurjrheum.2019.19057	results	3	NA	ss_ttt_ipd	461
10.5152/eurjrheum.2019.19057	results	3	NA	ss_adjusted_ttt_ipd	75
10.5152/eurjrheum.2019.19057	results	3	NA	weights_yn	Not mentioned
10.5152/eurjrheum.2019.19057	results	3	NA	covariates_yn	Yes
10.5152/eurjrheum.2019.19057	results	3	NA	covariates_n	11
10.5152/eurjrheum.2019.19057	results	3	NA	covariates_names	Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Race/ethnicity, Past treatments for the disease of interest, Other(s)
10.5152/eurjrheum.2019.19057	results	3	NA	contrast_effect_direction	Numerator if ratio, or left side if difference
10.5152/eurjrheum.2019.19057	results	3	NA	contrast_effect_unadjusted_value	NA
10.5152/eurjrheum.2019.19057	results	3	NA	contrast_effect_unadjusted_pvalci	NA
10.5152/eurjrheum.2019.19057	results	3	NA	contrast_effect_adjusted_value	0.86
10.5152/eurjrheum.2019.19057	results	3	NA	contrast_effect_adjusted_pvalci	0.722
10.5152/eurjrheum.2019.19057	results	3	NA	adjustment_geographical	Yes
10.5152/eurjrheum.2019.19057	results	3	NA	ss_total_ipd	NA
10.5152/eurjrheum.2019.19057	results	3	NA	ss_adjusted_total_ipd	NA
10.5152/eurjrheum.2019.19057	results	3	NA	ss_total_nonipd	NA
10.5152/eurjrheum.2019.19057	results	3	NA	ss_anchor_nonipd	104
10.5152/eurjrheum.2019.19057	results	3	NA	ss_anchor_ipd	567
10.5152/eurjrheum.2019.19057	results	3	NA	ss_adjusted_anchor_ipd	159
10.5152/eurjrheum.2019.19057	results	3	NA	effect_cutoff	1
10.5152/eurjrheum.2019.19057	results	3	NA	adjusted_pval	0.722
10.5152/eurjrheum.2019.19057	results	3	NA	adjusted_num_pval	0.722
10.5152/eurjrheum.2019.19057	results	3	NA	adjusted_significant	FALSE
10.5152/eurjrheum.2019.19057	results	4	NA	contrast_effect_type	OR
10.5152/eurjrheum.2019.19057	results	4	NA	direction_benefit	superior
10.5152/eurjrheum.2019.19057	results	4	NA	ss_ttt_nonipd	101
10.5152/eurjrheum.2019.19057	results	4	NA	ss_ttt_ipd	461
10.5152/eurjrheum.2019.19057	results	4	NA	ss_adjusted_ttt_ipd	75
10.5152/eurjrheum.2019.19057	results	4	NA	weights_yn	Not mentioned
10.5152/eurjrheum.2019.19057	results	4	NA	covariates_yn	Yes
10.5152/eurjrheum.2019.19057	results	4	NA	covariates_n	11
10.5152/eurjrheum.2019.19057	results	4	NA	covariates_names	Age, Sex, Disease severity/disease history (ie past conditions or symptoms directly related to the disease of interest, eg history of venous thromboembolism in sickle cell disease), Race/ethnicity, Past treatments for the disease of interest, Other(s)
10.5152/eurjrheum.2019.19057	results	4	NA	contrast_effect_direction	Numerator if ratio, or left side if difference
10.5152/eurjrheum.2019.19057	results	4	NA	contrast_effect_unadjusted_value	NA
10.5152/eurjrheum.2019.19057	results	4	NA	contrast_effect_unadjusted_pvalci	NA
10.5152/eurjrheum.2019.19057	results	4	NA	contrast_effect_adjusted_value	3.28
10.5152/eurjrheum.2019.19057	results	4	NA	contrast_effect_adjusted_pvalci	<0.001
10.5152/eurjrheum.2019.19057	results	4	NA	adjustment_geographical	Yes
10.5152/eurjrheum.2019.19057	results	4	NA	ss_total_ipd	NA
10.5152/eurjrheum.2019.19057	results	4	NA	ss_adjusted_total_ipd	NA
10.5152/eurjrheum.2019.19057	results	4	NA	ss_total_nonipd	NA
10.5152/eurjrheum.2019.19057	results	4	NA	ss_anchor_nonipd	NA
10.5152/eurjrheum.2019.19057	results	4	NA	ss_anchor_ipd	NA
10.5152/eurjrheum.2019.19057	results	4	NA	ss_adjusted_anchor_ipd	NA
10.5152/eurjrheum.2019.19057	results	4	NA	effect_cutoff	1
10.5152/eurjrheum.2019.19057	results	4	NA	adjusted_pval	<0.001
10.5152/eurjrheum.2019.19057	results	4	NA	adjusted_significant	TRUE
10.5152/eurjrheum.2019.19057	study_information	NA	1	ipd_yn	Yes
10.5152/eurjrheum.2019.19057	study_information	NA	1	ct_yn	Yes
10.5152/eurjrheum.2019.19057	study_information	NA	1	nct	NCT01752634
10.5152/eurjrheum.2019.19057	study_information	NA	1	country_study	international
10.5152/eurjrheum.2019.19057	study_information	NA	1	ct_phase	3
10.5152/eurjrheum.2019.19057	study_information	NA	1	ct_arms	2 or more
10.5152/eurjrheum.2019.19057	study_information	NA	2	ipd_yn	Yes
10.5152/eurjrheum.2019.19057	study_information	NA	2	ct_yn	Yes
10.5152/eurjrheum.2019.19057	study_information	NA	2	nct	NCT01989468
10.5152/eurjrheum.2019.19057	study_information	NA	2	country_study	international
10.5152/eurjrheum.2019.19057	study_information	NA	2	ct_phase	3
10.5152/eurjrheum.2019.19057	study_information	NA	2	ct_arms	2 or more
10.5152/eurjrheum.2019.19057	study_information	NA	3	ipd_yn	Yes
10.5152/eurjrheum.2019.19057	study_information	NA	3	ct_yn	Yes
10.5152/eurjrheum.2019.19057	study_information	NA	3	nct	NCT02404350
10.5152/eurjrheum.2019.19057	study_information	NA	3	country_study	international
10.5152/eurjrheum.2019.19057	study_information	NA	3	ct_phase	3
10.5152/eurjrheum.2019.19057	study_information	NA	3	ct_arms	2 or more
10.5152/eurjrheum.2019.19057	study_information	NA	4	ipd_yn	No
10.5152/eurjrheum.2019.19057	study_information	NA	4	ct_yn	Yes
10.5152/eurjrheum.2019.19057	study_information	NA	4	nct	NCT00317499
10.5152/eurjrheum.2019.19057	study_information	NA	4	ct_phase	3
10.5152/eurjrheum.2019.19057	study_information	NA	4	ct_arms	2 or more
10.5152/eurjrheum.2019.19057	study_information	NA	4	country_study	unknown
